<SEC-DOCUMENT>0001213900-14-005682.txt : 20140813
<SEC-HEADER>0001213900-14-005682.hdr.sgml : 20140812
<ACCEPTANCE-DATETIME>20140812164501
ACCESSION NUMBER:		0001213900-14-005682
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20140630
FILED AS OF DATE:		20140812
DATE AS OF CHANGE:		20140812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		141034499

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0614_actinium.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 0; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Wingdings 2"><B>&#83;
</B></FONT><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended<B> </B>June
30, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163; </FONT><B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from _______________________
to ___________________________</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <B>000-52446</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0; border-bottom: Black 1.5pt solid"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; padding: 0 0 1.5pt; text-indent: 0"><B>&nbsp;</B></TD>
    <TD STYLE="width: 49%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0; border-bottom: Black 1.5pt solid"><B>88-0378336</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0">(State or Other Jurisdiction of</P>
                                                               <P STYLE="margin-top: 0; margin-bottom: 0">Incorporation or Organization)</P></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0">(I.R.S. Employer</P>
                                                               <P STYLE="margin-top: 0; margin-bottom: 0">Identification No.)</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid; width: 49%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>501 Fifth Avenue, 3rd Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, NY</B></P></TD>
    <TD STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; width: 2%"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0; border-bottom: Black 1.5pt solid; width: 49%"><B>10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(Address of Principal Executive Offices)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(732) 243-9495</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s Telephone Number, Including
Area Code)</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">(Former Name, Former Address
and Former Fiscal Year, if Changed Since Last Report)</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Wingdings">x&nbsp;</FONT>Yes
&nbsp;&nbsp;&nbsp;No&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Wingdings">x&nbsp;</FONT>Yes
&nbsp;&nbsp;&nbsp;No&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 20%; text-align: left">Large accelerated filer</TD>
    <TD STYLE="vertical-align: top; width: 45%"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 25%">Accelerated filer</TD>
    <TD STYLE="vertical-align: top; width: 10%"><FONT STYLE="font-family: Wingdings">o</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="text-align: left">Non-accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings"> </FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Wingdings">o </FONT>(Do not check if a smaller reporting
    company)</TD>
    <TD>Smaller reporting company</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). <FONT STYLE="font-family: Wingdings"> o</FONT> Yes <FONT STYLE="font-family: Wingdings">
x</FONT> No</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PROCEEDINGS DURING THE PRECEDING FIVE YEARS:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent
to the distribution of securities under a plan confirmed by a court. <FONT STYLE="font-family: Wingdings"> o</FONT> Yes <FONT STYLE="font-family: Wingdings">
o</FONT> No</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPLICABLE ONLY TO CORPORATE ISSUERS:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding
of each of the issuer&rsquo;s classes of common stock, as of<B> </B>August 11, 2014: 28,147,064</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 0; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For period ended June 30, 2014</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left"><B><A HREF="#a_001"></A></B></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="text-align: left"><A HREF="#a_001"><B>PART I - FINANCIAL INFORMATION</B></A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 11%; text-align: left"><A HREF="#a_001">Item 1.</A></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 76%; text-align: left"><A HREF="#a_001"></A><A HREF="#a_001">Financial Statements</A></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_002">Item 2.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_002"></A><A HREF="#a_002">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_003">Item 3.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_003"></A><A HREF="#a_003">Quantitative and Qualitative Disclosures About Market Risk</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_004">Item 4.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_004"></A><A HREF="#a_004">Controls and Procedures</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left"><A HREF="#a_005">PART II - OTHER INFORMATION</A></TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Item 1.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Legal Proceedings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_006">Item 1A.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_006">Risk Factors</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_007">Item 2.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_007">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_008">Item 3.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_008">Defaults Upon Senior Securities</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_009">Item 4.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_009">Mine Safety Disclosures</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_010">Item 5.</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#a_010">Other Information</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_011">Item 6.</A></TD><TD>&nbsp;</TD>
    <TD><A HREF="#a_011">Exhibits</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B><A HREF="#a_012">SIGNATURES</A></B></TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_001"></A>PART I - FINANCIAL INFORMATION</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 1. &nbsp;&nbsp;FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position, results of operations and cash flows at June 30, 2014 and December
31, 2013 and for the six months ended June 30, 2014 and 2013 have been made. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America
have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements
and notes thereto included in the Company&rsquo;s audited financial statements for the year ended December 31, 2013. The results
of operations for the six months ended June 30, 2014 are not necessarily indicative of the operating results for the full year.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>Consolidated Balance Sheets</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><B>(Unaudited)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <BR>2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, <BR>2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9.9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">14,670,813</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,533,366</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9.9pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">608,105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">218,389</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 19.8pt">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,278,918</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,751,755</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net of accumulated depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Security deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,733</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">15,446,553</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,765,675</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders' Equity&nbsp;(Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9.9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,045,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">378,955</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9.9pt">Accounts payable and accrued expenses - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9.9pt">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,970</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,825</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9.9pt">Derivative liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,826,627</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,707,255</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 19.8pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,116,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,325,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,116,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,325,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity (Deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.9pt">Preferred stock, $0.01 par value; 10,000,000 authorized none issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22; text-indent: -9.9">Common stock, $0.001 par value; 100,000,000 shares authorized; 27,602,192 and 24,565,447&nbsp;&nbsp;shares
issued and outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,565</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9.9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,004,053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,933,145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9.9pt"><P STYLE="margin: 0">Accumulated deficit</P>


     </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(79,701,657</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(66,517,255</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 19.8pt">Total Stockholders' Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,329,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,559,545</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders' Equity (Deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">15,446,553</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,765,675</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><B>Actinium Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Statements of Operations</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended June&nbsp;30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended June&nbsp;30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; padding-left: 17.6pt">Research and development, net of reimbursements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,001,937</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">509,262</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,462,905</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,594,968</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 17.6pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,414,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">966,367</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,090,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,899,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 17.6pt">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 17.6pt">Loss on disposition of equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,122</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 17.6pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,424,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,475,629</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,563,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,498,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,424,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,475,629</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,563,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,498,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 17.6pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(634</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&mdash; &nbsp;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,209</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 17.6pt"><P STYLE="margin: 0">Gain (loss) on change in fair value of derivative liabilities</P> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,939,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,307,748</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,621,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,764</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 17.6pt"><P STYLE="margin: 0">Total other income and (expense)</P> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,939,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,308,382</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,621,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,555</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,515,095</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,784,011</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(13,184,402</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,473,038</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss) per common share&nbsp;&nbsp;- basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.52</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss) per common share - diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.52</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Weighted average common shares outstanding&nbsp;&nbsp;- basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,795,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,178,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,513,505</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,791,673</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Weighted average common shares outstanding&nbsp;&nbsp;- diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,862,173</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,178,637</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,513,505</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,791,673</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">See accompanying
notes to consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actinium Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Consolidated Statements of Cash Flows</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Unaudited)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">For the Six</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">For the Six</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Months Ended</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Months Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">(13,184,402</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">(3,473,038</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -7.5pt; padding-left: 7.5pt">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Stock-based compensation expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3,141,144</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">188,400</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Depreciation expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">9,457</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Loss on disposition of equipment</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,122</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Amortization of debt discount</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Amortization of deferred financing costs</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Gain on extinguishment of liability</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Loss (gain) on change in fair value of derivative liabilities</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,621,360</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(26,764</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">(Increase) decrease in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">R&amp;D reimbursable receivable</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(2,126</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(389,716</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">85,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Other assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(34,733</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Increase (decrease) in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">666,466</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(103,414</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accounts payable and accrued expenses - related party</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">108,352</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(5,062,072</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,327,820</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Purchase of property and equipment</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(128,439</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,112</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Investing Activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(128,439</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,112</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.1pt">Payments on note payable</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(102,855</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(103,050</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Sales of stock, net of offering costs</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">14,328,725</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Proceeds from the exercise of options and warrants for cash</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">102,088</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">3,463,641</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">14,327,958</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">3,360,591</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">Net change&nbsp;&nbsp;in cash</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">9,137,447</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">31,659</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Cash at beginning of period</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,533,366</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,618,669</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">14,670,813</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">5,650,328</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">561</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Conversion of notes payable and accrued interest to stock</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,501,988</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">590,217</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Transfer from liability classification to equity classification</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-align: center"><FONT STYLE="font-size: 10pt">See accompanying
notes to consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actinium Pharmaceuticals,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Notes to Consolidated
Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 1 &ndash;&nbsp;Description of Business
and Summary of Significant Accounting Policies</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Nature of Business
&ndash;</B> Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo; or &ldquo;Actinium&rdquo;) is a biotechnology company committed
to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other
related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred
to collectively as &ldquo;Actinium&rdquo;) initiated collaborative efforts with large institutions to establish the proof of concept
of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center
(&ldquo;MSKCC&rdquo;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial
in acute myeloid leukemia (AML) patients. Actinium&rsquo;s objective, through research and development, is to produce reliable
cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads
to provide very potent targeted therapies. The initial clinical trials of Actinium&rsquo;s compounds have been with patients having
acute myeloid leukemia and it is believed that Actinium&rsquo;s APIT platform will have wider applicability for different types
of cancer where suitable monoclonal antibodies can be found.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On December 28,
2012, the Company entered into a transaction (the &ldquo;Share Exchange&rdquo;), pursuant to which the Company acquired 100% of
the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&ldquo;API&rdquo;), in exchange for the issuance
of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the
Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder
received 0.333 shares (the &ldquo;Exchange Ratio&rdquo;) of Actinium common stock for each API share exchanged. At the closing,
all of the API shareholders&rsquo; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new
options or warrants, as applicable, to purchase Actinium common stock. The Share Exchange was accounted for as a reverse takeover/recapitalization
effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">As a result of
the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing
certain cancer treatments.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On March 20, 2013,
the Company&rsquo;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the
Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc.
to Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On September 25,
2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed
in Delaware, the Company merged (the &ldquo;Merger&rdquo;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium
Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each
share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&rsquo;s common stock. A total
of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Basis
of Presentation - Unaudited Interim Financial Information &ndash;</B> The accompanying unaudited interim condensed consolidated
financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United
States of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information, and in accordance with the rules and regulations
of the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) with respect to Form 10-Q and Article 8 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.
The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring
adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented.
Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated
financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year
ended December 31, 2013 and notes thereto contained in the Company&rsquo;s annual report on Form 10-K for the year ended December
31, 2013, as filed with the SEC February 28, 2014.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Principles
of Consolidation &ndash;</B> The condensed consolidated financial statements include the Company&rsquo;s accounts and those of
the Company&rsquo;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Use
of Estimates in Financial Statement Presentation &ndash;</B> The preparation of these condensed consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Reclassification
&ndash;</B> Certain prior period amounts have been reclassified to conform to current period presentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Cash
and Cash Equivalents &ndash;</B> The Company considers all highly liquid accounts with original maturities of three months or
less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2014 and December 31, 2013,
all of the Company&rsquo;s cash was deposited in one bank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Property
and Equipment &ndash;</B> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated
useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated
useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the
accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Impairment
of Long-Lived Assets &ndash; </B>Management reviews long-lived assets for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an
evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&rsquo;s
carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the
difference between the fair value of such asset and its carrying value.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Derivatives
&ndash;</B> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market
and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using
market based pricing models incorporating readily observable market data and requiring judgment and estimates.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Fair
Value of Financial Instruments &ndash;</B> Fair value is defined as the price that would be received to sell an asset, or paid
to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for
valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the
lowest priority to unobservable inputs. The fair value hierarchy is as follows:</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify"><FONT STYLE="font-size: 10pt">Level
1 Inputs &ndash; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has
the ability to access at the measurement date.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify"><FONT STYLE="font-size: 10pt">Level
2 Inputs &ndash; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly
or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical
or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset
or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally
from or corroborated by market data by correlation or other means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify"><FONT STYLE="font-size: 10pt">Level
3 Inputs &ndash; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions
about the assumptions that market participants would use in pricing the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">The following tables
set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy
as of June 30, 2014 and December 31, 2013. As required by ASC 820 &ldquo;<I>Fair Value Measurements and Disclosures&rdquo;</I>,
financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the
fair value measurement. The Company&rsquo;s assessment of the significance of a particular input to the fair value measurement
requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value
hierarchy levels.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Derivative
    liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 52%; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
    June 30, 2014</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,826,627</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,826,627</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
    December 31, 2013</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,707,255</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,707,255</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Income
Taxes &ndash;</B> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred
tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of
assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that
the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based
upon management&rsquo;s assessment as to their realization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Research
and Development Costs &ndash;</B> Research and development costs are expensed as incurred. Research and development reimbursements
and grants are recorded by the Company as a reduction of research and development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Share-Based
Payments &ndash;</B> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes
option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert
of the Company&rsquo;s common stock on the date of the share grant. The fair value determined represents the cost for the award
and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As
share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for
estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect
the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized
as an addition to paid-in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Earnings (Loss)
Per Common Share &ndash;</B> The Company provides basic and diluted earnings per common share information for each period
presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common
stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per
common share, as calculated for the three months ended June 30, 2014, is computed by dividing the net income available to
common stockholders by the weighted average number of common shares outstanding plus dilutive securities. For the three
months ended June 30, 2013 and the six months ended June 30, 2014 and 2013, the potentially dilutive securities (options,
warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect
would have been antidilutive. For the three months ended June&nbsp;30, 2014, potentially issuable shares included stock
options to purchase 1,398,937 shares and warrants to purchase 8,667,663 shares of the Company&rsquo;s common stock. For the
six months ended June 30, 2014, potentially issuable shares included stock options to purchase 2,952,829 shares and warrants
to purchase 9,418,058 shares of the Company&rsquo;s common stock. For the six months ended June 30, 2013, potentially
issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the
Company&rsquo;s common stock.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Recent Accounting Pronouncements
&ndash; </B>In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts
with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition
requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry
Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&mdash;Construction-Type
and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&mdash;Contracts with Customers.
In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods
or services. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230&mdash;Revenue
Recognition (Topic 605) and Proposed Accounting Standards Update 2011&ndash;250&mdash;Revenue Recognition (Topic 605): Codification
Amendments, both of which have been deleted. The amendments in this Update are effective for the Company for annual reporting periods
beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating
the effects of ASU 2014-09 on the consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.55in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">In June 2014, the Financial
Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update
remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage
entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage
entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&rsquo;s equity,
(2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage
activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage
entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks
and Uncertainties, is applicable to entities that have not commenced planned principal operations. Finally, the amendments also
remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a)
to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient
to permit it to finance the activities it is currently engaged in and (2) the entity&rsquo;s governing documents and contractual
arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest
Entities Subsections of Subtopic 810-10, Consolidation&mdash;Overall, would be required to evaluate whether the total equity investment
at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and
quantitative evaluations. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2013-320&mdash;Development
Stage Entities (Topic 915), which has been deleted. The amendments in this Update are effective for annual reporting periods beginning
after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10
for the reporting period ended June 30, 2014.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.55in"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">In
June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation.
The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of
the award provide that a performance target can be achieved after the requisite service period. This Accounting Standards Update
is the final version of Proposed Accounting Standards Update EITF-13D&mdash;Compensation&mdash;Stock Compensation (Topic 718):
Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite
Service Period, which has been deleted. The proposed amendments would apply to reporting entities that grant their employees share-based
payments in which the terms of the award provide that a performance target could be achieved after the requisite service period.
This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&mdash;Compensation&mdash;Stock
Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could
Be Achieved after the Requisite Service Period, which has been deleted. The amendments in this Update are effective for annual
periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The
Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>Subsequent
Events &ndash;</B> The Company&rsquo;s management reviewed all material events through the date of the condensed consolidated
financial statements were issued for subsequent event disclosure consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 2 &ndash; Related Party Transactions</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>MSKCC:</I></B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">In
2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly
named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">On
February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute
of Cancer Research (SKI), an entity related to MSKCC (&ldquo;License Agreement&rdquo;). The agreement was amended in August 2006.
Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect
to the Company&rsquo;s core technology, and also supports ongoing research and clinical development of related drug candidates.
MSKCC agreed, subject to certain conditions, to utilize the donated funds for certain clinical and preclinical programs and activities
related to the Company&rsquo;s drug development and clinical study programs, including the payment of certain costs and expenses
that would otherwise have been borne by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">The
Company is obligated to make the following milestone payments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Milestones</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Payments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">(1) filing of an New Drug Application (&ldquo;NDA&rdquo;) or regulatory approval for each licensed product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">Under
the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products
until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">Certain
amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement. On June 19, 2011,
the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement,
in respect of the $50,000 annual maintenance fees and research payments.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On September 4, 2013,
the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011
to 2014 under the License Agreement. The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus
all relevant licensed intellectual property related pass through costs to be determined. The amount owed does not include amounts
the Company may owe for patent expenses under the License Agreement. For 2013, the annual maintenance fee is $50,000 plus pass
through costs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">On
March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting
a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225. The Company will pay
$31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company paid a start-up fee
of $79,623 in 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">For the three months ended
June 30, 2014 and 2013, the Company did not incur any expenses for maintenance fees and research conducted by MSKCC. For the six
months ended June 30, 2014 and 2013, the Company incurred $189,537 and $129,850, respectively, for maintenance fees and research
conducted by MSKCC. As of June 30, 2014 and December 31, 2013, the Company has payable to MSKCC of $189,537 and $81,185, respectively,
related to clinical trials.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Placement
Agent:</I></B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On August 7, 2012,
the Company entered into an engagement agreement with a Healthcare Investment Bank as its placement agent for the 2012 Common Stock
Offering whereby a director of the Company, is the Head of Healthcare Investment Banking team. Pursuant to the agreement, the placement
agent was engaged as the exclusive agent for the 2012 Common Stock Offering. In consideration for its services, the placement agent
received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense
reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for
legal expenses incurred by the placement agent. The placement agent or its designees also received warrants to purchase shares
of the Company&rsquo;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in
the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.
The placement agent also received the same fee and expense schedule for any cash exercise of warrants within 6 months of the final
closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for
redemption by the Company. Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent was engaged
by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee
of $25,000. The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other
transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive
a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination
of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent
will have the right to act as the Company&rsquo;s financial advisor and investment banker in such financing or transaction pursuant
to a set fee schedule set forth in the August 7, 2012 engagement agreement. For a period ending one year after the expiration of
all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors
must be approved by the placement agent. The placement agent also was engaged by the Company as placement agent for its Stock Offering
and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold
warrants to purchase 1,251,015 shares of the Company&rsquo;s Common Stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">On
December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering.
The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the
gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase
shares of the Company&rsquo;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent
to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company
until three months after the Company had uplisted its securities for trading on a U.S. National Exchange for a monthly fee of
$25,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On January 10, 2014, the
Company conducted the final closing (the &ldquo;Final Closing&rdquo;) of its private placement of securities (the &ldquo;Offering&rdquo;)
pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &ldquo;Purchase Agreement&rdquo;) and Subscription Agreement,
dated as of January 10, 2014 (the &ldquo;Subscription Agreement&rdquo;), with certain accredited investors (the &ldquo;Investors&rdquo;)
pursuant to which: the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &ldquo;Shares&rdquo;)
of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an
exercise price of $9.00 per share. The Company received $3,310,860 in gross proceeds from the sale of securities under the Purchase
Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. The aggregate
offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">During the six
months ended June 30, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and
was issued warrants to purchase 68,976 shares of the Company&rsquo;s Common Stock at $9.00 per share for a period of 5 years.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">On
May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 3 &ndash; Property and Equipment</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-size: 10pt">Property
and equipment consisted of the following at June 30, 2014 and December 31, 2013:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lives</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 30, 2014</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 31, 2013</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 67%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office equipment</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;3-5 years</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">143,919</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,480</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Less: accumulated depreciation</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(11,017</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,560</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">132,902</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13,920</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Depreciation expense
for the three months ended June 30, 2014 and 2013 was $8,052 and $0, respectively. Depreciation expense for the six months ended
June 30, 2014 and 2013 was $9,457 and $0, respectively. The Company wrote off some of its undepreciated property and equipment
during the six months ended June 30, 2013 and recorded a loss of $4,122 on the disposition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 4 &ndash;&nbsp;Note Payable</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">On
December 28, 2013, the Company entered into a premium finance agreement to pay a $157,825 premium for its director and officer
liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and is required
to pay $15,995 in monthly installment for nine months. During the six months ended June 30, 2014 and 2013, the Company paid $102,855
and $103,050, respectively.</FONT> <FONT STYLE="font-size: 10pt">As of June 30, 2014 and December 31, 2013, the outstanding balance
related to the premium finance agreement was $54,970 and $157,825, respectively.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Note 5 &ndash;
Derivatives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">The
Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances
of the Company&rsquo;s common stock at prices below such warrants&rsquo; respective exercise prices and these provisions could
result in modification of the warrants&rsquo; exercise price based on a variable that is not an input to the fair value of a &ldquo;fixed-for-fixed&rdquo;
option as defined under FASB ASC Topic No. 815 &ndash; 40. The warrants granted in connection with the issuance of the Company&rsquo;s
Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent
warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that
future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable)
at a price per share (a &ldquo;Lower Price&rdquo;) that is less than the exercise price of such warrant at the time. The amount
of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of
shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise
price of the warrant at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Activities for
derivative warrant instruments during the six months ended June 30, 2014 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Units</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Balance, December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,968,623</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,707,255</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Transfer from liability classification to equity classification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(193,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,501,988</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,621,360</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance, June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,774,962</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,826,627</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">During the six months
ended June 30, 2014, 662,160 warrants were exercised, of which 193,661 were derivative warrants. The fair value of these warrants
totaling approximately $1,501,988 were measured on the various exercise dates and reclassified to additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in">The fair values of the derivative warrants
were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">June 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December&nbsp;31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Market value of common stock on measurement date (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Adjusted exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free interest rate (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.27</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant lives in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Probability of stock offering in any period over 5 years (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Range of percentage of existing shares offered (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Offering price range (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-size: 10pt">The market value of common stock at the above measurement
    dates is based on the Company&rsquo;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for
    June 30, 2014.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The risk-free interest rate was determined by management
    using the Treasury Bill as of the respective measurement date.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Because the Company does not have adequate trading
    history to determine its historical trading volatility, the volatility factor was estimated by management using the historical
    volatilities of comparable companies in the same industry and region.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-size: 10pt">Management determined the dividend yield to be 0%
    based upon its expectation that it will not pay dividends for the foreseeable future.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Management determines the probability of future
    stock offering at each evaluation date.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0">Management estimates that the range of percentages of existing shares offered in each stock offering will
be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.</P>


<FONT STYLE="font-size: 10pt"></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents the estimated offering price range in
    future offerings as determined by management.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 6 &ndash; Commitments and Contingencies</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>License and Research Agreements</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">The
Company has entered into license and research and development agreements with third parties under which the Company is obligated
to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category
are:</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.55in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Abbott Biotherapeutics Corp &ndash; The Company
    entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech
    formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha
    emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">The
Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Milestones</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Payments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">(1) when Company initiates a Phase I Clinical Trial of a licensed product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(2) when Company initiates a Phase II Clinical Trial of a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(3) when Company initiates a Phase III Clinical Trial of a licensed product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(4) Biological License Application filing with U.S. FDA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(5) First commercial sale</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(6) after the first $10,000,000 in net sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the agreement,
the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed
products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company met its first milestone in 2012 and upon reaching
the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. The milestone payment
for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase 2 Clinical
Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.55in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left; padding: 0"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Memorial Sloan Kettering Cancer Center (MSKCC) &ndash;
    see related party disclosure.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><P STYLE="margin: 0">Oak Ridge National Laboratory (ORNL) &ndash; The Company is contracted to purchase radioactive material to
be used for research and development, with a renewal option at the contract end.&nbsp;&nbsp;For 2013, the Company was obligated
and paid approximately $0.3 million to purchase of radioactive material with ORNL.&nbsp;&nbsp;For 2014, the Company signed a contract
with ORNL to purchase $0.4 million of radioactive material.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">AptivSolutions provides project
management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company&rsquo;s Phase 1 and Phase 2 clinical
trials.&nbsp;&nbsp;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the
total estimated project cost.&nbsp;&nbsp;The down payment totaling $239,000 was paid in 2007 and 2012.&nbsp;&nbsp;On August 6,
2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&nbsp;&nbsp;The total project
is now estimated at approximately $2.2 million. As of June 30, 2014, approximately $1.1 million has been expensed to date. &nbsp;AptivSolutions
bills the Company when services are rendered and the Company records the related expense to research and development costs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 15, 2012, the Company entered
into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC) to build upon previous and
ongoing clinical trials, with BC8 (licensed antibody). FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial
and the Company intends to start preparation for a pivotal trial leading to an FDA approval. The Company has been granted exclusive
rights to the BC8 antibody and related master cell bank developed by FHCRC. The cost to develop the trial will range from $13.2
million to $23.5 million, depending on the trial design as required by the FDA. Under the terms of the sponsored research agreement,
the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. Payments made toward
funding the lab will be credited toward royalty payments owed to FHCRC in the given year. A milestone payment of $1 million will
be due to FHCRC upon FDA approval of the first drug. Upon commercial sale of the drug, royalty payments of 2% of net sales will
be due to FHCRC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0">During the six months ended June 30, 2014 and 2013, the Company recorded fees of $75,000 and $75,000, respectively,
related to this agreement.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&nbsp;&nbsp;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&nbsp;&nbsp;During the clinical trial additional fees apply and will be invoiced when applicable. For the six months ended June 30, 2014, the Company paid approximately $16,000 for patient enrollment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">g.</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 28, 2012, the Company entered into
        a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. The total estimated cost of conducting the
        clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500. The estimated cost is
        based on treating 24 patients through 2013. Upon execution of the agreement, the Company paid $33,946. During 2013, there was one
        patient treated and the Company paid $34,383 in July 2013. There have been no patients treated in 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">h.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&nbsp;&nbsp;The Phase 1/2 clinical trial will be conducted with Actinium 225.&nbsp;&nbsp;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&nbsp;&nbsp;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. There were no payments made during the six months ended June 30, 2104 for this agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">i.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&nbsp;&nbsp;The Phase 1/2 clinical trial will be conducted with Actinium 225.&nbsp;&nbsp;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&nbsp;&nbsp;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable. The Company accrued the $16,000 fee at December 31, 2013 and paid the fee in January 2014.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">j.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&nbsp;&nbsp;(&ldquo;Goodwin&rdquo;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab&trade;-B. Total cost of the agreement is $2,813,960. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of June 30, 2014, the remaining cost of the agreement is approximately $2.1 million.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">k.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On June 20, 2014, the Company entered into a CRO agreement with Act Oncology. Act Oncology provides project management services for the study of Iomab-B used for the intended Phase 3 clinical trial. The total project is estimated to cost approximately $0.8 million. The Company paid approximately $0.1 million during the six months ended June 30, 2014. Act Oncology bills the Company when services are rendered and the Company records the related expense to research and development costs.&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">On August 1, 2012,
the Company entered into a rental agreement for office space at 501 Fifth Avenue, New York, NY. The agreement terminated on May
31, 2013. On June 4, 2013 and amended on October 4, 2013, the Company entered into two rental agreements for office space at 546
Fifth Avenue, New York, NY. One of the agreements terminated on July 6, 2014. The Company maintains office space at 546 Fifth Avenue,
New York, NY through December 31, 2014. The Company paid a one month refundable deposit. On April 22, 2014, the Company entered
into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement terminates on September 30,
2016. The Company issued a security deposit of $34,733 to the existing tenant.&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Note 7 &ndash;
Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
January 2014, the Company completed the final tranche of a private placement of the Company</FONT>&rsquo;<FONT STYLE="font-size: 10pt">s
common stock and warrants and received</FONT> <FONT STYLE="font-size: 10pt">approximately $3.3 million total gross proceeds from
accredited investors (</FONT>&ldquo;<FONT STYLE="font-size: 10pt">2014 Closing</FONT>&rdquo;<FONT STYLE="font-size: 10pt">). The
Company paid its placement agent total cash fees of</FONT> <FONT STYLE="font-size: 10pt">approximately $395,000 and paid attorney
fees of $40,000 for their services</FONT> resulting in net proceeds of $2,873,557<FONT STYLE="font-size: 10pt">. In the 2014 Closing,
the Company sold 551,810 shares of common stock at</FONT> <FONT STYLE="font-size: 10pt">$6.00 per share and granted 137,952 units
of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five</FONT> <FONT STYLE="font-size: 10pt">years
from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes
option pricing</FONT> <FONT STYLE="font-size: 10pt">model utilizing the following assumptions: risk free interest rateh1.64%, expected
volatility - 88%, expected dividend yield - 0%, and a contractual life of 5</FONT> <FONT STYLE="font-size: 10pt">years. As of </FONT>June
30<FONT STYLE="font-size: 10pt">, 2014, all the warrants were outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the</FONT> &ldquo;<FONT STYLE="font-size: 10pt">Registration
Statement</FONT>&rdquo;<FONT STYLE="font-size: 10pt">) which was effective on April 17,</FONT> <FONT STYLE="font-size: 10pt">2014.
This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the
Company of up to</FONT> <FONT STYLE="font-size: 10pt">$200,000,000 of its common stock, preferred stock, warrants and/or units;
and (ii) a sales agreement prospectus covering the offering, issuance and sale by</FONT> <FONT STYLE="font-size: 10pt">us of up
to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the
</FONT>&ldquo;<FONT STYLE="font-size: 10pt">Sales</FONT> <FONT STYLE="font-size: 10pt">Agreement</FONT>&rdquo;<FONT STYLE="font-size: 10pt">)
with MLV &amp; Co. LLC (</FONT>&ldquo;<FONT STYLE="font-size: 10pt">MLV</FONT>&rdquo;<FONT STYLE="font-size: 10pt">) dated March
24, 2014. The Company will pay MLV in cash, upon the sale of common stock pursuant to the</FONT> <FONT STYLE="font-size: 10pt">Sales
Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. </FONT>On April 28, 2014 the Company issued
<FONT STYLE="font-size: 10pt">500 shares </FONT>and received net proceeds of $6,000<FONT STYLE="font-size: 10pt"> under the Sales
Agreement</FONT> with MLV<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Placement Agent
&ndash; </B>During January 2014, in connection with the Common Stock Offering, the Company issued the Placement Agent warrants
to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair
value of the warrants of $0.2 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions:
risk free interest rate &ndash; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><B>Public Offering</B>
- On June 30, 2014, the Company received gross proceeds of $12,525,000. The Company paid an underwriting discount of $876,750,
paid the other offering expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting in net proceeds of $11,451,250
from the public offering of 1,670,000 shares of the Company&rsquo;s common stock, $0.001 par value per share at a price to the
public of $7.50 per share less underwriting discounts. Under the terms of the underwriting agreement, the Company also granted
the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any,
at the offering price.</P>

<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Approval of the Equity Incentive
Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">During the six months
ended June 30, 2013, the Company did not grant any shares of restricted stock. During the six months ended June 30, 2014, the Company
granted 445,167 shares of restricted stock and cancelled 50,000 shares of restricted stock. Of the total shares of
restricted stock, 20,000 shares vest 3 months from the grant date, 22,500 shares vest 1 year from the grant date, 199,167 shares
have a vesting period of 4 years and 200,000 shares vest at date of grant. The remaining restricted shares granted are performance
based and upon the achievement of certain milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in">The following is a summary of stock options
activities for the six months ended June 30, 2014:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom"><TD></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Remaining</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Number </TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Contractual</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Aggregate</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">of</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Units</P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Exercise&nbsp;<BR>
Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Term&nbsp;(in&nbsp;years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Intrinsic</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Value</P></TD></TR>
<TR STYLE="vertical-align: bottom"><TD></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Outstanding, December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,985,384</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8.34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,908,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">979,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,655</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Outstanding, June 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,952,829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,300,565</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Exercisable, June 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">868,287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,418,017</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">During the six months
ended June 30, 2014, the Company granted employees and board members 979,100 options to purchase the Company&rsquo;s common stock
with exercise prices ranging from $5.55 to $11.95 and a term of 10 years and with vesting over a 4-year period. The options have
a fair value of $7.1 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes
option-pricing model include: (1) discount rate of 1.88% - 2.07% (2) expected life of 6 years, (3) expected volatility of 87.06%
to 87.76%, and (4) zero expected dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">During six months ended
June 30, 2014, the Company received gross proceeds of $5,220 for exercise of options for 11,655 shares of the Company&rsquo;s common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">All options issued and
outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2014 was
$10,165,000. During the three months ended June 30, 2014 and 2013, the Company recorded option expense of $607,791 and $94,200,
respectively. During the six months ended June 30, 2014 and 2013, the Company recorded option expense of $889,195 and $188,400,
respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">Following is a summary
of warrant activities for the six months ended June 30, 2014:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Weighted</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Remaining</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Aggregate</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Number of</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Average</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Contractual</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Intrinsic</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Units</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Term&nbsp;(in&nbsp;years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Value</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Outstanding, December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,673,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">47,396,307</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1pt">Exercised</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(662,160</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">1.44</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding, June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,418,058</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">4.54</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">56,362,310</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable, June 30, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">9,195,074</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">4.42</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">56,183,393</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2014, the Company granted warrants to purchase 137,952 shares of the Company&rsquo;s common stock to investors and warrants
to purchase 68,976 shares of the Company&rsquo;s common stock to its placement agent in connection with the 2014 Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2014, the Company also granted consultants warrants to purchase 200,000 shares of the Company&rsquo;s common stock with
exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants vest when certain milestones are
met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2014, 662,160 warrants were exercised by the warrant holders. The Company issued 573,299 shares of common stock and received
gross proceeds of $96,868.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $98,224 and $0, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Note 8 &ndash;
Subsequent Events </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During July 2014,
the Company issued 176,211 shares of restricted stock to warrant holders.</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 7, 2014,
the Company filed a Form S-8 to offer the resale of up to 6,750,000 shares of common stock previously granted under the Equity
Incentive Plan. Pursuant to the Form S-8, the Company issued 61,538 shares to an investor and received proceeds of $48,000.</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 10, 2014,
the Underwriters exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per
share. Including the exercise of the over-allotment option of $1.2 million, gross, Actinium&rsquo;s offering totaled 1,827,123
shares, representing gross proceeds of approximately $13.7 million and approximately $12.5 million net after deducting the underwriting
discount and the other offering expenses.</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 25, 2014,
the Company entered into an agreement with a consultant. According to the agreement, the Company granted and issued 150,000 restricted
shares to a consultant and also made a $250,000 for services to be provided over a six month period.&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_002"></A>ITEM
2. &nbsp;&nbsp;MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FORWARD-LOOKING
STATEMENT NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate&rdquo; or &ldquo;continue&rdquo; or comparable terminology are intended to identify
forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may
differ materially depending on a variety of factors, many of which are not within our control. These factors include but are not
limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry,
including competition from much larger competitors; technological advances and failure to successfully develop business relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description
of Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Actinium is a biotechnology company committed
to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other
related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred
to collectively as &ldquo;Actinium&rdquo;) has initiated collaborative efforts with large institutions to establish the proof of
concept of alpha particle immunotherapy and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial
Sloan-Kettering Cancer Center (&ldquo;MSKCC&rdquo;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center
corporate sponsored trial in acute myeloid leukemia (AML) patients. Actinium&rsquo;s objective, through research and development,
is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other
appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&rsquo;s compounds have
been with patients having acute myeloid leukemia and it is believed that Actinium&rsquo;s APIT platform will have wider applicability
for different types of cancer where suitable monoclonal antibodies can be found.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
were incorporated under the laws of the State of Nevada on October 6, 1997. We were a shell entity that was in the market for
a merger with an appropriate operating company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 28, 2012, we entered into a transaction (the &ldquo;Share Exchange&rdquo;), pursuant to which the Company acquired 21%
of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo;), in exchange for the
issuance of 4,309,015 shares of common stock, par value $0.001 per share, of the Company (the &ldquo;Common Stock&rdquo;), which
were issued to the shareholders of Actinium. As a result of the Share Exchange, the former shareholders of Actinium became the
controlling shareholders of the Company. The Share Exchange was accounted for as a reverse takeover/recapitalization effected
by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. As a result
of the Share Exchange, the Company assumed the business and operations of Actinium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 11, 2013, Actinium Corporation continued its Share Exchange with us, whereby we acquired an additional 36% of the issued
and outstanding capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance
of 7,344,390 shares of Common Stock of us to the Actinium Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 11, 2013, the change of domicile from the State of Nevada to the State of Delaware and the change of Cactus Ventures, Inc.&rsquo;s
name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. became effective in accordance with Articles of Merger filed
with the State of Nevada and a Certificate of Merger filed with the State of Delaware. In connection with the name change we also
changed (i) the name of our subsidiary Actinium Pharmaceuticals, Inc. to Actinium Corporation, (ii) our par value to $0.001 per
share, and (iii) the number of authorized shares of preferred stock to 10 million shares. Effective April 18, 2013 our new trading
symbol became ATNM. On September 25, 2013, we merged with our subsidiary, Actinium Corporation, and we were the surviving entity
of the merger. In January 2014 we increased our authorized shares of common stock to 200 million shares and authorized shares
of preferred stock to 50 million shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 22, 2013, Actinium Corporation continued its Share Exchange with us, whereby we acquired an additional 38.2% of the issued
and outstanding capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance
of 8,009,550 shares of Common Stock of us to the Actinium Shareholders. On September 25, 2013 in accordance with a Certificate
of Ownership Merging Actinium Corporation into us, we merged with Actinium Corporation, and Actinium Corporation ceased to exist.
As a result of the merger, Actinium Corporation stock owned by us has been cancelled and each share of Actinium Corporation not
owned by us was exchanged for 0.333 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
March 26, 2014, we began trading our common stock on the NYSE MKT market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Plan
of Operation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
develop drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients. As of now
none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial operations in sales or
marketing of our products. All our product candidates are under development. In order to market and sell our products we must
conduct clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies like the Food and Drug
Administration (FDA) in the United States and similar agencies elsewhere in the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products under development are monoclonal
antibodies labeled with radioisotopes. We have one program with an antibody labeled with a beta emitter and several programs based
on a proprietary patent protected platform technology called APIT. Our APIT technology is based on attaching actinium 225 (Ac-225)
or bismuth 213 (Bi-213) alpha emitting radioisotopes to monoclonal antibodies. Alpha emitting radioisotopes are unstable chemical
elements that decay by releasing alpha particles. Alpha particles can kill any cell in the immediate proximity of where they are
released. Monoclonal antibodies are genetically engineered proteins that specifically target certain cells, including cancer cells.
It is crucial for the success of our drug candidates to contain monoclonal antibodies that can successfully seek cancer cells
and can kill them with the attached isotope while not harming nearby normal cells. We do not have technology and operational capabilities
to develop and manufacture such monoclonal antibodies and we therefore rely on collaboration with third parties to gain access
to such monoclonal antibodies. We have secured rights to two monoclonal antibodies, HuM195 (Lintuzumab), in 2003 through a collaborative
licensing agreement with Abbott Laboratories and BC8 in 2012 with the Fred Hutchinson Cancer Research Center (&ldquo;FHCRC&rdquo;).
We expect to negotiate collaborative agreements with other potential partners that would provide us with access to additional
monoclonal antibodies. Establishing and maintaining such collaborative agreements is a key to our success as a company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under our own sponsorship as well as
activity at FHCRC, we have four product candidates in active clinical trials: Actimab&trade;-A (HuM195-Ac-225), Iomab&trade;-B
(BC8-I-131), BC8-Y-90 and BC8-SA. At this time, the Company is actively pursuing development of Actimab&trade;-A and Iomab&trade;-B
while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase 1 trials at the FHCRC. Actimab&trade;-A is a combination of
the monoclonal antibody we have in-licensed, Lintuzumab (HuM195), and the alpha emitting isotope actinium 225. Actimab&trade;-A
has shown promising results throughout preclinical development and an ongoing clinical trial started in 2006 in AML in the elderly.
We have expanded the number of patients and number of clinical centers by commencing a new AML clinical trial which we have launched
in 2012. This trial targets newly diagnosed AML patients over the age of 60. In order to conduct the trial we are engaged in funding,
monitoring and quality assurance and control of the Lintuzumab antibody; procurement of actinium 225 isotope; funding, monitoring
and quality assurance and control of the drug candidate Actimab&trade;-A manufacturing and organizing and monitoring clinical trials.
We estimate that the direct costs to completion of both parts of the ongoing Phase 1/2 trial will be approximately $7 million.
Iomab&trade;-B is a combination of the in-licensed monoclonal antibody BC8 and the beta emitting radioisotope iodine 131. This
construct has been extensively tested in Phase I and Phase 2 clinical trials in approximately 250 patients with different blood
cancer indications who were in need of a hematopoietic stem cell transplantation (HSCT). Iomab&trade;-B is used to condition the
bone marrow of these patients by destroying blood cancer cells in their bone marrow and elsewhere thus allowing for a subsequent
transplant containing healthy donor bone marrow stem cells. We have decided to develop this drug candidate by initially focusing
on the patients over 50 with active acute myeloid leukemia in relapse and/or refractory to existing treatments. Our intention is
to request the FDA in 2014 to allow us to enter into a pivotal trial with Iomab&trade;-B. We estimate the direct costs of such
a trial to completion anticipated in 2016 will be approximately $25-30 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have primarily management position employees
and consultants who direct, organize and monitor the activities described above through contractors. Much of the<I> in vivo</I>
laboratory and clinical work contracted for by the Company has been conducted at MSKCC in New York. We also made clinical trial
arrangements with other well-known cancer centers. Our Actimab&trade;-A drug candidate and its components are contract manufactured
and maintained under our supervision by specialized contract manufacturers and suppliers in the United States, including IsoTex
Diagnostics, Oak Ridge National Laboratory, Pacific GMP, Fischer Bioservices, BioReliance and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a development stage company and have
never generated revenue. Currently we do not have a stable recurring source of revenues sufficient to cover our operating costs.
As of June 30, 2014, we had an accumulated deficit of $79.7 million. We incurred net income for the three months ended June 30,
2014 of approximately $3.5 million compared to a net loss of $2.8 million for the three months ended June 30, 2013. We incurred
net losses of $13.2 million and $3.5 million for the six months ended June 30, 2014 and 2013, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Opportunities,
Challenges and Risks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The market for drugs for cancer treatment
is a large market in need of novel products, in which successful products can command multibillion dollars in annual sales. A number
of large pharmaceutical and biotechnology company regularly acquire products in development, with preference given to products
in Phase 2 or later clinical trials. These deals are typically structured to include an upfront payment that ranges from several
million dollars to tens of million dollars or more and additional milestone payments tied to regulatory submissions and approvals
and sales milestones. Our goal is to develop our product candidates through Phase 2 clinical trials and enter into partnership
agreements with one or more large pharmaceutical and/or biotechnology companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe our future success will be
heavily dependent upon our ability to successfully conduct clinical trials and preclinical development of our drug candidates.
This will in turn depend on our ability to continue our collaboration with MSKCC and our Clinical Advisory Board members. In addition,
we plan to continue and expand other research and clinical trial collaborations. Moreover, we will have to maintain sufficient
supply of actinium 225 and successfully maintain and if and when needed replenish or obtain our reserves of monoclonal antibodies.
We will have to maintain and improve manufacturing procedures we have developed for production of our drug candidates from the
components that include the iodine 131 and actinium 225 isotopes, monoclonal antibodies and other materials. It is possible that
despite our best efforts our clinical trials results may not meet regulatory requirements for approval. If our efforts are successful,
we will be able to partner our development stage products on commercially favorable terms only if they enjoy appropriate patent
coverage and/or considerable know-how and other protection that ensures market exclusivity. For that reason we intend to continue
our efforts to maintain existing and generate new intellectual property. Intellectual property is a key factor in the success of
our business as well as market exclusivity.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
achieve the goals discussed above we intend to continue to invest in research and development at high and constantly increasing
rates thus incurring further losses until one or more of our products are sufficiently developed to partner them to large pharmaceutical
and biotechnology companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results
of Operations &ndash; Three Months Ended June 30, 2014 Compared to the Three Months Ended June 30, 2013</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended <BR> June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Revenues</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Research and development, net of reimbursements</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">2,001,937</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">509,262</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">General and administrative</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2,414,627</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">966,367</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Depreciation expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,052</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">4,424,616</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,475,629</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Interest expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(634</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Gain (loss) on change in fair value of derivative liabilities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">7,939,711</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,307,748</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other income (expense)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">7,939,711</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,308,382</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,515,095</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(2,784,011</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
recorded no commercial revenues for the three months ended June 30, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses increased
by approximately $1.5 million to approximately $2.0 million for the three months ended June 30, 2014 compared to approximately
$0.5 million for the three months ended June 30, 2013. The increase is primarily attributable to the manufacturing of BC8, the
antibody that is the key component of Iomab-B in-licensed by the Company in 2012 and the costs related to continuing the multi-center
clinical trial for Actimab&trade;-A which commenced in the third quarter of 2012. The increased expenses also reflect development
work on significantly improving the efficacy and cost structure of the Actimab&trade;-A manufacturing and costs related to Iomab-B&rsquo;s
clinical development and regulatory submissions. We expect to incur increased research and development costs in the future.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Overall,
total general and administrative expenses increased by approximately $1.4 million to $2.4 million for the three months ended June
30, 2014 compared to approximately $1.0 million for the three months ended June 30, 2013. The increase was largely attributable
to increases in professional fees, staffing, and the stock-based compensation incurred by the Company as discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
increase can also be attributed to additional professional fees associated with the Company listing its common stock on the NYSE
MKT. In addition to the professional fees incurred, we increased our personnel. As such, payroll-related expenses for the three
months ended June 30, 2014 increased compared to the same period in 2013. We expect to incur increased general and administrative
costs in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other
Income (Expense)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Other income
was approximately $7.9 million for the three months ended June 30, 2014 compared to other expense of $1.3 million for the three
months ended June 30, 2013.</FONT> <FONT STYLE="font-size: 10pt">The Company recorded a gain on the change in fair value of the
Company&rsquo;s embedded derivative liability in the approximate amount $7.9 million during the three months ended June 30, 2014
as compared to a loss of approximately $1.3 million during the comparable three-month period ended June 30, 2013. The change is
mainly attributable to the fluctuation of the Company&rsquo;s stock price.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net
Income (Loss)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
income increased by approximately $6.3 million to approximately $3.5 million for the three months ended June 30, 2014 compared
to a net loss of approximately $2.8 million for the three months ended June 30, 2013. The increase was primarily due to an increase
in the gain from change in fair value of the derivative liability, offset by additional costs incurred by the Company in research
and development expenses, non-cash stock-based compensation costs and professional fees as discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results
of Operations &ndash; Six Months Ended June 30, 2014 Compared to the Six Months Ended June 30 2013</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended <BR> June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Revenues</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Research and development, net of reimbursements</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">4,462,905</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">1,594,968</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">General and administrative</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,090,680</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,899,503</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Depreciation expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">9,457</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Loss on disposition of equipment</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">4,122</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,563,042</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">3,498,593</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Interest expense</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(1,209</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Gain (loss) on change in fair value of derivative liabilities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(4,621,360</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">26,764</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other income (expense)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(4,621,360</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">25,555</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(13,184,402</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(3,473,038</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
recorded no commercial revenues for the six months ended June 30, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development expenses increased by approximately $2.9 million to approximately $4.5 million for the six months ended June 30,
2014 compared to approximately $1.6 million for the six months ended June 30, 2013. The increase is primarily attributable to
the manufacturing of BC8, the antibody that is the key component of Iomab-B in-licensed by the Company in 2012 and the costs related
to continuing the multi-center clinical trial for Actimab&trade;-A which commenced in the third quarter of 2012. The increased
expenses also reflect development work on significantly improving the efficacy and cost structure of the Actimab&trade;-A manufacturing
and costs related to Iomab-B&rsquo;s clinical development and regulatory submissions. We expect to incur increased research and
development costs in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Overall,
total general and administrative expenses increased by approximately $2.2 million to $4.1 million for the six months ended June
30, 2014 compared to approximately $1.9 million for the six months ended June 30, 2013. The increase was largely attributable
to increases in professional fees, staffing, and the stock-based compensation incurred by the Company as discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
increase can also be attributed to additional professional fees associated with the Company listing its common stock on the NYSE
MKT. In addition to the professional fees incurred, we increased our personnel. As such, payroll-related expenses for the six
months ended June 30, 2014 increased compared to the same period in 2013. We expect to incur increased general and administrative
costs in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other
Income (Expense)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Other expense
was $4.6 million for the six months ended June 30, 2014 compared to other income of $25,555 for the six months ended June 30,
2013.</FONT> <FONT STYLE="font-size: 10pt">The Company recorded a loss on the change in fair value of the Company&rsquo;s embedded
derivative liability in the approximate amount $4.6 million during the six months ended June 30, 2014 as compared to a gain of
approximately $27,000 during the comparable six month period ended June 30, 2013. The change is mainly attributable to the fluctuation
of the Company&rsquo;s stock price</FONT>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net
Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
loss increased by approximately $9.7 million to approximately $13.2 million for the six months ended June 30, 2014 compared to
approximately $3.5 million for the six months ended June 30, 2013. The increase was primarily due to an increase in the loss from
change in fair value of the derivative liability, in conjunction with additional costs incurred by the Company in research and
development expenses, non-cash stock-based compensation costs and professional fees as discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have financed our operations primarily through
sales of the Company&rsquo;s stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
did not have any cash or cash equivalents held in financial institutions located outside of the United States as of June 30, 2014
and December 31, 2013. We do not anticipate this practice will change in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following tables sets forth selected cash flow information for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0">For the six months ended <BR>June 30,</TD><TD STYLE="padding: 0; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0">2014</TD><TD STYLE="padding: 0; font-weight: bold; text-indent: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0">2013</TD><TD STYLE="padding: 0; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding: 0; text-indent: 0">Cash used in operating activities</TD><TD STYLE="width: 1%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0">(5,062,072</TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0">)</TD><TD STYLE="width: 1%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0">(3,327,820</TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Cash used in investing activities</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: right; padding: 0; text-indent: 0">(128,439</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">)</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: right; padding: 0; text-indent: 0">(1,112</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Cash provided by financing activities</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-align: right; text-indent: 0">14,327,958</TD><TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-align: right; text-indent: 0">3,360,591</TD><TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Net change in cash</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding: 0; text-align: left; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; padding: 0; text-align: right; text-indent: 0">9,137,447</TD><TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding: 0; text-align: left; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; padding: 0; text-align: right; text-indent: 0">31,659</TD><TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities was approximately $5.1 million for the six months ended June 30, 2014 compared to approximately
$3.3 million used in operations for the same period in 2013. Cash used in operations increased due to the increase in spending
related to preparations and eventual launch and conduct of a multicenter clinical trial and an increase in spending related to
professional fees combined with an increase in payroll-related expenses. A significant increase in stock-based compensation as
well as the loss on the change in fair value of the derivative liabilities accounted for the increase in cash used in operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash provided by financing activities were approximately $14.3 million and approximately $3.4 million for the six months ended
June 30, 2014 and 2013, respectively. During the six months ended June 30, 2014, the Company issued common stock and received
net proceeds of approximately $14.3 million compared to approximately $3.5 million received during the six months ended June 30,
2013 from the exercise of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have experienced cumulative losses of approximately $79.7 million from inception (June 13, 2000) through June 30, 2014, and have
stockholders' equity of $4.3 million at June 30, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt 0 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Equity Offerings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2013, we completed the sale of units pursuant the Unit Purchase Agreement, dated December 27, 2013 (the &ldquo;December
Purchase Agreement&rdquo;), and Subscription Agreement, dated December 27, 2013 (the &ldquo;December Subscription Agreement&rdquo;),
among the Company and certain accredited investors. The securities sold in the offering consisted of an aggregate of (i) 554,310
shares of its common stock, and (ii) warrants to purchase 138,577 shares of its Common Stock at an in exercise price of $9.00
per share, subject to adjustment (&ldquo;2013 Common Stock Offering&rdquo;). The warrants are exercisable for a period of five
years from the date of issuance. The Company received gross proceeds of approximately $3.3 million from the sale of securities
under the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2014, we conducted the final
closing (the &ldquo;Final Closing&rdquo;) of its private placement of securities (the &ldquo;Offering&rdquo;) pursuant to a Unit
Purchase Agreement, dated as of January 10, 2014 (the &ldquo;January Purchase Agreement&rdquo;) and Subscription Agreement, dated
as of January 10, 2014 (the &ldquo;January Subscription Agreement&rdquo;), with certain accredited investors named therein (the
&ldquo;Investors&rdquo;) pursuant to which: the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares
( the &ldquo;Shares&rdquo;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952
shares of common stock at an exercise price of $9.00 per share (the &ldquo;Warrants&rdquo;). We received $3,310,860 in gross proceeds
from the sale of securities under the January Purchase Agreement at the Final Closing, bringing the total gross proceeds received
by the Company in the Offering to $6,636,720. The aggregate offering amount of securities sold to investors was increased from
$6,000,000 to $6,636,720 in order to cover over-allotments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 24, 2014, we filed a shelf registration
statement on Form S-3 (the &ldquo;Registration Statement&rdquo;) and deemed effective on April 17, 2014. This Registration Statement
contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000
of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance
and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under
a sales agreement (the &ldquo;Sales Agreement&rdquo;) with MLV &amp; Co. LLC (&ldquo;MLV&rdquo;). For the six months ended June
30, 2014, the Company issued 500 shares under this agreement totaling approximately $6,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sales
of the our common stock through MLV, if any, will be made on the NYSE MKT LLC, on any other existing trading market for the common
stock or to or through a market maker. Subject to the terms and conditions of the Sales Agreement, MLV will use commercially reasonable
efforts to sell our common stock from time to time, based upon our instructions (including any price, time or size limits or other
customary parameters or conditions we may impose). We will pay to MLV in cash, upon the sale of common stock pursuant to the Sales
Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. We have also provided MLV with customary
indemnification rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2014, the Company received
gross proceeds of approximately $12.5 million. The Company paid an underwriting discount of $0.9 million, paid the other offering
expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting in net proceeds of approximately $11.9 million from
the public offering of 1,670,000 shares of the Company&rsquo;s common stock, $0.001 par value per share at a price to the public
of $7.50 per share less underwriting discounts. Under the terms of the underwriting agreement, the Company granted the Underwriters
a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering
price. On July 10, 2014, the Underwriters exercised their over-allotment and purchased an additional 157,123 shares of the Company&rsquo;s
common stock for gross proceeds of approximately $1.2 million.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Seasonality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not have a seasonal business cycle. Our revenues and operating results are generally derived evenly throughout the calendar
year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
financial statements have been prepared in accordance with accounting principles generally accepted in the United States. To prepare
these consolidated financial statements, we must make estimates and assumptions that affect the reported amounts of assets and
liabilities. These estimates also affect our expenses. Judgments must also be made about the disclosure of contingent liabilities.
Actual results could be significantly different from these estimates. We believe that the following discussion addresses the accounting
policies that are necessary to understand and evaluate our reported financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Derivatives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
derivatives are recorded at fair value and recorded on the balance sheet. Fair values for securities traded in the open market
and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using
market based pricing models incorporating readily observable market data and requiring judgment and estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fair
Value of Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority
to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair
value hierarchy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
&nbsp;&nbsp;&nbsp;&nbsp;Level 1 Inputs &ndash; Unadjusted quoted prices in active markets for identical assets or liabilities
that the reporting entity has the ability to access at the measurement date.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
&nbsp;&nbsp;&nbsp;&nbsp;Level 2 Inputs &ndash; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either
directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable
for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived
principally from or corroborated by market data by correlation or other means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
&nbsp;&nbsp;&nbsp;&nbsp;Level 3 Inputs &ndash; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own
assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities
are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and
are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset
will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&rsquo;s
assessment as to their realization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company
as a reduction of research and development costs.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt 0 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Share-Based
Payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model
and common shares based on the last common stock valuation done by third party valuation expert of the Company&rsquo;s common
stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting
period during which an employee is required to provide service in exchange for the award. As share-based compensation expense
is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on
historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for
the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">In May 2014, the Financial
Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this
Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605,
Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification.
In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&mdash;Construction-Type and Production-Type
Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&mdash;Contracts with Customers. In summary, the core
principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in
an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This
Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230&mdash;Revenue Recognition (Topic
605) and Proposed Accounting Standards Update 2011&ndash;250&mdash;Revenue Recognition (Topic 605): Codification Amendments, both
of which have been deleted. Accounting Standards Update 2014-09. The amendments in this Update are effective for the Company for
annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company
is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, the Financial Accounting Standards
Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition
of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting
entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date
information on the statements of income, cash flows, and shareholder&rsquo;s equity, (2) label the financial statements as those
of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and
(4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the
development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities
that have not commenced planned principal operations.&nbsp; Finally, the amendments also remove paragraph 810-10-15-16, which states
that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE)
if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities
it is currently engaged in and (2) the entity&rsquo;s governing documents and contractual arrangements allow additional equity
investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10,
Consolidation&mdash;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the
guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. This
Accounting Standards Update is the final version of Proposed Accounting Standards Update 2013-320&mdash;Development Stage Entities
(Topic 915), which has been deleted. The amendments in this Update are effective for annual reporting periods beginning after December
15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 for the reporting
period ended April 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">In June 2014, the Financial
Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this
update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that
a performance target can be achieved after the requisite service period. This Accounting Standards Update is the final version
of Proposed Accounting Standards Update EITF-13D--Compensation--Stock Compensation (Topic 718): Accounting for Share-Based Payments
When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been
deleted. The proposed amendments would apply to reporting entities that grant their employees share-based payments in which the
terms of the award provide that a performance target could be achieved after the requisite service period. This Accounting Standards
Update is the final version of Proposed Accounting Standards Update EITF-13D&mdash;Compensation&mdash;Stock Compensation (Topic
718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after
the Requisite Service Period, which has been deleted. The amendments in this Update are effective for annual periods and interim
periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently
evaluating the effects of ASU 2014-12 on the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">The Company does not expect
that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position,
or cash flows of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_003"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
3. &nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
required by smaller reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
4. &nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Evaluation of Disclosure Controls and Procedures.</I>
We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive
officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &lsquo;&lsquo;Exchange Act&rsquo;&rsquo;).
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to
the issuer&rsquo;s management, including its principal executive and principal financial officers, or persons performing similar
functions, as appropriate to allow timely decisions regarding required disclosure. During the second quarter of 2014, we hired
outside consultants to draft and test our internal control policies. Based on our evaluation, our principal executive officer and
principal financial officer concluded that our disclosure controls and procedures are effective as of June 30, 2014, in ensuring
that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Changes in Internal Control over
Financial Reporting</I>. During the period covered by this report, the Company has adopted its initial internal control procedures
and guidelines, and has retained the services of outside consultants to assist in our internal control over financial reporting.
We believe the foregoing modifications have and will continue to materially and positively affect our internal control over financial
reporting.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_005"></A>PART
II &ndash; OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_006"></A>ITEM
1A.&nbsp;&nbsp;RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
Applicable to a smaller reporting company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_007"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
2. &nbsp;&nbsp;&nbsp;&nbsp;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 13, 2014 the Company issued 150,000
shares of common stock having a fair value of $1,237,500 ($10.88 per share) in exchange for consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 11, 2014 the Company issued 12,500
shares of common stock having a fair value of $104,375 ($11.60 per share) in exchange for consulting services.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Company
determined that the securities described above were issued in transactions that were exempt from the registration under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant to Section 4(a)(2) thereunder. This determination was based
on the non-public manner in which we offered the securities and on the representations of the recipients of the securities, which
included, in pertinent part, that they were &ldquo;accredited investors&rdquo; within the meaning of Rule 501 of Regulation D
promulgated under the Securities Act, that they were acquiring such securities for investment purposes for their own account and
not with a view toward resale or distribution, and that they understood such securities may not be sold or otherwise disposed
of without registration under the Securities Act or an applicable exemption therefrom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_008"></A>ITEM
3. &nbsp;&nbsp;&nbsp;&nbsp;DEFAULTS UPON SENIOR SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_009"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
4. &nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_010"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
5. &nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0.6in; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.6in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.6in"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 11, 2014, the Company amended and restated its bylaws (the &ldquo;Amended Bylaws&rdquo;) and appointed Sandesh Seth as Executive
Chairman. Article V (Officers) of the Company&rsquo;s bylaws were amended to add the role of Executive Chairman as an officer of
the Company.</FONT>&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.6in"></P>



<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.6in">A copy of the Amended
Bylaws have been included as Exhibit 3.1 to this report on Form 10-Q.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_011"></A>ITEM
6. &nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Copies
of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 10%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 76%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title
    of Document</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 12%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Location</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated
    Bylaws of Actinium Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification
    of the Principal Executive Officer and Principal Financial and Accounting Officer pursuant to Section 302 of the
    Sarbanes-Oxley Act of 2002</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification
    of the Principal Executive Officer and Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to
    Section 906 of the Sarbanes-Oxley Act of 2002*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X&nbsp;&nbsp;XBRL
    Instance Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X&nbsp;&nbsp;XBRL
    Taxonomy Extension Schema Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X&nbsp;&nbsp;XBRL
    Taxonomy Calculation Linkbase Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X&nbsp;&nbsp;XBRL
    Taxonomy Extension Definition Linkbase Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X&nbsp;&nbsp;XBRL
    Taxonomy Label Linkbase Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X&nbsp;&nbsp;XBRL
    Taxonomy Presentation Linkbase Document</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attached</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*
The Exhibit attached to this Form 10-Q shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange
Act of 1934 (the &quot;Exchange Act&quot;) or otherwise subject to liability under that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_012"></A><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.6in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 37%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 12,
    2014</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Kaushik J. Dave</I></FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Kaushik
    J. Dave</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President
                                         and Chief Executive Officer, and Interim Chief Financial Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Duly
        Authorized Officer,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
        Executive Officer and</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial and Accounting Officer)</FONT></P></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">30</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.7pt; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>f10q0614ex3i_actinium.htm
<DESCRIPTION>BY LAWS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDED AND RESTATED BYLAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE I&mdash;OFFICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 1.1&nbsp;&nbsp;Office</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The address of the registered office of Actinium
Pharmaceuticals, Inc. (hereinafter called the <B>&ldquo;Corporation&rdquo;</B>) in the State of Delaware shall be located at either
(i) the principal place of business of the Corporation in the State of Delaware or (ii) the office of the corporation or individual
acting as the Company&rsquo;s registered agent in Delaware.&nbsp;&nbsp;The Corporation may have other offices, both within and
without the State of Delaware, as the board of directors of the Corporation (the <B>&ldquo;Board of Directors&rdquo;</B>) from
time to time shall determine or the business of the Corporation may require. &nbsp;The registered office may be changed by resolution
of the Board of Directors to another location within the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 1.2&nbsp;&nbsp;Books and Records&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any records maintained by the Corporation in
the regular course of its business, including its stock ledger, books of account and minute books, may be maintained on any information
storage device or method; <I>provided that</I> the records so kept can be converted into clearly legible paper form within a reasonable
time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant
to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE II&mdash;STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.1&nbsp;&nbsp;Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An annual meeting of the stockholders, for
the selection of directors to succeed those whose terms expire and for the transaction of such other business as may properly come
before the meeting, shall be held at a location, either within or without the State of Delaware, and at such time each year as
designated by the Board of Directors.&nbsp;&nbsp;The Board of Directors may, in its sole discretion, determine that the meeting
shall not be held at any place, but may instead be held solely by means of remote communication.&nbsp;&nbsp;The Board of Directors
may adopt guidelines and procedures governing the participation of stockholders and proxy holders not physically present at a meeting
of stockholders by means of remote communication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.2&nbsp;&nbsp;Special Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Special meetings of the stockholders, for any
purpose or purposes prescribed in the notice of the meeting, may be called by the chairman, the Board of Directors, the president,
the chief executive officer, or the holders of not less than one-tenth of all the shares entitled to vote at the meeting, and shall
be held at such place, either within or without the State of Delaware, on such date, and at such time as they or he shall fix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.3&nbsp;&nbsp;Notice of Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Written notice of the place, date and time
of all meetings of the stockholders shall be given, not less than ten (10) nor more than sixty (60) days before the date on which
the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise provided herein or required
by law (meaning, here and hereinafter, as required from time to time by the laws of the State of Delaware or the Certificate of
Incorporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When a meeting is adjourned to another place,
date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the
meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty (30)
days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written
notice of the place, date, and time of the adjourned meeting shall be given in conformity herewith.&nbsp;&nbsp;At any adjourned
meeting, any business may be transacted which might have been transacted at the original meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.4&nbsp;&nbsp;Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise required by law, the Corporation&rsquo;s
Certificate of Incorporation (the <B>&ldquo;Certificate of Incorporation&rdquo;</B>) or these by-laws, at each meeting of the stockholders,
a majority in voting power of the shares of the Corporation entitled to vote at the meeting, present in person or represented by
proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a quorum shall fail to attend any meeting,
the chairman of the meeting or the holders of a majority of the shares of the stock entitled to vote who are present, in person
or by proxy, may adjourn the meeting to another place, date or time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a quorum shall fail to attend any meeting,
the presiding officer may adjourn the meeting to another place, date, or time.&nbsp; When a meeting is adjourned to another place,
date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the
meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty (30)
days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written
notice of the place, date, and time of the adjourned meeting shall be given in conformity herewith.&nbsp;&nbsp;At any adjourned
meeting, any business may be transacted that could have been transacted at the original meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.5&nbsp;&nbsp;Organization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the persons designated in these Bylaws to
conduct meetings of the stockholders are unavailable, the Board of Directors may designate the person to call to order any meeting
of the stockholders and act as chairman of the meeting.&nbsp;&nbsp;In the absence of the secretary of the Corporation, the secretary
of the meeting shall be such person as the chairman appoints.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.6&nbsp;&nbsp;Conduct of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The chairman of any meeting of stockholders
shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the
conduct of discussion as seem to him in order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.7&nbsp;&nbsp;Proxies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each stockholder shall have one vote for each
share of stock entitled to vote held of record by such stockholder unless otherwise provided by law or the Certificate of Incorporation.&nbsp;&nbsp;Each
stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action in writing
without a meeting, may vote or express such consent or dissent in person or may authorize another person or persons to vote or
act for the stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law, delivered in accordance
with the procedure established for the meeting.&nbsp;&nbsp;No such proxy shall be voted or acted upon after three (3) years from
the date of its execution, unless the proxy expressly provides for a longer period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All voting, except on the election of directors
and where otherwise required by law, may be by a voice vote; provided, however, that upon demand therefor by a stockholder entitled
to vote or his proxy, a stock vote shall be taken.&nbsp;&nbsp;Every stock vote shall be taken by ballots, each of which shall state
the name of the stockholder or proxy voting and such other information as may be required under the procedure established for the
meeting.&nbsp;&nbsp;Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a quorum is present, the affirmative vote
of the majority of the shares represented at the meeting and entitled to vote on the subject matter shall be the act of the stockholders,
unless the vote of a greater number or voting by class is required by law, the Certificate of Incorporation, or these Bylaws.&nbsp;&nbsp;Directors
shall be elected by a plurality of the votes cast at the election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.8&nbsp;&nbsp;Stock List</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A complete list of stockholders entitled to
vote at any meeting of stockholders, arranged in alphabetical order for each class of stock and showing the address of each such
stockholder and the number of shares registered in his name, shall be open to the examination of any such stockholder, for any
purpose germane to the meeting, during ordinary business hours for a period of at least ten (10) days prior to the meeting, either
at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or if
not so specified, at the place where the meeting is to be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock list shall also be kept at the place
of the meeting during the whole time thereof and shall be open to the examination of any such stockholder who is present.&nbsp;&nbsp;This
list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held
by each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 2.9&nbsp;&nbsp;Action by Written
Consent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any action, except the election of directors,
which may be taken by the vote of the stockholders at a meeting, may be taken without a meeting if authorized by the written consent
of stockholders holding at least a majority of the voting power; provided:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 45pt; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
if any greater proportion of voting power is required for such action at a meeting, then such greater proportion of written consents
shall be required; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 45pt; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That this general provision shall not
supersede any specific provision for action by written consent required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE III&mdash;BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.1&nbsp;&nbsp;Number; Term of Office;
Resignation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The number of directors who shall constitute
the whole board shall be such number not less than one (1) not more than nine (9) as the Board of Directors shall at the time have
designated.&nbsp;&nbsp;Each director shall be selected for a term of one (1) year and until his successor is elected and qualified,
except as otherwise provided herein, the Corporation&rsquo;s Certificate of Incorporation or required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Whenever the authorized number of directors
is increased between annual meetings of the stockholders, a majority of the directors then in office shall have the power to elect
such new directors for the balance of a term and until their successors are elected and qualified.&nbsp;&nbsp;Any decrease in the
authorized number of directors shall not become effective until the expiration of the term of the directors then in office unless,
at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The resignation of a director shall be in writing
or by electronic transmission and shall be effective the later of the time designated in the resignation or when:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hand-delivered
to the president, secretary, or chairman of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Received
when sent by facsimile at the published facsimile number of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Received
when scanned and sent by email at the published email address of the Corporation, its president, secretary, or chairman;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
next business day after same has been deposited with a national overnight delivery service, shipping prepaid, addressed to the
published address of the principal executive offices of the Corporation, the president, the secretary or the chairman of the Corporation,
with next-business day delivery guaranteed, provided that the sending party receives a confirmation of delivery from the delivery
service provider; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Three
business days after mailing if mailed postage prepaid from within the continental United States by registered or certified mail,
return receipt requested, addressed to the published address of the principal executive offices of the Corporation, the president,
the secretary or the chairman of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.2&nbsp;&nbsp;Vacancies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise restricted by the Certificate
of Incorporation, if the office of any director becomes vacant by reason of death, resignation, disqualification, removal or other
cause, a majority of the directors remaining in office, although less than a quorum, may elect a successor for the unexpired term
and until his successor is elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.3&nbsp;&nbsp;Regular Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regular meetings of the Board of Directors
shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board
of Directors and publicized among all directors.&nbsp;&nbsp;A notice of each regular meeting shall not be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.4&nbsp;&nbsp;Special Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Special meetings of the Board of Directors
(i) may be called by the chairman of the board or chief executive officer and (ii) may be called by the chief executive officer
or secretary on the written request of two directors or the sole director, as the case may be, and shall be held at such place,
on such date and at such time as they or he shall fix.&nbsp;&nbsp;Notice of the place, date and time of each such special meeting
shall be given by each director by whom it is not waived by mailing written notice not less than three (3) days before the meeting
or by electronic transmission not less than eighteen (18) hours before the meeting.&nbsp;&nbsp;Unless otherwise indicated in the
notice thereof, any and all business may be transacted at a special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.5&nbsp;&nbsp;Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At any meeting of the Board of Directors, a
majority of the total number of the whole board shall constitute a quorum for all purposes.&nbsp;&nbsp;If a quorum shall fail to
attend any meeting, a majority of those present may adjourn the meeting to another place, date or time, without further notice
or waiver thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.6&nbsp;&nbsp;Participation in
Meetings by Conference Telephone</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Members of the Board of Directors or of any
committee thereof, may participate in a meeting of such board or committee by means of conference telephone or similar communications
equipment that enables all persons participating in the meeting to hear each other.&nbsp;&nbsp;Such participation shall constitute
presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.7&nbsp;&nbsp;Conduct of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At any meeting of the Board of Directors, business
shall be transacted in such order and manner as the board may from time to time determine, and all matters shall be determined
by the vote of a majority of the directors present, except as otherwise provided herein or required by law.&nbsp;&nbsp;Action may
be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission
and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board
of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.8&nbsp;&nbsp;Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors may, except as otherwise
required by law, exercise all such powers and do all such acts and things as may be exercised or done by the Corporation, including,
without limiting the generality of the foregoing, the unqualified power:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
declare dividends from time to time in accordance with law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
purchase or otherwise acquire any property, rights or privileges on such terms as it shall determine;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
authorize the creation, making and issuance, in such form as it may determine, of written obligations of every kind, negotiable
or non-negotiable, secured or unsecured, and to do all things necessary in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
remove any officer of the Corporation with or without cause, and from time to time to devolve the powers and duties of any officer
upon any other person for the time being;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
confer upon any officer of the Corporation the power to appoint, remove and suspend subordinate officers and agents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;To adopt from time to time such stock option, stock purchase, bonus or other compensation plans for directors,
officers and agents of the Corporation and its subsidiaries as it may determine;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
adopt from time to time such insurance, retirement and other benefit plans for directors, officers and agents of the Corporation
and its subsidiaries as it may determine; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To adopt from
time to time regulations, not inconsistent with these Bylaws, for the management of the Corporation&rsquo;s business and affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.9&nbsp;&nbsp;Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Directors, as such, may receive, pursuant to
resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation,
their services as members of committees of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.10&nbsp;&nbsp;Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation shall not, either directly
or indirectly, including through any subsidiary, extend or maintain credit, arrange for the extension of credit, or renew an extension
of credit, in the form of a personal loan to or for any director, executive officer (or equivalent thereof), or control person,
but may lend money to and use its credit to assist any employee, excluding such executive officers, directors or other control
persons of the Corporation or of a subsidiary, if such loan or assistance benefits the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 3.11&nbsp;&nbsp;Consent In Lieu
of Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise restricted by the Certificate
of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or any
committee thereof may be taken without a meeting if a written consent shall be signed by all members of the Board of Directors
or committee and the writing or writings are filed with the minutes or proceedings of the Board of Directors or committee,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE IV&mdash;COMMITTEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 4.1&nbsp;&nbsp;Committees of the
Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors, by a vote of a majority
of the whole board, may from time to time designate committees of the board, with such lawfully delegable powers and duties as
it thereby confers, to serve at the pleasure of the board and shall, for those committees and any other provided for herein, elect
a director or directors to serve as the member or members, designating, if it desires, other directors as alternative members who
may replace any absent or disqualified member at any meeting of the committee.&nbsp;&nbsp;Any committee so designated may exercise
the power and authority of the Board of Directors to declare a dividend or to authorize the issuance of stock if the resolution
which designates the committee or a supplemental resolution of the Board of Directors shall so provide.&nbsp;&nbsp;In the absence
or disqualification of any member of any committee and any alternate member in his place, the member or members of the committee
present at the meeting and not disqualified from voting, whether or not he or they constitute a quorum, may by unanimous vote appoint
another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 4.2&nbsp;&nbsp;Conduct of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each committee may determine the procedural
rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required
by law.&nbsp;&nbsp;Adequate provision shall be made for notice to members of all meetings; a majority of the members shall constitute
a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all
matters shall be determined by a majority vote of the members present.&nbsp;&nbsp;Action may be taken by any committee without
a meeting if all members thereof consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings
of such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE V&mdash;OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.1&nbsp;&nbsp;Generally; Term;
Resignation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The officers of the Corporation shall consist
of a president, one or more vice-presidents, a secretary, a treasurer and such other subordinate officers as may from time to time
be appointed by the Board of Directors. The Corporation may also have a chairman of the board who shall be elected by the Board
of Directors and who shall be an officer of the Corporation. Officers shall be elected by the Board of Directors, which shall consider
that subject at its first meeting after every annual meeting of stockholders. Each officer shall hold his office until his successor
is elected and qualified or until his earlier resignation or removal. Any number of offices may be held by the same person. The
resignation of an officer shall be in writing and shall be effective the later of the time designated in the resignation or as
provided in Section 3.1 above; provided that the resignation of the president shall be made to a vice-president or any other designated
party, except the president.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.2 Chairman of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The chairman of the board (who may also be
designated as Executive Chairman if serving as an employee or consultant of the Corporation) shall, subject to the direction of
the Board of Directors, perform such executive, supervisory, and management functions and duties as may be assigned to him from
time to time by the Board of Directors. He shall, if present, preside at all meetings of the stockholders and of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.3&nbsp;&nbsp;President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise designated by the Board of
Directors, the president shall be the chief executive officer of the Corporation. Subject to the provisions of these Bylaws and
to the direction of the Board of Directors, he shall have the responsibility for the general management and control of the affairs
and business of the Corporation and shall perform all duties and have all powers which are commonly incident to the office of chief
executive or which are delegated to him by the Board of Directors. He shall have power to sign all stock certificates, contracts
and other instruments of the Corporation which are authorized. He shall have general supervision and direction of all of the other
officers and agents of the Corporation. He shall, when present, and in the absence of a chairman of the Board of Directors, preside
at all meetings of the stockholders and of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.4&nbsp;&nbsp;Vice-President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each vice-president shall perform such duties
as the Board of Directors shall prescribe.&nbsp;&nbsp;In the absence or disability of the President, the vice-president who has
served in such capacity for the longest time shall perform the duties and exercise the powers of the president.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.5&nbsp;&nbsp;Treasurer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The treasurer shall have the custody of the
monies and securities of the Corporation and shall keep regular books of account.&nbsp;&nbsp;He shall make such disbursements of
the funds of the Corporation as are proper and shall render from time to time an account of all such transactions and of the financial
condition of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.6&nbsp;&nbsp;Secretary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The secretary shall issue all authorized notices
from, and shall keep minutes of, all meetings of the stockholders and the Board of Directors.&nbsp;&nbsp;He shall have charge of
the corporate books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.7&nbsp;&nbsp;Delegation of Authority</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors may, from time to time,
delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.8&nbsp;&nbsp;Removal</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any officer of the Corporation may be removed
at any time, with or without cause, by the Board of Directors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Section 5.9&nbsp;&nbsp;Action with Respect
to Securities of Other Corporation</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise directed by the Board of Directors,
the chief executive officer shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at
any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this corporation
may hold securities and otherwise to exercise any and all rights and powers which this corporation may possess by reason of its
ownership of securities in such other corporation.&nbsp;&nbsp;The chief executive officer may delegate the foregoing rights to
another executive officer of the Corporation.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
VI&mdash;INDEMNIFICATION OF DIRECTORS AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.1&nbsp;&nbsp;Generally</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Corporation shall indemnify its officers and directors to the fullest extent permitted under Delaware law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.2&nbsp;&nbsp;Expenses</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expenses
(including attorneys&rsquo; fees) incurred by an officer or director of the Corporation in defending any civil, criminal, administrative
or investigative action, suit or proceeding may be paid by the Corporation in advance of the final disposition of such action,
suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall
ultimately be determined that such person is not entitled to be indemnified by the Corporation as authorized under Delaware law.&nbsp;&nbsp;Such
expenses (including attorneys&rsquo; fees) incurred by former directors and officers or other employees and agents of the Corporation
or by persons serving at the request of the Corporation as directors, officers, employees or agents of another corporation, partnership,
joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Corporation deems appropriate.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.3&nbsp;&nbsp;Determination by Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
indemnification under subsections (a) and (b) of Chapter 1, Delaware General Corporate Law, &sect; 145 (unless ordered by a court)
shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the present
or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard
of conduct set forth in subsections (a) and (b) of &sect; 145.&nbsp;&nbsp;Such determination shall be made, with respect to a
person who is a director or officer of the Corporation at the time of such determination:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum; or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
a committee of such directors designated by majority vote of such directors, even though less than a quorum; or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion; or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.4&nbsp;&nbsp;Not Exclusive of Other Rights</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
indemnification provided by this Article shall not be deemed exclusive of any other rights to which those seeking indemnification
or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise,
both as to action in such person&rsquo;s official capacity and as to action in another capacity while holding such office.&nbsp;&nbsp;A
right to indemnification or to advancement of expenses arising under a provision of the Certificate of Incorporation or a bylaw
shall not be eliminated or impaired by an amendment to the Certificate of Incorporation or the Bylaws after the occurrence of
the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for
which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission
explicitly authorizes such elimination or impairment after such action or omission has occurred.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.5&nbsp;&nbsp;Insurance</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director or officer of
the Corporation, or is or was serving at the request of the Corporation as a director or officer of another corporation, partnership,
joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity or
arising out of his status as such, whether or not the Corporation would have the power to indemnify him against such liability
under the provisions of this Article.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Corporation&rsquo;s indemnity of any person who is or was a director or officer of the Corporation, or is or was serving at the
request of the Corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise,
shall be reduced by any amounts such person may collect as indemnification (i) under any policy of insurance purchased and maintained
on his behalf by the Corporation or (ii) from such other corporation, partnership, joint venture, trust or other enterprise.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.6&nbsp;&nbsp;Violation of Law</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nothing
contained in this Article, or elsewhere in these Bylaws, shall operate to indemnify any director or officer if such indemnification
is for any reason contrary to law, either as a matter of public policy, or under the provisions of the Federal Securities Act
of 1933, the Securities Exchange Act of 1934, or any other applicable state or federal law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
6.7&nbsp;&nbsp;Coverage</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the purposes of this Article, references to &ldquo;the Corporation&rdquo; include all constituent corporations absorbed in a consolidation
or merger as well as the resulting or surviving corporation so that any person who is or was a director or officer of such a constituent
corporation or is or was serving at the request of such a constituent corporation as a director or officer of another corporation,
partnership, joint venture, trust or other enterprise shall stand in the same position under the provisions of this Article with
respect to the resulting or surviving corporation as he would if he had served the resulting or surviving corporation in the same
capacity.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
VII&mdash;STOCK</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
7.1&nbsp;&nbsp;Certificated and Uncertificated Shares</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of the Corporation shall be represented by certificates, provided that the Board of Directors of the Corporation may provide
by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares.&nbsp;&nbsp;Any
such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation.&nbsp;&nbsp;Each
share shall be numbered and entered into the books of the Corporation as they are issued. &nbsp;Each certificate representing
shares shall set forth upon the face thereof the following:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the corporation;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
the Corporation is organized under the laws of the State of Delaware;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name or names of the person or persons to whom the certificate is issued;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number and class of shares, and the designation of the series, if any, which the certificate represents;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any shares represented by the certificates are nonvoting shares, a statement or notation to that effect; and, if the shares represented
by the certificate are subordinate to shares of any other class or series with respect to dividends or amounts payable on liquidation,
the certificate shall further set forth on either the face or the back thereof a clear and concise statement to that effect; and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 81pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 81pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 81pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any shares represented by the certificates are subject to any restrictions on the transfer or the registration of transfer of
shares, then such restrictions shall be noted conspicuously on the front or back of such certificates.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every
holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of the Corporation
by the chairperson or vice-chairperson of the Board of Directors, or the president or vice-president, and by the treasurer or
an assistant treasurer, or the secretary or an assistant secretary of such corporation representing the number of shares registered
in certificate form.&nbsp;&nbsp;Any or all the signatures on the certificate may be a facsimile.&nbsp;&nbsp;In case any officer,
transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to
be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same
effect as if such person were such officer, transfer agent or registrar at the date of issue.&nbsp;&nbsp;The Corporation shall
not have power to issue a certificate in bearer form.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
a reasonable time after the issue or transfer of shares without certificates, the Corporation shall send the stockholder then
owning such shares a written statement of the information required to be placed on certificates by Section 7.1 (a) of these Bylaws
and applicable law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
7.2&nbsp;&nbsp;Transfers of Stock</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Transfers
of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents
designated to transfer shares of the stock of the Corporation.&nbsp;&nbsp;Except where a certificate is issued in accordance with
Section 7.4 of Article VII of these Bylaws, an outstanding certificate for the number of shares involved shall be surrendered
for cancellation before a new certificate is issued therefor.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
7.3&nbsp;&nbsp;Record Date</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Board of Directors may fix a record date, which shall not be more than sixty (60) nor less than ten (10) days before the date
of any meeting of stockholders, nor more than sixty (60) days prior to the time for the other action hereinafter described, as
of which there shall be determined the stockholders who are entitled to notice of or to vote at any meeting of stockholders or
any adjournment thereof; to express consent to corporate action in writing without a meeting; to receive payment of any dividend
or other distribution or allotment of any rights; or to exercise any rights with respect of any change, conversion or exchange
of stock or with respect to any other lawful action.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
7.4&nbsp;&nbsp;Lost, Stolen or Destroyed Certificates</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations
as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory
bond or bonds of indemnity.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
7.5&nbsp;&nbsp;Regulations</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board
of Directors may establish.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
VIII&mdash;NOTICES</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
8.1&nbsp;&nbsp;Notices</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Whenever
notice is required to be given to any stockholder, director, officer, or agent, such requirement shall not be construed to mean
personal notice.&nbsp;&nbsp;Such notice may in every instance be effectively given by depositing a writing in a post office or
letter box, in a postpaid, sealed wrapper, or by electronic transmission, addressed to such stockholder, director, officer, or
agent at his or her address or electronic address as the same appears on the books of the Corporation.&nbsp;&nbsp;The time when
such notice is dispatched shall be the time of the giving of the notice.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
8.2&nbsp;&nbsp;Waivers</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice,
whether before or after the time stated therein, shall be deemed equivalent to notice required to be given to such stockholder,
director, officer or agent.&nbsp;&nbsp;Neither the business to be transacted at, nor the purpose of, any regular or special meeting
of the stockholders, directors or members of a committee of directors need be specified in any written waiver of notice or any
waiver by electronic transmission.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
IX&mdash;MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
9.1&nbsp;&nbsp;Facsimile Signatures</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to the provisions for the use of facsimile signatures elsewhere specifically authorized in these Bylaws, facsimile signatures
of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors of a committee
thereof.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
9.2&nbsp;&nbsp;Corporate Seal</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the
secretary.&nbsp;&nbsp;If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be
kept and used by the treasurer or by the assistant secretary or assistant treasurer.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
9.3&nbsp;&nbsp;Reliance Upon Books, Reports and Records</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the
performance of his duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation,
including reports made to the Corporation by any of its officers, by an independent certified public accountant, or by an appraiser
selected with reasonable care.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
9.4&nbsp;&nbsp;Fiscal Year</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fiscal year of the Corporation shall be as fixed by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
9.5&nbsp;&nbsp;Time Periods</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
applying any of these Bylaws which require that an act be done or not done a specified number of days prior to an event or that
an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing
of the act shall be excluded and the day of the event shall be included.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
X&mdash;AMENDMENTS</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
10.1&nbsp;&nbsp;Amendments</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
Bylaws may be amended or repealed by the Board of Directors at any meeting or by the stockholders at any meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
10.2 Force and Effect</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
Bylaws are subject to the provisions of the General Corporation Law of the State of Delaware and the Certificate of Incorporation,
as the same may be amended from time to time.&nbsp;&nbsp;If any provision in these Bylaws is inconsistent with an express provision
of either the General Corporation Law of the State of Delaware or the Certificate of Incorporation, the provisions of the General
Corporation Law of the State of Delaware or the Certificate of Incorporation, as the case may be, shall govern, prevail, and control
the extent of such inconsistency.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;14</FONT></P>

<HR NOSHADE STYLE="color: Black; width: 100%; height: 1.5pt; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10q0614ex31i_actinium.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302
OF</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">I, Kaushik J. Dave, certify that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financing reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium Pharmaceutical, Inc.</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 97%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><U>/s/ Kaushik J. Dave&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Kaushik J. Dave</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">President,&nbsp;Chief Executive Officer and Interim Chief
        Financial Officer</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer and Principal Financial and
        Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">August 12, 2014&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal MS Mincho; margin: 0">&#8232;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0614ex32i_actinium.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 32.1</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly
Report of Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended&nbsp;June 30,
2014&nbsp;as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Kaushik J.
Dave, President,&nbsp;Chief Executive Officer&nbsp;and Interim Chief Financial Officer&nbsp;of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium Pharmaceuticals, Inc.</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 5%; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 95%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ Kaushik J. Dave</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Kaushik J. Dave</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">President,&nbsp;Chief Executive Officer and Interim Chief
        Financial Officer&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer and Principal Financial and
        Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">August 12, 2014</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>atnm-20140630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.1.0.0 [08/12/2014 12:39:24 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.0 on Tuesday, August 12, 2014 12:43:00 AM -->
<xbrli:xbrl xmlns:atnm="http://actiniumpharmaceuticals.com/20140630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="atnm-20140630.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_Custom_01_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-12-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-20
</xbrli:startDate>
<xbrli:endDate>
2011-06-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_Mar_2012T00_00_00_TO_27_Mar_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-06-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jul_2012T00_00_00_TO_19_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_07_Jul_2012T00_00_00_TO_06_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-07
</xbrli:startDate>
<xbrli:endDate>
2012-08-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-08
</xbrli:startDate>
<xbrli:endDate>
2012-08-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-01
</xbrli:startDate>
<xbrli:endDate>
2012-08-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_26_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-09-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2012T00_00_00_TO_22_Oct_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-11-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-11-01
</xbrli:startDate>
<xbrli:endDate>
2012-11-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-25
</xbrli:startDate>
<xbrli:endDate>
2012-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2013T00_00_00_TO_16_May_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-05-01
</xbrli:startDate>
<xbrli:endDate>
2013-05-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2013T00_00_00_TO_30_Jun_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Sep_2013T00_00_00_TO_04_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-03
</xbrli:startDate>
<xbrli:endDate>
2013-09-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">atnm:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-09
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2013T00_00_00_TO_28_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jan_2014T00_00_00_TO_20_Jan_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Jan_2014T00_00_00_TO_27_Jan_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-25
</xbrli:startDate>
<xbrli:endDate>
2014-01-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-04
</xbrli:startDate>
<xbrli:endDate>
2014-03-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09_Feb_2014T00_00_00_TO_28_Apr_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-02-09
</xbrli:startDate>
<xbrli:endDate>
2014-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseSecondClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseThirdClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:BiologicalLicenseApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:FirstCommercialSaleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:AfterFirstNetSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:NewDrugApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:ReceiptOfRegulatoryApprovalFromUSFdaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">atnm:AfterFirstNetSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndThirteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:PeriodAxis">atnm:TwoThousandAndThirteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndFourteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:PeriodAxis">atnm:TwoThousandAndFourteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_DerivativeByNatureAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_InvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atnm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atnm:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:PremiumFinanceAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atnm:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_InvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:InvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-05
</xbrli:startDate>
<xbrli:endDate>
2014-07-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-05
</xbrli:startDate>
<xbrli:endDate>
2014-07-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_10_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-07-10
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-03
</xbrli:startDate>
<xbrli:endDate>
2014-07-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_Jul_2014T00_00_00_TO_25_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atnm:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-20
</xbrli:startDate>
<xbrli:endDate>
2014-07-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_11_Aug_2014T00_00_00_TO_11_Aug_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-08-11
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw7;c444c555cT{h>=GF7<;=I1FHH<18=951EIFJ15;64<;884:F9 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="pures"><xbrli:measure>atnm:pures</xbrli:measure></xbrli:unit>
<xbrli:unit id="patients"><xbrli:measure>atnm:patients</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">0001388320</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">2014-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">2014</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Q2</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_11_Aug_2014T00_00_00_TO_11_Aug_2014T00_00_00" unitRef="shares" decimals="INF">28147064</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">5618669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">5650328</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5533366</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">14670813</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">218389</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">608105</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5751755</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">15278918</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">13920</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">132902</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">0</us-gaap:SecurityDeposit>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">34733</us-gaap:SecurityDeposit>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5765675</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">15446553</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">378955</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1045421</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">81185</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">189537</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">157825</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">54970</us-gaap:NotesPayableCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9826627</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">7325220</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">11116555</us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">7325220</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">11116555</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">24565</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">27602</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">64933145</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">84004053</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-66517255</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-797016575</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-1559545</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4329998</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5765675</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">15446553</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_28_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">24565447</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">27602192</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">24565447</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">27602192</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">509262</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">1594968</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">75000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2001937</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4462905</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">75000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">966367</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">1899503</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2414627</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4090680</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:Depreciation contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Depreciation contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">8052</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9457</us-gaap:Depreciation>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-4122</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">1475629</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">3498593</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4424616</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">8563042</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-1475629</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-3498593</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4424616</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-8563042</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">634</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">1209</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-1307748</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">26764</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">7939711</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4621360</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-1308382</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">25555</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">7939711</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4621360</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-2784011</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-3473038</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">3515095</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-13184402</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.13</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.14</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.52</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.13</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.52</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">22178637</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">21791673</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">25795573</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">25513505</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">22178637</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="shares" decimals="0">21791673</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">35862173</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">25513505</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">188400</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">3141144</us-gaap:ShareBasedCompensation>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9457</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">26764</atnm:GainOnChangeInFairValueOfDerivatives>
<atnm:GainOnChangeInFairValueOfDerivatives contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4621360</atnm:GainOnChangeInFairValueOfDerivatives>
<atnm:IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">2126</atnm:IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-85000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">389716</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-34733</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-103414</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">666466</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">108352</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-3327820</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-5062072</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">1112</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">128439</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">-1112</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-128439</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">103050</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">102855</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">14328725</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">3463641</atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash>
<atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">102088</atnm:ProceedsFromExerciseOfOptionsAndWarrantsForCash>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">3360591</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">14327958</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">31659</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9137447</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">561</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">590217</atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1501988</atnm:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<atnm:TransferFromLiabilityClassificationToEquityClassificationValue contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<atnm:TransferFromLiabilityClassificationToEquityClassificationValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">30000</atnm:TransferFromLiabilityClassificationToEquityClassificationValue>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;b&gt;Note 1 &amp;#8211;&amp;#160;Description of Business and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;b&gt;Nature of Business &amp;#8211;&lt;/b&gt;&amp;#160;Actinium Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Actinium&amp;#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;Actinium&amp;#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&amp;#8220;MSKCC&amp;#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. Actinium&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock. The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto;
 text-transform:
 none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On March 20, 2013, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&amp;#8217;s common stock. A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/b&gt;&amp;#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC February 28, 2014.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Principles of Consolidation &amp;#8211;&lt;/b&gt;&amp;#160;The condensed consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family:
 'times new roman', times,
 serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/b&gt;&amp;#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Reclassification &amp;#8211;&lt;/b&gt;&amp;#160;Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Cash and Cash Equivalents &amp;#8211;&lt;/b&gt;&amp;#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2014 and December 31, 2013, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Property and Equipment &amp;#8211;&lt;/b&gt;&amp;#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Impairment of Long-Lived Assets &amp;#8211;&amp;#160;&lt;/b&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Derivatives &amp;#8211;&lt;/b&gt;&amp;#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based
 pricing models incorporating readily
 observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/b&gt;&amp;#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of June 30, 2014 and December 31, 2013. As required by ASC 820 &amp;#8220;&lt;i&gt;Fair Value Measurements and Disclosures&amp;#8221;&lt;/i&gt;, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal;
 font-weight: normal; letter-spacing: normal;
 line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new
 roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"&gt;&lt;td style="width: 801.671875px; padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;At June 30, 2014&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align:
 right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;9,826,627&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;9,826,627&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;At December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;6,707,255&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;6,707,255&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Income Taxes &amp;#8211;&lt;/b&gt;&amp;#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Research and Development Costs &amp;#8211;&lt;/b&gt;&amp;#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Share-Based Payments &amp;#8211;&lt;/b&gt;&amp;#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based
 compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for
 estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;b&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/b&gt;&amp;#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share, as calculated for the three months ended June 30, 2014, is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. For the three months ended June 30, 2013 and the six months ended June 30, 2014 and 2013, the potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended June&amp;#160;30, 2014, potentially issuable shares included stock options to purchase 1,398,937 shares and warrants to purchase 8,667,663 shares of the Company&amp;#8217;s common stock. For the six months ended June 30, 2014, potentially issuable shares included stock options to purchase 2,952,829 shares and warrants to purchase 9,418,058 shares of the Company&amp;#8217;s common stock. For the six months ended June 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the Company&amp;#8217;s common stock.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;b&gt;Recent Accounting Pronouncements &amp;#8211;&amp;#160;&lt;/b&gt;In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&amp;#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&amp;#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230&amp;#8212;Revenue Recognition (Topic 605) and Proposed Accounting Standards Update 2011&amp;#8211;250&amp;#8212;Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&amp;#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Finally, the amendments also remove paragraph 810-10-15-16,
 which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable
 interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&amp;#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&amp;#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2013-320&amp;#8212;Development Stage Entities (Topic 915), which has been deleted. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&amp;#8212;Compensation&amp;#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The proposed amendments would apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target could be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&amp;#8212;Compensation&amp;#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Subsequent Events &amp;#8211;&lt;/b&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;b&gt;Note 2 &amp;#8211; Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: left;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;MSKCC:&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI), an entity related to MSKCC (&amp;#8220;License Agreement&amp;#8221;). The agreement was amended in August 2006. Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&amp;#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates. MSKCC agreed, subject to certain conditions, to utilize the donated funds for certain clinical and preclinical programs and activities related to the Company&amp;#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;The Company is obligated to make the following milestone payments:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;(1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval for each licensed product&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align:
 right;"&gt;750,000&lt;/td&gt;&lt;td style="width:
 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement. On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement. The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined. The amount owed does not include amounts the Company may owe for patent expenses under the License Agreement. For 2013, the annual maintenance fee is $50,000 plus pass through costs.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225. The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;For the three months ended June 30, 2014 and 2013, the Company did not incur any expenses for maintenance fees and research conducted by MSKCC. For the six months ended June 30, 2014 and 2013, the Company incurred $189,537 and $129,850, respectively, for maintenance fees and research conducted by MSKCC. As of June 30, 2014 and December 31, 2013, the Company has payable to MSKCC of $189,537 and $81,185, respectively, related to clinical trials.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color:
 #000000; font-family: 'times new roman', times, serif;
 font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Placement Agent:&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On August 7, 2012, the Company entered into an engagement agreement with a Healthcare Investment Bank as its placement agent for the 2012 Common Stock Offering whereby a director of the Company, is the Head of Healthcare Investment Banking team. Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. In consideration for its services, the placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent. The placement agent or its designees also received warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units. The placement agent also received the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company. Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent was engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000. The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&amp;#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement. For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent. The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&amp;#8217;s Common Stock.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering. The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had uplisted its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On January 10, 2014, the Company conducted the final closing (the &amp;#8220;Final Closing&amp;#8221;) of its private placement of securities (the &amp;#8220;Offering&amp;#8221;) pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &amp;#8220;Purchase Agreement&amp;#8221;) and Subscription Agreement, dated as of January 10, 2014 (the &amp;#8220;Subscription Agreement&amp;#8221;), with certain accredited investors (the &amp;#8220;Investors&amp;#8221;) pursuant to which: the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the
 &amp;#8220;Shares&amp;#8221;) of common stock at $6.00 per share and
 (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an exercise price of $9.00 per share. The Company received $3,310,860 in gross proceeds from the sale of securities under the Purchase Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;During the six months ended June 30, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&amp;#8217;s Common Stock at $9.00 per share for a period of 5 years.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;On May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement.&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 3 &amp;#8211; Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 8pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Property and equipment consisted of the following at June 30, 2014 and December 31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Lives&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;June 30, 2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1050px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 126px; text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;3-5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 126px; text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;143,919&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;15,480&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(11,017&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,560&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;132,902&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times,
 serif;"&gt;13,920&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Depreciation expense for the three months ended June 30, 2014 and 2013 was $8,052 and $0, respectively. Depreciation expense for the six months ended June 30, 2014 and 2013 was $9,457 and $0, respectively The Company wrote off certain some of its undepreciated property and equipment during the six months ended June 30, 2013 and recorded a loss of $4,122 on the disposition.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 4 &amp;#8211;&amp;#160;Note Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 12pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;On December 28, 2013, the Company entered into a premium finance agreement to pay a $157,825 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and is required to pay $15,995 in monthly installment for nine months. During the six months ended June 30, 2014 and 2013, the Company paid $102,855 and $103,050, respectively.&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;As of June 30, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $54,970 and $157,825, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Note 5 &amp;#8211; Derivatives&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&amp;#8217;s common stock at prices below such warrants&amp;#8217; respective exercise prices and these provisions could result in modification of the warrants&amp;#8217; exercise price based on a variable that is not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option as defined under FASB ASC Topic No. 815 &amp;#8211; 40. The warrants granted in connection with the issuance of the Company&amp;#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &amp;#8220;Lower Price&amp;#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Activities for derivative warrant instruments during the six months ended June 30, 2014 were as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,968,623&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Transfer from liability classification to equity classification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(193,661&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,501,988&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,621,360&lt;/td&gt;&lt;td style="text-align: left;
 padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;
 background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Balance, June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;1,774,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;9,826,627&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During the six months ended June 30, 2014, 662,160 warrants were exercised, of which 193,661 were derivative warrants. The fair value of these warrants totaling approximately $1,501,988 were measured on the various exercise dates and reclassified to additional paid-in capital.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;June 30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 953px; text-align: left;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 113px; text-align: right;"&gt;7.22&lt;/td&gt;&lt;td style="width: 13px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 112px; text-align: right;"&gt;5.89&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Adjusted exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.27&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Warrant lives in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;3.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;0.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Range of percentage of existing shares offered (6)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;35&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Offering price range (7)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;9&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 79px; text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1488px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;The market value of common stock at the above measurement dates is based on the Company&amp;#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for June 30, 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(3)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 79px; text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(4)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1488px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(5)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Management determines the probability of future stock offering at each evaluation date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(6)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;p style="margin: 0px;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.&lt;/p&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(7)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 7.7pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;b&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;License and Research Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.55in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 78px; text-align: left;"&gt;&lt;font style="font-size: 10pt;"&gt;a.&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Abbott Biotherapeutics Corp &amp;#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 12pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(5) First commercial sale&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(6) after the first $10,000,000 in net sales&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 12pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase 2 Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.55in;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 78px; text-align: left; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;b.&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 3px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Memorial Sloan Kettering Cancer Center (MSKCC) &amp;#8211; see related party disclosure.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;c.&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding: 0px; text-indent: 0px;"&gt;&lt;p style="margin: 0px;"&gt;Oak Ridge National Laboratory (ORNL) &amp;#8211; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end.&amp;#160;&amp;#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&amp;#160;&amp;#160;For 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;d.&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding: 0px; text-indent: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company&amp;#8217;s Phase 1 and Phase 2 clinical trials.&amp;#160;&amp;#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&amp;#160;&amp;#160;The down payment totaling $239,000 was paid in 2007 and 2012.&amp;#160;&amp;#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&amp;#160;&amp;#160;The total project is now estimated at approximately $2.2 million. As of June 30, 2014, approximately $1.1 million has been expensed to date. &amp;#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify; padding: 0px; text-indent:
 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;e.&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC) to build upon previous and ongoing clinical trials, with BC8 (licensed antibody). FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin: 0px;"&gt;During the six months ended June 30, 2014 and 2013, the Company recorded fees of $75,000 and $75,000, respectively, related to this agreement.&amp;#160;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 12pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 53px; text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 78px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;f.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&amp;#160;&amp;#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&amp;#160;&amp;#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the six months ended June 30, 2014, the Company paid approximately $16,000 for patient enrollment.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;g.&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500. The estimated cost is based on treating 24 patients through 2013. Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. There have been no patients treated in 2014.&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;h.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. There were no payments made during the six months ended June 30, 2104 for this agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal;
 font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;i.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable. The Company accrued the $16,000 fee at December 31, 2013 and paid the fee in January 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;j.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&amp;#160;&amp;#160;(&amp;#8220;Goodwin&amp;#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab&amp;#8482;-B. Total cost of the agreement is $2,813,960. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of June 30, 2014, the remaining cost of the agreement is approximately $2.1 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;k.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;On June 20, 2014, the Company entered into a CRO agreement with Act Oncology. Act Oncology provides project management services for the study of Iomab-B used for the intended Phase 3 clinical trial. The total project is estimated to cost approximately $0.8 million. The Company paid approximately $0.1 million during the six months ended June 30, 2014. Act Oncology bills the Company when services are rendered and the Company records the related expense to research and development costs.&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue, New York, NY. The agreement terminated on May 31, 2013. On June 4, 2013 and amended on October 4, 2013, the Company entered into two rental agreements for office space at 546 Fifth Avenue, New York, NY. One of the agreements terminated on July 6, 2014. The Company maintains office space at 546 Fifth Avenue, New York, NY through December 31, 2014. The Company paid a one month refundable deposit. On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement terminates on September 30, 2016. The Company issued a security deposit of $34,733 to the existing tenant.&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Note 7 &amp;#8211; Equity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 11pt; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;In January 2014, the Company completed the final tranche of a private placement of the Company&lt;/font&gt;&amp;#8217;&lt;font style="font-size: 10pt;"&gt;s common stock and warrants and received&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;approximately $3.3 million total gross proceeds from accredited investors (&lt;/font&gt;&amp;#8220;&lt;font style="font-size: 10pt;"&gt;2014 Closing&lt;/font&gt;&amp;#8221;&lt;font style="font-size: 10pt;"&gt;). The Company paid its placement agent total cash fees of&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;approximately $395,000 and paid attorney fees of $40,000 for their services&lt;/font&gt;&amp;#160;resulting in net proceeds of $2,873,557&lt;font style="font-size: 10pt;"&gt;. In the 2014 Closing, the Company sold 551,810 shares of common stock at&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;$6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;model utilizing the following assumptions: risk free interest rateh1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;years. As of&amp;#160;&lt;/font&gt;June 30&lt;font style="font-size: 10pt;"&gt;, 2014, all the warrants were outstanding.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 11pt; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;On March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the&lt;/font&gt;&amp;#160;&amp;#8220;&lt;font style="font-size: 10pt;"&gt;Registration Statement&lt;/font&gt;&amp;#8221;&lt;font style="font-size: 10pt;"&gt;) which was effective on April 17,&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;2014. This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;$200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the&amp;#160;&lt;/font&gt;&amp;#8220;&lt;font style="font-size: 10pt;"&gt;Sales&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;Agreement&lt;/font&gt;&amp;#8221;&lt;font style="font-size: 10pt;"&gt;) with MLV &amp;amp; Co. LLC (&lt;/font&gt;&amp;#8220;&lt;font style="font-size: 10pt;"&gt;MLV&lt;/font&gt;&amp;#8221;&lt;font style="font-size: 10pt;"&gt;) dated March 24, 2014. The Company will pay MLV in cash, upon the sale of common stock pursuant to the&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt;"&gt;Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&amp;#160;&lt;/font&gt;On April 28, 2014 the Company issued&amp;#160;&lt;font style="font-size: 10pt;"&gt;500 shares&amp;#160;&lt;/font&gt;and received net proceeds of $6,000&lt;font style="font-size: 10pt;"&gt;&amp;#160;under the Sales Agreement&lt;/font&gt;&amp;#160;with MLV&lt;font style="font-size: 10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;b&gt;Placement Agent &amp;#8211;&amp;#160;&lt;/b&gt;During January 2014, in connection with the Common Stock Offering, the Company issued the Placement Agent warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million
 was
 determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &amp;#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;b&gt;Public Offering&lt;/b&gt;&amp;#160;- On June 30, 2014, the Company received gross proceeds of $12,525,000. The Company paid an underwriting discount of $876,750, paid the other offering expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting in net proceeds of $11,451,250 from the public offering of 1,670,000 shares of the Company&amp;#8217;s common stock, $0.001 par value per share at a price to the public of $7.50 per share less underwriting discounts. Under the terms of the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Approval of the Equity Incentive Plan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;During the six months ended June 30, 2013, the Company did not grant any shares of restricted stock. During the six months ended June 30, 2014, the Company granted 445,167 shares of restricted stock and cancelled 50,000 shares of restricted stock. Of the total shares of restricted stock, 20,000 shares vest 3 months from the grant date, 22,500 shares vest 1 year from the grant date, 199,167 shares have a vesting period of 4 years and 200,000 shares vest at date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: right; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;b&gt;Stock Option Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"&gt;The following is a summary of stock options activities for the six months ended June 30, 2014:&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start;
 text-transform: none;
 white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Remaining&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Number&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Contractual&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;of&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Units&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Exercise&amp;#160;&lt;br /&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Term&amp;#160;(in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Intrinsic&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,985,384&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3.23&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;8.34&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;5,908,696&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;979,100&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.85&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(11,655&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.78&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Outstanding, June 30, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,952,829&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.45&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.35&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,300,565&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Exercisable, June 30, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;868,287&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.98&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,418,017&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000;
 font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto;
 text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;During the six months ended June 30, 2014, the Company granted employees and board members 979,100 options to purchase the Company&amp;#8217;s common stock with exercise prices ranging from $5.55 to $11.95 and a term of 10 years and with vesting over a 4-year period. The options have a fair value of $7.1 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.88% - 2.07% (2) expected life of 6 years, (3) expected volatility of 87.06% to 87.76%, and (4) zero expected dividends.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;During six months ended June 30, 2014, the Company received gross proceeds of $5,220 for exercise of options for 11,655 shares of the Company&amp;#8217;s common stock.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2014 was $10,165,000. During the three months ended June 30, 2014 and 2013, the Company recorded option expense of $607,791 and $94,200, respectively. During the six months ended June 30, 2014 and 2013, the Company recorded option expense of $889,195 and $188,400, respectively.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;Following is a summary of warrant activities for the six months ended June 30, 2014:&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none;
 white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times,
 serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Remaining&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Number of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Contractual&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Intrinsic&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Exercise&amp;#160;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Term&amp;#160;(in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Value&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;9,673,290&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1.06&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4.89&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47,396,307&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;406,928&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.96&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.46&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt; padding-bottom: 1pt;"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(662,160&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;1.44&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding, June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;"&gt;9,418,058&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;4.54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;56,362,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Exercisable, June
 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9,195,074&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align:
 left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;1.16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;4.42&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;56,183,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;During the six months ended June 30, 2014, the Company granted warrants to purchase 137,952 shares of the Company&amp;#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&amp;#8217;s common stock to its placement agent in connection with the 2014 Closing.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;During the six months ended June 30, 2014, the Company also granted consultants warrants to purchase 200,000 shares of the Company&amp;#8217;s common stock with exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants vest when certain milestones are met.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;During the six months ended June 30, 2014, 662,160 warrants were exercised by the warrant holders. The Company issued 573,299 shares of common stock and received gross proceeds of $96,868.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;During the six months ended June 30, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $98,224 and $0, respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Note 8 &amp;#8211; Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;During July 2014, the Company issued 176,211 shares of restricted stock to warrant holders.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;On July 7, 2014, the Company filed a Form S-8 to offer the resale of up to 6,750,000 shares of common stock previously granted under the Equity Incentive Plan. Pursuant to the Form S-8, the Company issued 61,538 shares to an investor and received proceeds of $48,000.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;On July 10, 2014, the Underwriters exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. Including the exercise of the over-allotment option of $1.2 million, gross, Actinium&amp;#8217;s offering totaled 1,827,123 shares, representing gross proceeds of approximately $13.7 million and approximately $12.5 million net after deducting the underwriting discount and the other offering expenses.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;On July 25, 2014, the Company entered into an agreement with a consultant. According to the agreement, the Company granted and issued 150,000 restricted shares to a consultant and also made a $250,000 for services to be provided over a six month period.&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;b&gt;Nature of Business &amp;#8211;&lt;/b&gt;&amp;#160;Actinium Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Actinium&amp;#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;Actinium&amp;#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&amp;#8220;MSKCC&amp;#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. Actinium&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock. The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On March 20, 2013, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start;
 text-transform:
 none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&amp;#8217;s common stock. A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/b&gt;&amp;#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC February 28, 2014.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Principles of Consolidation &amp;#8211;&lt;/b&gt;&amp;#160;The condensed consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/b&gt;&amp;#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Reclassification &amp;#8211;&lt;/b&gt;&amp;#160;Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/b&gt;&amp;#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2014 and December 31, 2013, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Property and Equipment &amp;#8211;&lt;/b&gt;&amp;#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Impairment of Long-Lived Assets &amp;#8211;&amp;#160;&lt;/b&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Derivatives &amp;#8211;&lt;/b&gt;&amp;#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/b&gt;&amp;#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of June 30, 2014 and December 31, 2013. As required by ASC 820 &amp;#8220;&lt;i&gt;Fair Value Measurements and Disclosures&amp;#8221;&lt;/i&gt;, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight:
 normal; font-size:
 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new
 roman', times, serif;"&gt;&lt;font
 style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"&gt;&lt;td style="width: 801.671875px; padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;At June 30, 2014&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight:
 normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;9,826,627&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;9,826,627&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;At December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;6,707,255&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;6,707,255&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Income Taxes &amp;#8211;&lt;/b&gt;&amp;#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Research and Development Costs &amp;#8211;&lt;/b&gt;&amp;#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Share-Based Payments &amp;#8211;&lt;/b&gt;&amp;#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;&lt;strong&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/strong&gt;&amp;#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share, as calculated for the three months ended June 30, 2014, is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. For the three months ended June 30, 2013 and the six months ended June 30, 2014 and 2013, the potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended June&amp;#160;30, 2014, potentially issuable shares included stock options to purchase 1,398,937 shares and warrants to purchase 8,667,663 shares of the Company&amp;#8217;s common stock. For the six months ended June 30, 2014, potentially issuable shares included stock options to purchase 2,952,829 shares and warrants to purchase 9,418,058 shares of the Company&amp;#8217;s common stock. For the six months ended June 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Recent Accounting Pronouncements &amp;#8211;&amp;#160;&lt;/b&gt;In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&amp;#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&amp;#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230&amp;#8212;Revenue Recognition (Topic 605) and Proposed Accounting Standards Update 2011&amp;#8211;250&amp;#8212;Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&amp;#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Finally, the amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&amp;#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&amp;#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2013-320&amp;#8212;Development Stage Entities (Topic 915), which has been deleted. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&amp;#8212;Compensation&amp;#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The proposed amendments would apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target could be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&amp;#8212;Compensation&amp;#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite
 Service Period, which has been deleted. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&lt;b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Subsequent Events &amp;#8211;&lt;/b&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style:
 normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"&gt;&lt;td style="width: 801.671875px; padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;At June 30, 2014&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size:
 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;9,826,627&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;9,826,627&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"&gt;&lt;td style="padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;At December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal;
 font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;6,707,255&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;6,707,255&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;(1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval for each licensed product&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Lives&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;June 30, 2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1050px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Office equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 126px; text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;3-5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 126px; text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;143,919&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;15,480&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(11,017&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,560&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;132,902&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;13,920&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Balance, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,968,623&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;6,707,255&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Transfer from liability classification to equity classification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(193,661&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,501,988&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;4,621,360&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Balance, June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;"&gt;1,774,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;"&gt;9,826,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;June 30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 953px; text-align: left;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 113px; text-align: right;"&gt;7.22&lt;/td&gt;&lt;td style="width: 13px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 112px; text-align: right;"&gt;5.89&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Adjusted exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.27&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Warrant lives in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;3.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;0.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;25&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Range of percentage of existing shares offered (6)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;35&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Offering price range (7)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;9&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 79px; text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1488px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;The market value of common stock at the above measurement dates is based on the Company&amp;#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for June 30, 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement
 date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(3)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 79px; text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(4)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1488px; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(5)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Management determines the probability of future stock offering at each evaluation date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(6)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;p style="margin: 0px;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.&lt;/p&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;(7)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 7.7pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</atnm:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
<atnm:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Milestones&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;(5) First commercial sale&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;(6) after the first $10,000,000 in net sales&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</atnm:MilestonePaymentsMilestoneMethodTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Remaining&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Number&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Contractual&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;of&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Units&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Exercise&amp;#160;&lt;br /&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Term&amp;#160;(in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Intrinsic&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,985,384&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3.23&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;8.34&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;5,908,696&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;979,100&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.85&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(11,655&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.78&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Outstanding, June 30, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,952,829&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.45&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.35&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,300,565&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Exercisable, June 30, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;868,287&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.98&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,418,017&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Remaining&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Number of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Contractual&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="3"&gt;Intrinsic&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Exercise&amp;#160;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Term&amp;#160;(in&amp;#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"&gt;Value&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Outstanding, December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;9,673,290&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1.06&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4.89&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47,396,307&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;406,928&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.96&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.46&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt; padding-bottom: 1pt;"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(662,160&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;1.44&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding, June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;"&gt;9,418,058&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;4.54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;56,362,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Exercisable, June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9,195,074&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:
 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;1.16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;4.42&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;56,183,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"&gt;&lt;/p&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9826627</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">9826627</us-gaap:DerivativeLiabilities>
<dei:EntityIncorporationDateOfIncorporation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">1997-10-06</dei:EntityIncorporationDateOfIncorporation>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_28_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="4">0.9370</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<atnm:CommonStockIssuableInConsiderationForEquityInterestAcquisition contextRef="Context_Custom_25_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">0.99</atnm:CommonStockIssuableInConsiderationForEquityInterestAcquisition>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<atnm:SharesExchangeRatio contextRef="Context_Custom_25_Dec_2012T00_00_00_TO_28_Dec_2012T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</atnm:SharesExchangeRatio>
<atnm:SharesExchangeRatio contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</atnm:SharesExchangeRatio>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">2280184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">9535694</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">1398937</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">8667663</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">2952829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="INF">9418058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<atnm:CommonStockShares contextRef="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">3970137</atnm:CommonStockShares>
<atnm:ExchangedInCommonStockShares contextRef="Context_As_Of_25_Sep_2013T00_00_00_TO_25_Sep_2013T00_00_00_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">1322055</atnm:ExchangedInCommonStockShares>
<atnm:RelatedPartyMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember" unitRef="USD" decimals="0">750000</atnm:RelatedPartyMilestonesPayment>
<atnm:RelatedPartyMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember" unitRef="USD" decimals="0">1750000</atnm:RelatedPartyMilestonesPayment>
<atnm:NumberOfPatients contextRef="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="patients" decimals="INF">24</atnm:NumberOfPatients>
<atnm:AmountPaidUnderAgreementInYearTwoThousandEleven contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:AmountPaidUnderAgreementInYearTwoThousandEleven>
<atnm:AmountPaidUnderAgreementInYearTwoThousandTwelve contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">200000</atnm:AmountPaidUnderAgreementInYearTwoThousandTwelve>
<atnm:AmountPaidUnderAgreementInYearTwoThousandThirteen contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">250000</atnm:AmountPaidUnderAgreementInYearTwoThousandThirteen>
<atnm:OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen contextRef="Context_Custom_03_Sep_2013T00_00_00_TO_04_Sep_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">815100</atnm:OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_Custom_20_May_2011T00_00_00_TO_19_Jun_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</atnm:MaintenanceFeesAndResearchPayments>
<atnm:MaintenanceFeesAndResearchPayments contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">0</atnm:MaintenanceFeesAndResearchPayments>
<atnm:PlacementAgentServicesFees contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">400000</atnm:PlacementAgentServicesFees>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="INF">68976</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">68976</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:WarrantsIssuedToPurchaseCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_InvestorMember" unitRef="shares" decimals="0">137952</atnm:WarrantsIssuedToPurchaseCommonStock>
<atnm:CommonStockExercisePriceParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">9.00</atnm:CommonStockExercisePriceParOrStatedValuePerShare>
<atnm:CommonStockExercisePriceParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="0">9</atnm:CommonStockExercisePriceParOrStatedValuePerShare>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_27_Mar_2012T00_00_00_TO_27_Mar_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31185</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_19_Jul_2012T00_00_00_TO_19_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31366</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_28_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500000</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_26_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">38501</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_21_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31771</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_31_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">34383</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</atnm:AmountPaidToEachPatient>
<atnm:AmountPaidToEachPatient contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" xsi:nil="true"/>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_28_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">33946</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_26_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">22847</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_21_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">79623</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpFeeForClinicalTrial contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">19749</atnm:StartUpFeeForClinicalTrial>
<atnm:StartUpDueCostPaidDate contextRef="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-12-31</atnm:StartUpDueCostPaidDate>
<atnm:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.</atnm:DescriptionOfReceivablesOfPlacementAgentForServices>
<atnm:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock</atnm:DescriptionOfReceivablesOfPlacementAgentForServices>
<atnm:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.</atnm:DescriptionOfWarrantsReceivablesByPlacement>
<atnm:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable</atnm:DescriptionOfWarrantsReceivablesByPlacement>
<atnm:PeriodOfExerciseOfWarrants contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Within 6 months of the final closing of the 2012 common stock Offering</atnm:PeriodOfExerciseOfWarrants>
<atnm:PeriodOfExerciseOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">5 years</atnm:PeriodOfExerciseOfWarrants>
<atnm:PercentageOfSolicitationFee contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.05</atnm:PercentageOfSolicitationFee>
<atnm:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">25000</atnm:PeriodicFeeForFinancialAdvisoryServices>
<atnm:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_01_Dec_2013T00_00_00_TO_09_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">25000</atnm:PeriodicFeeForFinancialAdvisoryServices>
<atnm:DescriptionOfAdditionalReceivableByPlacementAgent contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.</atnm:DescriptionOfAdditionalReceivableByPlacementAgent>
<atnm:CommonStockPurchaseByHoldingOfWarrant contextRef="Context_Custom_08_Jul_2012T00_00_00_TO_07_Aug_2012T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">1251015</atnm:CommonStockPurchaseByHoldingOfWarrant>
<us-gaap:OtherResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">129850</us-gaap:OtherResearchAndDevelopmentExpense>
<us-gaap:OtherResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">189537</us-gaap:OtherResearchAndDevelopmentExpense>
<us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</us-gaap:ArtistAdvancesAndRoyaltyGuaranteesCommitments>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">81185</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">189537</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">551810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_09_Feb_2014T00_00_00_TO_28_Apr_2014T00_00_00" unitRef="shares" decimals="0">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">573299</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="shares" decimals="INF">1670000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="shares" decimals="0">137952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">9.00</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">7.50</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_10_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">7.50</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">5.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">11.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">3310860</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="0">6636720</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">11451250</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_SubsidiarySaleOfStockAxis_PlacementAgentMember">Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00">The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014 the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">15480</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">143919</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1560</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">11017</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:NotesPayable contextRef="Context_As_Of_28_Dec_2013T00_00_00_TO_28_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">157825</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">157825</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">54970</us-gaap:NotesPayable>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">15995</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_PremiumFinanceAgreementMember" unitRef="USD" decimals="0">15995</us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent>
<atnm:DerivativeWarrantsUnits contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">1968623</atnm:DerivativeWarrantsUnits>
<atnm:DerivativeWarrantsUnits contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">1774962</atnm:DerivativeWarrantsUnits>
<atnm:TransferFromLiabilityClassificationToEquityClassification contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">-193661</atnm:TransferFromLiabilityClassificationToEquityClassification>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">6707255</us-gaap:DerivativeFairValueOfDerivativeNet>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9826627</us-gaap:DerivativeFairValueOfDerivativeNet>
<atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-1501988</atnm:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<atnm:ChangeInFairValueOfDerivativeWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4621360</atnm:ChangeInFairValueOfDerivativeWarrants>
<atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2" id="Footnote-1_1">5.89</atnm:MarketValueOfCommonStockOnMeasurementDate>
<atnm:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Footnote-1_2">7.22</atnm:MarketValueOfCommonStockOnMeasurementDate>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">2.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">2.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="4" id="Footnote-2_1">0.0127</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="4">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4" id="Footnote-2_2">0.0119</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">P6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P3Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">P10Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Footnote-3_1">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.88</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="2" id="Footnote-3_2">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.8706</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.8776</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" xsi:nil="true" id="Footnote-4_1"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" xsi:nil="true" id="Footnote-4_2"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Footnote-5_1">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="2" id="Footnote-5_2">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<atnm:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Footnote-6_1">0.35</atnm:RangeOfPercentageOfExistingSharesOffered>
<atnm:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" xsi:nil="true" id="Footnote-6_2"/>
<atnm:FairValueAssumptionOfferingPrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="0" id="Footnote-7_1">9</atnm:FairValueAssumptionOfferingPrice>
<atnm:FairValueAssumptionOfferingPrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Footnote-7_2">7.50</atnm:FairValueAssumptionOfferingPrice>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="USD" decimals="0">1501988</us-gaap:FairValueAdjustmentOfWarrants>
<atnm:NumberOfSharesWarrantExercise contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">662160</atnm:NumberOfSharesWarrantExercise>
<atnm:DerivativeNumberOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_DerivativeByNatureAxis_WarrantMember" unitRef="shares" decimals="INF">193661</atnm:DerivativeNumberOfWarrants>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember" unitRef="USD" decimals="0">1750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember" unitRef="USD" decimals="0">1500000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<atnm:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">7750000</atnm:LongTermPurchaseCommitmentMilestonesPayment>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-6">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<atnm:PaymentOfLicenseFee contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">3000000</atnm:PaymentOfLicenseFee>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<atnm:RoyaltyOfNetSalesPercentage contextRef="Context_Custom_01_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="pure" decimals="2">0.02</atnm:RoyaltyOfNetSalesPercentage>
<atnm:RoyaltyOfNetSalesPercentage contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="pure" decimals="2">0.12</atnm:RoyaltyOfNetSalesPercentage>
<atnm:FirstCommercialSalePeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">P12Y6M</atnm:FirstCommercialSalePeriod>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">233100</atnm:PurchaseOfRadioactiveMaterial>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndThirteenMember" unitRef="USD" decimals="-5">300000</atnm:PurchaseOfRadioactiveMaterial>
<atnm:PurchaseOfRadioactiveMaterial contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember_PeriodAxis_TwoThousandAndFourteenMember" unitRef="USD" decimals="-5">400000</atnm:PurchaseOfRadioactiveMaterial>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_07_Jul_2012T00_00_00_TO_06_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_01_Oct_2012T00_00_00_TO_22_Oct_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_01_May_2013T00_00_00_TO_16_May_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_Custom_25_Jan_2014T00_00_00_TO_27_Jan_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="0">2813960</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">1100000</atnm:ProjectEstimatedCost>
<atnm:ProjectEstimatedCost contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="-5">2100000</atnm:ProjectEstimatedCost>
<atnm:DownPaymentOfProjectEstimatedCostPercentage contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="pure" decimals="3">0.125</atnm:DownPaymentOfProjectEstimatedCostPercentage>
<atnm:DownPaymentForProject contextRef="Context_Custom_01_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</atnm:DownPaymentForProject>
<atnm:DownPaymentForProject contextRef="Context_Custom_07_Jul_2012T00_00_00_TO_06_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">1900000</atnm:DownPaymentForProject>
<atnm:DownPaymentForProject contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</atnm:DownPaymentForProject>
<atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember" unitRef="USD" decimals="-5">23500000</atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember" unitRef="USD" decimals="-5">13200000</atnm:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<atnm:FundToRelatedPartyUnderAgreementForFirstTwoYear contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">150000</atnm:FundToRelatedPartyUnderAgreementForFirstTwoYear>
<atnm:FundToRelatedPartyUnderAgreementAfterYearTwo contextRef="Context_As_Of_15_Jun_2012T00_00_00_TO_15_Jun_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">250000</atnm:FundToRelatedPartyUnderAgreementAfterYearTwo>
<atnm:NonRefundableInstitutionalFee contextRef="Context_Custom_01_Aug_2012T00_00_00_TO_28_Aug_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">14500</atnm:NonRefundableInstitutionalFee>
<atnm:NonRefundableInstitutionalFee contextRef="Context_Custom_25_Jan_2014T00_00_00_TO_27_Jan_2014T00_00_00_AgreementAxis_ManufacturingAgreementMember" unitRef="USD" decimals="0">562790</atnm:NonRefundableInstitutionalFee>
<atnm:PharmacyFee contextRef="Context_Custom_01_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">2025</atnm:PharmacyFee>
<atnm:AmendmentProcessingFee contextRef="Context_Custom_01_Sep_2012T00_00_00_TO_26_Sep_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500</atnm:AmendmentProcessingFee>
<atnm:NoticePeriodForTerminationOfAgreement contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_RentalAgreementMember">This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</atnm:NoticePeriodForTerminationOfAgreement>
<atnm:AgreementRenewalDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_RentalAgreementMember">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</atnm:AgreementRenewalDescription>
<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
<us-gaap:LegalFees contextRef="Context_Custom_01_Nov_2012T00_00_00_TO_21_Nov_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</us-gaap:LegalFees>
<us-gaap:DevelopmentInProcess contextRef="Context_As_Of_20_Jan_2014T00_00_00_TO_20_Jan_2014T00_00_00" unitRef="USD" decimals="-5">800000</us-gaap:DevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="-5">100000</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1985384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">9673290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2952829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">9418058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">312500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">979100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">406928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">11655</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">662160</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">868287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">9195074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">9.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">5.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">11.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">P4Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P10Y</atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">P7Y5M16D</atnm:Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y4M6D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">P4Y6M15D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P5Y11M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">P4Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5908696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">47396307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">8300565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">56362310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="-5">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5418017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="2">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<atnm:FairValueAssumptionsExpectedDiscountRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0188</atnm:FairValueAssumptionsExpectedDiscountRate>
<atnm:FairValueAssumptionsExpectedDiscountRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0207</atnm:FairValueAssumptionsExpectedDiscountRate>
<atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">445167</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">&lt;p&gt;&amp;#160;Of the total shares of restricted stock, 20,000 shares vest 3 months from the grant date, 22,500 shares vest 1 year from the grant date, 199,167 shares have a vesting period of 4 years and 200,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-5">7100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">2873557</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">5220</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">94200</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00" unitRef="USD" decimals="0">188400</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2013T00_00_00_TO_30_Jun_2013T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">607791</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">889195</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="USD" decimals="0">98224</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">10165000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">96868</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">12525000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<atnm:UnderwritingDiscount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">876750</atnm:UnderwritingDiscount>
<atnm:UnderwritingAgreementDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember">Under the terms of the underwriting agreement entered into with Canaccord Genuity Inc. as representative (the "Representative") of the several underwriters (collectively, the "Underwriters"), the Company also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.</atnm:UnderwritingAgreementDescription>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="-5">3300000</us-gaap:ProceedsFromIssuanceOfWarrants>
<atnm:PlacementAgentCashFees contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">395000</atnm:PlacementAgentCashFees>
<atnm:PlacementAgentAttorneyFees contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementClassOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">40000</atnm:PlacementAgentAttorneyFees>
<atnm:WarrantsExercisedByWarrantHolders contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_WarrantMember" unitRef="shares" decimals="0">662160</atnm:WarrantsExercisedByWarrantHolders>
<atnm:RegistrationStatementDescription contextRef="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00">This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the "Sales Agreement") with MLV &amp;amp; Co. LLC ("MLV") dated March 24, 2014.</atnm:RegistrationStatementDescription>
<atnm:MaximumOfferingPrice contextRef="Context_Custom_04_Mar_2014T00_00_00_TO_24_Mar_2014T00_00_00" unitRef="shares" decimals="INF">75000000</atnm:MaximumOfferingPrice>
<us-gaap:OtherExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">125000</us-gaap:OtherExpenses>
<us-gaap:ProfessionalFees contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_IPOMember" unitRef="USD" decimals="0">72000</us-gaap:ProfessionalFees>
<atnm:AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">157123</atnm:AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption>
<atnm:AmountExercisedThroughOverAllotmentOptionGross contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="-5">1200000</atnm:AmountExercisedThroughOverAllotmentOptionGross>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">1827123</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="-5">13700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="Context_Custom_03_Jul_2014T00_00_00_TO_10_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="-5">12500000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">176211</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_20_Jul_2014T00_00_00_TO_25_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_ConsultantMember" unitRef="shares" decimals="0">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_EquityIncentivePlanMember" unitRef="shares" decimals="0">6750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_05_Jul_2014T00_00_00_TO_07_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_InvestorsMember" unitRef="USD" decimals="0">48000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_20_Jul_2014T00_00_00_TO_25_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_StatementEquityComponentsAxis_ConsultantMember" unitRef="shares" decimals="0">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_1" xlink:label="lab_Footnote-3_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_2" xlink:label="lab_Footnote-3_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_1" xlink:label="lab_Footnote-4_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_2" xlink:label="lab_Footnote-4_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_1" xlink:label="lab_Footnote-5_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_2" xlink:label="lab_Footnote-5_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_1" xlink:label="lab_Footnote-6_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-6_2" xlink:label="lab_Footnote-6_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-6" xlink:from="lab_Footnote-6_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-7_1" xlink:label="lab_Footnote-7_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-7" xlink:from="lab_Footnote-7_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-7_2" xlink:label="lab_Footnote-7_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-7" xlink:from="lab_Footnote-7_2"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for June 30, 2014.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-3">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-4">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-5">Management determines the probability of future stock offering at each evaluation date.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-6">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-7">Represents the estimated offering price range in future offerings as determined by management.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>atnm-20140630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.0 on Tuesday, August 12, 2014 12:43:00 AM -->
<schema targetNamespace="http://actiniumpharmaceuticals.com/20140630" elementFormDefault="qualified" xmlns:atnm="http://actiniumpharmaceuticals.com/20140630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>007 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>008 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/NotePayable" id="NotePayable">
<link:definition>009 - Disclosure - Note Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Derivatives" id="Derivatives">
<link:definition>010 - Disclosure - Derivatives</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>011 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="Equity">
<link:definition>012 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>013 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<link:definition>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<link:definition>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>016 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables" id="PropertyandEquipmentTables">
<link:definition>017 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesTables" id="DerivativesTables">
<link:definition>018 - Disclosure - Derivatives (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>019 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="EquityTables">
<link:definition>020 - Disclosure - Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<link:definition>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>022 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>023 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
<link:definition>024 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails" id="PropertyandEquipmentDetails">
<link:definition>025 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
<link:definition>026 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails" id="NotePayableDetails">
<link:definition>027 - Disclosure - Note Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails" id="DerivativesDetails">
<link:definition>028 - Disclosure - Derivatives (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1" id="DerivativesDetails1">
<link:definition>029 - Disclosure - Derivatives (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual" id="DerivativesDetailsTextual">
<link:definition>030 - Disclosure - Derivatives (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>031 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual" id="Commitmentsandcontingenciesdetailstextual">
<link:definition>032 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="EquityDetails">
<link:definition>033 - Disclosure - Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
<link:definition>034 - Disclosure - Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>035 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="atnm-20140630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="atnm_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCTwoPreferredStockMember" id="atnm_SeriesCTwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCThreePreferredStockMember" id="atnm_SeriesCThreePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesCFourPreferredStockMember" id="atnm_SeriesCFourPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainOnChangeInFairValueOfDerivatives" id="atnm_GainOnChangeInFairValueOfDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" id="atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromExerciseOfOptionsAndWarrantsForCash" id="atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfNotesPayableAndAccruedInterestToCommonStock" id="atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransferFromLiabilityClassificationToEquityClassificationValue" id="atnm_TransferFromLiabilityClassificationToEquityClassificationValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DevelopmentStageCompanyPolicyTextBlock" id="atnm_DevelopmentStageCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" id="atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentsMilestoneMethodTableTextBlock" id="atnm_MilestonePaymentsMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" id="atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ActiniumMember" id="atnm_ActiniumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsAndWarrantsMember" id="atnm_OptionsAndWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" id="atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuableInConsiderationForEquityInterestAcquisition" id="atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesExchangeRatio" id="atnm_SharesExchangeRatio" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockShares" id="atnm_CommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExchangedInCommonStockShares" id="atnm_ExchangedInCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MemorialSloanKetteringCancerCenterMember" id="atnm_MemorialSloanKetteringCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NewDrugApplicationMember" id="atnm_NewDrugApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReceiptOfRegulatoryApprovalFromUSFdaMember" id="atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyMilestonesPayment" id="atnm_RelatedPartyMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SloanKetteringInstituteOfCancerResearchMember" id="atnm_SloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" id="atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RosemaryMazanetMember" id="atnm_RosemaryMazanetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaidlawAndCompanyMember" id="atnm_LaidlawAndCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JamessCapitalGroupMember" id="atnm_JamessCapitalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GuagentiAndAssociatesMember" id="atnm_GuagentiAndAssociatesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementAxis" id="atnm_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="atnm_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialAgreementMember" id="atnm_ClinicalTrialAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseDevelopmentAndCommercializationAgreementMember" id="atnm_LicenseDevelopmentAndCommercializationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingServicesAgreementMember" id="atnm_ConsultingServicesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EngagementAgreementMember" id="atnm_EngagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransactionManagementAgreementMember" id="atnm_TransactionManagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentMember" id="atnm_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyTransactionsTextualAbstract" id="atnm_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfPatients" id="atnm_NumberOfPatients" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreementInYearTwoThousandEleven" id="atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreementInYearTwoThousandTwelve" id="atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreementInYearTwoThousandThirteen" id="atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" id="atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaintenanceFeesAndResearchPayments" id="atnm_MaintenanceFeesAndResearchPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentServicesFees" id="atnm_PlacementAgentServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedToPurchaseCommonStock" id="atnm_WarrantsIssuedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockExercisePriceParOrStatedValuePerShare" id="atnm_CommonStockExercisePriceParOrStatedValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidUnderAgreement" id="atnm_AmountPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalAmountDueUnderAgreement" id="atnm_AdditionalAmountDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfConditionForTerminationOfForbearancePeriod" id="atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TerminationDateOfForbearanceAgreement" id="atnm_TerminationDateOfForbearanceAgreement" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" id="atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NewEquityFinanceRaisedByCompany" id="atnm_NewEquityFinanceRaisedByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ForgivenAmountOfObligations" id="atnm_ForgivenAmountOfObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidToEachPatient" id="atnm_AmountPaidToEachPatient" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StartUpFeeForClinicalTrial" id="atnm_StartUpFeeForClinicalTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StartUpDueCostPaidDate" id="atnm_StartUpDueCostPaidDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfSharesTransferTerm" id="atnm_DescriptionOfSharesTransferTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionExercisePriceRange" id="atnm_OptionExercisePriceRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsReceivedToPurchaseCommonStock" id="atnm_OptionsReceivedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfReceivablesOfPlacementAgentForServices" id="atnm_DescriptionOfReceivablesOfPlacementAgentForServices" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfWarrantsReceivablesByPlacement" id="atnm_DescriptionOfWarrantsReceivablesByPlacement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodOfExerciseOfWarrants" id="atnm_PeriodOfExerciseOfWarrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfSolicitationFee" id="atnm_PercentageOfSolicitationFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicFeeForFinancialAdvisoryServices" id="atnm_PeriodicFeeForFinancialAdvisoryServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfAdditionalReceivableByPlacementAgent" id="atnm_DescriptionOfAdditionalReceivableByPlacementAgent" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseByHoldingOfWarrant" id="atnm_CommonStockPurchaseByHoldingOfWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicFeeReceivedByManagementFirm" id="atnm_PeriodicFeeReceivedByManagementFirm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfFullyDilutedCapitalStockEqualToCommonStock" id="atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumAmountOfOutOfPocketExpenses" id="atnm_MaximumAmountOfOutOfPocketExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicAmountOfRent" id="atnm_PeriodicAmountOfRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidToPursuantLeaseAgreement" id="atnm_AmountPaidToPursuantLeaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingFee" id="atnm_ConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SettlementPaymentOfConsultingFee" id="atnm_SettlementPaymentOfConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsToPurchaseCommonStockDescription" id="atnm_WarrantsToPurchaseCommonStockDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PropertyAndEquipmentTextualAbstract" id="atnm_PropertyAndEquipmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumFinanceAgreementMember" id="atnm_PremiumFinanceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManagementFirmMember" id="atnm_ManagementFirmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotePayableAndConvertibleNotesTextualAbstract" id="atnm_NotePayableAndConvertibleNotesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseDueToIssuanceOfWarrants" id="atnm_CommonStockPurchaseDueToIssuanceOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizationPeriodOfNote" id="atnm_AmortizationPeriodOfNote" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumFinanceAgreementPrincipalAmount" id="atnm_PremiumFinanceAgreementPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentUnderPremiumFinanceAgreement" id="atnm_PaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicPaymentUnderPremiumFinanceAgreement" id="atnm_PeriodicPaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DurationOfPeriodicPaymentsForPremiumFinanceAgreement" id="atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PremiumFinanceAgreementOutstandingAmount" id="atnm_PremiumFinanceAgreementOutstandingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromConvertibleNotes" id="atnm_ProceedsFromConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" id="atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" id="atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsIssuedWithConvertibleNotes" id="atnm_DerivativeWarrantsIssuedWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestmentWarrantGrantDateFairValue" id="atnm_InvestmentWarrantGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtInstrumentDiscountRelatedToBeneficialConversionFeature" id="atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtInstrumentFairValuePerShare" id="atnm_DebtInstrumentFairValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExtendedMaturityPeriodOfConvertibleNotes" id="atnm_ExtendedMaturityPeriodOfConvertibleNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfExtendedMaturityDate" id="atnm_DescriptionOfExtendedMaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" id="atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsUnits" id="atnm_DerivativeWarrantsUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransferFromLiabilityClassificationToEquityClassification" id="atnm_TransferFromLiabilityClassificationToEquityClassification" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfTransferFromLiabilityClassificationToEquityClassification" id="atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfDerivativeWarrants" id="atnm_ChangeInFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" id="atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarketValueOfCommonStockOnMeasurementDate" id="atnm_MarketValueOfCommonStockOnMeasurementDate" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfPercentageOfExistingSharesOffered" id="atnm_RangeOfPercentageOfExistingSharesOffered" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueAssumptionOfferingPrice" id="atnm_FairValueAssumptionOfferingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeTextualAbstract" id="atnm_DerivativeTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfRiskFreeInterestRateDetermination" id="atnm_DescriptionOfRiskFreeInterestRateDetermination" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfProbabilityOfStockOffering" id="atnm_DescriptionOfProbabilityOfStockOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSharesWarrantExercise" id="atnm_NumberOfSharesWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeNumberOfWarrants" id="atnm_DerivativeNumberOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AbbottBiotherapeuticsCorpMember" id="atnm_AbbottBiotherapeuticsCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseFirstClinicalTrialOfLicensedProductMember" id="atnm_PhaseFirstClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseSecondClinicalTrialOfLicensedProductMember" id="atnm_PhaseSecondClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseThirdClinicalTrialOfLicensedProductMember" id="atnm_PhaseThirdClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BiologicalLicenseApplicationMember" id="atnm_BiologicalLicenseApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstCommercialSaleMember" id="atnm_FirstCommercialSaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AfterFirstNetSalesMember" id="atnm_AfterFirstNetSalesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentAbstract" id="atnm_MilestonePaymentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LongTermPurchaseCommitmentMilestonesPayment" id="atnm_LongTermPurchaseCommitmentMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTable" id="atnm_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="OakRidgeNationalLaboratoryMember" id="atnm_OakRidgeNationalLaboratoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AptivSolutionsMember" id="atnm_AptivSolutionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FredHutchinsonCancerResearchCenterMember" id="atnm_FredHutchinsonCancerResearchCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" id="atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfTexasMDAndersonCancerCenterMember" id="atnm_UniversityOfTexasMDAndersonCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JohnsHopkinsUniversityMember" id="atnm_JohnsHopkinsUniversityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaidlawAndCoMember" id="atnm_LaidlawAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfPennsylvaniaMember" id="atnm_UniversityOfPennsylvaniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FormerChiefExecutiveOfficerMember" id="atnm_FormerChiefExecutiveOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodAxis" id="atnm_PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="PeriodDomain" id="atnm_PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandAndThirteenMember" id="atnm_TwoThousandAndThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandAndFourteenMember" id="atnm_TwoThousandAndFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProductDevelopmentAndPatentLicenseAgreementMember" id="atnm_ProductDevelopmentAndPatentLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementMember" id="atnm_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAndSponsoredResearchAgreementMember" id="atnm_LicenseAndSponsoredResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentAgreementMember" id="atnm_PlacementAgentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeparationAndSettlementAgreementMember" id="atnm_SeparationAndSettlementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManufacturingAgreementMember" id="atnm_ManufacturingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RentalAgreementMember" id="atnm_RentalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesLineItems" id="atnm_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTextualAbstract" id="atnm_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfLicenseFee" id="atnm_PaymentOfLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentDate" id="atnm_MilestonePaymentDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfRoyaltyPaymentToRelatedParty" id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyOfNetSalesPercentage" id="atnm_RoyaltyOfNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstCommercialSalePeriod" id="atnm_FirstCommercialSalePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ResearchAndDevelopmentArrangement" id="atnm_ResearchAndDevelopmentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchaseOfRadioactiveMaterial" id="atnm_PurchaseOfRadioactiveMaterial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProjectEstimatedCost" id="atnm_ProjectEstimatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownPaymentOfProjectEstimatedCostPercentage" id="atnm_DownPaymentOfProjectEstimatedCostPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownPaymentForProject" id="atnm_DownPaymentForProject" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialCostForApprovalForFoodAndDrugAdministration" id="atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundToRelatedPartyUnderAgreementForFirstTwoYear" id="atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundToRelatedPartyUnderAgreementAfterYearTwo" id="atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementConsideration" id="atnm_AgreementConsideration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceBonusPayableUnderAgreementForService" id="atnm_PerformanceBonusPayableUnderAgreementForService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantExercisableNoticePeriodDescription" id="atnm_WarrantExercisableNoticePeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfSharesAvailabilityByExerciseOfWarrant" id="atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonRefundableInstitutionalFee" id="atnm_NonRefundableInstitutionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PharmacyFee" id="atnm_PharmacyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmendmentProcessingFee" id="atnm_AmendmentProcessingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoticePeriodForTerminationOfAgreement" id="atnm_NoticePeriodForTerminationOfAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementRenewalDescription" id="atnm_AgreementRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfAggregateAmount" id="atnm_PaymentOfAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfFinalInstallmentForServicesByCompany" id="atnm_PaymentOfFinalInstallmentForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfPerformanceBonusForServicesByCompany" id="atnm_PaymentOfPerformanceBonusForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesDirectorsAndConsultantsMember" id="atnm_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTextualsAbstract" id="atnm_EquityTextualsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueAssumptionsExpectedDiscountRate" id="atnm_FairValueAssumptionsExpectedDiscountRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnderwritingDiscount" id="atnm_UnderwritingDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnderwritingAgreementDescription" id="atnm_UnderwritingAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentCashFees" id="atnm_PlacementAgentCashFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentAttorneyFees" id="atnm_PlacementAgentAttorneyFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsExercisedByWarrantHolders" id="atnm_WarrantsExercisedByWarrantHolders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RegistrationStatementDescription" id="atnm_RegistrationStatementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumOfferingPrice" id="atnm_MaximumOfferingPrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoLegacyShareholdersMember" id="atnm_TwoLegacyShareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorsMember" id="atnm_InvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantMember" id="atnm_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityIncentivePlanMember" id="atnm_EquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubsequentEventsTextualAbstract" id="atnm_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" id="atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountExercisedThroughOverAllotmentOptionGross" id="atnm_AmountExercisedThroughOverAllotmentOptionGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>atnm-20140630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.0 on Tuesday, August 12, 2014 12:43:00 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_SecurityDeposit" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_Depreciation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnm_GainOnChangeInFairValueOfDerivatives"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnm_GainOnChangeInFairValueOfDerivatives" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xlink:label="loc_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="120" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:label="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="20" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>atnm-20140630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.0 on Tuesday, August 12, 2014 12:43:00 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#RelatedPartyTransactionsDetails" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#NotePayableDetails" roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DerivativesDetails1" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DerivativesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#Commitmentsandcontingenciesdetailstextual" roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#EquityDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#SubsequentEventsDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_AssetsCurrentAbstract_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_AssetsCurrent_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_SecurityDeposit_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_Assets_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_NotesPayableCurrent_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrent_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_Liabilities_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_30" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_31" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapital_32" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_34" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_18" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_7" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ActiniumMember" xlink:label="loc_atnm_ActiniumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_atnm_ActiniumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_CommonStockMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_WarrantMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionsAndWarrantsMember" xlink:label="loc_atnm_OptionsAndWarrantsMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_atnm_OptionsAndWarrantsMember_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_24" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SharesExchangeRatio" xlink:label="loc_atnm_SharesExchangeRatio_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_SharesExchangeRatio_25" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_26" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockShares" xlink:label="loc_atnm_CommonStockShares_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_CommonStockShares_27" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_atnm_ExchangedInCommonStockShares_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_19" xlink:to="loc_atnm_ExchangedInCommonStockShares_28" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_NewDrugApplicationMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_atnm_RelatedPartyMilestonesPayment_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_9" xlink:to="loc_atnm_RelatedPartyMilestonesPayment_10" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_atnm_RosemaryMazanetMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_RosemaryMazanetMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_atnm_LaidlawAndCompanyMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCompanyMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_atnm_GuagentiAndAssociatesMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_GuagentiAndAssociatesMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_WarrantMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_atnm_AgreementAxis_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_15" xlink:to="loc_atnm_AgreementDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_15" xlink:to="loc_atnm_AgreementDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_ClinicalTrialAgreementMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_atnm_ConsultingServicesAgreementMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_ConsultingServicesAgreementMember_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EngagementAgreementMember" xlink:label="loc_atnm_EngagementAgreementMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_EngagementAgreementMember_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_TransactionManagementAgreementMember_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_22" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_22" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_22" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23" xlink:to="loc_atnm_PlacementAgentMember_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_atnm_RelatedPartyTransactionsTextualAbstract_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_OfficersCompensation_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_NumberOfPatients_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_28" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_29" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_30" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_31" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_atnm_MaintenanceFeesAndResearchPayments_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_MaintenanceFeesAndResearchPayments_32" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_atnm_PlacementAgentServicesFees_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PlacementAgentServicesFees_33" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_34" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_35" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_atnm_AmountPaidUnderAgreement_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AmountPaidUnderAgreement_36" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_atnm_AdditionalAmountDueUnderAgreement_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AdditionalAmountDueUnderAgreement_37" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_38" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_atnm_TerminationDateOfForbearanceAgreement_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_TerminationDateOfForbearanceAgreement_39" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_40" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_atnm_NewEquityFinanceRaisedByCompany_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_NewEquityFinanceRaisedByCompany_41" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_atnm_ForgivenAmountOfObligations_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_ForgivenAmountOfObligations_42" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AmountPaidToEachPatient_43" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_44" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_StartUpDueCostPaidDate_45" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_atnm_DescriptionOfSharesTransferTerm_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_DescriptionOfSharesTransferTerm_46" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_atnm_OptionExercisePriceRange_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_OptionExercisePriceRange_47" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_atnm_OptionsReceivedToPurchaseCommonStock_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_OptionsReceivedToPurchaseCommonStock_48" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_49" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_50" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_atnm_PeriodOfExerciseOfWarrants_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PeriodOfExerciseOfWarrants_51" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_atnm_PercentageOfSolicitationFee_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PercentageOfSolicitationFee_52" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_53" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_54" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_55" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_56" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_57" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_58" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_atnm_PeriodicAmountOfRent_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_PeriodicAmountOfRent_59" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_atnm_AmountPaidToPursuantLeaseAgreement_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_AmountPaidToPursuantLeaseAgreement_60" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_61" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultingFee" xlink:label="loc_atnm_ConsultingFee_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_ConsultingFee_62" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_atnm_SettlementPaymentOfConsultingFee_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_SettlementPaymentOfConsultingFee_63" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_64" order="380" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_65" order="390" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_66"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_66" order="400" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67" order="410" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_68"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_68" order="420" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_69"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_DebtInstrumentTerm_69" order="430" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" order="440" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_71"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_71" order="450" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72" order="460" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_73"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_73" order="470" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsToPurchaseCommonStockDescription" xlink:label="loc_atnm_WarrantsToPurchaseCommonStockDescription_74"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_25" xlink:to="loc_atnm_WarrantsToPurchaseCommonStockDescription_74" order="480" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_atnm_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_atnm_PremiumFinanceAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_3" xlink:to="loc_atnm_PremiumFinanceAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_PlacementAgentMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ManagementFirmMember" xlink:label="loc_atnm_ManagementFirmMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_ManagementFirmMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_atnm_AmortizationPeriodOfNote_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_atnm_AmortizationPeriodOfNote_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_NotesPayable_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_9" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_17" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnm_FairValueAssumptionOfferingPrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_atnm_FairValueAssumptionOfferingPrice_15" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_atnm_DerivativeTextualAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_atnm_DerivativeTextualAbstract_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_atnm_DescriptionOfProbabilityOfStockOffering_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_DescriptionOfProbabilityOfStockOffering_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_atnm_NumberOfSharesWarrantExercise_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_NumberOfSharesWarrantExercise_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeNumberOfWarrants" xlink:label="loc_atnm_DerivativeNumberOfWarrants_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_DerivativeTextualAbstract_12" xlink:to="loc_atnm_DerivativeNumberOfWarrants_19" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_atnm_BiologicalLicenseApplicationMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_BiologicalLicenseApplicationMember_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_atnm_FirstCommercialSaleMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_FirstCommercialSaleMember_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_AfterFirstNetSalesMember_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_NewDrugApplicationMember_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_atnm_MilestonePaymentAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_atnm_MilestonePaymentAbstract_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_MilestonePaymentAbstract_16" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_17" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual">
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_atnm_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_atnm_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnm_OakRidgeNationalLaboratoryMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_OakRidgeNationalLaboratoryMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AptivSolutionsMember" xlink:label="loc_atnm_AptivSolutionsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AptivSolutionsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnm_FredHutchinsonCancerResearchCenterMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_atnm_JohnsHopkinsUniversityMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JohnsHopkinsUniversityMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCoMember_12" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_atnm_UniversityOfPennsylvaniaMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfPennsylvaniaMember_13" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_14" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_15" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_AfterFirstNetSalesMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MaximumMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MinimumMember_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodAxis" xlink:label="loc_atnm_PeriodAxis_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_PeriodAxis_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_atnm_TwoThousandAndThirteenMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndThirteenMember_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_atnm_TwoThousandAndFourteenMember_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndFourteenMember_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_AgreementAxis_28" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_atnm_AgreementAxis_28" xlink:to="loc_atnm_AgreementDomain_29" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_29_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_atnm_AgreementAxis_28" xlink:to="loc_atnm_AgreementDomain_29_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseAgreementMember" xlink:label="loc_atnm_LicenseAgreementMember_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAgreementMember_31" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ClinicalTrialAgreementMember_33" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_atnm_PlacementAgentAgreementMember_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_PlacementAgentAgreementMember_34" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_TransactionManagementAgreementMember_35" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_36" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_atnm_ManufacturingAgreementMember_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ManufacturingAgreementMember_37" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RentalAgreementMember" xlink:label="loc_atnm_RentalAgreementMember_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_RentalAgreementMember_38" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_40" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_TechnologyServicesCosts_41" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_MaintenanceCosts_42" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_atnm_PaymentOfLicenseFee_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PaymentOfLicenseFee_43" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_44" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentDate" xlink:label="loc_atnm_MilestonePaymentDate_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_MilestonePaymentDate_45" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_46" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_atnm_RoyaltyOfNetSalesPercentage_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_RoyaltyOfNetSalesPercentage_47" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnm_FirstCommercialSalePeriod_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_FirstCommercialSalePeriod_48" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_atnm_ResearchAndDevelopmentArrangement_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_ResearchAndDevelopmentArrangement_49" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_atnm_PurchaseOfRadioactiveMaterial_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PurchaseOfRadioactiveMaterial_50" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnm_ProjectEstimatedCost_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_ProjectEstimatedCost_51" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_52" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DownPaymentForProject" xlink:label="loc_atnm_DownPaymentForProject_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_DownPaymentForProject_53" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_54" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_55" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_56" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_NumberOfPatients_57" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_AmountPaidToEachPatient_58" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_59" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_StartUpDueCostPaidDate_60" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementConsideration" xlink:label="loc_atnm_AgreementConsideration_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_AgreementConsideration_61" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_atnm_PerformanceBonusPayableUnderAgreementForService_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PerformanceBonusPayableUnderAgreementForService_62" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_63" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_64" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_atnm_WarrantExercisableNoticePeriodDescription_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_WarrantExercisableNoticePeriodDescription_65" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_66"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_66" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_67"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_67" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_atnm_NonRefundableInstitutionalFee_68"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_NonRefundableInstitutionalFee_68" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PharmacyFee" xlink:label="loc_atnm_PharmacyFee_69"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PharmacyFee_69" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_atnm_AmendmentProcessingFee_70"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_AmendmentProcessingFee_70" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_atnm_NoticePeriodForTerminationOfAgreement_71"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_NoticePeriodForTerminationOfAgreement_71" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_72"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_LeaseExpirationDate1_72" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_atnm_AgreementRenewalDescription_73"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_AgreementRenewalDescription_73" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_atnm_PaymentOfAggregateAmount_74"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PaymentOfAggregateAmount_74" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_75"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_75" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_76"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_76" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_77"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_77" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_78"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_LegalFees_78" order="380" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_79"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_79" order="390" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaap_DevelopmentInProcess_80"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_DevelopmentInProcess_80" order="400" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_81"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_81" order="410" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_82"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_39" xlink:to="loc_us-gaap_SecurityDeposit_82" order="420" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_19" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_20" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_23" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24" order="170" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PrivatePlacementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_IPOMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" xlink:to="loc_atnm_LaidlawAndCoMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" xlink:to="loc_atnm_PlacementAgentMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_15" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_15" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnm_EmployeesDirectorsAndConsultantsMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16" xlink:to="loc_atnm_EmployeesDirectorsAndConsultantsMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16" xlink:to="loc_us-gaap_InvestorMember_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20" xlink:to="loc_us-gaap_EmployeeStockOptionMember_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RangeAxis_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MinimumMember_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MaximumMember_25" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnm_EquityTextualsAbstract_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_atnm_EquityTextualsAbstract_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_DebtInstrumentTerm_28" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_30" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_31" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_32" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_33" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnm_FairValueAssumptionsExpectedDiscountRate_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_FairValueAssumptionsExpectedDiscountRate_34" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_35" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:label="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_37" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_38" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_39" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_40" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_41" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_43" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_44" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_45" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_46" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_47" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_48" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_49" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_50" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_52" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UnderwritingDiscount" xlink:label="loc_atnm_UnderwritingDiscount_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_UnderwritingDiscount_53" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UnderwritingAgreementDescription" xlink:label="loc_atnm_UnderwritingAgreementDescription_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_UnderwritingAgreementDescription_54" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_55" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_atnm_PlacementAgentCashFees_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_PlacementAgentCashFees_56" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_atnm_PlacementAgentAttorneyFees_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_PlacementAgentAttorneyFees_57" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_58" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnm_WarrantsExercisedByWarrantHolders_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_WarrantsExercisedByWarrantHolders_59" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_atnm_RegistrationStatementDescription_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_RegistrationStatementDescription_60" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_atnm_MaximumOfferingPrice_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_atnm_MaximumOfferingPrice_61" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_62" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_OtherExpenses_63" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_EquityTextualsAbstract_26" xlink:to="loc_us-gaap_ProfessionalFees_64" order="370" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoLegacyShareholdersMember" xlink:label="loc_atnm_TwoLegacyShareholdersMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_TwoLegacyShareholdersMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_InvestorsMember" xlink:label="loc_atnm_InvestorsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_InvestorsMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultantMember" xlink:label="loc_atnm_ConsultantMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_ConsultantMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EquityIncentivePlanMember" xlink:label="loc_atnm_EquityIncentivePlanMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_EquityIncentivePlanMember_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnm_SubsequentEventsTextualAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_atnm_SubsequentEventsTextualAbstract_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xlink:label="loc_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountExercisedThroughOverAllotmentOptionGross" xlink:label="loc_atnm_AmountExercisedThroughOverAllotmentOptionGross_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_atnm_AmountExercisedThroughOverAllotmentOptionGross_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22" order="90" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>atnm-20140630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.0 on Tuesday, August 12, 2014 12:43:00 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_6275329951G0_atnm_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_DocumentAndEntityInformationAbstract" xlink:to="lab_8497541173I2_atnm_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityRegistrantName" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_6275329951G0_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityCentralIndexKey" xlink:to="lab_8497541173I2_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_4HG8324JGII39406FJGK_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_AmendmentFlag" xlink:to="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_6275329951G0_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_CurrentFiscalYearEndDate" xlink:to="lab_8497541173I2_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_4HG8324JGII39406FJGK_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_DocumentType" xlink:to="lab_6JI0546LIKK51628HLIM_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_6275329951G0_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_DocumentPeriodEndDate" xlink:to="lab_8497541173I2_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_4HG8324JGII39406FJGK_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_DocumentFiscalYearFocus" xlink:to="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_6275329951G0_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_DocumentFiscalPeriodFocus" xlink:to="lab_8497541173I2_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityFilerCategory" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_6275329951G0_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_6275329951G0_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StatementTable" xlink:to="lab_8497541173I2_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementClassOfStockAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_6275329951G0_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ClassOfStockDomain" xlink:to="lab_8497541173I2_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_6275329951G0_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_8497541173I2_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SeriesCPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_6275329951G0_us-gaap_SeriesDPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_8497541173I2_us-gaap_SeriesDPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SeriesEPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SeriesEPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_6275329951G0_atnm_SeriesCTwoPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C Two Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C-2 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_SeriesCTwoPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C two preferred stock or outstanding series C two preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_SeriesCTwoPreferredStockMember" xlink:to="lab_8497541173I2_atnm_SeriesCTwoPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_SeriesCThreePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C Three Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C-3 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SeriesCThreePreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C three preferred stock or outstanding series C three preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_SeriesCThreePreferredStockMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_SeriesCThreePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_6275329951G0_atnm_SeriesCFourPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C Four Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C-4 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_SeriesCFourPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C four preferred stock or outstanding series C four preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_SeriesCFourPreferredStockMember" xlink:to="lab_8497541173I2_atnm_SeriesCFourPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_6275329951G0_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AssetsAbstract" xlink:to="lab_8497541173I2_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AssetsCurrentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_6275329951G0_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_8497541173I2_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_6275329951G0_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AssetsCurrent" xlink:to="lab_8497541173I2_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net of accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_6275329951G0_us-gaap_SecurityDeposit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SecurityDeposit" xlink:to="lab_8497541173I2_us-gaap_SecurityDeposit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_Assets" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_6275329951G0_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_6275329951G0_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_8497541173I2_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_6275329951G0_us-gaap_NotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NotesPayableCurrent" xlink:to="lab_8497541173I2_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_6275329951G0_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LiabilitiesCurrent" xlink:to="lab_8497541173I2_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_Liabilities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_6275329951G0_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommitmentsAndContingencies" xlink:to="lab_8497541173I2_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity (Deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockholdersEquityAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_6275329951G0_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, 100,000,000 Shares .01 Par Authorized, 0 Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, 100,000,000 shares $.01 par authorized, 0 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.01 par value; 10,000,000 authorized none issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PreferredStockValue" xlink:to="lab_8497541173I2_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, 100,000,000 shares, $.01 par authorized, 11,155,008 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 27,602,192 and 24,565,447 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockValue" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_6275329951G0_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Paid in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AdditionalPaidInCapital" xlink:to="lab_8497541173I2_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_6275329951G0_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholder's Deficiency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StockholdersEquity" xlink:to="lab_8497541173I2_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_6275329951G0_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_8497541173I2_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_6275329951G0_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PreferredStockSharesIssued" xlink:to="lab_8497541173I2_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">No. of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_6275329951G0_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_8497541173I2_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_6275329951G0_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued in exchange of equity securities of company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock sold, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommonStockSharesIssued" xlink:to="lab_8497541173I2_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_6275329951G0_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements Of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeStatementAbstract" xlink:to="lab_8497541173I2_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SalesRevenueNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SalesRevenueNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_6275329951G0_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingExpensesAbstract" xlink:to="lab_8497541173I2_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research recorded fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development, net of reimbursements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_6275329951G0_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_Depreciation" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_6275329951G0_us-gaap_GainLossOnDispositionOfAssets1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_8497541173I2_us-gaap_GainLossOnDispositionOfAssets1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OperatingExpenses" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_6275329951G0_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingIncomeLoss" xlink:to="lab_8497541173I2_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_6275329951G0_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_InterestExpense" xlink:to="lab_8497541173I2_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) On Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain (loss) on change in fair value of derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain/loss on change in fair value of the derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_6275329951G0_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income and (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_8497541173I2_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetIncomeLoss" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_6275329951G0_us-gaap_EarningsPerShareBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net income (loss) per common share - basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_EarningsPerShareBasic" xlink:to="lab_8497541173I2_us-gaap_EarningsPerShareBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerShareDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net income (loss) per common share - diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerShareDiluted" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_6275329951G0_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average common shares outstanding - basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_8497541173I2_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average common shares outstanding - diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_6275329951G0_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_8497541173I2_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_6275329951G0_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensation" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_6275329951G0_us-gaap_DepreciationDepletionAndAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_8497541173I2_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Add: amortization of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_6275329951G0_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_8497541173I2_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gains (Losses) On Extinguishment Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_6275329951G0_atnm_GainOnChangeInFairValueOfDerivatives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain On Change In Fair Value Of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_atnm_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Loss (gain) on change in fair value of derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_GainOnChangeInFairValueOfDerivatives" xlink:to="lab_8497541173I2_atnm_GainOnChangeInFairValueOfDerivatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_6275329951G0_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xlink:label="loc_4HG8324JGII39406FJGK_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xml:lang="en-US">Increase Decrease In Research And Development Reimbursable Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xml:lang="en-US">Increase decrease in Research and development reimbursable receivable.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xml:lang="en-US">R&amp;D reimbursable receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_6275329951G0_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_8497541173I2_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_6275329951G0_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (decrease) in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_6275329951G0_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_8497541173I2_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_6275329951G0_us-gaap_RepaymentsOfNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_8497541173I2_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds From Issuance Of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Sales of stock, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from issuance of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:label="loc_6275329951G0_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xml:lang="en-US">Proceeds From Exercise Of Options And Warrants For Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xml:lang="en-US">Proceeds from the exercise of options and warrants for cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xml:lang="en-US">Proceeds from the exercise of options and warrants for cash.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:to="lab_8497541173I2_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_6275329951G0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">INCREASE IN CASH AND CASH EQUIVALENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_6275329951G0_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_InterestPaid" xlink:to="lab_8497541173I2_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxesPaid" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_6275329951G0_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_8497541173I2_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion Of Notes Payable and Accrued Interest To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransferFromLiabilityClassificationToEquityClassificationValue" xlink:label="loc_6275329951G0_atnm_TransferFromLiabilityClassificationToEquityClassificationValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassificationValue" xml:lang="en-US">Transfer From Liability Classification To Equity Classification, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassificationValue" xml:lang="en-US">Transfer from liability classification to equity classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassificationValue" xml:lang="en-US">Transfer from liability classification to equity classification, Value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_TransferFromLiabilityClassificationToEquityClassificationValue" xlink:to="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassificationValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_6275329951G0_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_8497541173I2_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Note Payable [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Amortization of debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_DebtDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Note Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivatives [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EquityAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_BusinessCombinationsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_BusinessCombinationsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DevelopmentStageCompanyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for development Stage of the company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DevelopmentStageCompanyPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DevelopmentStageCompanyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_ConsolidationPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_UseOfEstimates" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_6275329951G0_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_8497541173I2_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_DerivativesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Share-Based Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_6275329951G0_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of set forth liabilities measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_8497541173I2_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule Of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Summary of activities related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule Of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_6275329951G0_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair Value Of Derivative Warrants On Basis Of Valuation Model [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair value of derivative warrants on basis of valuation model.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="lab_8497541173I2_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone Payments Milestone Method [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Summary of milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AwardTypeAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EmployeeStockOptionMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_6275329951G0_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_WarrantMember" xml:lang="en-US">A Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_8497541173I2_us-gaap_WarrantMember" xml:lang="en-US">Warrant holders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_WarrantMember" xlink:to="lab_8497541173I2_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of option activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Summary of warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_6275329951G0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_8497541173I2_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_6275329951G0_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_8497541173I2_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_6275329951G0_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_8497541173I2_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_6275329951G0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_8497541173I2_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_4HG8324JGII39406FJGK_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xml:lang="en-US">Summary Of Liabilities Measured At Fair Value On Recurring Basis [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xml:lang="en-US">Summary of liabilities measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_6275329951G0_us-gaap_DerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeLiabilities" xlink:to="lab_8497541173I2_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description of business and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_6275329951G0_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_LegalEntityAxis" xlink:to="lab_8497541173I2_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityDomain" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ActiniumMember" xlink:label="loc_6275329951G0_atnm_ActiniumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ActiniumMember" xml:lang="en-US">Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ActiniumMember" xlink:to="lab_8497541173I2_atnm_ActiniumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_MachineryAndEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_MachineryAndEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_6275329951G0_us-gaap_FurnitureAndFixturesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_8497541173I2_us-gaap_FurnitureAndFixturesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_6275329951G0_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_8497541173I2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_6275329951G0_us-gaap_ConvertiblePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_8497541173I2_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ConvertibleNotesPayableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionsAndWarrantsMember" xlink:label="loc_6275329951G0_atnm_OptionsAndWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_OptionsAndWarrantsMember" xml:lang="en-US">Options And Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_OptionsAndWarrantsMember" xlink:to="lab_8497541173I2_atnm_OptionsAndWarrantsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description of business and summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_6275329951G0_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_8497541173I2_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityIncorporationDateOfIncorporation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityIncorporationDateOfIncorporation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_6275329951G0_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership interest acquired by company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_8497541173I2_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_4HG8324JGII39406FJGK_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock Issuable In Consideration For Equity Interest Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SharesExchangeRatio" xlink:label="loc_4HG8324JGII39406FJGK_atnm_SharesExchangeRatio"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SharesExchangeRatio" xml:lang="en-US">Shares Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SharesExchangeRatio" xml:lang="en-US">Shares received by each API shareholder of Actinium common stock for each API share exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SharesExchangeRatio" xml:lang="en-US">Shares exchange ratio.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_SharesExchangeRatio" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_SharesExchangeRatio"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_6275329951G0_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially issuable shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_8497541173I2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockShares" xlink:label="loc_4HG8324JGII39406FJGK_atnm_CommonStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockShares" xml:lang="en-US">Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockShares" xml:lang="en-US">Common stock shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockShares" xml:lang="en-US">Common stock shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_CommonStockShares" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_CommonStockShares"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_6275329951G0_atnm_ExchangedInCommonStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Exchanged In Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ExchangedInCommonStockShares" xlink:to="lab_8497541173I2_atnm_ExchangedInCommonStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_6275329951G0_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_8497541173I2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyDomain" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_6275329951G0_atnm_MemorialSloanKetteringCancerCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial sloan kettering cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_MemorialSloanKetteringCancerCenterMember" xlink:to="lab_8497541173I2_atnm_MemorialSloanKetteringCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_6275329951G0_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-Term Purchase Commitment, Category Of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_NewDrugApplicationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_NewDrugApplicationMember" xml:lang="en-US">New drug application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_NewDrugApplicationMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_NewDrugApplicationMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_6275329951G0_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt Of Regulatory Approval From U S Fda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of Regulatory Approval From U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of regulatory approval from U.S. FDA.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:to="lab_8497541173I2_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_6275329951G0_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Related Party Transaction, Due From (To) Related Party, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Summary of milestone payments related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:to="lab_8497541173I2_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_4HG8324JGII39406FJGK_atnm_RelatedPartyMilestonesPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Related Party Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_RelatedPartyMilestonesPayment" xml:lang="en-US">Related party milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_RelatedPartyMilestonesPayment" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_RelatedPartyMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_6275329951G0_atnm_SloanKetteringInstituteOfCancerResearchMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_8497541173I2_atnm_SloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">MSKCC and SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial sloan kettering cancer center sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_6275329951G0_atnm_RosemaryMazanetMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_RosemaryMazanetMember" xml:lang="en-US">Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_RosemaryMazanetMember" xml:lang="en-US">Dr. Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_RosemaryMazanetMember" xml:lang="en-US">Rosemary mazanet.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_RosemaryMazanetMember" xlink:to="lab_8497541173I2_atnm_RosemaryMazanetMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_LaidlawAndCompanyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_LaidlawAndCompanyMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_LaidlawAndCompanyMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_6275329951G0_atnm_JamessCapitalGroupMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_JamessCapitalGroupMember" xml:lang="en-US">Jamess capital group.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_JamessCapitalGroupMember" xlink:to="lab_8497541173I2_atnm_JamessCapitalGroupMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_GuagentiAndAssociatesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and Associates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti &amp; Associates LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and associates.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_GuagentiAndAssociatesMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_GuagentiAndAssociatesMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_6275329951G0_atnm_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AgreementAxis" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AgreementAxis" xlink:to="lab_8497541173I2_atnm_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AgreementDomain" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AgreementDomain" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_6275329951G0_atnm_ClinicalTrialAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical trial agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ClinicalTrialAgreementMember" xlink:to="lab_8497541173I2_atnm_ClinicalTrialAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_LicenseDevelopmentAndCommercializationAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License, Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License development and commercialization agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_LicenseDevelopmentAndCommercializationAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_6275329951G0_atnm_ConsultingServicesAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting services agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ConsultingServicesAgreementMember" xlink:to="lab_8497541173I2_atnm_ConsultingServicesAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EngagementAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_EngagementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_EngagementAgreementMember" xml:lang="en-US">Engagement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_EngagementAgreementMember" xml:lang="en-US">Engagement agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_EngagementAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_EngagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_6275329951G0_atnm_TransactionManagementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction Management Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_TransactionManagementAgreementMember" xlink:to="lab_8497541173I2_atnm_TransactionManagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PlacementAgentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentMember" xml:lang="en-US">Placement agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentMember" xml:lang="en-US">Placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PlacementAgentMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_6275329951G0_atnm_RelatedPartyTransactionsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_8497541173I2_atnm_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OfficersCompensation" xml:lang="en-US">Base salary at annual rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OfficersCompensation" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfPatients" xlink:label="loc_6275329951G0_atnm_NumberOfPatients"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_NumberOfPatients" xml:lang="en-US">Number Of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_NumberOfPatients" xml:lang="en-US">Number of Patients enrolled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_NumberOfPatients" xml:lang="en-US">Number of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_NumberOfPatients" xml:lang="en-US">Number of patients.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_NumberOfPatients" xlink:to="lab_8497541173I2_atnm_NumberOfPatients"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Eleven</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in year two thousand eleven.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_6275329951G0_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Twelve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in year two thousand twelve.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:to="lab_8497541173I2_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Thirteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in year two thousand thirteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_6275329951G0_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Owed Amount Under Agreement In Year Two Thousand Eleven To Fourteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Amount owed under agreement from 2011 to 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xml:lang="en-US">Owed amount under agreement in year two thousand eleven to fourteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:to="lab_8497541173I2_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MaintenanceFeesAndResearchPayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance Fees and Research Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees and research payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MaintenanceFeesAndResearchPayments" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MaintenanceFeesAndResearchPayments"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_6275329951G0_atnm_PlacementAgentServicesFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement Agent Services Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PlacementAgentServicesFees" xlink:to="lab_8497541173I2_atnm_PlacementAgentServicesFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_4HG8324JGII39406FJGK_atnm_WarrantsIssuedToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants issued to purchase common stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Aggregate Shares Of Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_WarrantsIssuedToPurchaseCommonStock" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_WarrantsIssuedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_6275329951G0_atnm_CommonStockExercisePriceParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common Stock Exercise Price Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common stock exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xml:lang="en-US">Common stock exercise price par or stated value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:to="lab_8497541173I2_atnm_CommonStockExercisePriceParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AmountPaidUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount Paid Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AmountPaidUnderAgreement" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidUnderAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_6275329951G0_atnm_AdditionalAmountDueUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional Amount Due Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AdditionalAmountDueUnderAgreement" xlink:to="lab_8497541173I2_atnm_AdditionalAmountDueUnderAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description Of Condition For Termination Of Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Condition for termination of forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description of condition for termination of forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_6275329951G0_atnm_TerminationDateOfForbearanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination Date Of Forbearance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_TerminationDateOfForbearanceAgreement" xlink:to="lab_8497541173I2_atnm_TerminationDateOfForbearanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum New Equity Financing Needed Under Condition For Termination Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new equity financing needed under condition for termination forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new Equity Financing needed under condition for termination Forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_6275329951G0_atnm_NewEquityFinanceRaisedByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New Equity Finance Raised By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_NewEquityFinanceRaisedByCompany" xlink:to="lab_8497541173I2_atnm_NewEquityFinanceRaisedByCompany"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ForgivenAmountOfObligations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven Amount Of Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ForgivenAmountOfObligations" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ForgivenAmountOfObligations"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_6275329951G0_atnm_AmountPaidToEachPatient"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount Paid To Each Patient</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount paid to each patient after Completing clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AmountPaidToEachPatient" xml:lang="en-US">Amount to be paid for each Patient that has completed the clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AmountPaidToEachPatient" xlink:to="lab_8497541173I2_atnm_AmountPaidToEachPatient"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_4HG8324JGII39406FJGK_atnm_StartUpFeeForClinicalTrial"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start Up Fee For Clinical Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_StartUpFeeForClinicalTrial" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_StartUpFeeForClinicalTrial"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_6275329951G0_atnm_StartUpDueCostPaidDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start Up Due Cost Paid Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Due date of start-up fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_StartUpDueCostPaidDate" xlink:to="lab_8497541173I2_atnm_StartUpDueCostPaidDate"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfSharesTransferTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description Of Shares Transfer Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term transfer by AHLB on behalf of AHL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfSharesTransferTerm" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesTransferTerm"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_6275329951G0_atnm_OptionExercisePriceRange"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_OptionExercisePriceRange" xml:lang="en-US">Option exercise price range.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_OptionExercisePriceRange" xlink:to="lab_8497541173I2_atnm_OptionExercisePriceRange"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_4HG8324JGII39406FJGK_atnm_OptionsReceivedToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options Received To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_OptionsReceivedToPurchaseCommonStock" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_OptionsReceivedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_6275329951G0_atnm_DescriptionOfReceivablesOfPlacementAgentForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description Of Receivables Of Placement Agent For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:to="lab_8497541173I2_atnm_DescriptionOfReceivablesOfPlacementAgentForServices"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfWarrantsReceivablesByPlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description Of Warrants Receivables By Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfWarrantsReceivablesByPlacement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_6275329951G0_atnm_PeriodOfExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period Of Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PeriodOfExerciseOfWarrants" xlink:to="lab_8497541173I2_atnm_PeriodOfExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PercentageOfSolicitationFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage Of Solicitation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PercentageOfSolicitationFee" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PercentageOfSolicitationFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_6275329951G0_atnm_PeriodicFeeForFinancialAdvisoryServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic Fee For Financial Advisory Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Monthly fee for financial advisory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic fee for financial advisory services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:to="lab_8497541173I2_atnm_PeriodicFeeForFinancialAdvisoryServices"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfAdditionalReceivableByPlacementAgent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description Of Additional Receivable By Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfAdditionalReceivableByPlacementAgent"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_6275329951G0_atnm_CommonStockPurchaseByHoldingOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common Stock Purchase By Holding Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Warrant held by placement agent to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common stock purchase by holding of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:to="lab_8497541173I2_atnm_CommonStockPurchaseByHoldingOfWarrant"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PeriodicFeeReceivedByManagementFirm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic Fee Received By Management Firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Monthly fee received by management firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic fee received by management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PeriodicFeeReceivedByManagementFirm" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PeriodicFeeReceivedByManagementFirm"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_6275329951G0_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock Equal To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:to="lab_8497541173I2_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MaximumAmountOfOutOfPocketExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum Amount Of Out Of Pocket Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MaximumAmountOfOutOfPocketExpenses" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MaximumAmountOfOutOfPocketExpenses"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_6275329951G0_atnm_PeriodicAmountOfRent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PeriodicAmountOfRent" xml:lang="en-US">Periodic Amount Of Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PeriodicAmountOfRent" xml:lang="en-US">Operating lease monthly amount of rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PeriodicAmountOfRent" xml:lang="en-US">Periodic amount of rent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PeriodicAmountOfRent" xlink:to="lab_8497541173I2_atnm_PeriodicAmountOfRent"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AmountPaidToPursuantLeaseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount Paid To Pursuant Lease Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AmountPaidToPursuantLeaseAgreement" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AmountPaidToPursuantLeaseAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_6275329951G0_us-gaap_OtherResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Other Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Paid for research conducted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_8497541173I2_us-gaap_OtherResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultingFee" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ConsultingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ConsultingFee" xml:lang="en-US">Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ConsultingFee" xml:lang="en-US">Consulting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ConsultingFee" xml:lang="en-US">Consulting expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ConsultingFee" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ConsultingFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_6275329951G0_atnm_SettlementPaymentOfConsultingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement Payment Of Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement Payment Of Consulting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_SettlementPaymentOfConsultingFee" xml:lang="en-US">Settlement payment of consulting fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_SettlementPaymentOfConsultingFee" xlink:to="lab_8497541173I2_atnm_SettlementPaymentOfConsultingFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xml:lang="en-US">Artist Advances and Royalty Guarantees, Commitments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xml:lang="en-US">Royalty description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_6275329951G0_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Net payable to MSKCC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_8497541173I2_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock sold, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Warrants granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Warrants granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SaleOfStockPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentTerm" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_6275329951G0_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xml:lang="en-US">Gross proceeds from the sale of securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="lab_8497541173I2_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Net proceeds from the public offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Gross proceeds received in Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Aggregate offering amount of securities sold to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Aggregate offering amount of securities sold to investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsToPurchaseCommonStockDescription" xlink:label="loc_4HG8324JGII39406FJGK_atnm_WarrantsToPurchaseCommonStockDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Warrants To Purchase Common Stock Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Warrants to purchase common stock description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Warrants to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_WarrantsToPurchaseCommonStockDescription" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_WarrantsToPurchaseCommonStockDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OfficeEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OfficeEquipmentMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_6275329951G0_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RangeAxis" xlink:to="lab_8497541173I2_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RangeMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_6275329951G0_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_MaximumMember" xlink:to="lab_8497541173I2_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_MinimumMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, By Type [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Office equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Equipment and parts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_6275329951G0_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_8497541173I2_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PropertyAndEquipmentTextualAbstract" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PropertyAndEquipmentTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PropertyAndEquipmentTextualAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PropertyAndEquipmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PremiumFinanceAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PremiumFinanceAgreementMember" xml:lang="en-US">Premium Finance Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PremiumFinanceAgreementMember" xml:lang="en-US">Premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PremiumFinanceAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PremiumFinanceAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ManagementFirmMember" xlink:label="loc_6275329951G0_atnm_ManagementFirmMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ManagementFirmMember" xml:lang="en-US">Management Firm [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ManagementFirmMember" xml:lang="en-US">Management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ManagementFirmMember" xlink:to="lab_8497541173I2_atnm_ManagementFirmMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_6275329951G0_atnm_NotePayableAndConvertibleNotesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:to="lab_8497541173I2_atnm_NotePayableAndConvertibleNotesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_4HG8324JGII39406FJGK_atnm_CommonStockPurchaseDueToIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common Stock Purchase Due To Issuance Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchasable through warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchase due to issuance of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_CommonStockPurchaseDueToIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_6275329951G0_invest_InvestmentWarrantsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_8497541173I2_invest_InvestmentWarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentFaceAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible promissory note amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Amount of original issue discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: original issuance discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AmortizationPeriodOfNote"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization Period Of Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AmortizationPeriodOfNote" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AmortizationPeriodOfNote"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_6275329951G0_us-gaap_NotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NotesPayable" xml:lang="en-US">Notes payable, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NotesPayable" xlink:to="lab_8497541173I2_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Down payment pursuant to the agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_6275329951G0_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Due to Officers or Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xml:lang="en-US">Amount required to pay in monthly installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="lab_8497541173I2_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Promissory note interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_6275329951G0_atnm_PremiumFinanceAgreementPrincipalAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium Finance Agreement Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PremiumFinanceAgreementPrincipalAmount" xlink:to="lab_8497541173I2_atnm_PremiumFinanceAgreementPrincipalAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PaymentUnderPremiumFinanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PaymentUnderPremiumFinanceAgreement" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_6275329951G0_atnm_PeriodicPaymentUnderPremiumFinanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Monthly amount payable under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic amount payable under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:to="lab_8497541173I2_atnm_PeriodicPaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration Of Periodic Payments For Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_6275329951G0_atnm_PremiumFinanceAgreementOutstandingAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium Finance Agreement Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PremiumFinanceAgreementOutstandingAmount" xlink:to="lab_8497541173I2_atnm_PremiumFinanceAgreementOutstandingAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProceedsFromConvertibleNotes" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ProceedsFromConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds From Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Net proceeds of promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds from senior subordinated unsecured convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ProceedsFromConvertibleNotes" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ProceedsFromConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_6275329951G0_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage Of Principle Amount In Which Convertible Note Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:to="lab_8497541173I2_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentMaturityDateDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Convertible note maturity term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_6275329951G0_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross Proceeds In Subsequent Offerings Of Common Stock Or Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:to="lab_8497541173I2_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DerivativeWarrantsIssuedWithConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative Warrants Issued With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Common stock issued to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with Convertible Notes (See Note 5), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative warrants Issued With Convertible Notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsIssuedWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_InvestmentWarrantGrantDateFairValue" xlink:label="loc_6275329951G0_atnm_InvestmentWarrantGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment Warrant Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_InvestmentWarrantGrantDateFairValue" xlink:to="lab_8497541173I2_atnm_InvestmentWarrantGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt instrument discount related to the beneficial conversion feature.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Less: discount related to the beneficial conversion feature</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DebtInstrumentFairValuePerShare" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DebtInstrumentFairValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt Instrument Fair Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Convertible note fair value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt instrument fair value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DebtInstrumentFairValuePerShare" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DebtInstrumentFairValuePerShare"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_6275329951G0_atnm_ExtendedMaturityPeriodOfConvertibleNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended Maturity Period Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:to="lab_8497541173I2_atnm_ExtendedMaturityPeriodOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfExtendedMaturityDate" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfExtendedMaturityDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description Of Extended Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfExtendedMaturityDate" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfExtendedMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_6275329951G0_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible notes and the accrued interest converted into common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_8497541173I2_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Common stock issued by conversion of note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_6275329951G0_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule Of Derivative Warrant Instruments Activity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:to="lab_8497541173I2_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DerivativeWarrantsUnits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Total warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Beginning balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits" xml:lang="en-US">Derivative warrants units.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DerivativeWarrantsUnits" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DerivativeWarrantsUnits"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_6275329951G0_atnm_TransferFromLiabilityClassificationToEquityClassification"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_8497541173I2_atnm_TransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Beginning balance, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Balance, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_6275329951G0_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair Value Of Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair value of Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_8497541173I2_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ChangeInFairValueOfDerivativeWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change In Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value of derivative warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ChangeInFairValueOfDerivativeWarrants" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ChangeInFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_6275329951G0_us-gaap_DerivativeTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeTable" xlink:to="lab_8497541173I2_us-gaap_DerivativeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_6275329951G0_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary Of Fair Value Of Derivative Warrants On Basis Of Valuation Model [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="lab_8497541173I2_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MarketValueOfCommonStockOnMeasurementDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market Value Of Common Stock On Measurement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MarketValueOfCommonStockOnMeasurementDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_6275329951G0_us-gaap_FairValueAssumptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Adjusted exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_8497541173I2_us-gaap_FairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (2)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair value assumptions, risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_6275329951G0_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Term of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Warrant lives in years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Contractual life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair value assumptions, expected term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (3)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair value assumptions, expected volatility rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_6275329951G0_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield (4)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair value assumptions, expected dividend rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_8497541173I2_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueInputsProbabilityOfDefault"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Fair Value Inputs, Probability Of Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Probability of stock offering in any period over 5 years (5)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueInputsProbabilityOfDefault"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_6275329951G0_atnm_RangeOfPercentageOfExistingSharesOffered"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range Of Percentage Of Existing Shares Offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered (6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_RangeOfPercentageOfExistingSharesOffered" xlink:to="lab_8497541173I2_atnm_RangeOfPercentageOfExistingSharesOffered"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_4HG8324JGII39406FJGK_atnm_FairValueAssumptionOfferingPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair Value Assumption Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Offering price range (7)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair value assumption offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_FairValueAssumptionOfferingPrice" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_FairValueAssumptionOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_6275329951G0_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) By Hedging Relationship, By Income Statement Location, By Derivative Instrument Risk [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_8497541173I2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeByNatureAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeByNatureAxis" xml:lang="en-US">Derivative, by Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeByNatureAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeByNatureAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_6275329951G0_us-gaap_DerivativeNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeNameDomain" xml:lang="en-US">Derivative, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeNameDomain" xlink:to="lab_8497541173I2_us-gaap_DerivativeNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeInstrumentsGainLossLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsGainLossLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_6275329951G0_atnm_DerivativeTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_DerivativeTextualAbstract" xml:lang="en-US">Derivative Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_DerivativeTextualAbstract" xml:lang="en-US">Derivatives (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_DerivativeTextualAbstract" xlink:to="lab_8497541173I2_atnm_DerivativeTextualAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfRiskFreeInterestRateDetermination"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description Of Risk Free Interest Rate Determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description of risk free interest rate determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description of risk free interest rate determination.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRiskFreeInterestRateDetermination"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_6275329951G0_atnm_DescriptionOfProbabilityOfStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description Of Probability Of Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_DescriptionOfProbabilityOfStockOffering" xlink:to="lab_8497541173I2_atnm_DescriptionOfProbabilityOfStockOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueAdjustmentOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_6275329951G0_atnm_NumberOfSharesWarrantExercise"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number Of Shares Warrant Exercise</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number of warrant exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_NumberOfSharesWarrantExercise" xml:lang="en-US">Number of shares warrant exercise.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_NumberOfSharesWarrantExercise" xlink:to="lab_8497541173I2_atnm_NumberOfSharesWarrantExercise"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeNumberOfWarrants" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DerivativeNumberOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeNumberOfWarrants" xml:lang="en-US">Derivative Number Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeNumberOfWarrants" xml:lang="en-US">Derivative warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DerivativeNumberOfWarrants" xml:lang="en-US">Derivative number of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DerivativeNumberOfWarrants" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DerivativeNumberOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_6275329951G0_us-gaap_LongTermPurchaseCommitmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-Term Purchase Commitment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-term Purchase Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AbbottBiotherapeuticsCorpMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott biotherapeutics corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AbbottBiotherapeuticsCorpMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AbbottBiotherapeuticsCorpMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_6275329951G0_atnm_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase First Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase I Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase first clinical trial of a licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:to="lab_8497541173I2_atnm_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Second Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase II Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase second clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_6275329951G0_atnm_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Third Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:to="lab_8497541173I2_atnm_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_BiologicalLicenseApplicationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application filing with U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological license application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_BiologicalLicenseApplicationMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_BiologicalLicenseApplicationMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_6275329951G0_atnm_FirstCommercialSaleMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FirstCommercialSaleMember" xml:lang="en-US">First commercial sale.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FirstCommercialSaleMember" xlink:to="lab_8497541173I2_atnm_FirstCommercialSaleMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AfterFirstNetSalesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AfterFirstNetSalesMember" xml:lang="en-US">After first net sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AfterFirstNetSalesMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AfterFirstNetSalesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_6275329951G0_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_8497541173I2_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MilestonePaymentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentAbstract" xml:lang="en-US">Milestone Payment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentAbstract" xml:lang="en-US">Summary of milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MilestonePaymentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MilestonePaymentAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_6275329951G0_atnm_LongTermPurchaseCommitmentMilestonesPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long Term Purchase Commitment Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long term purchase commitment milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="lab_8497541173I2_atnm_LongTermPurchaseCommitmentMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_4HG8324JGII39406FJGK_atnm_CommitmentsAndContingenciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_CommitmentsAndContingenciesTable" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_6275329951G0_atnm_OakRidgeNationalLaboratoryMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak ridge national laboratory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_OakRidgeNationalLaboratoryMember" xlink:to="lab_8497541173I2_atnm_OakRidgeNationalLaboratoryMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AptivSolutionsMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AptivSolutionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AptivSolutionsMember" xml:lang="en-US">Aptiv solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AptivSolutionsMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AptivSolutionsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_6275329951G0_atnm_FredHutchinsonCancerResearchCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred hutchinson cancer research center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FredHutchinsonCancerResearchCenterMember" xlink:to="lab_8497541173I2_atnm_FredHutchinsonCancerResearchCenterMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and Ii Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I/II Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and II clinical trial for actimab in elderly acute myeloid leukemia.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_6275329951G0_atnm_UniversityOfTexasMDAndersonCancerCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University Of Texas M D Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of Texas M.D. Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of texas M.D. anderson cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_8497541173I2_atnm_UniversityOfTexasMDAndersonCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_JohnsHopkinsUniversityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns hopkins university.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_JohnsHopkinsUniversityMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_JohnsHopkinsUniversityMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_6275329951G0_atnm_LaidlawAndCoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw &amp; Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_LaidlawAndCoMember" xlink:to="lab_8497541173I2_atnm_LaidlawAndCoMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_UniversityOfPennsylvaniaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University Of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of pennsylvania.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_UniversityOfPennsylvaniaMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_UniversityOfPennsylvaniaMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_6275329951G0_atnm_FormerChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FormerChiefExecutiveOfficerMember" xml:lang="en-US">former chief executive officer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FormerChiefExecutiveOfficerMember" xlink:to="lab_8497541173I2_atnm_FormerChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodAxis" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PeriodAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PeriodAxis" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PeriodAxis"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodDomain" xlink:label="loc_6275329951G0_atnm_PeriodDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PeriodDomain" xlink:to="lab_8497541173I2_atnm_PeriodDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_TwoThousandAndThirteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_TwoThousandAndThirteenMember" xml:lang="en-US">Two Thousand And Thirteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_TwoThousandAndThirteenMember" xml:lang="en-US">2013 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_TwoThousandAndThirteenMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_TwoThousandAndThirteenMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_6275329951G0_atnm_TwoThousandAndFourteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_TwoThousandAndFourteenMember" xml:lang="en-US">Two Thousand And Fourteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_TwoThousandAndFourteenMember" xml:lang="en-US">2014 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_TwoThousandAndFourteenMember" xlink:to="lab_8497541173I2_atnm_TwoThousandAndFourteenMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product Development and Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product development and patent license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseAgreementMember" xlink:label="loc_6275329951G0_atnm_LicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_LicenseAgreementMember" xml:lang="en-US">License agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_LicenseAgreementMember" xml:lang="en-US">License agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_LicenseAgreementMember" xlink:to="lab_8497541173I2_atnm_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_LicenseAndSponsoredResearchAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and Sponsored Research Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">license and sponsored research agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and sponsored research agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_LicenseAndSponsoredResearchAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_LicenseAndSponsoredResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_6275329951G0_atnm_PlacementAgentAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PlacementAgentAgreementMember" xml:lang="en-US">Placement agent agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PlacementAgentAgreementMember" xlink:to="lab_8497541173I2_atnm_PlacementAgentAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_SeparationAndSettlementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_SeparationAndSettlementAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_SeparationAndSettlementAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_6275329951G0_atnm_ManufacturingAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ManufacturingAgreementMember" xlink:to="lab_8497541173I2_atnm_ManufacturingAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RentalAgreementMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_RentalAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_RentalAgreementMember" xml:lang="en-US">Rental agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_RentalAgreementMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_RentalAgreementMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_6275329951G0_atnm_CommitmentsAndContingenciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_CommitmentsAndContingenciesLineItems" xlink:to="lab_8497541173I2_atnm_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_4HG8324JGII39406FJGK_atnm_CommitmentsAndContingenciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_6275329951G0_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Net sales in milestones payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_8497541173I2_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_TechnologyServicesCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology Services Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology access fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_TechnologyServicesCosts" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_TechnologyServicesCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_6275329951G0_us-gaap_MaintenanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_MaintenanceCosts" xml:lang="en-US">Maintenance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_MaintenanceCosts" xml:lang="en-US">Annual maintenance fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_MaintenanceCosts" xlink:to="lab_8497541173I2_us-gaap_MaintenanceCosts"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PaymentOfLicenseFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfLicenseFee" xml:lang="en-US">Payment Of License Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfLicenseFee" xml:lang="en-US">License fee payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfLicenseFee" xml:lang="en-US">License fee payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PaymentOfLicenseFee" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfLicenseFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentDate" xlink:label="loc_6275329951G0_atnm_MilestonePaymentDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone Payment Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone payment date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_MilestonePaymentDate" xml:lang="en-US">Milestone payment date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_MilestonePaymentDate" xlink:to="lab_8497541173I2_atnm_MilestonePaymentDate"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description Of Royalty Payment To Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment to related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_6275329951G0_atnm_RoyaltyOfNetSalesPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty Of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of net sales percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_RoyaltyOfNetSalesPercentage" xlink:to="lab_8497541173I2_atnm_RoyaltyOfNetSalesPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_4HG8324JGII39406FJGK_atnm_FirstCommercialSalePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First Commercial Sale Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_FirstCommercialSalePeriod" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_FirstCommercialSalePeriod"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_6275329951G0_atnm_ResearchAndDevelopmentArrangement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and Development Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Annual research funding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and development arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ResearchAndDevelopmentArrangement" xlink:to="lab_8497541173I2_atnm_ResearchAndDevelopmentArrangement"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PurchaseOfRadioactiveMaterial"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase Of Radioactive Material</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material used for research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PurchaseOfRadioactiveMaterial" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PurchaseOfRadioactiveMaterial"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_6275329951G0_atnm_ProjectEstimatedCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ProjectEstimatedCost" xml:lang="en-US">Project Estimated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost for clinical trials of drug Ac-225-HuM195</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ProjectEstimatedCost" xlink:to="lab_8497541173I2_atnm_ProjectEstimatedCost"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DownPaymentOfProjectEstimatedCostPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down Payment Of Project Estimated Cost Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down payment of project estimated cost percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Percentage of total estimated project cost required for down payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DownPaymentOfProjectEstimatedCostPercentage"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DownPaymentForProject" xlink:label="loc_6275329951G0_atnm_DownPaymentForProject"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_DownPaymentForProject" xml:lang="en-US">Down Payment For Project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_DownPaymentForProject" xml:lang="en-US">Down payment for project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_DownPaymentForProject" xml:lang="en-US">Down payment for project.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_DownPaymentForProject" xlink:to="lab_8497541173I2_atnm_DownPaymentForProject"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical Trial Cost For Approval For Food and Drug Administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_6275329951G0_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund To Related Party Under Agreement For First Two Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund to related party under agreement for first two Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:to="lab_8497541173I2_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_4HG8324JGII39406FJGK_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund To Related Party Under Agreement After Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund to related party under agreement after year two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementConsideration" xlink:label="loc_6275329951G0_atnm_AgreementConsideration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AgreementConsideration" xml:lang="en-US">Agreement Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_AgreementConsideration" xml:lang="en-US">Agreement consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AgreementConsideration" xml:lang="en-US">Agreement Consideration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AgreementConsideration" xlink:to="lab_8497541173I2_atnm_AgreementConsideration"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PerformanceBonusPayableUnderAgreementForService"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PerformanceBonusPayableUnderAgreementForService" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PerformanceBonusPayableUnderAgreementForService"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_6275329951G0_atnm_WarrantExercisableNoticePeriodDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant Exercisable Notice Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_WarrantExercisableNoticePeriodDescription" xlink:to="lab_8497541173I2_atnm_WarrantExercisableNoticePeriodDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description Of Shares Availability By Exercise Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of period of shares availability by exercise of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of shares availability by exercise of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_6275329951G0_atnm_NonRefundableInstitutionalFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non Refundable Institutional Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non - refundable institutional fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_NonRefundableInstitutionalFee" xml:lang="en-US">Non refundable institutional fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_NonRefundableInstitutionalFee" xlink:to="lab_8497541173I2_atnm_NonRefundableInstitutionalFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PharmacyFee" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PharmacyFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PharmacyFee" xml:lang="en-US">Pharmacy Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PharmacyFee" xml:lang="en-US">Annual pharmacy fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PharmacyFee" xml:lang="en-US">Pharmacy fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PharmacyFee" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PharmacyFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_6275329951G0_atnm_AmendmentProcessingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment Processing Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AmendmentProcessingFee" xlink:to="lab_8497541173I2_atnm_AmendmentProcessingFee"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_4HG8324JGII39406FJGK_atnm_NoticePeriodForTerminationOfAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period For Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice period for termination of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period for termination of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_NoticePeriodForTerminationOfAgreement" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_NoticePeriodForTerminationOfAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_6275329951G0_us-gaap_LeaseExpirationDate1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Sublease agreement termination date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Rent agreement termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LeaseExpirationDate1" xlink:to="lab_8497541173I2_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AgreementRenewalDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AgreementRenewalDescription" xml:lang="en-US">Agreement Renewal Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AgreementRenewalDescription" xml:lang="en-US">Rental agreement renewal description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AgreementRenewalDescription" xml:lang="en-US">Description regarding renewal of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AgreementRenewalDescription" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AgreementRenewalDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_6275329951G0_atnm_PaymentOfAggregateAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment Of Aggregate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount in installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PaymentOfAggregateAmount" xlink:to="lab_8497541173I2_atnm_PaymentOfAggregateAmount"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PaymentOfFinalInstallmentForServicesByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Payment Of Final Installment For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PaymentOfFinalInstallmentForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_6275329951G0_atnm_PaymentOfPerformanceBonusForServicesByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment Of Performance Bonus For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:to="lab_8497541173I2_atnm_PaymentOfPerformanceBonusForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_6275329951G0_us-gaap_LegalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LegalFees" xml:lang="en-US">Accrued fees paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LegalFees" xlink:to="lab_8497541173I2_us-gaap_LegalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DevelopmentInProcess"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DevelopmentInProcess" xml:lang="en-US">Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DevelopmentInProcess" xml:lang="en-US">Total project estimated to cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DevelopmentInProcess" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DevelopmentInProcess"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_6275329951G0_us-gaap_ResearchAndDevelopmentInProcess"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_8497541173I2_us-gaap_ResearchAndDevelopmentInProcess"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of warrants activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of stock option granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Units, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Cancellation and Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Stock option forfeitures during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of stock option cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of option exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Stock option cancelled during period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Warrants expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Restricted common stock and options, Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock option exercise prices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding, Beigning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_6275329951G0_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_8497541173I2_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_4HG8324JGII39406FJGK_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_6275329951G0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based compensation term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_8497541173I2_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Fair value of warrants determined utilizing the Black-Scholes option pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfStockByClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PrivatePlacementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PrivatePlacementMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_6275329951G0_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RestrictedStockMember" xlink:to="lab_8497541173I2_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IPOMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IPOMember" xml:lang="en-US">Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IPOMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IPOMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_6275329951G0_us-gaap_TypeOfArrangementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_TypeOfArrangementAxis" xlink:to="lab_8497541173I2_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_6275329951G0_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_TitleOfIndividualAxis" xlink:to="lab_8497541173I2_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_6275329951G0_atnm_EmployeesDirectorsAndConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees, consultants and board members [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees directors and consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_8497541173I2_atnm_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_InvestorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_InvestorMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_InvestorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_6275329951G0_us-gaap_ClassOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ClassOfStockLineItems" xlink:to="lab_8497541173I2_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_atnm_EquityTextualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_EquityTextualsAbstract" xml:lang="en-US">Equity Textuals [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_EquityTextualsAbstract" xml:lang="en-US">Equity (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_EquityTextualsAbstract" xml:lang="en-US">Equity textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_EquityTextualsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_EquityTextualsAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_6275329951G0_atnm_FairValueAssumptionsExpectedDiscountRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair Value Assumptions Expected Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair value assumptions, expected discount rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_FairValueAssumptionsExpectedDiscountRate" xml:lang="en-US">Fair Value Assumptions Expected Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_FairValueAssumptionsExpectedDiscountRate" xlink:to="lab_8497541173I2_atnm_FairValueAssumptionsExpectedDiscountRate"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:label="loc_4HG8324JGII39406FJGK_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Grants In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xml:lang="en-US">Number of additional stock option granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award options additional grants in period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Description restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based compensation term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_6275329951G0_us-gaap_ProceedsFromStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from the exercise of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_8497541173I2_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Expense related to common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_6275329951G0_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_8497541173I2_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Proceeds from common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UnderwritingDiscount" xlink:label="loc_6275329951G0_atnm_UnderwritingDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_UnderwritingDiscount" xml:lang="en-US">Underwriting Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_atnm_UnderwritingDiscount" xml:lang="en-US">Underwriting discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_UnderwritingDiscount" xml:lang="en-US">Underwriting discount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_UnderwritingDiscount" xlink:to="lab_8497541173I2_atnm_UnderwritingDiscount"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UnderwritingAgreementDescription" xlink:label="loc_4HG8324JGII39406FJGK_atnm_UnderwritingAgreementDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_UnderwritingAgreementDescription" xml:lang="en-US">Underwriting Agreement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_UnderwritingAgreementDescription" xml:lang="en-US">Underwriting agreement description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_UnderwritingAgreementDescription" xml:lang="en-US">Underwriting agreement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_UnderwritingAgreementDescription" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_UnderwritingAgreementDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_6275329951G0_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_8497541173I2_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_4HG8324JGII39406FJGK_atnm_PlacementAgentCashFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement Agent Cash Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_PlacementAgentCashFees" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_PlacementAgentCashFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_6275329951G0_atnm_PlacementAgentAttorneyFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement Agent Attorney Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement agent attorney fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_PlacementAgentAttorneyFees" xml:lang="en-US">Placement agent attorney fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_PlacementAgentAttorneyFees" xlink:to="lab_8497541173I2_atnm_PlacementAgentAttorneyFees"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_4HG8324JGII39406FJGK_atnm_WarrantsExercisedByWarrantHolders"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants Exercised By Warrant Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants exercised by warrant holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_WarrantsExercisedByWarrantHolders" xml:lang="en-US">Warrants exercised by warrant holders.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_WarrantsExercisedByWarrantHolders" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_WarrantsExercisedByWarrantHolders"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_6275329951G0_atnm_RegistrationStatementDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration Statement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration statement description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_RegistrationStatementDescription" xml:lang="en-US">Registration statement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_RegistrationStatementDescription" xlink:to="lab_8497541173I2_atnm_RegistrationStatementDescription"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_4HG8324JGII39406FJGK_atnm_MaximumOfferingPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum offering price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_MaximumOfferingPrice" xml:lang="en-US">Maximum offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_MaximumOfferingPrice" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_MaximumOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_6275329951G0_us-gaap_OtherExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OtherExpenses" xml:lang="en-US">Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OtherExpenses" xml:lang="en-US">Other offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OtherExpenses" xlink:to="lab_8497541173I2_us-gaap_OtherExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProfessionalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProfessionalFees" xml:lang="en-US">Auditor fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProfessionalFees" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProfessionalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventTable" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_6275329951G0_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_8497541173I2_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EquityComponentDomain" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoLegacyShareholdersMember" xlink:label="loc_6275329951G0_atnm_TwoLegacyShareholdersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_TwoLegacyShareholdersMember" xml:lang="en-US">Two Legacy Shareholders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_TwoLegacyShareholdersMember" xlink:to="lab_8497541173I2_atnm_TwoLegacyShareholdersMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_InvestorsMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_InvestorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_InvestorsMember" xml:lang="en-US">Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_InvestorsMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_InvestorsMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultantMember" xlink:label="loc_6275329951G0_atnm_ConsultantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_ConsultantMember" xlink:to="lab_8497541173I2_atnm_ConsultantMember"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EquityIncentivePlanMember" xlink:label="loc_4HG8324JGII39406FJGK_atnm_EquityIncentivePlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_EquityIncentivePlanMember" xml:lang="en-US">Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_EquityIncentivePlanMember" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_EquityIncentivePlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventLineItems" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_4HG8324JGII39406FJGK_atnm_SubsequentEventsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent events textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_SubsequentEventsTextualAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xlink:label="loc_6275329951G0_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xml:lang="en-US">Additional Shares Purchased By Underwriters Through Over Allotment Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xml:lang="en-US">Additional shares purchased by underwriters through over-allotment option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xml:lang="en-US">Additional shares purchased by underwriters through over-allotment option.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xlink:to="lab_8497541173I2_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountExercisedThroughOverAllotmentOptionGross" xlink:label="loc_4HG8324JGII39406FJGK_atnm_AmountExercisedThroughOverAllotmentOptionGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountExercisedThroughOverAllotmentOptionGross" xml:lang="en-US">Amount Exercised Through Over Allotment Option Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountExercisedThroughOverAllotmentOptionGross" xml:lang="en-US">Exercise of over-allotment option, gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_atnm_AmountExercisedThroughOverAllotmentOptionGross" xml:lang="en-US">Exercise of over allotment option amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_atnm_AmountExercisedThroughOverAllotmentOptionGross" xlink:to="lab_6JI0546LIKK51628HLIM_atnm_AmountExercisedThroughOverAllotmentOptionGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Total number of shares offered by Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Gross proceeds from shares offered by Actinium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Exercise of over-allotment option, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Net proceeds from shares offered by Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Issuance of restricted shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xml:lang="en-US">Common stock previously granted under the Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Received proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_6275329951G0_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Services provided</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>atnm-20140630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.0 on Tuesday, August 12, 2014 12:43:00 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#RelatedPartyTransactions" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#PropertyAndEquipment" roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#NotePayable" roleURI="http://actiniumpharmaceuticals.com/role/NotePayable"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#Derivatives" roleURI="http://actiniumpharmaceuticals.com/role/Derivatives"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#CommitmentsAndContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#SubsequentEvents" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#RelatedPartyTransactionsTables" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#PropertyandEquipmentTables" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DerivativesTables" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#CommitmentsandContingenciesTables" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#RelatedPartyTransactionsDetails" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#PropertyandEquipmentDetails" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#NotePayableDetails" roleURI="http://actiniumpharmaceuticals.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DerivativesDetails" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DerivativesDetails1" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#DerivativesDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#Commitmentsandcontingenciesdetailstextual" roleURI="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#EquityDetailsTextual" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="atnm-20140630.xsd#SubsequentEventsDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DocumentAndEntityInformationAbstract" xlink:label="loc_atnm_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_AssetsAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_SecurityDeposit_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_NotesPayableCurrent_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_LiabilitiesCurrent_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_Liabilities_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommitmentsAndContingencies_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquityAbstract_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_PreferredStockValue_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommonStockValue_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_AdditionalPaidInCapital_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCTwoPreferredStockMember" xlink:label="loc_atnm_SeriesCTwoPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCTwoPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCThreePreferredStockMember" xlink:label="loc_atnm_SeriesCThreePreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCThreePreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeriesCFourPreferredStockMember" xlink:label="loc_atnm_SeriesCFourPreferredStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_atnm_SeriesCFourPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesIssued_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesIssued_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_Depreciation_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_InterestExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_atnm_GainOnChangeInFairValueOfDerivatives_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_atnm_GainOnChangeInFairValueOfDerivatives_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable" xlink:label="loc_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash" xlink:label="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_InterestPaid_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_IncomeTaxesPaid_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransferFromLiabilityClassificationToEquityClassificationValue" xlink:label="loc_atnm_TransferFromLiabilityClassificationToEquityClassificationValue_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_atnm_TransferFromLiabilityClassificationToEquityClassificationValue_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Derivatives">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_atnm_DevelopmentStageCompanyPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_atnm_DevelopmentStageCompanyPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_atnm_MilestonePaymentsMilestoneMethodTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_atnm_MilestonePaymentsMilestoneMethodTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:label="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_8" xlink:to="loc_us-gaap_DerivativeLiabilities_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ActiniumMember" xlink:label="loc_atnm_ActiniumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_atnm_ActiniumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_CommonStockMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_WarrantMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionsAndWarrantsMember" xlink:label="loc_atnm_OptionsAndWarrantsMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_13" xlink:to="loc_atnm_OptionsAndWarrantsMember_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_19" xlink:to="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SharesExchangeRatio" xlink:label="loc_atnm_SharesExchangeRatio_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_SharesExchangeRatio_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockShares" xlink:label="loc_atnm_CommonStockShares_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_CommonStockShares_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ExchangedInCommonStockShares" xlink:label="loc_atnm_ExchangedInCommonStockShares_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_atnm_ExchangedInCommonStockShares_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_NewDrugApplicationMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_6" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RelatedPartyMilestonesPayment" xlink:label="loc_atnm_RelatedPartyMilestonesPayment_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_10" xlink:to="loc_atnm_RelatedPartyMilestonesPayment_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RosemaryMazanetMember" xlink:label="loc_atnm_RosemaryMazanetMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_RosemaryMazanetMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCompanyMember" xlink:label="loc_atnm_LaidlawAndCompanyMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCompanyMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GuagentiAndAssociatesMember" xlink:label="loc_atnm_GuagentiAndAssociatesMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_GuagentiAndAssociatesMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_WarrantMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_atnm_AgreementAxis_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_15" xlink:to="loc_atnm_AgreementDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_ClinicalTrialAgreementMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_LicenseDevelopmentAndCommercializationAgreementMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultingServicesAgreementMember" xlink:label="loc_atnm_ConsultingServicesAgreementMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_ConsultingServicesAgreementMember_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EngagementAgreementMember" xlink:label="loc_atnm_EngagementAgreementMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_EngagementAgreementMember_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_16" xlink:to="loc_atnm_TransactionManagementAgreementMember_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_22" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23" xlink:to="loc_atnm_PlacementAgentMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_atnm_RelatedPartyTransactionsTextualAbstract_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25" xlink:to="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_OfficersCompensation_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_NumberOfPatients_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen_31" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen" xlink:label="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaintenanceFeesAndResearchPayments" xlink:label="loc_atnm_MaintenanceFeesAndResearchPayments_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_MaintenanceFeesAndResearchPayments_33" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentServicesFees" xlink:label="loc_atnm_PlacementAgentServicesFees_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PlacementAgentServicesFees_34" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_35" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockExercisePriceParOrStatedValuePerShare" xlink:label="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_CommonStockExercisePriceParOrStatedValuePerShare_36" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidUnderAgreement" xlink:label="loc_atnm_AmountPaidUnderAgreement_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AmountPaidUnderAgreement_37" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AdditionalAmountDueUnderAgreement" xlink:label="loc_atnm_AdditionalAmountDueUnderAgreement_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AdditionalAmountDueUnderAgreement_38" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_DescriptionOfConditionForTerminationOfForbearancePeriod_39" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TerminationDateOfForbearanceAgreement" xlink:label="loc_atnm_TerminationDateOfForbearanceAgreement_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_TerminationDateOfForbearanceAgreement_40" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_41" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewEquityFinanceRaisedByCompany" xlink:label="loc_atnm_NewEquityFinanceRaisedByCompany_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_NewEquityFinanceRaisedByCompany_42" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ForgivenAmountOfObligations" xlink:label="loc_atnm_ForgivenAmountOfObligations_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_ForgivenAmountOfObligations_43" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AmountPaidToEachPatient_44" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_45" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_StartUpDueCostPaidDate_46" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfSharesTransferTerm" xlink:label="loc_atnm_DescriptionOfSharesTransferTerm_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_DescriptionOfSharesTransferTerm_47" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionExercisePriceRange" xlink:label="loc_atnm_OptionExercisePriceRange_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_OptionExercisePriceRange_48" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_atnm_OptionsReceivedToPurchaseCommonStock_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_OptionsReceivedToPurchaseCommonStock_49" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_DescriptionOfReceivablesOfPlacementAgentForServices_50" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_DescriptionOfWarrantsReceivablesByPlacement_51" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodOfExerciseOfWarrants" xlink:label="loc_atnm_PeriodOfExerciseOfWarrants_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PeriodOfExerciseOfWarrants_52" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfSolicitationFee" xlink:label="loc_atnm_PercentageOfSolicitationFee_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PercentageOfSolicitationFee_53" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PeriodicFeeForFinancialAdvisoryServices_54" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_DescriptionOfAdditionalReceivableByPlacementAgent_55" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_CommonStockPurchaseByHoldingOfWarrant_56" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_57" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_58" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_59" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicAmountOfRent" xlink:label="loc_atnm_PeriodicAmountOfRent_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_PeriodicAmountOfRent_60" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_atnm_AmountPaidToPursuantLeaseAgreement_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_AmountPaidToPursuantLeaseAgreement_61" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_62" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultingFee" xlink:label="loc_atnm_ConsultingFee_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_ConsultingFee_63" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SettlementPaymentOfConsultingFee" xlink:label="loc_atnm_SettlementPaymentOfConsultingFee_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_SettlementPaymentOfConsultingFee_64" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments" xlink:label="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments_65" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_66" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_69"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_69" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_70"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_DebtInstrumentTerm_70" order="430" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_72"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_72" order="450" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_73"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_73" order="460" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_74"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_74" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsToPurchaseCommonStockDescription" xlink:label="loc_atnm_WarrantsToPurchaseCommonStockDescription_75"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_RelatedPartyTransactionsTextualAbstract_26" xlink:to="loc_atnm_WarrantsToPurchaseCommonStockDescription_75" order="480" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PropertyAndEquipmentTextualAbstract" xlink:label="loc_atnm_PropertyAndEquipmentTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_atnm_PropertyAndEquipmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_atnm_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_2" xlink:to="loc_atnm_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementMember" xlink:label="loc_atnm_PremiumFinanceAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_3" xlink:to="loc_atnm_PremiumFinanceAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_PlacementAgentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ManagementFirmMember" xlink:label="loc_atnm_ManagementFirmMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_atnm_ManagementFirmMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_9" xlink:to="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_atnm_CommonStockPurchaseDueToIssuanceOfWarrants_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmortizationPeriodOfNote" xlink:label="loc_atnm_AmortizationPeriodOfNote_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_atnm_AmortizationPeriodOfNote_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_NotesPayable_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_NotePayableAndConvertibleNotesTextualAbstract_10" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_atnm_PremiumFinanceAgreementPrincipalAmount_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PremiumFinanceAgreementPrincipalAmount_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_atnm_PaymentUnderPremiumFinanceAgreement_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PaymentUnderPremiumFinanceAgreement_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_atnm_PeriodicPaymentUnderPremiumFinanceAgreement_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PeriodicPaymentUnderPremiumFinanceAgreement_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_atnm_PremiumFinanceAgreementOutstandingAmount_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PremiumFinanceAgreementOutstandingAmount_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProceedsFromConvertibleNotes" xlink:label="loc_atnm_ProceedsFromConvertibleNotes_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_ProceedsFromConvertibleNotes_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_atnm_DerivativeWarrantsIssuedWithConvertibleNotes_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DerivativeWarrantsIssuedWithConvertibleNotes_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_InvestmentWarrantGrantDateFairValue" xlink:label="loc_atnm_InvestmentWarrantGrantDateFairValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_InvestmentWarrantGrantDateFairValue_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DebtInstrumentFairValuePerShare" xlink:label="loc_atnm_DebtInstrumentFairValuePerShare_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DebtInstrumentFairValuePerShare_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_atnm_ExtendedMaturityPeriodOfConvertibleNotes_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_ExtendedMaturityPeriodOfConvertibleNotes_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfExtendedMaturityDate" xlink:label="loc_atnm_DescriptionOfExtendedMaturityDate_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_atnm_DescriptionOfExtendedMaturityDate_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_38" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_atnm_DerivativeWarrantsUnits_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsUnits_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_TransferFromLiabilityClassificationToEquityClassification_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_TransferFromLiabilityClassificationToEquityClassification_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeWarrantsUnits" xlink:label="loc_atnm_DerivativeWarrantsUnits_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_DerivativeWarrantsUnits_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_atnm_ChangeInFairValueOfDerivativeWarrants_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_atnm_ChangeInFairValueOfDerivativeWarrants_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_6" xlink:to="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_MarketValueOfCommonStockOnMeasurementDate_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueAssumptionOfferingPrice" xlink:label="loc_atnm_FairValueAssumptionOfferingPrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_atnm_FairValueAssumptionOfferingPrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_2" xlink:to="loc_us-gaap_DerivativeNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeTextualAbstract" xlink:label="loc_atnm_DerivativeTextualAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_12" xlink:to="loc_atnm_DerivativeTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_RangeOfPercentageOfExistingSharesOffered_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_DescriptionOfRiskFreeInterestRateDetermination_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_atnm_DescriptionOfProbabilityOfStockOffering_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_DescriptionOfProbabilityOfStockOffering_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfSharesWarrantExercise" xlink:label="loc_atnm_NumberOfSharesWarrantExercise_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_NumberOfSharesWarrantExercise_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DerivativeNumberOfWarrants" xlink:label="loc_atnm_DerivativeNumberOfWarrants_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_DerivativeTextualAbstract_13" xlink:to="loc_atnm_DerivativeNumberOfWarrants_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_BiologicalLicenseApplicationMember" xlink:label="loc_atnm_BiologicalLicenseApplicationMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_BiologicalLicenseApplicationMember_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FirstCommercialSaleMember" xlink:label="loc_atnm_FirstCommercialSaleMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_FirstCommercialSaleMember_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_AfterFirstNetSalesMember_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NewDrugApplicationMember" xlink:label="loc_atnm_NewDrugApplicationMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_NewDrugApplicationMember_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_atnm_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentAbstract" xlink:label="loc_atnm_MilestonePaymentAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" xlink:to="loc_atnm_MilestonePaymentAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_MilestonePaymentAbstract_17" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesTable" xlink:label="loc_atnm_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_atnm_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AbbottBiotherapeuticsCorpMember" xlink:label="loc_atnm_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_atnm_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_OakRidgeNationalLaboratoryMember" xlink:label="loc_atnm_OakRidgeNationalLaboratoryMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_OakRidgeNationalLaboratoryMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AptivSolutionsMember" xlink:label="loc_atnm_AptivSolutionsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_AptivSolutionsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_atnm_FredHutchinsonCancerResearchCenterMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JohnsHopkinsUniversityMember" xlink:label="loc_atnm_JohnsHopkinsUniversityMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JohnsHopkinsUniversityMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_LaidlawAndCoMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UniversityOfPennsylvaniaMember" xlink:label="loc_atnm_UniversityOfPennsylvaniaMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_UniversityOfPennsylvaniaMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_JamessCapitalGroupMember" xlink:label="loc_atnm_JamessCapitalGroupMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_JamessCapitalGroupMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FormerChiefExecutiveOfficerMember" xlink:label="loc_atnm_FormerChiefExecutiveOfficerMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_atnm_FormerChiefExecutiveOfficerMember_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AfterFirstNetSalesMember" xlink:label="loc_atnm_AfterFirstNetSalesMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_AfterFirstNetSalesMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_atnm_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_20" xlink:to="loc_us-gaap_RangeMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MaximumMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21" xlink:to="loc_us-gaap_MinimumMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodAxis" xlink:label="loc_atnm_PeriodAxis_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_PeriodAxis_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodDomain" xlink:label="loc_atnm_PeriodDomain_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodAxis_24" xlink:to="loc_atnm_PeriodDomain_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoThousandAndThirteenMember" xlink:label="loc_atnm_TwoThousandAndThirteenMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndThirteenMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoThousandAndFourteenMember" xlink:label="loc_atnm_TwoThousandAndFourteenMember_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_PeriodDomain_25" xlink:to="loc_atnm_TwoThousandAndFourteenMember_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementAxis" xlink:label="loc_atnm_AgreementAxis_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_AgreementAxis_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementDomain" xlink:label="loc_atnm_AgreementDomain_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementAxis_28" xlink:to="loc_atnm_AgreementDomain_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ProductDevelopmentAndPatentLicenseAgreementMember_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseAgreementMember" xlink:label="loc_atnm_LicenseAgreementMember_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAgreementMember_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_LicenseAndSponsoredResearchAgreementMember_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialAgreementMember" xlink:label="loc_atnm_ClinicalTrialAgreementMember_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ClinicalTrialAgreementMember_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentAgreementMember" xlink:label="loc_atnm_PlacementAgentAgreementMember_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_PlacementAgentAgreementMember_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TransactionManagementAgreementMember" xlink:label="loc_atnm_TransactionManagementAgreementMember_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_TransactionManagementAgreementMember_35" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SeparationAndSettlementAgreementMember" xlink:label="loc_atnm_SeparationAndSettlementAgreementMember_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_SeparationAndSettlementAgreementMember_36" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ManufacturingAgreementMember" xlink:label="loc_atnm_ManufacturingAgreementMember_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_ManufacturingAgreementMember_37" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RentalAgreementMember" xlink:label="loc_atnm_RentalAgreementMember_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_AgreementDomain_29" xlink:to="loc_atnm_RentalAgreementMember_38" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesLineItems" xlink:label="loc_atnm_CommitmentsAndContingenciesLineItems_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTable_1" xlink:to="loc_atnm_CommitmentsAndContingenciesLineItems_39" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesLineItems_39" xlink:to="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_41" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_TechnologyServicesCosts_42" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_MaintenanceCosts_43" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfLicenseFee" xlink:label="loc_atnm_PaymentOfLicenseFee_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PaymentOfLicenseFee_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_LongTermPurchaseCommitmentMilestonesPayment_45" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MilestonePaymentDate" xlink:label="loc_atnm_MilestonePaymentDate_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_MilestonePaymentDate_46" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_DescriptionOfRoyaltyPaymentToRelatedParty_47" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RoyaltyOfNetSalesPercentage" xlink:label="loc_atnm_RoyaltyOfNetSalesPercentage_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_RoyaltyOfNetSalesPercentage_48" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FirstCommercialSalePeriod" xlink:label="loc_atnm_FirstCommercialSalePeriod_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_FirstCommercialSalePeriod_49" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ResearchAndDevelopmentArrangement" xlink:label="loc_atnm_ResearchAndDevelopmentArrangement_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_ResearchAndDevelopmentArrangement_50" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PurchaseOfRadioactiveMaterial" xlink:label="loc_atnm_PurchaseOfRadioactiveMaterial_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PurchaseOfRadioactiveMaterial_51" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ProjectEstimatedCost" xlink:label="loc_atnm_ProjectEstimatedCost_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_ProjectEstimatedCost_52" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_DownPaymentOfProjectEstimatedCostPercentage_53" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DownPaymentForProject" xlink:label="loc_atnm_DownPaymentForProject_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_DownPaymentForProject_54" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_55" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear_56" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo_57" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NumberOfPatients" xlink:label="loc_atnm_NumberOfPatients_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_NumberOfPatients_58" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountPaidToEachPatient" xlink:label="loc_atnm_AmountPaidToEachPatient_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_AmountPaidToEachPatient_59" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpFeeForClinicalTrial" xlink:label="loc_atnm_StartUpFeeForClinicalTrial_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_StartUpFeeForClinicalTrial_60" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_StartUpDueCostPaidDate" xlink:label="loc_atnm_StartUpDueCostPaidDate_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_StartUpDueCostPaidDate_61" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementConsideration" xlink:label="loc_atnm_AgreementConsideration_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_AgreementConsideration_62" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_atnm_PerformanceBonusPayableUnderAgreementForService_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PerformanceBonusPayableUnderAgreementForService_63" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_atnm_PeriodicFeeReceivedByManagementFirm_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PeriodicFeeReceivedByManagementFirm_64" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_65" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantExercisableNoticePeriodDescription" xlink:label="loc_atnm_WarrantExercisableNoticePeriodDescription_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_WarrantExercisableNoticePeriodDescription_66" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_67"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_DescriptionOfSharesAvailabilityByExerciseOfWarrant_67" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_atnm_MaximumAmountOfOutOfPocketExpenses_68"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_MaximumAmountOfOutOfPocketExpenses_68" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NonRefundableInstitutionalFee" xlink:label="loc_atnm_NonRefundableInstitutionalFee_69"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_NonRefundableInstitutionalFee_69" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PharmacyFee" xlink:label="loc_atnm_PharmacyFee_70"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PharmacyFee_70" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmendmentProcessingFee" xlink:label="loc_atnm_AmendmentProcessingFee_71"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_AmendmentProcessingFee_71" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_NoticePeriodForTerminationOfAgreement" xlink:label="loc_atnm_NoticePeriodForTerminationOfAgreement_72"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_NoticePeriodForTerminationOfAgreement_72" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_73"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_LeaseExpirationDate1_73" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AgreementRenewalDescription" xlink:label="loc_atnm_AgreementRenewalDescription_74"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_AgreementRenewalDescription_74" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfAggregateAmount" xlink:label="loc_atnm_PaymentOfAggregateAmount_75"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PaymentOfAggregateAmount_75" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_76"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PaymentOfFinalInstallmentForServicesByCompany_76" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_77"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_atnm_PaymentOfPerformanceBonusForServicesByCompany_77" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_78"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_78" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_79"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_LegalFees_79" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_80"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_80" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="loc_us-gaap_DevelopmentInProcess_81"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_DevelopmentInProcess_81" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_82"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_82" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_83"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_CommitmentsAndContingenciesTextualAbstract_40" xlink:to="loc_us-gaap_SecurityDeposit_83" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_28" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PrivatePlacementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_IPOMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_LaidlawAndCoMember" xlink:label="loc_atnm_LaidlawAndCoMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" xlink:to="loc_atnm_LaidlawAndCoMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentMember" xlink:label="loc_atnm_PlacementAgentMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" xlink:to="loc_atnm_PlacementAgentMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_15" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_atnm_EmployeesDirectorsAndConsultantsMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16" xlink:to="loc_atnm_EmployeesDirectorsAndConsultantsMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_16" xlink:to="loc_us-gaap_InvestorMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20" xlink:to="loc_us-gaap_EmployeeStockOptionMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_RangeAxis_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MinimumMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MaximumMember_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EquityTextualsAbstract" xlink:label="loc_atnm_EquityTextualsAbstract_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26" xlink:to="loc_atnm_EquityTextualsAbstract_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_DebtInstrumentTerm_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_FairValueAssumptionsExpectedDiscountRate" xlink:label="loc_atnm_FairValueAssumptionsExpectedDiscountRate_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_FairValueAssumptionsExpectedDiscountRate_35" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_atnm_WarrantsIssuedToPurchaseCommonStock_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_WarrantsIssuedToPurchaseCommonStock_36" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod" xlink:label="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod_38" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_40" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_41" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_42" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_43" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_45" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_48" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_49" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_51" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_53" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UnderwritingDiscount" xlink:label="loc_atnm_UnderwritingDiscount_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_UnderwritingDiscount_54" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_UnderwritingAgreementDescription" xlink:label="loc_atnm_UnderwritingAgreementDescription_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_UnderwritingAgreementDescription_55" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_56" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentCashFees" xlink:label="loc_atnm_PlacementAgentCashFees_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_PlacementAgentCashFees_57" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_PlacementAgentAttorneyFees" xlink:label="loc_atnm_PlacementAgentAttorneyFees_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_PlacementAgentAttorneyFees_58" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_59" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_WarrantsExercisedByWarrantHolders" xlink:label="loc_atnm_WarrantsExercisedByWarrantHolders_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_WarrantsExercisedByWarrantHolders_60" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_RegistrationStatementDescription" xlink:label="loc_atnm_RegistrationStatementDescription_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_RegistrationStatementDescription_61" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_MaximumOfferingPrice" xlink:label="loc_atnm_MaximumOfferingPrice_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_atnm_MaximumOfferingPrice_62" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_63" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_OtherExpenses_64" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_EquityTextualsAbstract_27" xlink:to="loc_us-gaap_ProfessionalFees_65" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_TwoLegacyShareholdersMember" xlink:label="loc_atnm_TwoLegacyShareholdersMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_TwoLegacyShareholdersMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_InvestorsMember" xlink:label="loc_atnm_InvestorsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_InvestorsMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_ConsultantMember" xlink:label="loc_atnm_ConsultantMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_ConsultantMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_EquityIncentivePlanMember" xlink:label="loc_atnm_EquityIncentivePlanMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_atnm_EquityIncentivePlanMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_SubsequentEventsTextualAbstract" xlink:label="loc_atnm_SubsequentEventsTextualAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12" xlink:to="loc_atnm_SubsequentEventsTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption" xlink:label="loc_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="atnm-20140630.xsd#atnm_AmountExercisedThroughOverAllotmentOptionGross" xlink:label="loc_atnm_AmountExercisedThroughOverAllotmentOptionGross_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_atnm_AmountExercisedThroughOverAllotmentOptionGross_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_atnm_SubsequentEventsTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`=?[]DX`$``+H6```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-UNVC`8AL\G[1XBGT[$
MV-FZMB+T8#^'&]+8!;CQ!XE(;,MV.[C[.8&B"E$J5*2^)T00^WL?K.B1\D[N
MUEV;/9(/C34E$_F8960JJQNS+-G?^<_1-<M"5$:KUAHJV88"NYM^_#"9;QR%
M+.TVH61UC.Z6\U#5U*F06T<FW5E8WZF8OOHE=ZI:J25Q.1Y?\<J:2":.8C^#
M32??::$>VIC]6*>?MR2>VL"R;]N%?5;)E'-M4ZF82/FCT0<IHUU"GG8.:T+=
MN/`I83!^-*&_\W+`;M_O=#2^T93-E(^_5)<P^+KE_ZQ?W5N[RD\/.4)I%XNF
M(FVKARZ=0!Z<)Z5#312[-A^N>:<:\\1](G]8'/AP$1<&Z?_?,/A,#@G"48!P
M?`;A^`+"<07"\16$XQJ$XP:$0XQ10%",*E"4*E"<*E"D*E"L*E"T*E"\*E#$
M*E#,*E',*E',*E',*E',*E',*E',*E',*E',*E',*E',6J"8M4`Q:X%BU@+%
MK`6*68OW,FM,S2#QX?/MC^DPYI5J*L1-2^'"KY/;H:\EU\J3_A-]ZE`O#O!\
M]BF.U##.O'4A=:V>SC^%IS*UWSUR:1#YV-"^3CU62^X34T][?N!!+TI]$ZQ)
M'\GF0_,\_0\``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?
M<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````",DL].PS`,QN](
MO$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4
M'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBR
MBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'
MJC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB
M8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%
M#U1?````__\#`%!+`P04``8`"````"$`Z,')Y]\!``"K%0``&@`(`7AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````O)C+3L,P$$7W2/Q#Y#UU9P;*0Z1L$!);'A]@)6Y3
MT2:1;1[]>ZP*4BK!91/-)I(=U;FZ,[TGD^N;C\VZ>/,AKKJV-#29FL*W55>O
MVF5IGI_N3BY,$9-K:[?N6E^:K8_F9GY\=/W@UR[E'\5FU<<BG]+&TC0I]5?6
MQJKQ&Q<G7>_;?&?1A8U+>1F6MG?5BUMZR]/IS(:?9YCYP9G%?5V:<%^3F.)I
MV^='_W]XMUBL*G_;5:\;WZ9?GF'?N_`2&^]3/M2%I4^E&;:BW=TAF63-QOXA
M)_NA*^<"R>&9LAR>03FD+8>0'#E5EB.G2,ZYLIIS)(9860TQE*-M#D%W^$S9
M'3Y#[HAV"`H,01DU!&/C@J\?4\C,B=GVKUP^V$;F:#<R[F/M0"8<R)GGJKCB
M*2S5I;:<2R1'FU805MJ-`_N&U*V!WK`VR!F"7+0C1V#FR*CLC&F[SB_Y^QS>
MK='?2)N5$)6DK8:@'-8F-T-R\ZCD'D:G?;<,6U_3%,/Q148-O92G3K^7LEO:
MW16&"VDSDB`C29N1!!DIVB006"QM$$`.:%<*%HJTK2'H#6LSDB$C>51&#BFW
M3YMAZSOXX'PIVIDC,'-$&YH"H:D-*<RH7&/-[X\#O^W!)];Y)P```/__`P!0
M2P,$%``&``@````A`$GW4*I$`P```PL```\```!X;"]W;W)K8F]O:RYX;6R4
MEDU/XS`0AN\K[7^(<E_RU;"`:)&@72T7%FT+'",W<:F%8P?;:>F_WW%*PR0N
MT7)J)^F\'K_S>.K+J[>2>QNJ-)-B[$<GH>]1D<N"B>>Q_[#X]>/,][0AHB!<
M"CKV=U3[5Y/OWRZW4KTLI7SQ0$#HL;\VIKH(`IVO:4GTB:RH@#<KJ4IB(%3/
M@:X4)85>4VI*'L1A>!J4A`E_KW"A_D=#KE8LIU.9UR459B^B*"<&RM=K5FE_
M<KEBG#[N=^21JKHC)=3]QGV/$VUF!3.T&/LIA')+.P]475W7C,/;\R1,_&#2
M;O)>>05=D9J;!6SOH`Y^Q:,X/K6_M%8\,KK5'TDV]-Z>F"CDUOX4K-VU40(%
M;)M73ZPP:W@?AF'[[#=ESVMS>`CR`=)O'(1UFD]/--L[.))!I[*9,,SLLENQ
M=Y]):*%U_19V%OF>NF#P1=T6D2T<J]R`B9*S@H!%V37A1.0TF]M4G3U`HUJ5
M&*G$7U.!`EJ9!,DT?G]:S-Q`3;;E.I.K[$]%D<H(J8P&B^FJW!"-5,#[UIBT
MKS*E.E>LLI39]:]KS035NG%[7B.5Y!3)-&#@+?VUI(*U]T1!?Q:*"$WR!ETL
M\1-)_.Q7<J_@9-GLIM&O-:NL*S@=#FR[D;-^^ITT%);?D27'%B;G*.F\GS2E
MBFW@B&W@['\T;P0\MPM%83_I1I8E,_N6V5J!+0-#!88+Z\ITB'20G,$6S0XO
MB]F+'/CF]5+3UQH\R68;RPM.Q;Q%#G##3<;<CC!RD</<L!#4WQZ`$:8N<K#[
MG)=L0998!V,7.=P=A\9J\&XO,'J1PQ[BX$@NYBYRP!O$(<-;P2A&#HM['MSE
M4TPCC-K>9!MN"7#1MB3&/$+P)2'@HA5*.T(.J`.]G5)\H&-,+02]@H9U,+4I
M/CFQ0^TGD$`QA'%\C-).00ZTPSJX(/CG_)@@^[]1/"WQK,J.E($/83P(JYL<
M8UHAZ)F*27]/SCJ58TAC!])CZ0OZ9FH"MY`6D`0C"T&OAN$3@ZM)(&@G,01?
M$L+C*,7C*'&0?3][KIL))@*"7@'=O,QU(L4@)`Z9SDP_1@,>77"Y@A*"QFFX
M*.6$YW"#LQ_V"M0X'1SNKY-_````__\#`%!+`P04``8`"````"$`5=R-374%
M``#:%0``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)R86X^K-A#'WROU
M.R#>$S!WHB1'RV7;([525?7RS!(G01M"!.SE?/N.,0'/Y,9V'S8;^'D\_YFQ
M/>OEM\_RH+WSNBFJXTIG<U/7^#&O-L5QM]+__NMY%NA:TV;'37:HCGRE_^"-
M_FW]\T_+CZI^;?:<MQI8.#8K?=^VIX5A-/F>EUDSKT[\"&^V55UF+7RM=T9S
MJGFVZ0:5!\,R3<\HL^*H2PN+>HJ-:KLM<IY4^5O)CZTT4O-#UH+_S;XX-6=K
M93[%7)G5KV^G65Z5)S#Q4AR*]D=G5-?*?/%]=ZSJ[.4`NC^9D^5GV]V7"_-E
MD==54VW;.9@SI*.7FD,C-,#2>KDI0($(NU;S[4I_8HO4,G5CO>P"]$_!/QKE
M;ZW95Q^_U,7FM^+((=J0)Y&!EZIZ%>CWC7@$@XV+T<]=!OZHM0W?9F^']L_J
MXU=>[/8MI-L%14+88O,CX4T.$04S<\L5EO+J``[`;ZTL1&E`1++/[O.CV+3[
ME6Y[<]<W;0:X]L*;]KD0)G4M?VO:JOQ70JPW)8U8O1$;O._?PZ.)@YU^,'P.
M@[_L`?C:R8#/P<@C#PP9BBZR2=9FZV5=?6A0KB"V.66B^-D"#)Y#*@,P!/E6
MC"&XPLB3L++2?5V#\#50&.]K-U@:[Y#+O$>B*TB(D?B,B,P)L\GYP6B6X2'I
MF1!E`XH&69`25=;U"CE[+V#A_7G>2#X`VX,<"\\;7Q*>B9'D$B%&TDM",8+D
M0+%-ER-@*&W%>X^$+9((5.$@T,7>QP^)Y"&1WB.0/'!DNCP!KW2(W>"[1P(;
M2425YY`(Q(^1Y#&2WD601%A;TR4*F&30QOF))*)*I!E\2"0/B?0>@>1Y6)[8
M1FS8W^^O.S&(9-(A,B7B=5L*G+8LM'U,Q"KAFJ%%BR%1`<?QK-`DD4I5@KFA
M$WKCYH54P@8W/8D")NK(Q)%$>G4.`^>H.I4(/<_V")"H@&.&IA>0?2A5"1:$
MH6N.M834B39).0KNYT[`1)V',Q-)1*H+3)<LTEB^5BN8+M)$M1`Z+M&>WK6`
MI(5?D29@(HW,'$GDGN_Q8R1YC*02D3%TF#7&$,ECL-2FIZZCB<"QX+N3-^J9
M?F+'<CQ&TALCA#F^"TL+5T""D,#U;-,9%703I0BQG3!PPQOER<19/[D^.YJ(
M).Y%/2-%SISK*F6'T3,W9"+FAD[$W!<J^H+I0F47`6?M<![Z9`N(F&34>B5;
M4?P821XCZ5T$EZQH#J:+E*V$>NC[Y$2/V&6[03>4>&!$BSKS;'+<),/[,9C4
M1MHSYXJPS+&LL$((MZIPVIG(Q"A<MSY9,U'/2`_\T`Y]1H(1(V3&;-/W';+&
M$\S`X<-LI?_LEZ=T1TYE>;XW1@R+%9W"]'3*O@*E<USU_0XDF;LB542(#.R`
MQ"H1_Q]"//MLW1"I,I8+/\,^AD6*1F&Z2-E6()%C]'J1D@FZ_L9V&30PX]P=
M$C,5F5E^X)@TVPEFF,T"QS%))%(,V8YOF_98$EBHZ!D4H1-+5W8:2#!1$S')
MA)U@<\X<$_U<E+&*SX`G59(@>P#0+B.E@'*,8<FBF?BZ9-F"(,GDG(R89`;)
M0VWU^55?7Y5(@$N)!+@I43037Y<H6Q`DD;9#3&U3+-</7=<GF8HQ8S$_\&@O
MGV#&=9GM7C3KF&%^R#QE+I13N(OZ'X*[460''M>)7+<](W<5VPU@[U2<D(E%
MC'5=,&:N"\;,=<'RRDQ>[)2\WO&8'PZ-EE=OXCK,AM4V/!VNZIXL<>%!GD=L
M`=<PE\\3N-KKGAO#`+A9.V4[_GM6[XICHQWX%J8RYSYLIK6\FY-?VNK473.]
M5"W<J75_[N$.E<,%#ZQ77=M657O^(JYQAEO9]7\```#__P,`4$L#!!0`!@`(
M````(0".MH6)+`0``-8.```9````>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;*Q7VXZ;2!!]7VG_`?$>KC;8ENUH`$\2*2NM5IOD&4/;1@,THMOCF;_?*IK&
MT/@VT;X,0_G4Z7.JB[XL/[\5N?9*:I;1<J7;AJ5KI$QHFI7[E?[CW^=/,UUC
M/"[3.*<E6>GOA.F?UW_^L3S1^H4=".$:,)1LI1\XKQ:FR9(#*6)FT(J4\,N.
MUD7,X;7>FZRJ29PV245N.I;EF46<E;I@6-2/<-#=+DM(1)-C04HN2&J2QQST
MLT-6,<E6)(_0%7']<JP^);2H@&*;Y1E_;TAUK4@6W_8EK>-M#K[?[$F<2.[F
M941?9$E-&=UQ`^A,(73L>6[.36!:+],,'&#9M9KL5OJ3O=C8KFZNETV!?F;D
MQ'K_:^Q`3U_J+/V>E02J#?.$,["E]`6AWU(,0;(YRGYN9N#O6DO)+C[F_!]Z
M^DJR_8'#=$_!$1I;I.\180E4%&@,9XI,"<U!`/S5B@Q;`RH2OS7/4Y;RPTIW
M/6/J6ZX-<&U+&'_.D%+7DB/CM/@E0'9+)4B<E@2>%TAN)+IM(CS;1!LX;B1,
MV@1X?FPD,-/XA*<<:6KXMC5W?0B-1S1%G9JR1S&/U\N:GC3H9:@$JV+\,NP%
M9,IZ"X9N!JY-`%0>29Z09:7[N@:U9=`UK^N)/UF:KS#328L)QAA[B`@E`J<5
M:2,9.-.ZL^DP:2,QV%7@J3,&A?\?C"$+&I.2`ADX2W*&@D*)D"F1#/125!,2
MHIJ`1NJ;N/P5R$E`,/3[8!*4@0*!@7;K)DI!A!+1R9>!JRD;B5#5PS!]]=A;
M+JP(MUU@TDJ'@G0*)[XW+'$@,'T7$[67!&3J]7D\I26C%C1M.M8R7*46FSLD
M@WZ#CT<U:_NX2-WQBWFJ7U_Q*S`W_0J(XE?Q$]WGV=SA&5B&XO8MWYY7!`]]
MNG-7\2DP?9^*@U`BNNZ4@7.[*"D;B5"[$U:KQ]4C^-ZW)3"WU$M$IUX&KJN7
M"%4]'GAZZ_;MVB-X6/N)/U-J+S!>\RG84\N>SQ1$*!"3;BV,9."Z>HE0U<\_
MHA[!JOJYHEY@A'K/<VS/&@)"`>B)EX'KXB5"%6_#&O9X[1NT(G^FJ`M:4%O]
MN>MYZGK6(GH&NLAU!QUD9`%WS8?;QQ9[K'T>/!B'PG$H&H<V@]!@-<&C4E^3
MW"X^>A01>^E@`U$7_J`9"XX\L-IUVXSCJ#OY&07U:T\D@AT296@S0`T=X<;8
MJ_+O.A+[Z]"1LLH%<"C'KT1QI/19>$9)^=$XA`?\EJOK&W%@%R?'@M1[$I(\
M9UI"CW@8G\&JT47%10%*##<%!\LT^L65=PCE%[A</%W.6,#9<,P4X67D0CQP
M%G`*NX`'29?B3S82-4QF)PEN%56\)W_%]3XKF9:3'1BU##Q>U^)>(EXXK9I3
M])9RN$\T_Q[@_DC@_&H9`-Y1RN4+EK.[D:[_`P``__\#`%!+`P04``8`"```
M`"$`,R?.(7D%```)%@``&0```'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RL
M6-MNHT@0?5]I_P'Q'J`QQA?9'H5+=D>:E5:KO3P3W+91#&T!B3-_OU4T#73A
MV$F4/`2[^M2A3E7?7*MOK_G1>.%EE8EB;3++,0U>I&*;%?NU^<_?#W=STZCJ
MI-@F1U'PM?F35^:WS:^_K,ZB?*H.G-<&,!35VCS4]6EIVU5ZX'E26>+$"QC9
MB3)/:OA:[NWJ5/)DVSCE1]MU'-_.DZPP)<.R?`^'V.VRE$<B?<YY44N2DA^3
M&N*O#MFI4FQY^AZZ/"F?GD]WJ<A/0/&8';/Z9T-J&GFZ_+XO1)D\'D'W*_.2
M5'$W7T;T>9:6HA*[V@(Z6P8ZUKRP%S8P;5;;#!1@VHV2[];F/5O&KF/:FU63
MH'\S?JX&GXWJ(,Z_E=GV1U9PR#;4"2OP*,030K]OT03.]LC[H:G`GZ6QY;OD
M^5C_)<Z_\VQ_J*'<4U"$PI;;GQ&O4L@HT%CN%)E2<80`X+^19S@U("/):_,\
M9]OZL#8GOC6=.1,&<..15_5#AI2FD3Y7M<C_DR#64DD2MR6!YP62*XZ3UA&>
MK>/<8I[CX[NON'FM&SP_]CZ@;=3"LW5DCC6?3CU_/KOX2ENFJ\E^E-3)9E6*
MLP%3&A)2G1)<(&P)GBKM,NBN$&_5`0J`)/?(LC9GI@$IKF#RO&P\?[*R7Z#@
M:8L)QABF(T*%P.HB;:0,/>UD/M6=8H7!R06:.F%0PR\0ABPH3(44*$,?DJL'
M%"J$<HF48>!"12@(%0'SB8J8P-*ZO"A4,=`)IO^@&!//TX,,)`;F75<P$E*H
M$)T,97C3)58(J@)>\W$5Z+0V(3%=A*Y#8@PD9M%,N)GETDK(X:D_X/!\DHEH
MR#&UY@L]4?$-#FW*P?H9ZKQ>)013?;[^\D!BI#[7\N;Z<"B'O6YR1M?Q\0"O
MQ0T)&L;=[`&03H!?EX!^5,),CS&0F.FTJ1&SV,(9_K'XCA:M=8!'5WC/)X6/
M"*OK+[2_$6M\@U5+!VQCPW1<SP&":0[('`HD!F;20!$I=:@PW7)3AJ$326ZL
M,'3!X:6(;NKO*2CZ$3&,U">0F+:@CC4CVWS8CNOU(S,WND$2WR#1RK7XI%CT
MHV*)F$!BM,K10TM"R"9#9D!TFR>^P:-)9G`&T`+?/A<:+ZJ8;(=!"^KJZY*E
M%RJ`5N"9HR_[2*'DNL<[FPZ(%>`M&ETO'O)D0K]#K[P::$<((W$$3(*NEKC%
MZ#6>D8D0*922/"&OBA5`E]S3Z)+Q2D`DL_>L82;O$KIJLML$+4B=G"32L!TF
M@LE.$+6H>;.UDQD?WZ+0Q>+-82#V^I;+Y#V#]0=?,#:%8U,T-L6:28\)3_Y!
M3'@JXIS[Z,T8:?1%-[J#!"`%0?A[IS\B1CMKC^H.B;$IUDRZ(CS_OT"1O$8,
M)]CH@`Y0"E7D,G(,A#VJ5]0Y*E.LH71%L)2H(@\(/EHCI*$U(K$&3(*T&KF,
M3/NP1ZGPH[$IUDRZ(CS2OZ!&\F:@UXC$&C`)TA6Y9"</>U2OJ'-4IEA#Z8KP
M+">*\)4?K9&\$FB*Z*D3,`DBBOH=MOE5&?8H%7XT-L6:25>$1S51])F=09[X
MNB(2:\`DB"@B.W'8HWI%G:,RQ1I*4P2-G9&B3]2HH2'K:$9B#5H0440N7F&/
M4N%'8Q,VI-I=!E!2D6PPR19'SLL]#_GQ6!FI>,;F$6SWFU5GEITMB$BUMN@(
M\Y:XGP+Y:&0*(TT?:C3BPXA_T6<&(TTK8>0SAY'Y19\%C"PNC$`_[MZ]8`_8
M$OHHXX@CZ-]=L@?N$CH6%_`N).6"_9Y-@&B"(W8G`QIQIV3/_TC*?594QI'O
M(-?PVP"6>2E;>?)++4Y-Q^E1U-"":SX>H.7*H=?C6`#>"5&K+_B"KHF[^1\`
M`/__`P!02P,$%``&``@````A`)E<SG;U`@``,0@``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&ULC%5=;YLP%'V?M/]@^;V`^0Q12-6NZE9IDZ9I'\\.
MF&`5,+*=IOWWN\8)`=)&>>'S^)Q[SC67U>UK4Z,7)A47;8:)XV'$VEP4O-UF
M^,_OQYL%1DK3MJ"U:%F&WYC"M^O/GU9[(9]5Q9A&P-"J#%=:=TO757G%&JH<
MT;$6WI1"-E3#K=RZJI.,%OVBIG9]SXO=AO(66X:EO(9#E"7/V8/(=PUKM261
MK*8:ZE<5[]21K<FOH6NH?-YU-[EH.J#8\)KKMYX4HR9?/FU;(>FF!M^O)*3Y
MD;N_.:-O>"Z%$J5V@,ZUA9Y[3MW4!:;UJN#@P,2.)"LS?$>6]\3#[GK5!_27
ML[T:72-5B?U7R8OOO&60-O3)=&`CQ+.!/A7F$2QVSU8_]AWX*5'!2KJK]2^Q
M_\;XMM+0[@@<&6/+XNV!J1P2!1K'CPQ3+FHH`(ZHX69K0"+TM3_O>:&K#`>Q
M$R5>0`".-DSI1VXH,<IW2HOFGP61`Y4E\0\D<#Z0D,@)_2A97,'BVHIZ@P]4
MT_5*BCV"70.:JJ-F#Y(E,+_O"*P8[)T!9SC!"(I5T(:7=1C%*_<%HLL/F'N+
M@>.`(0/"!=%!&=2N5S9@HVRR-:7<VP=C&?]]F6`J8UH7P`:X;-0L`MS(1!`&
M`[^MP&+"$28:$!.C`+G>J`%G&-P-\851,O!:98N)^P:0-%[$_JFVB3)LKK'R
M==[-HGD%BUD%%F,KN"%I$,<?-#F>5G`Y=0.>*Z<S98LY>$^2,(T_Z#OLTK'W
MR\H&/%..O9FRQ2SZU./$2_SH@WZ;J3_ZI*Y+W2R:5W#*U/;=8HZI1QY)%Z?&
M3!J?3DNX;-Z`I](DG<=N,58ZC'T2C.*9*,,8GKB_+-VCI]K`/@O^`++)IPL_
MCOW3%V'%[>2V@ZUA<LN^L+I6*!<[,Y4)]&QX.OPQ[OQ^Y@\O8&!W=,M^4+GE
MK4(U*V&IYR2PUZ4=^?9&BZX?FQNA853WEQ7\FAE,)<\!<"F$/MZ8G\KPLU__
M!P``__\#`%!+`P04``8`"````"$`8O+Z/84#``"Y#```&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6R4EUV/HC`4AN\WV?]`N!\!!16B3D81=I/=9+/9
MC^L*59L!2MHZSOS[/:7"0'7`O4$Y/N?EG+<'J(O'USPS7C#CA!9+TQG9IH&+
MA*:D."S-W[^BA[EI<(&*%&6TP$OS#7/S<?7YT^),V3,_8BP,4"CXTCP*40:6
MQ9,CSA$?T1(7\,N>LAP).&4'BY<,H[1*RC-K;-M3*T>D,)5"P.[1H/L]27!(
MDU.."Z%$&,Z0@/KYD92\5LN3>^1RQ)Y/Y4-"\Q(D=B0CXJT2-8T\";X>"LK0
M+H.^7QT7);5V=7(EGY.$44[W8@1REBKTNF??\BU06BU2`AU(VPV&]TOSR0GB
MN6FM%I4_?P@^\]9W@Q_I.68D_48*#&;#,LD%V%'Z+-&OJ0Q!LG65'54+\(,9
M*=ZC4R9^TO,73`Y'`:OM04.RKR!]"S%/P%"0&8T]J930#`J`HY$3.1E@"'JM
M/L\D%<>E.9F.O)D]<0`W=IB+B$A)TTA.7-#\KX*<BY02&5]$)E#]Y7<(W9GL
M7I)G3?+]%5BJF\J<$`FT6C!Z-F#@H%Y>(CF^3@#"M2NJA\:GCVP"?Z3(DU19
MFI`/#G!8VI>5Z_H+ZP76([DPZVO&Z1*;FI#F2]E0!>#8R$ZF=C=I6S-U4J0'
MXE;`@JZ;UL'Y=NNW!Z'N4,*RP_HRZSKP7MNX6]GFFM"+#Q72:=#79+;7C$9$
M-PBO6TM\C;C>N_T=6V`VV[;(B9C`W=9OCTSJV*,'-GH@5(%V[ZZG+^X=3'0'
M$_<SG?;A+OO_]F42V-0:5-?35FFM&#@VPZPMTF:0"`>)[2`1#1)Q']'Q"AY\
M;:_Z1T3"2Q,&L>G?]2;=,5TK!J[?,+I'@T0X2&P5,:^>4Y[KS[2IB]J_.]YL
M/M:*B'N`CC_3KC_WW4HR2??)U7Q23)]/@T2HB&GE@N/YOM;D=E`A&B3B/J+C
M%+PZVI-TGU,R27=*ZV*MF#ZG!HEPD-@JXD,OHT&%N(_H."6WHZT7=O\])^&N
M0_Y,&R6%J)O!L<=S3W-PTP4FMOZ0#A708_%VD(@&"=@:RE9N7T49I+9^:G>3
M8W;`&YQEW$CH26[K7!CT)MKL.)\F\HVNQ==.`'N1&_%QL+[%;\8!O-Z`MQHA
MV#F6Z("_(W8@!3<RO(<2[-$,GAQ,[3W5B:!EM0?;40%[QNKK$?XB8-C]V".`
M]Y2*^D1>H/G3L?H'``#__P,`4$L#!!0`!@`(````(0"X+HC'S`(``,P'```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)15VXZ;,!!]K]1_L/R^7!+(
M!86L-B';KM1*5=7+LP,&K`6,;&>S^_<=X\`&:)/T!?!PYOB<&3.L[E_+`KU0
M(1FO0NQ:#D:TBGG"JBS$/W\\WBTPDHI4"2EX14/\1B6^7W_\L#IR\2QS2A4"
MADJ&.%>J#FQ;QCDMB;1X32MXDW)1$@5+D=FR%I0D35)9V!/'F=DE814V#(&X
MA8.G*8MIQ.-#22ME2`0MB`+],F>U;-G*^!:ZDHCG0WT7\[(&BCTKF'IK2#$J
MX^`IJ[@@^P)\O[H>B5ON9C&B+UDLN.2ILH#.-D+'GI?VT@:F]2IAX$"7'0F:
MAOC!#78^MM>KICZ_&#W*LV<D<W[\)%CRA544B@UMT@W8<_ZLH4^)#D&R/<I^
M;!KP3:"$IN10J._\^)FR+%?0;1\,:5]!\A91&4-!@<::-#)B7H``N**2Z9,!
M!2&OS?W($I6'>#JS_+DS=0&.]E2J1Z8I,8H/4O'RMP&Y6E1',CF10,:)Q(70
MY63;"&E\1421]4KP(X*S`EO)FNB3YP9`V!HRVW<6_^405&F2!\T2XCE&(%Y"
M5U[6GC=?V2]0ROB$V8PQ_K(/V;80[5;S1FW@G=?MI^Q:A.X:6.I\047.??V]
M0:U\#=;RVWTW)@#<G9])?]_M&#%S^I!H#!F0[,:(,Y*>G>G_V-%@.%EGZCUO
MT1>W,1CO#./W$=NKB.@J8G<)T?,'0FYOEP:'&(K7=6<VZXO?&,BB.8H+QQ\4
M?FM>P[5C\`8'*SIG6'K^X#3O+C+TK,%7=;LU#1Y8&^R\,9!+VK?7(=%U",Q1
MK<74\,YS)^]%-/[,E#33I*0BHUM:%!+%_*`GX!1JWT6[X?PPT1_9(+YQ`_CT
MQ_$(AGD3M[L$&*8UR>A7(C)62530%+9RK#EH%68<FX7B=3/;]ES!&&T><_AK
M4A@JC@7@E'/5+O3HZ/[#ZS\```#__P,`4$L#!!0`!@`(````(0"2G+G;/`,`
M`%\*```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)2676^;,!2&[R?M
M/R#N"YBO)"BD:D*Z5=JD:=K'M0,F6`6,;*=I__V.<4(#Z2B]P6`>O_@]Y]AF
M>?M<E<83X8*R.C:1Y9@&J5.6T7H?F[]_W=_,34-(7&>X9#6)S1<BS-O5YT_+
M(^./HB!$&J!0B]@LI&PBVQ9I02HL+-:0&M[DC%=8PB/?VZ+A!&?MH*JT7<<)
M[0K3VM0*$9^BP?*<IB1AZ:$BM=0BG)18POQ%01MQ5JO2*7(5YH^'YB9E50,2
M.UI2^=**FD:51@_[FG&\*\'W,_)Q>M9N'Z[D*YIR)E@N+9"S]42O/2_LA0U*
MJV5&P8$*N\%)'IMW*-K.3'NU;./SAY*CN+@W1,&.7SC-OM&:0+`A32H!.\8>
M%?J0J2X8;%^-OF\3\(,;&<GQH90_V?$KH?M"0K8#,*1\1=E+0D0*`049RPV4
M4LI*F`!<C8JJRH"`X.>V/=),%K'IA58P<SP$N+$C0MY3)6D:Z4%(5OW5$#I)
M:1'W)`+M203![<3!WFDPM-U@RYT'*`@_,`7_I`+M665AS8/`#^>SZ4:`;*,!
M[:O*Q&C8.K)MHA(L\6K)V=&`XH?8B0:KI80B$#YG2,>SR]G_4@:Y4B)W2B4V
M9Z8!V1!09D\KWW>6]A/41GIBUM>,VR<V;Q!!'TDT`M?N0P.1[1AA@^G..13!
MI?.W:_)L4,'*H*I1Y7@][-@,.Q+=<3E5WT=].]NWF%=#O>E"!4Z?KH)AL5R$
MR1M^>ZT9*,DNE(-@;]XEDG>)[1C1\P<3F>Y/P;$)T>OF[OM>/[9KS8SY>Y=(
MK@G?'>;P#<;WN[GT/,("F^Y1P7V/:!9VNKH*-3-O5QSRO05:](%-#PC\^6!1
M)OK]2)"V8T3/7/@1<PKNF_/]0?FM-1.VYFX0<M!L8*X/!.'0G'X_9FZ,Z)F#
MK6UZYA0\-#?,G&9.F?/<A?.Z[-O4;OK`PAV:T^_'S(T1VIP^N/5Y4!&^)QM2
MEL)(V4$=RAY$ONOM_A?N7+4)#OK7*((=\;I_@R+8&*'?[@;`^=[@/?F.^9[6
MPBA)#I]R+'4.<OV'H!\D:]K3:<<DG.SM;0$_<@0V7\<".&=,GA_4![I?P]4_
M````__\#`%!+`P04``8`"````"$`UL*R\&P,``",9P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6R<W5M3VT@6P/'WK=KO0/&^8/D"-A4R-4;W^\7:
M?7;`!-<`IFQG,O/MM]N2P&II^F\R#PGT_'1TZZ.6^BCVE]_^>GD^^W.UW:TW
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MHYEB_*Y11-`5G2CA"2;J&F5-<5>HW2KIDN%'GSF<R;1+1C/%9'U&.=MYGU'.
M9=$UXX%RGA9=H^QWV2,^-KB5"&)<^T0B2-U*!+7A3FTPU0:K:FCW:.4";9]@
MG!.,>X+Q>LR5<CS]$TQP@@E[S&S4SN:HSRCC8'R"24XPZ0DF.\'D?48YI\4)
M9G&"*?6FU;G%;5>K<\L[D_$_/A(T5WNY5*N3JPUW:H.I-EA50_5L(.\P;+7!
M41M<M<%3&WRU(6@:C@<'Y;"'C6G&KDAMB-6&1&U(FX:C]<R4X2X[P>1=,QXH
M`U5Q@EF<8$J]:743T2-:W41_,R"U>#8\&I''`^5Z,:^,V(3W4?OC\EO=':`P
M45@H;!0."A>%A\)'$:`(440H8A0)BA1%AB)'4:!8H"AUHI4`XOGR$PD@]6&:
MY+USCP?*(#:OC"X!4)@H+!0V"@>%B\)#X:,(4(0H(A0QB@1%BB)#D:,H*C$]
M3`1,!N*_]FW2`B.4.M'J_N()^!/=7VJU^ROW9_/*Z+H_"A.%A<)&X:!P47@H
M?!0!BA!%A")&D:!(460H<A1%):X.W5\4$KK]'T.4.M'J_[("<CR!I[__D5KM
M_\K=S;PRNOZ/PD1AH;!1."A<%!X*'T6`(D01H8A1)"A2%!F*'$51B;K_]UW_
M,42I$ZW^+^H5K?XO'Q-'HG:ASP.YE)H'RD/1O#*Z/$!AHK!0V"@<%"X*#X6/
M(D`1HHA0Q"@2%"F*#$5>B:J73XV)H=[E%!AB@:+4B58>R'I=*Q'T"7#@:@8H
M<Y[S&NE2@(G)Q&)B,W&8N$P\)CZ3@$G()&(2,TF8I$PR)CF3HB95UO0-#>\Q
M9!%1>6XH-4NWDT%6DTZ_*Y)5ZLYPH$SNSVND388JCH:8',5B8C-QF+@UJ<Z%
MF,SKW*=Z',1G$C`)F41,8B8)DY1)QB1G4C!9,"FUI)T5LK)TG!6GW2O)ES`Z
MV:',5,]KI.GZ=TQ,)A83FXG#Q*U)E1U7T]FU<G_H<0R?2<`D9!(QB9DD3%(F
M&9.<2<%DP:34DG9RR-+4<7+`_5-5R1*I\3&1:BC#U5R^>"0R1YL42,PZ2C6;
MIN2=Q:NPF3A,7-U6>+R\SR1@$C*)F,1,$B8IDXQ)SJ1@LF!2:DD[%42';:7"
MB>.$7$QYI#"4UQ_F\FTZ2@DD)D>QF-A,'"8N$X^)SR1@$C*)F,1,$B8IDZPF
MU1`[,HRC%[X.A=:<8Q1,%DQ*+6DGARS,?6*<J.IX[7%"K3C+-TLI*9"8',5B
M8C-QF+A,/"8^DX!)R"1B$C-)F*0UJ7K\]>QJJ-1>,XZ1,RF8+)B46M)."EFN
M.TX*.6(8$YR&E2]'=X8,Y9#,:R1&A?=;+:5D<<?$9&(QL7O(V%`*B$XO4C;9
M[4$*\9CX3`(F(9.(2<PD89(RR9CD3`HF"R:EEK1S1);T?B5'JE)@>P11GD7G
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MNR;5X^-0ED_;+U8Z!%Q>B<?$9Q(P"9E$3&(F"9.42<8D9U(P63`IM:2=&FHI
MO$H-?#27_QA8O:<:*D^Z\QII<X-KXAS%8F(S<7J(^.?][11R>Y!"/"8^DX!)
MR"1B$C-)F*1,,B8YDX+)@DFI)>T,$3='K3NJ$P</N9@Z>*C/Y<,*:1,$B<E1
M+"8V$Z<FU?@B/O3"&!A*WW<YBL?$9Q(P"9E$3&(F"9.42<8D9U(P63`IM:2=
M'I\KC`]["N-#9?9G7B-M6G!AG*-83&PF#A.7B<?$9Q(P"9E$-:D3?3J;C)13
M%+?%<#:=*/>:":\F99(QR9D43!9,2BUI)X7HNITQPQB((IW^<7PHEU,'#67:
M<UXC;794<33$Y"@6$YN)P\1EXC'QF01,0B91#QD/E?G$N`<I8V7")&62,<F9
M%$P63$HM:6>(+%B?/D\E/UQ*38R1<L69UTC3Z^^8F$PL)C83AXG+Q&/B,PF8
MA$RBFNB&#7Q/(6D%F7;?^DAY0S(F.9."R8))J27MG%#+Y#!8]%3'1\KL_EQ^
MM)M('&U.-$2^4B\FC=H/O"9'L)C83!PF+A.O)E4?G$R,J?K:I=\6UZ/A3+EV
M![R:D$G$)&:2,$F99$QR)@63!9-22]H)H=;$(2%Z2N$CM9@QQ(KP'1.3B<7$
M9N(P<9EX3'PF`9.P)O4(,+J>393C'W&0F$G")&62,<F9%$P63$HM:6>%6@6'
MK.BI?H_4EZB&6-J^8V(RL9C83!PF+A.O)M6;\\K4G,_+!TS"UBJ482;BY6,F
M"9.42<8D9U(P63`IM:2="K*F?/P4<>+<;%6*%C.K[Z\,CD>=X@76J^^&2$PF
M%A.;B</$9>(Q\9D$->E-K)"7CYC$3!(F*9.,2<ZD8+)@4FI)*S'D2U&_D!B'
MQ93YIY$R;3&OD>Z1@HG)Q*I)=3,Q&AF#J?H)GS9'<9BX3#PF/I.`2<@D8A(S
M29BD3#(F.9."R8))J27M]%"KWOI;J%%/L7NDW##,:Z1-"RYV<Q2K)O75]6IT
M=:V^^&=S%(>)R\1CXC,)F(1,(B8QDX1)RB1CDC,IF"R8E%K23@M9:U9OIXP1
MEBW$5S]T9V>5BM&\1L?Y,1XIM8V['J0,/R83JX>,1\K=M]V#E%4Y3%PF'A.?
M2<`D9!(QB9DD3%(F&9.<2<%DP41^><D_3Y-6.5)].4GU[0@OJ^WWU=WJ^7EW
M=K_Y(;]X1-ZDO+>^?RG*[V/YN?)*NV7<B"\<Z+9'QHWX4/YN^WQX,^^+<S>\
M$9]6W/7F\$9\:+%HOWQ?L?@NE+?E]U6TW'Y?O^[.GE>/8I,'%]<BL[?5MZE4
MO^PW;X?O?/BVV8MO03G\^"2^]68E/N5X<"'PXV:S;WZ1*WC_'IVO_P<``/__
M`P!02P,$%``&``@````A`*^M\`-O`P``,0T``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&ULE%==;]HP%'V?M/\0^;T)A@`I(E3MJFZ5-FF:]O%L$H=8
M3>+(-J7]][NV0YH02EP>@,#QN?<<7T[,^N:E++QG*B3C58RP/T$>K1*>LFH7
MHS^_'ZXBY$E%JI04O*(Q>J42W6P^?UH?N'B2.:7*`X9*QBA7JEX%@4QR6A+I
M\YI6\$W&14D47(I=(&M!26H6E44PG4P604E8A2S#2KAP\"QC";WGR;ZDE;(D
M@A9$0?\R9[4\LI6)"UU)Q-.^ODIX60/%EA5,O1I2Y)7)ZG%7<4&V!>A^P2%)
MCMSF8D!?LD1PR3/E`UU@&QUJO@ZN`V#:K%,&"K3MGJ!9C&[QZFXZ0<%F;0SZ
MR^A!=MY[,N>'KX*EWUE%P6W8)[T#6\Z?-/0QU1_!XF"P^L'LP$_AI30C^T+]
MXH=OE.UR!=L]!T5:V"I]O:<R`4>!QI_.-5/""V@`GKV2Z=$`1\B+>3VP5.4Q
MFBW\^7(RPP#WME2J!Z8ID9?LI>+E/PO"#94EF38D\-J0X+D?3N?+R($EL!T9
M@?=$D<U:\(,'4P,U94WT#.(5,&ME,_#']M%J?4\J:-0DMYHE1DODP7()^_.\
M"2.\#I[!TZ3!W%D,/+>8-T0`W;0M01O=ELZ;?*RLP;JR-EVW<F<_Z):9MHWT
MRLSZ98[*+Y?3BV($-5H18?3&;SNPF+"#F9_O`"#N0C48]J;#.@L7+:^M;#$.
ME6'JW"MK<%_S;*#98B*S]<OY!!YM:SW3%_W";J;K1?T&PFC6\EOI%N,@'8;4
M7;H&CYEN,0Z5]=V@\U.[/&@:W-<\--UB%J.F7_<+NYFN%_4;"*/PQ'2+<9".
M(5+<M1OTF.T-R*6X3AYGX['-J>Y/?.A\`[+68S/O[PP\UGG4*>YFOEEUZOY;
MBMB1;T`N#IQDW>71PS;`+D=-`W(I#IBN`R/%-;JO_(S]%M38?REO]%WZ`\6'
M41=&IR%K*&/DHOPD[4:4VP@;L=TYY_"'@LZ@1VVW4><R]1_*.CP,NS!:GF1-
M`W*Q_23O1FRW(39BNW/2P3'T`P-GT&.V-R![<ST?-O;D:@]V)14[^H46A?02
MOM>G4@QWB/;3]L1\.S5GWO8+.+#69$=_$+%CE?0*FL'2B;^$WX2P1UY[H7AM
MCHU;KN"H:M[F\->$PN%KX@,XXUP=+_2ANOVSL_D/``#__P,`4$L#!!0`!@`(
M````(0!X-0L,C!4``+Z_```9````>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;)S=27/;2!*&X?M$S']0\#X209#:PO)$<=_W_::6:5O1DN@@Z7;WOY\$`8BL
M!`9OR7.8;E<_3(``OE091(F?_OOWZ\O%7YO=_GG[]I#S+O.YB\W;T_;+\]NW
MA]QL6O_/;>YB?WA\^_+XLGW;/.3^V>QS__W\[W]]^K7=_;G_OMD<+J3"V_XA
M]_UP^'%_=;5_^KYY?=Q?;G]LWN2_?-WN7A\/\L?=MZO]C]WF\<OQ1:\O5X5\
M_OKJ]?'Y+1=6N-^YU-A^_?K\M*ENGWZ^;MX.89'=YN7Q(/N___[\8Q]7>WUR
M*??ZN/OSYX__/&U??TB)/YY?G@__'(OF+EZ?[EO?WK:[QS]>Y'W_[14?G^+:
MQS\DRK\^/^VV^^W7PZ64NPIW-/F>[Z[NKJ32YT]?GN4=!(?]8K?Y^I`SWKWI
M^<7<U>=/QR,T?][\VI_]^\7^^_978_?\I?O\MI'#+2<J.`5_;+=_!K3U)1B2
M%U\E7ET_GH+A[N++YNOCSY?#>/NKN7G^]OT@Y[LD;REX9_=?_JEN]D]R2*7,
M9:$45'K:OL@.R/]?O#X'UX8<DL>_C__\]?SE\/TAYU]?EF[ROB?\XH_-_E!_
M#DKF+IY^[@_;UT6(O*A46*00%9%71$4\&7)\\77T8OEG_&+O\K94*E[?WKCO
MPDU41?X95RE<%FY+7NGZ`V]$8G$\&G?O5?SBQ_?%D[,8'M3BJ<['CVIP&L,R
MIT/C%RZ+A=+-[4?.CA<?&^_L;7U\=PKQNPJ.9W2,"\6/[TXA/N'^J<YO7'/^
M>YG3*??]C^^.'Y]S_^SHX'5W%<;HF,KJX^'Q\Z?=]M>%]#H)RO['8]`YO?N@
M8IS',#WO"?U_`95D!E5,4.8A)^],LK>7MO+7Y^+M[:>KOZ03/$6FG#2E.YM4
M8A+D/JA;C0=.=3W[);58Q"^IAP-AX(,:#3W0C`=.17V])ZVX[,FH#;=C$6^X
MHP>Z>J"G!_IZ8!`.G'9^J`=&\4O^[XZ-8Q'OV$0/3..BIQJ)`S"+7W1FKO/V
ML9_')M[20@\LDUM2AW&5%/YMR=[..L7H$V92+D&U*?-^!<;[:Z(+[G2\373%
MG8U$5]C92'2)W1Q_IAPO_^@:.QM)N\CT\3/15796.KJJY`V_!\E/O"RZTLY>
M%EUJV2^++K_CRZXD_N\]0'[V63T@_6=Q'/5`!U&/#V(Y'CCM<L$^?Y6DT.^I
MFB2J2"TI=)%ZDA1O58MI)$U!76[-D)P?S.*=NO1;2:/VMXVB@Z*+HH>BCV*0
M%/Z=.B;#-'-CG^91TJAC,D8Q03$-1>DF_"GC%3UU:F;)$L4[=17,DZ:45W46
M:4:UE&72J+>\2HK$P5TG32FOZAB31)I$23R_<'5$3)3%<Z/+1%FTB+H<3)3&
M<U/*:Q3ET49Z:U$@LU%*)$OY:_OR,RF9+.75B3<IL2SI*\AP,DU*-$N>?F]I
MZ3P=)*L'^ZH'!_,P7V:PV;TX>)75B_5`10]4]4!-#]3U0$,/-,.!\U-6O%/)
M:#F8=II1Q["39GS[S'<=3,_!]!W,(&G\NZ*]/T,',TJ:HFZZ8P<S<3#3-*-F
MYS,',W<P"P>S=#`K![-.FE)>71O&N*"R"XJR='[9)S<7Y2L;19G+1E$.LU&4
MS6R4DM=27OWP-BF!3:*4Q)8\E7R3$MDD2LELR=/G+B6TY\AJH'+KPIK$NC70
MX%56`]4#%3U0U0,U/5#7`PT]T`P'3A/XEAYHZX%./'":91=UW^FFF%MUGGL.
MII]F5%\>)(U_IWXB#QW,*#;Q7R?&\<#Y&U6%)VE&O=%I;.+",STPUP,+/;#4
M`RL]L(X'3GM;RJL?!\:XH+(+BJ[&\[@GCKJ)KM!L%%VUV2BZDL]1L:CC'EW=
M-E)7BWF_XD_'*;GC[RG(0N_)R$(I:4EN+B4N2922EW-DM2"Y"_<;+2AXE=6"
M]$!%#U3U0$T/U/5`0P\TPX&S%J0'VGJ@HP>Z>J`7#YS.3:))]6,3YW*@!X9Z
M8*0'QGI@H@>F>F"F!^9Z8*$'EGI@I0?6>L"8Q$@Y,1*=S].A-]$)/1N)SNC9
M2'1*SV.6[#31:<Y&[Z?^=)9*>34=-*W$;B>N!Y.X($SBBC#OEX2<;BLL<CO\
M-\(2O$K^8G1V>ZSDJ79;#HVTT_=;:*>_<QWO*E=05%'44-11-%`T4;10M%%T
M4'11]%#T40Q0#%&,4(Q13%!,4<Q0S%$L4"Q1K%"L41C#A%-G.':&<V<X>(:3
M9SAZAK-G.'R&TV<X?H;S9S(#:'5>^93.ZKS9MY@"_9"3FX^G;NJI?EH.35;'
M15%%44-11]%`T4310M%&T4'11=$+Q>WQ/KB7#_]GWXCJ8Y$!BB&*$8HQB@F*
M*8H9BCF*!8HEBA6*=2BL4V>?.6.PB.'8F0I7X>`93I[AZ!G.GN'P&4Z?X?@9
MSI_A`)HH@>E]SVJYP>-KYT]99+?<0.N6J^Z`E$.3ONEPDHNBBJ*&HHZB@:*)
MHH6BC:(3BNMCN_33NF47:_10]%$,4`Q1C%",44Q03%',4,Q1+%`L4:Q0K%$8
MPX139RI<A7-G.'B&DV<X>H:S9SA\AM-GHOAE-"S#^3.9`;0ZKCS*]H&.&VB[
MX_JWZA9F.309;Z""HHJBAJ*.HH&BB:*%HHVB$XJPX][<R`,6^A&+[KGPCD`]
MA-'#K?3/:Z1M9(`EABA&*,8H)BBF*&8HYB@6*)8H5BC6*(QAPJ$SG#K#L3.<
M.\/!,YP\P]$SG#W#X3-1^C+ZE8GBET4R\V<UW.`A<JOC'I\DSLMMY.S)[O%U
M=N\M>>JSO'*$,O:TPJ3*I,:DSJ3!I,FDQ:3-I)-&/'6WOYN&[+^0]ICTF0R8
M#)F,F(R93)A,F<R8S)DLF"R9K)BLF<B3U$&4'W)6VCS]()U#)N7QZI1*]G4E
M#URS<8BE<<BE<0BF<4BF/+?-^^R039,:3G5\'+)ILL-IMVGY;-!JT]"=`ZZZ
M<T'-T<I>B*SKQ7X7%295)C4F=28-)DTF+29M)IV(E$K'VQ+Y2_T(:9=K])CT
MF0R8#)F,F(R93)A,F<R8S)DLF"R9K)BL(_)^*22?`.<BLL0%LRA=F8U#&HU#
M'*4K\[8<`BE=F>LX1-(X9%*Z,F_+(9?2E;/JV%TY>+C?_09QL%HUT975<UGE
M"&5VY;!.!JERE1J3.I,&DR:3%I,VDTX:*:C[0=TT9/_4ZS'I,QDP&3(9,1DS
MF3"9,IDQF3-9,%DR63%9,Y$Y,T9)>C.;BH-QR*3T9MZ60RIEQLQU''(I,V:N
MXY!,Z<U<QR&9TINSZMB].5@;<-Z;W9XL]\(E!;*9TX,3!?6`>SE"&0VXPJ3*
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M:/WD<?`[I_1'%?91J3"I,JDQJ3-I,&DR:3%I,^DPZ3+I,>DS&3`9,ADQ&3.9
M,)DRF3&9,UDP64;D_;:Q_*8U.P`K+K)F(@T:HR8-FHU#'J5!<QV'1$J#YCH.
MF90&S74<4BD-FNLXY%(:--?)3J;=H(/E/><-&CX3#%<#V8U9/Y_LX9*A"I,J
MDQJ3.I,&DR:3%I,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&9-Y1,()N'>7,@%?
M6*3@!\;NNDO>S@J+K+F(]&5,FO1E-@YQE+[,=1P"*7V9ZSA$4OHRUW$(I?1E
MKN,02^G+7"<[F'9?#E;OG/=EQSO/X:(?NS\GGJC#E4&5X/>P9L^MJTQJ3.I,
M&DR:3%I,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DS63*1#8Y"D
M0[-Q"*1T:*[C$$GIT&&=^,.(M&?SY</!<^3Y:;>JI$?S'CD$4WHTUW&(IO1H
MKI,=3KM'!^M]=(\NRO0<YM#A,B&[1ZNG<LL>KB6J,*DRJ3&I,VDP:3)I,6DS
MZ3#I,NDQZ3,9,!DR&3$9,YDPF3*9,9DS63!9,EDQ64<DFL^GK$.2%HU1DQ;-
MQB&/TJ*YCD,BI45S'8=,2H/F.@ZIE`;-=1QR*0V:ZV0GTV[0P2HCW:#Y-ZL&
MWSV0^'Q0/0-?CE#&/?D*DRJ3&I,ZDP:3)I,6DS:3#I,NDQZ3/I,!DR&3$9,Q
MDPF3*9,9DSF3!9,EDQ63=42BR69Z@W98+,A;DF>?N8Y#(.7Y.J[C$$F90G,=
MAU#*\W5<QR&6\GP=UW$(ICS`D57':M#!][18#3I[YGSDZL$-7]U\*T<HJS$S
MJ3*I,:DS:3!I,FDQ:3/I,.DRZ3'I,QDP&3(9,1DSF3"9,IDQF3-9,%DR63%9
M,Y'O)>"U<`YYE"\FX#H.B91O)N`Z#IDT#J$TIU0&WWA44(^/R1<2\*XX1%*^
MCH#K.(329*?2;LK!TI6/SYH+X8J7\]L:1?W[P<L1RFS.62MGPF^&XBHU)G4F
M#29-)BTF;28=)ETF/29])@,FPXB$\SK?\_07.XVXQIC)A,F4R8S)G,F"R9+)
MBLF:B;1FC)%Q2*.TYK!.=`/E.O%AIZDZ;"F.8WPU^-?JF0'CD$9IR_R>XCR&
M6TJ]=1WG,=J9HG^KEF;(%\6<OVGY3K*\6F`G;3FY*XG?CA[G,7[7-S>Z3'8<
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MVQ2Y3G8P[;XLL]F/].6`V_/DDJ]^W4.Y$*+,>3*2*E>I,:DS:3!I1B3\22A?
M.W^3_));?$-MWDZ'29=)CTF?R8#)D,F(R9C)A,F4R8S)G,F"R9+)BLF:B;1E
MO.RD+;.I.!B'0$I;YFTY1%+:,M>Q0^D5Y>:%_5RYW%3F*@ZIE,DRUW'(I=Q4
MSJICM^5@U<H'ILOA(A=[NJQNTY0+N!*FPJ3*I,:DSJ3!I,FDQ:3-I,.DRZ3'
MI,]DP&3(9,1DS&3"9,IDQF3.9,%DR63%9,U$^C)F3?HR&X=`R@UEKN,02;FE
MS'4<0BF?]'$=AUC*A#FL$]W$R.O%FM*6>4,.L92VG%7';LO!HI4/M.5PC8O=
MEM5'G^4"+H2I,*DRJ3&I,VDP:3)I,6DSZ3#I,NDQZ3,9,!DR&3$9,YDPF3*9
M,9DS63!9,EDQ63.1MHQ9D[;,QB&0TI:YCD,DI2US'8=02EOF.@ZQE+8<UPD>
MY$A.NAU"*?<PXAIGMW?5Y#T[EG97#I:IG'?E8/'?G3P(`O>8P]4M=G=6OQ&@
M7,`E,!4F528U)G4F#29-)BTF[33BJ\\J.FG(/LU=)CTF?28#)D,F(R9C)A,F
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M#)F,F(R93)A,F<R8S)DLF"R9K)BLF4AGQB!)9V93<3`.B90/`WE;#IF4#P.Y
MCD,JY>-`KN.02[GOS'4<DBGWG<,Z:<_767TY6(+]@;Y\Y.H9C:+Z;+0<(?E`
M\O2`G3WMJS"I,JDQJ3-I,&DR:3%I,^DPZ3+I,>DS&3`9,ADQ&3.9,)DRF3&9
M,UDP63)9,5DS,<;!..31.`32."32.$32.&32.(32.*32.,32..32.`33Q,E,
MZ[G'V:C)#J;=EX-%+>[S93]<`V/-E_4BF'*$X@\]\]Z=KVYW5"Q2RM\5KM4#
M>%5+%(O7A;N\NJ]=LXA7NBO>7:L[`_6(9/R(:#!I,FDQ:3/I,.DRZ3'I,QDP
M&3(9,1DSF3"9,IDQF3-9,%DR63%9,Y&V?+YJ[?AUZ/8$R-AA3!-Q%C,R(BTY
MN?9-I5%:,AN'/$I+YCH.B926S'4<,BDMF>LXI%*:<E8=NRE+?_U(4PZXGBRK
M?EKV0Y1QEBM,JDQJ3.H1"7]`W*;\PMT&%VDR:3%I,^DPZ3+I,>DS&3`9,ADQ
M&3.9,)DRF3&9,UDP63)9,5DSD::,49.VS,8AC]*8N8Y#(F6NS'4<0BES9:[C
M$$N9*W,=AV#*7)GK9$?3;LS!NI4/S);#92ZR"Z<;%$7]2+,?HF@VG](,*Y'(
M:-U5)C4F=28-)DTF+29M)ATF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R8K
M)FLFTIAYV5G9P3@$4AHS;\LADM*8N8Y#**4Q<QV'6$ICYCH.P93&S'6RHVDW
M9FF.'VG,`;=GS(F5V7YH;G/!,X)^\<97C;L2@<RV##5J7*/.I&'MJKI+WN37
MMYBTF728=)GTF/29#)@,F8R8C)E,F$R9S)C,F2R8+)FLF*R92#L.TY$1()DG
MLW$(HK1CKN,01FG'7">.8];[<DBEW,#@;3GD4FY@<!V'9,H-C*PZ83N^VG_?
M;`[5Q\/CYT^OF]VW367S\K*_>-K^?),IL'S1X-GPQ6[S]2$GOXS[7G[9=NXJ
M^5_J\E\::?^E7+@OEU)>42G<5]+&JX7[:MIXK7!?2QNO%^[K:>.-PGTC;3QX
M"VGC9>^^DK;_5>^^EC;>\N[[:>,C[WZ2-C[S[A?'\:O3L?[\Z<?CMTWO<??M
M^6U_\;+Y*L<]?WDCRX-VS]^"A\K#/QRV/^1\Y"[^V!X.V]?COW[?/'[9[`(@
M^.MV>XC_(*?FZM=V]^?QW'[^GP````#__P,`4$L#!!0`!@`(````(0"Z2(A\
MN@4``.`8```9````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;)R9VV[C-A"&
M[POT'03=1P=2E*4@SB+;1=H%6J`H>KA69-H68EF&I)S>OD,-)8JDM::3B\1V
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MBO?AYUNUZ?=KGZ8!6T4T!KGWQ+O^L1(A?:]\Z?JF_@]%L0R%08@,`C]E$)($
M"6&KS"%*B!4-`_Q6],7]7=N\>=`UD+,[%:('XUN(?'Y$,!2A?1#BM;_R/2BV
M@VEXO6=)<A>^@G6EU'Q%#7R?-/&D""'IE!FRN6<68I%9>"M*^8H?S-.0\VGH
M-6F$&"9G5CQ+V!07,Z,FF6LFA39`D+@/4(C7/HQJLHUDZ107,Z,F'8R/(_$U
M";3$T%/NB8583TR3;(J+B5'C,.3TFLQ"?,ELU#ADAJ9T'[,0ZV-FB6DV:J39
M><9HICI=<UM`WGD%";&>V9YFU&#F?)7#3$_3H27.KTDLQ&9B<YI1@XEOXCAE
MJO6UQ#$`U'W(@UI/S9+5-"3L,"G"W"1G)"/Y)-&3"\`X^QTCCN;KBEGM+468
M/$LSDJGR]-R".K/<8A^@8,8%:B*K]!K4Z*0!*$J&Q4T#0A=&;^#,L0)DEE8!
M4UTE*QC!)KB>!]G2Y`L*7>\!LDNO0&T,L@(4H0=1L%+]J<^"P3='#VS0,:;V
M#%G!2+IA;PMF[-<K,#CG6`'"3/=`S;.L8"2>J"`*\B4/#-Z)"A(H_D(GG@$?
M4UB3%:!(8^XB"0SX.1IA4Y`QD[\QBO0REM:E@4)'-VPF,J;\EFZ@2"]#+5ZM
M+8C!1;<RAJ<,/J;FXI0BK8Q4K1^]#(.0;I-"SI`R-=>'%"$I61YE::[F32]"
M\&R&B1\W)A%JTP-S:4C1W(-DR8)/89*<P61J+@\IDIL%C2*6+I"20*576"#4
MI@4J,G;C$'+M2_^3.(OBA24A_K"X(KD-1YI;_H]P5&=459\^^08?+TP^(@_,
MG\Z^]JF;C%R<B<YOD<1`XX7D9Y!HG06'D*/M>;JB)%<+5!^Y`<0+R6T0VL=!
M@B*<\R1*<Z(8I><V*'@AMTT_DJG(LM]0A+EOTI3$,S)IR<4QR+W?!K71[-:9
M4(HP>2Z:?49G/;E!O!^/G)XAG74FE"*9/,Y9M%(DT),;I'/#+3U#O$3M*VB_
M%.&!".Z7%EA+/T6[X2EC#JQ#H11A!:M@B?;40)VC!V>0QQ31I0<H&CV8W3?H
MLV#PSK$"FWOVH9".W!-'LCB@BHMZ!0;T'"M`KD$W*/@QE4%Z,,+O0@4&^40%
MEP^%]`P!K4.A%,%<J#+3I78T&.AHA,U"^U!(4:27L;`#4@.'CF[86+0/A4-H
M\%9S0[%3:XO$`*-;&<-3QN*<H1?;0HKT,A1#]#(,1+I-2G(&E=:A4(KD!K6B
M>4JCA3E)/L7*X2G3#$5C:08"%:M@*4T)C1<V:;@JOF*O&M1F=G7PD=GQZ#A2
M*F:Y]F6<5/"B&>]A:][N^"_\<.B\LGD1E\@QW`%,GTX7W`]DN**>?@'WRZ=B
MQ_\HVEUU[+P#W\*C\$<SP*K%&VI\TS>GX9;WJ>GA9GEXN8?_)'"X1(T"$&^;
MIA_?B#OPZ7\3]_\#``#__P,`4$L#!!0`!@`(````(0`_E!JYL@0``,81```8
M````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG%A=;^HX%'Q?:?]#E/>2V+'S
M@8"K&ZKN7FE76JWVXSD$`U%)C)*TM/]^CW-"$CN$PO:A0#N>C.?8<VP6WS[R
MH_4NRBJ3Q=(F,]>V1)'*;5;LE_;??[T\A;95U4FQ38ZR$$O[4U3VM]7//RW.
MLGRM#D+4%C`4U=(^U/5I[CA5>A!Y4LWD213PGYTL\Z2&C^7>J4ZE2+;-H/SH
M4-?UG3S)"AL9YN4]''*WRU+Q+-.W7!0UDI3BF-2@OSIDI^K"EJ?WT.5)^?IV
M>DIE?@**37;,ZL^&U+;R=/YC7\@RV1QAWA^$)>F%N_DPHL^SM)25W-4SH'-0
MZ'C.D1,YP+1:;#.8@;+=*L5N:7\G\S7U;&>U:`SZ)Q/G:O#>J@[R_$N9;7_+
M"@%N0YU4!392OBKHCZWZ$PQV1J-?F@K\45I;L4O>CO6?\ORKR/:'&LK-849J
M8O/MY[.H4G`4:&:4*Z94'D$`_+;R3"T-<"3Y:%[/V;8^+&W/G_'`]0C`K8VH
MZI=,4=I6^E;5,O\70:2E0A+:DL!K2T+@[9V#O78PO':#9S3DA/M?2W!P.HT[
MSTF=K!:E/%NPY$!P=4K4`B9S8%:V>&#N=5O`#S7FNQK4#`5T!;5\7U&V<-[!
M_K2%Q%<@.F)]!<$[B`/R.HW@T5#C;6T*#'.PK5Z;W]$V\F.$L`&D?W"#6-]"
M:-+@.?=+4^"E#=R]M,"0AI"P\90P/W!#XNF0]1#"N>=Y?C\_31M,<*CMOM*J
M08;&4!<0(\1O-/H@T#7=&P(H";TPZA@T@;!QA@)OUU6!#6$]+=85(2B,<!J$
M$3&TKX<0'G`2\%Z\ILW7M=UGGAJD:_3<;NJH$2&M1H]&+M4!:QT0T9Y`TQ?H
M^FY[I\"&+J(_-D8(ZO)8X)FK#O_/FJ)/2%*M<A`EMR4IL"')<")&R*6<C/FP
MVG75ZR&$!S[W@XER1H]H4V`]0DP[8H3`0N^V<O]@C)!;"*V2!.)VZ-M]2ZT9
M91@XRF#%O+1;!UW&&37*OFYIVKK#CIG:#^3_-0H,^6'D>891<</<J00%GA&*
M:PT1$A+V%+J3*K;O7H&J]9I+L$]2W*TM!NWA+`KZI8]5U@"$!R&=TO90IR#C
M5F&Z$K<8U!:%U/?IR#BD00@TDX!.EE=E]OW68<)K9362-B;#+D#@![9O[TWK
MWA`3>)33J;A31[4'](V;A6<VBX:Q6W83^H;MXK8^HU_<#C\R;A3,6%EQBP&'
MNHAAH]V+/!,8?6\\U#`(QCTLG_[A9CRWF.'#1_6]=(V>IH?H\HSFH4*0@?M?
M^#CN(LQH$3%!S%#FV,>;&%VHT4F44/_K`S-V@^&&8:.T1@QN5AKXHY,!T0",
M^Q->4J.AW/:P0>N-A/7$&(,M!J6%S'69.VK%&L9GD>>1`8_F(35ZR1<"QSV$
MF3G=,%XV\U,`.0UQ,S@+8-SH*-^'X]]D(-*'>DF#-DPTPCAN,6@B@Z-?%!F9
MN=8@3X3SB$]Z:/23^TX-<,,V>QXS1,0MIKV#\*OG+@US_>"%-W&\:YZ2O?@]
M*?=945E'L8,MX\X"V-TEWL/Q0RU/S9UR(VNX/S=O#_!]B8`+ISL#\$[*^O)!
MW?2[;V!6_P$``/__`P!02P,$%``&``@````A`,+0+?K1`@``XP@``!@```!X
M;"]W;W)K<VAE971S+W-H965T,RYX;6R4EEMOFS`8AN\G[3\@WY=3@)0HI&KH
MNE7JI&G:X=H!$ZP"1K;3M/]^GW%*:Z=E22X`A_=[\_CU*<NKI[9Q'@D7E'49
M"EP?.:0K6$F[;89^_[J]N$2.D+@K<<,ZDJ%G(M#5ZO.GY9[Q!U$3(AUPZ$2&
M:BG[A>>)HB8M%B[K20=O*L9;+*')MY[H.<'E4-0V7NC[B==BVB'ML."G>+"J
MH@6Y8<6N)9W4)IPT6`*_J&DO7MS:XA2[%O.'77]1L+8'BPUMJ'P>3)'3%HN[
M;<<XWC30[Z<@PL6+]]`XLF]IP9E@E73!SM.@QWU.O=0#I]6RI-`#%;O#296A
MZV"1I\A;+8=\_E"R%V^>'5&S_5=.RWO:$0@;ADD-P(:Q!R6]*]574.P=5=\.
M`_"#.R6I\*Z1/]G^&Z';6L)HQ]`AU:]%^7Q#1`&!@HT;QLJI8`T`P-5IJ9H9
M$`A^&NY[6LHZ0[/$C>?^+`"YLR%"WE)EB9QB)R1K_VI1<+#2)N'!!.X'DP`>
M3RR>'8KA/A:[X64<Q,G_$3S=G2&=&RSQ:LG9WH$9!\"BQVK^!@MP5K',(-SW
M8X$\5,VU*AI*02U@*!]74;KT'B'^XB!9'TM"4Y&_HXA'B0=X(R-D])9QFDV)
M,P37D2WV1]L!?ZTEZ0#NNWY@OLX_?&U`05BG0RFQ!67]ZEI+D@$J\/7'`IN4
M&'#1.7!*;,%98[76$KB.H486?SXI,>!@O9R>G!);<#,SEK663,)-2@RXY!PX
M);;@(@M.2_1<"[Y<6.SYAZ\-J/DY4$IL0;VN*[T`M,2<:]8BR:<U!IXZ(M_L
M(=/K4XDMO,3*3$LT7CA/_#!(K0F9&Y(H3N(HFH\N!EQZ#IP26W"OMCH[+9F$
M,R3OP^ES2N_$/=Z2[YAO:2><AE2PQ'QW#C.6ZU-*-R3KAQUWPR2<+L-C#7\F
M"&S'O@OBBC'YTE#GX/CW9/4/``#__P,`4$L#!!0`!@`(````(0"7\78[+&@`
M`))F`0`4````>&PO<VAA<F5D4W1R:6YG<RYX;6SLG=MN&UF6IN\'F'<()%R3
M,D`I)<J2[>PL-V3)KG*5#VI+636-P5R$R)#$2HID\6"GZJK>8>9F@!X@GR4?
MI9YDOG^MO7?LB"!EY:FR+P;([K+(B'U8AW\=]^97__KMS;CX4,T7H^GDMY_M
M[>Q^5E23P70XFES]]K.OSU]N/_FL6"S+R;`<3R?5;S^[K1:?_>NS__I?OEHL
ME@7O3A:__>QZN9Q]^<47B\%U=5,N=J:S:L(WE]/Y3;GDS_G5%XO9O"J'B^NJ
M6MZ,O^CO[AY^<5..)I\5@^EJLOSM9X_V'NU_5JPFH[^NJF/_Z'!__[-G7RU&
MS[Y:/CN9#E8WU619L([BQ60Y6MX6KR8^`>O^ZHOELZ^^T*/^^&'Q9CI97B]X
M=%@-V]_^8379*?9W>T5_=^]1^\NCU=5.L;>W_LM/+*/X'T<7B^6\'"S_9WO8
MS]L?A$V\KZY&>H6MO2UOJO93GQ\-EJ/):'53G%Z74'-0K9:C03E>]-C^8*?]
M>!CT&$K-RS&/#*MOBS]6M^WG/M_=W=W;?_)DO[_;_NH(,@^-U"_'Y57[V\\O
MF;NSRN/5?,Z4Q<O1@K45_UZ5<U&^."F7G6<_W][>ZV_O[[5'3J0]OYUU7]K;
MW?ZWC6^<5O/15&*Q?L8T<KZ\EPC4HCWBY^L$HOUZF&W]`/_6;X\96/)R-*[F
MQ3$$N9K.N_PXNRG'>N!]-9O.X?A5<3R]F963SI.1P].;F^FD.%M.!]_TBC-D
MHUH4[U9+4U1>;Z_B>#I93,>C(?,/B^?EN)P,*EY#&Q?%UM>3<C4<\<U#_GUV
M4CQXV'[]I!J@,:X4^^TO(_>/%@N&^[+S=;FX-K4=Z!_57U>C#^48:>E0_W1>
MS<K1L*B^!3X6[$>Z/EU>0Y9!$+#2IFC/<#Y=(G7-9;2?.9T#2G-00X-J$3/)
M>*^85,MB>EF4`_!E-3;R#"NP:C`JEVN`Y:QB*0(?'IHN1LOV-+X4IT3[N[C`
MUZ/R8C0>+4=5EUA'`\/#13$K;\N+<67+97'S%7R+A&D/?*^7BNUB7OD&9R6$
M:`_R=KJ$Y&':]I<G:-@'"/*A*L;UZMM/-?F0;7/]@W<\@/#?C);BD$O!`#1'
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MN5C-%TZ(MDS\KII`E;';A>$-OJ&\1VEW^\F3S(S%Y;2?>3U=+`H$83A:F#D#
M"F0-DWUL/^\J+DO*E-DNV\_9N)?SZ4T1GL7]:#_SSBS[B%#CIBJV`KVZR/QJ
MLJR`L.6F+?R.**+8&K.1A]K)X+K$3A1\=EF.`GAK2]B!>ULP]SG"RH3J:77M
M/;S%>X@[L"5\\H$"VA'SN/H)Y;'+%^5B-/A1;PY'XQ5^6_O=/U>CJVMY>B5Q
M70DY\@EA>(T?FV;_02-L6$4#ES,=@QO'<@5?CJ<?[Z7:V=,O)5.UEBDZ^K#>
MDQ)KQ)(V;8Z&?UDM@FNQG&(=\2T&..?F">J%@D_E%9J[.IM//XR&4/("[V&U
MX!^C"7*6%(!0;],"#`*WX2TO07_YM(9FFP3YZ$:>_]_\&9/8BZ44TQS"SBXZ
M#P?WY7(TP;>7;@ZFBZZ/;=J"FE3?2G]7H\6UA7I,%_VZCH_P6C39ND+-?@8%
MVR)J)1&PJ!ZBD?XO*-H%R?]6WLS^Y03N.!::*PRK*G08K[A-#8>2]<%!G+#8
MBA,^7#>CQ,7D[&OQZ]5DK9"UYVT+YJO)!Y!*Q+]#,$]7H#\4$"HA7HA2.RII
M3]-9V[IYVB^UU_8R"<9=:RMO@_F=X-HNJTWQP!D1'#AR&3T(Z0M_32^1PHVR
M1P@VJ*KAHC##`/HCA=5\,')23&=R1-W=_UC.E1'AR2E@"5:T-Y<HPIBNG\]O
MR3Y$T:]WN.[%VD2L&]KH5BZ+"Q(SDXDV(SZQK6D'9N.C)$PV/W2VFLW&9LNQ
MVE)G,&:E:)UA-7]Q"0PBD2F7U5$&F\8B8Y%C%.QA>V?-IY;EM]U`:<-2M!+B
MF&U;S2B)L`Q?C29W`!TXCYE1^M!'RN)(=U-"^!I7+H`US[.]A7.8OD""7$`2
M(!6#,:H](N9P;.1U.2AH3?.+]G`GU6(P'YE8:6'/5XO1I`++M+&SU<U-.;_5
MYV>CJXD-3@(K1-+B^BGIDG71YL\SZAV9PK?2N[WB'W__7]]_]_-,UB3,7/G4
MM^42(6R0A0G]01[0?Z?\O\7?%/Z2%=[[[(MG7PVF8P00Q;TA#6R?S%\2F/LC
MQ^5X=#$?Z;G+\F8TOO6/^_K`\L*5?X#+.IWKPR]LAN6S[[^3NF[.<19;@HI_
M_/T_CCTC]H^__]^"9?!!?(]/P'086UR,(-[@>L)"KQ`/?\&\G]%2_A"B$UQN
ML?@"2_3-\GH^75U=:UMS0E\44UHV'EU6?,0#R\I``,V5V5H4DJ*K8J3$Q'AV
M72I%0#R)_S"ZN5E-S'4L9S@+1Z>OSA\6,S(NTFP3.O<K8Q9&8K@802ER#&G1
MS+]CQD/TZ+'>JTH+*SZ.EM<VZ4=R&M!V^G'"=A:KB\5H.$*0>\6;:ACIX;GA
M8NO-T:N'O6*+]RN@\1(_&H,:_`0H`3O',3%0E(LN12=X5I81TY/EQ=3CC**Z
M9$?LW];$ZLW=QNPM24T+P:6?Y"$OQG@7(JNL''K&?W*UJIF9"I''B((I9!\S
MI3W9D=(I9+HQ"7M?]-%OY$(9Y>5\%&*>[('.UTN(@%^D1\_&TW*R_<<*KIM!
M.E;"D_PK\3__LX7PO#G[X_&Q2<Z*+/F<M13V$=/?XHZ/^/O5VY/B"/0.P+,C
MMX`,<;^7.%2,R]6$H@>>=D'Z<#G:'O@,@^F<'4&\@L"*"%>9)=\$D4DYP&DO
M;FX)_4AWCJO5-]7-J$1DWKQ&8@`YY;UJ,?C'W_\/UN+B+\XKA")(+$9D0R2)
M+L`$R#Y<D>9%X,C9(:$#)\*E@@,)L3\@3EZ/"$AAWYBD5D%F8(J54E(((SRZ
MH!2$W,.*;]B$,;TE^:Q>=&:1\Y"O+6>,/8,3[D+`C&%<DLRURDVWQ0Q=!3V6
MDB!3SJB!.\4Y4@/K$;]QB\MF-Z.@&V6DY12,F.":<`>[74U\E9&2^ES;W4!V
MZ>&(,&[!J^,1`3F<NL8!:$QBXIJ4^>-H//;9/K(;9,>%Q+*ZMX8?PY%<(=L>
MY8Q@[$T$/TH=D7B2;.+)>F+#*5;#2.PK%'E`XZS`]6Y2G.`.WUPP>_^)%:L0
M2RE;0$EJ>+"$O6!UITBG2DR+$J#%2D=`/;/X\\6W[A!)%WK%C,S#2M4HWG*Q
MR`<M!QA>C;JWN_L;:;2^7)]XC#9ZX1ESB1#/1Z*N+V>98D)J7PJ:4H6U&4WC
M7%:[8"P3LF]'E!C);!9/GWYJ00A*EO1*N;$BI'JAY$($Z<5]!4JBB#(M:!L*
M'K]KDLXI+YR/@X3,LVWY]!6\'%#<,VJ!@<LY>"J)M/FR1S-2,RL\@+KR%WFV
M5U0E.@IQ\K=8E6(B&+*[L[^_'_-MD<&1M<5[>4X&=CD/<H(8A9M3).H/NXNA
M6A5)T5K2`J4D0%[CS`N28NRCEQK3?\0,1&Z#IK[WYOIMB9/J8QH=N(F10D\&
M+*KA&!XV)HO^13ZC@TR3CPS'*%Z"@:9R!/0!5`:PL$G+\IMJRC^_@.R>)H_Q
M.C81>.8=\@2ELR%MIX<BF0DV[FD*9`"[;>HI%@>MPN_5A#Z]`5;M@8.#5,="
M:1`JDJW#4V@Z=LMG1_<3U"#8@KP)L4=92`0U(?2947/,\AO1UL`O2)RP>!O[
MCMG'W9JA,G59.HV0>5G8W:5R=,'Z+.5369#963Z@]L92HWVOS>\W$,W`/O=X
M[L:27D@%"MS9IZG?M,:?XV"@P<.=@HF/L%;C6/=O3MP8:#B]P3D`N%,0:YDM
M*</;ZD,Y!&FGIK?IXQ.J;HBIE_(&EI[,UF3#'`/,JT7Q)S![!<X$_XV![MYB
MF_ULXPSW*EB%`[,*;,4\#AR2H0&G&W`\(=Q6"ZDL"GB'/SE?7(]FN%!S`E_/
M8)A3GE'*C8E$]NZ%%5N7D$BV!ROENV^PL@`GK_@^XI3FK.:&3V:NX%@USHQ%
MOH2MLGBZO_,8L&^YP!@OF?*TLORE@7QW[#J>Z;<DS-="NB\B\^WR`2Q>#5.B
MXAE0&V:8;.--@UPLP6#4L-WP/Z)//AZ!PN;1:AP4(#20'3$+VAM]GV32V!0;
M5"6<A_9[3Q_O]O;V4W4PQ_U\(3DDVE::D^_U]OO]WN[!030M]0(:^-W299R5
MY;/GI+7-Z)_*4YU0VY'SL5VD=@/\:7R4T4W,W+#TK*='$;!+N*+1=D"Z^TL&
MI.<&R@$-I0RKV"$A#;`E`^%#=2DHMYM5L$+"A)V`D+&6)9F(41^,QQ.J/=69
MFA[<3S/H;VAI;0I`)[*Z))(6!55P58!P>3`54G?3,TGDUWC,_&7(X]X6>D;P
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MPCR3WR3::0"MF`!L"!M3E!:[ITS67,YX=%XAX"Q"'A)/!R:%\0SBR\ED90R6
M]Z<*9U2'/]YK.G.,W1JG_9V]."Y>5A?SE?@=HL='`<'S,--0_+1&'G9[G,!.
M0O3K(C1DNS<$1_T7=QK4=8AU<**K!Q%K\M1XL#[IYKDZ!'2199!-)003DH?@
MRX?1ZP@\-P#D'$B)8BO6!?K&`2I26M0+=%ZQ[D)2\M)K'0B&H;T5\4YS,_OK
ML@8@P*JYP7=ZLH<?QB\]CCZ16KH-2:>?RQH&>%]D`"@S<T-PI\1E(+*L%66'
MU4T(92TG5%J8%[!0"HG.EC=J5S9[ZQ5(T_!8O3##Y]&LFB^C=+&YNA^S-L`)
M<:-`"JFZ\R@>I?O$'XJ=)L5P909`(I[%BG@`4P7P1!@&(P['%)4!0L]2Q5!&
MPI_VOPD.WE?-HLNOB`$*88!-K,X(W'4;E+A1>UB8QE`_@EF.MI(K^V=H*PWO
M(K7)3]VT?RNS23;L'^HK#-VLOR(ASFM0,YNEU`*RH1PEJ5X,[9BN>C+-"8[,
M$I`H)]!#)@`5)$?MJ"Z=\\K2DFJ?AZYX>I:ZQ6A:@5"^4=CR#F4T<E(7WD[,
MC-CX%=E#^:;PA4A"[Z+_+T]>'?.)ZI[DN\$[2V\O"QKQJ]2(;VK3,9?8KSK5
ME".W+4;)E-")Z]93Y8&+<O+-)O:=Y@5W<<]ZKWY%WKTAJX?IQQ!+J$1<7Y%H
MB>3BS0IBZ$:AF\,>2=W)?(X))ME$:E<9_6U2BMJ\!5TDJ9(N#V%*A2<%Y6E/
MJ'DL+X4RPTNYG%8-U`HN1]]:#L*8^8LM8"$`,S>)!?SYFG]'Z+1M+\W[1OC`
MR*%G#M+^8R"%,&<-J:ANZ-@."[\A3\=NU"XD0(RB[V&-;',<1XTM)N=J<R%>
M#7YW$">0P:.;G>*]NM.E5U!)1U<H7EA"Q?"7-EIE;FQR<CR6W0!KZNZW30+Y
M"D]A1-Z8C#N*\GHZN=I^;0G=(VMUEV3&YF;%P/_$,/A-"@^@R8=11:\61:$K
MQ$R4#?R2QSNJMT"B<Z)<:2'^RB;2OF$9+W-:!J,Y/,/&40C1!^;]*RL>TKT#
MVCYN%=>X287*MQ8S`#WXZ]2FK&+"F#Q/O8U`YH:#,>X@`SG#VOY1.)E3,/TK
M'B[ANHN\N^5$)E0.`">U=;N#8DQ'\0`GE[5H!)&?E2D&59C0A\7.#7C4M`&W
M%XNIQ(Y/DW-MA'$YD!<HQ$,03`;%44_;Q(UJ$1!`56G6R8Z(J6QY&4T1BX5@
MU@=6SC;&:AYP>NI9>Y189R]^C,$.XP<GP=81:U,#%<N6'U4OT_*:_9+9E!)X
MY5`3>VS5FP3Z!(?#CPJHHOQK97".,!I8P;22-ISFF_7M!RM&GHM#,:!BZA[U
M<#<K8X&W`F5@0V1#Q2=(ZOP;6J!$J?:LW@`(4O]U1>I'T&&/XK2@!`9^0%[C
M0Q,>Q<H*4A4GEQ]*N@2H%O8R)CG6)+D1R$MUPD@^JR:Q#Z?#:BR-PY[@32+V
M/!E'GUXLJKFUU<67<51+VXM[RGKX+ZOAE8&4MACU(Q8@0*54FK2(Q8CW)Y-M
M6?\4J[R:8*Q6&N?7E(V:M<+[(4="%'KC28B=QA?^!<0D_<&V>)$-12(Q/19^
MF#92*L3QU)DEJ7CL7BHQM'["AR044L+3,N-S.)E78:/N1=Y;'\EHIKXWI7(O
MDP#BQ6&%:!J\)6^H*C4"!PL0",\4"8,S-)O,:._U'5R9P=>VY`CRCOO*"JE8
M<!!(ET1;*'D0<C&^(!=[7$E:`-2"81MVC[`^`612HO&!P_;P-,/4DC6R53E@
MK=T9G&!OEQ1&`=;0`I?+U?+9:VP*%9KBE6\0;%$FV3)CL._GV$PR1'7XI-U#
M+=%=VPQL%?7P**R9S&.[&PH,.`"F(HKS`CK6)U)]]?U\]6$CWA7$W`DB$D<L
M9VE($S=O2Q289;05_VUQLB^2R$S\*OJ&,(!#C-M@B0#RK>RN_Q63:C=R'X4.
MEB)M4E*#QRZE]2(@"6\(3J_%#/,1DAS=9[PH@6FW0D.?1!IE`KZ1;.FE>Y&H
MV`J6CG&7I./0$?!1-;@/TS%`Z>?TZ(M`)KPYEHX>=;%27\2VTS@R'RV^X:]J
M.=AYZ/2M%5"<,H.`A,)5I?`M.C*_%$J`Q_.I-5;Q`-GF@`4&P/RIKZF?67:2
MIWW+B-HD(F];OO9S^?JZJX"6,HPV0[@NN:GUT8*#]5PVJJ:<-`!DBO$Y;WPT
M,$QY$OK$5JX3#)0^M=?7(%T`60(4Z&_@&U>U=ADMM3)C<ZXM&&[8J[*3=)2A
M"<@=/F`81W8KZH4BW:"PX#X/UE!K$17:$9/IO*76V/H3CZ_@S=C@2&Y?<`2R
M46K`!C>P@/>(<X%\Q1[NADH4CLZ.BR?]77RH__C*3K>S6?VGMLR1>BK_":V9
M+T48M^-O:H`#J2'+2=W*3$6IL\1_QO)PAY)KL8'-4L`L_>.L8E,27W+OMXJ7
M43W8+DT(5LQ9"]\,:O@&&<$^Y6E>V?N&ZD2!D@5P,Y<G*[2ZQ<*L`\/JS7HP
MW'`^BXVDE+,$T4"(^10;YXBRLDBNF8>VBIFR+&7M%S!')J&;R`5C61T$HM>-
M]C(V8Y'-72)NU(J`A'`F5S"9;!>.-E9U3LJ[C=MO/VUGSMH?GB3?/M?J3NO\
M42O'U!YFN_W!@_8'C-#)236?8<O+9Z_\&-NYVNY_Q;#G''D)<J>D3W!:S"_(
M`1!#0ULQ5R;`UY`9$7::H?:-V/F!'1PLK!<2@?3[&SWYRWY0FD<V@:N;/<RI
M(EH,6]2Q.O*4&^NA9ZW"M=>EM2I84<L<LZ3`\QZI=M[4[`G>/2J2QI&NL0XM
MC6@FWF",[I3@+%M3YX79H1!2*YMARIJO6Z,KFO:Q=(",?,>B:NB\/K2$R3IB
MB<IEYK#C$$P_6B;)Z;2B85@=8ZP9)##DH:E9!^^_49\C:&1G<_0/M[/=2=!9
MHA3VHOJI4EU*GJ@J>[1N7EPJZL@QJ<!?*N2&8S6ETF/X1-TY<'FR]=:U9"]:
MUG@GS]G`$E`)61SY,\&2YWAABO2>%'PZ'GLB&^O'8Q%KCK/]BJK56%AV;M<R
MLQZ,AR2+Q9*(KXH+T'SCB_%PF\&L&]4K8DAV*1G#Y?#D+[Z`Q#>J-?140R*=
MW>X67O)'1K+.RC81^DR]KMO/335/X[&O7R]ADR,73G@HPFGCF=7"AGEOE>YH
M(/-B%%!SG;EQ>M@(6%BE#;K5RO\<<_;-]MF`3D=0,;RI.$NX=Z/TB*&!S*69
M8[#'&JM$)+`J`IBFH)BD='S=2YSIU-#J#V+8B#61_</#J$VPY$,U?/<``D,]
M(9@/%YP1VT1XUIO);',.-!E1HCL/T(*@$@:)D%9J.7/!C?X(9!*RRM$<3#GU
MI!LLU,]J#\2CBZ$8%K*IW@,.Y%1TODQO*0W9Z\%/1;,#5.!QSS^0TI))B2UD
M9E#2W.;AVD;N.!3;6EPBO*V>PS<<L0C]WCD&:^G-!D-3D&#_@EK::J)HD=J=
MSB^)CBUKGZ;!T"VIBRG?47_OUF*G.!6J3U<+0]1$/R2!#&`XVBN*JZZ,7PG%
M8VX"*L7(R:CAI=C6!(E8[II&?CG$TTL2Q:;)IAUU5%F%#JMV0?+]DDRM`3K)
M8#S"`"2!U\(.+'ZX]$.XK.35-BP+[<R;P.)%28UH<L4Y8)T&?EB<(C/(KU3$
M<.1N7/Y%#X^=(]M!E:(LFL*.!J;1X6PZN!%V@'@G[95V([!P`J%20PO_<H0)
M2A#423`.4C)D&B;<.-`=3=W=-[CO\GNH27`ZW%JKQ7B=D@UN37@]97;%"]Y+
MS9SQ4$``_X_M`_V3E1W]`![B6XY4^='^K!Y2NU:^L1W"-[LYH-Y0>R<(CU+^
MXX$:[-B,2*--Z%!<J@][CU,CO#7_X3XD^$7W/ANO2.UJC\IHULE[$OOWV\>^
M28\VO!A]JU,Z*H>OV:X]QJ&P?<<?/]/$L25`8LWTQ58X&<&9@'C&6<XN[2#`
M,&>M=(ZP3I+3P$=*2GBJS!P\B.7,*-6<#<%9:TMTY)HD^H*3"D0"8IW"7N]?
M\<QVW2*A8UYQM9^DT/??Q:OSR(K9$2[?KHX!68'.,-ZJ#;[JT#L=^VBR4R!T
M%S]]TGM:=RF+%HDP@J=X7N1)[_"0"Y`.TQ&73QC1>A=WL^\G;Z'?>WK0[SWI
M/XT-TANW\+3W:.\)K=1/XI,_SQ80O)_(A7ZO_X1>\2>/XL+NV,+!_D'O\&EZ
M\E-;\$AYC9.O8Y+6K;M"]'#!Z,N8T$;E*0=S\^^J>O^"!N65SJ#0%<G-D*[1
M=?7JJ&Y`H^F.^S#GPT7Q?"KO,QR!6_O$US/SY#3B]N[37O&>H(;F+5?F8YT&
M(RX-IVF/5R@+3=L+G"62+W8/HY7.+00/(^G:##K)SFGE'12'NX?W'-+S0QRU
M5;A**[2P3<&KUA+\0;.!(0FIW(]-'>?A/$E<^GMW'_4X<&]U`_>C\8PI+[")
M^>VV^K=UPF3M)%P]XL=1P@&CF#-^%=[VW5GR5.L\Y@QJ//]OQW"C#^,\XG!/
MI%5S?^8!I[GP<\Y6%\M`MX-M9'G=EO[Q]_\-6U2IM!!K6Q=2&LPCI"'L\L\2
M\YRT@2\ZH9:FV7^TN_V(TTSOV,6<%*]N2+2Q3F(:Q>):GW*#)""2)-))GGM/
M.\8"FQ"J"=@+=#"RZ%#NL^4%Y+!;ACZR]F\XPY';`"M=1*.!^Y:I;LE`./-T
MY6-IKJ93A!M3&=QZ"^*Y,=.E$R:SB=BF81,&!S<&'GZ^S9TJIJM/DH95N?=N
MHUXH-4.5+1P8:@4/:DKL+$8Q$#N]2]V,$"B9=;@I0R-CR`[AH<[.Z9R07:PC
MN:VUN=;5O>W^_BYL62/RQ5:D]\'#*!?W&Y/PNG]PCU&_;`A\!@7D7"@":1].
MT=J$$\'J$+5'AYD^P*D<.^3PNA,@ORCZ=,>A7UE_-_K-11WW&)6PBQ>B^%4"
M*2VZYR?-P*$:"JR8QLF>^'*JDY"SZCJCYZ;BWC,-XRQS,E&Y,G;IL`S!@*_<
M4.'H[&L#:2`U9N]QHN[NJ5T3W2ASZ^697PCQN3:2!'*=QD+6.#CY0@)O_>/:
M^F9V45$F/K>]DX&S$_$NQB4:7`]*,P"#!M4R)]$E]*E8(^2IB"-L+#%4E*2?
M";OK*:28B=TPHG4P*_[40!GS;#I]:1.F<S)WPW/J=K=5-$R-A.^.)8`B6WM<
MC^`)#HD:9Y]0ZNWE=-L,;!['023M$KK$,UBH#*]@6ZG;QEMW")3EZIB_Z@&7
M)6-4A%N"M5O]AR1[+D@-::PZ3YV-JN1F/#2PF24,M?]0)-=9;MC--ALWTQA#
M.NRT>K>WY:+$'01%3ZK)%7RG:4V[V'J436%:KS7/L<AV&F7#$).I-?7!V,W+
M9XMH+0-@<^"1M8TJ,7W-$1IK1@FS=9C7`2/NCB;,I<(UNK1$MAN@W#Z[W/8?
MRS*KKFY;^UH7)ZC56RIC\65]TEN!<Y)$6ZAAXH2&`47&%:^2B..^8Q4B4@D^
M;\RT_B3BM8XK8:L-&D@JKR3]-KLNGG`23?\=;.^!>,X6DPB)`G2Z@X[#*=JB
ME=W08F9"!6310B#3)/*NF^/15OE0>\1*JFC`E1H>(U)<(9<5=7[K3Z]><`7.
MI:F(Q"E@@>Z1&((A\F;D,]H*[7N3<695.@G*!!:.JZMR'%]&PA:K2]PNW4=B
MR2(5=)`$^\/UP;$I%U6^;R"XRZ@F,"E%I^KUF;I=*0/I=^R$2]Z=Z]#&'"(=
M6[!8V<^J\:4*)BF+I?7FFS&_M:Y<Y>B*HE`62=*2;!)`,:"-+V;8_A2I_"IV
MA+P(<"V_CER"&&9&*+EY+A0]S'8T03R"]_".K3$G<A)[,5.)7W+KJ>$**?)J
MCRCC1W@[6U*?@CI-1-V,*W6&.VD1/IQ?B9:+U"+*;?]@^]$!+/!+C_37XRC%
M86E8>OD8],[2^X('A_T1Y_A;5/`/HEUFN_\$7VQ_>[\OK^DDP\BSAAV-+AD&
M[V'<3NJ5^]&NT8]VA0@=1;*V$P1[=1.3?TDF$0>G'(9:!&R-HN&P&7VR*"24
M.!C2GI?W&MV?O=WDQ;7]*B1=2:-&=BZX0'4M_M4O[/YP*XUV$C/DVSC;JMWD
MGW7,A($1!%EYY"RPQUPHB3X+-V`D'39`\Z(/U%6&*Y0IT!(K<'EJ/[1N63Q;
M6U(5J%.(Z?61H#P.E/1D5'/<$HJ;%#;\GB*\![N:1\<V$$<X8O=J27.-?]P)
MKWRCUT+<^_VE->3%*WZD8V__Q(+(FM3\V:5U5)3'>T\>?IG'0/*^+)7?+@G^
M.1;!SR.U(,"1U=R(I>PVIW.W>Z<9L<[M4B?8K&-FSW5?1(=<[X5Q1JZS0"X&
MX*S:W?H+@SS6RIQF!]?_9&(2`?__"\I00?<_75`R^8AX$J+[;@P<@-[5U;V/
M-G8G9\$\>#^3'9__5&2,,ROL[B(^`]C5:2%LCY#?=*!"_?B.$'BO_T-#X!K_
MN[^=8&T8YNCP4SPX?B_\*,]_BM8`<QCK7A,@5WTV0F$<.Q6&[?(_<-E+X.EF
M1^\((`843LOION_5'59_"=E=0>1"#J#3Q6:)4=V*O`KCVJU.EO5:FVMXKV9>
M5GMJC0'GV8'P9DO9\MGF)S]U<VA?M5C2FO>=R2X][#3.X1:0$"%W$>^;/UH2
M0W$2H/@=1)T5KW6(DYW0\&`[$OT#>8/K&JI`BKN5W2:^QHBW[^S);MOYO=]!
MM2A>+U&'+9E=.S*AFYN&W67X%<B>I`Z+L3BI>0,DOWVTX09(VS:^(C8^]F7;
MZM)AL:",'8?IW:2^.\%_)HI?Y3"YBNJ+\.'GF?NGF_=>TQ7!13'--)#P@.?9
M(N?'=++-@L"C*VJKVI,?)VM?8JGC,[IETR*58SDE<Q@=FG^VSOZHVSXQSKRO
M,POS(`(X3GZQI6Z]#(LITDRZ#28X8/7DZA-@&?(>P4Y^$8O$+_*P>T@3Q*J^
M'U#*1%3L2V[2@#LSM6DB08_<S1>VZT85SLF(\SD79JB@R<+SU"%W]OJ)DQF2
M)3T6]+*;=!^,I@VT#LTS*-\R7?OJ8&O!>[A7%!]O<C55ZDO)H]1=EFX7S1,7
MR&LDW'"^XDHT.&4_FT2@XV2T'>.E``6ZDE..:=RDD,7"^074F!;Q0DTM."K*
MY4HW50I*TDOQDE/)Q(Q*3/P;*N'9XJ'JBRS$CNMCAC8I;,GY=O1J&G"Q7`VY
M=C,,F]-<X\3C#5`@+<W:631&Z*$).0YWN"PA^%'7=]=I:,XRZ!`R[GK-I(X*
MG=??*9R=<I#IRE"$'=DM#'JY;NGGBER2%.JLBFY\!Z[>Q$<6;2"-K6WMSY5+
MY%H4"04;1FO>4K8Y$<>/"#?L6AJR,E*9MR='=F42+)O[=4/\@)=?/HEI-E9:
M4UH0>?'0RD2=&4E]6&^G=@>;*ZZFUMQK!XV%?DNKOCSA.!C3WVN:KT/+[D;5
M!)@!:T@I$7619J?<[:=K+*C;7=QNAW^J[PW^T&XXO2W'J"NK[?]&_U^=+(MX
M![R&:V^>X`T4&IL8R!()5K^T[!0!JV<04S.#9RD'"0UM9#M:IPPLN1%/YD8X
M0!1IW>\(U7$`FM@C/*2LB:XQL^C]VO&HQCWOK$AMK9)QGK,.()V:FX1W2Q'^
M`LP0VG(,Q*UJEHZRRP,MQ-Y[:A?N\2-IFC`:`_U`%'_;+0J.'"*[J`_L%4KN
M/3CP7Y4":3&YO+YUP8>@K?W6E'_:-PS8&NB+QN/[:8]B5(W%O!81$W9I07&:
MX.OF)]@O*X!:%$CP&!6M0V6L7WW%(&D.5KS?W#"0G5L_JE+B?EI:L&SL'3+4
MIW2TPG#J.^4H(PEUM-"H)1W0@^YWN_$0R304__LHT6(-O]W&>7+MIT\$L1\\
MH;C"-;@DEU=0#QU`.DC68+R3,BB(Z!J]*$4S#F&P'W=2O7.0C9#HK3LZ@V6V
M&V9P3\SA@A@3<LA>:XM4TT"UT*D!D:<--%QM:@"_0R>\::9FZ7I1$61'8;*]
M=_>Q3FS>^,V>9!N9X$Z/"3"J?Y8L&:]P!7@4<9<CAZ_@"AV;Z'7<!1EE5?)!
M^C*[6]S'0SD`G@NJQ.:`0422_`9TRC$/%>P-;LG\</`3^R,=N52[!ME=,UCV
M`&.\AM.KOZUNRHOMHT&_?^!\BP)LW?A2^0=<`K;WY*`&<YCCR75E4)2P9#%V
MP9RA46VY;;$DM74T@!_-X/YPU0R"9B?=:BJBG4O6]2`$&]NX[&BYWGCP^&GO
ML+\OQTZ,Z+#J95"R3_7Y&3%J68E[Q5F*XKE2,9D:;OPY1ZGOW;`36(68XT$8
M;^_;Q[5A-2B)=>$7#_:>/.T=T&@F%C[8ZS_M/0%'(T8"^*K__+@%'ED*L9%E
MM5E2?3S>_-9DC[B-3%@Y![4/AAC^-%;ZQ`2FO="((+S7U(]X#*N.[T_3.:XC
M+HY<=CPG`#WX]_?23"\Y6HB2Q,XUKBQ^SS&3Y36'=2I.H:JN9(\]YS8>M9(J
M"J0.%PZ54;<$*".@2Q`M'$*H/6?Y3M>G2V4Q_U:]IJQFIY:1H2#V0>*L'BCP
M8WIKDMZ\#(VWK,J;3T8Q[77:Y=2AD,56-)OU9"ZL.'+/K5AAO)$CL/V++@M/
M@"IJD'EK4<E\1:6:Y2W@IUGY&F4FT,;_1`;V=LTIT[M7<^L(C;^TP\U`ZG5!
MU_7E9C*[TU':6=?2&V-,,(/NHB?9;]+5$[LS^)/FE3[*KVG.()S"MIH')"$)
M=<F()$FM0Z#1HIBC;^M#.YH-K:F]<UV?>3RJ1B?BKFT[K9,8VF20.`LZ^;=U
MOULU`_H2002W8AU;ZG$&_A[Q#%60D%@R)*@/AO`CV)()\B&?9IPAC=96S]!<
M66S*M<@C_[TEO?2\;K8-[H1-:2?B;17K*5DV"&>SDRXP`R-V1J'1K[X,N2G6
MQ%R6P"0W7T.B><BN'L9&ZZ#BWKT5;L"/>K]9BHT897'P&Q&/LK6*E2"*#)^$
M2$M(,\9E$%E;A)-N][^@0J>PWVYSUFND<B@JV4BMN-;ML?;_0Q<:]F<T7J_T
M.>0TI[7X(2348Z!>-Z>4PP^CA0+4B"EZ7$L,PNN4B"XTZ\#Q&'.V>UDDXANM
MG!.D[*+;T#^0-@:'-'EA)@H$O$KOA^3`UL@Z$?(YA7KJ8.1>!>,":2_N^R91
MHY^3H`0$E^AL4RU;1UE0D>20">X9";^_3I;21.\?Z22DICFS<QP<A+&KI@@9
ME3`2M^FH(&K%-_-?0L&IFJI[83UJ;."#U7$"2H"^(L<Z#2^OH(FR&"P_2P-+
M@TV=LO4#\X9Z(R,4Y2Z_0\"JC?H=<YB".0Q'#D)Y486"X*,&V>DRVKN*+L![
M[F#X0,(Q9T$J[K,%/S2/E$/==+='E)MLH39`&T;KWS[1\-PAR-4AD!6G6)J4
M36DPV1%,V[JWG9A[<(%[`'LCF1IKRY?"28#TNR0XM>0?Q(D$,74D&6Q=TZDA
M)ZI6J:;?XKYE(GM%[DXTP<^WCJFZL&L9!\<2*8S2':"W?.KD`ZD9*XM[601B
MP)E:@PV3QZZ@2@P`11/:B/0+_0!/X'#4V`MK,>?#Z`%QPDP)62)%:I[HGOO+
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M"6)>;"JV5FH+B`9<@W&63GYK4$;H$"UF\`G,XG0M?CN/C7+\H>1.<GP,%0B1
M+O*`&7^$?$JX:/N03VB@'_&R7S%*O_CQTCX]]D\]O>Z%0JIQW!Z8(QD84)_?
M2P/$`-'>;1H'_0R"ZE0@*^F;H^BK@"N6LT$K&+*]A31P]T6;0C*JHGCZ1<D?
M.N[ZES6V>P"IZ$+\A<MIU56WDU,N'8V_E.*!-9]T]FUM35\:R=-#<N[$@P:U
M'9Q<-B.1Y+-)A9(3`X4.P%#Z&B.&;ME(U$/.[*2IS<]3.&N*@SR>8;H'ASO*
MB0*'IKR"_F)+GLXEL?*V&=:UJMZ>G9\NT<FZ./N:F7@C.O$HF8Z>\]"#IXWI
M'4*CJJ18[\%^;Q_9?7*X*^QHQ<RI+J$"A\;,I*].GG;%9"VQ<6N5QK#,`XSP
M_'-KPK2LEI_/TL2\*.D"DP>'O</]P][C?G+$H]<9$2E&H<UU6S#)^[5`R?X3
M\W&43`D"VS.#X^%;S-V82C2R"PRU@H&Z=>W2@&T<H>F&7W(Z`8&4;&'YGSI_
MJ6?:]CU1)#-0;,B\G?2#;_QLVR,N@>67U)"_NYCFYH7M`O+L=:WX'7(,]?%A
M)FU:5I";;KPO.6\*6B>L.O`JUSK7PLX7^F_VM9!3*UU'#S/>IK$R[`H$$"46
MV/$!UKD@G26<QNJ[IGM!!#:37]R&^?5/?:K[9-^Z3]:_>^<,Q%3AYFO,!U5'
MF0]8KEW6E6#H?H\\:R?'J0N5.X5AU$J8D>9MKXYCSMN!B>VO7A.E?DG$PV7&
MJ['9E'0I-[+8?GJ+FM[NWN/VQP_C`=<Z5[NUUSLXW&T_V"!F6JY^LJ7#LQ/=
M_Q'OP8YI&',"(..]$_IHB,I;'%7VLN.#5J*<RP/NFN=NA3>#@,^P[[-P*/H@
M).5;L]AO@$;D_C@GLD`>ZM:$A2Z'0D#D6@N5P\:1FEDNWHE>^>W0=ZYPWU8(
M&</5Z\1ZY"28Z<&CWEZ_+]=;0LEI'OI0+7714;"W6NRIY_;;W,R_^Y0R/9(R
M??]=_DIS.&O5PQ]+.!!^S.7.:`4"\8.M7)SM<1I!9/20S%VE3%62?#UXS*'V
M@_K9$`#&$-2(!#]0H>R^42S%8F6E<LZDDX&[_62F/3(X%*N&NDTR%)^-YM18
MGSX]D`6*#IO\39N=,F3LF(\+9]GQ\>C,ZC8%#)5%_M($#IK$VRN0X_N:J22U
M34_75DVBF@L`^(4TP2E_[*,X+5D.$@*[]%_CA[7[O^3OF+FTK)OV%_SYM*,?
M5@_+;RR)=W!G]2TSAQL%UI#JX)%^["Z0W^6V63"KR9_=37A"?2G<4]Y4JN6S
M[*M/J>B!V;OLA?98YV!%%'*5_.K:/C""/8L9W-HK:;T0O!;%E)R`$[J1X,7,
MA&PK?R_5A>;G%\-AS'!MO46U]*T80T3(L)#0-==TW,V%UBE?%;XM91F7Q.-H
MFK7?J=[5=+J5T#6GA5`K6QL=1&1G>$N_F<NRN6(K'>"78FLU^?C-0>L+M[(S
M;T8NE'ZBNX!U8&[]'9D,7L*4_^"'+*KA-BJ_;?\B7HG7?AD7`#]LA?OS+X_.
MGG.BYCB<HW\[W>&TE'/V47"TXUK]@C'>9$^PI)/ABR2/>\PIOB9Y9JD9GE$(
MU?PZ`DU]+\Q;2ZYM@=[Q%JH@&F(`:\$OQVE2'+?>B4Q;B**D?MYMO_:%Z3/F
M&:7M[V&HG,#)>.$<&Q?S6@R#Z@V9$7WL,;5BNZ0'H1SD`>,6B)R%5V$7X1H<
MH@V^#A-9.5(`GK]/H2&Y]1KJ`JM]@[AKAVK3H#Y*/L-XPJE)2(/DL%'Y?76$
MR@^*JC&6?IDY!Q7XSD+;*&W6N,4?]]EUC`"YHRS<!QE*@I))4KU&H?KW^;3X
M#`Z@F$JO^0]`BH(97YIZD]EML1P7B`RV#DT%#Z6^(JI.H^7$B_&0"#=4#R]"
M;1&2T4E39S1)4E5]JZ9<&=SZ'%7^''OZ%,DT=!#&!L7:T'E$]OQ#G<@:)L!.
M;V=7)=W;OWODG7^`@,<5\;+YV@U7_J@3+M17(;>7^=Q__DC]W>$'V6/#1_O)
MK;VG^]QAM-?^_&'[`P4"NWN]IT^>M+\Y3M6"^@;`]C-I08U8J?W4O7V?7G%X
MV._MD2M)"!)NI5+S.MD#6C7C?11A@[&Y,EK8]*;G8^JE!YC$=J2Q+46BY$$K
MVD\D\<'3!:]!VG4TFKOY(ES@H!.8N7'"EQ_3:H?]0<01W*R[;/WU=[4HG".J
M]6J3'>V*(EWJ]*FH;!SO2_.3N?Q,C5D^9J:FR>4JY$+K"R']XLE4'LH"710Q
M_O`<H&6-O]$YLA\HL>UU`H_(\`ZO@V02T^[UVE_2F*??+M&J+*)J8`34#90V
M#UI$51=O>XRC>-5ATRRT'].1?E(U%.[L>!4M0G:WHFY::#_ZF_8'?_;[TFBN
M))B7>;$NXO93^SL;8O;=35^\B'?Y?HCW_=_JNH;VP.DQN]$/I"UN1Q4N#M<N
MM!\]Y4K_^$,1LHM^66EL:!+,JS0-FJG6JVQ:6'*Q==`9ZWTYX68/1N%YW9E%
M$5-_V:]82TD2M%./0,:V#CLCD.=@*AYUNT=TQA!;CSO/2=3#!?WK10$Y%');
M;;DC%#+#M=>FYX[]3AGS-6,-PI<0?F`B*.Z[\V/]ZCLBZ/6*#HJ:Z0D/O_WW
MLQ?%FS^>6[HM2KN5(#JZH/WHP/SV&GE3V)!97O*NV9DR5UQMX5S9T15UCN>Z
M3IEWH+P^SYSAMG)TEO&\OG\ODH2V4B1X@AMKYR;*(4D*R^B%2HU?0FKM^6F1
MEN?(;B>-%*V%UAW&^F]P:\!=I@`KH+CP:U.MKW+M5K.ATQ"J(+%C\("JK?E?
M]L^)/@_NW4)]/_'&+V,431`$)QTRO*E_3"SM"3"&F"U]`I^I:^_^)@B3>3/*
M\2B;-0@-/>Z;+:FMPA;14;VU<9Q0]6)DO$6.^U3N.=H/>=UK65XTQ>W*E3@X
MKRU=CM!<7X>P'I>SW4=6A/#-Q*FKXT;X34H.[?-;D*-^QSN_H9W\P7W:H(*\
M1I#@=X%T;YT9UWME4M>&T;5U?-^\;CAN38G;-9C#L@,5X]=6H<[$H:&''5X!
M*)PYE!ERLWYL55::+[F?I..NW?GPIX+Z0POJ[QRBC?GQ?(DH_SX>,DLEPL[R
MSA%/QI_)$B@KP*;J0Q/A^$!0I^S`6N-@5TS:A?-Q]8W34D^/:VL//<X%2'=/
M6X5\6U)J].9&HK.:457!UT_?L]"/]O-7-*#$`U>^RG`^*#ZY4[R=ZO>IA`U<
M7>KI"H,,%C``ZZ[L"-6\ZJ3JRP[;CRZXCF0)!%N313FKZ'T?+*#>?&9LRDG9
M("/-_GX0"\>\OBI+##IE!>PK\BRQR9LU[I@P/Y?ZDE9F7Q8G#X4U?ESUFXG_
M((XF7])*R.1J9BE>EQ?<F\S?'.S9EQ=J8:_B:",0>15KI0(6=&8TW9VH&/UB
MRJD].P9%7/N7E1^5\QZW\>RZY,J+T9)^`TXW4NF?TOVWY'3EX@>>%KC!##%Q
ME#WUY@1N2A0HF(;28(<_.?WK.I4=XZN%)`H&NR,;J[4^>-Q['$XR*:H7#H:;
M$LS1#,AUF7[7IQY:'(P!/BY/FJ0;R.F,G]$MB3^1G7ZN$0`))T%>%<?QN.6Y
MG1UGXD2%.X_R?6K@'SDR%X5]<N0?.307A*%%X^F5W6^>I']&\P@Z:554/Q!I
MLA5/'K:1#B>5?@+=*S8`D!4"$M*H5-YY\)!$0KH<Q0_YD1Z/@B1=2,<(V^]^
MG0[N&=\E$C$AYJ")2</V(U;2ESLT5N6:^QYMW/OI9QO[,<KH[+Q%K!]\O#%7
M,WZ*Q?Q!IVE2`$<76D>E(>8XX;_JUX6]$%\_)V6+*F$EC#L(N`/YZC=S2(CJ
M"X7_L"+-UJ>8K7RFQ_C==Z*:GUI;SEY;\>2GUE4W_7N#Y0MUS69KAXSHQ$[%
MN88/DX;WVQ.).EQ[%[>B-R_TDXJ&@'=+TP[=#'85$`1L[#F.UD''B\XG/^R"
M`C-Q.+&0PRO-WM(<[A)<K3D'.^C,^*[\ALOTAH1]J?,+:Z2?`945WGKW_NWK
MAQU3*D,=LJB>-:'':F"<,RM#;*%:0+IR`[KAMJ^LEP0XW\2\T.JD'S#AFER`
M(_Z&A\>6<4;\H>&.;B9YR5@J%C>57Z)2NS'BIY</9SCM>7O(?FH/87EI_2#\
MVBT8ZHD8^<RM!@WK2Y5LI96FMP1$:8Y&;\J&"3M\&G8^.>+8P8>SJ6ZQ5\&'
M[7F?/?^PJP>R4"ZU^T<U\\/^P8[:O0!'@VV.)F[_?O5FCY+JEM*K=F"18^G9
M(:$`#!:W1U45B?W?_<Z!,[%)X.2M37%EB$\=#D`9NXBYG=';>9H8I!FR%G50
MA/"E70T6;ODT]=AQ0DU@C--:&B_6+D=__ZEU-TE^3&+<'?/^`X,N;>9=.A''
M_8[ZE-N;B:0O2-3T^;<^,815&X^N@*SE,]DJ"[KC#1J2B]`#*MYDV<?(L[3N
M#@UQ)C,ZJGS1E/'^#@<%O`5J1S\@"+L;61&:=9LO[.WLQ1>*A'P!42TYJ@S?
M3O']=RW1NV`2#XRCX3`O)>Z@T*$_=)K$*&@A9N8VQF'=7X\X%N:4UFP""Q.:
M[HG&[M%_.&:[UFVWSK!\]E90$#U<+9(6#NYKU)+K-<2XRH.!E_KR]ZNES.@"
M2]>^=26<.=YZ^?OC]\</M9N+U8BTH)G?_\?>F>7&<65Y?RL)0VZQ`)+F/%1U
M"Z`HR6:5!D*D;!2,?DB1E)0EBB283,GJI^_A6T(O0.BE:"F]DO[]S[E3W(C(
MI&71++3[P0:5$7&'<\\]\W`17'4&D%B"I$K8#!3Q_N[68"XL30!TJ9_*+#:P
M'95ELEI59&2)D"3<=4'#E6_.TSH3&6#E+F+%EB$,CM+@%)Y@<J#P='`Q>B]I
MG0ABB7@D"9GE@`]PAJDDA:$6ML(V)S9^:E7Y@%Z7AJ/ST9;C1FUY$37>D8W$
M93N2JJGT$$QUIK\Q%A8"`XA/:42%]83GAG.^6+.%N*G30QN75_--T9[OK,A2
M'*Z.,@[D/).DQ!EK<3Z,)R+(\I<B35B!GK/_LL8HZ\V5!*=A5<7(9,!211@?
M4S@TH.*PHQ[!+!Z,*5>E!<Y&TNYRW]6'<[>!&_!270A6A]@GN9O@F]C7*\@V
M.%F(]62^*!/Z9((SO@M0W:*.KVA'QWNQZ$<0E"`NJC\`[!PEH9T"A!?+T/(@
M0`(HI+DHU6+*8R8YT4:EXAQI)+LK)4+I(XWM^Q3O"LHLB%]J'/$]O8&IJC)"
MZ&DMT7?-W^*ZU_:,&>`S^8^4,4FQ*-%&DN]0SACUV<_)_VY:UO0O%^\`BI5K
M3ZP$WE`K1Z]:*S8"B`@>2I!,K:Y0,?#"BVRBC%^OR-3CE@QN(()5,%C=V##[
MNQDA+Z`8,J:8358<)1,G'6&3"C4IA0MM[0(%[&)S;3MH,ZO&'(LC:8Y8LE,#
M-T0)0(BXQ[,FYOD<KSX_J+Z+GJ/N8INZ;FF!YI7MDC21`G2\NIX1'"=GEY@N
MI+>V#NMUZQ>.+];8\K#@WW*`AT`=#S9^):(3K9+%X<DOG,N3Q0?<4''H@H\Y
M^_)CJ24KHZ[<(43=6#^C?:)R^U0BQKK'D,/8WHRPC(7$8IE<U$D93!<!"L9!
M_!+4,X/EP&!D<F*Z.Z23,(2O*<MYMAHF2ZW:KJ!R9O5:68M0EX01ZAJC,_Q*
M`Y@=[)W5U?GM-<J<!81+EQOQQK0.*T(5,%X+`*UJ:2<,M#:_NK4J)'9%T1;$
MV3!0KI9E:JB-QM+#<":3+J^UD.1-ZQ?0)M?B64G"J@XIWMM*]JGO3E/6^>OY
M&Y2,'\XOWB+K%#B4Q-,@;7Q7*P'IJ@54T5U3"JXTC#-%FJ)VI$&J-<1;FC\%
M.V!XV@5B,[[3<P1/\`",&>'Z-AF@W*+`C]Z5DT//0O4)U11SS$JEO1[^$C.Y
MY_:>/B!]:6MI\T\#JC/5HZ;51D`6!'!+L1D6/Q0NNS#]W$6T))AIA<V=-FD?
MF)Q$"FB^2&M'J1;TC2W5YT;@BB5*2;YY-SPJTK+GEPC3%1#T$@3'>@8)=&H+
M*#X?[Y7N99L&'AI*6O!"-HI@WY<Y^'ARG2R.Y:4U(WT5WZJYUJ@+?Y_B_[9&
M=BO4O9HINC<!6G,N@;Q)^/9/SL[&'T^IR30:IA/]/R1V+KZY^9N1.-[=:V!R
M8)&&I[FXT_"89!9R/:1V8$T2`^]&T430E!QGB94<]IW(=V$<J,;=@0-&C84:
MN@:BQB%U$61KT]A_=.%H^L(+Y%06H8K"8I&9R/'N-R=)<4X/OZ>IT@?6(%]6
M*E<)M3HRY%2MP?"&(A`7!_%U`[,"160'-,*BFD;(7'J!V(ERQGVK3J60W[FC
M[Y_LJU]*[%DEYHHMESYK)&.*X1;*%RZU$=0,Z@HQ0A>(!B%HRN0"B4YTY,*L
M?ZL56=.H>^?8D?[[___7PGV(G*F,47;0:C,0('IWH&B8\[8W`H./]-7%*I,0
M"@$AJ!XF%JP3A+:YO>2:-6%&/36P4'HLLH9*M4EQB7AJ1*UI&(_AUTEQ&??8
M4;03PM`)P18L>O=7R4(KV=S20JVWK5],C$?"6(%0"S^;DF>%:;O/GQ6@C?QV
M\(PF-[AXR+R`^Z9_"0V^P'1H![MP/]MU!06W'(`J3DEKA"B%268U.R4'GR4Y
M,,S`5X%J:7$KZN--5NFH<<%8I6TWZY37XU*Z[DV0W*))JZW3917@.HQ0MU\7
M.,EO4CT\&P>;%HYIT4-)*8]&KR2'$80]H1Z(Y*"_GU^^Y:^_.XSS"+)@6&(A
MT1O>`C%&L>8*E^[@675I0Z(&2,#+T3H:'D_!6IDLZK5[O$YK\6L;4Q?_C&L"
MY6G0%V3HQB9,\':QF+,_!'4CM;$J=%QE:>>6!9B!-G7>I%_4O*8:/U`SV4$L
M#ZE4>C`U*6_,H+I#0-QIM"I/O^Y4&U:9GI*<M@Z=JB2ND5P-5C>WV3'%>.4F
M/4"W.+F:'SS$;:1*.T__*G!P*3N.'Y"4:D5H]8I&5,(O)A[$V'VBKWQ71JE7
MU^8W5U?%270\*8H)>R,<!U972X8/2?V\^MC]ZZQ0G4US7'6-8+EQ>TV&WT1-
M^%HPHVJ=RH8[5;6$,\I6:1^6*="N1:!W`Q[YDKO2JVZP02F.F?YY;S"MRRP[
MRE/Q&#A)<BEF6__`ZG6"$'?<O[@;!$I$JJZSN$&85"QL=;'T.(I"5YG^9HN6
M"-NN[W`K8$/B[)_W!N$FX0:WO)4$Z5_`#>(+`G;_O#>X<:3ZDHX:G^@J#N2V
MN%CI46RJ?[DW"*9_DFNUG<WGSEFOB%PX.S$CB!O8:;$;+;#09]I`1<?D+8$-
M=R*)C](44/<4Y83T>G1R@K\-QB(=:'-U?GT]U`3XG8F6U2$5%RMO89,SCE5:
MJZK_PL)AF`4#"-4'NE;_OP\EN\K:1`=G+%4SL;J=P*FCU(WI9VC3S?P8PX9F
M(1$G$)FS8B\.WYC)7#(?@HFIN/I:4]T2CO=/>X,$U))^<K47RT<"#);B2626
M0T]"W!@CC%S9]D9.X1+,A/L)P/R;8!UJ7WH4A5GYBY!TG!-T9]%%UE?W*8OW
M=N'@B&1K>?:\**B26GBA'QS_^VZ#YZTU85.$ZN;DM3];"DY'RM>;Y<6-M6_G
MP6VE=:!'IJR3CX.%P=96^2AF=H2,JP6R0V02Q^(-14J)OH0NOS*Y??V/=!)V
M'X+):AJWOD$<#`%'_5"_07(0[632<AO7VAP:16F)8&N#6:42$/Q]=>^9;!T$
M-L;HU4H)IT,,N(EG!A^1=6H)QFI3@]"UY>"5POQ(*1,'"ZM6IZT?$C=X"I\_
MW98P_YR,+S?A`XB#JP"56P'"K8GUP=<M%['WJ)<[`W"X@6=Y,R3=_C%D)7.M
MN(&I&S>,;&-^XVK)(HAL;,5%<#I05LM*$9J;OW@0X&O%Y^3E%Z'W%#.5_Y?O
M5S9/6(+5[`LQ6M':!XNG5._5^:V@Y#2B?(.$,?8/,K5(`A))<Z7X/@]P3X"@
MPAO-H(/?S1.LL0J>'7^'F&GB[%\,JE;`$2IH'9^RT3`?'&/CGXIBTO2S^2,=
MP\04/L,^N,B[(1X,PB'*,IN.Q9R&BI)(&`WQ85)G.\X-W,>TK_X^>.FB&59X
M+XW-(R?:YZ3BH=/P\`;9TFTQI0.AZA\)TW:B+^A6-GV+C%>!1D\>_SCXE^&[
MB[]@F5\</'Z\.YB[)3#<CCV5_=_2?F_)C&IJO6(?2M&]:5M-$5M"#JQP,J;.
M>_2`Y`<3%""P)5-LQ)'QTJW`=!JAOD&!P0AF62S;PLG4$C*WNUA=7/HV&E"Z
M/!M]<$T^O]]9_GT6!?!0%G/-),<H%CKWO"5P$XP7:K=,6\`-,N;29=>V4%M`
M<S_ZWR`>?OZ4XS\KG.Q?SPW"Z?,G,]U.I;`W"(X^N\5^:M!A;=WD!;\E1`J1
MTBE*SN*61&\[JB-R]>1`.+"*2,^2!B>ZT;R5=E'K/28%10&S,1M59*JL6M\J
MY-T@\+_2#/_K#<DI'>_+#<FJ&'9R&II'1Y7JUUE7+2CB!BVLC=KF+9O:/J$J
MA-_%\[VE:[M`\%N=#%DB6HQ7J'WTTL'(^5PO^UU%Y'3O8^@-_$%--G`,*!?;
M^*2^W-JD.K_*_]JKFL][PT25V`S>UAC=YS'/IENSFZY-LV]/2,A"$U=<K.N&
M*Z;/3_<N4FY\C=8-]`G.?I(+/Y*T"B9?GM_8=*]I+`_DGI&P5\O_+>_.O/PD
M2XI\'UZ&8G%*3+./%6YFX3+HL"'L)\V(1KO(4O*[5A[2B'P-06(O7Z3@?\5R
MV:X%Q,;KR0#1=%I:4Z#HD]-'-I;F('*6Y:TN+1RC-P>O34E#@GX.)<FAR;'-
M<@9."0SMLK,3`N8HJ_7)D2HG*MNI7,/O(.=7]W8N,*201QE%*X]F4EPPUF49
M$B&$9WZ+<NVE0'8UQ?1RYDT@Q?:L!B=L.Q0EM78>FANT(NW1O#%F$DI9,#,G
MJ:SF\1#6UNB0O+$Y90JS+AW)>F?M]D+"X[0E/7,L]0")_A?E&+"[$EY1.](!
MT3GXB]X0<1C;JSL8Y"/D`RY]DLH&]L%RR+OL>GUY>[O<G)=RL\]$%+*'=JU(
MTHQ-O<M%@2?1BVFK<2TFAQJ7I^)'%<&KG&OFP25,U#DWSU.C1#@LQEFG5I74
MZ8AVKO$J\&9W;78AWB'#9FZD($+JVM+;CU(2X)`A3KAC/,('6U1PG8U'K7I0
M/YVHP5R,*LOH3TCK);40Z]4_CQ':]8.G$Z69U+_N9O=A_6@G"A7U@QB*D]="
M5I$50HT"6'ZR+ZM>/<`AA.WSI[G1V>=/YKUK56+<PZ=);.KHJ/[R1Y7HK']\
MEJNZ7:,$[9Y5^*W'6%"^9_UCW%:(Z,N[4D.+C?7U^OW&0AI5".HWP\@*:)AO
MLNCZS>M2N1X"1+;7Z?E'Z_7*K?`^>N\LX6@\V*8/MMJW.S_`J5`(E4+4/C[H
MJ1PA)D,Y:APQR5S4\-.]]VSS]47:`3#@G>7E14IM&"^WX&1=$5HJ>12#?C:!
M5+1&'ULQT.%@S=LD.0EQ<A`7&:A,,YX!!INCX<T^+#_445V*5IOJ"F!8T!8T
MO<F=BX,?J:2KHZ&*7%$69/:7&%DH979\@@N'NEM)*B*WQPS;RXMX]?'MKRPN
M;7ZKBJ_9]Q\]]QL.&)H14P6K*S(`Z&UM+BYM?"O@\M?F1H@$H`KKX#].+L_S
M5S%HH%T_(N#45*Y9X=,T67%]?F7%<W\33K#,>&"*U_'K4G#!:>@5)(1\VW9P
M;<?1"H-_X=NVXAO>MI9ZXY=7M)`D+A\"*0&$6#@XB((L)$E$3'/<0MXZ!"DF
M9\I8?WUFWR'E4`IA;*F345B5+-.XT*;<J);7\D;H"EM<U&OWF6E*)EK#I644
M..^)!4(`YIV-):K%;5L?21HOK<V+CQ;;.B7;I5C`]).UVXB+<O7ZTV_1.UXE
M<W1A:<^^-;_6FK\F7#\%9UK]^Z-4T*[FG$&[_0H\TWD=I*:>/%+TSY\Z&=/W
M$+$.5CL7RG_7HUT;XDU`1^FE4YN/H719L)MV5T0%<D<S(Z?1AUE2\Y9)8.:8
M.$LODH$%,0,C:(]%HXRA;%W=+X100Y'!C*)04DZ&XIM=NZMD2J[+U.T9PTF4
M:B;WHM0#M")J>>#_L,7'C(B,BY`Z$YVMV$);WC1:1?VZWP*K&>7H8WOG>*%"
M9Q2G=8&K1]?I.G&X*]O;!6UN:'E"J6FT?WN#'H);7[Z76;3(I.D%E^L;A+E1
M+J0`O8CE]A8<:<V)54TFZSNLII14GQ:"/U2GCE:AVM8+4Q)RBG<IV-,QV%/2
M7@=;9IPJWNV>.-R=6#RA8LB!$2YC;5FAOW`F%Z6V9%9&"$&-"#40S$Y$T9#.
M_-X8`18BO+9$<\R,8M>,Z4*32+<AN/%'OON\I`9&7>3N+9$0FFW#1NM4_-LM
MM.)2FG0U@&2#/@FK6W%Z%HN!--)(PXF$SXV0]#7:O5%THP\TS4:O#<-*I"7$
M\IBT(<$CMX8,HHN@UC#99D.+.HTMKZS&%2?5/-Y425"5"4D1[!(U);2*V,4E
M2+K6O[N7H+NQG*M`S;OA;SY5J3"+5[*0F8$!.8H>J"OE`B5W<(AC\%O35VXP
MYJAR@JA#LIF"BT5/ZN<J&1J#CY4IX"53$80FB&QA@PWS5Y*L-9IME_]9^J='
MX`3!J2WX1CS'LCDSO5A6=9(&+;[1C>8RZ`=.I$1:"6NV/,_R2V\WD3+BN)8:
M[VPP\I0WU>T:0M9B%L-6XX66MTU3NFB3$TK$!`]A%J$PLJ"-3'J4W(M)8O1+
M2+T,:E1;OZ4P<VKFR[G=5]U_2F;8M`?9HG%`]69K706-U+8G?O#[ZF^G4MMS
M\:^6'D^U30IT"BGCV/7UNC^DTZ5>V'>,<JE[`<OE4*9?T`];`*?ZSCKX4N@<
M(^'>&=NG[B;![?5P2'6\0TZCC8EQ@ZB@$<:ECE=?P+"9]R&*IVIX6NUO=0GV
M.5(49V-A]73/4U\5+Q_<?&[AM?4KHOW^VN_L"O[\:9?V6$.D.$0>T,>Q(C3+
M'5.\!>7(JM9!'D_+9C%@O>`M-`L%^.*W@0H8>`/A+%TA5_=VB3@P;+(_1-PQ
M\K;YH@&J]]U;A-@AI#1285U^[I<,Z>BC;S#*P3!/1^P)BN:W(A2B/Z>.N:72
M@E>3T(<<3&MHA1R`>0'\[BHRP_JP!O`LTFB;B.S0[X89N4038CRMEY=2:%39
M1MC[Z,'>+LR-%AW<E-,19=#1:'=J756TI\[71OG3/FQ=:9/N\M!B9#\)&<V,
M#-(HD_LEI0@[SWF/DM0CRK]#(!CP,84>%]1Q]IB"G&.ZFG1<BQE?Z,PCO?J=
M[PG51-!W;"^25$X^T,Y+&U+7'4[:-F35?D9YTQ+U$?AHU692GYJV'5F;*J,J
M1Z-+^N12OPD3M7XX5K%QU3$)#I(CE)J/XB2A5YIB&\^HY`Q1IR(6R3>R16E,
MWB>$DOH;%D)Y1@=Z(<0Q.!:XY*OSR27!8#13H1&>&*)Q1]G:$!CDE6&!6%"=
MR$)W8]D:9UFRP8D4JD"BT6V8;O#L\9OAZ"M:(X*.X_&Y>NSRJW%&L6`#C"&J
MQ'00%LX<&*-`%C`K;%2+,#]9RC-RI]&@@"F+]VYQ^AS628B&L!XKN^LQ'F6N
M/<J'4WSXP1HO`CSFCR84K9#VBZ\H/F9^@I.K#RIXK9^;EL1B2N/8"AJ.QV.K
M[L!_(U\/8%*AF>8M$JP=KC0T*JW$B](&LQ+H4V[6M]_HJ45!0.ZQ^S:]*D71
MFI!0`(D7T`*!C08+*AANC;,$J7K65*4N]#H*K[JZO3CXR8IN-7XTY!'>@_3T
M9*0<V/OAB/*<,I'G=3LQ3'B#I\=*?(61?%9-HBMAYES=.`!PH6K?^C&.?H[>
M=_G>KE;X&#EA:-S*KX5>_L?D^+61`FTQWH\H5S9YG4'N1T-L<#)+$GNTW[V<
M:)"*#E[=0X97#^?#X2\Q4C<:/0VERL>WB%.'G'9D@DI0L.,/UQVHG&(J)T.0
M0HL8-=Y0C@D$"?Q0$)2DJ@-@GU?:9W9P<Z7]"Q6?Y68:R1C^$DFL(!['EI0I
M5"Z./>%7OM:J8N_W6I4L7(Y#59$]F(78=4X+R;?:B:YQTT#<6S.S$LV>&NXY
MRND64-##O,5L#0>(M=70LH<027=#J+PMI`B8!'IE5B%]6JY;HR=K/V0+QJ-:
M5TV#3>1&7<`2E-4H-M)V&`,E;+-+U-RA3,W$'(>14^SD)P#X[0DWC;62I,W5
M2SRI/0FDWO?R:B*NXYSIY!AQHVM>BP)(%%LI*EE!&;Y&"L49W9YC/!]<N+9>
M?+J!$QOWT.F,QWX;S5G%9LRV;RQ2(GX';;ZZ]QQ-U8)D=:QE'YQ=ZJ6WKN2!
M%+$%M!(HW7ZH'=PAOG2]]D]R11.5LGN:":<X9=DTRWT,0TQ#8+=.GDK&,G^[
M+YX$HHSE79XO<_OI7GFLEH#K7)UIN.V6)>]*;;JIF@+-PMNF$`3GGO*,M,<F
M8PH;1ZP)&0*:DI_J?ER:?*EQ`D%RL:),RF=</8\!!?K;#%&^.;]1!5`*BI*L
M&D[AK$*7[I6&"&!BDR8U)5]1]#%5;J4HDWG]5XE=P0WKGZ,S!/DH*.U1ES<Z
M\8N+CJ&B9)B;:S;VC7090Z.8TUQ<`KRM'F<F]1@DWW%[2V(C8W739L'B)A)5
MM?,XM"`140L!\?SRU0F%:U':PXT%[D4'O?S<R2(FO&SV0\'L]+4)XJJ[:9D]
MWB38I4CRM$YQW_E)6$_C8@$V00(6;!;8QO/R3TXX-K!2NVEZ_Q8'#UV3$OE^
MB0C_"OVIB%]BH&*M:$2<9`R0DG2I>+4%2/O1\&)$K9M.\O-P>*EZ>5A)'I^/
MZ7^U#P$&>2T(5/>C@[C,^F0ZH9D=BGM(<^:QE4)[3MG"LV^^N_>OKX88X.RV
M_=LW%DK\W>6^R2"?/QT"MG#;(@FW,R>^49?>NF=S3-!8WR>WM$$`P&FP`;Q3
M+0+#(D)R*@N"V`@TER'3,'/4Q@%<[=$LBX_&Y\P)D3(GM\B03E?&PR!KA,^3
M"&G6BX).Q&;Q(5'R0PBR0>:TJ)I!;AW=)&:ET[E0O+*8P8+I:HHW=D3/DFEP
M0?]NA"@(--I$PTP`ZC)&P_-LO)1%S03!C>[]@IYV?O9RJF<M(9<4G[&/5<,>
M;3@9*LD<;F_77LO.Z@L<*%QQ5WP%XN;T@[D0*-!,YI1-E8.EI80UY$L".9W&
MT`BA<1:V`5F+86X1JX6$;1R,@27"Z)>YNRG"2!3R3`7-)C78ZLB&9+4S(42+
MXE3]LMRNK,>FKA@_,[5&P28A>S5%2(@NQ=#PY?E5?&';JRD`43>VTX>Z15?N
M3?Y+7HA`,,/-;_'9O(OIQT<8<'%B7["%E?GM=:H%K20/9>\6MN?7EO'AK"?7
MS]?9`H:RW[R%E2T"1;;6HH=GRA;65]?G-[;3F[.VX-RCJ8@^QTY26>II8HG5
MGM[L;2W4J/RL3\1QIIGC9O.<783TEY>CFM>LZ(<QY091#Q'U_NT;K%OGE_HQ
M,J`]+\6I*`,74K)F7?@B,-=34?_R>#RX?RZ!-GA:.M]X<6'"H49<6-J>'SR7
MT0YSE%U^7`;8.8Z00\RRM3M!2*7A!FKK#L"SRN)FT[-2WV$DBMDA55'W]P(&
MMK%$O<UK#>DQ[^,)'`-M0X1?XH:O)8@=QC.#D<[.3@)BG`<?5IR'\Y-$I==A
M#\DS^`Z!BG\>LXG+CPNIHV;7)*\Q8YN^"-D^G[Q^`Y^S!>V%KWU6TY*USEUK
MZ>Y.#ZNF%<4B/Z-4A1V9M;$_$ZK37&P&+SB].@UNZPO@?M>6_OO__2?'(J*-
M/Y`&"H<?+Y#PH&3[J;*S_Y8.ST$;SH4V:WF:U;6E!4JE#9ZQB\M@GK:Q'D03
MA*F%/F4/)H"2(=[7=XMUR:(@W?,D43,>T8;D?=.II0/`!-!HPM'^!R)8/`A(
M-K9VXLX-Y)9R@SU$`Z$?O!M)%WU-H6N@W_3Z'47L%%I(-GUG61@V89"9HR[C
MO@L7PI@N]\4-JW*%@+?-EV@_JNX+X\(<S90=1.QSW&:MQ4BM8J?3KIL!(M88
ME75#S),=<H94@V6J:1]S5Y<75E:7.)8.E!_,17C3F#/@Q?7&A*SA49T]ZI\;
M"%^0`NP59+=H'P[1S/))8#I!_G.%L[@/0+2D'4.)']BEP6SDJ"@#1GE;_PYM
M#VH)4\8NO$Q6B]L=YLG#$YJ`08<R*5#):GE173QUZF9+0?6OA_8UQS5P<+GO
M5G0?!(';5VY48>?@A;G4(:DJ^R(B@=`5W*\<;S;)X0CQLD%==E1C1ZW0F.D:
MSXWF/AX:M;.6JR8$9:.4KB_N(?:&-(K:*@`/3Z,+*-!1`X3Q&W`D`.68Z%*^
MF@D>%TX#*Q,JC'.LDCF:$,#'5+*7]\]&DWO2KGBG)OJUO/V'$D+'+5]_$3`@
MAPWKY6*4!MQD/FWY(=0,4S@F/0ZCQ:AEE7L>>D/MFTWH$#-5*&Z'6CU[.44.
M1A$U%O\T.U-3"[^Z)ZJ$ON!ME.2WOC"[XS4F@V+G+PDL\R_K\1\4/IK>01&+
MCB?R_+V"/42?3A3?N=M)C8D1LQ_K:8HSR38ONZ[M`?D9;2:&8V2[F]GWZH$A
M#OV=Z*]S)JG;`$:4CX)M/4.(!.L%CB?0FA%S//B9EK(DM_Q[/<B!67/=#B9Z
MEL*Z=R[!H>#EQ010OA>LOH,=LXS^_)B0F,$>!&O<'CV'R+C6&<\!=T6]DI]B
MX&K?4K_6[7QP0HS'*9:3N1<'#P9WIEW3KW0Y,RZGZ]Y"Q,?0J]/!<N]!^?.5
M&<]7>Y]_9>@-:!AVA7>]%XI+@R>>1_=0%HOZL)>G/GT6D'8'"78F6NBB<2\/
M#-W[<.>)];@^N71RE8C.%&@=+0Y"18B5>O$[B"+6LJIO-JP+;?RF#1=#>EC=
M:CWDUSJ=>"KU^`]=LM[+?E[I00^DE$$[&S_7G^Z3N`;UP<^D5\\_G"&9OAE=
M0%VOL`RA/@V/@K4>,G&DR(:S%G(WSBB9.)"NQ.$33W;;)X/!59JCTPL!8;A>
M61C5G"1*IFZE'-<?/$SA&WAI<=)Q&S%WUV_=/7Q#5*.G&=7/C`Q*+?$Z]K*O
MFL=H9W_/31=N-16D$I8`$_/U&()*2&E^D=2'UB79[[<+U>LJ01%L*-=XI7_J
M:>)$II_7;%,>K\G\H)O@IM9K)#FK[Z+I]/&C>AL%PVYQ2!W,*3A]+"4M_MDI
MO3R)/4BQ77;Z,.45Y8POS)U&A<()XZH3>LK#?B1#Z(O%`\Q\M+GM6^TUX#B3
MDM)*>AHI?:+0I15,/S+7U-#:N=!#;QC9>D@YCD4R#;N_)*W7K6$$^7+]>W>(
M3K4XD)&(Z5MDC8Z5//28^189M>E#`YG6V@+9[YWVR<'?=G=[G]JBPM"M>7=/
MH=X8J`>'IHVDHFB]HSF$>W9A9'W)P=_:_\'?]GI'?4Q.*%J.\G&M<[&)S]+-
M=9>5+)R<]KGB4N]@^#\X2C^%Y1H)IB%A'\/8<4.)U9N86+V%%+T-;=9AMZ:9
M_4GK*&9_T@)I^,3Z#-<+,_NDEJ;[WW4=GA!682UFR(17P8P:4C72IP#RKI>3
M9!+T3^9,;H62YL]?AR"G]`0+_S*'RKCM_*0.1'$N3-AHK^M&#M!''6ND*39[
M(=:;Q2)\>;5`3HJZWHDO37^]$E&<!9JB*VYW49$+4\:)'E/B<SWQW7SEH"P(
M$69%0X9+]IE`3@BYQG=#S.XIO)T7J?6!1U`V`@YW)6<?E&8<L@,4G:L](>9Q
MRX'2\M*W6J,^K'(Q+H>R'6(,M:YR0P]2-A=2].I?GHS>O9Q@?[;[F8;TIM&]
M(YJ1[4/4:$K,L%,U!5,?Z["0E^Z.[=9',;8%L!HO+=`H""&#N2$VO2_8M>YQ
M@J6(3IP^5>4AR?JEQE9/WJ\(FVO,*SHX=_0GF'@)?<Z0A.+<QN/TY+7,282]
M6+4<;'EJ>ICZM%8X&4P^,8#PZEZ%T>FX2M1&P$O#M(XE48!?>\`"?;9&)Z0J
M\#2C24E*HM>&RQJEZ-:B#D&KM.3`O/4^#IOCDS&)*BIUX#4"3L<2DX(HF[;_
M>V^&*RT9+=Y0[Y!AM6IG(HI=,^%P!E<#D2.04D-(J\$19[H?+46%IY@I+<#9
M5M'"&'0A0A?T?:+7_!TAUSJ*GZ@[RH`TCG!5.-`@&7I/H;;6VB@NQBA:XZR?
MA=IGK6'7NW63IJ(FN_+1"$.RO`A0PWH4$RD):(G$/UN?A\?O:0&'K!NY7_UI
M=6^B8XL]Y9LCS:C"PGH8]"R<5"F#S+*XL`UZ"TKST*C,-Z62=,`<JPBE*8PR
M*EV!Q/HWDM+KDTL(N)105Q/Q."@P3_D?P/,EP#88<`>\S)9YCV3Q!#!SX2=%
M=VJ:`_%<Q3R90X?@!U6.U3RF14@K-8>::QA$B;)+?5;MU)U>U8\#C[J/5'O8
MRZ)RJ;JF=AQ1LUC_V-UX5GI[](J(#D>XLOD+?#)@GXL'8J,))`[;UH&+4)#V
M]I)M#E\2P.?[B4<0O*W`/[HL$#6`;F34:;ABH5U0\G!9HT2"(2E!;W#OD=^'
MER^P^3`E[+&%GG;U/6G5.+,R;_`(1B"%]WUEY4(0T7(;<%`<.SRB@ASL9DG.
MAGE&TK)08?`AAKS?%5R4KV/N2T+=%ID(?"$U#:\QH:2PH*@8KQDQZANR3_2<
M26;860C[(B@,C%#.9]N@]OS\X_`4NXF?G-G/ZM'NOC`Y7IM*2V^>+%04/PT*
ML8[!-2R6IGS+"8C_<>'EQX7P9S"#XY8(\T+:7"12A)GRG4W$T7"0(??F<+>U
M=J(L,48AE[$.*>ORXGHYF%3T)@49O1I=`GN!R!4B&WE>R*;:,"E0_()A5/L`
M28#0QM9Q/&5);,K$NKBQ&CA@6CH&*Y0^[[2@);PFGA_25NN!#D*NM]DCYW'>
MLGT+:3324K^]2[2O02JB#%M[KHM`(\Y?M&=\R3X$`$Y3QY=:B_N>+@D61NY]
MQ!(<=2!B-#D*K5Y(]662"K@%?7PH5;]B9)SQ4CB&KITT9O*R\\`]9IBW5FV,
M(%QU)PI"P2\OR3S0&>!KCZQ%1#(N+<E:7URG6"4C,:NH)VNPJQ@JQ_4'9;"H
M$B=9-L%3UX.+D/N\615=KUUHXU1K=PX$+%I8C1;%!E^#^K\6_@@L)O$0E",O
MJV')'5N'5</CJ/C7QBIU"BA:!`*HY`[Z5T\UPQJ3]DOWWL/HWAO,9;-AMQ7P
M26A\T&=*>Q*R^OJ>OW"3KK(JVQBVVBTR/49(^+/B*B;O9.`#&$29<%9D[G78
MFQL[`Y&Z'9>-M]K['T2+2Y_[J>_[^%T-[Z<JF+$?R-M,*.]3-'!$>XE'EO\#
M>XN7I->T9+:T@.JK4R=WXU4.(]7*Y'X.GJ*N;\W\*L(,4<\UZNHW'^!U$`4W
M1E\R\`8OJ[\*II*8P2D$%ET!H4T@0O:5@Q@6I6'KCQ\D=S([F(6Z]U.<2<@5
MQ-*M/G_UH(=RRRMNZ9&,QX]36IAQ`:L?8$+IX?E`>`,W;SZHA[L_I.;G$:#K
MG*QC43D!KQXJK<R(071[(FZ+/^65`4+A/2MK/ICWK,@?E=M7#YU6V3][%[`'
MU(?K<=#^O-QR-/^\TOKI;KCS2?VJ%W8WZF7U@Y]76X/]O-;^:;W]TT;[I\W6
M3X<(/B&?4C$$QI@EXD0I,.8:F>@=4^H,]14E`^4N$DIT`0+G04A&SCT6&X8[
M(72$M%*&U5O/#G?5"N$MR>8F4B9;6VSA;@)U>/GIWP\>#I[\[=#>;,36M]A0
MY]G%*]]W@HV/XLOU,3Q7_(&D%J)%"@]DZA6.M*KD&A,^V@+QP]@TT/(?3N#!
M'T<GI\?U)(:4Z1@^!(M=_5:JEA9U_:3_MP;,6XOOML@`!S8M-"13FYV7Q,Y=
M#>Z/3$L=7IP0S'\D4^'E12+7?4ZU_3=J!+\'"6EX.P#GL"62I\'J?8=!OM(H
MOW$8P'!Z_MH\-\%W(F\<ZD6P<9!B"^Z;QC[3+_?(%`L=1%`L3&SO$RUV7EV)
M:-LW4B9<1NM[^WK'.U,.,/<8!8H['1G^T%U2+=\9]1DFK]"B)R:3S^;PS^%_
M&&]FOW@=?&RAD&M]+2_7/K0,MV(ZR9ERR+/A6U2C8T@"-7.0SECQ8T@DX7RR
M5?4=!F:U_I@8N8AZO]Q!B7X_.#A7!@U1"KWO/3NZPL6Z8N?4=G"9`Y0X4YGW
M:M`47LJET.8Y&Z?=H[?>_>4C6;E_F%P=85X<0[-W)0>@.48SP2Z@Y=]]0`DJ
MN5'\\85B4#5>,C(,9YX%%=>2N[&U+7/Z]L7.(*I8:#,B!*0(TH\J\F3Q`<D#
M,DX4>YFQ!53^$9MLT59;661I-<`]!*?G-/YZ_H93_N'\XBTPE4@5U]D'Q:?G
M[SGXY>X3*KYGG_LG9V?CCZ?OAV>C8>^IS*`;?6Q2!&EL"J\DVU9<0PV#>.%D
M]0HB=?W*@V;1JVCBZ7G[+NN^D(FT83V:1BI`V.O:E)9_NU%)M=-"+64CXQ*&
MOHY=Z6XTN@7(F"&G7G"L"7",H(?X_.B'W>>[+2$J#@2J9/Z2[?GU`3DG.LK<
M2^<?`M?K=^]B`/;M]XF[^Q,LBQ(6F%T"Y+ELXX3:IWAM@J4J,Z0TO>,<ME#/
MB0K[#^+UBVSHE"K>]#$;Q(XO)Z_1P1=65M87?I@\H8AN/5Y#_V.5%]WC9SEQ
MZ@!R38<1ZO>2L$1Q=?A+6K75XT-*%(A>D6=BE-/6/3S&FIY:V];C/2)"P63H
M:Q)L:KD,YLQ:J".S+S.ZJ@VJGV0K9/7+YF%H3$!V*5HC9HD71MU):5/X@##;
M(&7!(M)1:C`\Y<8OP%]>`0ZSPDKQ)C<^L/$.[]2.E6X:7"#BOQL>F9>J'C1E
MF[D]#345Z:]CJ*?G",WQ=CA(FRZ0Q.[J&;!+HFNEQQ:!(->)E`ZUC<&"X+QD
MC9(ML%'3L\P&[1(IR*+3@Q._<SM['FHX(6F.MXXP/RCAB0PL&Y3B57(5+ER=
M+]@?T<YN)D0T;RD\5-<%$_SQF6].,^5-M<F+"WAY>IL0=#[.E+YC\X6?8/#[
M+AB+W.4$HA-=^_7BXG..6Q:D44L+2Y(0QCRO&*Y7ZV$.SR7WMJD)=%H(7;^>
M!JW(G[W<&CR8<&8:CXJ`1G,"Q6JH1H6)>VTO.]]-,_S,#UJFGGKEK2\>4K>,
MZQ)L,_7KP?6@JUH_BKTV!J&Y1N6FN,9:9HZPU]E^8N9GT2/?PH697TX'QNS/
MW5%S+6BEWB,H\9Y&JQ"E0^XN/:W/G+S_B=S+;`L51%5=].QU?11WMP([6(L>
MWA6*NGQL(6)K`]=<1/<YW(U>NGHY7SI-8Z]^%/70[9UN?-6=3L'WNU%X)*C0
M2.YXL++9.7EVQ^QQLG`X4G9_E'WO&G=BRK?1#=A"ZVG?3+W=TS[L1^6[L4?1
M5H3#<O<AW-T,:$G)8@][Z7LQCA@%T\'R>B=DT]1Y1+U78TE%<*5<3LU0,0_M
MP'--K'U6KV;V,+:(F8?4QP+'BC\AU,R2Z6._F#Y5<0^G",2]7R/'QTMI1.OB
M%:*N^X9Z#+>C>II-OGO>N^2JOU[O>Q%H$5@U4+OMHP@.+F_`HY'B*,`I;B)A
M9W8AK'J&B.#P8<EIB#)]5MAB+7@E)N\\2XABVZ/Q6[R8*+0I:T25YNJ)^CZ7
MD&$EZMZ?XP/T0GU?]+U`4D^*D\%D]OKWF8M)9NLO6DJL2FJEG^JYLS30$#AZ
M`AKRVT6@UZ_[L/%VZN16+ZLT.R#G0D-SF[GZW<^?G@7AVD2XY`J0$:OQH:PS
M?]P>;Z(ZH<L/%:U:>L&!/"A=U=*Z,+E\62:?E"FJ273]4;\)CJQ/*A+O^O?B
M`G#E2PRIWSRPQ*F0/QJE/*<6+5D'RT,5^I(^8!8?H_51QO!JDM9FY%0BU!@L
M\V@!4Q0*SUW/%7HQJWE2O649@5!+JJVD=ID>;5-_!`]Q/=>C8>O',B^BHSJD
M/4JE+S.A"479F:H/Z[%?R'A;=^J<^E+61:?IH#9N4J+-6B0F,RFGRR.9T1N.
M!!>@?H<B-[&+*VZ=<C??4\!&?FM2'1<579A*&4+QL77-:=AOGL>N#?;C-W\2
M,]*#,::N2^3T-"^6:L+3:=,$X^#STX^NWW^3X,`+WR#'ZV/=%9E'&QU[]*!\
M&:7^GZCU:/9"-#%!6&,E<(!+'Y/>KQ)!8C9&Z];5+PZO$)#.3LS6TWHYA;[%
MZVQ!_F$-@U"JKD:XYX1EP`TX3$-?1`+WHD\U>F#Q:7R'F2M\A^BGY@`@F.PO
M7$_KF(9QE!`B12H/9:S!T)0>A(HGU@/6TU9BH)PJU`502H@T\VT()8[H`HB]
M7<R=T+S)N!B_*I"_O))DOF)9\^+`=KF;A=V^0^J<*!CE+R8R6J@PK2_,89"O
M3K%H6VX4YV8L>&)7,K3&Q6#\B]==;P>F)=GNSJ9W,U;[FX[-<&.H?1$*7#J1
MLF5;.H!=/\!<+]XO[T$SZ(_;:R1`883_,GQW\1<NXN+@\>/=P=PW_,9C62J/
M%1-!7&W,GVRQR!B5%@$!L*&R-:8]XSXKCM4)<[_9JNC57`_1KNA26([JATF<
M[_/^NX.NQWD<+E.\-FFP>DDV2,C>7*L?1I6FWS%JG\<^,O7GF#]"HYC>Z8-J
M`L6&L(M(0S'.>M^N030E\&PG-Q8*@F/,VS.JTJ#RL4A-9[N@>E-)E0&S.S\(
M_83J[]P.>6;M9W4KDC@+/H&B4(8=^(Q*#M1?M@6%ZW^[%TD0,Y9BLX75U!-!
MEK(0`,%Y/SJ?C#%=!XFG"&#M/+9ZN.<QZPC"8U)._<)!R!T4.;6F/?F%[\;C
MJWO_(P````#__P,`4$L#!!0`!@`(````(0"VE,NHP0L``-=H```-````>&PO
M<W1Y;&5S+GAM;-1=_V_BR!7_O5+_!\O;5G=2LX`Q`7(AIX7$[4K;]'2;JI5Z
M567`)+[X"S5F-[E3__>^-_[V!K`]AC&3'KH-&.:]S_LZ\Y[']O7W+[ZG?7&B
MC1L&$[WWOJMK3K`(EV[P.-'_]F!=C'1M$]O!TO;"P)GHK\Y&__[FM[^YWL2O
MGO/YR7%B#4@$FXG^%,?KJTYGLWAR?'OS/EP[`7RS"B/?CN%C]-C9K"/'7FYP
MD.]UC&[WLN/;;J`G%*[\A0@1WXZ>M^N+1>BO[=B=NYX;OS):NN8OKCX^!F%D
MSSV`^M(S[45&FWW8(^^[BRC<A*OX/9#KA*N5NW#V48X[XPY0NKD.MK[EQQMM
M$6Z#>*(;^2$M^>;C<J)?ZEHB\BQ<`H@__&<;QM_]+OGS[H_OWG7__>UW__S1
M6?[KIV_VO_OI6[V3L2$TP0;5--]W*\G"UPGE3BK!S?4J#(@@0U`3:NOJ.0B_
M!A9^!\X`XN'/;JXWOVA?;`^.]!#>(O3"2(O!RB`?.Q+8OI/\8F9[[CQR\6<K
MVW>]U^2P@0>88Z2_\UTP$Q[L)!S.RV>.:#*91@B#DZF/1ZA,/HADX\%JF>R?
M#\C$\1K4\SI%?QPO)D6U7-)X[?O%G@Y/X97;BO")'N<3W;(@A_2Z750K-5A+
MS,:S+O`[&[/+P=DDZUM]:RA5,LX7]^V&#/N63%76,+0^#&_/ID[YS,JD2]/P
MN2(``TZN%ET(W8KX'EKX.H>?G'E":\=BC"J7]%GHR<J-G!>VS*O,,=JP$\K%
M\6M9MMSAV<*H/7OE?(@\^<0I.Y(/,3MLK`?7=S;:O?-5^S'T[0"CFZZLF,MR
M"\-F?M>8/-0_\0?/?0R2U>IFNX:":!&YZQBAY7*16>RP7,>N?IFL&U""ZWEY
M==$?X/H;CMQ<0Z$3.U%@P0<M??_PNH;5=P`U&4+L)+^K^?5C9+_V#+8&%1NP
M"3UWB2@>9VS-G[K.[/+.FMTQO@29*(H2HI8U&[9`]&XZGLE'.AN/91,U+'A)
M)OIA@"_)1"WX;R9-IVD@F;)`YO2TV,4:O?M^.!Z/1[W+T6@T-OL]TV1*GJ<>
M[09+Y\7!LEV:FO81#`#!N#\:7QH`I&N.&*NS(N@#@.%@,!KTQH8)_[-,UCX"
MV3H=Z*JM2A`HLBI!H,BJK$SL2,C\::1`QTQQK!($BJQ*$"BRZE!R!H:6HF*K
M$@2*K$H0*+(J:VY*C%7H1"NV*D&@R*H$@2*K2EM\IAEXK-RJ!($BJQ($Y[9J
M6E;APMIBK:[]E9FT]7%6PLWN[IKS8E4CU*GS,%I"A9R=!^N94",FQVZN/6<5
M0T4:N8]/^#<.U_#O/(QC.,%V<[UT[<<PL#UXV\E&9'\K1L(I2#C;.-'C)W?Q
M#,RXCDFBFX1%6QSRK&=B-6$.S>[0'!B72<$FB;7O+-VMOR]=SON@7X(:4;?U
M@A,=!CF3U!V*+FL'K9":3W`$,S6SM.``\(G,)01'R)"Q..,@*B,9(28C&2`H
M(QDA*B.$SJ'@RC2Y#+=P]GO7P)8UZG:3OIHHGVJ"!/@!CSD,@HS9UV?MD`,:
MK1W35%;(+WNQ,37PQ5;'!R2M&;$O9\V``U+6C!"5D?>;S+H<\;QU@>GY`)(=
M?7,_/PX&,$H&$CPDPZ?I"3O5R5DGX6S'2[O'9D>2UOCLY'19?$2U16P(*C@T
M^::S,$SJ"\?S/N,T^X]5/K-#L^SF^F5%MJ+`_B#<JX$[7?`M=*33M\DLGGP`
M7F6#C-)!FKU>>Z_W6W_N1!;;-,18L*/8^2X^3=GRH_C,6O>^P]I]>D+FARB,
MG47,-C6Q<Q]E>/HE>'HI(1$\I_`W2_B#GH3U<0I_:"<=-"+H12E_<"YA_C+]
M`;=OI4X-)J!.785')@)H&F0(P`@J$.!VLU0'X)XJ$$`QEB$`!RT0`)P*KS@E
M#GHDFX$/%"R!?ULL(<=D4G(L6Y2R+/T"_PHI+2[]GJ1FDF_!T0LUPX<*`">Q
M+$NQJE(,,3M$6J$"^%"A`@MF73E37J\LYRM3"$FZ@*'0"*2!*HW(\TJ2<X%G
M`:!:(U.)ZQ#B%)B*5$,`.$H@$$/T%,V_/8I!T0Q,O4'1%$PA<'/P&6."6H*;
M(15A`#Q*HJ)8)_2X&>.,:B`05&5(X@V&JA1),:C*D84I#%4IDD!0E2&I)52E
M2(I!58XDIE"5(@D$T(B2#$DMH2I%4@RJ<F1ABKZJ%$D@J,J0Q!+]EE-DA[9-
MDR8JZ9\.1D?U3[6756TCM5=6-('=L^%)]914CF`+5DN14AHO\+-QVS/V3K6G
M,')_@2(3+_1;P`$GTO'"T-A=T"-?(WO]X+Q`*9J<37I9E?=Z`4G6W]AU1AYA
M*::"/W2R=:T)<^GZ.0'+Z8JHE9P5];6-^1W/X)O;M1Y2"P*;.ZHQH*Y3#-)=
M0%*(8.2J5A-,DLHQ4%,AGK3G#(>Y-02?*RS0'":?FFQ6ZZN4.<S6YV5.`@4K
M.C'FAZ.U#7T(0VJ!.=I%R!%*)XTFIC^=VPG3@O3\U$3RWMF=GD8<\;#^;@59
M%>\6Z_G*C?Z6L=!)`S>0-%S&G!$=VZQR`KS=,ER"(24JKP5TM?%6DN?[U5A$
M$KU@(%#]B9JW#'1UG"H&79)<X'"QEL`3*U4^.4W/Y]2F%ZK5K%2J]06"T``.
M8I-<"Q,L77#4."+/_0B7.T8Y'#[.Y^KLQP,4MF83RYT=''4UT0`FGL;AK<XZ
M)QM;*CRXU5!EK+9EZ[+DQ^EN'USS["?LGL=X`.T&4!>H28<B4AR%^^0\P*N_
M)H\?Z1M4T2<NU,X-5S3TQ+Q[3[TB?B%!Z:)2".6W_1BM2G!'>?5I3L+%XI[*
M>;"EM2[UV5.#K#5`IY3(I/R1CN_G[29V5Z^TS=V\S=PFP#0@WI+^WA(6ZOQ)
M++XE=&\)R]O6%$4G.R;;Z"Y1O/MS@(;W%$EZU'`=1*?J!!E=FK5=BDD#*CT-
MRYWVX7QO58U_QF5*V6*+KVGWZIS_C\46YP4]$*E*Z4>MKHYP"P-5+G3RX(CE
M59Z9FO0+X&Y;<A'5,F<7,J@^NPC>L4HQ&++W*=1K`'6><A<_Q2(2=HV6X<7\
M7[4P9_M'8,<(N?Z.O_HNWU^BX4T<X:;3W=]K%]J'!1+-<P>>S)EO70_NS8$;
M1W#OSP(6MZ$_30ZFNS6J:.5Y$X.(TH):MBFM/!T8N!^,X(+%<E-:P#Y)+7V0
MEM""2Q,;TP+'2&GA;KT"EPD^VA07#$EI\;H?".K>/&1'MJ^UP(4BB^"BM`H[
M8A."T`*1F](J[`B&H[1`Y*:T"CL"0D++!"9-:15V!"M06N!N36GE=C1Q2BOT
M-1#4_>5!._*^BIO01'!16H4=>5_M"_HJI578D?=5%+DIKL*.0)7HRX0OFM(J
M[,CG"5,P3U`9"SORNA\(ZGXWH_(>;PAZ?$*EL!V\(SK"8D1$1PF5PFJ\E_<%
MO3RA4MB+]V]3T+\3*H6E@!Z1R(0OQ"7*;=3GM6L*:G=J+[.LRSL,SC,B,.`&
MK8NM!X^-"/&A$VR3)?8)B4"XI5Z(TI.S>-9F<,U\3HB/!YQ&10C=O:P].[#C
M,'K5<&-E3HXW^D"0W)_",-<13P$78B*`_@R/Z("G?VB@ET1#O`_CBJH)F3P6
M>/7@559-R,#H!`WO?UA!-R$#HQ,R?%+%]9,(F8_!>IM;B,^E.'6+D/CD!L_.
MDO<<7L,&@!2A=.]LX\C._8\/*4-0,?=XIX6<!I\BDIM&9[>%2->?]W!CA4R)
M>)J)Q`Z6'B+`_[J-B1IQ%"&"Y\9%B#RX,=SF)@MBC@3"$B(1PF;GG,1.1A&D
M\7<["C!:N-#=\=$2B8JMX[#Z7[X4=]U@>H_Q(3;L?AQY/0"*6CHK>^O%#_F7
M$[UX_Q=V`REPIO17/[A?PIB1F.C%^T]X9RZ(8FA.0;KYM(&[/<%?;1NY$_W7
MN^EP?'MG&1>C[G1T8?:=P<5X,+V]&)BSZ>VM->X:W=E_067XQ)\K>&3,"4_4
M84_^@<WC/?-JX\%S=Z)4V!3\Y^+81"<?$OCL=CP`&QILF1"=3?Y$HIO_`0``
M__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H
M96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B
M0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$
M(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:
MWIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&
M`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&
M.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?
M_-)UZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&
MK9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%
M-Y;P]<YVM]MT\`9D\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RC
MFL(7*(B&/+HTBPF/U:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8
ML4.^7!K2O)#T!4U4V_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M
M+6?A+HZ#XL*7WW[VY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\
M]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V
M">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#
M\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G
M^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U
M."O3>H<<NDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`
M&$>],9&R;,UM`?H6G'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X
M+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXG
MW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=
M/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5G
MY*8TO;>$#6C<AT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S21
M0*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09
MHW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]
M$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,
M^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76
M&A[R<=+V)G!4AL<H`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZD
ML%,'$B'5#I:A#0TSE88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83
MXJNBLPLCVG;V-2VE?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E
M%N<TZ8J78@9GQS%+0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA
M_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005W
MU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X
M,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?
M[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4
MX9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F
M!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q
M\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q
M)4TPP:<J@:&''I@\@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0"S?N[D
M?P0``-T2```9````>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)2878^C-A2&
M[ROU/R#N%V((Y$-)5D.`=J56JJK=]IH0)T$#.,+,9.;?]Q@;%CO43N8B))['
M+S[O.3;&FZ\?56F]XX86I-[:R)G9%JYS<BSJ\];^\3W]LK0MVF;U,2M)C;?V
M)Z;VU]VOOVQNI'FE%XQ;"Q1JNK4O;7M=NR[-+[C*J$.NN(;_G$A392W\;,XN
MO38X.W:=JM+U9K/0K;*BMKG"NGE$@YQ.18YCDK]5N&ZY2(/+K(7QTTMQI;U:
ME3\B5V7-Z]OU2TZJ*T@<BK)H/SM1VZKR];=S39KL4$+<'VB>Y;UV]^-.OBKR
MAE!R:AV0<_E`[V->N2L7E':;8P$1,-NM!I^V]@M:IVANN[M-9]`_!;[1T7>+
M7LCMMZ8X_E'4&-R&/+$,'`AY9>BW(VN"SNY=[[3+P%^-=<2G[*UL_R:WWW%Q
MOK20[@`B8H&MCY\QICDX"C*.%S"EG)0P`/BTJH*5!CB2?7376W%L+UO;#YU@
M,?,1X-8!TS8MF*1MY6^T)=6_'$)"BHMX0@2N0@0%SMP+%LMG5'RA`E>AX@5/
M#V4N1.#:#V7U<!P0<6<&7/L1S)Z/(Q0J<.U55LXR".;A<F'TU.7YZ=(=9VVV
MVS3D9L$<@@S0:\9F)%J#<I]GGI4A\_^7>,@X$WEA*EM[85N04PK5^KX+4;AQ
MWZ'"<L%$G('/@?&#E<SL[QDD$_']G>Y4DIYA9<F&EXX:7(A["!X*:QS\=''W
M,3*8Q=BK1GW#SX!"M)"'N^<,W'\(VI.)^)X(D6)+,L%XBC'I!#/2D<*&F?!X
MV`R6PE8;]KQA'&.(EDJ4$XPWDYEDBE'<2J<8?]"1HH2I^GB4#(8U:I2GT)L/
MNET519R!SR&7@4SLC41L)!(CD>H(R0%8%<8.L+D]AS9]F;-.6QNJ:8@R])0X
M(\Z$W41'P0)Y/U/06;7G``QT$%$D8B.1&(E41TA&P,(V-D)O`(,5`V;*9(LX
ML^H,6#A*;'O^7UWT1B(Q$JF.D**'97D</2L#'S8$>A=8)\4%3UW1.;/D90`;
M-/A3)@0G=$X8B<1(I#I"<H+M3I6'G=D)UDEU0EGF(\Z(";'T)F8$)W1.&(G$
M2*0Z0G("-B_/.\$ZJ4ZH-<$9X82_F"H*CNBL,!*)D4AUA&0%@KGPO!==+]4,
MY:D7"4BXX053;@A&9X<92<Q(JD5D1]A^:31/]"L%XKLK^8FA[&`B`6FBW`M$
MF+4(/:2LNK%9))%%.L/E)2G5BL@VL"W5R(;'%D[$-V*2';ZR+D8"TMK!=31(
M;%9)S$@J$.Y[N)`]DPUANZ^1(8:ZX'LUV0@EI1'BD";*O1F)!<*?1//EW7,H
M,6ND6D2V`4;[A`V,5A8*7]G61O`JSR"M#48D-JLD`N')Y@N2.C]T]^$^\%,#
M_AI9X>:,][@LJ963-W8BX,-^8&@=3BM>?/;BI+3'[!1CHCWRUE''NT,'.%RX
M9F?\9]:<BYI:)3[!K68.>_-M^/$$_]&2:_=2>R`M'"MT7R]PC(3A-7#F`'PB
MI.U_P(#<X6!J]Q\```#__P,`4$L#!!0`!@`(````(0!5#=B/#!H``"G&```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;*R=67.;RM:&[[^J[S^X?']L
M:QXJR2F)66A``P+ISMM1$M>.K93M/9Q_?U8+NJ7N!;QHU\F%[;P\K$;0ZZ6!
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MSX>_WB_^OGG_<?S+>WO^.GU^/=#NI@,E#L%OQ^/O`@V^"HE6OF=KNZ=#$+W=
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MWKN^6S:I`V4)?I%?5^\3D8I9E'.2--O7[MFFS)'F^?A<LTOD@6G^DP-SGQG?
MR4?MQX_'+Y_>CG_=T-F)]N_[KT=QKFL,163IH%FW5YY:9JGDI2+*2(3Y?$N?
MD-SRG4X$?WXA%_UT_R=Y]U/.C#.&?BJFU348JR#.0`]C2T2XN6C;,057"N>&
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MF4ZOK;>UY4QK8&Q/4H-):S"[`J9K'(M]#68TJ@.-ZT!Y2NA=\7Q^U+*2+@"T
MK*S.1D%KV6@*EBG8IN"8@FL*GBGXIA"8PL04PDS([DB(P<E4"N=S;KMM'*99
M$6.D\%PR\JR[,(5("A4M+8L8HZ659&1+:U/8F$)L"EM32$PA-86=*>Q-8322
MROD3LE0>C3G4Z1G#`+H+=NI0I\.D=4NZM+RB6PI:ZY:F8)F";0J.*;BFX)F"
M;PJ!*4Q,(<R$BVYI"C-3F)O"PA0B4UB:PLH4UJ:P,878%+:FD)A":@H[4]B;
MPFC$E+%4JCI7?CQYOZ$[$5?T&T'3(.3B:JG3,ZX`QAE#_51=41F=V(*$#0D'
M$BXD/$E(O_"E4+KI`20FDI!!0RF4!IU"8@:).206D(@@L83$"A)K2&P@$4-B
M"XD$$BDD=I#80V(TP@C.J5%E4FEG"KJYIF6\N*QHDX=4#V3$6J?G&^>L[AE7
MAN.,J<I\2-B0<"#A0L*3A$Q27PJE21I`8B()&324PCEHVQBR3#EBF.4,$G-(
M+"`106()B14DUI#80"*&Q#8C^J>[Q]T'\4^_V$E@B!02.TCL(3$:94BVI?3(
MEVWI*$^I"L*J:D;+>WI:H.5]=;X+VLQWX^)SG#%5^0X)&Q(.)%Q(>)*0J>E+
MX9R:1MX%D)A(0@8-I5`:=`J)&23FD%A`(LJ(0?:`Y:YC?/;EY>)&XZY[OA0^
MW2E9P0;6D-A`(H;$%A())%)([""QA\1HE"&Y*>E^-,H3J7BA515<2W!ZZJ8E
M>+W[A6(M(]'[AF&.,Z8JT2%A0\*!A)L1G<ZIWS;N&H.39\H?#>=?QOT)+U^!
M1EAJV-+N&O>^?-AN8+3;[`ZT?ZS=29UV0]CN%!(S2,PAL8!$!(DE)%:06$-B
M`XD8$EM())!((;&#Q!X2HQ%&\LQ4&=%MRV0X_>89,;*J@FIV(NI8_H&?G%8S
M#<48]HYSJ,I1,&)CQ,&(FR/Y/GRXZQGWO3T)Z"YBG#-]W%(@`V7^Q5N:2*"R
MI1"W-)6!9$O]WD,V$LZ[AV&!,\[W--[XL'.\"0N,1!A98F2%D35&-AB),;+%
M2(*1%",[C.PQ0F4+(L?I\O_B_&@<:JI:R!B5'^8#X9%5&47W%'K$HGE*]45(
M0^"FEQCG^'$.57P&"R,V1AR,N`5(VQP]>PJ2%PZ^4L[#%.,P!`5(NVO<>ITH
M2$8.E7(1N6\8W+0(TH>H,XS,BY".L86+(DAO*L+($B,KC*PQLL%(C)$M1A*,
MI!C9862/$7*%+.TJ,HI<@3/MIG&:)V?@U+ECZ\X@"BS,`D)<[2`JI)E#&&>W
M<0Y5?!X+(S9&'(RX!8AY4]#+F8X^###NMOH%D<[[]G2='A0@9F.36HV%DLH'
M%'K*3@O:,39EAI$Y1A88B3"RQ,@*(VN,;#`28V2+D00C*49V&-ECA.PCR\F*
M="/[R!@YJ-#[$_E&50C=-T1]QS_PC:PLA)I1-P8Z9C7L6)3C5X^.+(S8&'$P
MXF+$4X@\^_M*N?B4^JX.,#)1B(P;*J4T[C1'U)5IOP^N3&?Z&LV[AQZ[KS+'
M#2\P$F%DB9$51M88V6`DQL@6(PE&4HSL,++'"%D$S"RR",Q4IY_N$V1'_\0G
MQ&KZ%4C[P7P.(KYX@WP"(C:.XF#$Q8BG$)G/OE)*\SG`R$0A,FZHE-*X4XS,
M,#+'R`(C$4:6&%GE2#>[2=WJ#3K&%>L:!]EH0;K]0<]X!!/C&%N,)!A),;+#
MR!XC9`HP1\@4,B;;N07[A88.55%T2Q"%4Y=#!W`S(JNSTH<,QF$9BR^-(BN`
MB(VC.!AQ<R3OB*?3KW[R]U00F;&^4DHS-L#(1"$R;I@KV;8,>H.&^5!^JM8I
M;7F&D;G63M$C]85&B._GFEL2X6:6&%EA9(V1#49BC&PQDF`DQ<@.(WN,D!/`
M%"$GP(Q5R>A>0-?:FA?4>WC:$*OIPX..^96H<0Z1+YVO-?1$M#!B8\3!B(L1
M3R$R>7VEE'Z``",3A<BXH5)*XTXQ,L/(/$<R]VFW.PWSSND"!XDPLL3("B-K
MC&PP$F-DBY$$(RE&=AC98X1L(<NVBD0B6\!,=;;IMB"JJZX8(F3%6/H0P;AO
M-Q;?SD=#!(C8.(J#$1<CGD)DVOI**4W;`",3A<BXH5)*XTXQ,L/(/$<R.Z#S
MOSD"6.`8$4:6&%EA9(V1#49BC&PQDF`DQ<@.(WN,D!O`)"$WP(Q5R>AN($JQ
MKG"#K')+#$+.)W[S&WQC\98-L@-QV7*FS.$!9NP:<9P:C%N#\<Z,3%[_+)5^
MC*`&,SDS,G1XEDI#3VLPLQK,/&<J#L:B1IBH!K.LP:QJ,.L:S*8&$]=@MC68
MI`:3UF!V-9A]#8:,`F</.44-R*J&=*\0=597>$56ED5>(;O]6+PX)S,&*5E<
MLKGD<,GEDL<EGTL!ER9<"KDTY=*,2_-<:JM/O>!0Q*4EEU9<6G-IPZ682ULN
M)5Q*N;3CTIY+U"/9H:4.R#7]>&O=2[P.2>M>XGJUT:)33?5-K--Z1%[T,RF=
M#X+%)9M+#I=<+GE<\KD4<&G"I9!+4R[-N#3/)<W6!T:5\X*O%W%IR:45E]9<
MVG`IYM*62PF74B[MN+3G$KW'(JOFHN&&=!5Z;077]"Z@=SU1TU'?V9I9"8AV
M330P"D7&.:0='V,,A!$;(PY&7(QX"I'[T%=*Z1`EP,A$(3)NJ)2+N&91U;0(
MTO?>#"-SC"PP$F%DB9$51M88V6`DQL@6(PE&4HSL,++'"&5X5<W5J2Z(,AXS
M5B6C.P(EM^8(]6Z>BI?JF3=/S?<$C7.HTAFR.!6(C:,X&'$QXBE$9K"OE(L,
MUI,SP,A$(3)NJ)2+N.8K6Z9%D-[X#"-SC"PP$F%DB9$51M88V6`DQL@6(PE&
M4HSL,++'"#D#3!1R!LQ8E8SN#**&XXJQ0E;R09MPOA4R,*LYF[`NQ,*(C1$'
M(RY&/(7(S/65<O$I]:0,,#)1B(P;YDIV6Y->6<MO;$[52J5-SS`RQ\@"(Q%&
MEAA9862-D0U&8HQL,9)@),7(#B-[C)`?P$PB/\!,=;KI?D`GZ6O\0.#&X]6!
M45D\;F90Q>G?PHB-$0<C+D8\A<B\]952FI0!1B8*D7'#7,F^Y4W?-C,>1$VU
MY1WV+?"9MIR^!F[N^;EJLG3#%QB),++$R`HC:XQL,!)C9(N1!",I1G88V6.$
M?`!F$/D`9JK33/<!4;QQQ;@@J_70QP5FZ95XNS:91:4/0,3&41R,N!CQ%"+S
MU5=*:3H%&)DH1,8-<R5_W-EL&O>]IFJ-TG9G&)EC9(&1""-+C*PPLL;(!B-Q
MCF2[MMGOM3KFS9DMCI)@),7(#B-[C)`9P!PA,\",5<GH9F#67H%;V`4U5P/C
M>X9C\4)\9`80L7$4!R,N1CR%R*3UE5*:E`%&)@J1<<-<R7ILH]$UW_TR5:N4
M-CS#R!PC"XQ$&%EB9(61-48V&(DQLL5(@I$4(SN,[#%";@"3A-P`,U8EH[N!
M*-FX'!K4O)F857KH0P1CQ#MNPG(0*T>R_.@^]*A46;\VMW$01PLR:%,=LA[#
MU8!^?]`PQ]:>:D5FKJ^MT^CWZ54?>M1`K5.:NA.%R+"A4DI7FF)DAI$Y1A88
MB3"RQ,@*(VN,;#`28V2+D21'LDXYZ#>;QCVQ5,40,Z88W6*G%I8>X3U&R`I@
M\I`58$9F6/$X7;<"49-Q:05@8)"5<.@68'Y72TR:@P8&&9*?(A_H',DJ!&T<
MQL&(FR-5+7DJC,Q87RFEQS/`R$0A,FZHE-*X4XS,,#+'R`(C$4:6&%EA9(V1
M#49BC&PQDF`DQ<@.(WN,D"/`7")'P(Q5R>B.((IDKG"$K*;FTA'HM4;Z67,L
M9JM"C@`1&T=Q,.)BQ%.(S%M?*:5Y&V!DHA`9-U1*:=PI1F88F6-D@9$((TN,
MK#"RSI%\B-AM=7OF+94-CA)C9(N1!",I1G88V6.$_`"F"?D!9JR<R4^+#?J^
M#GU+3V6M9@CB#3%7&,()UQ\H=!^,`?XXAXH'**<""@LC-D8<C+@8\10B$]=7
M2FGB!AB9*$3&#952&G>*D1E&YAA98"3"R!(C*XRL,;+!2(R1;8YD+XHU1K8)
M7C_%R$YKPKC%OL?KTZ0\63%A1?:,:F382*98]O2J=W=^ZJ?G_W7%B*V"8D3C
M6FJ<,Q4?P,J1;-OH)9O&"]5L',+!B`M:\50(F:"^4DH3-`!!)RJ$#!HJI33H
M%",SC,PQLL!(A)$E1E8866-D@Y$8(UN,)!A),;+#R!XCY`"XN+!&DI$#9''D
M\^N+\[1N`32\OV8(('!S"&"\H6/<RJ!*#X"(K:*<YK$U+SP<M;@TL5R,>`J1
M">LKI31N@)&)0F3<4"FE<:<8F6%DCI$%1B*,+#&RPL@:(QN,Q!C98B3!2(J1
M78YD`_!.I]%OG(??IP'P7B=ZK>;`&(Z0#<`$H8$`9BRM*?KFOE;6ICN!J%6J
M?W>@E94VT2:H:L/N@W$J'^=0I1/`$BD;1W$PXF+$4XC,6E\IYT]Y'DMEKXG$
MR$0A,FZHE-*X4XS,,#+'R`(C$4:6&%EA9(V1#49BC&PQDF`DQ<@.(_L<R0QC
MT.UWC2=OY`8P2<@-,&-I+=%]`?'^GK,YZ79`27N-'0C<'!BPBX,,JK0#B-@M
MB#@8<3'B*42FK:^4TK0-,#)1B(P;*J4T[A0C,XS,,;+`2(21)496&%EC9(.1
M&"-;C"0823&RP\@>(V0(,`?($#!CY4QF/?U>MU=ZJU`4+5V.#DY?F>V26OU8
M47RIEOF"<0H=YQ!MKQI+&(B%$1LC#D9<C'@*D?GK*Z7T`P08F2A$Q@V54AIW
MBI$91N8866`DPL@2(RN,K#&RP4B,D2U&$HRD&-EA9(\1\@5<6U@CV^CN`8_3
M?3C?T-1'"J*"Z=(:@"-D!4_ZA8-9@=B"55$61FR,.!AQ,>(I1&:NKY32S`TP
M,E&(C!LJI33N%",SC,PQLL!(A)$E1E8866-D@Y$X1[+38:LE+I;/P^/3Y=X6
M1TDPDF)DAY$]1L@18";12`$SU>FF^X$H8[K"#[*J)]T/C"N@<0N61ED8L3'B
M8,3%B*<0F;>^4DKS-L#(1"$R;JB4TKA3C,PP,L?(`B,11I8866%DC9$-1N(<
MR?U@H%TMYW8`.V:"VTDQLL/('B-D!W![R0XP4YUMNAV(&J8K["`K>=+MP+@]
M.F[!NB@+(S9&'(RX&/$4(M/65TIIV@88F2A$Q@V54AIWBI$91N8866`DPL@2
M(RN,K#&RP4B<(YD=G":+5'4UN1O`?IG@9E*,[#"RQPBY`=Q><@/,5">;[@:B
M@ND*-\@*GB[=H-UBSQMA5935@HB-$0<C+D8\A<BL]952FK4!1B8*D7%#I93&
MG6)DAI$Y1A88B3"RQ,@*(VN,;#`28V2;(YEA-`IFLTAPD!0C.XSL,4)V`+.$
M[``SU=FFV4'[N@K$$VX\93"?KHYSJ.IN(D9LC#@8<3'B*42FK:^4TK0-,#)1
MB(P;*J4T[A0C,XS,,;+`2(21)496&%EC9(.1&"-;C"0YDCE&M]ML=(T;$"D.
MLL/('B.C40VF1K*-K,HXNAV8!8GB*4-3S)!;?4^QS2L3NPVS,CF'+GVAVS#&
M$E8!9#R*L#'B8,3%B*<0F<&^4DHS.,#(1"$R;JB4TKA3C,PP,L?(`B,11I88
M66%DC9$-1F*,;#&28"3%R`XC>XR0-=2H4JS!5*>;;@UT#7#%A4-;X.9(P2Q/
MRJ',;.G19\']7BMG+EV#&4+65@7BX"@N1CR%R,3UE5*:N`%&)@J1<4.EE,:=
M8F2&D3E&%AB),++$R`HC:XQL,!)C9(N1!",I1G88V6.$#`'FP&A<@ZE.-]T0
M1+W3Y9V$4T6">'`)Q@I9G11MKRHV:+?,YX]M7DS5;AD/):P"B%D#CV,@#H[B
M8L13B$QA7RGGSVDT'6!DHA`9-U1*:=PI1F88F6-D@9$((TN,K#"R+D#:+>/&
M]:8`,@Y*C)$M1A*,I!C9862/$3('F`5D#IBI3CC='.ADK)D#\`2!FZ,%LWJQ
MG4$5IWD+(S9&'(RX&/$4(C/75TIIY@88F2A$Q@V54AIWBI$91N8866`DPL@2
M(RN,K#&RP4B,D2U&$HRD&-EA9(\1\@.82>0'F)'IEM]>K2AF;HMRILNQ`K"#
MK/KI<HC0;1@^/3[%K'YC(D9LC#@8<3'B*42FK:^4TK0-,#)1B(P;*J4T[A0C
M,XS,,;+`2(21)496&%EC9(.1&"-;C"0823&RP\@>(V0'O-C02#:R`\Q8.9-]
MP9M>*W%1NZ4/#D2YTQ5ND%5'74SZ,FXSR>*2S26'2RZ7/"[Y7`JX-.%2R*4I
MEV9<FG-IP:6(2TLNK;BTYM*&2S&7MEQ*N)1R:<>E/9>H-[)C2[V/:_H!U_N7
MJ)^Y[%^G*U/JP$]_O'\<7_S#\_>3`J]4LSJ<R]-0N\M&I1FDS9/8;+!+545)
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MS=/QCU>ZBTQ=_$*^>3M\^WQ+_7Y(C[[[8J9`M89<-!"+!@6+:$[6H9AYD*\D
M9F(=TEO""I?1!*Q#>CM8X3*:=Y5:*U[6[HH-Z18T1R<5L:A7L(CFPQV*^1CY
M-M(LN$,Q+2-?0G/?#L7LC'P)S7@[%),T\B4TS^U0S-7(E]#LMD,Q92-?0M,4
M#\44EGP)S3P\%)-4\B4TW_!0S%7)E]`LPT,Q925?0G,+#\7,E7P)S2@\%!-8
M\B4T\?/0*UQ"\S\/Q;R>?!V:]7DHIO?D2VBNYZ&8Y9,OH2F?AV*R3[Z$)GH>
MBCD_^9)3YRI<(KI6<<\2':NX7]%TVD,QYREOAR;1'HJI3_D2FCI[*&9`Y4OB
MQG#;*-"3QC`MTBE3*!F*EHR;P_%I[E8C(:WFT"K2[>;0+M*=YM`ITMWFT"O2
M_>;0+]*#YG!2I(L/4*1;C:%3]+G<QM`OTH/&<%*DAXWAO$B/&L/E2;]7.^C]
MRZ=?C]\/L\>W[\^O[S<_#]_([V@Z'+J:><LN8[+_?!Q_T<2XMS>_'3_H$N?T
MYX_#X]?#FZ`)_G8\?LC_T"&^_^OX]OO)4[_\5P````#__P,`4$L#!!0`!@`(
M````(0"P[,$+>@,``+,+```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME)9;;YLP%,??)^T[(+\W8'*/0JI"U:W2)DV[/CO@)%8!,]MIVF^_8TR(,4W%
M7A(N?Y_S\[GA]>U+D7O/5$C&RPCA48`\6J8\8^4^0K]^/MPLD"<5*3.2\Y)&
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M]=GE0YVV;\++Z(X<<_6=GSY3MC\H\#2%,.AHK++7>RI32`/X&H53;37E.9B`
M7Z]@NIX@C.3%T+%,'2(TGHVF\V",0>YMJ50/3)M$7GJ4BA=_C`@WIHR1L#$"
M_R?S/EP.7CQN%L-_LQB'HTDXG2\&(/AF.W6D[HDBF[7@)P_J%(!E1735XQ58
M?CL<$`>MO=/B",TA81&2D)/G3;#VGR'J::.(C0)^6P7N*I*S0B<.&%H0B,EP
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M8LL5G'OJRP,<CBE\EH,1B'><J_.-_NBWQ^W-/P```/__`P!02P,$%``&``@`
M```A`$;CVJ&O`@``4`<``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
ME%5=;YLP%'V?M/]@^;T80FG2**1J5W6;M$G3M(]GQUS`*L;(=IKVW^\:)Y2F
M6<?R0/@X/O><<\UE=?6H&O(`QDK=YC2)8DJ@%;J0;973GS_NSA:46,?;@C>Z
MA9P^@:57Z_?O5CMM[FT-X`@RM#:GM7/=DC$K:E#<1KJ#%I^4VBCN\-)4S'8&
M>-$O4@V;Q?$%4URV-#`LS10.7992P*T66P6M"R0&&NY0OZUE9P]L2DRA4]S<
M;[LSH56'%!O92/?4DU*BQ/)SU6K#-PWZ?DS.N3AP]Q>OZ)441EM=N@CI6!#Z
MVO,ENV3(M%X5$AWXV(F!,J?7R?)F0=EZU>?S2\+.CLZ)K?7NHY'%%]D"AHUM
M\@W8:'WOH9\+?PL7LU>K[_H&?#.D@))O&_==[SZ!K&J'W<[0D/>U+)YNP0H,
M%&FB6>:9A&Y0`!Z)DGYG8"#\L?_?R<+5.4TOHFP>IPG"R0:LNY.>DA*QM4ZK
MWP&4[*D"R6Q/@O][DB2+SF?9?#&!A05%O<%;[OAZ9?2.X*;!FK;C?@LF2V3V
MSE+,)^@8O/[-*GKT)->>):=S2G"YQ?8\K-/YY8H]8*9BC[D)&#P.F&1`,%0S
M2$(98TFG0SY4]F!?V8?NI=R$&^,RL]-ETO\IX\$Y1>Y!?+J(!]Y0.6#.1YAL
M0+PPB)"QP4/F;QOUB[`W(_9T\1Q@4!`P$Q3@KALK>+NR!Q][?\XT5`Z81=_Z
M>1;C[[3UBY>%IUGWBXX%I`-_$!`P$ZSC)AU;GZ;`+_I7^`$S08'_*(Q>N;?#
M]^!C[\?A!TP(/SF9?IALX<578"KX`$UCB=!;/[42;-MP=QBHU[-^)@X/<*!U
MO(*OW%2RM:2!$I?&T1Q;;\)(#!=.=_U8V6B'HZP_K?'+!?ARQA&"2ZW=X<(/
MW>%;N/X#``#__P,`4$L#!!0`!@`(````(0!,,#?C%P,``.\*```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;)2676_:,!2&[R?M/T2^;T(""1\B5(6J
MVZ1-FJ9]7)O$(5:3.+)-:?_]CN-`8\,,NVD(?<_+X_-:QU[>O]:5]T*XH*Q)
M4>B/D$>:C.6TV:7HU\^GNQGRA,1-CBO6D!2]$8'N5Q\_+`^,/XN2$.F!0R-2
M5$K9+H)`9"6IL?!92QKX3\%XC26\\ET@6DYPWA7551"-1DE08]H@[;#@MWBP
MHJ`9>639OB:-U":<5%@"ORAI*XYN=7:+78WY\[Z]RUC=@L665E2^=:;(J[/%
MEUW#.-Y6L.[7<(*SHW?W<F9?TXPSP0KI@UV@0<_7/`_F`3BMECF%%:BV>YP4
M*7H(%YLP0L%JV37H-R4',?CLB9(=/G&:?Z4-@6Y#3BJ!+6//2OHE5U]!<7!6
M_=0E\)U[.2GPOI(_V.$SH;M20MPQK$@M;)&_/1*104?!QH]BY92Q"@#@KU=3
MM36@(_BU>QYH+LL4C1,_GH[&(<B]+1'RB2I+Y&5[(5G]1XO"WDJ;1+T)/'L3
M6/*MQ>.^&)ZG8C^:Q6&<7$<(]'*Z[CQBB5=+S@X>;#D`%BU6&SA<@+-JR^2?
M;8%^J)H'5=25@EI`EB^K<1PM@Q?H?]9KUN<:2[&YH(A/)@'PG2"A23;D&';`
MY>R.D*H(4D+>`')\\N\6LM::R4#S3M`I-BZ%P0@_-&1TLREQBL![P#:QV+1F
MUK5W/HN2))J:BLU0D4Q'TRA^IS?88(&WLRFQS?;NJ_NF-:Z^N10&&VRV(9O:
M@->S5477LM4:%Z-+83`F)J,[6R6V^V=GJS5#MDEHA>N4&'33_Z%38ILN,7]Z
MK35#.BO_C4MAL*GCTQHOU]-51=?2U1H7HTMA,,Y-1G>Z2FSWSTY7:X9L9^DZ
M)09="(-NV$(W7J>V^:RYL>Y%0T`[8*?$Y+MP@ER/.-3#'R;88`+:T[D7.3FU
MSV6)R:DF^6`K7NFCGOON":T.;]@,KA%M2"[/:'UET8=RBW?D&^8[V@BO(@7T
M9N1/84QQ?6'1+Y*UW>&[91(N&MW'$BZ6!$[FD0_B@C%Y?%%7HM-5=?47``#_
M_P,`4$L#!!0`!@`(````(0!W04/ID0L``',Z```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;*R;76_KN!&&[POT/QB^WSCZ](F19!&+9+O`%BB*[>ZU
MCZ,DQHFMP/;Y^O<=BD-QAL/C2`?M1<_FX9!Z.4/QE63I]M=O^]?9E_9XVG6'
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M\._C[+%]VGQ^/?^G^_K/=O?\<H9R5S`C.['5XW?5GK:041CF*J_L2-ON%03`
M_\_V.[LT(".;;W?S'`Z\>SR_W,V+^JI:7A<9A,\^MJ>SV=DAY[/MY].YV__E
M@C(<R@U2X"#P+PZ27Y5YM?S0#W*A8XD=X5"3C[YP,^D3HS;GS?WML?LZ@]4&
M6D]O&[MVLU4]G_F,.!E#CGZ4(LB-'>3!CG(W7\YG,/L3U/7+?9Z7MXLO4(LM
MQJQE3,8C&A]A$V^'53'0,3`$+&!&P[2@0O^':=E1[+2\H+4'9)[1''R$[Z)B
MH&-@"&!S@`42SZ&`)9]>K+X2MA,L2U:)BFM<NY@,UM-0KBBD&4*&>0BB!3&4
ML*G`H>*IV/-NXBJSH\`ZA8Z#;KG,,.C2Y(:087*":$$,)6QRH(=.[G)];'`_
M!W_L-9)R6&6-($H0+8BAA.F#TYKJ^\E3W(["A2.!?T@Y:K[6FB'(SU<)H@4Q
ME+"YP!9#YW(YUS:82T9"<BV($D0+8BAA^NR5`ME.+^NSP5P?DMX"^RVP$40)
MH@4QE#!]-U/TV6"N#PG)GR!*$"V(H83IRV"#&Y_`/IHK]`@J1%;E,EJ5(6I8
MEA)IB0Q#7+FUHM&ESYQQP5[F!:P](LF52$FD)3(,<9G6;<;+=-[$9"(B:S03
M2$FD)3(,<9G62L;+1..AV:1>Y$ZE3"`ED9;(,,1E6E,@,NW>FE=7L!5/M#9K
MQM&YYA&H)BOY0[R2L6,HAPH=_=K2$AF&^*2LDY!)7=[$K!W'RJD58>X%4KYC
M6.]:(L,0EVE-8KQ,M!2Z1!"%U#690$HB+9%AB,NT7C%>)CH+E4G-!K,ID,H$
MTA(9AKA,:QE$9G^5D"_M4GZG_N@U5+%#93YL;DV&B"_F&[Z8E8\*';5'X`OA
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MM&9$2A'/\8_N[4=SA`,,DT1+"X=<YX@^#"H:B91'-T.41@2;79"/8_517'["
M"_/:/A),584JEEZ8.V2WKR&[>9$/_N5,QD<%XU,>T8Y9$5W^:1]EE\:7^V5U
M#?_C8QL?TC^%Y/.T/A:5:=P\T0!I91#!/V2>!=?2Y!@5ZJ<\HL5R47"J_WA2
MP^&@GFQ2]A'93TVJ[\CW5T11\:('FXV/(L7SR#WYM<\RM4>N4EE?J;A4/D:6
MJK#N^C.EZCM&L[)C`>*E$D\`,8J4RH]%2H4(2Y4E%R#KQFLUR;H+:=V(H@+%
MFYZ/H@5R8T%'OQ]H'W6Q0+0;G\HD+R^DEWO$JQ)MPXV/HE7!L6A5'/)52:\U
MVHU/99+?%]+O/2)&*I&22$MD&.(RK5V34R)AF&1K+FQT=!X@(I<E/BH@)9&6
MR##$949^_XY,:>P%(II-@92,TA(9AKC,A&7_U).,0KJV1[#BB#=$5M:$*']*
M*HFT1(8A/JG(R-_)O73O`A'-O4!*1FF)#$-<IC6S\2L9K8^8;X$H+-M&(B61
MEL@PQ&26D;->SF8?S4\XCT@V)5(2:8D,0UQFPBIKD#[QB5R)_D?2[!'L>&0=
M1P\QFA`UK&.)M$2&(3ZE23X)SUWBK<XCFGF,"DC)*"V188C+M)8R>AV7:$`T
MP8C(.O91`2F)M$2&(2YSDK^5TM\\"JEK)%(2:8D,0UQFY&_AV?([)YYTNM(A
MJ)Q?DHU';$\NHPM2Y:-"1^T1O<_,R_"TA,]ADOF5TOP0,>4N"LX6/QDEH[1'
M[H40^FI`F7"Z;,R3SKYCM*,YLV/R$/'$1C=\"L<B';5'/+'A#HHG=I*SE=+9
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MC(SHG6PZ7X'?0_U*7U>(PK51(Y&22$MD&.(R)UE-):W&(YI-C`I(R2@MD6&(
MRTRXSRA;KZ3Y(`+#\+EN`J([773MKY)15;BJ8HKM3<GXS:>/YIL/(BI3(L40
M%Y"PE:RH^M\B)MXMU<Y4Z.I$!!=B0Q(#(DFLPK5C_S!<^2C8C8*I5.$*BL]A
MDJG4TE00,9EH*D&Y\E']@N4"[-X^VD)JYP0L3V@.X6@-1A%-RJ.$`+MKCQ?@
M]G@FP"&VC`12-44\`W9O)@+ZZ[ZL[I?1Y3VM=KLZ$X,;/3GU,(I?OE7APAA7
MS="1KIIP=<@E3W*(6CH$(I8S%T608E%<0+3W]SF[AA2_DS!I`K5#Y+!-0#05
MX7H7$S9TI%'AHH_KG60"M30!1$RFBR)(L2@N(+6]WV0C+H%KN;\C(D=N`J+9
M"%>RF#,W%G2D43^X#%E.VM_[:+Z_(Z(R)5(,L9PM4_M[[?;WR^NL[QF)<3L\
M$S,@FHW8$W$LGK/Z!YZXG+2=]]&13-SAPY5%XZ,"4A)IB0Q#/+/1IF]/WQLH
M]T37A&]=XAL*CV`K".971Q;9A"COK4HB+9']NJ8_(K$1][6,^RADWQZ?VZ9]
M?3W-MMUG^R4,W$[?WP[8?::SKNJ5O:Z%8XN6);3T'TR(E@_0TO]L%;<L<_CJ
MI[_I$"V%_QXH;BEN5O9)=4)!>;VR#X=3+?!UD7MJ%(]6@@)W)R9:0`$\24R-
M5D)+G\:X3PZCP4L_B3XYC`;OV:1:8#3XN2[54D%+?]$?'Z>`/O#S6*)/`7W@
M%ZE$2P8MSF[CT3*H*;S%F.H#-847!U,M4`7X&3G1DD,5W,L6\7%RJ(+[V35N
M@<&28V4P%KQWG3A*!F/!J\ZI%J@!O%V<:H$:P`N]J1;(IWOY)U(&GZ4]I,>"
M#JF1[`)(<3ATZL@/Y>H!3LR$)+O&4ARJF"POU#!90JA@LH!P3J9.2977*_O&
M3T)1E:W6<!<O6^`ATJI)ML"#HY5*MJQK&`VN;!.C08N]#)8M<'NPLE?#LF5=
MP/3A%\Y4"R0`?B9,M4`*X)<Y:%D,58=/_MXVS^V_-L?GW>$T>VV?8".\[J]G
MC^ZC0??'&5]C^MB=X6,_\"'X?@X^[FSA=8]K^^+L4]>=_1_V`,/GHO?_`P``
M__\#`%!+`P04``8`"````"$`(R>#)EX.``#M2P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6RLG-MNXS@2AN\7V'<(?#^V)=E*'"0]Z.A`D=@%%HO9
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M[C^2V7+%NML_0/UVL]KO#KNGXYC43;J)HLV+R6)"FC[=/6[(`NOVJ_WZZ7[T
M.;DU^6(T^737.NB_F_7W0_#_J\/+[KO:;Q[_L7E;D[=IG>P*?-GMOEI1_6@1
M=9Y`[[I=@7_MKQ[73\MOK\=_[[XWZ\WSRY&6>TX66<-N'_\LUX<5>934C-.Y
MU;3:O=($Z-^K[<:&!GED^4?[^GWS>'RY'Z73\2R=7]\D)'_U97TXUANK<W2U
M^G8X[K;_ZZ02IZO3DCHM&4V_:\_R\?QZF@U1,G-*Z-4IH0F<&91:VZG3*T\]
M':<W\V2>VZF?Z9F[GO3*(XVOD^DBNS[?[]KUHU<>,1LGL^E'X]%F:V=*KSS>
MV?DMG#R]\CCDE#,&)10WW3+:`.I68'[.I$D7!FU4E<OC\M/=?O?]BK8JK?/A
M?6DW?G)KM7(\=8.?(NQ'`4:19;5\MFKN1^0G"IT#[8K?/R4W-W>3WRF25T[F
MH4=&2A0L8</6JBUC4,6@CH&*01,#'0,3@`FYY>0;BO*?X1NKQOJ&K7I@X)V5
M1HY@">Y2QJ"*01T#%8,F!CH&)@#"$;3-?X8CK)K[$?T;!,E"6O[0R204_B>A
MN10I3B(G[P"I@-1`%)`&B`9B0B*<1%/^&4ZR:F@STL%T<@!N)2=TSDLGD9.7
M@%1`:B`*2`-$`S$A$5XBNX27^O,6'RM6NG4&&_'@R.RTFPH@)9`*2`U$`6F`
M:"`F),)0RC4##+72TE!'Q)&ZF$9;X23$_BF!5$!J(`I(`T0#,2$1MM.D!]AN
MI:7MC@2+#*0$4@&I@2@@#1`-Q(1$&&JKZC![GH]F*RT-=23ST0RD!%(!J8$H
M(`T0#<2$1!A*E<D`0ZVT--218$6!E$`J(#40!:0!HH&8D`A#;0TD++4%T<W"
M%M.N(+N\)K*JI!M:[80HB?C3?9%$N]I+G;8UH@I1C4@A:A!I1$8@Z2);+UT>
M]4E77E%&8VL>&`7A@*A$5"&J$2E$#2*-R`@D;;:ET0";NTI*V.Q0L-<30"6B
M"E&-2"%J$&E$1B!ILRUU!MCL*J-PG<-BJ:WH"QOZ=E/XI2\158AJ1`I1@T@C
M,@))FVWA,L!F5^>$-CM$=@9;/"[P;8%KW>"CH414(:H1*40-(HW(""3=8,N:
M`6YP55#HAK`P<DL/J+1EKHR&"E&-2"%J$&E$1B!ILRUG!MCLJI_09H?\HA8)
MH!)1A:A&I!`UB#0B(Y"TV58V`VQVA5!H<U@;N74&5":`*D0U(H6H0:01&8&D
MS;;("6WNKCS&]B[H^+)9?7W8T<:EI-53S&5TM=$:^3EQI5+H"H?:"SSG"D"E
MZVCKB>!\R&0)4'DI3IHUC^C5*T2-[QBJGTGUVDNQ>B-T28?98NF<PW[;O?_(
M863FR6.NY@H]YM#-J30H$D`EH_96M?5KY5#J?5&CE&+DU3>,O"Z-NHR0$KZ@
M$:4O>H(DL+D5)]\$-CN44NX/UC^^X_!2O$`EH^XFUEZ/58QL6-*-VR*_R=,H
MDFJ6\=T4H_3D]H81A;V?51;=X&F6ZL;+KZ?7Z3R:N6&9=CSINV%U8XIU(R._
MH`6BDI%?X\HAFAN[LT8IQ<BK;QAY71IU&2$E;;8E7KQWTKQ]G/@@=%QQ&(9.
MA^QH?I&FT0U:82.+<BJ]L*TE(Q\#E4,9Q;/7M<CE.5'[CJ'4M912+.5';!CY
M$77_B%&(&=^Q?T3I75M,AM[]P*6N]@Q=ZI!?\B(%5#+R45`Y)"+*=?12BCMZ
M]0TC+Z51EQ%2TN:X0OU+Z2O%PM4A&5T+B*ZN(RV3CZX.9;ZDKYRN3"2Y+(J;
MVH_(NA0CK[YA75Z]9I2WY]XL3Y,LCZ[&#&OJ.8=LT1E&3>S!R_*9S>"V=@VC
MR2&_W`5+>50R\A%0.22BR>GR4HH[>ET-(R^E49<14C*:XJ(W]L5%Q5"*M;!#
M=CN?SA=ZJUB>'(67X@@H'<K\^R45H[1+<]?7LT4>/5#5K,D?.(I1&$O=1$FY
MGU6":<Y)=>,M;M(\3Z/8-:R\)[QLK?L3PLN5S&%X015=I(!*1!6B&I%"U"#2
MB(Q`,KSB6ON#`QJ+ZM2AX)D*48FH0E0C4H@:1!J1$4C:')?+']B,97'JD#_Q
M"D0EH@I1C4@A:A!I1$8@8;,M(R#FT_F8SK"!;R2WFN2IRHC2:W"4Q)>F7NIT
ME""J$-6(%*(&D49D!)(>&E;\9EC\,@JB`E&)J$)4(U*(&D0:D1%(VFPKT?`D
M/+\3LJYP#1,JHV#W(RH158AJ1`I1@T@C,@))FVT1.,!F5S,&IWSF4+C.@$J4
MJA#5B!2B!I%&9`22-L<EZ0?KC+4GU8[N.C3<XE&.+[R4W^*GCHPJE*H1*40-
M(HW(""3=8"NV`4OO"KQPZ1T*EQY0::OJZ-(448U((6H0:41&(&ES7#]^L/18
M*&8.A5L<4(E2%:(:D4+4(-*(C$#2YKC`^\!F+.1L_2E7L$!4(JH0U8@4H@:1
M1F0$DC8/*^0R+.08^2N8`E'ID'T)<GUTIU5Y*=[U->I2B!K?,50?WXYZ*59O
MA"[IF;C<^TM/4!E6@8Q"ASDICTHG14]X]@HPG2:1,9478&-JU*P0-;ZCTQRM
M@O8"K-D(-<)-L[X*,:'/+-)AUMZZ7_;0W:J1Y2$C_U1<("H9^0?ERJ'PH1NE
M%".OOF'D=6G49824]$5<"]J0N>A2<(9EH4/BVB:=1K>R!4OY9^&2$:D\;35X
M%JZ<%!6V-@JNQVF4E&NOAJ-`,?*#-8S.#J;E8//Q373[9+P:&DSZ=%BM.<-:
MDY$\>J(;T<)+L;DE(]J<YQS9C4C1UFZG\2RZ^:R]&M:L&(6QYR9^=C#M.OYP
M,,.:VQ"6CAQ6P,ZP@'4HBLCH`J5@*1\D)2-_AU,YY,(O&2=11-2^CW=^.HU\
MJUC*#]8P\H/I>#"X]/%]^@>3CAQ6%<^P*F84KG4*]_TLY8.D9.0/J,HABHA@
MZDET'U=C1\7(JV\8>?6Z7WWTC&Y$1^DL6]->7CO/7`D<U,X.R:A+HM.J8"D?
M""4C'PB50WSH18FO]CT"7V+,=7,,;LH;WY&WN#X_E/$]^H>23AQ6C,^P&&<D
M(BZ)["]8RH=$R<B'1.60B+@$W@/`CHJ15]\P\NKU1>J-Z"B=%5?QER=A+.AG
M'8J"+RK%"I8*@^_4D2.B<E(N^-(HD]>L),RD/0>>T^N':GQ''DJ?'\KX'I<$
M7_R$<+D_\6%AYI#(Q4GDBL)+L44E(Q\HE4,?Q:$;T7=4K"N,0Y#27KW-ZUDT
M1\-*Q(X*S@H9DR0UY!2TXE$QW"'YMDL"1<Q)RCO.H3"L>JK!3HH/QG%D;3T[
M:6'%BE$8B2<I'U<PEG8=W5A1WC>L%M]_F<=/&N<?SUMQZ41&P34,HA)1A:A&
MI!`UB#0B(Y`(G#DMVX#`:<4CFZT&0L$U#$MY5"*J$-6(%*(&D49D!)(V#ZOX
MYUCQ,PK7V4EY5*)4A:A&I!`UB#0B(Y"T.2[.[2&;9^U3]`=ACG7ZO$/TS&Y/
MKE^B8JUPS?8Q]O18DR:^C)<3&U;LSK'8=8AFPT='X1#-@)`<+BX7K1^RFPL^
M5C/'RM$A]D-<,KKFR`_^"4-.;%@)-L<2S"'AATZJSP\VS8=EL_7#-7T5M_?3
MB^TE4??QQ7E7'X3OM3C$;HB+/M<<N<$?R](--D^&\_H@.%U:#<KYN4-^(Q:(
M2D05HAJ10M0@THB,0-)FF]4&V-PE0;$"#OD#MY@#*A%5B&I$"E&#2",R`@F;
M\V&YMA67>8=1L,Z(2D05HAJ10M0@THB,0-+F.-?:/6?3U/D8SUV"#6+<(=YQ
M\>.":Y8[+O6/[')6P[)ACMG0(;IB.QW`C/``SOL2T44'<-LSB@&9B**BLG`]
M(C_X="7],"P1Y9B('!)^Z*1Z#N"\+Q%=E)#;GI$?NMS$\1!7[:Y'Y`>?KJ0?
MAB6B'!.10\(//TQ$>5\BNBP>,!.URBB?N\+$EQS=A^I=<^0'GZ^D'X9EHAPS
M$:/PA(+D5*)4A:A&I!`UB#0B(Y"T>5@FHI\KB1\C&069"%&)J$)4(U*(&D0:
MD?UE%?^4TMG<_5)*]YL6V_7^>5VL7U\/5ZO=-_LK*'3C^.GNA+N?:'F8I[>V
MQJ9C#EINJ*5]WH>6!;6TM6G<DD_I%U_:$Q):2!NM4L\X.6DC6WI:LMFM_8A!
M7\N<6MKL$8^3Y=22]_:YII;VDY1QGSG-FIXG>\:9TR_84#KK:4EH!EV]$FM+
M:`;T+:.^/C0#^BY.3TM*+?3)P;X6\AM]OJZOA?Q&GT+K::&&7IZ0G?15UIX>
M"=E)7_CL:Z'XH*]%]K5DU-)N"O``K1M]GP[[T`\"?>[711UZY!]H\%YY&KIO
MY,^SV\_]H40SZIO0`ZUB;QC1&O8N(:U3[S+1*O4M$GW#Z=9^?PE=05].NK5?
M/<(6>M__UKZKCRWTEOVM[FVAM[ZI3]^BTUO7U*>OY2&C<*`;)1SG(:-PH(^R
M];70BM`'OOI:[)JTBS(YQ0/]V-+[\GG]S^7^>?-VN'I=/]$Q-&V?T/?=SS5U
M?QS=EZ:^[([T*TM4"-!O[]#/:JWI>SU3^_SVM-L=^0\:>G+ZH:Y/_P<``/__
M`P!02P,$%``&``@````A`+9W!NVT`@``D@<``!@```!X;"]W;W)K<VAE971S
M+W-H965T.2YX;6R455MOFS`4?I^T_V#YO1AHKBBD2E=EJ[1*T[3+LV,,6,48
MV4[2_OL=XX1"4FGT!?#QY^\[-Q]6=R^R0@>NC5!UBJ,@Q(C73&6B+E+\^]?V
M9H&1L;3.:*5JGN)7;O#=^O.GU5'I9U-R;A$PU";%I;5-0HAA)9?4!*KA->SD
M2DMJ8:D+8AK-:=8>DA6)PW!&)!4U]@R)'L.A\EPP_J#87O+:>A+-*VK!?U.*
MQIS9)!M#)ZE^WC<W3,D&*':B$O:U)<5(LN2QJ)6FNPKB?HDFE)VYV\45O11,
M*Z-R&P`=\8Y>Q[PD2P),ZU4F(`*7=J1YGN)-E-Q'(2;K59N@/X(?3>\;F5(=
MOVJ1?1<UAVQ#G5P%=DH].^ACYDQPF%R=WK85^*%1QG.ZK^Q/=?S&15%:*/<4
M(G*!)=GK`S<,,@HT03QU3$Q5X``\D12N-2`C]*5]'T5FRQ3'<3")I_-%!'BT
MX\9NA>/$B.V-5?*O1T4G+L\2GUC@?6*YG073>7@[@H1XC]H`'ZBEZY561P1=
M`Y*FH:X'HP2(WX\(0G'8C0.G>(X1^&J@#(=UM)BLR`%2QTZ8>X^!YQNF0Q`0
M[91!;;RR`SMEEUOGRKTW]&7B]V5N/R+CP"F&YYOSBVG'ZY4]9M+#O"$&`0)D
M?(`.##6`;NA)7^;6@T9(`\UX:0=NI;OD>LNDO1/]DLT^0NO`0]J3I5^T:#'K
MTCM('C39^`@<>"CE+=<1N(D\NMT=>$A[LOAIT<_,\B.\#CSD]99K=V&H#?QM
M!\\2RO.?>^J.#15:)C#!3J_!YA?)]Q/0#PC)=<&_\*HRB*F]FVXQ7/G.VDW>
M3>SZY-(^239^(I-N!R9B0PO^1'4A:H,JG@-G&,PA'.UGJE]8U8"C,!:5A5'8
M?I;P[^-P[<,`P+E2]KP`9=+]3=?_````__\#`%!+`P04``8`"````"$`Y[X4
M0L<'``!P)0``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*R:6V_B.!3'
MWU?:[X!XGT("M(#:CJ;-_:;5:B_/*:0E&B`H2:<SWWZ/$SNQ_<^RL)J74GXY
M/K;_Q[=C<O_Y^V$_^I:555X<'\;&S70\RHZ;8IL?WQ[&?_[A?%J.1U6='K?I
MOCAF#^,?637^_/CK+_<?1?FUVF59/2(/Q^IAO*OKTWHRJ3:[[)!6-\4I.]*3
MUZ(\I#5]+=\FU:G,TFU3Z+"?F-/I[>20YL=QZV%=7N*C>'W--YE5;-X/V;%N
MG939/JVI_=4N/U7"VV%SB;M#6GY]/WW:%(<3N7C)]WG]HW$Z'ATV:__M6)3I
MRY[Z_=V8IQOAN_D"[@_YIBRJXK6^(7>3MJ'8Y]5D-2%/C_?;G'K`9!^5V>O#
M^(NQ3DQS/'F\;P3Z*\\^*NG_4;4K/MPRWT;Y,2.U*4XL`B]%\969^EN&J/`$
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MR^)C1(L)=;`ZI6QI,M8&.1$CO@U$-P?^;0K0V&=>OC`W#V,:!#2X*YJWWQZ-
M.^-^\HWFVH;;/`W8J!;/PH)-+.;6TH&M`T<'K@X\'?@Z"'00ZB#20:R#1`(3
MDK;3EP;!S]"7N6'Z"F6>!.@%-S4QA84H8NG`UH&C`U<'G@Y\'00Z"'40Z2#6
M02(!14R:'S]#3.:&5F9EL&KJ/;4V;$9T(WJA"=R9=`H#L8$X0%P@'A`?2``D
M!!(!B8$D,E'$IJ[_#+&9&UI<:&/IA,2E@1N=4[LSZ=0&8@-Q@+A`/"`^D`!(
M""0"$@-)9**H3?HH:@^?.,1RRZP;48483YS,NQ7B&8@%Q`;B`'&!>$!\(`&0
M$$@$)`:2R$01C+:Y*P1CUJI@G*A;UDR;XIV1T-D"8@-Q@+A`/"`^D`!(""0"
M$@-)9*)H2)V_0D-FK6K(B33H@%A`;"`.$!>(!\0'$@`)@41`8B")3!3!6)XG
MGY;.SU)FK0K&R:R?I4`L(#80!X@+Q`/B`PF`A$`B(#&01":*8'18OT(P9JT*
MQHDTPH!80&P@#A`7B`?$!Q(`"8%$0&(@B4P4P5BR<H5BC;DJF4"TL4L[[EQ;
MV7JK;FE#9"-R$+F(/$0^H@!1B"A"%"-*%*1*RL[FE\]:EOQIHU`@:1@BLA#9
MB!Q$+B(/D8\H0!0BBA#%B!(%J?JQX_@5^K6G=SKQB9'UQ%)A)JFT[B&R$-F(
M'$0N(@^1CRA`%"**$,6($@6I^K$C]A7Z\1.YK!]'LGZ`+'9]H*IL(W(0N8@\
M1#ZB`%&(*$(4(TH4I.K'#LVR?NT=Q0V[TJIW^>;K4T$+'<W:@=UX1G<1_(:"
M'[UE63EJ[@0;JV>6\#$->V1QQ.[OI/542P;MWDJ,>@=]N8@\CF:LI=\>Y\;2
MG*I+M=];"-<!^@D117W!UO7M;*6ZCGL+X3I1_*AQ8&?Q<W'XHSC]6QQ(O2X0
M_$@O!X*C9;=D/+.$D06B1Q8BFR.S#Y>#5BXB#Y&/O@*T"A%%B&+TE2A6JJ[L
M?"[K.C".9?WX<5[6KT5T,RX/T5LUV,]&9R6";2&R!:(SL#3<[U1?CK!J[N*;
MJ>,B\GHD^9HM55^^L&IG@#&?K0QMG`;"I*\N1!3UZ$QUL;#BU2WF2VW")<*B
MJ4T-%<L,Y%#]OZ6(YQ=R!#FB@[2DNJ;4L]%9]1$$9',K95*`E8N^/%&PGW.^
M0'1>E=H%X>G<2U:ZK"'6&`GW?8VQ0$J-2^TN.>E]#=>H1HVE)Q`U^GV#.L7V
M#[%N7;&9\(1'CF"+U#FXU*X5GVD]8\M:^QL6O^,&9'.KF;RL@96+OCQ1D#;#
M/EPXX5I?,[.]J)^9JZG6S@!]AXBBBZJ+A96H;J7O<(GB6@T=2Y0@=(M^[Q>Q
M^X\UD^=;<KPXDL_T@"P#D(W(0>0B\A#YB`)$(:((48PH49"B*RT.JJ[G]6O,
M:3>6]!-(.I,BLA#9B!Q$+B(/D8\H0!0BBA#%B!(%J?I=EU.:F%,*)(T_1!8B
M&Y&#R$7D(?(1!8A"1!&B&%&B(%4_/:=D&ZFY8$ORE;\\L@67'13EH=FEF](J
MN-3O=D7!?@!;B&Q$#B(7D8?(1Q0@"A%%B&)$[,6(1HFF0ZW:[8L.[0^^AZQ\
MRYZS_;X:;8IW]A(#%7B\[W#[A@7EZFN6R](!`Y[,Z$GC')ZLZ,EJJ(PYI1<V
MFFU,+V.R5SF:]Q[@";6`FC;0@MLUW64/\+LU7=D.\.6:;B8'.#5WL+4&M;9-
M_?0V&=1:NB%!7Y0>KEGRAT\HLUNSW`V?4&*V9JD7/J'W6[X,]IQ5/V#_Q*0:
MXA2JH4A]F9/_P0+S-?TVA0UZ6JSI)QCBDTX1>M_EE+YE<5J^Y<=JM,]>:2A-
MFQVY;-^8:;_4/!M\*6IZT:5)#'?T9E-&O^M/V3Q_+8I:?&$5=.]*/?X#``#_
M_P,`4$L#!!0`!@`(````(0")_6(#>@L``&,]```8````>&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULK)M?;R(Y%L7?5]KO@'B?0`$%291DE)3MW9%VI=5J9O:9
M)I4$=:`BH#O=WWZ/"[OLZ^,A5*OG8>C\[K6Y]]8M'U-_;G[]MGD=?*UW^W6S
MO1T6%^/AH-ZNFL?U]OEV^,?OYI?+X6!_6&X?EZ_-MKX=?J_WPU_O_OZWF_=F
M]WG_4M>'`6;8[F^'+X?#V_5HM%^]U)OE_J)YJ[>P/#6[S?*`/W?/H_W;KEX^
MMH,VKZ/)>#P?;9;K[?`XP_7NG#F:IZ?UJE;-ZLNFWAZ.D^SJU^4!\>]?UF][
M/]MF=<YTF^7N\Y>W7U;-Y@U3?%J_K@_?VTF'@\WJ^K?G;;-;?GI%WM^*V7+E
MYV[_H.DWZ]6NV3=/APM,-SH&RCE?C:Y&F.GNYG&-#&S9![OZZ79X7UR;13$<
MW=VT!?IS7;_OHW\/]B_-^S]VZ\=_K;<UJHWC9(_`IZ;Y;%U_>[0(@T<TVK1'
MX#^[P6/]M/SR>OAO\_[/>OW\<L#A+I&13>SZ\;NJ]RM4%--<3$H[TZIY10#X
M_V"SMJV!BBR_M9_OZ\?#R^UP.KN87)9%.8?_X%.]/YBUG7,X6'W9'YK-_XY>
M;4K=+!,W"S[]+/.+<C&>%CTFF;I)\.DF*187LTFYN&QG.?'U,S<2G_[KP[>?
M&(<$V^3QZ;]Q?K$HQE?3!=")@7,W$)]^X.E01\>RMT=1+0_+NYM=\S[`J8&Z
M[M^6]D0KKC&;/WS'[^X.Z%\=3QQ(.\F]G>5VN!@.<*3V:,*O=\7LZF;T%8VS
M<CX/&1_I47D/VR5V6I4"G0(3@1$RZM)"(_R$M.PL-BT?T(,'(<])DH/W\$-4
M"G0*3`1$#NC#GY"#G04G57QHRK$,^N'H4Z!]N^-72I>J<^D2(Z*)F)B(W/!5
M/R$W.PL:%^=*%S?WG7,ZE5SGTB5'1!,Q,1')(9XXN?Q2Z$\=Z]SFX+_[P9%9
MUW85$45$$S$Q$?'A/(_C^\%SWLXB`W<$'^%PE$722)V3SU<1T41,3$0N6'/B
M7$[7VCK+D!V):DU$$=%$3$Q$?':?$ZVOI^.SSC(^1Z:A%X@H(IJ(B8F([ZI/
M?-99QN=(5#\BBH@F8F(BXBNP(SF_@*VWC-"A"3HHZLITV0Y>75LRTHR,0#)R
MJTUG'_KBJ&18RWP`#QY%Q66D&&E&1B`9II6?\\,\BI4(TZ&H1PM"BI%F9`22
M85HI.3],)SQQ-6,M:K<754%(,=*,C$`R3"L*49AV;9U>VJVOV\Z=OZ5R\A*G
MX!#"CEIYFBRP5L;M61J.AV*D&1F!9%962J*L3J]B5H^39<*CN)5C>7+;/4*:
M!QJ!9)A6)<X/TVE*7&"'0NFJ@I!BI!D9@6285BS.#]-)2QQFK#:NE0FI@I!F
M9`2285K-B,)LMPECG-E]?QLX[8D3Z.0H;N19VLB=EU\254%(,S("R9RLSD0Y
M?=#(3I7BR&.A<J4GI`I"FI$12(0YZ25ZK;<4/8^B1F:D&&E&1B`99B^%F[#"
M>10M"XP4(\W(""3#M&IT]D&?..V*#KI'<MU-?R$%KZY=&6E&1B`9N16H\R-W
M<A9'[E!<8$)J0D@S,@+),!/1.WU635C8/(K;E56,O30C(Y`,LY>*6<E.5,RC
MN)HD68J]-",CD`PS4;'CS[,+>T7H\+)>?7YH(/XXES)5GN+22[LHW=OM;AJ]
M0UA;HMW#/%ET_<#VJM]1EAVR$4<#%W*@#EZ^_8V82^9HM2EJ[#3'WYNWO\H1
M871).H6+&]ZARVX;74T(*8^N.B_M$!:[$+X;V'K)\*T,)>%/L>9G#DD<KA.O
M.-PCLFM75-I+6=IJXKPF76S*(S%PF@S4WLOVQ=>[13G&?W)NXUW:ZZDR22MB
M29*3>;N5_2!/IWYQG@[A(\HSN4)839Q7.'C*H_A(';UPGK?7&?-9==^'HRFR
MFO:2UM9;2JM'T2+`2#'2C(Q`,DPKEE'Q3U=\:KV3,!V*EE3O%9!BI!D9@628
MO:1URM+J45Q-YQ608B_-R`@DP[0"%U73+C>3\@(+6L^][-0I9=3:'L$26GN>
MG&95\/++BV*D&1F!9%*]5'?*JNM1*'3%2#'2C(Q`,DRKD%'M/^ADZYUTLD.A
M;:LI(<5(,S("R3`3U?T@3);7J4-Q-0DI]M*,C$`R3*M)435M)Y<XU?OVL9.V
MN(\=DGV<7KV==EZACPEI]C("R902,?V@\BRB4X?BRA-2[*49&8%DF%92HLI_
M$*83H+C`#L5]3$C9;80]`8*79F0$$F'.>NE;ZRU/-X^B:C)2C#0C(Y`,,]$W
MV\=7"+UG'\]8^#S">A>MQ^GUWN#5]3$CS<@()%/JI84SUD*/XLJS%K*79F0$
MDF$F6GBZCV<L>!Z%#JT8*4::D1%(AME+W6:L;A[%U71>`2GVTHR,0#+,1-U^
M<#V>L>QY)-?C]&)O\`I]3.*HV<L()%/JI80S5D*/0IDK1HJ19F0$DF%:V3E[
M/9XYD8K68X_B/B8I4^RE&1F!9)B]U&W&ZN917$U6-_;2C(Q`,DPK.U$U;1^'
M9U#.OFDQ<^H5E]DAN1ZGUWK]P)"E8J09&8%$2F4O)6R]I1)Z%&*J&"E&FI$1
M2(:9*.'I]=CN]9+]L4?A,96*D6*D&1F!9)B]U*UD=?,HKB:K&WMI1D8@&68O
M=2M9W1RREZZB[4-ZK3=X=<LN(\W(""0C[R5X)0N>1W&!6?#82S,R`LDP$\'[
MH%U9UTJ2IXJ18J09&8%DF+U$K&01\RBNIO,*2+&79F0$DF$F(F:7W=GXZ@+?
MU',G7++`>217WO2";_`*K>SF"HEJ]C("R:QZ:5[)FN=1"*!BI!AI1D8@&69&
M\XH?N,%9LNAY)#=OR27S*GB%TKNYPJ9$LY<12.0T[R5ZK;<4/8^BTC-2C#0C
M(Y`,LY?HS5GT/`IUJA@I1IJ1$4B&V4OTYBQZ'L759-%C+\W(""3#3$3/KB+%
M'.MLSS5DSG+HD5Q#DOL,5?#J&IF19F0$DCE9Z8HVI*=U9NZ$+MIW>A27WGD%
MI-A+,S("R3![R:$])LGNS:.XD4DA%7MI1D8@&68O.9RS''H42E<Q4HPT(R.0
M##,GAS_0QZR%\T[2XFU=>@,J>(4^[@9ZI-G+""13ZJ6%<]9"C^+*.Z^`%'MI
M1D8@&6:BA1^<;JQX<Q*NBI%BI!D9@428BU[RUGI+>?,HE*YBI!AI1D8@&68B
M;W9!_J'[37AS)UTP/!);BT5ZOREX^;95C#0C^ZY0N/Y\3.KX[L_QK9%-O7NN
MJ_KU=3]8-5_L>SVHPMU-AX\O'3W,Y]?V-,=WDV4!2_M3E2R7L+2W?LER!4M[
M!SBU+,9XNZF]94^6[KVGU#+'&.Q,<K%A##8#.<L$EO;V.\TVA:5=O,DR@Z7M
M,[*4L+12E5I*C,%OKTP$)<;@YT[.@EKC%T;.@EICEYZSH-;8&.<LJ#6VEQG+
M#&-P`2EGP1A<A\E82M0:ESYR%M0:5QMR%M0:/_!S%M0:/Z`SEAG&X))WSH(Q
MN,J<LZ#6N+";LZ#6N#Z:LZ#6N"29LZ#6N`J8L4PQ!C?T<A:,P7VQG`6UQJVH
MG`6UQMV?C&6&6N.&2\Z"6N.^1<8RQ1@\A)"S8`SN^^<LJ#5NM><LJ#7N5^<L
MJ#5N$><LJ#7NRF8L$\1V?!PG/4LFB`V/S.3&(#8\3I>S(#8\P9:S(#8\3)*S
M(#8\OY.Q%!B#QZ5S%HS!$\HY"_H`#P7G+.@#/(>;LZ`/\#1KSH(^P`.D&0N&
M9$=@0-:_0)WQ%D-FI@)UQHL#.0OJC&?U<Q;4^7CS,CEJ:C*_M@^)\1B\HGJ?
MGPM39?P?[$'.<=M^&7X_N[Z'K/$7/]@5(,=Q#+.'$$<PE\`#CE][^$9=SGC%
M]6WY7/][N7M>;_>#U_H)4CEN'^+;'5^2/?YQ<`^Z?6H.>+<5>Q6\@HF7F6N\
M_3BVSZ<\-<W!_X$$1MWKT7?_!P``__\#`%!+`P04``8`"````"$`],+F`AX<
M``!5S@``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*S=6V_<QIKN\?L-
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M-=P*:HS@U_O[?XQ=\T\CZ>#7.#K91]`]''VZ_7SS^]>GX?Z/[/;NMR]/ROM,
MO]+XF[WY]._H]O&CAE2G>;4]&\_T\?ZK[H#^>_3M;OS;T)#<_&O_[Q]WGYZ^
MO#O>G;\ZNSC9;=3]Z-?;QZ?D;CSE\=''WQ^?[K_]]W.GS72JYY-LIY/HW\!)
M7CAP-QUX.A\H>N$`W:?]W=6_TRV=S??VA>/.I^/T=^_NX<LW=#4=H']7W=!&
M"3X/J(;LYVYJXX9O_&$ZY.+5YO3D?(S@A5]JXX9O_,'=EL[QTB$:Z>>[-X_@
M[N61V+BQ&W]8=?<NW&WIAY^\>\KG^>[]55"OG_^.]],BNGFZ>?_VX?Z/(SW8
M:-@??]R,#UV;-YIX1VY"/`_*88K\V0S1U!C/\LMXFG?'NN/ZXW_4O/[G^\WF
MY.WK?VHJ?ISZ?`CTL3VN78]QWHVGC980+R%90KJ$;`GY$HHEE$NHEE`OH5E"
MNX1N"?T2!@]>*YY#1OH;_=_(:#S-F)$;W0\.YM"VBT!<#W=(M(1X"<D2TB5D
M2\B74"RA7$*UA'H)S1+:)71+Z)<P>&`"T2,``CG5(T1X%7%S9#Q*ZX69(QL[
MX!^>^VSTL'.82&>VR_6ARR$42`Q)("DD@^20`E)"*D@-:2`MI(/TD,$7DY&&
M$!F-*_W*![;Q-'ILU(&'0/C(-G5Z*;5#ET-JD!B20%)(!LDA!:2$5)`:TD!:
M2`?I(8,O)C6-LTGMY1DU]MZ'XP;UPR2GAP>Y:T@$B2$))(5DD!Q20$I(!:DA
M#:2%=)`>,OAB!EX7*V;@_^9UP'@:F\@D^L>;0,MUYM#)!1E!8D@"22$9)(<4
MD!)206I(`VDA':2'#+Z8D'1]94)Z>7:,O6T6DWBS`Q)!8D@"22$9)(<4D!)2
M06I(`VDA':2'#+Z8@=>%\8J!'WO;@9]D-S\L02)(#$D@*22#Y)`"4D(J2`UI
M("VD@_20P1<S\*HG5PS\V-L._"3>7SPD@L20!))",D@.*2`EI(+4D`;20CI(
M#QE\,0,_%N9FY,<%8;S&77G]M#^/S<21'N:\)6&WN,R=>QW6!%),2D@I*2/E
MI()4DBI236I(+:DC]:3!D,UM+"+]@O[E-6+S7'/J^M:-\@='WIPA1:28E)!2
M4D;*206I)%6DFM206E)'ZDG:KWQ^U-F/E\UBK!]79/%<;IHL)O*S`$7C1MCX
MN#?WBDD)*25EI)Q4D$I21:I)#:DE=:2>-!BR68R%XHHLIKK2GQ=^J;G?GKH>
M-Q+MP$>DF)204E)&RDD%J215I)K4D%I21^I)@R&;Q5C^^5G\W;5E*B/]D`Z5
MI;^VG"[7ED,O]Z@7C5LN-LJ8E)!24D;*206I)%6DFM206E)'ZDF#(9O;6#WZ
MN?W%VC(5FWX\?OTYS2%0-.ZV++,`)>R5DC)23BI():DBU:2&U)(Z4D\:#-DL
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M9C$6U2NRF&IP/PN4Y=?CB_`6-20I)B6DE)21<E)!*DD5J28UI);4D7K28,AF
ML:SGQ[5EIPNQE<^W;%GH.]*,\.J6B^7:PMI_/M`M-S$I(:6DC)23"E))JD@U
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M8EGE_\42PF)^-Y&_A(`B]HI)"2DE9:2<5)!*4D6J20VI)76DGC08LEF,1?:*
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MDEL`CK2(>9=IRY=#SKW<'TA$BDD)*25EI)Q4D$I21:I)#:DE=:2>-!BR\:S;
M`KCD%H`C&\_RI49SKSF>Z5SSA(KG7G[4B^><D[F7.U=*RDCY3"^<OIA[N=.7
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M!:DD5:2:U)!:4D?J28,AD\7F9%GGO[S_]=S?5O,'FU>3ZX!%`8L#E@0L#5@6
ML#Q@1<#*@%4!JP/6!*P-6!>P/F"#M44\ZXKYS0FK^8-YLR5@BF<Z=NZG>&"*
M!Z9X8(H'IGA@B@>F>&"*!Z9X8(H'IGA@B@>F>&"*Q[=%/,OZ?ER$QL]87KE'
MMCEAY7\P7:MYNV2+Y_TUTZ9#SP\O@5"4,$4)4Y0P10E3E#!%"5.4,$4)4Y0P
M10E3E#!%"5.4,$4)4Y2^+:)<MSVP.>'^P,'F&:1XN$,0,,6#?HH'IGA@B@>F
M>&"*!Z9X8(H'IGA@B@>F>&"*!Z9X8(K'MT4\ZW8,-B?<,CB86:>F?K-I]L`4
M#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQ^+:(9]V.P>:$6P8'
M,[-GZC>;XH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*!*1Z8XH$I'ICB\6T1
MSW(385RGQL\B6KU.<7MA<S*97:<6+R#3`^&AFRN-%"5,4<(4)4Q1PA0E3%'"
M%"5,4<(4)4Q1PA0E3%'"%"5,4<(4I6^+*-?M06Q.N`EQL'E6*1YN0P1,\:"?
MXH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*!*1Z8XO%M$<]R6^*OZBEN/FQ.
M)IO7),4#T^R!*1Z8XH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.*!*1Z8XO%M
M$<^ZO8?-"3<?#F9FS]1O-L4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%`U,\
M,,4#4SPPQ>.;C6>SW(T8UZGQ/7MKUZG]B1;;%,YT%>/54XO7A%UOYF[S.D6+
M`_V2@*4!RP*6!ZP(6!FP*F!UP)J`M0'K`M8';+"VB'*LFG]^KWRSF:IL;[/\
M8/.L4CQ^-?[QZ.'=<10PQ8-^B@>F>&"*!Z9X8(H'IGA@B@>F>&"*!Z9X8(H'
MU@=,\?C]%O&,E?":>*;*V<0SF;].;6"*!Z9X8(H'IGA@B@>F>&"*!Z9X8(H'
MIGA@B@>F>&"*!Z9X8(K'MT4\8R6\)IZI<C;Q^-7T?J9H]L`4#TSQP!0/3/'`
M%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQP!2/;XMXQDK8CV=<IW:7K[9_9ZF:
MJFH3W:'2]I>JY6OZ-YM#-V^I@BE-F-*$*4V8TH0I39C2A"E-F-*$*4V8TH0I
M39C2A"E-F-+T;9'F6#C[:?[%-?MF*K1-8I.9I0JFR093/##%`U,\,,4#4SPP
MQ0-3/##%`U,\,,4#4SPPQ0-3/##%X]LBGK$87A//5#R;>";3E/:N_1;O9=##
MXZ&;-Z%@2@RFQ&!*#*;$8$H,IL1@2@RFQ&!*#*;$8$H,IL1@2@RFQ'Q;)#;6
MQVL2F^IIDYA?8[O5"Z8)!5,\,,4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%
M`U,\,,7CVR*>L3Y>$\]43YMX)M.M>!-J\?8K3:A#-V]"P9083(G!E!A,B<&4
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MH18-N5X='FK1@.NURH&6"_VF^FB<4(ONM3Y\)=2B>ZV/`@FT7.I>ZX,I0BVZ
MU_J8A%"+[H'>O19HN=`Q^D3$4(M^4WT^7ZA%OZD^+2[4HK\0?5!9J$5_(=J"
M"[7H+T0?XA1H.=<Q^FSL4(N.T<<RAUKTF^I#@D,M&FM]9&VH16.M#U`-M%QH
MK/79G8&6,QVCKT0)M)SK&#TI%FK16.OK(D(M&FM]4T&H16.MS\T/M6BL]2GN
M@98S':,OQPNUZ!A]+UNH16.M;PD+M6BL]9U5H1:-M;Y!*=2BL=:7]P1:3G6,
MOA,YU*)C]`V]H1:-M;XO-M!RIK'65Y6&6C36^N+,4(O&6E_C&&@YU3&GP6-.
M=<QI^!B-]6EPK$\UUOK2^M#M:*SU\IY0B\9:W]X=:-GIF%WPF)V.V86/T5CO
M@F.]TUCO@F.]TUCO@F-]JK$^#8[U5L=L@\?L=,PN>,Q.8[T+CO5.8[T+CO5.
M8[T+CO5.8[T+CO56QVR#QVQUS#9\C,9:>S"!%+8:ZVUPK+<:ZVUPK+<:ZVUP
MK#<ZYD^N7'2,+N0"]V"CL=8%6Z!EJ['>!L=ZJ['>!L=ZJ['>!L?Z^7(E=#L;
M'?,GUWX:ZS^Y\M-8_\EUG\;Z3Z[Z--;A:SX=$DQ'!P2ST3`'D]$@!\=80QP<
MX?WE76B$]=%`;\8/_F$J^E2?-^-G]K!%'\CS9ORX';;HLW3>C)^4PY9?-F]^
M"?D'!1S.5_$&SO-AG$@!_^7TS2]C`<%;_C`^F(W^^G"1_?C^[8^;WV[KFX??
M[KX_'GV]_:QBXN35^#S;P]UOXU;F\_\\W?]0D7%\].O]T]/]M_V/7VYO/MWJ
M.9>3\8W`G^_OG]S_C#?PQ_W#/_8%R_O_$0```/__`P!02P,$%``&``@````A
M``$B&Z$]!@``ZAH``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R<6=N.
MHT80?8^4?T"\V^X+U]%X5@.K359*I"C*Y9G!V$9KC`7,SN[?IYIJ0W<1,WA?
MQF-\*$Z?NAR@'S]\JT[.UZ)IR_J\=?F:N4YQSNM=>3YLW;__^K2*7*?MLO,N
M.]7G8NM^+UKWP]///SV^U<V7]E@4G0,1SNW6/7;=Y6&S:?-C467MNKX49_AE
M7S=5UL'7YK!I+TV1[?J3JM-&,!9LJJP\NQCAH5D2H][OR[SX6.>O57'N,$A3
MG+(.^+?'\M)>HU7YDG!5UGQYO:SRNKI`B)?R5';?^Z"N4^4/GP_GNLE>3K#N
M;]S+\FOL_LLD?%7F3=W6^VX-X39(=+KF>!-O(-+3XZZ$%2C9G:;8;]UG_I#*
MT-T\/?8"_5,6;ZWQO],>Z[=?FG+W6WDN0&W(D\K`2UU_4=#/.W4(3MY,SO[4
M9^"/QMD5^^SUU/U9O_U:E(=C!^GV845J80^[[Q^+-@=%(<Q:^"I27I^``/QU
MJE*5!BB2?>L_W\I==]RZ,EC[(9,<X,Y+T7:?2A72=?+7MJNK?Q'$=2@,(G00
M^-1!N+@[B-1!X',(\AZ##:ZF%^=CUF5/CTW]YD#%`=_VDJGZY0\0\*H*KF'0
MZ99,H(\*\JRB;-W0=4"!%G+[]2F,'S=?(1VYAB13"+<1Z16AL@CL!HH@EDGQ
M_Q-V9:+`BHE*H**6X`&(/5`3Y+I31,`&B,4$!%K.1(&A2(P+1V-8Y(80SX#X
MPX5[1#J'L*A!D.74%'CKPKH'32*2C`0A49_+%9<\\CQ&A;,PT@LED]'`WV('
M'6*R4U7FW>R]:RK5241`PB!!"/`8%D(%G$-8%`.;XGR5*3`14`XKQ]PB).@%
ME-SCW/-L1&HB>!1Y;"P/BQFTE2G>/#,%MID%@7W=!"'(+/;\T/XYQ9]-3;VQ
M."QBRAJ-V3%/3($),7+E!"$WKHS]@!#D[G$QUH-%++Z'F`+;Q"*2J00AL\1F
M(18Y#M9ERJ::0<*Q>?GZLPA-4NN)QLSRG,?81-5`7IQ?CN/;&BJT\C1FGB#&
MN8&Q":K);1!<J"3.>XLHK42.&%UG@>#2L`2L1`NR$D$8C%5CLU0SW&#Y3IYQ
MXL/?8:1%XU#%T<+G7$&SFX/8]$#I.^@I-"G#B=,CQLP@J=24(P3U70DNQDJQ
MR:GQ;6BW,,,X],T,BXF&B-$,9!2'?.2@-30AD<]NS6=^EW7T:%O!>!S\.L&F
M-:R4LQ)W27444^-;4YK?Y1\]VG;=>!S_FM[4(B8)GH/8*28NLC#%4SN18_]I
MFJ99!$'@42=,N8E8<28]/@:Q61)+6<ARZBV2*)5PQ&`A<A9)?S0U78?+O440
M;YF?-3V:E"*Y>*(QND]\%@@6$DQJ8Z04823&DK9T%'=Y2H\FQ4@Z(=$8LQ.(
MQ.DLQ*:GYKXQ;][1#UW"G#/Q6#]8A`(Q6C\N(D^2>9D2".>COC8Y-=.7DT,'
ML,@181*!F%ER-N0V.371EY/#^0^Q!Y>+R?A-!&)F$SL'L;4C1O).8J<&$M-;
M!/74#TYXU8Z)R"?RIA0BF7^K+>ZR$('V8*66^IO&(#WN21&%8L(/XY@*WS(1
M04QDV?SKSR(#AE1_HC&:*!.,WNZD%D)Z@0QNLOPA+Q%3+^&&U^L^-JU"Z1G&
M/M$\U8%P*1)N&7W#.NUR)';R3CE.;80S:LK"])&8R]#S2,FF%D3RP!]S8;%3
M3R/+>[E'VTGF]%5!HD$HC>]+4(?T>VI#`AX%P2U^=YF(G#Z8@-/;#[V)!EW;
M)0A9Q`DFM3!^X#-HJB&,+:`:^L8P7-8M$JW"'(J<43_1(+-G:5O/0FR>:K@;
M/.?+4*(5F&.',W+Q1(-,?D:WX@W-@%$O"OU@K&2;G!KNR\DI-*U"4F*)1-`\
MN5F,S9"8RL(THW'8:2:MFD@$F4R)TNDLQ.9)W&4ASZG+P.WI4/`X%B6"=-_X
MC,>3\6U!_)@)/B[6IOE#'@-[!M/$CX-#TT00OLZ4\"0W^K`N2028>AMEBS1Q
M:P'?GE=%<RC2XG1JG;Q^5=L&`M[T#4>'+8UGH=Y$D^,);'7T^P*;X0?8:;AD
MA^+WK#F4Y]8Y%7L(R=8AE$&#>Q7XI:LO_3O[E[J#/8;^WR/L*17PIINM`;RO
MZ^[Z1;U''W:IGOX#``#__P,`4$L#!!0`!@`(````(0!BP1*DT@4``/@=```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)R96Y.B.!3'W[=JOP/%^W`5
M1*OMJ9'[9:NVMO;R3",J-2(6T-,SWWY."*`)#D>W'UH]_/(G.?^0A.3E\_?R
M)'S+ZZ:HSAM1E111R,]9M2O.AXWXS]_>)TL4FC8][])3=<XWXH^\$3^__O[;
MRT=5?VV.>=X*H'!N-N*Q;2]K66ZR8UZFC51=\C-<V5=UF;;PLS[(S:7.TUU7
MJ#S)FJ*8<ID69Y$JK.M'-*K]OLARI\K>R_S<4I$Z/Z4MU+\Y%I=F4"NS1^3*
MM/[Z?OF45>4%)-Z*4]'^Z$1%H<S6X>%<U>G;"=K]75VDV:#=_9C(ET565TVU
M;R60DVE%IVU>R2L9E%Y?=@6T@*1=J//]1ORBKA-U(<JO+UV"_BWRC^;FN]`<
MJP^_+G9)<<XAV^`3<>"MJKX2--R1$!26)Z6]SH$_:V&7[]/W4_M7]1'DQ>'8
M@MT&M(@T;+W[X>1-!AD%&4DSB%)6G:`"\%\H"](U("/I]^[SH]BUQXVHFY*Q
M5'05<.$M;UJO()*BD+TW;57^1R&UEZ(B6B\"G[V(:D@+S5A:SZCHO0I\#BJ:
MI%F&:IA/U&71JYBCBJY(EF$L3&OY>(N6O<IJ5-$6DKI0GJF)"F;2W!)7^^0N
MGJ^+.GITDU_K81V9.MYU("=MT]>7NOH0X*D$V>:2DF=<7:L@/70=:O38F7[5
MEZ`3$94O1&8C0L*@FS3P`'Q[U0WK1?X&G3;KF2UEX/_(J"QA#P3IH436&0+7
M(L:*+>-2Y/;.G*HW$(.JCZL&0YGKC3G5<"`&U8@/Q-/;Z'SMDSN,J8PME,&D
MT2DPAW'J_L,]&$)H8LA0O>T0N+9(&^_3)=N^0Q@LXE`$*CU:R(FX*.%-B9L6
M=S7QIPAWFP`EPBG!WR::(MQMXBFAFPLV)\D]9CDRC(4PJ#UA(:$9"_F`S0<<
M&KCU1S>YCNL^P'@/,/X]ALM?\``3/L!$]QA]S''7:>)[#-=_DWF&\0JFD">\
M(C3C%1^P^8!#`W0.)8.=RP<\/N#S@8`/A'P@X@/Q$+@^PKIILJE,YADF33";
M,FDB\\?BETN/870BI6"1<3..Z"8_75`&JC*.-9R;-DHX*.&BA(<2/DH$*!&B
M1(02,4HD<P1C*RR<)K;JL(*9GW1(J8T(`^)HF6YR\_66,D:_1E@JW'6;7I^Q
MW4$)%R4\E/!1(D")$"4BE(A1(IDC&%-AD?0_3"6E.%.7UR5*-_9N*3-CFHT2
M#DJX*.&AA(\2`4J$*!&A1$P)@SX'W!2=,!<5::4OE=N_ZW#-V$O>YOFE/#X4
MDU*\O5Q]MI29LQ<E')1P4<)#"1\E`I0(42)"B9@2O;W@(#?*)7,*C*GP[LF8
M.C\`$YHWDUN3;2FSZ@9@U?W$+:/L^<L.O3S3%5R4\%#"1XD`)4*4B%`BI@3-
ME2(IW'.1S`DP+I)=@"=L['#>1\ZH;0_-6&'CB(,C+HYX..+C2(`C(8Y$=Q!]
MR;VTQ7<@;G69S"*LN^0M_OF1EVSI3)Y6KA;;'IIUF>K,(`ZNXN*(AR,^C@0X
M$N)(A"/QB)#M*$72=?UV$E6X<3%Y&&>])Z__M][/#]!DBVWB^74^IZNI'IHQ
MU,81IT=,.M#K*PN6$>Q[GLL@VLK0+(V;J#P6T2Q%M;AGR6<0RS27ILF-50&#
MK!:JI?"[@R&+&+IAKK@;13TRDY<81Y)9A/66;!<\X2W=76!>?Y9<RK<JA6;:
M8..(@R,NCG@XXN-(@",ACD0X$N-(TB.TS^NKI:+>]'G66W#@&6\)SL_(_(X%
M'/$0:-9;%'%P%1='/!SQ<23`D1!'(AR)<80<H)'L#N.9IBG&=;*DWM(#,GJ^
M4>;U(;?STZD1LNJ=''Z1=ZTQ.A[,?>G.Y;BXJZ[AV`#VSKEXH*YAGW\:WVKK
M[3T=6UO#QA_P\B@$YVZ7])#_D=:'XMP(IWP/55,D<BQ5TY,[^J.M+MWIS%O5
MPHE;]_4()ZPY[!0J$L#[JFJ''^0&XYGMZT\```#__P,`4$L#!!0`!@`(````
M(0"MU7E23QT``#2_```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*S=
MV7+;2):`X?N)F'=0Z+XE<16IL-U1)O8=B)Z9:Y4LVXJR+(>D6OKMYX#,9"Y_
MMB0XJB]:Y2\/#L`\`(%,$L2[?_YU_^WDC]O'I[N'[^]/9V<7IR>WWV\>/MU]
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M4&,)?GUX^&T,S3^-)`N?8^ED7X+N\>33[>?KW[\]#P]_9K=W7[X^2[U7\I+&
M5W;UZ=_1[=.-=*FD.9OO-^/FX9ML@/S_R?W=N&](EUS_M?_[Y]VGYZ_CTF>;
MU6JYWEQ*FE]OGYZ3NS'GZ<G-[T_/#_?_IZ+&K3IFF:LL\E=E6:S/5I<7BYFL
M]*4%%VK!I5E0-G2SFJW6KRPI>?<;+G_5*N?;L^5\=;EY;9UKM:3\54NNSF;+
MB]=6>*D6D[_Z-;YQ4^5@VV^J_%5+OJUSMFHY^:N6F[UMP9GL1H>J6@5YX\;.
M=$G&_YBX6JGB8;6F*(NWKE9796;*\L87JPLSLRHS/[N<76P7XR[\PFX[TY49
M_^-M13T_'#_[PS&Z?K[^\.[QX<\3>9.3`^3IQ_7XECF[&M/I`_&P^N.A^9^.
M3#F8QBR_C&G>G\HKD6/N2=Y/_O@P7\_?G?\A;P$W*N8C8V9NQ$Y'C,?HF#;R
M(?8A\2'U(?,A]Z'PH?2A\J'VH?&A]:'SH?=AL.!<RG.LD1P-?T>-QC1CC73O
M?M1@%<TKB([0BT0^Q#XD/J0^9#[D/A0^E#Y4/M0^-#ZT/G0^]#X,%C@%D;>8
MOZ,@8YKWI_+_UD&S<"OP\1`SD[>H8]#*#=D=0XY5@L20!))",D@.*2`EI(+4
MD`;20CI(#QEL<8HF7?AW%&U,,UYM6`7A6YT*>JEJQY!CU2`Q)(&DD`R20PI(
M":D@-:2!M)`.TD,&6YRJ23\[50M?(.K3T!B]+X[NU(]*EL=WO1TD@L20!))"
M,D@.*2`EI(+4D`;20CI(#QEL<3I>KF<F=/P8[7:\$O>28.F]=1V#=+TB2`Q)
M("DD@^20`E)"*D@-:2`MI(/TD,$6IQ;2B1-J,4:[M5!B'020"!)#$D@*R2`Y
MI("4D`I20QI("^D@/62PQ>EXN2">T/%CM-OQ2LPUUPX206)(`DDA&22'%)`2
M4D%J2`-I(1VDAPRV.!TO8\<)'3]&NQVOQ-KC(1$DAB20%))!<D@!*2$5I(8T
MD!;207K(8(O3\>,8W.GY<4"X$)PZ(!SSN#79IQ:2*[3CM>Q\[5_-FJCC.8$4
MDQ)22LI(.:D@E:2*5),:4DOJ2#UI<,BMVSAXM`?R+U\HS0YC3;F,U;W\49-U
MS)`B4DQ*2"DI(^6D@E22*E)-:D@MJ2/UI,$AMQ;CN'%"+0[#3*<6BNQ:@*(9
M*"8EI)24D7)202I)%:DF-:26U)%ZTN"06XMQ/#BA%FKX:!\7]HAR/RVU&]_"
MQC<W4YZ(%),24DK*2#FI()6DBE23&E)+ZD@]:7#(K<4XRK-K\;/G%C5:M(ND
M2`ICG5O6WG!CG$89Z[8XONM%I)B4D%)21LI)!:DD5:2:U)!:4D?J28-#;MW&
M0:)=MU?.+6I,:9?''F:J8P@4C9,J[F$5DQ)22LI(.:D@E:2*5),:4DOJ2#UI
M<,BMQ3A(G%`+-::T:Z'(O'GMQ@\OW(Z/2#$I(:6DC)23"E))JD@UJ2&UI([4
MDP:'W%J,X\8)M5##3+L6]LA3'1>@:/R$R"U/3$I(*2DCY:2"5)(J4DUJ2"VI
M(_6DP2&W%N-0TJ[%SYY;U)#4+I(B.4BL<\NE?VXY1NDKZFC\/&VLV_IXNHE)
M"2DE9:2<5)!*4D6J20VI)76DGC0XY-9M'(G:=7OEW*(&KG9Y[+&L.H9`T0P4
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MI)24D7)202I)%:DF-:26U)%ZTN"06YYQ.#VA/&KT;9<'`_+='!218E)"2DD9
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M!H?<6HSC[`FU4,-RNQ:*[%J`H@4H)B6DE)21<E)!*DD5J28UI);4D7K2X)!;
MBVGC^07'\YKL6G`\SZB8E)!24D;*206I)%6DFM206E)'ZDF#0TXMEOYX_B?/
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MOB&U3-^9*#N]]R7'WD3I](-#;EW',?W;YPZ6:@K`FCO09(ZQ'2E2Y-75^Q)!
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M\^9LX;V,ALNTFDSF3M.++Z/748=N6VTO-NNM=VH==,Q^&]U=8-I4P(I3`8K&
MLY&U"WA;L-,+FDO02-/6V@4.Z>7+N6-)MI?;V87W=I]PJ523R9UI,KES17)3
MR3ZW_!ZJNY<67*;49#)7FDSFVLT\\[:XX1*M)I.WTV3R]B:OW;/>A<?@+.C6
M=MK4PHI3"XK&,Y)56^]`VJDHN=5`'R>1)G-0Q(K&;P=9N;R+A<0L:*)F6^\U
MISK*K#'39-:8FS6.%;\XN_0VO.`RI2:3N=)D,M<FL]G*^<;;RH8+MII,^DZ3
M2=^_*?W@+.@6?MH\QHKS&)KD(L`4:^OMV3L=97;C2)/9C6-%ZJ">;U?SS1QE
M5YM@%DMU)I,\TV1O5>!]_9!+'>BKLR4.=*RLU)G-RBI-9I-J12JSO*][F1LN
MTVHRF3M-+[Z,7J_L\%ZX65Q<K/R?`QI,)CGRW%U@'/*_?0BP.LP0V'<K*G)/
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MN;60BPCG&'JE%F.X5PM%=BU`T1H4DQ)22LI(.:D@E:2*5),:4DOJ2#UI<,BM
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M=R;*3N]](;0W43K]X)!;Q&E3`!M.`6@RO;PC18K<CO>_"Q^;*+WI"2EE^LQ$
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M@-]VON7,R^9`K]RVJ*+LVQ8UF2,E5C3>1'T\4N5>+/?>T<0L:*)XVZ*.,L=,
MILFL,5=T/.J7WEFNX#*E)I.YTF0RUR:SKD[#J%:3R=5I,KEZYAJ<*+?2_@3.
MSU6:\SH;13++<*P.WI-W.LKLNY$FL^_&BN1>Z?T-PN/M5BL<S,?UZ1Y,=2:3
M/--D;U7@W?V02]U-.#M;>!>OA4FC5U9J,BNK-)E74BM2F9=G*V\/:KA,J\ED
M[C2]^#)ZO;+#?8JK]6(]7_CW0`\FE;P4=]<8)XCL>59_UWCC5=B8QGN?/Y![
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M:7#(K9L_%_3*^QGG?+:*S`&S(T6DF)204E)&RDD%J215I)K4D%I21^I)@T-N
M+:;-^6PYYZ/)KH6*,A0Q*B8EI)24D7)202I)%:DF-:26U)%ZTN"06XMILRU;
M]5T3ZUL0FDS'[T@1*28EI)24D7)202I)%:DF-:26U)%ZTN"06XOP=,GT<PLG
M3+:*W'.+-Q;8F2AS;CDNJ"EF5$)*21DI)Q6DDE21:E)#:DD=J2<-#KEU&\?Y
M]@CWE7.+FF*PCR%%]C$$BK:@F)204E)&RDD%J215I)K4D%I21^I)@T-N+<91
M\81:'`;1]L\B;179M0!%C(I)"2DE9:2<5)!*4D6J20VI)76DGC0XY-1"?MMO
M4C$.\>XH\FA6.0(6!2P.6!*P-&!9P/*`%0$K`U8%K`Y8$[`V8%W`^H`-KGGE
M\<?XAYFYR>>;V05'_T=SSSC>#.C."M/G%RFE2F=*+J6$22EA4DJ8E!(FI81)
M*6%22IB4$B:EA$DI85)*F)02)J6$22EM\THY;8I@=L$Y@J.9;I?R<)8@8%(>
MQ$EY8%(>F)0')N6!27E@4AZ8E`<FY8%)>6!2'IB4!R;E@4EY;//*X\\:O'R%
M,+O@[,#1G/*H.&-R],"D/#`I#TS*`Y/RP*0\,"D/3,H#D_+`I#PP*0],R@.3
M\L"D/#`ICVU>><:A_=LO&F87:BK`NH([FBF%'#TJSIB4!R;E@4EY8%(>F)0'
M)N6!27E@4AZ8E`<FY8%)>6!2'IB4!R;E@4EY;//*X\\7_/1YBC,)LXOCO('Y
M@'%QX7WT(Z4\AEGG*9B4$B:EA$DI85)*F)02)J6$22EA4DJ8E!(FI81)*6%2
M2IB4$B:EM.U0RO.GK[>WS]'U\_6'=_>WCU]N=[??OCV=W#S\_ET^UIW)$RLM
M/WF\_?S^]*.<[ZXDV?YSHN,RQ[;YV+;_A(IMB[%M_R$#VY9CV_Z`9-MJ;-L?
MU'[;5IID$D5JCY:UM.R?.8J62VG9WW>(EHVT[#^'1<M66O8?]/HM<B$W;MW^
MZV5^VZ7DDR_TA[9.%I(/>4(MTKGRD4.H1;I6)L!#+=*Q,L4::I%NE0F_0,NE
M9),;/$,MDDUN-PRU2#:Y^2W4(G60VZM"+5('N=DGU")UD%M/`BUK649^`R34
M(LO(KTR$6J2OY3</0BU2.[D#/]!R*560^\%#+5(%N14YT+*69>0WX4(MLHS\
M0EFH1?I:?B\KU")]+;_(%&J1OI;?!PJU2%_+K]4$6I:R!?+PN5"+;($\"BW4
M(EL@#^8*M*RD"O++JJ$6J8+\SF>H1:H@OSH9:%G(5LN#BT,MLAYYHPFUR'KD
M0:VA%EF/?#T[U"+5EH=8!EJ64CEY3&*@92[+S(/++&09^2Y`8)F%]/4BV-<+
MZ6MYC'QH&>EK>:AYJ$6J+8_8#K3,99EY<)FY+"/??PLM(WTMWV8.M4A?SX-]
M/9>^G@?[>BY]/0_V]4R6F067F<DRL_`RTM>S8%_/I:_EFS.AK9:^/OQDM/\.
M.Y>^/GR/S&^9R3*S8'UFLLPL6)^9]/4LV-<SZ>M9L*]GTM>':2IL@?3U+-C7
MLDBP.K)`,%ZZ.=C+TLG!/I8N#O;P3'IX%NKA:+.\&K_PS+Z7+SA?C5]?9HM\
M7?EJ_#(R6^3+Q[)AH99?9E>_A'M>-BR0Z>-8WI"/!U+`?UE>_?(?KA1DDT);
M)/=ZR"L/K4-NTY!7'FJ1.RSDE8=:Y.8(>>6A%KG)0-83VF:Y/T#6$VJ1K_;+
M>D(M\JU\64^H1>X/D_6$:BQW>\EZ0BUR[Y:L)]0BMUW)>D(M<J.3K"=4,[EM
M2=83:I$[CF0]H1:Y64C6$VJ1YT==C0\5XEXFCY&Z&I\:Q!9Y*-35^/`@MLBS
MH60W"!TS\F0A:0DM(S=$7HVW.S*;W-YX-=Z\R!:Y6?%JO.^0+7*?H1S,H9:/
M*VF17_[E,A]EJS\&MTV>#7:U"[;((\*NQJ=],9L\34I:0NN11X%=C<^'XC+R
M1+"K\>%>H1;I@^`R\KA`64_H_4P>_B?+A%KDN7U2TU"+/')/ZA-JD8?<R7I"
M[X_R?#I93ZA%'BTGZPFUR%/A9#VA%GEXJ*PG]!XBCP*5]81:Y,&>LIY0BSR3
M4]83:I&G8,IZ0N<'>::EK"?4(D^HE/6$6N3ADK*>?<OY\03U].'=C^LOM_7U
MXY>[[T\GWVX_RV!/'M,BX\/'NR_C*/[PCV?UY*M?'YZ?'^YE/'AZ\O7V^M/M
MXQ@@P9\?'I[U/V37./_SX?&W_8#RP_\+````__\#`%!+`P04``8`"````"$`
M;`XIKU(8```SK```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RLW5MS
MV[B2P/'WK=KOX/+[B4/)]TIRRA+O=[+V\NQQE,0U<92R/9,YW_XT9()@X\]5
M1MZ\3#P_-"`)+9!$Z_;NGW\]?#WZ<_/X=+_]]OXX>//V^&CS[6[[\?[;Y_?'
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M_#%TN7@3G+X]-RG8\Z`".WWF#WM;,L:^+C+3+W?/S>!R_TP$=N[,'P?=O0M[
M6_+'W[Q[DI^7N_>S1)V\/(]WRR*\?;[]\.YQ^^-(CC4R[4_?;\V1*[@.9!2[
M(%XF95PB_]<*D6>U&>7&#//^6.ZX//F?9%G_^6$9+-^=_"E+\6Z(63$FT!%K
M&V$6BQDV]"'R(?8A\2'U(?,A]Z'PH?2A\J'VH?&A]:'SH9_`B:1GS)$\1W]%
MCLPP)D=V=E<67-(67D)LA.T2^A#Y$/N0^)#ZD/F0^U#X4/I0^5#[T/C0^M#Y
MT$]`)42.`$C(J1PAYL\B=HV87G*^F*R1(/!6P.HE)I##SKB0SKR<C"%C4B`1
M)(8DD!2207)(`2DA%:2&-)`6TD'ZJ:@<R10B1^9,?^"!S0PCQT;I."9D&9SJ
ME*R&H'U9&T/&K$$B2`Q)("DD@^20`E)"*D@-:2`MI(/T4U%9DWE66=N_HDST
M+CEV4E>#G(X'N34DA$20&))`4D@&R2$%I(14D!K20%I(!^FGHB9>+E;4Q)OK
M`'-(.W"YF&%T1@:1?\8%%/B7!NLQR"8RA$20&))`4D@&R2$%I(14D!K20%I(
M!^FGHI(DUU<J2?M7AXG6N1ADLCH@(22"Q)`$DD(R2`XI("6D@M20!M)".D@_
M%37Q<F%\P,2;:#WQ@TPF'A)"(D@,22`I)(/DD`)20BI(#6D@+:2#]%-1$R_[
MR0,FWD3KB1]D,O&0$!)!8D@"22$9)(<4D!)206I(`VDA':2?BIIXLS%7,__*
M$\)N')T32W(1,#DE>-=4:Q<UGA-($2DF):24E)%R4D$J216I)C6DEM21>D4Z
M;V83.=W0[S]'!"][3KF^M;.\LC19,Z20%)%B4D)*21DI)Q6DDE21:E)#:DD=
MJ5>D<V'VCP?DXF6[J7(QT#07H-`4PLQQST5%I)B4D%)21LI)!:DD5:2:U)!:
M4D?J%>E<F(WB`;D8]I73=3'=:N[*4VM32-03'Y(B4DQ*2"DI(^6D@E22*E)-
M:D@MJ2/UBG0NS/9OFHO7%AV';>0T2>/.<GIN\4LHIK[BYPT4,2HF):24E)%R
M4D$J216I)C6DEM21>D4Z;V;W.,W;3\XMPV9SFI[I_G-80Z#05%MT>B)23$I(
M*2DCY:2"5)(J4DUJ2"VI(_6*="[,)O&`7`Q[RFDN!G)GC;5YR4)/?$B*2#$I
M(:6DC)23"E))JD@UJ2&UI([4*]*Y,/O&`W(Q;#.GN9CN/(=U`0H#4$2*20DI
M)66DG%202E)%JDD-J25UI%Z1SH792DYS\=ISR[`EG29IW*5.SRWGNA:\-B^B
M^6L(%#$J)B6DE)21<E)!*DD5J28UI);4D7I%.F]F)SK-VT_.+</&=9J>Z5YV
M6$.@,`!%I)B4D%)21LI)!:DD5:2:U)!:4D?J%:E<+/R]__Y<[,+U%M_2Y-Q"
M"DD1*28EI)24D7)202I)%:DF-:26U)%Z13H7A^WG%]S/6YKF8HAR%#(J(L6D
MA)22,E).*D@EJ2+5I(;4DCI2KTCGPNRSI\<H<VY9RF(Y\$62Q;!?GQR\+,DN
M9%(3N_#.+2[*5FM"4D2*20DI)66DG%202E)%JDD-J25UI%Z1SIN_]W_E-<%B
M+`JX)"T#;W.YLE'35'HQ:Q?C$HE:0L2HF)204E)&RDD%J215I)K4D%I21^H5
MZ42:3?IT`?[DQ#3LZ:?K;"!WY%LO0"$I(L6DA)22,E).*D@EJ2+5I(;4DCI2
MKTCGPFS2I[G8'0POS=LF#SX>#OO]:9X&DAW/Y'AXZ1\/QRBWC$"1N4?FBMR]
M\RDF):24E)%R4D$J216I)C6DEM21>D4Z=8?5#A:L'5B:+B/6#A@5D6)20DI)
M&2DG%:225)%J4D-J21VI5Z1S8?;TTV7TDT/:4`*8+I6!EN-+..L%*"1%I)B4
MD%)21LI)!:DD5:2:U)!:4D?J%>E<F'WZ-!>OO4X8]OMRW!D/7LO`*Q2L%F-5
MP$7A.F&,<0<X4.1&LE$Q*2&EI(R4DPI22:I(-:DAM:2.U"O2B32;_&DB?[*H
MAIK`=%&A3+!>@$)21(I)"2DE9:2<5)!*4D6J20VI)76D7I'*A=D?'9"+7;@N
M)EB2@]JXG(+@RKL6<%%V$82DB!23$E)*RD@YJ2"5I(I4DQI22^I(O2*='K^^
M\,ICWG(L/+@D+0-O`[NR47+)/:;2/^:Y&)=(U"LB1L6DA)22,E).*D@EJ2+5
MI(;4DCI2KT@GTB].[#_F+5F#L#2YJ".%I(@4DQ)22LI(.:D@E:2*5),:4DOJ
M2+TBG0N_X/"37(QU!?N,7YD/&;WL6=Q""19O_6/>&&4[AJZCI8@4DQ)22LI(
M.:D@E:2*5),:4DOJ2+TBG1ZSXY]>'KSVF#=4#O1UGK=)72W'^H)+)8YY8XS-
M6NBZ68I(,2DAI:2,E),*4DFJ2#6I(;6DCM0KTHDT._M?D<BA0C"Y`%P.)+O:
M\4RUY$7'&&63%+J.EB)23$I(*2DCY:2"5)(J4DUJ2"VI(_6*=-[\`L1K%^!8
MF9@DR3]*KI9C9<)%80&.,39KH>MF*2+%I(24DC)23BI():DBU:2&U)(Z4J](
M)](4&G[%`AP*%M,%.)`DQBW`A?=YN?5RC+))"DD1*28EI)24D7)202I)%:DF
M-:26U)%Z13IOIHCP*_(V%"/D,#@F*;CPDK1:CB4+%X4%.,:X1((B-Y*-BDD)
M*25EI)Q4D$I21:I)#:DE=:1>D4[D896.)2L=EJ97_:QT,"HBQ:2$E)(R4DXJ
M2"6I(M6DAM22.E*O2.7B]+!*QRY<5SHLR4'-+:>%]SGZM8NRBR`D1:28E)!2
M4D;*206I)%6DFM206E)'ZA7I]/RB2L?I7*5CX7UR?F6CY,)^3*5_S',Q+I&L
M=#`J)B6DE)21<E)!*DD5J28UI);4D7I%.I%^I<-</9H*UX%OPSAE"<22ONC`
M`APZGH^ON(2NHTUE1(I)"2DE9:2<5)!*4D6J20VI)76D7I'.FU\5>>55_^E8
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M782DB!23$E)*RD@YJ2"5I(I4DQI22^I(O2*='E-$."`]0\UAFAZ4(=:GH)`4
MD6)20DI)&2DG%:225)%J4D-J21VI5Z1S<5BQXI3%"DN3]SJ10E)$BDD)*25E
MI)Q4D$I21:I)#:DE=:1>D<K%V6'%BEVX/H58<N>+-2DD1:28E)!24D;*206I
M)%6DFM206E)'ZA7I7/B5B?VG\[.Q`&'/!"M+LE,9JPW!PGOWQ=I%V8XA*2+%
MI(24DC)23BI():DBU:2&U)(Z4J](I\>O-_PD/2PKG`TT72J@D%$1*28EI)24
MD7)202I)%:DF-:26U)%Z13H79B_^]T_G9\/6?7(ZMS0YA9!"4D2*20DI)66D
MG%202E)%JDD-J25UI%Z1SH5?!OC)NN!N_VR@Z;H`A8R*2#$I(:6DC)23"E))
MJD@UJ2&UI([4*]*Y,+OF`];%L,F>KHN!]"G$JZJMS\8H=PH!18R*20DI)66D
MG%202E)%JDD-J25UI%Z13L]A&_8S;M@M39<*]O`AHR)23$I(*2DCY:2"5)(J
M4DUJ2"VI(_6*="[,1OJ`I3+LNZ=+9:#I*004GH$B4DQ*2"DI(^6D@E22*E)-
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M*EQ+_P,1+FH\MY`B4DQ*2"DI(^6D@E22*E)-:D@MJ2/UBG3>S*;[[U\2GP][
M],DEL:7I&N).GE$1*28EI)24D7)202I)%:DF-:26U)%Z13H79CM]0"Z&W?<T
M%]B0K\]!(2DBQ:2$E)(R4DXJ2"6I(M6DAM22.E*O2.?BL&W[.;?MEJ;K@MMV
M1D6DF)204E)&RDD%J215I)K4D%I21^H5Z5R8[?0!ZV+8?4_7Q4"[7XA[^8*X
M<U!H26UBEMY;VB,794\TL24W?$)*+>GAO7>/9B[*#I];<L,7I-*2'MY[`V/E
MHNSPM24W?$-J+>GAO;=G=2[*#M];V@VO\WI8">"<)0!+[JZO22$I(L6DA)22
M,E).*D@EJ2+5I(;4DCI2KTCGXK`2P#E+`)9DLSJY3//?]N6B[!,D)$6DF)20
M4E)&RDD%J215I)K4D%I21^H5J?1<'%8"V(7K$H`EG1[_K48N:DP/*7(T3;7W
MFG/LHNQ8"2DE98[V#)^[*#M\02H=3<?R7MNH;-1B]_N%5Y>+\W/_)?3:QKAC
M34-J'>VYO<Y&[;F]WL;PN'EQ6`UB%^X]&8:RA'XR^.4ZV]$]XI`4.9H^8CP9
MQENTV4I<1TLI*7.T9_C<1=FQ"E))JBR]9.+\XNW%XLP[9M4VQLU#0VI)G:4]
M@_<V9B;-AY4W+EC>L#2Y!"6%I(@4DQ)22LI(.:D@E:2*5),:4DOJ2+TB??R5
MRQYU"?K*#S!<F'%V:]$]FY<+[RB\LE'3BH?WI%R[&/N,#TD1*28EI)24D7)2
M02I)%:DF-:26U)%Z13J1?KWCE76J"Q9"+,DF;[P`6OJGD;6+<GD;QG(?*HH8
M%9,24DK*2#FI()6DBE23&E)+ZDB](ITWOS;RV@4X%DVF2?*N!U870]3>!3C&
MN$2"(C>2C8I)"2DE9:2<5)!*4D6J20VI)76D7I%.Y&&%E0L65BQ-SVHLK#`J
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M'G_)DL=`YNW2XP7)<NF]R+)V46X9O8PE'2U%C(I)"2DE9:2<5)!*4D6J20VI
M)76D7I%.W2^J@ES.54&6WDM5*QLU3:5?!7$Q-FLA*2+%I(24DC)23BI():DB
MU:2&U)(Z4J]()U+F5)6S]G]^X]*$ZPJR);=<UJ20%)%B4D)*21DI)Q6DDE21
M:E)#:DD=J5>D<V&*!M-7M_\?Q\.A_C`];PTTW:`ME][+MNO+,<HM(U#$J)B4
MD%)21LI)!:DD5:2:U)!:4D?J%>G4'5;+N&0MP])T&;&6P:B(%),24DK*2#FI
M()6DBE23&E)+ZDB](IV+PVH9EZQE6)J\,9<4DB)23$I(*2DCY:2"5)(J4DUJ
M2"VI(_6*="Y,36!Z2/O)Z64H(4P/6Z@JK"]!(2DBQ:2$E)(R4DXJ2"6I(M6D
MAM22.E*O2.=BKO9@/O%\X%>F7;+V8$FNYL9K[>`4EVA#1[>L0M?1GFXB4DQ*
M2"DI(^6D@E22*E)-:D@MJ2/UBE3>KOS:P_XUM`O7EVB6)N<64DB*2#$I(:6D
MC)23"E))JD@UJ2&UI([4*]*Y.*Q\<,7R@26W"-:DD!218E)"2DD9*2<5I))4
MD6I20VI)':E7I'/AEP]^LBY8(K@::+HN0"&C(E),2D@I*2/EI()4DBI236I(
M+:DC]8IT+N;J`<M7E7*NQI*`/26L+.G3B_=>B;6+LAU#4D2*20DI)66DG%20
M2E)%JDD-J25UI%Z13IU?`7AE:?MJ+`VX:X#E6^\:8&6C)'B\4O!BUB[&)7(8
MW*W4B%$Q*2&EI(R4DPI22:I(-:DAM:2.U"O2B33[].FU]FL3.>SW)Q?A5P/I
MUY:0MS'*Y0T4N;%L5$Q*2"DI(^6D@E22*E)-:D@MJ2/UBE[R=O+T9;-Y#F^?
M;S^\>]@\?MZL-U^_/AW=;?_X)FLC"`)Y#^KH1X^;3^^/;ZY.KV]D*)DZKT56
MUK5Y<LRUG$G+;)_+RVNS89CI<WDE+5=S+5=O9;3=>Q1Q#P)I"6;[+*1E,=NR
ME);=M9`WVLWEV^L;*4#/W3>Y!_(*SUR+W`-YO6&N1>[![&@WETN9T;E[(&5G
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MEJ7,Z.QH-TN94?GYN+D^,J/R&XQS+3*C\HN`<RWRC)\=[68AJT1^CGBFC[3T
MB]E[L)`LR*^RS_61+,B/?L^UR%S+3U#/M<A<S]^#0%I>?C+=/QX$,M?![%P'
M,M?![%PO9*X7\YF3&5W,SNA"9G0Q.Z.!])%+I)G'$TB?8+Z/S&@P.Z.!S&@P
M.Z.!S&@P.Z.!S&@P.Z/29;:'=)B-EVF>?0;(),_.L4SQ[`P',L/!W`S+)UJO
MS>=5.5OR8=1K\U%3MLCG2*_-IT39(A\!O38?\&3+C2R:^9F7.S83OS+IG7.S
M7&;\1@Y,\T\'<]XP'4[&9^K3AW??;S]OJMO'S_??GHZ^;C[)5?7;-^8-R8_W
MG\WFZ.5_GK??Y6K[^.BW[?/S]F'WYY?-[<?-HPF0X$_;[;/]'W,#/[:/O^^N
MW#_\6P````#__P,`4$L#!!0`!@`(````(0!X.%L[.P\``(Q+```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;*R<VW(;-Q*&[[=JWT&E^U`DAZ1(ENV4
MQ3F?9RJ[>TU+M,V*)*I(VD[>?AL<-!O`/U'$)+D(K0^-'X<&,(/&S+S[^;>G
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M\N%W?W.XIQXEF<%XJI3N=X]4`?K_U=-6#0WJD?5OI]\?VX?CU_?7WFPPO1UZ
M(S*_^K0Y',.MDKR^NO]V..Z>_M<9C;14)S+6(O2K1<:W@]%D.+M`@TH[581^
MM<9\,)].)[/Y[=LK,M,B]*M%1A<WAF;&J2+TRXUY<T<L=%[ZU7G?7O>1IS.K
M?UR>FYL^DK:3.][HP-$METW_T&4OWMS]-]V8.@U1?WU<?WBWW_VXHGE/H^;P
MLE:KR&@YHO[DP=D-I?-P_:/12L-4J7Q4,N^OJ68T$`\TQ;Y_\":W[VZ^T[2X
MUS9W:#.R+59LH>:`DO5=$+@@=$'D@M@%B0M2%V0NR%U0N*!T0>6"V@6-"UH#
MW)![SCZB0?)/^$C)*!]Q[]XQ$*>-'8>P!6?Q71"X('1!Y(+8!8D+4A=D+LA=
M4+B@=$'E@MH%C0M:`U@.H=G_3SA$R;R_ID*,23.W/7#7V8PFAM'4-EF=3<Y>
M`A(`"8%$0&(@"9`42`8D!U(`*8%40&H@#9#6));3J`O!:1-:^_LOP[RPJ5QT
MP36ZWYLL;`?<=3:O^NAL<O81D`!(""0"$@-)@*1`,B`YD`)(":0"4@-I@+0F
ML7Q$[@`?J5NE"Z]&2H8N:/0C,VLZ=+RFC:@N9R-W9IU-SEX#$@`)@41`8B`)
MD!1(!B0'4@`I@51`:B`-D-8DEM?H=L;RVNLS2EF?G,.=>J?)Y'QE6@'Q@01`
M0B`1D!A(`B0%D@')@11`2B`5D!I(`Z0UB=7Q=+]U0<<K:[OC-3$Z'H@/)``2
M`HF`Q$`2("F0#$@.I`!2`JF`U$`:(*U)K(Y76W/SKOGU$:^L[8[7Q.AX(#Z0
M`$@()`(2`TF`I$`R(#F0`D@)I`)2`VF`M":Q.IYV;1=TO+*V.UZ3TX;]M,58
M`?$U\<[+40`D!!*!3@PV"9`42`8Z>4<\ZI/SA6I\Z]E7L^)LQ*MJ":0"Z5H3
M:6H#I#6)Y8L114(N<,;)W/8&(\,=B'Q&4LL`48@H8B3R,2/12A"EB#)&HI5K
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M_M>['5VQ:5WMN3WT*$BJ0Z=Z-VRZ6R.I_DI%%UQW=T@%\,\W!J.%TZ)`9R0K
M;E&(*$+Y6*Q$?CQW0K:)6+%\BBA#^1RM"D0EH@JU:K$RJ^JL.(U8<55;"]F^
M5;O=UWS[R^[ECWQ+?7UVKMXT2^_?J;"$\N1IC;;+5!L]L\R><6-JZWVAJ=VA
M,8VY\Y`8SYT+W$J=/U`-QN/SD/`9=8=&*O8>,%(C]?N'T6(^]>9.EX9L(]DB
M1B(>,S)K-?*<)3715MZP.SX8C)V1G(H,^R]C)(7EC*1*A:T\'WA.,TK,4S$2
MY9K1J\UHV*KKMNEB.)\MG$MKRS:G.MI#0&TY+Q@">H=J#H$.3>C'&`).#5;J
M-$D-PKDQ!#1:G%&@K<:3DTL6MXO1T%GN0Q:27!$CT8X9B57"VIV[U4F6??^1
M8IZ,D2CGC$2YL)5'3HU+S%$Q$MV:D>@VHLOCK[6L;$>J+>P%CM0[7M.1'9I8
M^[ZY,VM6ZLS.G<L:R0P(M!7-+7-0.'<&(6M9`WSAW%E%;"4S(V8D)292HEH]
MAH-;I^(IYLD8B7+.2)0+43;;XM2RQ(P5(Y&O&8E\\R;YULIH.U[MER]PO-Y>
MFX[7B'YD!B^<8;P::2L9LSXC&;.!1GH&CQ?3\7P,;C^7Q^,Z8B41CQF9M>I9
MQ#NM<3>KIX,)S&HH+&-E*2QG)"TI--+*M(@[RB7FJ1B)<LWHU68T7%BW\,V]
MX7`Z<\IK18FZS1H"5,=+AL#)G-9B8PAH9%_'%\Z]UXJM9$#[C&1`!XRZ"])\
M-A_/G<D2LHGDBAB)=LS(6A[@,JZM]&5\.%BX$U]D>+AEC*2PG)%4J;"5IX.%
M,Y!+S%,Q$N6:T:O-:-A*7\8GH_EPY'1;RS:G.MHC@,0O6`24G]75V!P!&ADA
M8K82Y",*$(6((D0QH@11BBA#E",J$)6(*D0UH@91:R';%VY4Y2\^XD*WRZ<K
MK;$J>U-G2MYI([6O.*_=SL*Q$AN>`#ZB`%&(*$(4(TH0I8@R1#FB`E&)J$)4
M(VH0M1:R_>A&490?__P`?]S%2>C_9X?@";XV>MUM.N!B3C]`@2BQ<T-$$:(8
M48(H190ARA$5B$I$%:(:48.HM9#M-A6E,.^'_NKTTP$0,]KAP:$^W>B<5M)7
MY]_9AEWD2S9&`:(0480H1I0@2A%EB')$!:(2486H1M0@:BUD.]*-B+P>G5!A
M*?>:9D8^NM,WMI*`M<](@E\!HA!1Q$BT8D:BE2!*$66,1"O7R(FN.D&*0JQX
M))6(*I2O&4E5&T2MA6SW7!8\&F/PB)&T>87(9R3U#!"%B")&(A\S$JT$48HH
M8R1:N4:.>YQ(3R%6XIZN)R@CHPKE:T92U091:R';/2JZ8BZ#?S)[=##&O"/4
M2-J\&@/R&4D]`T0AHHB1R,<:.5WJC/A$K+C_4D09RN=B)9?F\:USMU2(%<N7
MB"J4K\7*E'=V(XU8L7QK(=N)*K)R@1.[0(QU6Z^1]/)J#,C7R.YX-Q`3B!57
M/404H7PL5F;/.%,E$2N63Q%E*)^+E2GO;)X*L6+Y$E&%\K58&?)S9U0V8L7R
MK85LOZJ@A.G7OW20,]:A#7/.:F2Z&Y"O,ZJU_7R/B@<Y8L4M"A%%7`DI,18K
MD1^[V_)$K%@^192A?"Y6AOS</;<3*Y8O$54H7XN5*>\,UD:L6+ZUD.5N%09]
MU=UO.]LYR=B[=HTF$K=:L94XQ-=H*D&)`%&(*$*M&*T21"FB#+5RM"H0E8@J
MU*K1JD'46LCVT641%`\C*!JIP,!Y5N%9&%N)+WQ&$GH*&'71H,7LUAN[`=F0
M;21;Q$C$8T9BE6A$?7$Z:!L,G<.:%/-DC$0Y9R3*A:T\&<SG"_,_9TDN4:%B
M).74C*2<AE'7/9-;;S'SAHYZRT:G?+:OW0C-Z_=&GGZBQ5AG-;(/O=SXX(HS
MRIV>ST@F;*`1;824.^@-N<78N6D(,5?$2+1C1J*=L';GZMN!>S*88IZ,D2CG
MC$2Y<)4GSB`J,4_%2)1K1J+<B/)Y:;6L;%>JB,C?OI)Z.JYB>KA#?W(:IC-2
M$(GKZC.2X1IH-#5/PRC$;Y\_AI)1UH^1>Q,6L964&#.2$A.-SE-\XER_4LR3
M,1+EG)$H%Z+,+2[1JF(D6C4CT6I0J[6L;$^K*,K?][2.Q9B>UHCNDV3==E?;
ME:>M9.SZC&3L!AI-1]T!MHKB3V$RG\OC'HQ82<1C1F:M\/A+6]'!0+>4>\YM
M:2HR7%C&2`K+&4E+"EMY,I@Z(ZC$/!4C4:X9O=J,A@OKEL#IS)N-/?<<O14I
M:HH]--Q(D7L[_<;[*XP@>1VRK^EP+L96,MI]1C+:`T;ZFCY:3(>W3J>&;"/9
M(D8B'C,R[S1ZQD97]_,:,)J:UV+W8I6*J(P4W7HI.D>K0B-=SF0P<6[%2\Q3
M,1+EFM&KC6K82A^3S49SSW,?06O9Z-2+]DBY+&CE8="*D43E5XA\1`&B$%&$
M*$:4($H198AR1`6B$E&%J$;4(&HM9/OBL@@5?3'!C>\R,GVAK03Y:!4@"A%%
MB&)$":(4488H1U0@*A%5B&I$#2+UT0E]6'%>0;N/2'1OZ#]M]E\VJ\WCX^'J
M?O=-?2!BMJ#KRAGKKU>,)\N/I$023LH=I:AX?D^*-Z-/7LQZ4V[Y8QBNVG39
MGJ[2+B>I7B42ZJW5?-F>+DBNSI@^PT$+>T]MQV-*.2U-3A[:22_5/AGST+YX
MJ7:]F$*[W*7:PV(*[5FI[7TI](60CWWEWU&5^VM,%>XIX<ZC`OHX.:K/3Q^G
M5&Y?`10A7*I@'S:"@GM+%:?#%(K++56(#5,HI$;U[4NAT!25<[H-<;J>HDI4
M3E\*!82HG+X4BN50.7TI=*I`Y?0-(SHCH'+Z4BCB3^7TI5"PGLKI2Z'P.)73
M-RPIV$WE]*50G)K*Z4NA$#.5TY="S[<OU4//V-?TF/M2/=6,*?30^E(]W(PI
M].PZC;.^@4-//E-*7QXZ1J.6]DU8.A2CEO:ET!$7M;0OA4ZGJ*5]*7=CJAN=
M_F*M[ZC6=[UUHW<7ENJ!=LQ#KS`LU=L(?2D32NG+0Z\J+-7SZYB'WEA8JI</
M^E(FE-*7AUYGHG+ZYAR]G$1Y^E+HO2+R:5\*O1)$_NE+H9=PJ)R^18+>GZ%R
M^E+HU1<JIR^%WEJA<OI2?)K`?3,NING;QW.:O'V\IJG;Q^GM/&I'WZ))[]I1
M._I2Z,TY:D=?"KWT1NTXI=R<%QSZ%M++^LNF6.^_;)\/5X^;SW0II"=*Z6YX
MWWU-J?OCJ)_(_[0[TE>0*#!+7[.AKUYMZ&'VX8",/^]V1_Z#AL3-^3M:'_X/
M``#__P,`4$L#!!0`!@`(````(0"?Z9JBCP0``#`0```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;*Q7VX[B1A!]CY1_L/R^&%^XC`6L,,;)2ALIBC:;
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MT?3+'B%P]BSO;%#@[];9DT-^J?I_Z.N?I#R>>I![`HR06+Q_3TE70$4AS"@8
MTBAH!0G`;Z<NL36@(OG;T@U@X7+?GY9N.!U-9N/0!W-G1[H^*S&DZQ27KJ?U
M?\S(QZ1DD(@'@4\>!,(]Z`NK#`G`)_>=C^:3232=SSY,P&-DAMJD>9^O%BU]
M=:#A(-WNG&/[^O'4=411&`59IA]5"9AAD#5&6;HSUX$"="#MRRJ,)@OO!>0H
MN$UBV_BZQ4988,$P;&H"6Q/(%,`#1I(65/47T,(H2$LDE`C@RC,P.`@+X9*:
MP-8$,@70.(0VAQ"Z_G:_"B70"3I342((3"68C0\]*.4R3#;21/*PD*V%9"JB
M48&E?H$<&`7Z%)I=YAU&4UV`A!O=(R=-)#D+V5I(IB(:.<A')7=?'S0>.(BU
M$XY$LLLV%I):R-9",A71\H-M_7A^:*SGQY'PFI^%I!:RM9!,1;3\X-AX/#\T
MUO/CB%(_"TDM9&LAF8IH^>$%P#HB1WCF]J>R>$XH._5OZ!["4<@.2(RAI\T1
MV-"RF?V)T<P;:22Z)64(3AS%;:;O@:TT$FZ9&D@C]W2?W#=ZAK0_.G0PB,Z.
M(_-KTUA(RI$G:;-E2##,\:%NF6JCY>U#X4Q5@BE.[@\.R,%13Y9#`?"410U"
M\V075H',-Q60ZNB'<T,-887=\+*:3<;PHYMDPF2X+.@\<<(9W?<83W0T>'((
MBJKP#/5<-CZWNFJ7"DB1BD-!=(>47`[:4">%(^^G2+%9R:Z)0X<D/H,,\2*3
M%+=2Q9..8I=L12RFE#\H94FENNFL</S]%"L^-]FM$V\^B<\A72IS2@LK52KI
M>&7%("Z5?[L!53>=%<X]A=6-8PXVG3CG\%)A=AV##(',DXX[!JI`TO%*A4-W
M!5+=="HX(A^G@M;&!N*0KHIQ^F[P@H*.JBK2\4J%04*5V[VFNC$J['G#KO`U
M:8]D0ZJJ<PIZP:<+G".KA839NRJ=QS`08%T#A_?6>JBV@2?X#KMAGP0Q7%7M
M.$D8P\7/QM=1O&8;U5P@BN$R93LDDQ@N,3?P:0R7AQOX+(:A#;@G%X#WVCD_
MDK_R]E@VG5.1`Q1E/,SJEKWXV)>>C[4=[>&E!G6#EP^\S`ELO?$(BGZ@M!=?
M<`'YUE_]#P``__\#`%!+`P04``8`"````"$`'5=.SF`#```=#```&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6R45EMOVC`4?I^T_Q#EO20.4`HB5'15
MMTJ;-$V[/)O$(5:3.+)-:?_]SK%#E@N,Y"60P^?O7#]SUO=O>>:\,JFX*$*7
M3'S7844D8E[L0_?7SZ>;.]=1FA8QS43!0O>=*?=^\_'#^BCDBTH9TPXP%"IT
M4ZW+E>>I*&4Y51-1L@)^283,J897N?=4*1F-S:$\\P+?O_5RR@O7,JSD$`Z1
M)#QBCR(ZY*S0ED2RC&J(7Z6\5">V/!I"EU/Y<BAO(I&70+'C&=?OAM1U\FCU
MO"^$I+L,\GXC,QJ=N,U+CS[GD11*)'H"=)X-M)_STEMZP+19QQPRP+([DB6A
MNR6KAR!PO<W:%.@W9T?5^.ZH5!P_2QY_Y06#:D.?L`,[(5X0^ARC"0Y[O=-/
MI@/?I1.SA!XR_4,<OS"^3S6T>PX986*K^/V1J0@J"C238(Y,D<@@`'@Z.<?1
M@(K0-_-YY+%.0S=83.8+?TH`[NR8TD\<*5TG.B@M\C\61"HJ2Q)4)/!9D4QO
MAY)X-B"3WR/5=+.6XNC`T(!+55(<0;("XO,)02:(W2(X=!>N`[$JZ,+K9NK/
MU]XK5"ZJ,`\6`\\:0VJ$!TYKS^!MN&<$HV<L+8;R8`U--\%Y-],Q;A`<NO"L
M@Y_ZMS6O]6PQLP;F7PE:"0)D>(((AA[`-#1<+SJN+6B`:Z`9[AK!QG5=7&N9
M&4DT6W8[AA;!;=K*TFS:U+^K<VP5#X9L>`8(;KNREGX&>"$/'G<$MVFMI4^[
M'$.+X#:MM?1I"5Q4S7#QVIE!<ZZH%$^U'1@B.-N:KN7YRA-4\.`:&73'&1*@
M,[Q1F^-#1DG>H#O,5O7S:9]ZE,R)U3"HK1[YRG0F:!1=HQSFZ@^@Q%>:8+7:
M<F%-K280_T(31BD8KXUNQR]IF(P2L4%WFF!E?*X)HT1+^JJM3&>:T-&M:<+R
MNA+Z"B8G"3?N67+A'XJ,DK5!=TIU2=@X/\VA^O\L&72;N3*=:4(P2KX&W:&^
M)%]8L%I!FR;X5YM@CG5<6!VWE=#]_[;+F%U6<B;W[!/+,N5$XH"+5@#K1VVM
ME\"MV0&[]MEJ"T'@;53_`LM92??L&Y5[7B@G8PEP^I,%9"/M>F=?M"@A=%C1
MA(:US'Q-80UGL(+X$P`G0NC3"SJH%_O-7P```/__`P!02P,$%``&``@````A
M`'77!.ZC"P``A3@``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK)M9
M;R/)#8#?`^0_"'H?27WHA.V%W7<C`8)@DSQKY+8MC*4V),VQ_WY9W<5FD>S1
ML9F7T?AKDE5DL8HL'7>__=B]#[Y5A^.VWM\/O=%D.*CVF_IYNW^]'_[G]_33
M8C@XGM;[Y_5[O:_NAW]4Q^%O#W__V]WW^O#E^%95IP%8V!_OAV^GT\=J/#YN
MWJK=^CBJ/ZH]/'FI#[OU"?X\O(Z/'X=J_=PH[=['_F0R&^_6V_VPM;`Z7&.C
M?GG9;JJXWGS=5?M3:^10O:]/,/_CV_;CB-9VFVO,[=:'+U\_/FWJW0>8^+Q]
MWY[^:(P.![O-JGC=UX?UYW?P^X<7KC=HN_E#F=]M-X?Z6+^<1F!NW$Y4^[P<
M+\=@Z>'N>0L>F+`/#M7+_?#16Y53;SA^N&L"]-]M]?WH_']P?*N_9X?M\S^V
M^PJB#>MD5N!S77\QHL6S0:`\5MIILP+_.@R>JY?UU_?3O^OO>;5]?3O!<D_!
M(^/8ZOF/N#IN(*)@9N1/C:5-_0X3@'\'NZU)#8C(^L?],("!M\^G-_C?;#2=
M3P(/Q`>?J^,IW1J3P\'FZ_%4[_[7"C4>=49":P1>K1'_:ET8I9D`O%K=Q6@Q
MG8:SQ?SZ"<RL$7C%"8S\Q=2;SF[P`K9$,Q-X12-7>[&TNO!J=9>CT)_.%[>$
MT8/5;V9@_H-3N-J/<;NR3:+$Z]/ZX>Y0?Q_`[H.U.WZLS5[V5L8RIDB[H%W2
M_"QG(%F,E4=CYGXX'PX@'8Z0Z-\>@M"_&W^#Y-Q8F2<MXW&)""5,)AJSL02)
M!*D$F02Y!(4$I0/&$)8N-I"GOR(VQHR)#7KUA("")4(5H02JQ!(D$J029!+D
M$A02E`Y@@8#]_RL"8<PTATF7)-YBR5/@J97QX+#HA*9<).I$NN@HDBB2*I(I
MDBM2*%*ZA`4)IOPK@F3,P&:$XZT+0!`&/`1/5NA<E#J1+DJ*)(JDBF2*Y(H4
MBI0N85$"OUB4^DL1'BM&N@D&.O%D2=CMIDB16)%$D5213)%<D4*1TB7,4:@V
M-SAJI+FCE@3DJ"*Q(HDBJ2*9(KDBA2*E2YBC<.C?X*B1YHY:XJRH(K$BB2*I
M(IDBN2*%(J5+F*.F*]:E<F0ZD=/;=O/EJ88="[6D)Z4#*(EMH31&N/^6-)U<
M(Q,I$K?$M"O=H>`MQ:&0=$*X65)E*%,D[[1<TR$_;XI."$V7KB$6)6ARSD;I
M]_KC9U$"_S!,Q@H/DR4+V@^*Q)8L.YFD)3X%-U4RF;*3*YE"V2E=&18`TT6Q
M"/3D@^-I(\Y=M<B'<NPLMRR#)(6+$B-J&W#3026(3`9^>_"6L\7,%XF3H@RI
M98C\+I0Y(LAPFE6P$)F"4NUXL_ED[D_%S$N4:<;CL3.MF+O'+L2N[=R@6&((
MGCR+G#S1*$;D9(I%;JIHJ0P1F<\1D:U"VRJ9%/?9=%VNSZ8%]V?F1M9WE+BI
MT_9KS/T6^6R1)J+)BCPK1:L;(Z(<2"P*()]IP9<SON`I*;I2<RZ5H12-F".B
M$8O^$46*E:38/R*/KNG7W.A>R"C;WKD991$M>>0I%".B+$@L8AEE%4DJ0T4R
MGR,BJ4+;*ID4]]ET7Z[/[:7NQDIE>G!Q!EO$LVNILJM5A.,+=V5L%0,J\@DB
M5M,"D3<IC8BV,D1D/D=;9+Y`-&O.O7#F>\%LPI.R1$L]YQ#,ZFP$KZMBIHN7
M(;2(ECM"*4(Q(LJ`Q"*63=86266H2+9R1"15:%LED^+99#J__S^;;/_H;JP6
ML3(';Q#R18J\3@HS(+8HH"MU@LAOR]Q\'BYGXE*=HB4Z<#)$;BZUXX%QYW31
M9<Y*M>,M%_YLYHO<+=%X3WJ9'O-<2*],+]NJNC%UN]>VF_04BC5*-$HURC3*
M-2HT*AGBZ64Z21T+?$OQ^G>@;$<*>Z*K5D$H&MDGSTK!$=5)B?8D(AG*N$X-
M4:*E4HTRC7*-"HU*AGC`3.?I!NQ"1;.-JILD%CEW2T^A6*-$HU2C3*-<HT*C
MDB'F,YQZM_C<B/.>&A'=!"*-8HL"6.XN/?R)Z)<3DL)L2+6M3*.<%%WS(D<+
MDD+S);/%(R,[YK]4ZTU%%X4*D1LP*T4HME)-4_KMP9]XPIF$!-"95%O.-,I)
MT5Q<P+)8A8($T'+)S/`P]379WI1:HNM.7%.K9)PLHHH;H12A&!$5X<0B6%J<
M?ZJE,D1D*T=$M@IMJV12/!:F"74/D*LO'+YM7YVSQ"(3>6?'R",5I:C.QHA<
M14_6V<1*P1W$9,%\Y,NB3F8PBADB&BQ'=':P@@\V'<DWITLR`X/QF,J6^_RA
M[.O>&A$_>L1M*R(I=#=&!"=XMP(]@;1->1M(?Q2*6U5*9M!RALC-/3OQLX,5
M5A%2N]F[:K`2+3<IS`-I>EHW.2\$TK;`;D:V2&2D:,XB<[N&G0R[!-V-$5%_
MF%ADT\\;>>*NDY(.!=^?B-AF*$6#Y8AHL$(.IAI*TND?C`?2=*@W!+)M:.$:
M@/%X\BURU]I7[R6@%"5)C(@.J,0B4\>Z)/4]T>NG6C%#1.9S1&2^Z#<O/EXL
MF2(/EFS(+V2=;KS]%O&L\\1I%:$4)4*,B!(AL0@//5'X4M)P8JESSDZ(ALI)
M$=>X.#]421K]0_$@FB;YAHRS/;6;<1:QC).%/_*M%*5$C(A2(K&(99RGWE_0
MBADB,I\C(O/%5>9+ILB#!3ZR8%U?A(VF:&Y;)))/M&*1;Z4H(V)$;O*U4C;Y
M?%')4]+HSXCFSIFA%`V5(Z*A"HM^,E1)&OU#L7B"D;\8ST:3QQ,1))IS6HE0
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M13`;/#HBBV`&:H_+=M'$(5A<\9&=>5M9GIDMPCC(EM%JB#C0#8/'P;1&-YS@
MMI-R6C#SUA=,D,6A17UQ,+V".YR)PQR^(GKIDTLPK\)@^PZ;#J+IC:R&"`,=
MRRP,1HK-ZWQR-N*\D"&B71=I%&N4:)1JE&F4:U1H5#+$?3:EUUV+"SZWE=J]
M[X46.6>P1K%&B4:I1IE&N4:%1B5#W.?;:FVH:RTB=YVM%*%82R4:I1IE&N4:
M%1J5#'&?9:TU>PZ^1'[ANP*AKKD6X<$CKPOVL<DX&*']4J_OTY6=S^JV:ACJ
M:F@1+'9W`"/2!W#85XBN.H`;3;'7>2$2365D-40<J%SQ.-Q6B$)=B"QB<6BE
M8`:R$(5]A>BJ@MQHBCCP0B2[=JLAXD#EBL?AMD(4ZD)D$8O#3PM1V%>(KLL'
M78D:8TT)-+>,3]1RM)^GVL<B#E2O6!RFMU6B1IRO"B(ZCB*-8HT2C5*-,HUR
MC0J-2H:XS[=5(G-VB98(D5.)-(HU2C1*-<HTRC4J-#*_U6FFVLRK];G][4W[
MDXI==7BMHNK]_3C8U%_-[VK@_;.'NPZW/_IYFG:_^A%/'KW%ZA'&@%TNGL#G
MUBOSD7#?DR4\:;I6J1/X*W-GZ]$)`GC2.*%T0GC2I)I\$DY6IOOHL1:"/^TV
M53HP`ZAD/3I3L`89I)_`3Z(>>S5@D-[(P!"]\L;%/OOAZA&^C*`'?@+/>QV?
MPDS[Y&<K^$YTCYWY"KY"W,,]>-`[<KQ8P7=WM4:^6,$7;S6'3ZE7YC-H_00^
M8%Z9CX_U$_B@%G3Z`@@?M().\V3<K1_\".QC_5K]<WUXW>Z/@_?J!9)YTMSS
M#NW/R-H_3O;+O)_K$_S\"PXN^`$1_-RO@F^>3LPMX*6N3_@'3&K<_8#PX4\`
M``#__P,`4$L#!!0`!@`(````(0"E<J"*N`,``'P+```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;*Q6WV^;,!!^G[3_`?&^$"#D!THRA0#;I$V:IOUX
M=L`)5@$C[#3M?[^S#2Z&;NU#^U#*U[N/^^[.Y]M^?*A*ZQZWC-!Z9[NSN6WA
M.J,YJ2\[^]?/],/:MAA'=8Y*6N.=_8B9_7'__MWV1ML[5F#,+6"HV<XN.&]"
MQV%9@2O$9K3!-?SG3-L*<7AM+PYK6HQRZ525CC>?+YT*D=I6#&'[&@YZ/I,,
MQS2[5KCFBJ3%)>(0/RM(PWJV*GL-787:NVOS(:-5`Q0G4A+^*$EMJ\K"+Y>:
MMNA4@NX'=X&RGEN^3.@KDK64T3.?`9VC`IUJWC@;!YCVVYR``I%VJ\7GG7UP
MPW1C._NMS,]O@F]L\+?%"GK[U)+\*ZDQ)!O*)`IPHO1.F'[)!03.SL0[E07X
MWEHY/J-KR7_0VV=,+@6':@<@2.@*\\<8LPP2"C0S+Q!,&2TA`/AM541T!B0$
M/>QL#SY,<E[L;'\Y"U9SWP5SZX093XF@M*WLRCBM_B@CMZ-2)(N.!)X="="]
MTA>^(@.`9^>[GJV#8+%<KUX,P%%B9&YBQ-%^V]*;!?T&X;(&B>YUPZ5M]4E1
M$G2:_I4E2(\@.0B6G;VR+4@`@\K>[WU_O77NH1Q99Q--;5S3XMA;B-P+VG@,
M)&,@'0`.*-*R(*MO($NP"%E]0%$//.GT1AIZB]XE'@/)&$@'@*'!?Q,-@@5:
M=5`:-YB;04?*QH6FU/4+3).C-M'")D@R0=(A8FB#3[U!?00+-"YTOX[;]S=F
MY%%G]#]QVD2+FR#)!$F'B"$.XAF*>W[`]$='&$L-_;>C#EGHMCM.D'B")!,D
M'2)&?'#.A_&I,S\30X07)+N+J!ICS\3MP]E6)UYPF&%W",QE70PW6)K%.&JC
M7FVL$#%"!VXKTRW11KU;.B0RQ,$0^I^XG[2!L%^:9X+$5-<AZZ>B3)"X0^0=
M)K.4*,23%Y-$TJ&-$;?8,D:#V-^\%*=P,N-4B`<*!^D<C>)C9^1I,?%S;N,)
MGG1&H@GN]ZM@#C]FG5)-`W4RU(&2L3IO*>[9?UR_?9L)/U-@A\!C('!TYH^=
MT5.U8NW6=U"B$&\AU;C/RADZ*3EJNU`W:(7;"S[BLF161J]B<U@#ET;54A,O
M0^A>^.@(AV7G(/,_PB-8@N3*,,:]$"Z**4_DAS!EI_AA$1YD(XYY%B$,KJE]
M%(0P,`!WM`,L/PVZX&^HO9":624^@\2YG!.M6I_4"^^.U(ER6'ODZ2I@R\5P
M@\]G4.$SI;Q_$1_0>_/^+P```/__`P!02P,$%``&``@````A`)?(=K/`!0``
MYQD``!D```!X;"]W;W)K<VAE971S+W-H965T,34N>&ULK)E=DZ(X%(;OMVK_
M`\7]B/C5-J5.M1\(BHK6?ES3B$J-B`7T],R_GQ,@$?+VNNW6WK3X>/(2SIN$
MY/3@ZX_HK'P/DC2,+T-5;S15);CX\3Z\'(?JGW^87_JJDF;>9>^=XTLP5'\&
MJ?IU]/MO@_<X^9:>@B!32.&2#M53EET-34O]4Q!Y:2.^!A?ZY1`GD9?1U^2H
MI=<D\/9YH^BLM9K-GA9YX44M%(SD,QKQX1#ZP33VWZ+@DA4B27#V,NI_>@JO
M*5>+_,_(15[R[>WZQ8^C*TF\AN<P^YF+JDKD&_;Q$B?>ZYF>^X?>\7RNG7\!
M^2CTDSB-#UF#Y+2BH_C,S]JS1DJCP3ZD)V!I5Y+@,%1?=&.GMU1M-,@3]%<8
MO*>5:R4]Q>_S)-P[X26@;)-/S('7./[&0NT]0]18@]9F[H";*/O@X+V=LUW\
M;@7A\921W5UZ(O9@QO[G-$A]RBC)-%I=IN3'9^H`_56BD`T-RHCW(_]\#_?9
M::BV>XWN4[.M4[CR&J29&3))5?'?TBR._BZ"]%*J$&F5(O19BNC]1JO?U;N]
M!U3H?GE7Z).K/-R3YU*#/O^S!ME5YN3V/'3UR5SH;=Z:+LH^]!O];K?3ZS]]
M/J5ZC\O012GS0">>>&NZ>+@36C%&\B$W]3)O-$CB=X7F,8V"].JQ54$W=%I!
M^&`KAH88?O\T^FC8,947)C-4J6<TL%*:,M]'[79OH'VG8>Z7,6.,T>L1$Q[!
MQC23G<I@)@-3!G,96#*P9;"0P5(&C@Q6,EC+8",#5P9;&>PJ0"-[A$<T2/X/
MCY@,\XAG=\S!S;269`B/X$VF,IC)P)3!7`:6#&P9+&2PE($C@Y4,UC+8R,"5
MP58&NPJH&4++`!C2H87@XQ6:SQ'6BM;BRAS1=6D&C(L8O5,)ZDJ>B!!A"I`9
M$!/('(@%Q`:R`+($X@!9`5D#V0!Q@6R![*JDYA&E$#QB;]$'%S8F0VLC-:RL
M;$]U2\9ET#W71(AP#<@,B`ED#L0"8@-9`%D"<8"L@*R!;("X0+9`=E52<XWR
M7'/M_HQBT;DY/*GCDG3$(C<!,@4R`V("F0.Q@-A`%D"60!P@*R!K(!L@+I`M
MD%V5U!)/6Y('$L^BZXDO2;ZSS=_=$R#3DM"4%7-);TLKX$P$<4]-$)H#L42K
MJK3T-K-%$)=>@-`2B"-:5:7;]15@)8*X]!J$-D!<T:HJW:E+;T40E]Y5A6HF
MTO[K`1-9=-W$DE1,!#(%,@-B`ID#L8#80!9`ED`<("L@:R`;("Z0+9!=E=02
MSX[>U5WT_66+1=<37Q(Z*E9FAOSB%T%\($R!S("80.9`+"`VD`60)1`'R`K(
M&L@&B`MD"V17)34OZ)SX@!<LNNY%2>I>2&>9B0@27@"9"5(U5=HZF"*("\V!
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M"T1+1`ZB%:(UH@TB%]$6$:L\W_)5>%%4DHNR7A0DQV`2G,^IXL=OK$I,F1T-
M!"Y*V..N04<!\D#F.JMMYY5@^*7%J][2+].>09MVU+)Z!NVXD3L]@[;+R-V>
M07M=Y%1N?\FK[=)]QZRK'\2/J:,?QK<-JA9\H-\Q7BBI^,.X8]!!E;@F[DQE
M]JMW#%9><@POJ7(.#I3@9H,5@9.B4%]\R>(K)9X*S'%&!?;\\D3_4`FHIMEL
M4/`ACC/^A=U`_(MF]`L``/__`P!02P,$%``&``@````A`*0D+>I+!0``9!0`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)C;DJHX%(;OIVK>@>)^
MBX!'2MW5BHJ*UM34GIEK&J-2+<0"^O3VLT)((%D]CKMJWS3R]<J?Y,_*@4R^
M?Z17XXWD14*SJ6EWNJ9!LI@>D^P\-?_ZL?HV,HVBC+)C=*49F9J?I#"_SW[_
M;?).\Y?B0DAI@$)63,U+6=X\RRKB"TFCHD-O)(/_G&B>1B6\YF>KN.4D.E:%
MTJOE=+L#*XV2S.0*7OZ(!CV=DICX-'Y-259RD9Q<HQ+:7UR26R'4TO@1N33*
M7UYOWV*:WD#B.;DFY6<E:AII[&W.&<VCYROT^\/N1;'0KEZ0?)K$.2WHJ>R`
MG,4;BOL\ML86*,TFQP1ZP&PW<G*:FD^V=["[IC6;5`;]G9#WHO7;*"[T?9TG
MQS#)"+@-X\1&X)G2%Q:Z.3($A2U4>E6-P!^Y<22GZ/5:_DG?`Y*<+R4,=Q]Z
MQ#KF'3]]4L3@*,ATG#Y3BND5&@!_C31AJ0&.1!_5\STYEI>IZ?8Z_6'7M2'<
M>"9%N4J8I&G$KT5)TW]XD%U+<1&G%H%G+>(,.LZH;_<'/Z$"]55-@6>M,NH,
M[>[8'3[>$DCK2@.>HB4/]V)<EX5G77;8Z3G]X>AGK("QK@UE0\G-`EL>--(6
M3K(?3>D[UMNNJ`]^U"4&C6WW2O9$2?C1U'6_I19/GRH;_:B,9I.<OALPQ2%!
MBEO$%@S;LT%0Y"%O@,S,_TI,R$BF\L1DIN;0-"#G"IA-;S.WUYU8;S`#XCIF
MCF-L-6(A(EBZ,UE?!TL=K'2PUD&@@XT.MCK8Z2#4P5X'AQ:PP%KI+^3#K_"7
MR3!_A3-S`1K#'<U,$2&*^#I8ZF"E@[4.`AUL=+#5P4X'H0[V.CBT@&(F3)5?
M82:3@?6RE:SV4'-OSF/8C)`9W=<,EB'28426B*P062,2(+)!9(O(#I$0D3TB
MAS91S(:N_PJSF0PL+K`52"/=GC;QYW70/;=EB'0;D24B*T36B`2(;!#9(K)#
M)$1DC\BA312WP1_%[:_/`6*Y9=&5J<*,>4U<N4(L$/$162*R0F2-2(#(!I$M
M(CM$0D3VB!S:1#%LH!G&-ZX..W.4ER1^F5-^_/G"2!<V*+YM,1'5QYI4A[<J
M9H&(SPD[(<F4MH?:ZK"406*(5DAHC4C`B<M:^#;KV2-'VT0W,D#(;I'(#I%0
MEN*R`W>LKF5[&2!D#VT1Q7C8Y)5,U8W_06]@Z?\=&)B*ZGQ-1DT&(^(CLN3$
M:<9KA6+6B`2(;)#.%L7L$`D1V2.=0SM&,9)]RK6/7E]D*N282%46K1K&B0.;
M92L-!^K`+F20&%@?D65-H*$MH:$JM$+%UH@$DK2$W)$JM*F#>(K;/7=L:\FX
ME3*BS3M$0DGN5+57J^KW1MIL.D@5J$D9&_B64,9&3_*'5A<FH@Y93:#:EM.:
M00L9)+KO([+DI)WV*&:-2%"7:J;8IB;P:#5('P\IU`K2K=S)(-'JL-9N:MO7
M!!Y-;2/M+'"00NV@9N"486)?;7B<!AVQ"8BUZ/$=H5)4!ZU&ZD0;:0?&11,E
M#/`Q6M;(;:U7.&J-42`*PL+:>(?FEHARJOW#=IUQ5VOG%FOO,`J%T-WJ]B)*
M5#?6MRMVA<+F`'@G9QB_$N$?H2G)SV1!KM?"B.DKN^Z``K.)Q/PNQA]XL)V"
M@,:#@0?[(>;AP(,-#7.XTWFJ&J+IS-E=SQ?Q<\>#3Q&L,W<].#9C_M3SGJ#]
M^!_SG@<GOR]XWX,##G!+M@CN>&[1F>RC_)QDA7$E)S"E6QUK<GY+Q%_*>I=]
MIB7<[H!O\.D.MWD$OIJ[+/U/E);BA54@[P=G_P(``/__`P!02P,$%``&``@`
M```A`"D4<"<R`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````)R1T4K#,!2&[P7?H>2^
M3=L--T*;@<JN'`A.%.]B<K8%FS3D1+N]O5G7546OO`S_GR_?.:D6>],D'^!1
MM[8F19:3!*QLE;;;FCRNE^F<)!B$5:)I+=3D`$@6_/*BDH[)UL.];QWXH`&3
M2++(I*O)+@3'*$6Y`R,PBPT;PTWKC0CQZ+?4"?DFMD#+/+^B!H)0(@AZ!*9N
M))(!J>2(=.^^Z0%*4FC`@`U(BZR@7]T`WN"?%_KD6]/H<'!QID'W.UO)4SBV
M]ZC'8M=U63?I-:)_09]7=P_]J*FVQUU)(/RXGT9@6,55;C2HZP/?O_HF0=Q5
M]'=6*=G;,>E!!%!)?(^=[,[)T^3F=KTDO,R+:9K/TZ)<ESF;SE@Y>ZGHN37<
MYR/0#`+_)IX!O/?^^>?\$P``__\#`%!+`P04``8`"````"$`EX(RT[@"```T
M"0``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````"<5E%/VS`0?I^T_Q#E'5(H3!-*@T;;B4G;J);`
M'BW7N5`+UPZV$]']^IT36I)A/&UOCGWWW7??G7U)+Y^V(FI!&Z[D+#XYGL01
M2*9*+N]G\6WQ^>AC'!E+94F%DC"+=V#BR^S]NW2E50W:<C`10D@SBS?6UA=)
M8M@&MM0<X['$DTKI+;7XJ>\3556<P4*Q9@O2)J>3R8<$GBS($LJC^@`8]X@7
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M=IG341D.+@LP3//:=91#OFH,EV!,)T?>>*/\`-&E[@3?D4)3:2AS`/X(SS=L
MURO\V/#:Y>%%_JXLD!7=T;7P)[@`S5ML_Q;\L>9JN^6VU\D5%`6QV,WX%.`%
M]X9<(B&[\Q[ES=K`8X-DR;)UTGNMP@+Z2QOV.?7&>5MU4M"UU\6OO#/'"^/U
M&.@;,@O*3+S(O<XAT+`H4R]JV.?,ZQ,0<@'^O@R[^&O\AO@8@G+A5S_LX@\S
MO#(D!#XL[3_:$7]H#R(I<`XV%(?1X8$9ODZ!R_E&C'"G^6_*<ZN%DAR;!%F_
M>@5\*H_&TQ\#Z2N7#^:V+M0"7\W]Q!UOIOF&:BAQ%NW/7S;2:QRV6CB0^8;B
M6U;N;5X?N/^#N_XG*#LY.YY,)SCZ!WMI\MQB^!IFOP$``/__`P!02P$"+0`4
M``8`"````"$`'7^_9.`!``"Z%@``$P``````````````````````6T-O;G1E
M;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+````
M`````````````!D$``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0#HP<GG
MWP$``*L5```:`````````````````#\'``!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+`0(M`!0`!@`(````(0!)]U"J1`,```,+```/````````````
M`````%X*``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`5=R-374%
M``#:%0``&`````````````````#/#0``>&PO=V]R:W-H965T<R]S:&5E=#0N
M>&UL4$L!`BT`%``&``@````A`(ZVA8DL!```U@X``!D`````````````````
M>A,``'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`
M,R?.(7D%```)%@``&0````````````````#=%P``>&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+`0(M`!0`!@`(````(0"97,YV]0(``#$(```9````````
M`````````(T=``!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!`BT`%``&
M``@````A`&+R^CV%`P``N0P``!D`````````````````N2```'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"+0`4``8`"````"$`N"Z(Q\P"``#,!P``
M&0````````````````!U)```>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M`0(M`!0`!@`(````(0"2G+G;/`,``%\*```9`````````````````'@G``!X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A`-;"LO!L
M#```C&<``!D`````````````````ZRH``'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"+0`4``8`"````"$`KZWP`V\#```Q#0``&0``````````````
M``".-P``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````
M(0!X-0L,C!4``+Z_```9`````````````````#0[``!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L!`BT`%``&``@````A`+I(B'RZ!0``X!@``!D`````
M````````````]U```'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"+0`4
M``8`"````"$`/Y0:N;($``#&$0``&`````````````````#H5@``>&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L!`BT`%``&``@````A`,+0+?K1`@``XP@`
M`!@`````````````````T%L``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M`0(M`!0`!@`(````(0"7\78[+&@``))F`0`4`````````````````-=>``!X
M;"]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(````(0"VE,NHP0L``-=H
M```-`````````````````#7'``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@`
M```A`/MBI6V4!@``IQL``!,`````````````````(=,``'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"+0`4``8`"````"$`LW[NY'\$``#=$@``&0``````````
M``````#FV0``>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+`0(M`!0`!@`(
M````(0!5#=B/#!H``"G&```9`````````````````)S>``!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L!`BT`%``&``@````A`+#LP0MZ`P``LPL``!@`
M````````````````W_@``'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M
M`!0`!@`(````(0!&X]JAKP(``%`'```9`````````````````(_\``!X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L!`BT`%``&``@````A`$PP-^,7`P``
M[PH``!D`````````````````=?\``'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"+0`4``8`"````"$`=T%#Z9$+``!S.@``&0````````````````##
M`@$`>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(````(0`C
M)X,F7@X``.U+```9`````````````````(L.`0!X;"]W;W)K<VAE971S+W-H
M965T,3`N>&UL4$L!`BT`%``&``@````A`+9W!NVT`@``D@<``!@`````````
M````````(!T!`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(
M````(0#GOA1"QP<``'`E```8``````````````````H@`0!X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"+0`4``8`"````"$`B?UB`WH+``!C/0``&```
M```````````````'*`$`>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!`BT`
M%``&``@````A`/3"Y@(>'```5<X``!@`````````````````MS,!`'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`!@`(````(0`!(ANA/08``.H:
M```8``````````````````M0`0!X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"+0`4``8`"````"$`8L$2I-(%``#X'0``&0````````````````!^5@$`
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0"MU7E2
M3QT``#2_```9`````````````````(=<`0!X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L!`BT`%``&``@````A`&P.*:]2&```,ZP``!D`````````````
M````#7H!`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"```
M`"$`>#A;.SL/``",2P``&0````````````````"6D@$`>&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+`0(M`!0`!@`(````(0"?Z9JBCP0``#`0```9````
M``````````````BB`0!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`
M%``&``@````A`!U73LY@`P``'0P``!D`````````````````SJ8!`'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`==<$[J,+``"%
M.```&0````````````````!EJ@$`>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+`0(M`!0`!@`(````(0"E<J"*N`,``'P+```9`````````````````#^V
M`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A`)?(
M=K/`!0``YQD``!D`````````````````+KH!`'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"+0`4``8`"````"$`I"0MZDL%``!D%```&0``````````
M```````EP`$`>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(
M````(0`I%'`G,@$``$`"```1`````````````````*?%`0!D;V-0<F]P<R]C
M;W)E+GAM;%!+`0(M`!0`!@`(````(0"7@C+3N`(``#0)```0````````````
M`````!#(`0!D;V-0<F]P<R]A<'`N>&UL4$L%!@`````L`"P`Y@L``/[+`0``
!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIQAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">1,985,384<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">979,100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(11,655)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">2,952,829<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
        <td class="nump">868,287<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 3.23<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
        <td class="nump">$ 9.85<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 0.78<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 5.45<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 0.98<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Beigning</a></td>
        <td class="text">8 years 4 months 2 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Issued</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending</a></td>
        <td class="text">8 years 4 months 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
        <td class="text">5 years 11 months 27 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 5,908,696<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">8,300,565<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">5,418,017<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">9,673,290<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued</a></td>
        <td class="nump">406,928<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(662,160)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">9,418,058<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
        <td class="nump">9,195,074<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 1.06<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
        <td class="nump">$ 7.96<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 1.44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 1.33<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 1.33<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Beigning</a></td>
        <td class="text">4 years 8 months 16 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Issued</a></td>
        <td class="text">7 years 5 months 16 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years), Outstanding, Ending</a></td>
        <td class="text">4 years 6 months 15 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
        <td class="text">4 years 5 months 1 day<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">47,396,307<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">56,362,310<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">$ 1.16<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_Share-BasedCompensationArrangementByShare-BasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Minimum [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment</a></td>
        <td class="nump">$ 143,919<span></span></td>
        <td class="nump">$ 15,480<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
        <td class="num">(11,017)<span></span></td>
        <td class="num">(1,560)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
        <td class="nump">$ 132,902<span></span></td>
        <td class="nump">$ 13,920<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Note 4 &#8211;&#160;Note Payable</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="font: 12pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">On December 28, 2013, the Company entered into a premium finance agreement to pay a $157,825 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $15,995 in January 2014 and is required to pay $15,995 in monthly installment for nine months. During the six months ended June 30, 2014 and 2013, the Company paid $102,855 and $103,050, respectively.</font>&#160;<font style="font-size: 10pt;">As of June 30, 2014 and December 31, 2013, the outstanding balance related to the premium finance agreement was $54,970 and $157,825, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V
M,#)A-3DX-V8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B
M83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R
M8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U5N,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7T]P93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYO=&5?4&%Y86)L93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E
M;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%
M<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D1E<V-R:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97-C<FEP=&EO
M;E]O9E]"=7-I;F5S<U]A;F1?4W4R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G-?5&%B
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=%]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y$97)I=F%T:79E<U]486)L97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?
M0V]N=&EN9V5N8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y%<75I='E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1&5S8W)I<'1I;VY?;V9?0G5S:6YE<W-?86YD7U-U
M,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=30\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N
M<U]$970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2
M96QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<U]$970Q/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N
M=%]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]$971A:6QS,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?4&%Y86)L95]$971A
M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5R
M:79A=&EV97-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I;'-?,3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I;'-?
M5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7S$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N
M=&EN9V5N8VEE<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^17%U:71Y7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y%<75I='E?1&5T86EL<U]497AT=6%L/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N
M='-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T
M>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@
M/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C
M=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0
M<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z
M17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*
M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I
M=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F.#)?
M-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8O
M5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44%!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`Q,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG06-T:6YI=6T@4&AA<FUA8V5U=&EC86QS+"!);F,N/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,#`P,3,X.#,R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I
M<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<Q,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*=6X@,S`L#0H)
M"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@
M4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M43(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=3;6%L;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L,30W+#`V-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S,SA?,V8X,E\T
M-F5C7SDQ.31?8F$P-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9B]7
M;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5064%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H
M56YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT($%S<V5T
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$T+#8W,"PX,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-3,S+#,V-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I
M9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8P."PQ,#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3@L,S@Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M0W5R<F5N="!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#(W."PY,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#<U,2PW-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L
M(&YE="!O9B!A8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S,BPY,#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPY,C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E8W5R:71Y(&1E
M<&]S:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#<S,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#0T-BPU-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#<V-2PV-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!,:6%B:6QI
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`T-2PT,C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S@L.34U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S("T@<F5L
M871E9"!P87)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@Y
M+#4S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@Q+#$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-30L.3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34W+#@R-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX,C8L-C(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPW,#<L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@0W5R<F5N="!,:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,3$V+#4U-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S(U+#(R,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q+#$Q-BPU-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#,R-2PR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT
M:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G
M($5Q=6ET>2`H1&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"`D,"XP,2!P87(@
M=F%L=64[(#$P+#`P,"PP,#`@875T:&]R:7IE9"!N;VYE(&ES<W5E9"!A;F0@
M;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P
M,2!P87(@=F%L=64[(#$P,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R`R
M-RPV,#(L,3DR(&%N9"`R-"PU-C4L-#0W('-H87)E<R!I<W-U960@86YD(&]U
M='-T86YD:6YG+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(W+#8P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T+#4V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T+#`P-"PP
M-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-"PY,S,L,30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@W.3<L,#$V+#4W-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-BPU,3<L,C4U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$969I8VET*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,CDL.3DX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU-3DL-30U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L($QI86)I;&ET:65S(&%N9"!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H
M1&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34L
M-#0V+#4U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2PW-C4L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A
M-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?
M,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970P
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14--04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5;F%U9&ET960I("A087)E
M;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@
M=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(W+#8P,BPQ.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-"PU-C4L-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL('-H87)E<R!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L
M-C`R+#$Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(T+#4V-2PT-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U
M.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-S)B,C,S.%\S
M9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8O5V]R:W-H965T<R]3:&5E=#`T
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3DE!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A5;F%U9&ET
M960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N=',@3V8@
M3W!E<F%T:6]N<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!E
M>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="P@;F5T(&]F(')E
M:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#`P,2PY,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#DL,C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PT-C(L.3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU.30L.38X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N
M9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPT,30L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.38V+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L,#DP+#8X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#DY+#4P,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C
M:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L,#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL-#4W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O
M;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0L,3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0R-"PV,38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0W-2PV,CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#4V,RPP-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#0Y."PU.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PT,C0L-C$V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#<U+#8R
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X+#4V,RPP-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,RPT.3@L-3DS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@
M*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PR,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'86EN("AL;W-S*2!O;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O
M9B!D97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#DS.2PW,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,P-RPW-#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV,C$L,S8P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#<V
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&]T:&5R(&EN8V]M92!A;F0@*&5X<&5N<V4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#DS.2PW,3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,P."PS.#(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV
M,C$L,S8P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+#4U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3$U+#`Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPW.#0L,#$Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,3,L,3@T+#0P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#,L-#<S+#`S."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I('!E
M<B!C;VUM;VX@<VAA<F4@+2!B87-I8SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XU,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,38I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC
M;VUE("AL;W-S*2!P97(@8V]M;6]N('-H87)E("T@9&EL=71E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C4R*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,"XQ-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9R`M(&)A<VEC/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-2PW.34L-3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C(L,3<X+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(U+#4Q,RPU,#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PW.3$L-C<S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@+2!D:6QU
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PX-C(L,3<S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C(L,3<X+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U+#4Q,RPU,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,2PW.3$L-C<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?
M.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS
M:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-104<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S:"!&
M;&]W<R`H56YA=61I=&5D*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@
M3W!E<F%T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,3,L,3@T+#0P,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L-#<S+#`S."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE
M="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!O<&5R871I;F<@86-T:79I
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-#$L,30T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@X+#0P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P
M<F5C:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL-#4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!D:7-P;W-I=&EO;B!O
M9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#$R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@9&ES8V]U
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R960@9FEN
M86YC:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!E>'1I;F=U:7-H
M;65N="!O9B!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S("AG86EN*2!O
M;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8R,2PS-C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-BPW-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/BA);F-R96%S92D@9&5C<F5A<V4@:6XZ/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4B9A;7`[
M1"!R96EM8G5R<V%B;&4@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L,3(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,X.2PW,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,T+#<S,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DEN8W)E87-E("AD96-R96%S92D@:6XZ/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A
M;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C8V+#0V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$P,RPT,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A
M8V-R=65D(&5X<&5N<V5S("T@<F5L871E9"!P87)T>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`X+#,U,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M0V%S:"!5<V5D($EN($]P97)A=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U+#`V,BPP-S(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPS,C<L.#(P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#87-H($9L;W=S($9R;VT@26YV97-T:6YG($%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R
M8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3(X+#0S.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$Q,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S:"!5
M<V5D($EN($EN=F5S=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,C@L-#,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,3$R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L
M;W=S($9R;VT@1FEN86YC:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N=',@;VX@;F]T
M92!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#(L
M.#4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$P,RPP-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y386QE<R!O9B!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS,C@L
M-S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!T:&4@97AE<F-I<V4@
M;V8@;W!T:6]N<R!A;F0@=V%R<F%N=',@9F]R(&-A<V@\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,BPP.#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0V,RPV-#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S
M:"!0<F]V:61E9"!">2!&:6YA;F-I;F<@06-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,S(W+#DU.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S8P+#4Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C:&%N9V4@:6X@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PQ,S<L-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S$L-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&)E9VEN;FEN9R!O9B!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3,S+#,V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-C$X+#8V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-"PV-S`L.#$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV-3`L,S(X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!C87-H(&9L;W<@:6YF;W)M
M871I;VXZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED(&9O
M<B!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I
M<V-L;W-U<F4@;V8@;F]N+6-A<V@@:6YV97-T:6YG(&%N9"!F:6YA;F-I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(&YO=&5S('!A>6%B;&4@86YD(&%C
M8W)U960@:6YT97)E<W0@=&\@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-3`Q+#DX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4Y,"PR,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&9R;VT@;&EA
M8FEL:71Y(&-L87-S:69I8V%T:6]N('1O(&5Q=6ET>2!C;&%S<VEF:6-A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C
M7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<V-R:7!T:6]N
M(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CY.;W1E(#$@
M)B,X,C$Q.R8C,38P.T1E<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^/"]P
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M;&EG;CH@:G5S=&EF>3LG/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M.R!F;VYT+7-I>F4Z(#AP=#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
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M(#`N-35I;CLG/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\8CY.871U<F4@;V8@
M0G5S:6YE<W,@)B,X,C$Q.SPO8CXF(S$V,#M!8W1I;FEU;2!0:&%R;6%C975T
M:6-A;',L($EN8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3L@;W(@)B,X
M,C(P.T%C=&EN:75M)B,X,C(Q.RD@:7,@82!B:6]T96-H;F]L;V=Y(&-O;7!A
M;GD@8V]M;6ET=&5D('1O(&1E=F5L;W!I;F<@8G)E86MT:')O=6=H('1H97)A
M<&EE<R!F;W(@;&EF92!T:')E871E;FEN9R!D:7-E87-E<R!U<VEN9R!I=',@
M86QP:&$@<&%R=&EC;&4@:6UM=6YO=&AE<F%P>2`H05!)5"D@<&QA=&9O<FT@
M86YD(&]T:&5R(')E;&%T960@86YD('-I;6EL87(@=&5C:&YO;&]G:65S+B!!
M8W1I;FEU;2P@=&]G971H97(@=VET:"!I=',@=VAO;&QY(&]W;F5D('-U8G-I
M9&EA<GDL($UE9$%C=&EN:75M+"!);F,N("A-04DI+"`H:&5R96EN869T97(@
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M86-U=&4@;7EE;&]I9"!L975K96UI82`H04U,*2!P871I96YT<RX@06-T:6YI
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M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C4U:6X[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,CDN-W!T.R<^/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M;G0Z(#(Y+C=P=#LG/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
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M86QS+"!);F,N("@F(S@R,C`[05!))B,X,C(Q.RDL(&EN(&5X8VAA;F=E(&9O
M<B!T:&4@:7-S=6%N8V4@;V8@87!P<F]X:6UA=&5L>2`Y.24@;V8@=&AE(&ES
M<W5E9"!A;F0@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K+"!P87(@=F%L=64@
M)#`N,#$@<&5R('-H87)E+"!O9B!T:&4@0V]M<&%N>2X@07,@82!R97-U;'0@
M;V8@=&AE(%-H87)E($5X8VAA;F=E+"!T:&4@9F]R;65R('-H87)E:&]L9&5R
M<R!O9B!!4$D@8F5C86UE('1H92!C;VYT<F]L;&EN9R!S:&%R96AO;&1E<G,@
M;V8@=&AE($-O;7!A;GDN($%T('1H92!C;&]S:6YG+"!E86-H($%022!S:&%R
M96AO;&1E<B!R96-E:79E9"`P+C,S,R!S:&%R97,@*'1H92`F(S@R,C`[17AC
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M9R!A;F0@9FEN86YC:6%L(')E<&]R=&EN9R!P=7)P;W-E<RX\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M(#`N-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS
M.B!A=71O.PT*('1E>'0M=')A;G-F;W)M.@T*(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SY!<R!A
M(')E<W5L="!O9B!T:&4@4VAA<F4@17AC:&%N9V4L('1H92!#;VUP86YY(&ES
M(&YO=R!A(&AO;&1I;F<@8V]M<&%N>2!O<&5R871I;F<@=&AR;W5G:"!!4$DL
M(&$@8VQI;FEC86PM<W1A9V4@8FEO<&AA<FUA8V5U=&EC86P@8V]M<&%N>2!D
M979E;&]P:6YG(&-E<G1A:6X@8V%N8V5R('1R96%T;65N=',N/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R
M=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT
M.B`P+C5I;CLG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SY/;B!-87)C
M:"`R,"P@,C`Q,RP@=&AE($-O;7!A;GDF(S@R,3<[<R!S=6)S:61I87)Y+"!!
M8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RXL(&-H86YG960@:71S(&YA
M;64@=&\@06-T:6YI=6T@0V]R<&]R871I;VXN($]N($%P<FEL(#$Q+"`R,#$S
M+"!T:&4@0V]M<&%N>2!C:&%N9V5D(&ET<R!D;VUI8VEL92!F<F]M('1H92!3
M=&%T92!O9B!.979A9&$@=&\@=&AE(%-T871E(&]F($1E;&%W87)E(&%N9"!C
M:&%N9V5D(&ET<R!N86UE(&9R;VT@0V%C='5S(%9E;G1U<F5S+"!);F,N('1O
M($%C=&EN:75M(%!H87)M86-E=71I8V%L<RP@26YC+CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU
M:6X[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^3VX@4V5P=&5M8F5R
M(#(U+"`R,#$S+"!I;B!A8V-O<F1A;F-E('=I=&@@82!#97)T:69I8V%T92!O
M9B!/=VYE<G-H:7`@365R9VEN9R!!8W1I;FEU;2!#;W)P;W)A=&EO;B!I;G1O
M('1H92!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@*&9I;&5D(&EN
M($1E;&%W87)E+"!T:&4@0V]M<&%N>2!M97)G960@*'1H92`F(S@R,C`[365R
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M<R!E>&-H86YG960@9F]R(#`N,S,S('-H87)E<R!O9B!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K+B!!('1O=&%L(&]F(#,L.3<P+#$S-R!S:&%R97,@
M;V8@06-T:6YI=6T@0V]R<&]R871I;VX@8V]M;6]N('-T;V-K('=A<R!E>&-H
M86YG960@9F]R(#$L,S(R+#`U-2!S:&%R97,@;V8@0V]M<&%N>2!C;VUM;VX@
M<W1O8VLN/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X\<"!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
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M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R.2XW
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/CQB/D)A<VES(&]F(%!R97-E;G1A=&EO;B`M(%5N
M875D:71E9"!);G1E<FEM($9I;F%N8VEA;"!);F9O<FUA=&EO;B`F(S@R,3$[
M/"]B/B8C,38P.U1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&EN=&5R:6T@
M8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A
M;F0@<F5L871E9"!N;W1E<R!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D
M86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C
M97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC82`H)B,X,C(P
M.U4N4RX@1T%!4"8C.#(R,3LI(&9O<B!I;G1E<FEM(&9I;F%N8VEA;"!I;F9O
M<FUA=&EO;BP@86YD(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@<G5L97,@86YD
M(')E9W5L871I;VYS(&]F('1H92!5;FET960@4W1A=&5S(%-E8W5R:71I97,@
M86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*'1H92`F(S@R,C`[4T5#)B,X,C(Q
M.RD@=VET:"!R97-P96-T('1O($9O<FT@,3`M42!A;F0@07)T:6-L92`X(&]F
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M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+"!A
M<R!F:6QE9"!W:71H('1H92!314,@1F5B<G5A<GD@,C@L(#(P,30N/"]F;VYT
M/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
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M=#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQB/E!R:6YC:7!L97,@;V8@
M0V]N<V]L:61A=&EO;B`F(S@R,3$[/"]B/B8C,38P.U1H92!C;VYD96YS960@
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M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.@T*("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP-"B!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
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M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T
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M<V4@97-T:6UA=&5S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SX\8CY296-L87-S:69I8V%T:6]N("8C.#(Q,3L\+V(^)B,Q-C`[
M0V5R=&%I;B!P<FEO<B!P97)I;V0@86UO=6YT<R!H879E(&)E96X@<F5C;&%S
M<VEF:65D('1O(&-O;F9O<FT@=&\@8W5R<F5N="!P97)I;V0@<')E<V5N=&%T
M:6]N+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\
M8CY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S("8C.#(Q,3L\+V(^)B,Q-C`[
M5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@;&EQ=6ED(&%C8V]U
M;G1S('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O9B!T:')E92!M;VYT:',@
M;W(@;&5S<R!T;R!B92!C87-H(&5Q=6EV86QE;G1S+B!3=6-H(&)A;&%N8V5S
M(&%R92!U<W5A;&QY(&EN(&5X8V5S<R!O9B!&1$E#(&EN<W5R960@;&EM:71S
M+B!!="!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@86QL
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V%S:"!W87,@9&5P;W-I=&5D(&EN
M(&]N92!B86YK+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SX\8CY0<F]P97)T>2!A;F0@17%U:7!M96YT("8C.#(Q,3L\+V(^)B,Q
M-C`[36%C:&EN97)Y(&%N9"!E<75I<&UE;G0@87)E(')E8V]R9&5D(&%T(&-O
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M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`R.2XW<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
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M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
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M('9A;'5E+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M9F]N="US:7IE.B`X<'0[(&UA<F=I;CH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\8CY$
M97)I=F%T:79E<R`F(S@R,3$[/"]B/B8C,38P.T%L;"!D97)I=F%T:79E<R!A
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M('5S:6YG(&UA<FME="!B87-E9`T*('!R:6-I;F<@;6]D96QS(&EN8V]R<&]R
M871I;F<@<F5A9&EL>0T*(&]B<V5R=F%B;&4@;6%R:V5T(&1A=&$@86YD(')E
M<75I<FEN9R!J=61G;65N="!A;F0@97-T:6UA=&5S+CPO9F]N=#X\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US:7IE.B`X<'0[(&UA<F=I
M;CH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SX\8CY&86ER(%9A;'5E(&]F($9I;F%N8VEA
M;"!);G-T<G5M96YT<R`F(S@R,3$[/"]B/B8C,38P.T9A:7(@=F%L=64@:7,@
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M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M>F4Z(#AP=#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
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M:#H@,'!X.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#`N-35I;CL@=&5X="UA;&EG
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M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[
M('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<VEZ
M93H@.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[
M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU-6EN.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
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M86)I;&ET>2`H<W5C:"!A<R!I;G1E<F5S="!R871E<RP@=F]L871I;&ET:65S
M+"!P<F5P87EM96YT('-P965D<RP@8W)E9&ET(')I<VMS+"!E=&,N*2!O<B!I
M;G!U=',@=&AA="!A<F4@9&5R:79E9"!P<FEN8VEP86QL>2!F<F]M(&]R(&-O
M<G)O8F]R871E9"!B>2!M87)K970@9&%T82!B>2!C;W)R96QA=&EO;B!O<B!O
M=&AE<B!M96%N<RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@@,'!X(#!P>"`P
M+C4U:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S($EN<'5T<R`F(S@R,3$[(%5N;V)S
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M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X(#<N-W!T.R!T97AT+6EN
M9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
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M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/E1H92!F;VQL
M;W=I;F<@=&%B;&5S('-E="!F;W)T:"!A<W-E=',@86YD(&QI86)I;&ET:65S
M(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@86YD(&YO
M;BUR96-U<G)I;F<@8F%S:7,@8GD@;&5V96P@=VET:&EN('1H92!F86ER('9A
M;'5E(&AI97)A<F-H>2!A<R!O9B!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E
M<B`S,2P@,C`Q,RX@07,@<F5Q=6ER960@8GD@05-#(#@R,"`F(S@R,C`[/&D^
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M+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-38W<'@[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
M="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T
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M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@
M8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DQE=F5L
M(#(\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M:6UE<RP@<V5R:68[)SY,979E;"`S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&]T86P\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=PT*(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.@T*(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`X,#$N-C<Q.#<U<'@[('!A9&1I;F<M;&5F=#H@,3!P=#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY!="!*=6YE
M(#,P+"`R,#$T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^.2PX
M,C8L-C(W/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,35P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CDL.#(V+#8R-SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^070@1&5C
M96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A
M=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C
M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R
M9VEN.B`P<'@@-RXW<'0[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^/&(^26YC;VUE(%1A>&5S("8C.#(Q,3L\+V(^)B,Q-C`[5&AE($-O;7!A
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M;VXN/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
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M(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQB
M/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;W-T<R`F(S@R,3$[/"]B/B8C
M,38P.U)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T<R!A<F4@97AP96YS
M960@87,@:6YC=7)R960N(%)E<V5A<F-H(&%N9"!D979E;&]P;65N="!R96EM
M8G5R<V5M96YT<R!A;F0@9W)A;G1S(&%R92!R96-O<F1E9"!B>2!T:&4@0V]M
M<&%N>2!A<R!A(')E9'5C=&EO;B!O9B!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@8V]S=',N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
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M;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/CQB/E-H87)E+4)A<V5D(%!A>6UE;G1S("8C.#(Q,3L\+V(^)B,Q-C`[
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M92UB87-E9`T*(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&ES(')E8V]G;FEZ960@
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M:6X@8V%P:71A;"X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU-6EN.R<^/&(^16%R;FEN9W,@*$QO<W,I(%!E<B!#;VUM
M;VX@4VAA<F4@)B,X,C$Q.SPO8CXF(S$V,#M4:&4@0V]M<&%N>2!P<F]V:61E
M<R!B87-I8R!A;F0@9&EL=71E9"!E87)N:6YG<R!P97(@8V]M;6]N('-H87)E
M(&EN9F]R;6%T:6]N(&9O<B!E86-H('!E<FEO9"!P<F5S96YT960N($)A<VEC
M(&5A<FYI;F=S("AL;W-S*2!P97(@8V]M;6]N('-H87)E(&ES(&-O;7!U=&5D
M(&)Y(&1I=FED:6YG('1H92!N970@:6YC;VUE("AL;W-S*2!A=F%I;&%B;&4@
M=&\@8V]M;6]N('-T;V-K:&]L9&5R<R!B>2!T:&4@=V5I9VAT960@879E<F%G
M92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!D=7)I;F<@
M=&AE(')E<&]R=&EN9R!P97)I;V0N($1I;'5T960@96%R;FEN9W,@<&5R(&-O
M;6UO;B!S:&%R92P@87,@8V%L8W5L871E9"!F;W(@=&AE('1H<F5E(&UO;G1H
M<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!I<R!C;VUP=71E9"!B>2!D:79I9&EN
M9R!T:&4@;F5T(&EN8V]M92!A=F%I;&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L
M9&5R<R!B>2!T:&4@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9R!P;'5S(&1I;'5T:79E('-E8W5R:71I97,N
M($9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3,@86YD
M('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(#(P,3,L
M('1H92!P;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S("AO<'1I;VYS
M+"!W87)R86YT<R!A;F0@8V]N=F5R=&EB;&4@:6YS=')U;65N=',I('=E<F4@
M97AC;'5D960@9G)O;2!T:&4@9&EL=71E9"!L;W-S('!E<B!C;VUM;VX@<VAA
M<F4@8V%L8W5L871I;VX@8F5C875S92!T:&5I<B!E9F9E8W0@=V]U;&0@:&%V
M92!B965N(&%N=&ED:6QU=&EV92X@1F]R('1H92!T:')E92!M;VYT:',@96YD
M960@2G5N928C,38P.S,P+"`R,#$T+"!P;W1E;G1I86QL>2!I<W-U86)L92!S
M:&%R97,@:6YC;'5D960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`Q+#,Y
M."PY,S<@<VAA<F5S(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92`X+#8V-RPV
M-C,@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M+B!&;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"P@<&]T
M96YT:6%L;'D@:7-S=6%B;&4@<VAA<F5S(&EN8VQU9&5D('-T;V-K(&]P=&EO
M;G,@=&\@<'5R8VAA<V4@,BPY-3(L.#(Y('-H87)E<R!A;F0@=V%R<F%N=',@
M=&\@<'5R8VAA<V4@.2PT,3@L,#4X('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:RX@1F]R('1H92!S:7@@;6]N=&AS(&5N9&5D
M($IU;F4@,S`L(#(P,3,L('!O=&5N=&EA;&QY(&ES<W5A8FQE('-H87)E<R!I
M;F-L=61E9"!S=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(#(L,C@P+#$X-"!S
M:&%R97,@86YD('=A<G)A;G1S('1O('!U<F-H87-E(#DL-3,U+#8Y-"!S:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
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M;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&(^4F5C
M96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',@)B,X,C$Q.R8C,38P.SPO
M8CY);B!-87D@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD
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M=',@:6X@5&]P:6,@-C`U+"!2979E;G5E(%)E8V]G;FET:6]N+"!I;F-L=61I
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M92`R,#$Q)B,X,C$Q.S(U,"8C.#(Q,CM2979E;G5E(%)E8V]G;FET:6]N("A4
M;W!I8R`V,#4I.B!#;V1I9FEC871I;VX@06UE;F1M96YT<RP@8F]T:"!O9B!W
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M=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
M,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SY);B!*=6YE
M(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A
M<F0@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`R,#$T+3$P
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M9G)O;2!5+E,N($=!05`N($EN(&%D9&ET:6]N+"!T:&4@86UE;F1M96YT<R!E
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M8W1I=FET:65S(&ET(&ES(&-U<G)E;G1L>2!E;F=A9V5D(&EN(&%N9"`H,BD@
M=&AE(&5N=&ET>28C.#(Q-SMS(&=O=F5R;FEN9R!D;V-U;65N=',@86YD(&-O
M;G1R86-T=6%L(&%R<F%N9V5M96YT<R!A;&QO=R!A9&1I=&EO;F%L(&5Q=6ET
M>2!I;G9E<W1M96YT<RX@56YD97(@=&AE(&%M96YD;65N=',L(&%L;"!E;G1I
M=&EE<R!W:71H:6X@=&AE('-C;W!E(&]F('1H92!687)I86)L92!);G1E<F5S
M="!%;G1I=&EE<R!3=6)S96-T:6]N<R!O9B!3=6)T;W!I8R`X,3`M,3`L($-O
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M8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`R,#$S+3,R,"8C.#(Q,CM$979E
M;&]P;65N="!3=&%G92!%;G1I=&EE<R`H5&]P:6,@.3$U*2P@=VAI8V@@:&%S
M(&)E96X@9&5L971E9"X@5&AE(&%M96YD;65N=',@:6X@=&AI<R!5<&1A=&4@
M87)E(&5F9F5C=&EV92!F;W(@86YN=6%L(')E<&]R=&EN9R!P97)I;V1S(&)E
M9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-"P@86YD(&EN=&5R:6T@
M<&5R:6]D<R!T:&5R96EN+"!A;F0@96%R;'D@861O<'1I;VX@:7,@<F5Q=6ER
M960N(%1H92!#;VUP86YY(&5V86QU871E9"!A;F0@861O<'1E9"!!4U4@,C`Q
M-"TQ,"!F;W(@=&AE(')E<&]R=&EN9R!P97)I;V0@96YD960@2G5N92`S,"P@
M,C`Q-"X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H
M:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG
M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U
M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY);B!*=6YE
M(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A
M<F0@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`R,#$T+3$R
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M;B`H5&]P:6,@-S$X*3H@06-C;W5N=&EN9R!F;W(@4VAA<F4M0F%S960@4&%Y
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M,C$R.U-T;V-K($-O;7!E;G-A=&EO;B`H5&]P:6,@-S$X*3H@06-C;W5N=&EN
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M97)I;V1S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-2P@86YD
M(&5A<FQY(&%D;W!T:6]N(&ES('!E<FUI='1E9"X@5&AE($-O;7!A;GD@:7,@
M8W5R<F5N=&QY(&5V86QU871I;F<@=&AE(&5F9F5C=',@;V8@05-5(#(P,30M
M,3(@;VX@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
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M+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$W,F(R,S,X7S-F.#)?-#9E
M8U\Y,3DT7V)A,#8P,F$U.3@W9B]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A
M<G1Y(%1R86YS86-T:6]N<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M,B`F(S@R,3$[(%)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS/"]B/CPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UI;F1E;G0Z
M(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN+71O<#H@,'!X.R!M87)G
M:6XM<FEG:'0Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!T97AT+6%L:6=N
M.B!L969T.R<^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A
M<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W
M:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN
M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M
M<VEZ93H@.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U
M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&(^/&D^35-+0T,Z
M/"]I/CPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG
M;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<VEZ93H@.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA
M<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^26X@
M,C`Q,"P@1V5N97)A;"!!=&QA;G1I8R!'<F]U<"!,:6UI=&5D(&1O;F%T960@
M86QL(&]F('1H92!E<75I='D@<VAA<F5S(&]F(&ET<R!W:&]L;'D@;W=N960@
M<W5B<VED:6%R>2P@06-T:6YI=6T@2&]L9&EN9W,@3'1D+B`H9F]R;65R;'D@
M;F%M960@1V5N97)A;"!!=&QA;G1I8R!);G9E<W1M96YT<R!,:6UI=&5D*2!T
M;R!-96UO<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B`H35-+
M0T,I+"!A('!R:6YC:7!A;"!O=VYE<B!O9B!T:&4@0V]M<&%N>2X\+V9O;G0^
M/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^3VX@1F5B<G5A<GD@
M,3$L(#(P,#(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A($QI8V5N<V4L
M($1E=F5L;W!M96YT(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!!9W)E96UE;G0@
M=VET:"!3;&]A;BU+971T97)I;F<@26YS=&ET=71E(&]F($-A;F-E<B!297-E
M87)C:"`H4TM)*2P@86X@96YT:71Y(')E;&%T960@=&\@35-+0T,@*"8C.#(R
M,#M,:6-E;G-E($%G<F5E;65N="8C.#(R,3LI+B!4:&4@86=R965M96YT('=A
M<R!A;65N9&5D(&EN($%U9W5S="`R,#`V+B!0=7)S=6%N="!T;R!T:&4@86=R
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M('1H92!#;VUP86YY+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SY4:&4@0V]M<&%N>2!I<R!O8FQI9V%T960@=&\@;6%K92!T:&4@
M9F]L;&]W:6YG(&UI;&5S=&]N92!P87EM96YT<SH\+V9O;G0^/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0^36EL97-T;VYE<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB
M;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI
M9#LG(&-O;'-P86X],T0R/E!A>6UE;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,S<Y<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXH,2D@9FEL:6YG(&]F(&%N($YE=R!$<G5G($%P
M<&QI8V%T:6]N("@F(S@R,C`[3D1!)B,X,C(Q.RD@;W(@<F5G=6QA=&]R>2!A
M<'!R;W9A;"!F;W(@96%C:"!L:6-E;G-E9"!P<F]D=6-T/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ#0H@<FEG:'0[)SXW-3`L
M,#`P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z#0H@,35P>#L@=&5X="UA;&EG
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M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L-S4P+#`P,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA
M<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^56YD
M97(@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD@<VAA;&P@<&%Y('1O($U3
M2T-#(&]N(&$@8V]U;G1R>2UB>2UC;W5N=')Y(&)A<VES(&$@<F]Y86QT>2!O
M9B`R)2!O9B!N970@<V%L97,@;V8@86QL(&QI8V5N<V5D('!R;V1U8W1S('5N
M=&EL('1H92!L871E<B!O9CH@*#$I(#$P('EE87)S(&9R;VT@=&AE(&9I<G-T
M(&-O;6UE<F-I86P@<V%L92P@;W(@*#(I('=H96X@=&AE('!A=&5N=',@97AP
M:7)E+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY#
M97)T86EN(&%M;W5N=',@9'5E('5N9&5R('1H92!,:6-E;G-E($%G<F5E;65N
M="!W97)E(&1E9F5R<F5D(&%N9"!T:&5N(&9O<F=I=F5N('5N9&5R(&$@9F]R
M8F5A<F%N8V4M<F5L871E9"!A<G)A;F=E;65N="X@3VX@2G5N92`Q.2P@,C`Q
M,2P@=&AE($-O;7!A;GD@;F]N971H96QE<W,@86=R965D('1O('!A>2!32TD@
M*&$I("0U,"PP,#`@:6X@,C`Q,2P@*&(I("0R,#`L,#`P(&EN(#(P,3(@86YD
M("AC*2`D,C4P+#`P,"!I;B`R,#$S('5N9&5R('1H:7,@86=R965M96YT+"!I
M;B!R97-P96-T(&]F('1H92`D-3`L,#`P(&%N;G5A;"!M86EN=&5N86YC92!F
M965S(&%N9"!R97-E87)C:"!P87EM96YT<RX\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<VEZ93H@.'!T.R!M87)G:6XZ(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^3VX@4V5P=&5M8F5R(#0L(#(P
M,3,L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&QE='1E<B!A9W)E96UE
M;G0@=VET:"!32TD@=&\@<V5T(&9O<G1H('1H92!A;6]U;G0@=&AA="!T:&4@
M0V]M<&%N>2!O=V5S(%-+22!F;W(@=&AE('!E<FEO9"!F<F]M(#(P,3$@=&\@
M,C`Q-"!U;F1E<B!T:&4@3&EC96YS92!!9W)E96UE;G0N(%1H92!T;W1A;"!A
M;6]U;G0@=&AA="!T:&4@0V]M<&%N>2!O=V5S(%-+22!F;W(@=&AE('!E<FEO
M9"!F<F]M(#(P,3$@=&\@,C`Q-"!I<R`D.#$U+#$P,"!P;'5S(&%L;"!R96QE
M=F%N="!L:6-E;G-E9"!I;G1E;&QE8W1U86P@<')O<&5R='D@<F5L871E9"!P
M87-S('1H<F]U9V@@8V]S=',@=&\@8F4@9&5T97)M:6YE9"X@5&AE(&%M;W5N
M="!O=V5D(&1O97,@;F]T(&EN8VQU9&4@86UO=6YT<R!T:&4@0V]M<&%N>2!M
M87D@;W=E(&9O<B!P871E;G0@97AP96YS97,@=6YD97(@=&AE($QI8V5N<V4@
M06=R965M96YT+B!&;W(@,C`Q,RP@=&AE(&%N;G5A;"!M86EN=&5N86YC92!F
M964@:7,@)#4P+#`P,"!P;'5S('!A<W,@=&AR;W5G:"!C;W-T<RX\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY/;B!-87)C:"`R-RP@,C`Q,BP@
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M<W1A<G0M=7`@9F5E(&]F("0W.2PV,C,@:6X@,C`Q,BX\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
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M;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^1F]R('1H
M92!T:')E92!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@
M=&AE($-O;7!A;GD@9&ED(&YO="!I;F-U<B!A;GD@97AP96YS97,@9F]R(&UA
M:6YT96YA;F-E(&9E97,@86YD(')E<V5A<F-H(&-O;F1U8W1E9"!B>2!-4TM#
M0RX@1F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD
M(#(P,3,L('1H92!#;VUP86YY(&EN8W5R<F5D("0Q.#DL-3,W(&%N9"`D,3(Y
M+#@U,"P@<F5S<&5C=&EV96QY+"!F;W(@;6%I;G1E;F%N8V4@9F5E<R!A;F0@
M<F5S96%R8V@@8V]N9'5C=&5D(&)Y($U32T-#+B!!<R!O9B!*=6YE(#,P+"`R
M,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@=&AE($-O;7!A;GD@:&%S('!A
M>6%B;&4@=&\@35-+0T,@;V8@)#$X.2PU,S<@86YD("0X,2PQ.#4L(')E<W!E
M8W1I=F5L>2P@<F5L871E9"!T;R!C;&EN:6-A;"!T<FEA;',N/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.@T*
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\8CX\:3Y0;&%C96UE
M;G0@06=E;G0Z/"]I/CPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@
M=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U
M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&9O;G0M<VEZ93H@.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
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M96YG86=E9"!A<R!T:&4@97AC;'5S:79E(&%G96YT(&9O<B!T:&4@,C`Q,B!#
M;VUM;VX@4W1O8VL@3V9F97)I;F<N($EN(&-O;G-I9&5R871I;VX@9F]R(&ET
M<R!S97)V:6-E<RP@=&AE('!L86-E;65N="!A9V5N="!R96-E:79E9"`H82D@
M82!C87-H(&9E92!E<75A;"!T;R`Q,"4@;V8@=&AE(&=R;W-S('!R;V-E961S
M(')A:7-E9"!I;B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L("AB
M*2!A(&YO;BUA8V-O=6YT86)L92!E>'!E;G-E(')E:6UB=7)S96UE;G0@97%U
M86P@=&\@,B4@;V8@=&AE(&=R;W-S('!R;V-E961S(')A:7-E9"!I;B!T:&4@
M,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L(&%N9"`H8RD@<F5I;6)U<G-E
M;65N="!O9B`D,3`P+#`P,"!F;W(@;&5G86P@97AP96YS97,@:6YC=7)R960@
M8GD@=&AE('!L86-E;65N="!A9V5N="X@5&AE('!L86-E;65N="!A9V5N="!O
M<B!I=',@9&5S:6=N965S(&%L<V\@<F5C96EV960@=V%R<F%N=',@=&\@<'5R
M8VAA<V4@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@0V]M;6]N(%-T
M;V-K(&EN(&%N(&%M;W5N="!E<75A;"!T;R`Q,"4@;V8@=&AE('-H87)E<R!O
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M('=A<G)A;G1S('=I=&AI;B`V(&UO;G1H<R!O9B!T:&4@9FEN86P@8VQO<VEN
M9R!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<@86YD(&$@-24@
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M('1H92!#;VUP86YY(&9O<B!A('!E<FEO9"!O9B!A="!L96%S="`V(&UO;G1H
M<R!F;W(@82!M;VYT:&QY(&9E92!O9B`D,C4L,#`P+B!4:&4@86=R965M96YT
M(&%L<V\@<')O=FED97,@=&AA="`H:2D@:68@=&AE($-O;7!A;GD@8V]N<W5M
M;6%T97,@86YY(&UE<F=E<BP@86-Q=6ES:71I;VXL(&)U<VEN97-S(&-O;6)I
M;F%T:6]N(&]R(&]T:&5R('1R86YS86-T:6]N("AO=&AE<B!T:&%N('1H92!3
M:&%R92!%>&-H86YG92D@=VET:"!A;GD@<&%R='D@:6YT<F]D=6-E9"!T;R!I
M="!B>2!T:&4@<&QA8V5M96YT(&%G96YT+"!T:&4@<&QA8V5M96YT(&%G96YT
M('=O=6QD(')E8V5I=F4@82!F964@97%U86P@=&\@,3`E(&]F('1H92!A9V=R
M96=A=&4@8V]N<VED97)A=&EO;B!I;B!S=6-H('1R86YS86-T:6]N<RP@86YD
M("AI:2D@:68L('=I=&AI;B!A('!E<FEO9"!O9B`Q,B!M;VYT:',@869T97(@
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M="`W+"`R,#$R(&5N9V%G96UE;G0@86=R965M96YT+B!&;W(@82!P97)I;V0@
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M97)T:6)L92!.;W1E<R!F:6YA;F-I;F<@:6X@,C`Q,2!A;F0L(&%S(&$@<&%R
M="!O9B!T:&4@9F5E(&9O<B!T:&%T(&5N9V%G96UE;G0L(&1E<VEG;F5E<R!O
M9B!T:&4@<&QA8V5M96YT(&%G96YT(&%L<V\@:&]L9"!W87)R86YT<R!T;R!P
M=7)C:&%S92`Q+#(U,2PP,34@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@0V]M;6]N(%-T;V-K+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^3VX@1&5C96UB97(@.2P@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I
M;G1O(&%N;W1H97(@96YG86=E;65N="!A9W)E96UE;G0@=VET:"!I=',@<&QA
M8V5M96YT(&%G96YT(&9O<B!T:&4@,C`Q,R!#;VUM;VX@4W1O8VL@3V9F97)I
M;F<N(%1H92!A9W)E96UE;G0@96YT97)E9"!I;B!O;B!$96-E;6)E<B`Y+"`R
M,#$S(&AA9"!S:6UI;&%R('1E<FUS(&%S('1H92`R,#$R(&%G<F5E;65N="P@
M:6YC;'5D:6YG(&$@8V%S:"!F964@97%U86P@=&\@,3`E(&]F('1H92!G<F]S
M<R!P<F]C965D<R!R86ES960L(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@
M<F5I;6)U<G-E;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E
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M;6]N=&AL>2!F964@;V8@)#(U+#`P,"X\+V9O;G0^/"]P/CQP('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
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M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^3VX@2F%N=6%R>2`Q,"P@
M,C`Q-"P@=&AE($-O;7!A;GD@8V]N9'5C=&5D('1H92!F:6YA;"!C;&]S:6YG
M("AT:&4@)B,X,C(P.T9I;F%L($-L;W-I;F<F(S@R,C$[*2!O9B!I=',@<')I
M=F%T92!P;&%C96UE;G0@;V8@<V5C=7)I=&EE<R`H=&AE("8C.#(R,#M/9F9E
M<FEN9R8C.#(R,3LI('!U<G-U86YT('1O(&$@56YI="!0=7)C:&%S92!!9W)E
M96UE;G0L(&1A=&5D(&%S(&]F($IA;G5A<GD@,3`L(#(P,30@*'1H92`F(S@R
M,C`[4'5R8VAA<V4@06=R965M96YT)B,X,C(Q.RD@86YD(%-U8G-C<FEP=&EO
M;B!!9W)E96UE;G0L(&1A=&5D(&%S(&]F($IA;G5A<GD@,3`L(#(P,30@*'1H
M92`F(S@R,C`[4W5B<V-R:7!T:6]N($%G<F5E;65N="8C.#(R,3LI+"!W:71H
M(&-E<G1A:6X@86-C<F5D:71E9"!I;G9E<W1O<G,@*'1H92`F(S@R,C`[26YV
M97-T;W)S)B,X,C(Q.RD@<'5R<W5A;G0@=&\@=VAI8V@Z('1H92!);G9E<W1O
M<G,@870@=&AE($9I;F%L($-L;W-I;F<@86=R965D('1O('!U<F-H87-E("AI
M*2!A;B!A9V=R96=A=&4@;V8@-34Q+#@Q,"!S:&%R97,@*"!T:&4-"B`F(S@R
M,C`[4VAA<F5S)B,X,C(Q.RD@;V8@8V]M;6]N('-T;V-K(&%T("0V+C`P('!E
M<B!S:&%R92!A;F0-"B`H:6DI(&9I=F4M>65A<B!W87)R86YT<R!T;R!P=7)C
M:&%S92!A;B!A9V=R96=A=&4@;V8@,3,W+#DU,B!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0Y+C`P('!E<B!S:&%R
M92X@5&AE($-O;7!A;GD@<F5C96EV960@)#,L,S$P+#@V,"!I;B!G<F]S<R!P
M<F]C965D<R!F<F]M('1H92!S86QE(&]F('-E8W5R:71I97,@=6YD97(@=&AE
M(%!U<F-H87-E($%G<F5E;65N="!A="!T:&4@1FEN86P@0VQO<VEN9RP@8G)I
M;F=I;F<@=&AE('1O=&%L(&=R;W-S('!R;V-E961S(')E8V5I=F5D(&)Y('1H
M92!#;VUP86YY(&EN('1H92!/9F9E<FEN9R!T;R`D-BPV,S8L-S(P+B!4:&4@
M86=G<F5G871E(&]F9F5R:6YG(&%M;W5N="!O9B!S96-U<FET:65S('-O;&0@
M=&\@:6YV97-T;W)S('=A<R!I;F-R96%S960@9G)O;2`D-BPP,#`L,#`P('1O
M("0V+#8S-BPW,C`@:6X@;W)D97(@=&\@8V]V97(@;W9E<BUA;&QO=&UE;G1S
M+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
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M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG
M/D1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!T
M:&4@<&QA8V5M96YT(&%G96YT(')E8V5I=F5D(&$@8V%S:"!F964@;V8@87!P
M<F]X:6UA=&5L>2`D,"XT(&UI;&QI;VX@9G)O;2!T:&4@<V%L92!O9B!S96-U
M<FET:65S(&%N9"!W87,@:7-S=65D('=A<G)A;G1S('1O('!U<F-H87-E(#8X
M+#DW-B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O
M8VL@870@)#DN,#`@<&5R('-H87)E(&9O<B!A('!E<FEO9"!O9B`U('EE87)S
M+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
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M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/D]N($UA>2`R."P@
M,C`Q-"P@=&AE($-O;7!A;GD@86YD('1H92!P;&%C96UE;G0@86=E;G0@86=R
M965D('1O('1E<FUI;F%T92!T:&4@1&5C96UB97(@.2P@,C`Q,R!E;F=A9V5M
M96YT(&%G<F5E;65N="X\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?
M8F$P-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$W
M,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9B]7;W)K<VAE971S
M+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='D@86YD($5Q
M=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/CQB/DYO=&4@,R`F(S@R,3$[(%!R;W!E<G1Y(&%N9"!%<75I<&UE
M;G0\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,CDN-W!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^4')O<&5R='D@86YD(&5Q=6EP;65N="!C;VYS
M:7-T960@;V8@=&AE(&9O;&QO=VEN9R!A="!*=6YE(#,P+"`R,#$T(&%N9"!$
M96-E;6)E<B`S,2P@,C`Q,SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`R.2XW
M<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#(Y+C=P=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L
M:6)R:2P@:&5L=F5T:6-A+"!S86YS+7-E<FEF.R!W:61T:#H@,34V-W!X.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^2G5N92`S,"P@,C`Q-#PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#XF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[
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M/3-$)W=I9'1H.B`Q-G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B0\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$R-G!X.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXQ-#,L.3$Y/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,35P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C5P>#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,34L-#@P/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3&5S<SH@86-C
M=6UU;&%T960@9&5P<F5C:6%T:6]N/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@
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M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B@Q+#4V,#PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`R+C(U<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
M93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,BXR-7!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M,3,R+#DP,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,BXR
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#(N,C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+`T*('-E<FEF.R<^,3,L.3(P/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP#0H@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#(Y+C=P=#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`R.2XW<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/D1E<')E8VEA=&EO;B!E>'!E;G-E(&9O<B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(#(P,3,@
M=V%S("0X+#`U,B!A;F0@)#`L(')E<W!E8W1I=F5L>2X@1&5P<F5C:6%T:6]N
M(&5X<&5N<V4@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P
M,30@86YD(#(P,3,@=V%S("0Y+#0U-R!A;F0@)#`L(')E<W!E8W1I=F5L>2!4
M:&4@0V]M<&%N>2!W<F]T92!O9F8@8V5R=&%I;B!S;VUE(&]F(&ET<R!U;F1E
M<')E8VEA=&5D('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@9'5R:6YG('1H92!S
M:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3,@86YD(')E8V]R9&5D(&$@
M;&]S<R!O9B`D-"PQ,C(@;VX@=&AE(&1I<W!O<VET:6]N+CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F
M.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX
M-V8O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^3F]T92!087EA8FQE/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T92!087EA8FQE
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYO=&4@4&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY.;W1E(#0@
M)B,X,C$Q.R8C,38P.TYO=&4@4&%Y86)L93PO8CX\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3)P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/D]N($1E8V5M8F5R
M(#(X+"`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!P<F5M:75M
M(&9I;F%N8V4@86=R965M96YT('1O('!A>2!A("0Q-3<L.#(U('!R96UI=6T@
M9F]R(&ET<R!D:7)E8W1O<B!A;F0@;V9F:6-E<B!L:6%B:6QI='D@:6YS=7)A
M;F-E('!O;&EC>2X@4'5R<W5A;G0@=&\@=&AE(&%G<F5E;65N="P@=&AE($-O
M;7!A;GD@<&%I9"!A(&1O=VX@<&%Y;65N="!O9B`D,34L.3DU(&EN($IA;G5A
M<GD@,C`Q-"!A;F0@:7,@<F5Q=6ER960@=&\@<&%Y("0Q-2PY.34@:6X@;6]N
M=&AL>2!I;G-T86QL;65N="!F;W(@;FEN92!M;VYT:',N($1U<FEN9R!T:&4@
M<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T(&%N9"`R,#$S+"!T:&4@
M0V]M<&%N>2!P86ED("0Q,#(L.#4U(&%N9"`D,3`S+#`U,"P@<F5S<&5C=&EV
M96QY+CPO9F]N=#XF(S$V,#L\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SY!<R!O9B!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q
M,RP@=&AE(&]U='-T86YD:6YG(&)A;&%N8V4@<F5L871E9"!T;R!T:&4@<')E
M;6EU;2!F:6YA;F-E(&%G<F5E;65N="!W87,@)#4T+#DW,"!A;F0@)#$U-RPX
M,C4L(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S,SA?,V8X,E\T-F5C7SDQ
M.31?8F$P-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9B]7;W)K<VAE
M971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY$97)I=F%T:79E<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F5S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<FEV871I=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#LG/CQB/DYO=&4@-2`F(S@R,3$[($1E<FEV871I=F5S/"]B/CPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^5&AE($-O;7!A;GD@:&%S(&1E=&5R;6EN960@=&AA="!C
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M<R!N;W0@86X@:6YP=70@=&\@=&AE(&9A:7(@=F%L=64@;V8@82`F(S@R,C`[
M9FEX960M9F]R+69I>&5D)B,X,C(Q.R!O<'1I;VX@87,@9&5F:6YE9"!U;F1E
M<B!&05-"($%30R!4;W!I8R!.;RX@.#$U("8C.#(Q,3L@-#`N(%1H92!W87)R
M86YT<R!G<F%N=&5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!3=&]C:R!/9F9E<FEN9R!A;F0@,C`Q
M,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L('1H92!#;VYV97)T:6)L92!.;W1E
M<R`H<')E=FEO=7-L>2!I<W-U960@86YD(&-O;G9E<G1E9"D@86YD('1H92!P
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,CDN-W!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[)SY!8W1I=FET:65S(&9O<B!D97)I=F%T:79E('=A<G)A
M;G0@:6YS=')U;65N=',@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU
M;F4@,S`L(#(P,30@=V5R92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
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M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY5
M;FET<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
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M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,3DQ
M<'@[)SY"86QA;F-E+"!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^,2PY
M-C@L-C(S/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P
M>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXV+#<P-RPR-34\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/D-H86YG92!I;B!F86ER('9A;'5E
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R
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M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C0L-C(Q+#,V,#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[#0H@<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/D)A;&%N8V4L($IU;F4@,S`L(#(P,30\+W1D/CQT9"!S='EL
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R
M+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,BXU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CDL.#(V+#8R-SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L
M(#(P,30L(#8V,BPQ-C`@=V%R<F%N=',@=V5R92!E>&5R8VES960L(&]F('=H
M:6-H(#$Y,RPV-C$@=V5R92!D97)I=F%T:79E('=A<G)A;G1S+B!4:&4@9F%I
M<B!V86QU92!O9B!T:&5S92!W87)R86YT<R!T;W1A;&EN9R!A<'!R;WAI;6%T
M96QY("0Q+#4P,2PY.#@@=V5R92!M96%S=7)E9"!O;B!T:&4@=F%R:6]U<R!E
M>&5R8VES92!D871E<R!A;F0@<F5C;&%S<VEF:65D('1O(&%D9&ET:6]N86P@
M<&%I9"UI;B!C87!I=&%L+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,CDN-W!T.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY4:&4@9F%I<B!V86QU97,@;V8@=&AE(&1E
M<FEV871I=F4@=V%R<F%N=',@=V5R92!C86QC=6QA=&5D('5S:6YG(&$@;6]D
M:69I960@8FEN;VUI86P@=F%L=6%T:6]N(&UO9&5L('=I=&@@=&AE(&9O;&QO
M=VEN9R!A<W-U;7!T:6]N<R!A="!E86-H(&)A;&%N8V4@<VAE970@9&%T92X\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I
M;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$R-3-P>#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
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M86X],T0R/D1E8V5M8F5R)B,Q-C`[,S$L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
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M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
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M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,W!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$R<'@[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3)P>#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3$R<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R<^-2XX.3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
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M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^,2XQ.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M,"XU('EE87)S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/D5X<&5C=&5D('9O;&%T
M:6QI='D@*#,I/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH-"B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXW,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^-S,\+W1D/CQT9`T*('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXE/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^17AP96-T960@9&EV:61E
M;F0@>6EE;&0@*#0I/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M>65A<G,@*#4I/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^,C4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/C(U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B4\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D/E)A
M;F=E(&]F('!E<F-E;G1A9V4@;V8@97AI<W1I;F<@<VAA<F5S(&]F9F5R960@
M*#8I/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXS-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXE/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D/D]F
M9F5R:6YG('!R:6-E(')A;F=E("@W*3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW+C4P/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXY/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[)SX\=&0@<W1Y;&4],T0G=VED=&@Z(#<Y<'@[('1E>'0M86QI9VXZ
M(&-E;G1E<CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B@Q
M*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30X.'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^5&AE(&UA<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL@870@=&AE
M(&%B;W9E(&UE87-U<F5M96YT(&1A=&5S(&ES(&)A<V5D(&]N('1H92!#;VUP
M86YY)B,X,C$W.W,@=')A9&EN9R!P<FEC92!Q=6]T960@;VX@=&AE($]40R!-
M87)K971S(&9O<B!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@;VX@=&AE($Y94T4@
M34M4(&9O<B!*=6YE(#,P+"`R,#$T+CPO9F]N=#X\+W1D/CPO='(^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/B@S*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^0F5C
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M<"!S='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQT86)L92!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`W.7!X.R!T97AT
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M<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B@U*3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^36%N86=E;65N="!D971E
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M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^*#8I/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SX\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/DUA;F%G96UE
M;G0@97-T:6UA=&5S('1H870@=&AE(')A;F=E(&]F('!E<F-E;G1A9V5S(&]F
M(&5X:7-T:6YG('-H87)E<R!O9F9E<F5D(&EN(&5A8V@@<W1O8VL@;V9F97)I
M;F<@=VEL;"!B92`P)2!A;F0@,S4E(&]F('1H92!S:&%R97,@;W5T<W1A;F1I
M;F<@870@2G5N92`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L(')E
M<W!E8W1I=F5L>2X\+W`^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF
M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^*#<I/"]F;VYT/CPO=&0^/'1D
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V
M,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S
M,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE
M970Q,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@
M86YD($-O;G1I;F=E;F-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[)SX\8CY.;W1E(#8@)B,X,C$Q.R!#;VUM:71M96YT<R!A
M;F0@0V]N=&EN9V5N8VEE<SPO8CX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@
M<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A
M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA
M<F=I;CH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M/&(^3&EC96YS92!A;F0@4F5S96%R8V@@06=R965M96YT<SPO8CX\+V9O;G0^
M/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M
M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<VEZ93H@.'!T
M.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^5&AE($-O;7!A;GD@:&%S(&5N
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M(&EN('1H:7,@8V%T96=O<GD@87)E.CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@9F]N="US:7IE.B`X<'0[(&UA<F=I;CH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
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M:#H@,"XU-6EN.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#<X
M<'@[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SYA+CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,W!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/D%B8F]T
M="!":6]T:&5R87!E=71I8W,@0V]R<"`F(S@R,3$[(%1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!A(%!R;V1U8W0@1&5V96QO<&UE;G0@86YD(%!A=&5N="!,
M:6-E;G-E($%G<F5E;65N="!W:71H($%B8F]T="!":6]T:&5R87!E=71I8W,@
M0V]R<"X@*&9O<FUE<FQY($9A8V5T($)I;W1E8V@@9F]R;65R;'D@:VYO=VX@
M87,@4')O=&5I;B!$97-I9VX@3&%B<RD@:6X@,C`P,R!T;R!S96-U<F4@97AC
M;'5S:79E(')I9VAT<R!T;R!A('-P96-I9FEC(&%N=&EB;V1Y('=H96X@8V]N
M:G5G871E9"!W:71H(&%L<&AA(&5M:71T:6YG(')A9&EO:7-O=&]P97,N(%5P
M;VX@97AE8W5T:6]N(&]F('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY(&UA
M9&4@82!L:6-E;G-E(&9E92!P87EM96YT(&]F("0S+#`P,"PP,#`N/"]F;VYT
M/CPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG
M;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<VEZ93H@,3)P=#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
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M(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/E1H
M92!#;VUP86YY(&%G<F5E9"!T;R!M86ME(&UI;&5S=&]N92!P87EM96YT<R!T
M;W1A;&EN9R`D-RPW-3`L,#`P(&9O<B!T:&4@86-H:65V96UE;G0@;V8@=&AE
M(&9O;&QO=VEN9R!A9W)E960@=&\@86YD(&-O;G1R86-T960@;6EL97-T;VYE
M<SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A
M<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W
M:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN
M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M
M<VEZ93H@.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX\=&0^36EL97-T;VYE<SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E!A>6UE;G1S/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,S<Y<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXH,2D@=VAE;B!#;VUP86YY
M(&EN:71I871E<R!A(%!H87-E($D@0VQI;FEC86P@5')I86P@;V8@82!L:6-E
M;G-E9"!P<F]D=6-T/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E
M>'0M86QI9VXZ(')I9VAT.R<^-S4P+#`P,#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW-3`L
M,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^*#,I('=H96X@0V]M<&%N>2!I;FET:6%T97,@
M82!0:&%S92!)24D@0VQI;FEC86P@5')I86P@;V8@82!L:6-E;G-E9"!P<F]D
M=6-T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D#0H@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ+#4P,"PP,#`\+W1D/CQT9`T*('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXH-"D@0FEO;&]G
M:6-A;"!,:6-E;G-E($%P<&QI8V%T:6]N(&9I;&EN9R!W:71H(%4N4RX@1D1!
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^,2PW-3`L,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M+6%L:6=N.B!R:6=H=#LG/C$L-3`P+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXH-BD@869T
M97(@=&AE(&9I<G-T("0Q,"PP,#`L,#`P(&EN(&YE="!S86QE<SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M-3`P+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY5
M;F1E<B!T:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!S:&%L;"!P87D@=&\@
M06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(&]N(&$@8V]U;G1R>2UB>2UC
M;W5N=')Y(&)A<VES(&$@<F]Y86QT>2!O9B`Q,B4@;V8@;F5T('-A;&5S(&]F
M(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T97(@;V8Z("@Q
M*2`Q,BXU('EE87)S(&%F=&5R('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4L
M(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
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M,'!X.R!M87)G:6XZ(#!P>"`W+C=P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT
M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R<^5&AE($-O
M;7!A;GD@;65T(&ET<R!F:7)S="!M:6QE<W1O;F4@:6X@,C`Q,B!A;F0@=7!O
M;B!R96%C:&EN9R!T:&4@;6EL97-T;VYE('1H92!#;VUP86YY('!A:60@06)B
M;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P+B!A(&UI;&5S=&]N92!P87EM96YT
M(&]F("0W-3`L,#`P(&]N($IU;'D@,C0L(#(P,3(N(%1H92!M:6QE<W1O;F4@
M<&%Y;65N="!F;W(@=&AE(%!H87-E(#$@0VQI;FEC86P@5')I86P@=V%S(')E
M8V]R9&5D(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E+B!4
M:&4@0V]M<&%N>2!H87,@;F]T(&EN:71I871E9"!A(%!H87-E(#(@0VQI;FEC
M86P@5')I86P@86YD(&YO('!A>6UE;G0@:&%S(&)E96X@;6%D92!T;R!!8F)O
M='0@0FEO=&AE<F%P975T:6-S($-O<G`N('-I;F-E('1H92!*=6QY(#(T+"`R
M,#$R('!A>6UE;G0N/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
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M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#<X<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/F(N/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`S<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY-96UO<FEA;"!3;&]A;B!+
M971T97)I;F<@0V%N8V5R($-E;G1E<B`H35-+0T,I("8C.#(Q,3L@<V5E(')E
M;&%T960@<&%R='D@9&ES8VQO<W5R92X\+V9O;G0^/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SYC+CPO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG.B`P<'@[('1E>'0M:6YD
M96YT.B`P<'@[)SX\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/D]A:R!2:61G
M92!.871I;VYA;"!,86)O<F%T;W)Y("A/4DY,*2`F(S@R,3$[(%1H92!#;VUP
M86YY(&ES(&-O;G1R86-T960@=&\@<'5R8VAA<V4@<F%D:6]A8W1I=F4@;6%T
M97)I86P@=&\@8F4@=7-E9"!F;W(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M+"!W:71H(&$@<F5N97=A;"!O<'1I;VX@870@=&AE(&-O;G1R86-T(&5N9"XF
M(S$V,#LF(S$V,#M&;W(@,C`Q,RP@=&AE($-O;7!A;GD@=V%S(&]B;&EG871E
M9"!A;F0@<&%I9"!A<'!R;WAI;6%T96QY("0P+C,@;6EL;&EO;B!T;R!P=7)C
M:&%S92!O9B!R861I;V%C=&EV92!M871E<FEA;"!W:71H($]23DPN)B,Q-C`[
M)B,Q-C`[1F]R(#(P,30L('1H92!#;VUP86YY('-I9VYE9"!A(&-O;G1R86-T
M('=I=&@@3U).3"!T;R!P=7)C:&%S92`D,"XT(&UI;&QI;VX@;V8@<F%D:6]A
M8W1I=F4@;6%T97)I86PN/"]P/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#LG/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9SH@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^9"X\+V9O
M;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^07!T:793;VQU=&EO
M;G,@<')O=FED97,@<')O:F5C="!M86YA9V5M96YT('-E<G9I8V5S(&9O<B!T
M:&4@<W1U9'D@;V8@=&AE(&1R=6<@06,M,C(U+4AU33$Y-2`H06-T:6UA8BU!
M*2!U<V5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@4&AA<V4@,2!A;F0@4&AA
M<V4@,B!C;&EN:6-A;"!T<FEA;',N)B,Q-C`[)B,Q-C`[5&AE('1O=&%L('!R
M;VIE8W0@:7,@97-T:6UA=&5D('1O(&-O<W0@87!P<F]X:6UA=&5L>2`D,2XY
M(&UI;&QI;VX@86YD(')E<75I<F5S(&$@,3(N-24@9&]W;B!P87EM96YT(&]F
M('1H92!T;W1A;"!E<W1I;6%T960@<')O:F5C="!C;W-T+B8C,38P.R8C,38P
M.U1H92!D;W=N('!A>6UE;G0@=&]T86QI;F<@)#(S.2PP,#`@=V%S('!A:60@
M:6X@,C`P-R!A;F0@,C`Q,BXF(S$V,#LF(S$V,#M/;B!!=6=U<W0@-BP@,C`Q
M,BP@3V-T;V)E<B`R,BP@,C`Q,B!A;F0@36%Y(#$V+"`R,#$S+"!T:&4@86=R
M965M96YT('=A<R!A;65N9&5D('1O('!R;W9I9&4@9F]R(&%D9&ET:6]N86P@
M<V5R=FEC97,N)B,Q-C`[)B,Q-C`[5&AE('1O=&%L('!R;VIE8W0@:7,@;F]W
M(&5S=&EM871E9"!A="!A<'!R;WAI;6%T96QY("0R+C(@;6EL;&EO;BX@07,@
M;V8@2G5N92`S,"P@,C`Q-"P@87!P<F]X:6UA=&5L>2`D,2XQ(&UI;&QI;VX@
M:&%S(&)E96X@97AP96YS960@=&\@9&%T92X@)B,Q-C`[07!T:793;VQU=&EO
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M<&%D9&EN9SH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<Z(#!P>#L@=&5X="UI
M;F1E;G0Z#0H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#LG/CQT9#XF(S$V,#L\+W1D/CQT9`T*('-T>6QE/3-$
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M92`Q-2P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;&EC96YS
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M)#$S+C(@;6EL;&EO;B!T;R`D,C,N-2!M:6QL:6]N+"!D97!E;F1I;F<@;VX@
M=&AE('1R:6%L(&1E<VEG;B!A<R!R97%U:7)E9"!B>2!T:&4@1D1!+B!5;F1E
M<B!T:&4@=&5R;7,@;V8@=&AE('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE
M;G0L('1H92!#;VUP86YY('=I;&P@9G5N9"!T:&4@1DA#4D,@;&%B('=I=&@@
M)#$U,"PP,#`@<&5R('EE87(@9F]R('1H92!F:7)S="!T=V\@>65A<G,@86YD
M("0R-3`L,#`P('1H97)E869T97(N(%!A>6UE;G1S(&UA9&4@=&]W87)D(&9U
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[
M/"]P/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R<^1'5R:6YG('1H92!S:7@@
M;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(#(P,3,L('1H92!#;VUP
M86YY(')E8V]R9&5D(&9E97,@;V8@)#<U+#`P,"!A;F0@)#<U+#`P,"P@<F5S
M<&5C=&EV96QY+"!R96QA=&5D('1O('1H:7,@86=R965M96YT+B8C,38P.SPO
M<#X\<"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3LG/CPO<#X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M8V%L:6)R:2P@:&5L=F5T:6-A+"!S86YS+7-E<FEF.R!W:61T:#H@,34V-W!X
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`U,W!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#<X<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M86XG+"!T:6UE<RP@<V5R:68[)SY/;B!*=6QY(#$Y+"`R,#$R+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA;"!A9W)E96UE;G0@
M=VET:"!&2$-20RXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A>2`D
M,S$L,S8V(&9O<B!E86-H('!A=&EE;G0@=&AA="!H87,@8V]M<&QE=&5D('1H
M92!C;&EN:6-A;"!T<FEA;"X@5&AE($-O;7!A;GD@<&%I9"!A('-T87)T+75P
M(&9E92!O9B`D,3DL-S0Y(&EN(#(P,3,N)B,Q-C`[)B,Q-C`[1'5R:6YG('1H
M92!C;&EN:6-A;"!T<FEA;"!A9&1I=&EO;F%L(&9E97,@87!P;'D@86YD('=I
M;&P@8F4@:6YV;VEC960@=VAE;B!A<'!L:6-A8FQE+B!&;W(@=&AE('-I>"!M
M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@<&%I9"!A
M<'!R;WAI;6%T96QY("0Q-BPP,#`@9F]R('!A=&EE;G0@96YR;VQL;65N="X\
M+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C
M,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/D]N($%U9W5S="`R."P@,C`Q,BP@=&AE($-O;7!A;GD@96YT
M97)E9"!I;G1O(&$@8VQI;FEC86P@=')I86P@86=R965M96YT('=I=&@@5&AE
M(%5N:79E<G-I='D@;V8@5&5X87,@32Y$+B!!;F1E<G-O;B!#86YC97(@0V5N
M=&5R+B!4:&4@=&]T86P@97-T:6UA=&5D(&-O<W0@;V8@8V]N9'5C=&EN9R!T
M:&4@8VQI;FEC86P@=')I86P@:7,@87!P<F]X:6UA=&5L>2`D-3`P+#`P,"P@
M=VAI8V@@:6YC;'5D97,@82!N;VXM(')E9G5N9&%B;&4@:6YS=&ET=71I;VYA
M;"!F964@;V8@)#$T+#4P,"X@5&AE(&5S=&EM871E9"!C;W-T(&ES(&)A<V5D
M(&]N('1R96%T:6YG(#(T('!A=&EE;G1S('1H<F]U9V@@,C`Q,RX@57!O;B!E
M>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD@<&%I9"`D
M,S,L.30V+B!$=7)I;F<@,C`Q,RP@=&AE<F4@=V%S(&]N92!P871I96YT('1R
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M,#L\+W`^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C
M,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[
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M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/D]N(%-E<'1E;6)E<B`R-BP@,C`Q,BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&$@8VQI;FEC86P@=')I86P@86=R965M96YT('=I=&@@
M2F]H;G,@2&]P:VEN<R!5;FEV97)S:71Y+B8C,38P.R8C,38P.U1H92!0:&%S
M92`Q+S(@8VQI;FEC86P@=')I86P@=VEL;"!B92!C;VYD=6-T960@=VET:"!!
M8W1I;FEU;2`R,C4N)B,Q-C`[)B,Q-C`[5&AE(&-L:6YI8V%L('1R:6%L('=I
M;&P@8F4@8V]N9'5C=&5D('5N9&5R('1H92!P<F]T;V-O;',@97-T86)L:7-H
M960@8GD@=&AE($-O;7!A;GD@86YD('!U<G-U86YT('1O(&%N($EN=F5S=&EG
M871I;VYA;"!.97<@1')U9R!%>&5M<'1I;VX@*$E.1"`Q,#@P-RD@:&5L9"!B
M>2!T:&4@0V]M<&%N>2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A
M>2`D,S@L-3`Q('!E<B!P871I96YT+"!W:&\@:&%S(&-O;7!L971E9"!T:&4@
M8VQI;FEC86P@=')I86PN(%1H92!#;VUP86YY(&ES(')E<75I<F5D('1O('!A
M>2!A('-T87)T+75P(&9E92!O9B`D,C(L.#0W+"!A;B!A;FYU86P@<&AA<FUA
M8WD@9F5E(&]F("0R+#`R-2!A;F0@86X@86UE;F1M96YT('!R;V-E<W-I;F<@
M9F5E(&]F("0U,#`L('=H96X@87!P;&EC86)L92X@5&AE<F4@=V5R92!N;R!P
M87EM96YT<R!M861E(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE
M(#,P+"`R,3`T(&9O<B!T:&ES(&%G<F5E;65N="X\+V9O;G0^/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH-"B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.PT*(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;B!.;W9E;6)E<B`R,2P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O
M(&$@8VQI;FEC86P@=')I86P@86=R965M96YT('=I=&@@=&AE(%5N:79E<G-I
M='D@;V8@4&5N;G-Y;'9A;FEA+B8C,38P.R8C,38P.U1H92!0:&%S92`Q+S(@
M8VQI;FEC86P@=')I86P@=VEL;"!B92!C;VYD=6-T960@=VET:"!!8W1I;FEU
M;2`R,C4N)B,Q-C`[)B,Q-C`[5&AE(&-L:6YI8V%L('1R:6%L('=I;&P@8F4@
M8V]N9'5C=&5D('5N9&5R('1H92!P<F]T;V-O;',@97-T86)L:7-H960@8GD@
M=&AE($-O;7!A;GD@86YD('!U<G-U86YT('1O(&%N($EN=F5S=&EG871I;VYA
M;"!.97<@1')U9R!%>&5M<'1I;VX@*$E.1"`Q,#@P-RD@:&5L9"!B>2!T:&4@
M0V]M<&%N>2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A>2`D,S$L
M-S<Q('!E<B!P871I96YT+"!W:&\@:&%S(&-O;7!L971E9"!T:&4@8VQI;FEC
M86P@=')I86PN(%1H92!#;VUP86YY('=I;&P@8F4@<F5Q=6ER960@=&\@<&%Y
M(&$@<W1A<G0M=7`@9F5E(&]F("0Q-BPP,#`@86YD(&%D9&ET:6]N86P@861M
M:6YI<W1R871I=F4@9F5E<RP@=VAE;B!A<'!L:6-A8FQE+B!4:&4@0V]M<&%N
M>2!A8V-R=65D('1H92`D,38L,#`P(&9E92!A="!$96-E;6)E<B`S,2P@,C`Q
M,R!A;F0@<&%I9"!T:&4@9F5E(&EN($IA;G5A<GD@,C`Q-"X\+V9O;G0^/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\=&0@
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/D]N($IA;G5A<GD@,C<L(#(P,30L('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!A(&UA;G5F86-T=7)I;F<@86=R965M96YT('=I=&@@1V]O9'=I;B!":6]T
M96-H;F]L;V=Y($EN8RXF(S$V,#LF(S$V,#LH)B,X,C(P.T=O;V1W:6XF(S@R
M,C$[*2X@1V]O9'=I;B!W:6QL(&]V97)S964@=&AE(&-U<G)E;G0@1V]O9"!-
M86YU9F%C='5R:6YG(%!R86-T:6-E<R`H8T=-4"D@<')O9'5C=&EO;B!O9B!A
M(&UO;F]C;&]N86P@86YT:6)O9'D@86YT:6-I<&%T960@=&\@8F4@=7-E9"!I
M;B!A;B!U<&-O;6EN9R!P:&%S92`S(&-L:6YI8V%L('1R:6%L(&]F($EO;6%B
M)B,X-#@R.RU"+B!4;W1A;"!C;W-T(&]F('1H92!A9W)E96UE;G0@:7,@)#(L
M.#$S+#DV,"X@5&AE($-O;7!A;GD@<&%I9"!A(&YO;BUR969U;F1A8FQE('!A
M>6UE;G0@;V8@)#4V,BPW.3`@=7!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E
M;65N="X@4&5R:6]D:6,@<&%Y;65N=',@=VEL;"!B92!M861E('5P;VX@<F5A
M8VAI;F<@8V5R=&%I;B!M:6QE<W1O;F5S+B!!<R!O9B!*=6YE(#,P+"`R,#$T
M+"!T:&4@<F5M86EN:6YG(&-O<W0@;V8@=&AE(&%G<F5E;65N="!I<R!A<'!R
M;WAI;6%T96QY("0R+C$@;6EL;&EO;BX\+V9O;G0^/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($IU;F4@,C`L
M(#(P,30L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A($-23R!A9W)E96UE
M;G0@=VET:"!!8W0@3VYC;VQO9WDN($%C="!/;F-O;&]G>2!P<F]V:61E<R!P
M<F]J96-T(&UA;F%G96UE;G0@<V5R=FEC97,@9F]R('1H92!S='5D>2!O9B!)
M;VUA8BU"('5S960@9F]R('1H92!I;G1E;F1E9"!0:&%S92`S(&-L:6YI8V%L
M('1R:6%L+B!4:&4@=&]T86P@<')O:F5C="!I<R!E<W1I;6%T960@=&\@8V]S
M="!A<'!R;WAI;6%T96QY("0P+C@@;6EL;&EO;BX@5&AE($-O;7!A;GD@<&%I
M9"!A<'!R;WAI;6%T96QY("0P+C$@;6EL;&EO;B!D=7)I;F<@=&AE('-I>"!M
M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"X@06-T($]N8V]L;V=Y(&)I;&QS
M('1H92!#;VUP86YY('=H96X@<V5R=FEC97,@87)E(')E;F1E<F5D(&%N9"!T
M:&4@0V]M<&%N>2!R96-O<F1S('1H92!R96QA=&5D(&5X<&5N<V4@=&\@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S+B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
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M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I
M;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I
M;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M-6EN.R<^3VX@075G=7-T(#$L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A(')E;G1A;"!A9W)E96UE;G0@9F]R(&]F9FEC92!S<&%C92!A="`U
M,#$@1FEF=&@@079E;G5E+"!.97<@66]R:RP@3EDN(%1H92!A9W)E96UE;G0@
M=&5R;6EN871E9"!O;B!-87D@,S$L(#(P,3,N($]N($IU;F4@-"P@,C`Q,R!A
M;F0@86UE;F1E9"!O;B!/8W1O8F5R(#0L(#(P,3,L('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!T=V\@<F5N=&%L(&%G<F5E;65N=',@9F]R(&]F9FEC92!S
M<&%C92!A="`U-#8@1FEF=&@@079E;G5E+"!.97<@66]R:RP@3EDN($]N92!O
M9B!T:&4@86=R965M96YT<R!T97)M:6YA=&5D(&]N($IU;'D@-BP@,C`Q-"X@
M5&AE($-O;7!A;GD@;6%I;G1A:6YS(&]F9FEC92!S<&%C92!A="`U-#8@1FEF
M=&@@079E;G5E+"!.97<@66]R:RP@3ED@=&AR;W5G:"!$96-E;6)E<B`S,2P@
M,C`Q-"X@5&AE($-O;7!A;GD@<&%I9"!A(&]N92!M;VYT:"!R969U;F1A8FQE
M(&1E<&]S:70N($]N($%P<FEL(#(R+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!S=6)L96%S92!A9W)E96UE;G0@9F]R(&]F9FEC92!S<&%C
M92!L;V-A=&5D(&%T(#,W.2!4:&]R;F%L;"!3=')E970L($5D:7-O;BP@3DHN
M(%1H:7,@86=R965M96YT('1E<FUI;F%T97,@;VX@4V5P=&5M8F5R(#,P+"`R
M,#$V+B!4:&4@0V]M<&%N>2!I<W-U960@82!S96-U<FET>2!D97!O<VET(&]F
M("0S-"PW,S,@=&\@=&AE(&5X:7-T:6YG('1E;F%N="XF(S$V,#L\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S
M.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R
M834Y.#=F+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UI;F1E;G0Z(#!P
M>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\
M8CY.;W1E(#<@)B,X,C$Q.R!%<75I='D\+V(^/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\8CXF
M(S$V,#L\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
M,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US
M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M961S(&9R;VT@86-C<F5D:71E9"!I;G9E<W1O<G,@*#PO9F]N=#XF(S@R,C`[
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^,C`Q-"!#;&]S:6YG
M/"]F;VYT/B8C.#(R,3L\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXI+B!4:&4@0V]M<&%N>2!P86ED(&ET<R!P;&%C96UE;G0@86=E;G0@=&]T
M86P@8V%S:"!F965S(&]F/"]F;VYT/B8C,38P.SQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/F%P<')O>&EM871E;'D@)#,Y-2PP,#`@86YD('!A
M:60@871T;W)N97D@9F5E<R!O9B`D-#`L,#`P(&9O<B!T:&5I<B!S97)V:6-E
M<SPO9F]N=#XF(S$V,#MR97-U;'1I;F<@:6X@;F5T('!R;V-E961S(&]F("0R
M+#@W,RPU-3<\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXN($EN
M('1H92`R,#$T($-L;W-I;F<L('1H92!#;VUP86YY('-O;&0@-34Q+#@Q,"!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T/"]F;VYT/B8C,38P.SQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B0V+C`P('!E<B!S:&%R92!A;F0@
M9W)A;G1E9"`Q,S<L.34R('5N:71S(&]F(&9I=F4M>65A<B!W87)R86YT<R!W
M:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0Y+C`P('!E<B!S:&%R92X@5&AE
M('=A<G)A;G1S(&%R92!E>&5R8VES86)L92!F;W(@82!P97)I;V0@;V8@9FEV
M93PO9F]N=#XF(S$V,#L\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SYY96%R<R!F<F]M('1H92!D871E(&]F(&ES<W5A;F-E+B!4:&4@=')A;G-A
M8W1I;VX@9&%T92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!O9B`D,"XV
M(&UI;&QI;VX@=V%S(&1E=&5R;6EN960@=71I;&EZ:6YG('1H92!";&%C:RU3
M8VAO;&5S(&]P=&EO;B!P<FEC:6YG/"]F;VYT/B8C,38P.SQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/FUO9&5L('5T:6QI>FEN9R!T:&4@9F]L
M;&]W:6YG(&%S<W5M<'1I;VYS.B!R:7-K(&9R964@:6YT97)E<W0@<F%T96@Q
M+C8T)2P@97AP96-T960@=F]L871I;&ET>2`M(#@X)2P@97AP96-T960@9&EV
M:61E;F0@>6EE;&0@+2`P)2P@86YD(&$@8V]N=')A8W1U86P@;&EF92!O9B`U
M/"]F;VYT/B8C,38P.SQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/GEE87)S+B!!<R!O9B8C,38P.SPO9F]N=#Y*=6YE(#,P/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^+"`R,#$T+"!A;&P@=&AE('=A<G)A;G1S
M('=E<F4@;W5T<W1A;F1I;F<N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO
M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG
M/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<VEZ93H@,3%P=#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/D]N($UA<F-H(#(T+"`R,#$T+"!T:&4@0V]M<&%N
M>2!F:6QE9"!A('-H96QF(')E9VES=')A=&EO;B!S=&%T96UE;G0@;VX@1F]R
M;2!3+3,@*'1H93PO9F]N=#XF(S$V,#LF(S@R,C`[/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^4F5G:7-T<F%T:6]N(%-T871E;65N=#PO9F]N
M=#XF(S@R,C$[/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^*2!W
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M<'0[)SXD,C`P+#`P,"PP,#`@;V8@:71S(&-O;6UO;B!S=&]C:RP@<')E9F5R
M<F5D('-T;V-K+"!W87)R86YT<R!A;F0O;W(@=6YI=',[(&%N9"`H:6DI(&$@
M<V%L97,@86=R965M96YT('!R;W-P96-T=7,@8V]V97)I;F<@=&AE(&]F9F5R
M:6YG+"!I<W-U86YC92!A;F0@<V%L92!B>3PO9F]N=#XF(S$V,#L\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SYU<R!O9B!U<"!T;R!A(&UA>&EM
M=6T@86=G<F5G871E(&]F9F5R:6YG('!R:6-E(&]F("0W-2PP,#`L,#`P(&]F
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M.B`Q,'!T.R<^*2!W:71H($U,5B`F86UP.R!#;RX@3$Q#("@\+V9O;G0^)B,X
M,C(P.SQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/DU,5CPO9F]N
M=#XF(S@R,C$[/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^*2!D
M871E9"!-87)C:"`R-"P@,C`Q-"X@5&AE($-O;7!A;GD@=VEL;"!P87D@34Q6
M(&EN(&-A<V@L('5P;VX@=&AE('-A;&4@;V8@8V]M;6]N('-T;V-K('!U<G-U
M86YT('1O('1H93PO9F]N=#XF(S$V,#L\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SY386QE<R!!9W)E96UE;G0L(&%N(&%M;W5N="!E<75A;"!T
M;R`S+C`E(&]F('1H92!G<F]S<R!P<F]C965D<R!F<F]M('1H92!S86QE(&]F
M(&-O;6UO;B!S=&]C:RXF(S$V,#L\+V9O;G0^3VX@07!R:6P@,C@L(#(P,30@
M=&AE($-O;7!A;GD@:7-S=65D)B,Q-C`[/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^-3`P('-H87)E<R8C,38P.SPO9F]N=#YA;F0@<F5C96EV
M960@;F5T('!R;V-E961S(&]F("0V+#`P,#QF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.W5N9&5R('1H92!386QE<R!!9W)E96UE;G0\
M+V9O;G0^)B,Q-C`[=VET:"!-3%8\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXN/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU-6EN.R<^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQB/E!L
M86-E;65N="!!9V5N="`F(S@R,3$[)B,Q-C`[/"]B/D1U<FEN9R!*86YU87)Y
M(#(P,30L(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0V]M;6]N(%-T;V-K($]F
M9F5R:6YG+"!T:&4@0V]M<&%N>2!I<W-U960@=&AE(%!L86-E;65N="!!9V5N
M="!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@-C@L.3<V
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=VET:"!A;B!E>&5R8VES92!P<FEC
M92!O9B`D.2XP,"!P97(@<VAA<F4N(%1H92!T<F%N<V%C=&EO;B!D871E(&9A
M:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&]F("0P+C(@;6EL;&EO;@T*('=A
M<PT*(&1E=&5R;6EN960@=71I;&EZ:6YG('1H92!";&%C:RU38VAO;&5S(&]P
M=&EO;B!P<FEC:6YG(&UO9&5L('5T:6QI>FEN9R!T:&4@9F]L;&]W:6YG(&%S
M<W5M<'1I;VYS.B!R:7-K(&9R964@:6YT97)E<W0@<F%T92`F(S@R,3$[(#$N
M-C0E+"!E>'!E8W1E9"!V;VQA=&EL:71Y("T@.#@E+"!E>'!E8W1E9"!D:79I
M9&5N9"!Y:65L9"`M(#`E+"!A;F0@82!C;VYT<F%C='5A;"!L:69E(&]F(#4@
M>65A<G,N/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US
M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C4U:6X[)SX\8CY0=6)L:6,@3V9F97)I;F<\+V(^)B,Q-C`[+2!/;B!*
M=6YE(#,P+"`R,#$T+"!T:&4@0V]M<&%N>2!R96-E:79E9"!G<F]S<R!P<F]C
M965D<R!O9B`D,3(L-3(U+#`P,"X@5&AE($-O;7!A;GD@<&%I9"!A;B!U;F1E
M<G=R:71I;F<@9&ES8V]U;G0@;V8@)#@W-BPW-3`L('!A:60@=&AE(&]T:&5R
M(&]F9F5R:6YG(&5X<&5N<V5S(&]F("0Q,C4L,#`P+"!A;F0@<&%I9"!A='1O
M<FYE>2!A;F0@875D:71O<B!F965S(&]F("0W,BPP,#`@<F5S=6QT:6YG(&EN
M(&YE="!P<F]C965D<R!O9B`D,3$L-#4Q+#(U,"!F<F]M('1H92!P=6)L:6,@
M;V9F97)I;F<@;V8@,2PV-S`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:RP@)#`N,#`Q('!A<B!V86QU92!P97(@<VAA
M<F4@870@82!P<FEC92!T;R!T:&4@<'5B;&EC(&]F("0W+C4P('!E<B!S:&%R
M92!L97-S('5N9&5R=W)I=&EN9R!D:7-C;W5N=',N(%5N9&5R('1H92!T97)M
M<R!O9B!T:&4@=6YD97)W<FET:6YG(&%G<F5E;65N="P@=&AE($-O;7!A;GD@
M86QS;R!G<F%N=&5D('1H92!5;F1E<G=R:71E<G,@82`S,"UD87D@;W!T:6]N
M('1O('!U<F-H87-E('5P('1O(&%N(&%D9&ET:6]N86P@,C4P+#`P,"!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K('1O(&-O=F5R(&]V97(M86QL;W1M96YT<RP@
M:68@86YY+"!A="!T:&4@;V9F97)I;F<@<')I8V4N/"]P/CQP('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I
M;CLG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H
M86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SY$=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@
M2G5N92`S,"P@,C`Q,RP@=&AE($-O;7!A;GD@9&ED(&YO="!G<F%N="!A;GD@
M<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VLN($1U<FEN9R!T:&4@<VEX(&UO
M;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D
M(#0T-2PQ-C<@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VL@86YD(&-A;F-E
M;&QE9"`U,"PP,#`@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VLN($]F('1H
M92!T;W1A;"!S:&%R97,@;V8@<F5S=')I8W1E9"!S=&]C:RP@,C`L,#`P('-H
M87)E<R!V97-T(#,@;6]N=&AS(&9R;VT@=&AE(&=R86YT(&1A=&4L(#(R+#4P
M,"!S:&%R97,@=F5S="`Q('EE87(@9G)O;2!T:&4@9W)A;G0@9&%T92P@,3DY
M+#$V-R!S:&%R97,@:&%V92!A('9E<W1I;F<@<&5R:6]D(&]F(#0@>65A<G,@
M86YD(#(P,"PP,#`@<VAA<F5S('9E<W0@870@9&%T92!O9B!G<F%N="X@5&AE
M(')E;6%I;FEN9R!R97-T<FEC=&5D('-H87)E<R!G<F%N=&5D(&%R92!P97)F
M;W)M86YC92!B87-E9"!A;F0@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@8V5R
M=&%I;B!M:6QE<W1O;F5S+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,"XU:6X[)SXF(S$V,#L\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT
M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^/&(^4W1O8VL@3W!T:6]N(%!L86X\+V(^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S
M=&%R=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD
M96YT.B`P+C5I;CLG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^5&AE(&9O
M;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N<R!A8W1I=FET
M:65S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T.CPO
M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6EN9&5N=#H@,"XU-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L-"B!T97AT+71R
M86YS9F]R;3H@;F]N93L-"B!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU-6EN
M.R<^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/CPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0S/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D(&-O;'-P86X],T0S/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0S/E=E:6=H=&5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A
M;CTS1#,^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
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M)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS
M1#,^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#,^3G5M8F5R/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#,^079E<F%G93PO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0S/D-O
M;G1R86-T=6%L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#,^06=G<F5G871E/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O
M;'-P86X],T0S/CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN
M+6)O='1O;3H@,'!X.R<^;V8\+W`^/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@
M,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SY5;FET<SPO<#X\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,SY%>&5R8VES
M928C,38P.SQB<B`O/E!R:6-E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#,^5&5R;28C,38P.RAI;B8C,38P.WEE87)S
M*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X]
M,T0S/CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O
M;3H@,'!X.R<^26YT<FEN<VEC/"]P/CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^5F%L=64\+W`^/"]T9#X\+W1R
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M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T
M,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L.3@U+#,X-#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R<^,RXR,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXX+C,T/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^
M)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@
M<FEG:'0[)SXU+#DP."PV.38\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUL969T.B`Q,'!T.R<^27-S=65D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^.3<Y+#$P,#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXY+C@U
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C$P+C`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/BTF(S$V,#LF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
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M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-S@\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M+28C,38P.R8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXM)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/D]U
M='-T86YD:6YG+"!*=6YE(#,P+"`R,#$T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C@L,S`P+#4V-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/D5X97)C:7-A8FQE+"!*=6YE
M(#,P+"`R,#$T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU+CDY/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU+#0Q."PP,3<\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
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M(#!P>#L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[#0H@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M(#`N-35I;CLG/D1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P
M+"`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&5M<&QO>65E<R!A;F0@8F]A
M<F0@;65M8F5R<R`Y-SDL,3`P(&]P=&EO;G,@=&\@<'5R8VAA<V4@=&AE($-O
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M.B`H,2D@9&ES8V]U;G0@<F%T92!O9B`Q+C@X)2`M(#(N,#<E("@R*2!E>'!E
M8W1E9"!L:69E(&]F(#8@>65A<G,L("@S*2!E>'!E8W1E9"!V;VQA=&EL:71Y
M(&]F(#@W+C`V)2!T;R`X-RXW-B4L(&%N9"`H-"D@>F5R;R!E>'!E8W1E9"!D
M:79I9&5N9',N/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
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M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C4U:6X[)SY$=7)I;F<@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P
M+"`R,#$T+"!T:&4@0V]M<&%N>2!R96-E:79E9"!G<F]S<R!P<F]C965D<R!O
M9B`D-2PR,C`@9F]R(&5X97)C:7-E(&]F(&]P=&EO;G,@9F]R(#$Q+#8U-2!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN/"]P
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M="UI;F1E;G0Z(#`N-35I;CLG/B8C,38P.SPO<#X\<"!S='EL93TS1"=C;VQO
M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[
M)SY!;&P@;W!T:6]N<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%R92!B96EN
M9R!A;6]R=&EZ960@;W9E<B!T:&5I<B!R97-P96-T:79E('9E<W1I;F<@<&5R
M:6]D<RX@5&AE('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@97AP96YS92!A
M="!*=6YE(#,P+"`R,#$T('=A<R`D,3`L,38U+#`P,"X@1'5R:6YG('1H92!T
M:')E92!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@=&AE
M($-O;7!A;GD@<F5C;W)D960@;W!T:6]N(&5X<&5N<V4@;V8@)#8P-RPW.3$@
M86YD("0Y-"PR,#`L(')E<W!E8W1I=F5L>2X@1'5R:6YG('1H92!S:7@@;6]N
M=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(#(P,3,L('1H92!#;VUP86YY
M(')E8V]R9&5D(&]P=&EO;B!E>'!E;G-E(&]F("0X.#DL,3DU(&%N9"`D,3@X
M+#0P,"P@<F5S<&5C=&EV96QY+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M
M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^/&(^)B,Q-C`[/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I
M;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M-6EN.R<^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/D9O;&QO=VEN9R!I<R!A('-U
M;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET:65S(&9O<B!T:&4@<VEX(&UO;G1H
M<R!E;F1E9"!*=6YE(#,P+"`R,#$T.CPO<#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\+W`^/'1A8FQE('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP-"B!S
M97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
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M.B!C96YT97([)R!C;VQS<&%N/3-$,SY!=F5R86=E/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#,^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0S/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0S/E=E:6=H=&5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#,^4F5M
M86EN:6YG/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N
M/3-$,SY5;FET<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M(&-O;'-P86X],T0S/D5X97)C:7-E)B,Q-C`[4')I8V4\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,SY497)M)B,Q-C`[
M*&EN)B,Q-C`[>65A<G,I/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M(')I9VAT.R<@8V]L<W!A;CTS1#,^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
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M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/CDL-C<S+#(Y,#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XP
M-CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXT+C@Y/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXT
M-RPS.38L,S`W/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F
M=#H@,3!P=#LG/D=R86YT960\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXT,#8L.3(X/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C<N.38\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-RXT
M-CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/D5X97)C:7-E9#PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#8V,BPQ-C`\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,7!T.R<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXQ+C0T/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/D]U='-T86YD:6YG+"!*=6YE(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#(N-7!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^.2PT,3@L
M,#4X/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ+C,S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
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M=#LG/C4V+#,V,BPS,3`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^17AE<F-I<V%B;&4L($IU
M;F4-"B`S,"P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXT+C0R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXU-BPQ.#,L,SDS/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/"]P
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M="UI;F1E;G0Z(#`N-6EN.R<^1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D
M($IU;F4@,S`L(#(P,30L('1H92!#;VUP86YY(&=R86YT960@=V%R<F%N=',@
M=&\@<'5R8VAA<V4@,3,W+#DU,B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!C;VUM;VX@<W1O8VL@=&\@:6YV97-T;W)S(&%N9"!W87)R86YT<R!T
M;R!P=7)C:&%S92`V."PY-S8@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K('1O(&ET<R!P;&%C96UE;G0@86=E;G0@:6X@8V]N
M;F5C=&EO;B!W:71H('1H92`R,#$T($-L;W-I;F<N/"]P/CQP('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
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M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
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M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^1'5R:6YG('1H92!S
M:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30L('1H92!#;VUP86YY(&%L
M<V\@9W)A;G1E9"!C;VYS=6QT86YT<R!W87)R86YT<R!T;R!P=7)C:&%S92`R
M,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:R!W:71H(&5X97)C:7-E('!R:6-E<R!R86YG:6YG(&9R;VT@)#4N-34@
M=&\@)#$Q+C8V('!E<B!S:&%R92!A;F0@82!T97)M(&]F(#$P('EE87)S+B!4
M:&5S92!W87)R86YT<R!V97-T('=H96X@8V5R=&%I;B!M:6QE<W1O;F5S(&%R
M92!M970N/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
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M(#`N-6EN.R<^1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L
M(#(P,30L(#8V,BPQ-C`@=V%R<F%N=',@=V5R92!E>&5R8VES960@8GD@=&AE
M('=A<G)A;G0@:&]L9&5R<RX@5&AE($-O;7!A;GD@:7-S=65D(#4W,RPR.3D@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@<F5C96EV960@9W)O<W,@<')O
M8V5E9',@;V8@)#DV+#@V."X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[)SXF(S$V,#L\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6X[)SY$=7)I;F<@=&AE('-I>"!M;VYT:',@96YD
M960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;W)D
M960@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@=&AE('=A
M<G)A;G1S(&]F("0Y."PR,C0@86YD("0P+"!R97-P96-T:79E;'DN/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S
M,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P
M,F$U.3@W9B]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M8G-E<75E;G0@179E;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@979E;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U
M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&(^3F]T92`X("8C
M.#(Q,3L@4W5B<V5Q=65N="!%=F5N=',\+V(^/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;CLG/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CLG/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;CLG/D1U<FEN9R!*=6QY(#(P,30L('1H92!#;VUP86YY(&ES<W5E
M9"`Q-S8L,C$Q('-H87)E<R!O9B!R97-T<FEC=&5D('-T;V-K('1O('=A<G)A
M;G0@:&]L9&5R<RX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="UF86UI;'DZ(&-A;&EB<FDL(&AE
M;'9E=&EC82P@<V%N<RUS97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CLG/D]N($IU;'D@-RP@,C`Q-"P@=&AE($-O;7!A;GD@9FEL
M960@82!&;W)M(%,M."!T;R!O9F9E<B!T:&4@<F5S86QE(&]F('5P('1O(#8L
M-S4P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('!R979I;W5S;'D@9W)A
M;G1E9"!U;F1E<B!T:&4@17%U:71Y($EN8V5N=&EV92!0;&%N+B!0=7)S=6%N
M="!T;R!T:&4@1F]R;2!3+3@L('1H92!#;VUP86YY(&ES<W5E9"`V,2PU,S@@
M<VAA<F5S('1O(&%N(&EN=F5S=&]R(&%N9"!R96-E:79E9"!P<F]C965D<R!O
M9B`D-#@L,#`P+CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
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M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M;G0Z(#`N-6EN.R<^3VX@2G5L>2`Q,"P@,C`Q-"P@=&AE(%5N9&5R=W)I=&5R
M<R!E>&5R8VES960@=&AE:7(@;W9E<BUA;&QO=&UE;G0@;W!T:6]N('1O('!U
M<F-H87-E(&%N(&%D9&ET:6]N86P@,34W+#$R,R!S:&%R97,@9G)O;2!T:&4@
M0V]M<&%N>2!F;W(@)#<N-3`@<&5R('-H87)E+B!);F-L=61I;F<@=&AE(&5X
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M9R!E>'!E;G-E<RX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="UF86UI;'DZ(&-A;&EB<FDL(&AE
M;'9E=&EC82P@<V%N<RUS97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CLG/D]N($IU;'D@,C4L(#(P,30L('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!A;B!A9W)E96UE;G0@=VET:"!A(&-O;G-U;'1A;G0N($%C
M8V]R9&EN9R!T;R!T:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!G<F%N=&5D
M(&%N9"!I<W-U960@,34P+#`P,"!R97-T<FEC=&5D('-H87)E<R!T;R!A(&-O
M;G-U;'1A;G0@86YD(&%L<V\@;6%D92!A("0R-3`L,#`P(&9O<B!S97)V:6-E
M<R!T;R!B92!P<F]V:61E9"!O=F5R(&$@<VEX(&UO;G1H('!E<FEO9"XF(S$V
M,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ
M.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970Q-"YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15!#044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@
M;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S
M:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.871U<F4@;V8@0G5S:6YE<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\8CY.
M871U<F4@;V8@0G5S:6YE<W,@)B,X,C$Q.SPO8CXF(S$V,#M!8W1I;FEU;2!0
M:&%R;6%C975T:6-A;',L($EN8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R
M,3L@;W(@)B,X,C(P.T%C=&EN:75M)B,X,C(Q.RD@:7,@82!B:6]T96-H;F]L
M;V=Y(&-O;7!A;GD@8V]M;6ET=&5D('1O(&1E=F5L;W!I;F<@8G)E86MT:')O
M=6=H('1H97)A<&EE<R!F;W(@;&EF92!T:')E871E;FEN9R!D:7-E87-E<R!U
M<VEN9R!I=',@86QP:&$@<&%R=&EC;&4@:6UM=6YO=&AE<F%P>2`H05!)5"D@
M<&QA=&9O<FT@86YD(&]T:&5R(')E;&%T960@86YD('-I;6EL87(@=&5C:&YO
M;&]G:65S+B!!8W1I;FEU;2P@=&]G971H97(@=VET:"!I=',@=VAO;&QY(&]W
M;F5D('-U8G-I9&EA<GDL($UE9$%C=&EN:75M+"!);F,N("A-04DI+"`H:&5R
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M=')I86P@:6X@86-U=&4@;7EE;&]I9"!L975K96UI82`H04U,*2!P871I96YT
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M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C4U:6X[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,CDN-W!T.R<^
M/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
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M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU-6EN.R<^3VX@1&5C96UB97(@,C@L(#(P,3(L('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!A('1R86YS86-T:6]N("AT:&4@)B,X
M,C(P.U-H87)E($5X8VAA;F=E)B,X,C(Q.RDL('!U<G-U86YT('1O('=H:6-H
M('1H92!#;VUP86YY(&%C<75I<F5D(#$P,"4@;V8@=&AE(&ES<W5E9"!A;F0@
M;W5T<W1A;F1I;F<@97%U:71Y('-E8W5R:71I97,@;V8@06-T:6YI=6T@4&AA
M<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[05!))B,X,C(Q.RDL(&EN(&5X
M8VAA;F=E(&9O<B!T:&4@:7-S=6%N8V4@;V8@87!P<F]X:6UA=&5L>2`Y.24@
M;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K+"!P
M87(@=F%L=64@)#`N,#$@<&5R('-H87)E+"!O9B!T:&4@0V]M<&%N>2X@07,@
M82!R97-U;'0@;V8@=&AE(%-H87)E($5X8VAA;F=E+"!T:&4@9F]R;65R('-H
M87)E:&]L9&5R<R!O9B!!4$D@8F5C86UE('1H92!C;VYT<F]L;&EN9R!S:&%R
M96AO;&1E<G,@;V8@=&AE($-O;7!A;GDN($%T('1H92!C;&]S:6YG+"!E86-H
M($%022!S:&%R96AO;&1E<B!R96-E:79E9"`P+C,S,R!S:&%R97,@*'1H92`F
M(S@R,C`[17AC:&%N9V4@4F%T:6\F(S@R,C$[*2!O9B!!8W1I;FEU;2!C;VUM
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M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M="UI;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
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M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG
M/D%S(&$@<F5S=6QT(&]F('1H92!3:&%R92!%>&-H86YG92P@=&AE($-O;7!A
M;GD@:7,@;F]W(&$@:&]L9&EN9R!C;VUP86YY(&]P97)A=&EN9R!T:')O=6=H
M($%022P@82!C;&EN:6-A;"US=&%G92!B:6]P:&%R;6%C975T:6-A;"!C;VUP
M86YY(&1E=F5L;W!I;F<@8V5R=&%I;B!C86YC97(@=')E871M96YT<RX\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
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M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/D]N
M($UA<F-H(#(P+"`R,#$S+"!T:&4@0V]M<&%N>28C.#(Q-SMS('-U8G-I9&EA
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M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R
M=#L-"B!T97AT+71R86YS9F]R;3H-"B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT+6EN
M9&5N=#H@,"XU:6X[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^3VX@
M4V5P=&5M8F5R(#(U+"`R,#$S+"!I;B!A8V-O<F1A;F-E('=I=&@@82!#97)T
M:69I8V%T92!O9B!/=VYE<G-H:7`@365R9VEN9R!!8W1I;FEU;2!#;W)P;W)A
M=&EO;B!I;G1O('1H92!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@
M*&9I;&5D(&EN($1E;&%W87)E+"!T:&4@0V]M<&%N>2!M97)G960@*'1H92`F
M(S@R,C`[365R9V5R)B,X,C(Q.RD@:6YT;R!I='-E;&8@06-T:6YI=6T@0V]R
M<&]R871I;VX@*&$@.3,N-R4@;W=N960@<W5B<VED:6%R>2DL(&%N9"!!8W1I
M;FEU;2!#;W)P;W)A=&EO;B!C96%S960@=&\@97AI<W0N($%S(&$@<F5S=6QT
M(&]F('1H92!-97)G97(L($%C=&EN:75M($-O<G!O<F%T:6]N('-T;V-K(&]W
M;F5D(&)Y('1H92!#;VUP86YY('=A<R!C86YC96QL960@86YD(&5A8V@@<VAA
M<F4@;V8@06-T:6YI=6T@0V]R<&]R871I;VX@;F]T(&]W;F5D(&)Y('1H92!#
M;VUP86YY('=A<R!E>&-H86YG960@9F]R(#`N,S,S('-H87)E<R!O9B!#;VUP
M86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+B!!('1O=&%L(&]F(#,L.3<P+#$S
M-R!S:&%R97,@;V8@06-T:6YI=6T@0V]R<&]R871I;VX@8V]M;6]N('-T;V-K
M('=A<R!E>&-H86YG960@9F]R(#$L,S(R+#`U-2!S:&%R97,@;V8@0V]M<&%N
M>2!C;VUM;VX@<W1O8VLN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T:6]N("T@
M56YA=61I=&5D($EN=&5R:6T@1FEN86YC:6%L($EN9F]R;6%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&(^0F%S:7,@;V8@
M4')E<V5N=&%T:6]N("T@56YA=61I=&5D($EN=&5R:6T@1FEN86YC:6%L($EN
M9F]R;6%T:6]N("8C.#(Q,3L\+V(^)B,Q-C`[5&AE(&%C8V]M<&%N>6EN9R!U
M;F%U9&ET960@:6YT97)I;2!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%N9"!R96QA=&5D(&YO=&5S(&AA=F4@8F5E;B!P
M<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP
M;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O
M9B!!;65R:6-A("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R
M:6T@9FEN86YC:6%L(&EN9F]R;6%T:6]N+"!A;F0@:6X@86-C;W)D86YC92!W
M:71H('1H92!R=6QE<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%5N:71E9"!3
M=&%T97,@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE
M("8C.#(R,#M314,F(S@R,C$[*2!W:71H(')E<W!E8W0@=&\@1F]R;2`Q,"U1
M(&%N9"!!<G1I8VQE(#@@;V8@4F5G=6QA=&EO;B!3+5@N($%C8V]R9&EN9VQY
M+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@
M86YD(&9O;W1N;W1E<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L
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M<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@;F]T97,@
M=&AE<F5T;R!C;VYT86EN960@:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!A;FYU
M86P@<F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C
M96UB97(@,S$L(#(P,3,L(&%S(&9I;&5D('=I=&@@=&AE(%-%0R!&96)R=6%R
M>2`R."P@,C`Q-"X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA
M;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&9O;G0M<VEZ93H@.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN
M8VEP;&5S(&]F($-O;G-O;&ED871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F
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M8F5E;B!E;&EM:6YA=&5D+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S
M(&EN($9I;F%N8VEA;"!3=&%T96UE;G0@4')E<V5N=&%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU-6EN.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&(^57-E(&]F($5S=&EM
M871E<R!I;B!&:6YA;F-I86P@4W1A=&5M96YT(%!R97-E;G1A=&EO;B`F(S@R
M,3$[/"]B/B8C,38P.U1H92!P<F5P87)A=&EO;B!O9B!T:&5S92!C;VYD96YS
M960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O
M<FUI='D@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A;&QY(&%C
M8V5P=&5D(&EN('1H92!5;FET960@4W1A=&5S(&]F($%M97)I8V$@<F5Q=6ER
M97,@;6%N86=E;65N="!T;R!M86ME(&5S=&EM871E<R!A;F0@87-S=6UP=&EO
M;G,@=&AA="!A9F9E8W0@=&AE(')E<&]R=&5D(&%M;W5N=',@;V8@87-S971S
M(&%N9"!L:6%B:6QI=&EE<R!A="!T:&4@9&%T92!O9B!T:&4@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!T:&4@<F5P;W)T960@86UO
M=6YT<R!O9B!R979E;G5E<R!A;F0@97AP96YS97,@9'5R:6YG('1H92!R97!O
M<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D:69F97(@9G)O
M;2!T:&]S92!E<W1I;6%T97,N/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQB('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,W!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS
M.B!A=71O.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@-3(N
M-SDY.3DY,C,W,#8P-35P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/E)E8VQA<W-I
M9FEC871I;VX@)B,X,C$Q.SPO8CXF(S$V,#M#97)T86EN('!R:6]R('!E<FEO
M9"!A;6]U;G1S(&AA=F4@8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;2!T
M;R!C=7)R96YT('!E<FEO9"!P<F5S96YT871I;VXN/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX\8B!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#4R+C<Y.3DY.3(S-S`V,#4U<'@[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[
M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S("8C.#(Q,3L\+V(^
M)B,Q-C`[5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@;&EQ=6ED
M(&%C8V]U;G1S('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O9B!T:')E92!M
M;VYT:',@;W(@;&5S<R!T;R!B92!C87-H(&5Q=6EV86QE;G1S+B!3=6-H(&)A
M;&%N8V5S(&%R92!U<W5A;&QY(&EN(&5X8V5S<R!O9B!&1$E#(&EN<W5R960@
M;&EM:71S+B!!="!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q
M,RP@86QL(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V%S:"!W87,@9&5P;W-I
M=&5D(&EN(&]N92!B86YK+CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
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M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&(@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`U,BXW.3DY.3DR,S<P-C`U-7!X
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M=VED;W=S.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^26UP86ER;65N="!O9B!,;VYG+4QI=F5D
M($%S<V5T<R`F(S@R,3$[)B,Q-C`[/"]B/DUA;F%G96UE;G0@<F5V:65W<R!L
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M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I
M=F%T:79E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M/&(@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$S<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`U,BXW.3DY.3DR,S<P-C`U-7!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B!A=71O.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^1&5R
M:79A=&EV97,@)B,X,C$Q.SPO8CXF(S$V,#M!;&P@9&5R:79A=&EV97,@87)E
M(')E8V]R9&5D(&%T(&9A:7(@=F%L=64@;VX@=&AE(&)A;&%N8V4@<VAE970N
M($9A:7(@=F%L=65S(&9O<B!S96-U<FET:65S('1R861E9"!I;B!T:&4@;W!E
M;B!M87)K970@86YD(&1E<FEV871I=F5S(&%R92!B87-E9"!O;B!Q=6]T960@
M;6%R:V5T('!R:6-E<RX@5VAE<F4@;6%R:V5T('!R:6-E<R!A<F4@;F]T(')E
M861I;'D@879A:6QA8FQE+"!F86ER('9A;'5E<R!A<F4@9&5T97)M:6YE9"!U
M<VEN9R!M87)K970@8F%S960@<')I8VEN9R!M;V1E;',@:6YC;W)P;W)A=&EN
M9R!R96%D:6QY(&]B<V5R=F%B;&4@;6%R:V5T(&1A=&$@86YD(')E<75I<FEN
M9R!J=61G;65N="!A;F0@97-T:6UA=&5S+CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O
M9B!&:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[)SX\8CY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!)
M;G-T<G5M96YT<R`F(S@R,3$[/"]B/B8C,38P.T9A:7(@=F%L=64@:7,@9&5F
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M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M(#AP=#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
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M,'!X.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#`N-35I;CL@=&5X="UA;&EG;CH@
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M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E
M>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US
M<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<VEZ93H@
M.'!T.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU-6EN.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^3&5V
M96P@,B!);G!U=',@)B,X,C$Q.R!);G!U=',@;W1H97(@=&AA;B!Q=6]T960@
M<')I8V5S(&EN8VQU9&5D(&EN($QE=F5L(#$@=&AA="!A<F4@;V)S97)V86)L
M92!F;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2P@96ET:&5R(&1I<F5C=&QY
M(&]R(&EN9&ER96-T;'DN(%1H97-E(&UI9VAT(&EN8VQU9&4@<75O=&5D('!R
M:6-E<R!F;W(@<VEM:6QA<B!A<W-E=',@;W(@;&EA8FEL:71I97,@:6X@86-T
M:79E(&UA<FME=',L('%U;W1E9"!P<FEC97,@9F]R(&ED96YT:6-A;"!O<B!S
M:6UI;&%R(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!I;B!M87)K971S('1H870@
M87)E(&YO="!A8W1I=F4L(&EN<'5T<R!O=&AE<B!T:&%N('%U;W1E9"!P<FEC
M97,@=&AA="!A<F4@;V)S97)V86)L92!F;W(@=&AE(&%S<V5T(&]R(&QI86)I
M;&ET>2`H<W5C:"!A<R!I;G1E<F5S="!R871E<RP@=F]L871I;&ET:65S+"!P
M<F5P87EM96YT('-P965D<RP@8W)E9&ET(')I<VMS+"!E=&,N*2!O<B!I;G!U
M=',@=&AA="!A<F4@9&5R:79E9"!P<FEN8VEP86QL>2!F<F]M(&]R(&-O<G)O
M8F]R871E9"!B>2!M87)K970@9&%T82!B>2!C;W)R96QA=&EO;B!O<B!O=&AE
M<B!M96%N<RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
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M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@@,'!X(#!P>"`P+C4U
M:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[)SY,979E;"`S($EN<'5T<R`F(S@R,3$[(%5N;V)S97)V
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M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X(#<N-W!T.R!T97AT+6EN9&5N
M=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
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M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/E1H92!F;VQL;W=I
M;F<@=&%B;&5S('-E="!F;W)T:"!A<W-E=',@86YD(&QI86)I;&ET:65S(&UE
M87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@86YD(&YO;BUR
M96-U<G)I;F<@8F%S:7,@8GD@;&5V96P@=VET:&EN('1H92!F86ER('9A;'5E
M(&AI97)A<F-H>2!A<R!O9B!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S
M,2P@,C`Q,RX@07,@<F5Q=6ER960@8GD@05-#(#@R,"`F(S@R,C`[/&D^1F%I
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M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C4U:6X[)SX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M,'!X.R!M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!B;W)D97(M8V]L;&%P<V4Z
M(&-O;&QA<'-E.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L-"B`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D('-T
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY,979E;"`R/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/E1O=&%L/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=PT*(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0-"B!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T
M:#H@.#`Q+C8W,3@W-7!X.R!P861D:6YG+6QE9G0Z(#$P<'0[(&9O;G0M<W1Y
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^070@2G5N92`S,"P@
M,C`Q-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.@T*(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.PT*(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,35P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CDL.#(V+#8R
M-SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B0\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D%T($1E8V5M8F5R
M(#,Q+"`R,#$S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-BPW,#<L,C4U
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/C8L-S`W+#(U-3PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^/"]T86)L93X\9&EV/B8C,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE(%1A>&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\8B!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3-P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T
M;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#4R+C<Y.3DY
M.3(S-S`V,#4U<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY);F-O;64@5&%X97,@
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M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H
M(&%N9"!$979E;&]P;65N="!#;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/CQB/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#
M;W-T<R`F(S@R,3$[/"]B/B8C,38P.U)E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!C;W-T<R!A<F4@97AP96YS960@87,@:6YC=7)R960N(%)E<V5A<F-H(&%N
M9"!D979E;&]P;65N="!R96EM8G5R<V5M96YT<R!A;F0@9W)A;G1S(&%R92!R
M96-O<F1E9"!B>2!T:&4@0V]M<&%N>2!A<R!A(')E9'5C=&EO;B!O9B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',N/"]F;VYT/CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+4)A<V5D(%!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX\8B!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#4R+C<Y.3DY.3(S-S`V,#4U<'@[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SY3:&%R92U"87-E9"!087EM96YT<R`F(S@R,3$[/"]B/B8C,38P.U1H
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M:71A;"X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5A<FYI;F=S("A,;W-S*2!097(@0V]M;6]N(%-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`^/&9O;G0@<VEZ
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M(&5N9&5D($IU;F4@,S`L(#(P,30L(&ES(&-O;7!U=&5D(&)Y(&1I=FED:6YG
M('1H92!N970@:6YC;VUE(&%V86EL86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD
M97)S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@
M<VAA<F5S(&]U='-T86YD:6YG('!L=7,@9&EL=71I=F4@<V5C=7)I=&EE<RX@
M1F]R('1H92!T:')E92!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,R!A;F0@
M=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@
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M9"!*=6YE)B,Q-C`[,S`L(#(P,30L('!O=&5N=&EA;&QY(&ES<W5A8FQE('-H
M87)E<R!I;F-L=61E9"!S=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(#$L,SDX
M+#DS-R!S:&%R97,@86YD('=A<G)A;G1S('1O('!U<F-H87-E(#@L-C8W+#8V
M,R!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN
M($9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!P;W1E
M;G1I86QL>2!I<W-U86)L92!S:&%R97,@:6YC;'5D960@<W1O8VL@;W!T:6]N
M<R!T;R!P=7)C:&%S92`R+#DU,BPX,CD@<VAA<F5S(&%N9"!W87)R86YT<R!T
M;R!P=7)C:&%S92`Y+#0Q."PP-3@@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X
M,C$W.W,@8V]M;6]N('-T;V-K+B!&;W(@=&AE('-I>"!M;VYT:',@96YD960@
M2G5N92`S,"P@,C`Q,RP@<&]T96YT:6%L;'D@:7-S=6%B;&4@<VAA<F5S(&EN
M8VQU9&5D('-T;V-K(&]P=&EO;G,@=&\@<'5R8VAA<V4@,BPR.#`L,3@T('-H
M87)E<R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA<V4@.2PU,S4L-CDT('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX\+V9O;G0^
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/&(^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',@
M)B,X,C$Q.R8C,38P.SPO8CY);B!-87D@,C`Q-"P@=&AE($9I;F%N8VEA;"!!
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M=&EO;B!R97%U:7)E;65N=',@:6X@5&]P:6,@-C`U+"!2979E;G5E(%)E8V]G
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M4W1A;F1A<F1S(%5P9&%T92`R,#$Q)B,X,C$Q.S(U,"8C.#(Q,CM2979E;G5E
M(%)E8V]G;FET:6]N("A4;W!I8R`V,#4I.B!#;V1I9FEC871I;VX@06UE;F1M
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M=&5M96YT<RX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@@,'!X
M(#!P>"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SY);B!*=6YE(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N
M9&%R9',@0F]A<F0@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T
M92`R,#$T+3$P+"!$979E;&]P;65N="!3=&%G92!%;G1I=&EE<RX@5&AE(&%M
M96YD;65N=',@:6X@=&AI<R!5<&1A=&4@<F5M;W9E('1H92!D969I;FET:6]N
M(&]F(&$@9&5V96QO<&UE;G0@<W1A9V4@96YT:71Y(&9R;VT@5&]P:6,@.3$U
M+"!T:&5R96)Y(')E;6]V:6YG('1H92!D:7-T:6YC=&EO;B!B971W965N(&1E
M=F5L;W!M96YT('-T86=E(&5N=&ET:65S(&%N9"!O=&AE<B!R97!O<G1I;F<@
M96YT:71I97,@9G)O;2!5+E,N($=!05`N($EN(&%D9&ET:6]N+"!T:&4@86UE
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M<F%G<F%P:"`X,3`M,3`M,34M,30H82D@=&\@8F4@82!V87)I86)L92!I;G1E
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M.T1E=F5L;W!M96YT(%-T86=E($5N=&ET:65S("A4;W!I8R`Y,34I+"!W:&EC
M:"!H87,@8F5E;B!D96QE=&5D+B!4:&4@86UE;F1M96YT<R!I;B!T:&ES(%5P
M9&%T92!A<F4@969F96-T:79E(&9O<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO
M9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$T+"!A;F0@:6YT
M97)I;2!P97)I;V1S('1H97)E:6XL(&%N9"!E87)L>2!A9&]P=&EO;B!I<R!R
M97%U:7)E9"X@5&AE($-O;7!A;GD@979A;'5A=&5D(&%N9"!A9&]P=&5D($%3
M52`R,#$T+3$P(&9O<B!T:&4@<F5P;W)T:6YG('!E<FEO9"!E;F1E9"!*=6YE
M(#,P+"`R,#$T+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X(#!P>"`P<'@@,"XU:6X[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#`N-6EN
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^
M/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SY);B!*=6YE(#(P,30L('1H92!&:6YA;F-I
M86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@:7-S=65D($%C8V]U;G1I
M;F<@4W1A;F1A<F1S(%5P9&%T92`R,#$T+3$R+"!#;VUP96YS871I;VXM(%-T
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M:6]N)B,X,C$R.U-T;V-K($-O;7!E;G-A=&EO;B`H5&]P:6,@-S$X*3H@06-C
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M=&EO;B`H5&]P:6,@-S$X*3H@06-C;W5N=&EN9R!F;W(@4VAA<F4M0F%S960@
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M(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$U+"!A;F0@96%R;'D@861O<'1I;VX@
M:7,@<&5R;6ET=&5D+B!4:&4@0V]M<&%N>2!I<R!C=7)R96YT;'D@979A;'5A
M=&EN9R!T:&4@969F96-T<R!O9B!!4U4@,C`Q-"TQ,B!O;B!T:&4@8V]N<V]L
M:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9F]N=#X\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S
M97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^/&(@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z
M(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`U,BXW.3DY.3DR,S<P-C`U-7!X.R!T97AT+71R86YS9F]R;3H@
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M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y
M-%]B83`V,#)A-3DX-V8O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@
M0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S
M(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W5M;6%R>2!O9B!S970@9F]R=&@@;&EA8FEL:71I97,@
M;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG
M/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQT
M9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M86XG+"!T:6UE<RP@<V5R:68[)SY,979E;"`Q/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3&5V96P@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC
M;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\
M=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z#0H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.PT*
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T
M:#H@.#`Q+C8W,3@W-7!X.R!P861D:6YG+6QE9G0Z(#$P<'0[(&9O;G0M<W1Y
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^070@2G5N92`S,"P@
M,C`Q-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.@T*(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B0\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^.2PX,C8L-C(W/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ
M93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY!="!$96-E;6)E<B`S
M,2P@,C`Q,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L-"B!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\
M+W1A8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@@
M-RXW<'0[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V
M96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O
M<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS("A486)L
M97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M
M;6%R>2!O9B!A8W1I=FET:65S(')E;&%T960@=&\@<F5L871E9"!P87)T>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
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M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I
M;CLG/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
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M:#H@,39P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXW-3`L,#`P/"]T9#X\=&0@
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M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#<U,"PP,#`\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B
M,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P
M-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE
M;G0@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-U;6UA<GD@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`R.2XW<'0[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(&-A
M;&EB<FDL(&AE;'9E=&EC82P@<V%N<RUS97)I9CL@=VED=&@Z(#$U-C=P>#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
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M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
M+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$
M,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3&EV97,\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/DIU;F4@,S`L(#(P,30\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/D1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,#4P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3V9F:6-E(&5Q=6EP;65N
M=#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$R-G!X.R!T97AT+6%L:6=N.B!C96YT97([
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[,RTU('EE87)S/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,39P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C9P>#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,30S+#DQ.3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO
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M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
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M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXI)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,2PU-C`\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/BDF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SY0<F]P97)T>2!A;F0@97%U:7!M96YT
M+"!N970\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
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M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
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M97(M8F]T=&]M+7=I9'1H.B`R+C(U<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXQ,RPY,C`\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V
M,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S
M,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE
M970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D1E<FEV871I=F5S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5R:79A=&EV97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@9&5R:79A=&EV92!W87)R86YT(&EN<W1R=6UE;G1S(&%C
M=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U
M-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
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M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
M<&%N/3-$,CY5;FET<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,3DQ<'@[)SY"86QA;F-E+"!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R<^,2PY-C@L-C(S/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,35P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXV+#<P-RPR-34\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/D-H86YG92!I;B!F
M86ER('9A;'5E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC
M;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0L-C(Q
M+#,V,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M;W1T;VTZ(#(N-7!T.R<^0F%L86YC92P@2G5N92`S,"P@,C`Q-#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`R+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#(N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,2PW-S0L.38R/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO
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M.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/&1I=CXF(S$V,#L\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U;6UA<GD@;V8@9F%I<B!V86QU97,@;V8@9&5R:79A=&EV92!W
M87)R86YT<R!O;B!B87-I<R!O9B!V86QU871I;VX@;6]D96P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/CQT86)L92!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,3(U,W!X.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0R/DIU;F4@,S`L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(^1&5C96UB97(F(S$V,#LS,2P\+W1D/CQT9#XF(S$V
M,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Y-3-P>#L@=&5X="UA;&EG;CH@;&5F=#LG/DUA<FME="!V86QU
M92!O9B!C;VUM;VX@<W1O8VL@;VX@;65A<W5R96UE;G0@9&%T92`H,2D\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,3-P>#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,W!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,3-P>#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXW+C(R/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S<'@[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3)P
M>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,G!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,3)P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXU+C@Y/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$R<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D/D%D:G5S=&5D(&5X97)C:7-E('!R
M:6-E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C(N-#@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C(N-#@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY2:7-K(&9R964@:6YT97)E<W0@
M<F%T92`H,BD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ+C$Y/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+C(W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B4\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY787)R86YT(&QI=F5S(&EN
M('EE87)S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M,RXU('EE87)S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M960@=F]L871I;&ET>2`H,RD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW,SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
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M<B`U('EE87)S("@U*3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C(U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^,S4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)3PO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT
M9#Y/9F9E<FEN9R!P<FEC92!R86YG92`H-RD\+W1D/CQT9#XF(S$V,#L\+W1D
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M93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]P/CQT86)L92!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`W.7!X.R!T97AT+6%L
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M65-%($U+5"!F;W(@2G5N92`S,"P@,C`Q-"X\+V9O;G0^/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^*#(I/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY4
M:&4@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@=V%S(&1E=&5R;6EN960@8GD@
M;6%N86=E;65N="!U<VEN9R!T:&4@5')E87-U<GD@0FEL;"!A<R!O9B!T:&4@
M<F5S<&5C=&EV92!M96%S=7)E;65N=`T*(&1A=&4N/"]F;VYT/CPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.@T*(&IU<W1I9GD[)SXF(S$V,#L\+W1D/CPO='(^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^*#,I/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
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M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M
M.B`P<'@[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^
M/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4],T0G=VED=&@Z(#<Y
M<'@[('1E>'0M86QI9VXZ(&-E;G1E<CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/B@T*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,30X.'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^36%N86=E;65N="!D971E<FUI;F5D('1H
M92!D:79I9&5N9"!Y:65L9"!T;R!B92`P)2!B87-E9"!U<&]N(&ET<R!E>'!E
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M)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@
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M:R!O9F9E<FEN9R!W:6QL(&)E(#`E(&%N9"`S-24@;V8@=&AE('-H87)E<R!O
M=71S=&%N9&EN9R!A="!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@
M,C`Q,RP@<F5S<&5C=&EV96QY+CPO<#X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SX\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
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M+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@@-RXW
M<'0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F.#)?-#9E8U\Y
M,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8O5V]R:W-H
M965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
M="US:7IE.B`X<'0[(&UA<F=I;CH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
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M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXW-3`L,#`P/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXH,BD@=VAE;B!#;VUP86YY(&EN:71I871E<R!A(%!H87-E($E)
M($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O9'5C=#PO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C<U
M,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXH,RD@=VAE;B!#;VUP86YY(&EN:71I871E
M<R!A(%!H87-E($E)22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R
M;V1U8W0\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ+#4P,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
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M=#LG/C$L-S4P+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B@U*2!&:7)S="!C;VUM97)C
M:6%L('-A;&4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ+#4P,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*#8I(&%F=&5R
M('1H92!F:7)S="`D,3`L,#`P+#`P,"!I;B!N970@<V%L97,\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#4P
M,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V
M,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S
M,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE
M970R,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14=&04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^17%U:71Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE
M;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&]P=&EO;B!A8W1I=FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M<F]K92UW:61T:#H@,'!X.R!M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N
M-35I;CLG/B8C,38P.SPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z
M(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
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M/3-$,SY!=F5R86=E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS
M1#,^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M(&-O;'-P86X],T0S/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0S/E=E:6=H
M=&5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#,^4F5M86EN:6YG/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L
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M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,SX\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P
M<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/F]F/"]P/CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^56YI=',\+W`^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS
M1#,^17AE<F-I<V4F(S$V,#L\8G(@+SY0<FEC93PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
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M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)R!C;VQS<&%N/3-$,SX\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&UA
M<F=I;BUB;W1T;VTZ(#!P>#LG/DEN=')I;G-I8SPO<#X\<"!S='EL93TS1"=M
M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/E9A;'5E/"]P
M/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQT9#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y
M;&4],T0G=VED=&@Z(#@Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^3W5T<W1A
M;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#DX-2PS.#0\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C,N,C,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^."XS
M-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF
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M,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^.2XX-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ,"XP,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
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M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-S@\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^+28C,38P.R8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXM)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/D]U='-T86YD:6YG+"!*=6YE(#,P+"`R,#$T/"]T9#X\=&0^)B,Q-C`[/"]T
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M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C@L,S`P+#4V-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/D5X97)C:7-A8FQE+"!*
M=6YE(#,P+"`R,#$T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU+CDY/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU+#0Q."PP,3<\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CPO=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3
M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O
M9B!O<'1I;VX@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0S/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0S/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0S/E=E:6=H=&5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#,^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
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M;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L
M<W!A;CTS1#,^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#,^5V5I9VAT960\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,SY296UA:6YI;F<\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,SY!9V=R96=A=&4\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#,^3G5M8F5R(&]F/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#,^079E<F%G93PO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0S/D-O;G1R86-T=6%L/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#,^26YT<FEN<VEC/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0S/E5N:71S/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#,^17AE<F-I<V4F
M(S$V,#M0<FEC93PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,SY686QU
M93PO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<@8V]L<W!A;CTS1#,^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)R!C;VQS<&%N/3-$,SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG(&-O;'-P86X],T0S/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@8V]L<W!A
M;CTS1#,^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)W=I9'1H.B`X,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/D]U
M='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^.2PV-S,L
M,CDP/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T
M,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#8\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R<^-"XX.3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXT-RPS.38L,S`W/"]T
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M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXT,#8L.3(X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C<N.38\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-RXT-CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/D5X97)C:7-E9#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#8V,BPQ-C`\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^
M*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXQ+C0T/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/D]U='-T86YD:6YG
M+"!*=6YE(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#(N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^.2PT,3@L,#4X/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXQ+C,S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0N-30\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/C4V+#,V,BPS
M,3`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V5E9F8[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^17AE<F-I<V%B;&4L($IU;F4@,S`L(#(P,30\
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(')I
M9VAT.R<^-38L,3@S+#,Y,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T
M<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
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M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-35I;CLG/CPO<#X\<"!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
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M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C4U
M:6X[)SX\+W`^/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT
M7V)A,#8P,F$U.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q
M-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8O5V]R:W-H965T
M<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%1$M!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O
M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&QI86)I;&ET:65S(&UE
M87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I
M=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Y+#@R-BPV,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8L-S`W+#(U-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@,2!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M
M;6%R>2!O9B!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N
M(&$@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&QI86)I;&ET:65S
M(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U;6UA<GD@;V8@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V
M86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL.#(V+#8R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-BPW,#<L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C
M7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14]#0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I
M;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D]P=&EO;G,@06YD(%=A<G)A;G1S
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^3W!T:6]N<R!!;F0@5V%R<F%N=',@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,SQB<CY/<'1I;VYS($%N9"!787)R86YT<R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;6UO
M;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S
M/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/DUA8VAI;F5R>2!A;F0@
M97%U:7!M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,C@L(#(P,3(\8G(^06-T:6YI=6T@6TUE;6)E<ET\8G(^
M<'5R97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`R
M-2P@,C`Q,SQB<CY!8W1I;FEU;2!;365M8F5R73QB<CYP=7)E<SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$97-C<FEP
M=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!
M8V-O=6YT:6YG(%!O;&EC:65S("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!)
M;F-O<G!O<F%T:6]N+"!$871E(&]F($EN8V]R<&]R871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D]C="`V+`T*"0DQ.3DW/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&5R8V5N=&%G92!O9B!O=VYE<G-H:7`@:6YT97)E<W0@86-Q=6ER960@
M8GD@8V]M<&%N>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDS+C<P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K(&ES<W5A8FQE(&EN
M(&-O;G-I9&5R871I;VX@9F]R(&5Q=6ET>2!I;G1E<F5S="!A8W%U:7-I=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DN
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%<W1I;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:')E92!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R97,@<F5C96EV960@8GD@96%C:"!!4$D@<VAA<F5H;VQD97(@;V8@06-T
M:6YI=6T@8V]M;6]N('-T;V-K(&9O<B!E86-H($%022!S:&%R92!E>&-H86YG
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!O=&5N=&EA;&QY(&ES<W5A8FQE('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,Y."PY,S<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DU,BPX,CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#(X,"PQ.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX+#8V-RPV-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#0Q."PP-3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4S-2PV.30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#DW,"PQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,@97AC
M:&%N9V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PS,C(L,#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T
M-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970R,RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14I*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5L871E
M9"!087)T>2!4<F%N<V%C=&EO;G,@*$1E=&%I;',I("A-96UO<FEA;"!3;&]A
M;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B!;365M8F5R72P@55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE=R!$<G5G
M($%P<&QI8V%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE
M;G1S(')E;&%T960@=&\@<F5L871E9"!P87)T>3PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M96-E:7!T(&]F(%)E9W5L871O<GD@07!P<F]V86P@1G)O;2!5+E,N($9$02!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT<R!R96QA=&5D('1O
M(')E;&%T960@<&%R='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;&5S=&]N97,@<&%Y;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PW-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?
M.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS
M:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15581$L^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@*$1E=&%I
M;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`R-"P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#(X
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N
M+B`Q,"P@,C`Q-#QB<CY0;&%C96UE;G0@86=E;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`P.2P@,C`Q,SQB<CY0
M;&%C96UE;G0@86=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^075G+B`P-RP@,C`Q,CQB<CY0;&%C96UE;G0@86=E;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q-#QB<CY0;&%C96UE;G0@86=E;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q-#QB<CY#
M;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY#;VUM;VX@4W1O8VL@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@
M,C`Q-#QB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^4&QA8V5M96YT(&%G
M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIA;BX@,S$L(#(P,30\8G(^5V%R<F%N="!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/DU32T-#
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3,\8G(^35-+0T,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY-4TM#0R!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/DU32T-#(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G
M<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#(W+"`R,#$R/&)R/DU32T-#(%M-96UB97)=/&)R/D-L:6YI
M8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#`T+"`R,#$S/&)R/E-+22!;365M8F5R
M73QB<CY,:6-E;G-E+"!$979E;&]P;65N="!A;F0@0V]M;65R8VEA;&EZ871I
M;VX@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,3DL(#(P,3$\8G(^4TM)(%M-96UB97)=/&)R/DQI
M8V5N<V4L($1E=F5L;W!M96YT(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!!9W)E
M96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CY32TD@6TUE;6)E<ET\8G(^3&EC96YS92P@
M1&5V96QO<&UE;G0@86YD($-O;6UE<F-I86QI>F%T:6]N($%G<F5E;65N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/E-+22!;365M8F5R73QB<CY,:6-E;G-E+"!$979E;&]P
M;65N="!A;F0@0V]M;65R8VEA;&EZ871I;VX@06=R965M96YT(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS("A497AT=6%L*3PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M;W5N="!P86ED('5N9&5R(&%G<F5E;65N="!I;B`R,#$Q
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!P86ED('5N9&5R(&%G<F5E;65N="!I
M;B`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT('!A:60@=6YD97(@86=R965M
M96YT(&EN(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@;W=E9"!U;F1E<B!A
M9W)E96UE;G0@9G)O;2`R,#$Q('1O(#(P,30\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,34L,3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86EN
M=&5N86YC92!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!L86-E;65N="!A9V5N
M="!S97)V:6-E<R!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D
M('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:RP@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PY-S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@97AE<F-I<V4@<')I8V4@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%M;W5N="!P86ED('1O(&5A8V@@<&%T:65N="!A9G1E<B!#;VUP
M;&5T:6YG(&-L:6YI8V%L('1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PQ.#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%R="UU<"!F
M964@9F]R(&-L:6YI8V%L('1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#8R,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO
M;B!O9B!R96-E:79A8FQE<R!O9B!P;&%C96UE;G0@86=E;G0@9F]R('-E<G9I
M8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%G<F5E
M;65N="!E;G1E<F5D(&EN(&]N($1E8V5M8F5R(#DL(#(P,3,@:&%D('-I;6EL
M87(@=&5R;7,@87,@=&AE(#(P,3(@86=R965M96YT+"!I;F-L=61I;F<@82!C
M87-H(&9E92!E<75A;"!T;R`Q,"4@;V8@=&AE(&=R;W-S('!R;V-E961S(')A
M:7-E9"P@82!N;VXM86-C;W5N=&%B;&4@97AP96YS92!R96EM8G5R<V5M96YT
M(&5Q=6%L('1O(#(E(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960@86YD
M('=A<G)A;G1S('1O('!U<F-H87-E('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S
M($-O;6UO;B!3=&]C:SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=0;&%C96UE;G0@86=E;G0@=VEL;"!R96-E:79E("AA
M*2!A(&-A<V@@9F5E(&5Q=6%L('1O(#$P)2!O9B!T:&4@9W)O<W,@<')O8V5E
M9',@<F%I<V5D(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@
M*&(I(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E;65N="!E
M<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D(&EN('1H
M92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RP@86YD("AC*2!R96EM8G5R
M<V5M96YT(&]F("0Q,#`L,#`P(&9O<B!L96=A;"!E>'!E;G-E<R!I;F-U<G)E
M9"!B>2!T:&4@<&QA8V5M96YT(&%G96YT+CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C
M<FEP=&EO;B!O9B!W87)R86YT<R!R96-E:79A8FQE<R!B>2!P;&%C96UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5V%R<F%N=',@
M=&\@<'5R8VAA<V4@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@0V]M;6]N(%-T
M;V-K(&EN(&%N(&%M;W5N="!E<75A;"!T;R`Q,"4@;V8@=&AE('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@:7-S=65D(&]R(&ES<W5A8FQE/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!P;&%C96UE
M;G0@86=E;G0@;W(@:71S(&1E<VEG;F5E<R!H879E(&%L<V\@<F5C96EV960@
M=V%R<F%N=',@=&\@<'5R8VAA<V4@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@
M0V]M;6]N(%-T;V-K(&EN(&%N(&%M;W5N="!E<75A;"!T;R`Q,"4@;V8@=&AE
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D(&%S('!A<G0@;V8@=&AE
M('5N:71S('-O;&0@:6X@=&AE(#(P,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG
M(&%N9"!T:&4@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!I<W-U86)L92!U<&]N
M(&5X97)C:7-E(&]F('1H92!"('=A<G)A;G1S(&EN8VQU9&5D(&EN('-U8V@@
M=6YI=',N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FEO9"!O9B!E>&5R8VES92!O9B!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M5VET:&EN(#8@;6]N=&AS(&]F('1H92!F:6YA;"!C;&]S:6YG(&]F('1H92`R
M,#$R(&-O;6UO;B!S=&]C:R!/9F9E<FEN9SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&5R8V5N=&%G92!O9B!S;VQI8VET871I;VX@9F5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUO;G1H;'D@9F5E(&9O<B!F:6YA;F-I86P@861V:7-O<GD@<V5R=FEC97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@861D:71I;VYA;"!R
M96-E:79A8FQE(&)Y('!L86-E;65N="!A9V5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE(&%G<F5E;65N="!A;'-O('!R;W9I
M9&5S('1H870@*&DI(&EF('1H92!#;VUP86YY(&-O;G-U;6UA=&5S(&%N>2!M
M97)G97(L(&%C<75I<VET:6]N+"!B=7-I;F5S<R!C;VUB:6YA=&EO;B!O<B!O
M=&AE<B!T<F%N<V%C=&EO;B`H;W1H97(@=&AA;B!T:&4@4VAA<F4@17AC:&%N
M9V4I('=I=&@@86YY('!A<G1Y(&EN=')O9'5C960@=&\@:70@8GD@=&AE('!L
M86-E;65N="!A9V5N="P@=&AE('!L86-E;65N="!A9V5N="!W;W5L9"!R96-E
M:79E(&$@9F5E(&5Q=6%L('1O(#$P)2!O9B!T:&4@86=G<F5G871E(&-O;G-I
M9&5R871I;VX@:6X@<W5C:"!T<F%N<V%C=&EO;G,L(&%N9"`H:6DI(&EF+"!W
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M961U;&4@<V5T(&9O<G1H(&EN('1H92!!=6=U<W0@-RP@,C`Q,B!E;F=A9V5M
M96YT(&%G<F5E;65N="X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!H96QD(&)Y
M('!L86-E;65N="!A9V5N="!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-3$L,#$U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!A:60@9F]R(')E<V5A<F-H(&-O;F1U8W1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#DL-3,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(Y+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@9&5S8W)I<'1I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U5N9&5R('1H92!A
M9W)E96UE;G0L('1H92!#;VUP86YY('-H86QL('!A>2!T;R!-4TM#0R!O;B!A
M(&-O=6YT<GDM8GDM8V]U;G1R>2!B87-I<R!A(')O>6%L='D@;V8@,B4@;V8@
M;F5T('-A;&5S(&]F(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@
M;&%T97(@;V8Z("@Q*2`Q,"!Y96%R<R!F<F]M('1H92!F:7)S="!C;VUM97)C
M:6%L('-A;&4L(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T('!A>6%B;&4@=&\@35-+0T,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@Y+#4S-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PQ.#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:R!S;VQD+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,2PX,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S,L,CDY/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,S<L.34R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(%-T
M;V-K+"!0<FEC92!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQA<W,@;V8@5V%R
M<F%N="!O<B!2:6=H="P@17AE<F-I<V4@4')I8V4@;V8@5V%R<F%N=',@;W(@
M4FEG:'1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]C965D<R!F<F]M('1H92!S86QE
M(&]F('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,S$P+#@V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S('!R;V-E961S
M(')E8V5I=F5D(&EN($]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8L-C,V+#<R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E
M9V%T92!O9F9E<FEN9R!A;6]U;G0@;V8@<V5C=7)I=&EE<R!S;VQD('1O(&EN
M=F5S=&]R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!#
M;VUP86YY('=I;&P@<&%Y($U,5B!I;B!C87-H+"!U<&]N('1H92!S86QE(&]F
M(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T;R!T:&4@4V%L97,@06=R965M96YT
M+"!A;B!A;6]U;G0@97%U86P@=&\@,RXP)2!O9B!T:&4@9W)O<W,@<')O8V5E
M9',@9G)O;2!T:&4@<V%L92!O9B!C;VUM;VX@<W1O8VLN($]N($%P<FEL(#(X
M+"`R,#$T('1H92!#;VUP86YY(&ES<W5E9"`U,#`@<VAA<F5S(&%N9"!R96-E
M:79E9"!N970@<')O8V5E9',@;V8@)#8L,#`P('5N9&5R('1H92!386QE<R!!
M9W)E96UE;G0@=VET:"!-3%8N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG06=G<F5G871E(&]F9F5R:6YG(&%M;W5N
M="!O9B!S96-U<FET:65S('-O;&0@=&\@:6YV97-T;W)S('=A<R!I;F-R96%S
M960@9G)O;2`D-BPP,#`L,#`P('1O("0V+#8S-BPW,C`@:6X@;W)D97(@=&\@
M8V]V97(@;W9E<BUA;&QO=&UE;G1S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S,SA?,V8X
M,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W
M9B]7;W)K<VAE971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$553D%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E
M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^36%X:6UU;2!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/DUI;FEM=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5<V5F=6P@3&EV97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F:6-E(&5Q
M=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#,L
M.3$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q-2PT.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&5S<SH@06-C=6UU;&%T960@9&5P<F5C:6%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PP,3<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU-C`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$S,BPY,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S+#DR,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V
M96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O
M<FMS:&5E=',O4VAE970R-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M(04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H1&5T86EL
M<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T
M>2!A;F0@17%U:7!M96YT("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PP-3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Y+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@9&ES<&]S
M:71I;VX@;V8@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#0L,3(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$W,F(R,S,X7S-F.#)?-#9E8U\Y
M,3DT7V)A,#8P,F$U.3@W9B]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5.2$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@4&%Y86)L
M92`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$T/&)R/E!R96UI=6T@1FEN86YC
M92!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY0<F5M:75M($9I;F%N8V4@06=R
M965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^4')E;6EU;2!&:6YA;F-E($%G<F5E;65N
M="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#(X+"`R,#$S/&)R/E!R96UI=6T@1FEN86YC92!!9W)E96UE;G0@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F]T92!087EA8FQE(&%N9"!#;VYV97)T:6)L92!.;W1E<R`H5&5X
M='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]T97,@<&%Y86)L92P@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-30L.3<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-3<L.#(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-3<L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;W=N('!A>6UE;G0@<'5R<W5A;G0@=&\@=&AE(&%G<F5E;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PY.34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M;W5N="!R97%U:7)E9"!T;R!P87D@:6X@;6]N=&AL>2!I;G-T86QL;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L.3DU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!A>6UE;G1S(&]N(&YO=&4@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q,#(L.#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#,L,#4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S,SA?,V8X,E\T
M-F5C7SDQ.31?8F$P-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9B]7
M;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S1D%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D1E<FEV871I=F5S("A$971A:6QS*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4V-H961U;&4@;V8@9&5R:79A=&EV92!W87)R86YT(&EN<W1R=6UE;G1S
M(&%C=&EV:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC92P@56YI=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.38X+#8R,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-F97(@1G)O;2!,
M:6%B:6QI='D@0VQA<W-I9FEC871I;VX@5&\@17%U:71Y($-L87-S:69I8V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.3,L-C8Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%L86YC92P@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S<T+#DV,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F5G:6YN:6YG(&)A;&%N8V4L($9A:7(@5F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPW,#<L,C4U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%N
M<V9E<B!F<F]M(&QI86)I;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I='D@
M8VQA<W-I9FEC871I;VXL($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-3`Q+#DX."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8R,2PS-C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M;&%N8V4L($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.2PX,C8L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX
M-V8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X
M,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970R.2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P135!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R
M:79A=&EV97,@*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!F86ER('9A;'5E
M<R!O9B!D97)I=F%T:79E('=A<G)A;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO
M;B!M;V1E;#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA<FME="!V86QU92!O9B!C;VUM;VX@
M<W1O8VL@;VX@;65A<W5R96UE;G0@9&%T92`H,2D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-RXR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C@Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D:G5S=&5D(&5X97)C:7-E
M('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E
M("@R*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XQ.24\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M,ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,C<E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS
M=7`^6S)=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G0@;&EV97,@:6X@>65A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<S('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S-=/"]S=7`^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RXP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,UT\+W-U<#X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV:61E
M;F0@>6EE;&0@*#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CQS=7`^6S1=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S1=/"]S=7`^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V)A8FEL:71Y(&]F('-T;V-K
M(&]F9F5R:6YG(&EN(&%N>2!P97)I;V0@;W9E<B`U('EE87)S("@U*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S5=/"]S=7`^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-5T\
M+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@
M;V8@<&5R8V5N=&%G92!O9B!E>&ES=&EN9R!S:&%R97,@;V9F97)E9"`H-BD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U
M<#Y;-ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELV73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/9F9E<FEN9R!P<FEC92!R86YG92`H-RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-RXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S==/"]S=7`^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-UT\+W-U<#X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0U
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&
M;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*
M("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/E1H92!M87)K
M970@=F%L=64@;V8@8V]M;6]N('-T;V-K(&%T('1H92!A8F]V92!M96%S=7)E
M;65N="!D871E<R!I<R!B87-E9"!O;B!T:&4@0V]M<&%N>2=S('1R861I;F<@
M<')I8V4@<75O=&5D(&]N('1H92!/5$,@36%R:V5T<R!F;W(@1&5C96UB97(@
M,S$L(#(P,3,@86YD(&]N('1H92!.65-%($U+5"!F;W(@2G5N92`S,"P@,C`Q
M-"X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R
M1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-
M"B`@("`@("`@/'1D(&-O;'-P86X],T0T('9A;&EG;CTS1'1O<#Y4:&4@<FES
M:RUF<F5E(&EN=&5R97-T(')A=&4@=V%S(&1E=&5R;6EN960@8GD@;6%N86=E
M;65N="!U<VEN9R!T:&4@5')E87-U<GD@0FEL;"!A<R!O9B!T:&4@<F5S<&5C
M=&EV92!M96%S=7)E;65N="!D871E+CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A
M;&EG;CTS1'1O<#Y;,UT\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@
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M97,@:6X@=&AE('-A;64@:6YD=7-T<GD@86YD(')E9VEO;BX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@
M("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S1=/"]T9#X-"B`@("`@("`@/'1D
M(&-O;'-P86X],T0T('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&1E=&5R;6EN
M960@=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S
M(&5X<&5C=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD<R!F
M;W(@=&AE(&9O<F5S965A8FQE(&9U='5R92X\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT
M9"!V86QI9VX],T1T;W`^6S5=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X]
M,T0T('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&1E=&5R;6EN97,@=&AE('!R
M;V)A8FEL:71Y(&]F(&9U='5R92!S=&]C:R!O9F9E<FEN9R!A="!E86-H(&5V
M86QU871I;VX@9&%T92X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T
M;W`^6S9=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0T('9A;&EG;CTS
M1'1O<#Y-86YA9V5M96YT(&5S=&EM871E<R!T:&%T('1H92!R86YG92!O9B!P
M97)C96YT86=E<R!O9B!E>&ES=&EN9R!S:&%R97,@;V9F97)E9"!I;B!E86-H
M('-T;V-K(&]F9F5R:6YG('=I;&P@8F4@,"4@86YD(#,U)2!O9B!T:&4@<VAA
M<F5S(&]U='-T86YD:6YG(&%T($IU;F4@,S`L(#(P,30@86YD($1E8V5M8F5R
M(#,Q+"`R,#$S+"!R97-P96-T:79E;'DN/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@
M=F%L:6=N/3-$=&]P/ELW73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$
M-"!V86QI9VX],T1T;W`^4F5P<F5S96YT<R!T:&4@97-T:6UA=&5D(&]F9F5R
M:6YG('!R:6-E(')A;F=E(&EN(&9U='5R92!O9F9E<FEN9W,@87,@9&5T97)M
M:6YE9"!B>2!M86YA9V5M96YT+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ
M.31?8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970S,"YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P155!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV97,@
M*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY*=6XN(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5R:79A=&EV97,@*%1E>'1U86PI/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F%N9V4@;V8@<&5R8V5N=&%G92!O9B!E>&ES=&EN9R!S
M:&%R97,@;V9F97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^
M6S)=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV
M871I=F5S("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q+#4P
M,2PY.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@=V%R<F%N="!E>&5R
M8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V,BPQ-C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E('=A<G)A;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3,L-C8Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1D(&-O;'-P86X],T0U/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D
M('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS
M1#0@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@97-T:6UA=&5S('1H870@=&AE
M(')A;F=E(&]F('!E<F-E;G1A9V5S(&]F(&5X:7-T:6YG('-H87)E<R!O9F9E
M<F5D(&EN(&5A8V@@<W1O8VL@;V9F97)I;F<@=VEL;"!B92`P)2!A;F0@,S4E
M(&]F('1H92!S:&%R97,@;W5T<W1A;F1I;F<@870@2G5N92`S,"P@,C`Q-"!A
M;F0@1&5C96UB97(@,S$L(#(P,3,L(')E<W!E8W1I=F5L>2X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@
M("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@("`@/'1D
M(&-O;'-P86X],T0T('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&1E=&5R;6EN
M960@=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S
M(&5X<&5C=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD<R!F
M;W(@=&AE(&9O<F5S965A8FQE(&9U='5R92X\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P-C`R834Y.#=F
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$W,F(R,S,X7S-F.#)?
M-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9B]7;W)K<VAE971S+U-H965T,S$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$535T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$971A:6QS*2`H06)B;W1T($)I
M;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&AA<V4@22!#;&EN:6-A
M;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O
M9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0:&%S92!)22!#
M;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M
M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&AA<V4@
M24E)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O9'5C="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)I;VQO9VEC86P@3&EC96YS92!!<'!L:6-A=&EO;B!F:6QI;F<@=VET:"!5
M+E,N($9$02!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE
M<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9I<G-T($-O;6UE<F-I86P@4V%L92!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM
M87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%F=&5R
M($9I<G-T($YE="!386QE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P
M87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?8F$P
M-C`R834Y.#=F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$W,F(R
M,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9B]7;W)K<VAE971S+U-H
M965T,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$550D=-/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$971A:6QS(%1E
M>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#8^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,SXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#(P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`R-RP@
M,C`Q-#QB<CY-86YU9F%C='5R:6YG($%G<F5E;65N="!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R
M/DUA;G5F86-T=7)I;F<@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^4F5N=&%L
M($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D%B8F]T="!":6]T:&5R87!E=71I
M8W,@0V]R<"!;365M8F5R73QB<CY0<F]D=6-T($1E=F5L;W!M96YT(&%N9"!0
M871E;G0@3&EC96YS92!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY!8F)O='0@
M0FEO=&AE<F%P975T:6-S($-O<G`@6TUE;6)E<ET\8G(^069T97(@1FER<W0@
M3F5T(%-A;&5S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^06)B;W1T($)I;W1H97)A<&5U=&EC
M<R!#;W)P(%M-96UB97)=/&)R/D%F=&5R($9I<G-T($YE="!386QE<R!;365M
M8F5R73QB<CY0<F]D=6-T($1E=F5L;W!M96YT(&%N9"!0871E;G0@3&EC96YS
M92!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY!8F)O='0@0FEO=&AE<F%P975T
M:6-S($-O<G`@6TUE;6)E<ET\8G(^4&AA<V4@22!#;&EN:6-A;"!4<FEA;"!O
M9B!A(&QI8V5N<V5D('!R;V1U8W0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY-4TM#0R!;365M
M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`R-RP@,C`Q,CQB
M<CY-4TM#0R!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q-#QB<CY/86L@4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/D]A:R!2:61G92!.871I;VYA;"!,86)O<F%T;W)Y(%M-
M96UB97)=/&)R/C(P,3,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY/86L@4FED9V4@3F%T:6]N
M86P@3&%B;W)A=&]R>2!;365M8F5R73QB<CXR,#$T(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`Q-BP@,C`Q,SQB<CY!
M<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3V-T+B`R,BP@,C`Q,CQB<CY!<'1I=B!3;VQU=&EO;G,@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G
M+B`P-BP@,C`Q,CQB<CY!<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P-SQB<CY!
M<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY!<'1I=B!3;VQU=&EO;G,@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CY!<'1I=B!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q-2P@,C`Q,CQB<CY&
M<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M8F5R
M73QB<CYL:6-E;G-E(&%N9"!S<&]N<V]R960@<F5S96%R8V@@86=R965M96YT
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C
M:"!#96YT97(@6TUE;6)E<ET\8G(^;&EC96YS92!A;F0@<W!O;G-O<F5D(')E
M<V5A<F-H(&%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/D9R960@2'5T8VAI;G-O
M;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=/&)R/FQI8V5N<V4@
M86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB
M<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M
M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M
M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`Q.2P@,C`Q,CQB
M<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M
M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q-2P@,C`Q,CQB
M<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M
M8F5R73QB<CY-87AI;75M(%M-96UB97)=/&)R/FQI8V5N<V4@86YD('-P;VYS
M;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q-2P@,C`Q,CQB<CY&<F5D($AU
M=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;365M8F5R73QB<CY-
M:6YI;75M(%M-96UB97)=/&)R/FQI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E
M87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^075G+B`R."P@,C`Q,CQB<CY5;FEV97)S:71Y(&]F(%1E
M>&%S($TN1"X@06YD97)S;VX@0V%N8V5R($-E;G1E<B!;365M8F5R73QB<CY#
M;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^<&%T:65N=',\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q
M,SQB<CY5;FEV97)S:71Y(&]F(%1E>&%S($TN1"X@06YD97)S;VX@0V%N8V5R
M($-E;G1E<B!;365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`R-BP@,C`Q,CQB<CY*;VAN<R!(;W!K:6YS(%5N:79E<G-I='D@6TUE;6)E
M<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M2F]H;G,@2&]P:VEN<R!5;FEV97)S:71Y(%M-96UB97)=/&)R/D-L:6YI8V%L
M(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y.;W8N(#(Q+"`R,#$R/&)R/E5N:79E<G-I='D@;V8@
M4&5N;G-Y;'9A;FEA(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E
M;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/E5N:79E<G-I='D@;V8@4&5N;G-Y;'9A;FEA
M(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&5X='5A;"D\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<V%L97,@:6X@
M;6EL97-T;VYE<R!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!F964@<&%Y;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!R;WEA;'1Y('!A>6UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=#;VUP86YY('-H
M86QL('!A>2!T;R!!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@;VX@82!C
M;W5N=')Y+6)Y+6-O=6YT<GD@8F%S:7,@82!R;WEA;'1Y(&]F(#$R)2!O9B!N
M970@<V%L97,@;V8@86QL(&QI8V5N<V5D('!R;V1U8W1S('5N=&EL('1H92!L
M871E<B!O9CH@*#$I(#$R+C4@>65A<G,@869T97(@=&AE(&9I<G-T(&-O;6UE
M<F-I86P@<V%L92P@;W(@*#(I('=H96X@=&AE('!A=&5N=',@97AP:7)E+CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=2;WEA;'1Y('!A>6UE;G1S(&]F(#(E(&]F(&YE="!S
M86QE<R!W:6QL(&)E(&1U92!T;R!&2$-20RX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L
M='D@;V8@3F5T(%-A;&5S(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&:7)S="!C;VUM97)C:6%L('-A;&4@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3(@
M>65A<G,@-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M=7)C:&%S92!O9B!R861I;V%C=&EV92!M871E<FEA;"!U<V5D(&9O<B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(S,RPQ,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]J96-T(&5S=&EM871E9"!C;W-T(&9O
M<B!C;&EN:6-A;"!T<FEA;',@;V8@9')U9R!!8RTR,C4M2'5-,3DU/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@Q,RPY-C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]W;B!P87EM96YT(&]F('!R;VIE
M8W0@97-T:6UA=&5D(&-O<W0@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C4P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]W;B!P87EM96YT(&9O<B!P<F]J96-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(S.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&EN
M:6-A;"!T<FEA;"!C;W-T(&9O<B!A<'!R;W9A;"!O9B!F;V]D(&%N9"!D<G5G
M(&%D;6EN:7-T<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L
M,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1G5N9"!F;W(@1G)E9"!(=71C:&EN<V]N($-A;F-E
M<B!297-E87)C:"!#96YT97(@;&%B("@@4&5R('EE87(@9F]R('1H92!F:7)S
M="!T=V\@>65A<G,@*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9U;F0@9F]R($9R960@2'5T8VAI;G-O;B!#86YC97(@4F5S96%R8V@@0V5N
M=&5R(&QA8B`H('1H97)E869T97(@*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!0871I96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;6]U;G0@<&%I9"!T;R!E86-H('!A=&EE;G0@869T97(@
M0V]M<&QE=&EN9R!C;&EN:6-A;"!T<FEA;#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PQ.#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$L,S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L,S@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L-3`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Q+#<W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T87)T+75P(&9E92!F;W(@8VQI;FEC86P@=')I86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.2PV
M,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Y+#<T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#DT-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPX-#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1A<G0M=7`@9'5E(&-O<W0@<&%I9"!D871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D1E8R`S,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VX@+2!R969U;F1A8FQE(&EN
M<W1I='5T:6]N86P@9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU-C(L-SDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#4P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;FYU86P@<&AA<FUA8WD@9F5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPP,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%M96YD;65N="!P<F]C97-S:6YG(&9E93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]T:6-E('!E<FEO9"!F;W(@=&5R;6EN
M871I;VX@;V8@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=4:&ES(&%G<F5E;65N="!T97)M:6YA=&5S(&]N($IU
M;'D@-BP@,C`Q-"X@57!O;B!T:&4@97AP:7)A=&EO;B!O9B!T:&4@=&5R;2P@
M=&AE(&%G<F5E;65N="!A=71O;6%T:6-A;&QY(')E;F5W<R!O;B!A(&UO;G1H
M+71O+6UO;G1H(&)A<VES(&%N9"!R97%U:7)E<R!A('1W;R!M;VYT:"!N;W1I
M8V4@;V8@=&5R;6EN871I;VXN/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E;G1A;"!A9W)E96UE;G0@<F5N97=A;"!D97-C<FEP=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE(&%G<F5E
M;65N="!A=71O;6%T:6-A;&QY(')E;F5W<R!O;B!A(&UO;G1H+71O+6UO;G1H
M(&)A<VES(&%N9"!R97%U:7)E<R!A('1W;R!M;VYT:"!N;W1I8V4@;V8@=&5R
M;6EN871I;VXN/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U
M960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@9F5E<R!P86ED/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-E87)C:"!R96-O<F1E9"!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#`P,2PY,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,#DL,C8R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT-C(L.3`U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU.30L.38X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L('!R;VIE8W0@97-T:6UA=&5D('1O(&-O<W0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396-U<FET
M>2!D97!O<VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,T
M+#<S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,T+#<S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S$W,F(R,S,X7S-F.#)?-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y
M-%]B83`V,#)A-3DX-V8O5V]R:W-H965T<R]3:&5E=#,S+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%25%!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@*$1E=&%I
M;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F('-T;V-K(&]P=&EO;B!A8W1I=FET
M:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!S=&]C:R!O<'1I
M;VX@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F(%5N:71S+"!"96=I;FYI;F<@8F%L86YC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY.#4L,S@T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW.2PQ,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L
M-C4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F(%5N:71S+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-3(L.#(Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8X+#(X-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@0F5G:6YN:6YG(&)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`S+C(S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!)<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B`Y+C@U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M($5X97)C:7-E(%!R:6-E+"!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B`P+C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E
M(%!R:6-E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^(#4N-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I
M8V4L($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#X@,"XY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U
M86P@5&5R;2`H:6X@>65A<G,I+"!/=71S=&%N9&EN9RP@0F5I9VYI;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S(#0@;6]N=&AS
M(#(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U
M86P@5&5R;2`H:6X@>65A<G,I+"!)<W-U960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!/=71S=&%N9&EN
M9RP@16YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y
M96%R<R`T(&UO;G1H<R`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN
M:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S*2P@17AE<F-I<V%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#$Q(&UO
M;G1H<R`R-R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!"96=I
M;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M(#4L.3`X+#8Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@17AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%;F1I;F<@0F%L86YC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PS,#`L-38U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%>&5R8VES86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT,3@L,#$W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71I97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!5;FET<RP@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDL-C<S+#(Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,#8L.3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8V,BPQ-C`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI
M=',L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#0Q."PP-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#$Y-2PP-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE
M<F-I<V4@4')I8V4L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#X@,2XP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R
M8VES92!0<FEC92P@27-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#X@-RXY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@
M97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,2XT
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@16YD:6YG($)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q+C,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!%>&5R8VES86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#$N,S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE87)S
M*2P@3W5T<W1A;F1I;F<L($)E:6=N:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-"!Y96%R<R`X(&UO;G1H<R`Q-B!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M("AI;B!Y96%R
M<RDL($ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@
M>65A<G,@-2!M;VYT:',@,38@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!/=71S=&%N9&EN
M9RP@16YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y
M96%R<R`V(&UO;G1H<R`Q-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I
M;FEN9R!#;VYT<F%C='5A;"!497)M("AI;B!Y96%R<RDL($5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<R`U(&UO
M;G1H<R`Q(&1A>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@0F5G:6YN
M:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W
M+#,Y-BPS,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L($5N9&EN9R!"
M86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-BPS-C(L
M,S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%>&5R8VES86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#$N,38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F.#)?
M-#9E8U\Y,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8O
M5V]R:W-H965T<R]3:&5E=#,T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%259$33X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@*$1E=&%I;',@5&5X='5A;"D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$-#XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#(T+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^07!R+B`R."P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^4W1O8VL@3W!T:6]N(%!L86X@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q-#QB<CY3=&]C:R!/<'1I;VX@4&QA;B!;365M8F5R73QB<CY-:6YI;75M
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^4W1O8VL@3W!T:6]N(%!L86X@6TUE;6)E<ET\8G(^
M36%X:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D5M<&QO>65E<RP@8V]N<W5L=&%N=',@
M86YD(&)O87)D(&UE;6)E<G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY%;7!L;WEE97,L(&-O
M;G-U;'1A;G1S(&%N9"!B;V%R9"!M96UB97)S(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^16UP
M;&]Y965S+"!C;VYS=6QT86YT<R!A;F0@8F]A<F0@;65M8F5R<R!;365M8F5R
M73QB<CY-:6YI;75M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^16UP;&]Y965S+"!C;VYS=6QT
M86YT<R!A;F0@8F]A<F0@;65M8F5R<R!;365M8F5R73QB<CY-87AI;75M(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^26YV97-T;W(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2F%N+B`Q,"P@,C`Q-#QB<CY0;&%C96UE;G0@
M86=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CY0;&%C96UE;G0@86=E;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q
M-#QB<CY0<FEV871E(%!L86-E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$T/&)R/E=A<G)A;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q-#QB<CY787)R86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^5V%R<F%N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN
M(#,Q+"`R,#$T/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;6UO
M;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*86XN(#,Q+"`R,#$T/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB
M<CY0;&%C96UE;G0@86=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q-#QB<CY#;VUM;VX@4W1O8VL@
M6TUE;6)E<ET\8G(^3&%I9&QA=R!A;F0@0V\@6TUE;6)E<ET\8G(^4&QA8V5M
M96YT(&%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^4'5B;&EC($]F9F5R:6YG(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D5Q=6ET>2`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S(&1E=&5R;6EN
M960@=71I;&EZ:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG
M(&UO9&5L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@;V8@
M=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XU-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$N-C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M<'1I;VYS+"!R:7-K(&9R964@:6YT
M97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N,3DE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2XR-R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV-"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E
M(&%S<W5M<'1I;VYS+"!E>'!E8W1E9"!V;VQA=&EL:71Y(')A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RXP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,ET\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RXP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M,ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-RXP
M-B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX-RXW-B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@X+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S
M=6UP=&EO;G,L(&5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,R!Y96%R<R`V(&UO;G1H<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!A<W-U;7!T:6]N<RP@97AP96-T960@9&EV
M:61E;F0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/'-U<#Y;,UT\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S-=/"]S=7`^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S=6UP=&EO;G,L(&5X<&5C=&5D(&1I
M<V-O=6YT(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2XX."4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C`W)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S(&ES<W5E9"!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VLL
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S<L.34R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+#DW-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M."PY-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@<W1O8VL@;W!T:6]N(&=R86YT960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY-SDL,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$R+#4P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@;V8@861D:71I;VYA;"!S=&]C:R!O<'1I;VX@9W)A;G1E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0T-2PQ-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S
M=&]C:R!O<'1I;VX@8V%N8V5L;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!R97-T<FEC=&5D('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQP/B8C,38P.T]F('1H92!T;W1A;"!S:&%R97,@;V8@<F5S=')I
M8W1E9"!S=&]C:RP@,C`L,#`P('-H87)E<R!V97-T(#,@;6]N=&AS(&9R;VT@
M=&AE(&=R86YT(&1A=&4L(#(R+#4P,"!S:&%R97,@=F5S="`Q('EE87(@9G)O
M;2!T:&4@9W)A;G0@9&%T92P@,3DY+#$V-R!S:&%R97,@:&%V92!A('9E<W1I
M;F<@<&5R:6]D(&]F(#0@>65A<G,@86YD(#(P,"PP,#`@<VAA<F5S('9E<W0@
M870@9&%T92!O9B!G<F%N="X@5&AE(')E;6%I;FEN9R!R97-T<FEC=&5D('-H
M87)E<R!G<F%N=&5D(&%R92!P97)F;W)M86YC92!B87-E9"!A;F0@=F5S="!O
M=F5R('1I;64N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!V97-T:6YG('!E<FEO
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<T('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A
M;'5E(&]F('-T;V-K(&]P=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N(&5X97)C:7-E('!R:6-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2XU-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3$N.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M('1H92!E>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#@W,RPU-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO
M;B!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV-34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5N<V4@<F5L871E9"!T;R!C;VUM;VX@<W1O8VL@9W)A;G1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P-RPW.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30L,C`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@Y
M+#$Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X."PT,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@L,C(T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ-C4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ
M-C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@<')O8V5E9',@9G)O;2!T:&4@<'5B;&EC(&]F9F5R:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#8S-BPW,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PT-3$L,C4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEC92!P
M97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@
M:7-S=65D+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34Q+#@Q
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4W,RPR.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-C<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!C;VUM;VX@<W1O
M8VL@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38L.#8X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU
M,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;F1E<G=R:71I;F<@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX-S8L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<G=R:71I;F<@86=R965M96YT(&1E
M<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U5N9&5R('1H
M92!T97)M<R!O9B!T:&4@=6YD97)W<FET:6YG(&%G<F5E;65N="!E;G1E<F5D
M(&EN=&\@=VET:"!#86YA8V-O<F0@1V5N=6ET>2!);F,N(&%S(')E<')E<V5N
M=&%T:79E("AT:&4@(E)E<')E<V5N=&%T:79E(BD@;V8@=&AE('-E=F5R86P@
M=6YD97)W<FET97)S("AC;VQL96-T:79E;'DL('1H92`B56YD97)W<FET97)S
M(BDL('1H92!#;VUP86YY(&%L<V\@9W)A;G1E9"!T:&4@56YD97)W<FET97)S
M(&$@,S`M9&%Y(&]P=&EO;B!T;R!P=7)C:&%S92!U<"!T;R!A;B!A9&1I=&EO
M;F%L(#(U,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!C;W9E<B!O
M=F5R+6%L;&]T;65N=',L(&EF(&%N>2P@870@=&AE(&]F9F5R:6YG('!R:6-E
M+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!W87)R86YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&QA8V5M96YT(&%G96YT
M(&-A<V@@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.34L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!L86-E;65N="!A9V5N="!A='1O<FYE>2!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!G<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,S<L.34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AE<F-I<V5D
M(&)Y('=A<G)A;G0@:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V,BPQ
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E9VES=')A=&EO;B!S=&%T96UE;G0@9&5S8W)I<'1I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&ES(%)E9VES=')A
M=&EO;B!3=&%T96UE;G0@8V]N=&%I;F5D('1W;R!P<F]S<&5C='5S97,Z("AI
M*2!A(&)A<V4@<')O<W!E8W1U<R!W:&EC:"!C;W9E<G,@=&AE(&]F9F5R:6YG
M+"!I<W-U86YC92!A;F0@<V%L92!B>2!T:&4@0V]M<&%N>2!O9B!U<"!T;R`D
M,C`P+#`P,"PP,#`@;V8@:71S(&-O;6UO;B!S=&]C:RP@<')E9F5R<F5D('-T
M;V-K+"!W87)R86YT<R!A;F0O;W(@=6YI=',[(&%N9"`H:6DI(&$@<V%L97,@
M86=R965M96YT('!R;W-P96-T=7,@8V]V97)I;F<@=&AE(&]F9F5R:6YG+"!I
M<W-U86YC92!A;F0@<V%L92!B>2!U<R!O9B!U<"!T;R!A(&UA>&EM=6T@86=G
M<F5G871E(&]F9F5R:6YG('!R:6-E(&]F("0W-2PP,#`L,#`P(&]F(&ET<R!C
M;VUM;VX@<W1O8VL@=&AA="!M87D@8F4@:7-S=65D(&%N9"!S;VQD('5N9&5R
M(&$@<V%L97,@86=R965M96YT("AT:&4@(E-A;&5S($%G<F5E;65N="(I('=I
M=&@@34Q6("9A;7`[($-O+B!,3$,@*")-3%8B*2!D871E9"!-87)C:"`R-"P@
M,C`Q-"X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-87AI;75M(&]F9F5R:6YG('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&]F9F5R:6YG(&%M;W5N="!O
M9B!S96-U<FET:65S('-O;&0@=&\@:6YV97-T;W)S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG5&AE($-O;7!A;GD@=VEL;"!P87D@34Q6(&EN
M(&-A<V@L('5P;VX@=&AE('-A;&4@;V8@8V]M;6]N('-T;V-K('!U<G-U86YT
M('1O('1H92!386QE<R!!9W)E96UE;G0L(&%N(&%M;W5N="!E<75A;"!T;R`S
M+C`E(&]F('1H92!G<F]S<R!P<F]C965D<R!F<F]M('1H92!S86QE(&]F(&-O
M;6UO;B!S=&]C:RX@3VX@07!R:6P@,C@L(#(P,30@=&AE($-O;7!A;GD@:7-S
M=65D(#4P,"!S:&%R97,@86YD(')E8V5I=F5D(&YE="!P<F]C965D<R!O9B`D
M-BPP,#`@=6YD97(@=&AE(%-A;&5S($%G<F5E;65N="!W:71H($U,5BX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!9V=R96=A=&4@;V9F97)I;F<@
M86UO=6YT(&]F('-E8W5R:71I97,@<V]L9"!T;R!I;G9E<W1O<G,@=V%S(&EN
M8W)E87-E9"!F<F]M("0V+#`P,"PP,#`@=&\@)#8L-C,V+#<R,"!I;B!O<F1E
M<B!T;R!C;W9E<B!O=F5R+6%L;&]T;65N=',\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!O
M9F9E<FEN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%U9&ET;W(@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#(Y/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@
M("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\=&0@
M8V]L<W!A;CTS1#(X('9A;&EG;CTS1'1O<#Y4:&4@<FES:RUF<F5E(&EN=&5R
M97-T(')A=&4@=V%S(&1E=&5R;6EN960@8GD@;6%N86=E;65N="!U<VEN9R!T
M:&4@5')E87-U<GD@0FEL;"!A<R!O9B!T:&4@<F5S<&5C=&EV92!M96%S=7)E
M;65N="!D871E+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;
M,ET\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#(X('9A;&EG;CTS1'1O
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M86UE(&EN9'5S=')Y(&%N9"!R96=I;VXN/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@
M=F%L:6=N/3-$=&]P/ELS73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,C@@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@9&5T97)M:6YE9"!T:&4@9&EV
M:61E;F0@>6EE;&0@=&\@8F4@,"4@8F%S960@=7!O;B!I=',@97AP96-T871I
M;VX@=&AA="!I="!W:6QL(&YO="!P87D@9&EV:61E;F1S(&9O<B!T:&4@9F]R
M97-E96%B;&4@9G5T=7)E+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q
M-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3<R8C(S,SA?,V8X,E\T-F5C7SDQ.31?
M8F$P-C`R834Y.#=F+U=O<FMS:&5E=',O4VAE970S-2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M140S044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N
M=',@*$1E=&%I;',I("A3=6)S97%U96YT($5V96YT(%M-96UB97)=+"!54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C`@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;"X@,3`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY787)R86YT(&AO;&1E
M<G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5L+B`P-RP@,C`Q-#QB<CY);G9E<W1O<G,@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`R-2P@,C`Q-#QB<CY#;VYS
M=6QT86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,#<L(#(P,30\8G(^17%U:71Y($EN8V5N=&EV92!0;&%N(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G1S("A497AT=6%L*3PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N
M86P@<VAA<F5S('!U<F-H87-E9"!B>2!U;F1E<G=R:71E<G,@=&AR;W5G:"!O
M=F5R+6%L;&]T;65N="!O<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U-RPQ,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEC92!P97(@<VAA<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXU/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@
M;W9E<BUA;&QO=&UE;G0@;W!T:6]N+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!N=6UB97(@
M;V8@<VAA<F5S(&]F9F5R960@8GD@06-T:6YI=6T\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.#(W+#$R,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]V
M97(M86QL;W1M96YT(&]P=&EO;BP@9W)O<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$S+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O
M;2!S:&%R97,@;V9F97)E9"!B>2!!8W1I;FEU;3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(')E
M<W1R:6-T960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<V+#(Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('!R979I;W5S;'D@
M9W)A;G1E9"!U;F1E<B!T:&4@17%U:71Y($EN8V5N=&EV92!0;&%N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E
M:79E9"!P<F]C965D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y397)V:6-E<R!P<F]V:61E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$W,F(R,S,X7S-F.#)?-#9E8U\Y
M,3DT7V)A,#8P,F$U.3@W9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\Q-S)B,C,S.%\S9C@R7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8O5V]R:W-H
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M/3-$(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,U+FAT
M;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\Q-S)B,C,S.%\S9C@R
;7S0V96-?.3$Y-%]B83`V,#)A-3DX-V8M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MarketValueOfCommonStockOnMeasurementDate', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 7.22<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 5.89<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 2.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 2.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">1.19%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">1.27%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">3 years 6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered (6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionOfferingPrice', window );">Offering price range (7)</a></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
        <td class="nump">$ 9<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for June 30, 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[5]</td>
              <td style="vertical-align: top;" valign="top">Management determines the probability of future stock offering at each evaluation date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[6]</td>
              <td style="vertical-align: top;" valign="top">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[7]</td>
              <td style="vertical-align: top;" valign="top">Represents the estimated offering price range in future offerings as determined by management.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assumption offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueAssumptionOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MarketValueOfCommonStockOnMeasurementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Market value of common stock on measurement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MarketValueOfCommonStockOnMeasurementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsProbabilityOfDefault</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract', window );"><strong>Schedule of derivative warrant instruments activity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeWarrantsUnits', window );">Beginning balance, Units</a></td>
        <td class="nump">1,968,623<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_TransferFromLiabilityClassificationToEquityClassification', window );">Transfer From Liability Classification To Equity Classification</a></td>
        <td class="num">(193,661)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeWarrantsUnits', window );">Balance, Units</a></td>
        <td class="nump">1,774,962<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Beginning balance, Fair Value</a></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification, Fair Value</a></td>
        <td class="num">(1,501,988)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ChangeInFairValueOfDerivativeWarrants', window );">Change in fair value</a></td>
        <td class="nump">4,621,360<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Balance, Fair Value</a></td>
        <td class="nump">$ 9,826,627<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ChangeInFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ChangeInFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeWarrantsUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeWarrantsUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_TransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_TransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeTextualAbstract', window );"><strong>Derivatives (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeTextualAbstract', window );"><strong>Derivatives (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
        <td class="nump">$ 1,501,988<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfSharesWarrantExercise', window );">Number of warrant exercised</a></td>
        <td class="nump">662,160<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DerivativeNumberOfWarrants', window );">Derivative warrants</a></td>
        <td class="nump">193,661<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeNumberOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative number of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeNumberOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DerivativeTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DerivativeTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfSharesWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NumberOfSharesWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (Abbott Biotherapeutics Corp [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase I Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase II Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Phase III Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Biological License Application filing with U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">First Commercial Sale [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">After First Net Sales [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePaymentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MilestonePaymentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Note 3 &#8211; Property and Equipment</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 8pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">Property and equipment consisted of the following at June 30, 2014 and December 31, 2013:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Lives</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">June 30, 2014</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">December 31, 2013</font></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1050px;"><font style="font: 10pt/normal 'times new roman', times, serif;">Office equipment</font></td><td style="width: 16px;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 126px; text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;3-5 years</font></td><td style="width: 16px;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="width: 126px; text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">143,919</font></td><td style="width: 15px;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="width: 125px; text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">15,480</font></td><td style="width: 15px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">Less: accumulated depreciation</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">(11,017</font></td><td style="padding-bottom: 1.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,560</font></td><td style="padding-bottom: 1.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 2.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">Property and equipment, net</font></td><td style="padding-bottom: 2.5pt;">&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">132,902</font></td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times,
 serif;">13,920</font></td><td style="padding-bottom: 2.5pt;">&#160;</td></tr></table><p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Depreciation expense for the three months ended June 30, 2014 and 2013 was $8,052 and $0, respectively. Depreciation expense for the six months ended June 30, 2014 and 2013 was $9,457 and $0, respectively The Company wrote off certain some of its undepreciated property and equipment during the six months ended June 30, 2013 and recorded a loss of $4,122 on the disposition.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUBGM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="6">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">6 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 20, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 27, 2014

</div>
          <div>Manufacturing Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Manufacturing Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]

</div>
          <div>2013 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Oak Ridge National Laboratory [Member]

</div>
          <div>2014 [Member]</div>
        </th>
        <th class="th">
          <div>May 16, 2013

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 22, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 06, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 19, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Maximum [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Minimum [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 28, 2012

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]

</div>
          <div>patients</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 26, 2012

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 21, 2012

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net sales in milestones payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PaymentOfLicenseFee', window );">License fee payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,750,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RoyaltyOfNetSalesPercentage', window );">Royalty of Net Sales Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FirstCommercialSalePeriod', window );">First commercial sale period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PurchaseOfRadioactiveMaterial', window );">Purchase of radioactive material used for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">233,100<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProjectEstimatedCost', window );">Project estimated cost for clinical trials of drug Ac-225-HuM195</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,813,960<span></span></td>
        <td class="nump">2,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DownPaymentOfProjectEstimatedCostPercentage', window );">Down payment of project estimated cost percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DownPaymentForProject', window );">Down payment for project</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,900,000<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration', window );">Clinical trial cost for approval of food and drug administration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,500,000<span></span></td>
        <td class="nump">13,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear', window );">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo', window );">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NumberOfPatients', window );">Number of Patients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,366<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">34,383<span></span></td>
        <td class="nump">38,501<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">31,771<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,749<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,946<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,847<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpDueCostPaidDate', window );">Start-up due cost paid date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NonRefundableInstitutionalFee', window );">Non - refundable institutional fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">562,790<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PharmacyFee', window );">Annual pharmacy fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,025<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmendmentProcessingFee', window );">Amendment processing fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NoticePeriodForTerminationOfAgreement', window );">Notice period for termination of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AgreementRenewalDescription', window );">Rental agreement renewal description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Accrued fees paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research recorded fees</a></td>
        <td class="nump">2,001,937<span></span></td>
        <td class="nump">509,262<span></span></td>
        <td class="nump">4,462,905<span></span></td>
        <td class="nump">1,594,968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentInProcess', window );">Total project estimated to cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development costs</a></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
        <td class="nump">$ 34,733<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,733<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementRenewalDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description regarding renewal of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AgreementRenewalDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmendmentProcessingFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amendment processing fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmendmentProcessingFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical trial cost for approval of food and drug administration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of royalty payment to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfRoyaltyPaymentToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DownPaymentForProject">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Down payment for project.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DownPaymentForProject</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DownPaymentOfProjectEstimatedCostPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of total estimated project cost required for down payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DownPaymentOfProjectEstimatedCostPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FirstCommercialSalePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>First commercial sale period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FirstCommercialSalePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FundToRelatedPartyUnderAgreementAfterYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement after year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FundToRelatedPartyUnderAgreementAfterYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement for first two Year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundableInstitutionalFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non refundable institutional fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NonRefundableInstitutionalFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NoticePeriodForTerminationOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice Period for termination of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NoticePeriodForTerminationOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NumberOfPatients</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentOfLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License fee payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PaymentOfLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PharmacyFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Pharmacy fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PharmacyFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProjectEstimatedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Project estimated cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ProjectEstimatedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PurchaseOfRadioactiveMaterial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of radioactive material.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PurchaseOfRadioactiveMaterial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RoyaltyOfNetSalesPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty of net sales percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RoyaltyOfNetSalesPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpDueCostPaidDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up due cost paid date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpDueCostPaidDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current amount of expenditures for a real estate project that has not yet been completed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LegalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8,17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecurityDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 14,670,813<span></span></td>
        <td class="nump">$ 5,533,366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">608,105<span></span></td>
        <td class="nump">218,389<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">15,278,918<span></span></td>
        <td class="nump">5,751,755<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
        <td class="nump">132,902<span></span></td>
        <td class="nump">13,920<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
        <td class="nump">34,733<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">15,446,553<span></span></td>
        <td class="nump">5,765,675<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">1,045,421<span></span></td>
        <td class="nump">378,955<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">189,537<span></span></td>
        <td class="nump">81,185<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
        <td class="nump">54,970<span></span></td>
        <td class="nump">157,825<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">9,826,627<span></span></td>
        <td class="nump">6,707,255<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">11,116,555<span></span></td>
        <td class="nump">7,325,220<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">11,116,555<span></span></td>
        <td class="nump">7,325,220<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 10,000,000 authorized none issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 27,602,192 and 24,565,447 shares issued and outstanding, respectively</a></td>
        <td class="nump">27,602<span></span></td>
        <td class="nump">24,565<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">84,004,053<span></span></td>
        <td class="nump">64,933,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(797,016,575)<span></span></td>
        <td class="num">(66,517,255)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity (Deficit)</a></td>
        <td class="nump">4,329,998<span></span></td>
        <td class="num">(1,559,545)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
        <td class="nump">$ 15,446,553<span></span></td>
        <td class="nump">$ 5,765,675<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8,17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecurityDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><b>Note 1 &#8211;&#160;Description of Business and Summary of Significant Accounting Policies</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><b>Nature of Business &#8211;</b>&#160;Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&#8220;MSKCC&#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock. The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto;
 text-transform:
 none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On March 20, 2013, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock. A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Basis of Presentation - Unaudited Interim Financial Information &#8211;</b>&#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC February 28, 2014.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Principles of Consolidation &#8211;</b>&#160;The condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family:
 'times new roman', times,
 serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Use of Estimates in Financial Statement Presentation &#8211;</b>&#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Reclassification &#8211;</b>&#160;Certain prior period amounts have been reclassified to conform to current period presentation.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Cash and Cash Equivalents &#8211;</b>&#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Property and Equipment &#8211;</b>&#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Impairment of Long-Lived Assets &#8211;&#160;</b>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Derivatives &#8211;</b>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based
 pricing models incorporating readily
 observable market data and requiring judgment and estimates.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Fair Value of Financial Instruments &#8211;</b>&#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-size: 10pt;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-size: 10pt;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-size: 10pt;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of June 30, 2014 and December 31, 2013. As required by ASC 820 &#8220;<i>Fair Value Measurements and Disclosures&#8221;</i>, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal;
 font-weight: normal; letter-spacing: normal;
 line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 1</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 2</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 3</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Total</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Derivative liabilities:</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new
 roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"><td style="width: 801.671875px; padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">At June 30, 2014</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align:
 right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9,826,627</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9,826,627</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">At December 31, 2013</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">6,707,255</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">6,707,255</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Income Taxes &#8211;</b>&#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Research and Development Costs &#8211;</b>&#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Share-Based Payments &#8211;</b>&#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based
 compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for
 estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><b>Earnings (Loss) Per Common Share &#8211;</b>&#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share, as calculated for the three months ended June 30, 2014, is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. For the three months ended June 30, 2013 and the six months ended June 30, 2014 and 2013, the potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended June&#160;30, 2014, potentially issuable shares included stock options to purchase 1,398,937 shares and warrants to purchase 8,667,663 shares of the Company&#8217;s common stock. For the six months ended June 30, 2014, potentially issuable shares included stock options to purchase 2,952,829 shares and warrants to purchase 9,418,058 shares of the Company&#8217;s common stock. For the six months ended June 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the Company&#8217;s common stock.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><b>Recent Accounting Pronouncements &#8211;&#160;</b>In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230&#8212;Revenue Recognition (Topic 605) and Proposed Accounting Standards Update 2011&#8211;250&#8212;Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Finally, the amendments also remove paragraph 810-10-15-16,
 which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable
 interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2013-320&#8212;Development Stage Entities (Topic 915), which has been deleted. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&#8212;Compensation&#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The proposed amendments would apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target could be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&#8212;Compensation&#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Subsequent Events &#8211;</b>&#160;The Company&#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ED3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (Subsequent Event [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 10, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Warrant holders [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 07, 2014

</div>
          <div>Investors [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 25, 2014

</div>
          <div>Consultant [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 07, 2014

</div>
          <div>Equity Incentive Plan [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption', window );">Additional shares purchased by underwriters through over-allotment option</a></td>
        <td class="nump">157,123<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
        <td class="nump">$ 7.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountExercisedThroughOverAllotmentOptionGross', window );">Exercise of over-allotment option, gross</a></td>
        <td class="nump">$ 1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Total number of shares offered by Actinium</a></td>
        <td class="nump">1,827,123<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Exercise of over-allotment option, gross</a></td>
        <td class="nump">13,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Net proceeds from shares offered by Actinium</a></td>
        <td class="nump">12,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">176,211<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Common stock previously granted under the Equity Incentive Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,750,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 48,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Services provided</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional shares purchased by underwriters through over-allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AdditionalSharesPurchasedByUnderwritersThroughOverAllotmentOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountExercisedThroughOverAllotmentOptionGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise of over allotment option amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountExercisedThroughOverAllotmentOptionGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SubsequentEventsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received on stock transaction after deduction of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockConsiderationReceivedOnTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockConsiderationReceivedPerTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOCBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="3">6 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Options And Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Options And Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Options And Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Machinery and equipment [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
        <td class="text">Oct.
				06,
				 1997<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest acquired by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">93.70%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition', window );">Common Stock issuable in consideration for equity interest acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Three years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SharesExchangeRatio', window );">Shares received by each API shareholder of Actinium common stock for each API share exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.333<span></span></td>
        <td class="nump">0.333<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially issuable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,398,937<span></span></td>
        <td class="nump">2,952,829<span></span></td>
        <td class="nump">2,280,184<span></span></td>
        <td class="nump">8,667,663<span></span></td>
        <td class="nump">9,418,058<span></span></td>
        <td class="nump">9,535,694<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockShares', window );">Common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,970,137<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ExchangedInCommonStockShares', window );">Common stock shares exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,322,055<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock issuable in consideration for equity interest acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockIssuableInConsiderationForEquityInterestAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ExchangedInCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares exchanged.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ExchangedInCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharesExchangeRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares exchange ratio.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SharesExchangeRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when an entity was incorporated</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityIncorporationDateOfIncorporation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6539997&amp;loc=d3e1205-110223<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUXDK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 24, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 10, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 09, 2013

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 07, 2012

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>MSKCC [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>MSKCC [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 04, 2013

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2011

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven', window );">Amount paid under agreement in 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve', window );">Amount paid under agreement in 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen', window );">Amount paid under agreement in 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen', window );">Amount owed under agreement from 2011 to 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">815,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaintenanceFeesAndResearchPayments', window );">Maintenance fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentServicesFees', window );">Placement agent services fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsIssuedToPurchaseCommonStock', window );">Warrants issued to purchase common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockExercisePriceParOrStatedValuePerShare', window );">Common stock exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfReceivablesOfPlacementAgentForServices', window );">Description of receivables of placement agent for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock<span></span></td>
        <td class="text">Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfWarrantsReceivablesByPlacement', window );">Description of warrants receivables by placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable<span></span></td>
        <td class="text">The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PeriodOfExerciseOfWarrants', window );">Period of exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Within 6 months of the final closing of the 2012 common stock Offering<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PercentageOfSolicitationFee', window );">Percentage of solicitation fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PeriodicFeeForFinancialAdvisoryServices', window );">Monthly fee for financial advisory services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DescriptionOfAdditionalReceivableByPlacementAgent', window );">Description of additional receivable by placement agent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_CommonStockPurchaseByHoldingOfWarrant', window );">Warrant held by placement agent to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,251,015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Paid for research conducted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">189,537<span></span></td>
        <td class="nump">129,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments', window );">Royalty description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Net payable to MSKCC</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">189,537<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">81,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">551,810<span></span></td>
        <td class="nump">573,299<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Gross proceeds from the sale of securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,310,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds received in Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,636,720<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Aggregate offering amount of securities sold to investors</a></td>
        <td class="text">The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014 the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandEleven">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand eleven.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandEleven</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand thirteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand twelve.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockExercisePriceParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock exercise price par or stated value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockExercisePriceParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CommonStockPurchaseByHoldingOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock purchase by holding of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_CommonStockPurchaseByHoldingOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfAdditionalReceivableByPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of additional receivable by placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfAdditionalReceivableByPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfReceivablesOfPlacementAgentForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of receivables of placement agent for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfReceivablesOfPlacementAgentForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfWarrantsReceivablesByPlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of warrants receivables by placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DescriptionOfWarrantsReceivablesByPlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaintenanceFeesAndResearchPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maintenance fees and research payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MaintenanceFeesAndResearchPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Owed amount under agreement in year two thousand eleven to fourteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PercentageOfSolicitationFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of solicitation fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PercentageOfSolicitationFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PeriodicFeeForFinancialAdvisoryServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic fee for financial advisory services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PeriodicFeeForFinancialAdvisoryServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PeriodOfExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PeriodOfExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentServicesFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent services fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentServicesFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RelatedPartyTransactionsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RelatedPartyTransactionsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the commitments made for future artist advances payable and royalty guarantees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 928<br><br> -SubTopic 440<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569655-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockDescriptionOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><b>Note 2 &#8211; Related Party Transactions</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: left;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b><i>MSKCC:</i></b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI), an entity related to MSKCC (&#8220;License Agreement&#8221;). The agreement was amended in August 2006. Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates. MSKCC agreed, subject to certain conditions, to utilize the donated funds for certain clinical and preclinical programs and activities related to the Company&#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">The Company is obligated to make the following milestone payments:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval for each licensed product</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align:
 right;">750,000</td><td style="width:
 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">Certain amounts due under the License Agreement were deferred and then forgiven under a forbearance-related arrangement. On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On September 4, 2013, the Company entered into a letter agreement with SKI to set forth the amount that the Company owes SKI for the period from 2011 to 2014 under the License Agreement. The total amount that the Company owes SKI for the period from 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined. The amount owed does not include amounts the Company may owe for patent expenses under the License Agreement. For 2013, the annual maintenance fee is $50,000 plus pass through costs.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225. The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company paid a start-up fee of $79,623 in 2012.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">For the three months ended June 30, 2014 and 2013, the Company did not incur any expenses for maintenance fees and research conducted by MSKCC. For the six months ended June 30, 2014 and 2013, the Company incurred $189,537 and $129,850, respectively, for maintenance fees and research conducted by MSKCC. As of June 30, 2014 and December 31, 2013, the Company has payable to MSKCC of $189,537 and $81,185, respectively, related to clinical trials.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>&#160;</b></font></p><p style="color:
 #000000; font-family: 'times new roman', times, serif;
 font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b><i>Placement Agent:</i></b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On August 7, 2012, the Company entered into an engagement agreement with a Healthcare Investment Bank as its placement agent for the 2012 Common Stock Offering whereby a director of the Company, is the Head of Healthcare Investment Banking team. Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. In consideration for its services, the placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent. The placement agent or its designees also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units. The placement agent also received the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company. Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent was engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000. The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement. For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent. The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&#8217;s Common Stock.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">On December 9, 2013, the Company entered into another engagement agreement with its placement agent for the 2013 Common Stock Offering. The agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had uplisted its securities for trading on a U.S. National Exchange for a monthly fee of $25,000.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On January 10, 2014, the Company conducted the final closing (the &#8220;Final Closing&#8221;) of its private placement of securities (the &#8220;Offering&#8221;) pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &#8220;Purchase Agreement&#8221;) and Subscription Agreement, dated as of January 10, 2014 (the &#8220;Subscription Agreement&#8221;), with certain accredited investors (the &#8220;Investors&#8221;) pursuant to which: the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the
 &#8220;Shares&#8221;) of common stock at $6.00 per share and
 (ii) five-year warrants to purchase an aggregate of 137,952 shares of common stock at an exercise price of $9.00 per share. The Company received $3,310,860 in gross proceeds from the sale of securities under the Purchase Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">During the six months ended June 30, 2014, the placement agent received a cash fee of approximately $0.4 million from the sale of securities and was issued warrants to purchase 68,976 shares of the Company&#8217;s Common Stock at $9.00 per share for a period of 5 years.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">On May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">27,602,192<span></span></td>
        <td class="nump">24,565,447<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">27,602,192<span></span></td>
        <td class="nump">24,565,447<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Lives</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">June 30, 2014</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">December 31, 2013</font></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1050px;"><font style="font: 10pt/normal 'times new roman', times, serif;">Office equipment</font></td><td style="width: 16px;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 126px; text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;3-5 years</font></td><td style="width: 16px;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="width: 126px; text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">143,919</font></td><td style="width: 15px;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="width: 125px; text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">15,480</font></td><td style="width: 15px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">Less: accumulated depreciation</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">(11,017</font></td><td style="padding-bottom: 1.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,560</font></td><td style="padding-bottom: 1.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 2.5pt;"><font style="font: 10pt/normal 'times new roman', times, serif;">Property and equipment, net</font></td><td style="padding-bottom: 2.5pt;">&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">132,902</font></td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.25pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">13,920</font></td><td style="padding-bottom: 2.5pt;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Aug. 11, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Actinium Pharmaceuticals, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001388320<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">28,147,064<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative warrant instruments activity</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1,968,623</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">6,707,255</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Transfer from liability classification to equity classification</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(193,661</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,501,988</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">4,621,360</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 2.5pt;">Balance, June 30, 2014</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;">1,774,962</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;">9,826,627</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock', window );">Summary of fair values of derivative warrants on basis of valuation model</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">June 30,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 953px; text-align: left;">Market value of common stock on measurement date (1)</td><td style="width: 13px;">&#160;</td><td style="width: 13px; text-align: left;">$</td><td style="width: 113px; text-align: right;">7.22</td><td style="width: 13px; text-align: left;">&#160;</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: left;">$</td><td style="width: 112px; text-align: right;">5.89</td><td style="width: 12px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Adjusted exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.19</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.27</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Warrant lives in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font-size: 10pt;">3.5 years</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font-size: 10pt;">0.5 years</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected dividend yield (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Probability of stock offering in any period over 5 years (5)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Range of percentage of existing shares offered (6)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">35</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Offering price range (7)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7.50</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">9</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 79px; text-align: center;"><font style="font-size: 10pt;">(1)</font></td><td style="width: 1488px; text-align: justify;"><font style="font-size: 10pt;">The market value of common stock at the above measurement dates is based on the Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for June 30, 2014.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: center;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(2)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement
 date.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: center;">&#160;</td><td style="text-align:
 justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(3)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></td></tr></table><p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 79px; text-align: center;"><font style="font-size: 10pt;">(4)</font></td><td style="width: 1488px; text-align: justify;"><font style="font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: right;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(5)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Management determines the probability of future stock offering at each evaluation date.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: right;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(6)</font></td><td style="text-align: justify;"><p style="margin: 0px;">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.</p><font style="font-size: 10pt;"></font></td></tr><tr style="vertical-align: top;"><td style="text-align: right;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(7)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Represents the estimated offering price range in future offerings as determined by management.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 7.7pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants on basis of valuation model.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41678-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5580258-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41641-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>34
<FILENAME>0001213900-14-005682-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-14-005682-xbrl.zip
M4$L#!!0````(`*B%#$6X7J!DO,$``.NY"``1`!P`871N;2TR,#$T,#8S,"YX
M;6Q55`D``]M\ZE/;?.I3=7@+``$$)0X```0Y`0``[%UM<YM(MOZ^5?L?M/Z\
MLG@'>9)L.;8U\8P=>6UG9K;NO:7"T):[@D##BV/-K;J__7;S(H'48!`-$E*G
M4HG=3=//.><YIU\X-!_^]3:S>J_`]:!C?SSA3[F3'K`-QX3V]./)M\=17SOY
MUZ>__^W#/_K]WL_`!J[N`[,7>*B^=_57_X_/]S=)\YYZBMJ?<KW_XK0!+PP$
MCI=ZO'`F#L\$J7=^^S^]?C^YU6?=0[=!;<(;"*?\JBXLN72,8`9LOW>+H#Q#
M=.T/Z+_@'J],Z#MN[[>X3S[N$_WX&`#/U!?_[)T'T\#S4=?_["48)/&,XQ"&
MN)NW)]>"9_C?'I+?]LYTWYY]/'GQ_?G98*`;/K1A,)N_Z.Y,-T#@0T.WO%/#
MF85"<8J(U!0UM*#]?=GPQX\?I_BFIXX[15=RX@!7/R%9D\MQK0F7#=(7*X.H
M<GGIQJU_B.&U_'`X'(2URTL]2+H0W90?_'%[\V"\@)G>A[;GZ[:1P0(+L*]?
M#SU'$GBUJ$5T1=+`=FP[F)&O-WUWX"_F8(`NZJ.K@`N-9;OW&V4;F&#N`@,S
M,Q?<<*"[ANM88/",S-L';W-+MW7$I,4(_9[<R`7/N7=0!JAV"1'X!5V%_:!+
M,E;WB5:7(ZLO+S6<P/;=1?9:#QBG4^=U$%=B$HI]CN^+_+)9X+K(;_/:Q;4A
M>[,-30#);5`%X7+P9KR0K\<UN(&0;0#M5^#YY"91'4$:6X>&1VX35N$F?+:)
M!PUR`U1!NMR?NSG7HQI"@\#K3W5]OFSSK'M/H0WC"H*NXIJ^[OOYS5"E"Y\"
M'WBI9ICC'K%-6$/HZ\TJ<,L_;E*Q(O#=`N:BVA,<('%T.?/"N'$/GGMAM#F+
M/:@X)@WFKC,'K@\1SE3T"V^`T7\\\>!L;BW+7D*?P_&WG\36TS?//!DD0\6%
M8_O@S>\]`!2649C/A'`CKH3(\^,+)Q<H^#NS"<=/+H$Q06*ICQPWB?X^CB<B
MJ?P>6#A\W.FNOWAT==O3P\Z\SXMTS?D;]";G<Q^^/CA6$%YP"V9/(-)9A`@-
M6M!?K'Z')BY!0YC;"_6955_"NHOK7T\^<2A>BYHF"MR'P7KCU0T],,4C8U)@
MHBY1,(,&]",L/1.B^F@\CUEV5EZ\DT_8%&<D(3\,B/UA((,-:`.R-A`SH&.F
MA/%1QY<(`2K"%NF'\2-UQU3]4L'F6@.13W>8U"8EJRX'&<Z4(I'`36[UQ03'
M@PR)^.'DE\!>*Z]`H@?+T>U?@>\C</;T&HVTT$=!8/Q\@4=<]QYX`'G;2Z3A
MR?G4!0!K-FQ[`PUD7W`)7H'ES,-BV[QP9FA(-*!NP;]TW.NRS8$RM)(&"ZC[
M+L+('](6B!%L98?FG0B/7#**I:6="#=0^OR0OA.=>Y/Q\T10D0^YV%>$C`\1
MRROX$-*<XR)%9YD0F?\"Z0RX1/>Y0,,.GL\_XK:'[B5E==2(@Q1IN@D_B!8L
M?D1J-(Z(?4%=M5[5TB`U+R<#0);4Q/(*I!ZYP/P2^,8+@NO8V5A60.HX%J$`
M]#!'-W;079)6:XJ?W.OV%$0.I+_!63`[4.J7U6238T,)>]3I?JF;Q*0GGY*B
MC&W;<#8T@LC,V0J<#<5"YFP'ZFQIVS)GVY&S,:?:.Z?:<\*O=HH8XQGC=\OX
MM45\R/D*.V&;3D)W$1]N>%D$'R&5-^\C1[6(WZE7['H1KV9VIFA'?I7,:DZ9
MG`?3[5G-GA$T&AE5]+=29-10<&SL&0&GY9!()9#H(7CRH`EU=_&@6V#\_.`[
MQO>0,W>6;D3.-^U,*,N5)J8(2:;6**)5I8A*GR+Q#KA&8`+>`2>55P@SWVP8
MYM[XB_'S(WC3O=M+-'M!)<DHP4;0B(>5%'60PZC6%U+^0'\!Q?C-^-TFOS<C
MOE9UN91U"<H17YD\@#G!(TCE%3SB%^?%]KXX\^_(@U=&9PY0I)>#X/MZ/!_V
M!:7)>,[8R]C;9+0>5HW66<+37L+QD['A$P@O$,K9/L">[`/P7$42H0:"T-B0
MST^^.J\$#I'*MYP$WP';]A;6JVY#G87-8LT<1.!<&_9YOB^D&$]_V&<,9@QN
M.FKS5:-VEO34M^:BMP$VMRXVRV_`5+>N0H&CX3U^46R_V6D">+:&/!FY,_C;
MB%]"D]M0@LQLV:`M-ST965.NY,E"(ULNH_]<A3D<.B&'8_FV#YO![^$,GJL\
M%C3SMD\T%A"YDL.A=CBP=905&Y@E5E<2>YN#O<U!<>K0!*E72Y_X/3\QF]ZD
M$,K9\+$7PX>(WW.K,GR$#?@&=A'%VW`"<CYW-QDD<DD2J;B?@\>F5J6J6E7Z
M(D=?J\IM>EK7>:U6F^KLC599PG.3H9,E/!^7AY2=P1T<T2E,71G3)N=(4A/B
MB=8K>`!&X$)\SLK5FV$%)C!'KC.[<&;SP`]/'A@_7^FNC;3LW0'WX45WP><%
M^08A-<?ST((H&ORNN\BD?D>FJPWJ).9NGF885XNX^H`T'@XA%Y;N>>E,9WQ&
MAF.'OW>#8KFBK%X!W9")D6,[<L0N=C#$R,AS5*2(]PM)YN_""BZS_[2A).J;
MJO$K).+ZINIF.4N@9@G4E+=71?S"3)/;JV*2.)KE-R<1RMDQ:BT2GQVC5C"0
M#ON<6&D@10VDI@9202;[$+&<93?4C8?#3&Y#8PGVS)9M>7*U*7'6_/33S>-G
MY6O#X9!0SMX8;H4BU0Z>C1LT=V:F1F8(L3P[K[ESP0QYUPC:>`3OR/PE=W90
M*$T+XT!#&8O9E+6-1=^&C?=J95Q_QZ&A-*ZJ6F5+#;;4V).E1E<]Z!'Z>!B_
MMDWX"LU`MT+"7\WFEK,`P+N$+C!\Q_5"1=M>8/G=>;)$E"VF4CD)CXH[Z_FA
M'1O5-@?^-I)HZ0Y2[#2U/4^YV?$N;R=)S5X?/.+7!P^!P"SI:P=)7WM+'+9;
M<Q16_J&[YN-B#C+KH7"W,THGVV\++Y/KTF*LDEIRY3EB&W<J<2G'KHTG*^VM
M+4<Z='_3K0!\7BQ__(+4C%<%BQN\810ML)*Z:WL>^%Y8P7?#Y.4D7'&A0%3&
MC'+,$(Z'&0)C1A5FB,?##+'KS$A])23:%I>RKPASA'+VT+Z%K6^IZM9WV(!O
M+-59(#$!/[0GE._OUG>H)*&!5.?5*3UD+:F$\NQB^5:W`_SY]@!O(W1]K5PD
M3%O.4^7XGJA!8V?DBSGAE5C.WBUJ=BR-OR[?X"R+AJT[M>+>AU>%.FCC#>X?
MVM2*KOMW;DIW$)3$&VGCYW/LO=-4UI<.34O_$>:%,.Y2Y"Y1W4F*UX;2F;=0
M7O"R&=E.WO;>;K7;1*(777ZP6=PQ\X(]#6?,8&N"_9A7[<LLYVAIS-81;!W!
M/(R>A]VY\!75+;5Z,.Y`%NPHF2)-;G67\#2)4+Y7S]PV%2MF#H\HH5BQ+S1P
MVD2BV.%D!)X(BM62<XX[H]CLB]HE%"LU\IF*["G1:X%M>1I69[1:[91HJ:E3
MQJIJE9VA>6QG:':8JVQ7]7C(D3U#L_/#0^5IXGYHE7W<8S\^[G$<#&*'BK!#
M19@'U?$@]LF13IU_L%>?'.FPAQS8`X##V1;?$WZPTPGV^W2"PV$:VTX[ONVT
MKG*5;:<Q<FQ!#I:A>+2D8,=;[OAXRPYSAQT!Q$CQ#BDZ-;+LZLR@`S(^>YN=
MD:*8%/?HA\X<7)K+!J(4C`9%-+AS'=23O[BS]/`)TM6?`0R?)GU>+(>+6QWO
MV@-WD:[?;XJL,E;?%6\UI!3(R4A$*WGAZ<GQ_<_0\5^`J\]!X$/#NW#<>?R\
M[,:QIX_`G=T%KO&B>P#O)D`_LM@%NM74<1=H\8#6FLD59O3\`?_X`)`X9N:L
MX/%S_.S'1%0P`Z,CO*V>+U&LUSI/U1),6YHF>9A2S4#,X;K@<(\OT&7^MK_^
M5MH^S-WVW-W0'2UGBLV8Y#+,L:'T[FSH')Z+O6\3YE9[[E8CZ'K^*FL.YX$P
M;]J--^6:@CG1GCO1^;,/W-!\7X&/[=:1)U&'YT-YEF`NM.<N%,[6HPC(5E-[
MZ%C5[,/<K>4DT:W][BOX<>D&T\-?3%'(.FW)U?),PIRJ*TYU#PP`Y_[X^1Y,
M`]0YN@Q9TW5>=0LGH7Y[&)DZ<[,=NUEY(S'':VGRN'XH83BCR+[@=X?N:/O)
M=E,W'M?OXZRPX/#$BEIGWK'G2ZN\-3%SMZXMPK;8W6"!H'N!8*Q_OX?F%'P-
M)_^Z=:,_.6XX03E0QWM/8,:LEI@UN0LAA]<^_G`>7YS`TVT3.3Y^D.X#<*B[
M`S486"["KA0;]UBD7L;WG?-]Y`2,[\WQ/:M>QO<BOE^"\-19^`H^+Y"]`K>#
M[["096`OLS3W>MOD'I^N'>UW0AO.@EDWF$+QM;?RX3-152H5/JTS1DC*A-3?
M&"&K$C*M,T;(P@EB-R,?BT*4C-ZEZ,(\O9FS0Z[OQMT@0(ES0Y:R,#)4/S/D
MVGX%'EK8=H,-.6>#+)F0$8;1X;VC&L&?`1+XZA7]LYR@KI7'D].E&^+W7OT%
M/B?,L=&O7O?6VCF"KUA$U`"-:6NA$MEB?_D]9&+TZL!I\^N?P<TJB?)'HRLH
MJ86#BS-9KX?^('RG1Q47:;J)8+&WI&9G#1^5N2O$L%^<%]O[XLR_([C?;/@*
M7`_)S.)6D5Y8K-H3\I;-$#XX=E)(C3X\XK#OD!^%E=F1G$=FXT[MF.SJA,V]
MM>5(A^YONA6`SXOECU^0FO$"<'&#,X*CM712=VW/`]\+*_ANF+R<A"LN%(C*
MF%&.&<+Q,$-@S*C"#/%XF"$>(3/84]K#M6V=#S5T-5&GT0\XE-]_V$&ZT,'3
ML$NI0_M+PZ83F-JAX47@^<YLPLF(;]8F#SF54$XSZ2!)]NC(86)[FW80.L2:
M,MO).E#[G)RZX_M9!ZB!FNZ03M;!KHD<%5[;!M;@*\!'T3-*UZ=TKEJ/BMS1
M9('GR-PFEE?B]M%QE-JHK/;Y!D=ED1E\UP8GQ@2Q8DS@&TBSBSDBY`0%@300
MTASP5A/M(Z44U7%N79MM45G@*E)9D.E3.1[>^,EY,"5$.T+Y7F>,:GT^E8=;
M;4SX1[_?^V9#O_<`PDR+7J_?3\K__K?K_^/_>_3;W1?P!BYE1=7^<P_^A)^N
M7[Z#UZOOT'W[H?YD2))DR+)L//[ORZ>//X_4#S]]O.9'7[Y\X+6/0YF_NA[]
MPLL_*=*'GS1-.AL-XPXB)`'N&IO&P]^*1N2,RV=`]P(7?(J)$E8FZ).ZY'=\
M#\(=OSU<;MP.>HXD\.H9JJM^M\D<QR@,97G?<),`?$I=_#68@?"=_RV[WFB/
M"R^![<R@3;IM605E;C'(HB^6?!ZD!,YVBZLJZA$WV31S&)+"JJJWTWV((UO.
M'>/:]VZ*R7YEA2$SXP<?3`#/KD)OO`=3Z/GXR?57?09ZL0?=@^?M7Z8X^72.
MNK)A,.O=(?O-=",\'$NWO'_VT`+D],,@KWN,>56'TYQ<W;JV3?#V*UA0PI:.
M5;E])4#.D>I,K+Z1I4\I`7A&B@!1WYG;)WU>!*Z+BZ"'5/8?H+M7T>A`J?M^
MGQ?Z(A\!R.LKP7+I&,$L'N0I]<]S_7]'G:=OOMYA="((7<E7VW_9_C-]K0-9
MJ6:$2CR*4+(@UOHAPXB0T@3R;X$$(]5/UB5'T`)N<O0<)0@/,]U"=^W=@[GC
MHK@Q[>&)G6XOTOZ9Z7@M3#BSF6.'S]C"0<P;!SZ>*9CX5B2(6\R2>CBBAC>)
MQ_.>"0R(@'L?3ZZ_CI!!-5Y2.47*Q)0"8%B$9%I[H7LO>,,=_8<GMJ^Z%<YI
M_0O==1?HVO"I<($D(C^Y!`9&+&3532A/28+G$2DQD"5DA=<49?AA4`D955&6
M#!%SF".6%47F1$';I2A+[8LY5BDKBBR*HJ+LA55*^'.1*+RDJ)S&BS5DN7/!
M7(?FU=L\/%32-L?X_,USSP.^%X]F;1A%X#512WE*"5@4I:!E#P49@Y.WEJ)U
MK<NJS*MR"G!]:-2H+0NJ-N2U$MARO[+[%;2B15X<XLEO&3@T8%/3L"@,.:$Z
M;K3P"5PT'%^B^84'6]%P2KMKO6\)C)8.14D5Q5+@(O:VX]2*K*@;3ET-##TW
MEB0%C;B%:`S#"=`H=:<O]"<+ATE4X@;`O('Z$[0@6INW&11%%'<R,;$\O`:D
MHF8(3I(E@:<M5NIMJW:MI/&\EF\D(BR:8E`S"^*:J&XOQU?'!\G%+6J?EU5-
M2*F?`*,&2EK*E:6ARI4&N3HE<S=Q!TWE52$=>(H`T0!.2\U#35`40:T.?#=Z
M5D5!%M(3-IH@J<4%]`>-F_(6*'>MPRU@M:*US`I^^>6'.#43[Y,!VVA.?6\>
M/+.A]?'$1V/LR8`"F!I**P"#EJS/`-'+#/?9FMR4H0>B&4VDMAM;VYL2)%E)
ML7<=PK;P:/F7H"KI%6,1O'/3A-'IYG<Z-*_M"WT.?=UJ92"5AJ+(2^G9(1E,
M3;RTM*I)'"=QF372^WCO@:]#&YA7NFNC<.&AB6,P"\+9XB5XQHD9;:BZKR@R
MGYVUO`^,GABT+-!7T401C1SJUG*$3O#B6"9PO2B;IA7U\[(\E--,W\2Q/4I:
MVI5$83@<:F5!IH9L-!SN1K$;>RCO@:(E0'/[+E4DR(Z_:/4Y=L-<,3,,\W?`
M#9^_-6*(5/),2B+AY!-WRO&9G?42".G*M+5M6I(I>BAZ'O@OC@O_`B9]^^0\
MK.6YZ$^>*.O`Z(BPG3E:$N':\X(F+5!Z\EP63CUM5H13+J.@7165Q-28GE*3
MZ2V"DZ"1<Q:(Y3=@JEM13D7TC<HXO2S.E]XF=I5`3T]8VJ.+&$JS.W$H#RP=
M$J?4Z03M\G'GHRA'E*)H`-H2/:T!E*.*O>F1<SW1#.^X2)):`#Q"5!,TU=E*
MN`_##\E;,:5!MS(*5U=W7E;?EO#;5GP._/"#P??@%=@!R$OP$*-<S_.YNUW&
M7L'LHDSWV533UKO/2D]U*[>Z]%2[3T[O1NONU`>=XZRP1IB0W<S@AH(BI'>V
M"N#4PUV70FM[&$-IJ&A[";R%0^^3[WS;YL,<W=A!=UG*M78V:^&C.CDS+#>H
MP[H.G'W4@":PPW1F1&O&K[O;*2G"D)/W$OCAL_9G8`-7MW`VDSE#BUK\+A1.
M1&@MV`X51512M'T'4%WL=`.N-AS*G-@:>+H!0^*E3!9*JYJO&S2X(:=HW%;@
M+\'<1?<*OR7=]K3RW;X;G%-6E+ON0UI.3DVATGW7T$?=Q"M)5M_']+,.[1O'
M\\;V)?3"O&1TP?@YRL/EVV;,%FBHQKB^Q`LI0Q;#H:I&JDN*VFJDBF8\Q^^B
MHQ5O')[(>4M4QUE>4F4TT5I9<@-#=8!4B29*0TT>BE0!4HUHDB1("J\TJ,&Z
M(5=61$X2J@*\M@UG!K!S-,_"?CX-5S"V04DWYN5SL1Y*JGSLYQ.2IB[KHLQG
M)1GE-5XJ`:^][1Y%E%;@UGJO"HSN\D+@AM20-3BV5E<,U>Y7V?.I07Y9UM3>
M\5I8$SE5E;3TY/(=4/4EH,HU05$5J57X5&.A.A2'*L_O4/^U@[DB\*+";2G!
M5\=VLF&UM?")N:^)6BK`YX+9'C%=KLN95QX:@-LLMQO7+W4NET,,_%:GHH*J
M25Q&KVD`U9#1GGZJ(B=J5)!1I:(H\S(WE!M065W*\2*O25+Z98M<:$F">I+7
M\EGWH-$`WW(S;_K<:?H($B*>[0#7HV$A8*41P/7869#;Q$LM*)@:7J3@]&YI
M9<"7T`K\G'R:W9`X1K0MZ-T0N2;HYLC,M:3HM@A-`/T[@-,75';^BN8)4_`U
MP(\\Q\\;.4*-1&MBCIX@\*JFI!^I5\)(5[@:#D$6CE>'O***>R%<#<<A"R>K
M0UG>$^%J>%B.<#(ORNF$"=K"Q=Y9+FMP9UZ7AY*V@#OSO+8$I.U]HJRA]=\>
M";@S#RPC8#+!`R8^=12MB9O+#5C+7<&O4:?>,27BH(*T[J*3EWA>DJI`33_:
M1S];`/^`<T-F^(37OW:>?E$#4V,I$'F8,B_]I\H1O<&3?PF]\`"F^.OQ;2N5
M!B"J#R.R@$;0UFT#>?R%X^6<']>:<BICH9Y_X>&=&!0([:LWO!$80.\%9R5&
M=FM;.30`4=%0>*`^1C.V+U[PYPFO[>6G>#&29,>_A8W'^"%0:42TX5/;=ZXN
MP;5MN``-*9<@^O_:)J?0W@,X>PI<+SILS@#H1NBG%DS#"THL5SVHV0>WZW>*
M#^"]C%_W)1[$V\(&N);-9MX.9RN2UIW;:$,UO2/5A*3AA<NDBP9M6)@B0`E5
MW1"Q=@!M.5S%DI0Y&+0%G^$Y4>*E(M'*`&U%U)I&5!1%4@J=AKJDV7-%=^\]
M=>'5/AQ7$]/[NQ4!KCTHQ(?OW[D._F:2^7GQ#:WKD!LN/=!``W5;/B2*@JJE
MCVDLCZXQF>I&/)E3!$X5ZLJ$#!F>N/CHG!M_!M`%N<>?M[!WP?/I<]A+(VM,
MGKKN)&B2.*PK48Y=HV])M^U)61.5A]:80+43#-9LM)U(]V@R%]EV_)P^7KD%
MG^%$3LZ\(4A&0@EM[0%&T+*')+Z/%IG"`,#T1JXSPZ<YX#<PQ\_9HXN0[T0%
M`%6&)6V/Y8VAK*MQ210T5<A\C&4;I,L5=;KYU1MP#>BAYN-Y^/XL:O>[[N+/
M[GFC_V_O79O;-I(%T.^IRG^8Z^.<(U6!-`&*KWB3*EFV=[UK6[J6G+W[R04"
M0Q(Q"#!X2.;^^MO=,X,'";X?`B5L;1*1!&9ZNGOZ-=T]?H`;Z1@%)NUF^T*7
M7O2&X!UP6;MOE4:WN_VJ5@BT)&QX3/71;+8;K9Z^4MH6`'>P)>UA?W5ZK>ZN
M:RJ^L$I<F#=KAA^!4'J[M?*^MF+@#KBH7<](]&8GWW)GRV6IP@AL2GQX6K3:
M>M8C2Z?>`:0]UXE@.N:=^0/5]X$PLM?I]Q??A_'O>1#204S6?DDC$XHP=WZF
M0](1F*;7,/2.U!Y;0GF$5>[<W;>A]Q(EN>LRJ1$(V#RH9%5`:4K]^)R!8]%Q
MVYTOKXC/?;NX[_P!V/XXH.X:_Q8]\/8`:Z[0,1B:GCSXO,*F*JYCF_)H&\S5
M$*1W_E#4=).^BB$>(+L^7F>-/5F<H4?S@-LM(EJ@F&]@/+QLX@[0\<;=&P/_
M_K]N]'K"PFCJ\M]>6+[K![^R_Q%M`E^S`0Q;&YACQYW^ROXO<L9@M'C\@0&R
M3.__-$;?:"P$I3203X?.?_FO3&],(O4%#OTK\_P`"""_NS<#!U8W\^T#);2D
M7[H\@AU1"R<F6B:9[QV/UT8S#_O!9`2D_)69<>2_9HB-FN/9'&=I3'[(;R(B
M-[R"+WK\-7L8.1&G*3(P/CBV_Y`,]>`'=@H$C06@]K\[,!R.&4:!_YW7X*5H
M)'\?F\'0\;(3FRX0]5?V9PQ^^F#Z^L7_#J/7B/H^_H'R@.GL?\WQY/7_=`U=
M?RW^U-N-UV]Y:`4.V=+,'[`W<0BK#T-F>C:[C<<PTQ2_S_`,2YF&*:[!J5[U
MU:2O)NJOBO*/1OD#$>'Q<"X7&D9F$#TV&3(,V45^S)(EH0`^I%`_R\'BH607
M$L'PF>>SA<JR868XJ=YJ.=[!=U%%APWI(/28&8$%DU-369V6ZJ!D7ZFFYNQF
M9,)"+!Y'H,-<(`<X3G5V%HUX,H31>(VIEZ8W3;[1$679!]1XF2?.F0/:DO4=
M4++6R`/F&.+E'C00_G?L1%BG$OE@)%(:"^K-/KC5WZ-1X,?#$</#>7."`1L@
M`Q!NP.$K>"#B6%_";"=$'SQDN.8A<R*8S@4ZL@D>/%HN9\YX''N^&&;*SBYO
M/MR=LXEK1DA6TN3T(PO$@25]$SK`L&;`$J!A_CI3ZP.N]8><7GIPHA%-^C#R
M71>,@0</A@CC?NC8#E@'&OO$[?0]@==/EQ_.-78&[W,P1@<132Y"K(@)V$(N
MQT@0AP'-<#6&P=AV3%'NX[IFWQ=]T!@?P`H1-(015C,$7'C`3E%,L4&<"AP>
M<(.<D-#,)H$/W`/_!^/6XI,(_T1T$4I&`$D83R8P),P$>P&Y)@3+Z97!+-A/
MR#DL@DWI"IRF#\S]'`%2QC[]?>OZIE?[%VU3I)]HHLA$]T1VEEGZI]M_75WE
MUAW#;@A@,D8_P6S3$,PM^/SA\UMV.9FXTEFH`]H9&-Z&EE`0T!%[U@BIS<:Q
M&SDU2\QH@1!`_'$6JMZ,$FK'8Z85PP_C*?"I8X-LB;_SL6,"2WWZ"!P%<Z$S
MD;))LOLZKT/F]_\4--68XNQ`YG`1ONPTBTO#/0/$`7+8L<61,1UQ!B.0,T"Q
MA<@2#Q#S.3`,D-4%T<G`>_7!G_&($I'3]VW</4"#[[`88H:9'<)I%P8A;F>Q
M%\P)C#T)D*O@L2D0R58@8>22@3,]91/8TZ##(^0LVL1JI];9W8A+MG1GJ!\2
M4Q5A"*4"6,XPT<@$[NUS[@EH%6;Q>USV`C(@%IT(<=<'A`$Z$2(S*IZ,V#H1
M`@^.ZXI902B+Y2/S"'^4Y([M#.C(`Y8[G7!:A*3&`VYCV!E.1#0J1CX\"U#!
M2+"^>J4Y2Z(Y\P9F19%'H8C1JW<2D[^B0T6'9TZ'RL<J'QVN/?:66]22FQE=
M31J3:#)+GXB1]0@6A^.!E62R*&T</N=&B<N!WOVPJ$PA:]%J;!('F'41H:TE
MC+KL)*9(#;.!;HU?T`3!'QUQKPK9W)FJ2"[N40RY%0?BO#MC=RUR^+*>QLV'
M/&A@_W(),UE$:FZT@G!L,AE_.&,P&<%MZ?56`6C1,0NPM&]]U]`69?=T`/$2
M;REB$\`T56)J:AB)!#"OT:$$VQG,=O5;'J6",LA0:A!YBZ/T9\`2L\PQIZ<P
MC!^`UX00S3Z:GS42S[L^^ID:XR80!P?+O`508<T%++91;S:;XJ=PC@$4G.P+
MNB<YER9+HRR""./Y*1-JV//`F6#.R@7,@!AFK&#FBR01(LV#3!,A*S\&KP1=
M-WPY!\8#.(')O.C(X13Y]1"H*'W4Z/!1#:ZA.ZN,:Q<)E9VL:.'"E<C3EZ`P
M19@=H,#Y3,$3>,8'=#6_<Q_^?`7D$+<"JUI+\(C!"8-W^K"99M"H"4L>V!Q7
MC5,`;X3H#@C71NV^0$R81OD1>P-UJ`1`H(=,WED,KF0(WM#SD.(%`>A'$^P9
M&?[\C/V??YK%/GQ34L6ZIBQ7"A!\>\]_@%=0F$DE0C\DK>:2X`IL8I`V2?`!
MX#9!<O0=?Y)3?<D(F?`C>/5XK[5R\",,-M(Y<;63JYU<F<>%YO$G"F0:#;*-
MF[E=FXN[92/CRZU1C2DS`\/K'AEL?OK.E0S44GP7`+B<!([+=+T`@-Q`MC]V
M+,<%^Q#(+P0.YH&@]/G,[TW;Q%ER7[_EKOF`,@D5_1Q,-,P5F/IQR/X`S,0!
M5^9T%MS")3X/_JW$2:G(<1+BY)9/(NENM]2.I@,8"R`ACU.<8[`KT-4B*XSV
MZO6#!R[`R)FP3QSG'Q8*#.&EDW>TPB$>@*1`ISX1`GG!`@XF"H-9!P_GYL',
M&1W,"$*#NX-BD,Y,UFO6.[_,G2""ZXV"I_`E"X\^Z<R0_W#"J-`W%L!HQ0,(
MKTY,"3Y1=FWD`2&J75=Z[^1_"J?)7[`*SX\6CY8ZCNA!Y5QD&*](6^0]P4M8
M*#AS^'!3ZW4:FM[L9`8HQM!B[Q6!T+6F86B-5FL>D/SDE6PHAVRHZ%">$X(J
M@^OT:#B[EU;34*4782M)DH_9=&I68U\],[8=#*I1"KTS9DF&-7R#"!!/KLA%
MNJ,(F_3&47''R;B.'-?R<1&A:&LK,[QY-O86)AG=I*]40H^'"?^9I(()]E<1
MP?IYBR*-ZX%#`<-.7'AW**X:Q'0<"Q-CQ+NHW[YZ!"(Y"T(+@4T`)D0NEOZU
M?EMG?[^\O,F9!*A_U-+2-3@IRH3B+P`2)PYB!$PL<QB[IHRU#@J@NDW/`/#Y
M)(R*A0Y.&!:>4;S+I]K0M$#W";?H;.(]9DWHC=K_*VP3F4?2Q?F_)."PV]K_
M5Z=\Z`"#->Z4C*<IN&!D)P!VW=CFV6!U9O$BK.K[D:!>P.71!]@5"3H)A<@R
ML%EY(1^(\/%NK#2(`\\),5<HX`-,S"*(31LWF'CBC"+%5`..*Q%[&P\#XH"2
MFC+/GLMC'3(E)0]AU$DFF(-D,X=<)`%YW.)AB!GF%'!F`],)4K@4RH2Q%Z9'
M,G*%$RI5"Y'9<;?B*8':G^H5-.20$&HB$+3PNDU94_=\T02#&%8_Y69`N`UW
MQ6XX\F/7QN28@)O$[?#.G[$GSLX2=E=3K!XP?W"3@(T0,PYPV>E17E-&"XC7
M!)]A#A.G'#P/8X#I1B\R3TW/BY.0/P-PU;;XUUK3TFF(\#"2=<+&8^]Y/XB1
M[O*H\:)^+/59JB!!E;Y>&3]E,7YN4EN`/,1,@=DZALTF`E&IQ85"1[99(J$5
MC?R0SXB\W-/%:<DBFQGD>)@I7"+I;26I!ME9,M>@9^PH[CIC6`'JEHK%R\/B
MFW'XWJ34SS\M)B+\5I'Q.)+JJY`'[V#4,5G_8+^D#EE2\YKWXM808<)I,E4E
M9$2FWV9R#1]"3&->TGZ=+>D=A!G[&;V4L?F=8XF#Q`2*,C,,X[%,3*'L<)-2
M0J2E*XL;S+&0?9C5)+I4XJMNIN&AS'RQ9=A99A*MX9,NF@=S5[Q8`LG5_<%V
M'(@S;9[-*R'+GLH,A/4I['.+[&B1IZX.MU`Y).NOA/3I[N[*ECQ]&BH)_85;
MN5X&JZ3OE4Q'`1$)3J78_8GH2*VQ(!E659&1L*4_XX!*5^2[DXSHKX3"Z3)4
M)11.GX9**%#C.-3]]$>FY=0ZMEEZ8BD25D.*4(X`BV!$N0X,9J<.'5E>?N#`
MNL!Z&&/1<)(?CH6U5,(6C2AOU\4B8A`@?:P]!+AX"E>=W<;6B/5-%^/2(I@8
MAS'9;2)5'-^%,=^__7"%=:<Q1F_18Z02R8C],_8X:XJ$H0M:>E&`+(T-%YX/
M(U!XJFN#=13*&"25GO9-[WLEVTYW7U2R[?1IF`;/1"MC<?J4]%A>(=@^F=8(
M,!:(UWCR&@H:L'5@O:("P?+#2%90RYN-J#P=\_L!D8CM&F(>)`*=7]Z#?%$N
MD0T2BP]B%TASGQ6`&+0'(?4>#WZHIX)(\?]!R7V'!2!$/U`!\.\1_*T\4)HU
MHC,PD,S@:MJ:]#OE]$G_`LN*Q['XV\[<]B2'&/M8H))D/RJ](`X;48NH<89H
M=*(2P.N<G5"=?DD9*Q*N0>'4&7;J=0+ANHY-#"-Z=%9);JSMI%BS1B;E2X%&
MR;Q?[?"2[/`JO^/T:;B]E/XPQEVLCI8_^MZP]I%JV>1%+87]T5+!_2F-O`7\
MWN$/(0@.&,.E,:00HY2'=)X'D&^<Y.&].+H-9'ZUB!8Z`0@RK!>TZ`M;9'E2
MU(X$GQD$E"DB?&'`U)2.L\51,M9\83\&/#J/L,N'XSGC>"S/;,%(S<36!GX<
M@%'\5VP&V`-$&ISBC/O#`#N,<*Q-E+FC:3*"$,"I,!_$I"UB`#54U6EDH@Y<
M8`)$@B_50WJNC8@1PA'M6]D!)OEEQMJ5"Q:%DM0S!^`=HW)Q"$PG1\,0#70Q
M`1;.J'0"D1,A2N$HQ(F%-1FBJ/-XRBJE0*2(=<H.&!;&&Z('##D0[C`K00"4
MGU*TXYB%NCK*KHZR*SG_F'(^>S_?JOY@X'W;F<=G+=_LWA?20(8#6#CB/`(+
M.GE`R/Y,-3J@U4Y/=L`<]!`%W[DRI?.S]BG/'2;Y*_91?LI')X%C<6$HPT.Y
M+Y/L)DPKPLPF\]YT7%%U/,B`A8\E8M267<3D2#3KSS_1B/2U;W.73NA5ACE\
M*<>'Q_P^\+"X'%`.8)N1*6USU!CX^)^Q/11^#'HU1S^;J<1B)18KL5@@%DE4
M_:'LF&P*,T`5C]<)Q:;2#NTMFP](HIBA[*T'4DD8KP]IQJ-L%P&F5L@QJ52Z
M^QJ:K7@')!F#LDDV&+'J"'HJJJ'0/0=)"<(MVV]$66=*'%*7-V=BBMYT6:$]
M<L`)#ZS1E)K[B9P>U1!0%LAD[%YO$D?RT'Q(@AF7A4%F>$<<3N'!/@`L9;24
MPY2_3`FE`B#I!2"]J`!;N@;4VS%SP"[/RL%PGAT^]C*"5D`E3-K"E6'[29S2
M11/\UTK,5F+VI,1L&5III_\(Z;J\L_9*>G[$3@M,!\E*`B4C5+&6A%+E07KL
M0X@DH8(T>09?B(2\(R=;MGC$IDT6G5C)-\;<Q!,KLM0PI:<RT"K)44F.4D@.
MHTARR*]$]UK8]]Z<`*&L:G(XE0`2^7]8S9S:$ZIN0\2P,O($3"[NT.BV`W9;
MA$G5`44EQ2=5#3-&RB1)W'D@R`66G:6+)=:<G-,*ADC%WCKC*8&9K!:=8E.V
M(G96H&TS%+$S&?\3N>1HN&$K95C$O8\E80(H3>22TMV.+)S@W74:LP)N._"X
M$WZ'3SRRZN<"OZG1*3SU@`QFF2Y*@5PZRJ)"L"#PJ?FU*!/+^N#]*?W,96%:
MTN<8Q'QU`E4J]ZU*$WCV`KY9;!K.>7TDB53L+CG+R<3VTOSM(L,PJ>;TI%7X
M?R'6R>12Q,V^'T=*VN43QPO<:^G9QR%"F$0-$UDY"\9SE#NE:`;$.G307<F>
MIZ<^$AI20(BB/K0'46R$#`T6O!-CM*BN0[I]!:<;9K:>F\J%O5KZC<CM`2O#
M)0F&Q[O.W/EH&I0R23:MD0%)'7VRM>^7MU>L:S2RM?K(9\Y,"/-3ZKZ*1:97
MW"4=8`T9Q:1WM4S)RJ*:%SRD3E/,Q?J<@(1GP,'Z2PYI,H$[@0]8+(EL(3D!
M4]FZ0WG>G4%4QOD6D;W".DB`,@RSI?#IH+(CL13.,=K'<OYE<Z5E1.J01I,Y
M3=-LF5`:$H4Y,B,M0IN(9,)C$Q=VASAC7\$?A+7GTFZR_+*D9'3X^:>-*`&/
MGY9Z/H9B%I>U9(81([P2ZUE-/0FZWFIW%IO?\V;ZHLU2@+`^G>W4Z$JG20@K
M5']E6*<FPJ5J/LE!((RM43KV"LR_8-CB3<Z--[32YXEIV_)S@K)`X>L>F^YA
M4UW)+GT_BOSQSI)D;D<4LNU&NRP%WL[S3"F!G&?M\H&Y9'-%]CRV)1_5!(L`
M,/76'G1.182-B)`5[>*>LT2\"+K4I"KK@X7R??8W)>H$Y?*_2=Q0X7,IJ8I2
M$V2;]]L+XY0H+$/4U1X[F3U6$:$$1*@$W6D*.J/:8R>SQRHBE(`(E:`[34'7
MK/;8R>RQB@@E($(EZ$Y-T-WA'0W5#BOY#GL5!:<<UV5]V.W#`*]35P*`CB5>
M5P'?1Q;895W&T\1V5CVZ?/!LA>>B,\[U`$W:T^Y,@P"G?ZY$J#;!\\1_69?Q
M-+%=<7MY\%^)^VH#/#O\EW493Q/;%;>7!_^5N*\VP+/#?UF7\32Q77%[>?!?
MB?MJ`SP3_#^CXZ"*P?8+9MI/,EOV5M!IJS(N*ME:X;\R+DI"@&H#K`GFSS\=
MTYN$V9X]QBN.?Y+XKT1^M0&>'?[+NHRGB>V*V\N#_TK<5QO@V>&_K,MXFMBN
MN+T\^*_$?;4!G@G^G]YIT?]8%N>#PGY1LH:PV]#K[8[>[;2P.9>J7$.>VU,?
MO6?.>;,W@J^W_U6!9SN]-*!T*SL1`FPJ>G.HK^1P.8AQ8<Q2HS)+]@!FK=H2
MCP_F+O*IK&MZ!JBO]L$2,%4KW\=1#GBR6ZF'2CT\!1ILNRE:E7IX5-17^V"_
M8+[<4"?HE<-P`#![6M=H:VVC4^V(QP>ST@PGB?IJ'U2:X>E1H=(,)0+SF9YV
M+:R-JHZU#G"L-7>I6Y5)4Y:M7242E!'_E9UQO)ADQ?=5ON3SP7;%[>7!?R7E
M*RF_.]J/62ZZ6YO@IX+QTY,T3XOC3P__E:3?`YAMK=/H:$:K5?'_*?!_69?Q
M-+%=<7MY\%])^TK:GSKZ-SX8>A69?9>K3Q.U/%5=U*#_;0C)_.IVQ);+HX@'
MM7!B6HXWS'Q?A#0_F(Q,+_R5F7'DYX\>P\@,(OE5%,!#`W@'W_3X:W&V1'-D
M@'QP;/\A&>O!#^P4B@:>;`*L_>\.#(=CAE'@?^?J\C;Z?6P&0\>C#ZQ3[TS4
M](YG<UQWH]YRO&4LEF)Q)8$G3YV,QZ=9GG_^C,/(&4SG2;@A#>&A/O[QP;/\
M,6=WY@^@@Z!LU]!U0<U^GMQW(\ZN_/'$]*8L#N'Y"+XPPY!'S/3LI(/AE(UY
M-/)MYGC,M"P_]B)8.-`C@&]HM@AGJ[.O`'T`@SBA?$-C-A_P(.`V/B*&#G-C
M.S"K&7!X#L@X!J+9K&^&\&_?8[8S@)>Y9\$S?1X]<.ZQ@>.9GN68+@OXQ`\(
M$!PO!8199A!,Z?LQ@AHR?[!P9OB,LX^Y&<8(91SBBX@&[IE6).$.S$@^[)H/
MB"4S`HYP78`*<<(!3`N^&0%\^&H6;AR=_YAP,98/4-_S(.1UEL4]?.EP&+@(
M68AED]V;;FQ&#B#%=%W_`5#`)9[B"7P)4\/$0(Z((>[]`-M/?N?N%&'U@(LC
M`31!-S=)LI9![+H(#;#F?[E=9Y=%\VK,&<`&A\6%9C#5<,))X-\[-@QI#DW'
M"Z.BA6A9>$$RF$,^!E9/.+3S.J0GPQ"_AC\16P"O$TB`"(QZ):%.5D)56N;T
M::BTS!<><C.P1B04W^)MSOZ$]NV5'T8K]4[N;3OSMD5O*YGIH;P`00"R/49I
M4F<+7PRX,^['(%CQDQ#50T"Y'"S@%MYV"ZIE2B)0R5T8VX0?[=@B$0=Z(E@*
M625]3I=S*^ES^C14TN=V!+NZ]H;LB1MS*O;\!K8N!W#&9-.A-!B88&.@H<-1
M`G`3=G\8^=9WYD^$Y?-@!B"'A/5$4H79\#(*D]1<?(,W;M=NK9'OPK#RS4G@
M(/K`(+.Y2R(EF0:LU3$\$>)*PM3DQ:%<,XR2WPF0U`JS@7Q"BCD`TP1<SVGF
M5Q2:083#9Z1<SL+*#2OGH\7(=P@>L4AAHF:0DS'1P?9&28EHQ[=0.)*A2OZ#
M0!?:Y"%)WJ&'UB3S[[EXX![1#U@!6!UP*NPXP$_`DB1V&1]/7'_*N7C]K]@)
MA.4LC4S<9/>.)0SO'Q;P^I#GYP:[-10+J1%>?_X)EXWJ),42J)89\!(2T!@A
MBUW!(V`09^UW!%[+*1'2'Y*5U-``#\RJV,S&SP/N1'&.UN`F17Z`>;.9WX6O
M46<WZ!/X<4CV>`)D;AU"68[-*9KNIHV;3/D8`Q<=$L*(%<7S$R0(`Q("?O,L
MSH%TDAWRI*JS=S_0[">KOL\]/G#0K@=W`/"@)9I6PHK*%;!IVPY!BQ0T'1MV
M/SAH$R<RW4J;GJXDKK1IV6E(ZN^=&7@P8\C./OIA>,YN0`1?"15`.G03I2GE
M+PDPQQ(&LN/&*'.XF@;D1$ZS@9!&1`EYA3*'M*L4_%*%H%W_AH9,ACES"=KY
MT4B!36A.4(*V`P`I!>SQ2`6!Y.OFO>FX&(E&V9-5?*"C;1Z$RAL0#((2"S24
M"=K$BRE#?4Y+^W$41K!NG%)J+7P_#40I,?EV%5XTE(X@^*W85?J!AHI&`2@^
M>"P:A2B'X:=<'RAM710<=.T3-PX%[?&>DY"#=T;AM#I[O]XZFL0]9&\X/Y8L
MEQ[#YX7&G?@1ZBL3@U0%T[,S87:!Z`!U)KT_#Y6F1P4JB`V,3@4Q&8SGL'AR
M-"TWQID'('YD^$Y0#[EHG@<5U9"C^]PRXY#+,)4*`_JQ:[,1(!1^YZ`!`60%
M[4H,I5LO)7EVV4X8QD16218@MX`^:[%2Z&P2@QL+I@;3M6:OJ_6:'?4.XB1!
M4/;)KM9N=^"?9D+T]0S)=%7+R;GS4@RMUS*TKM%;N92>=J%WM4:K>YBE-/>P
M%*/;T/3NQ1I+:35;6KMWL>E2*FU<'FU<652G3T,9^+0P''B9'H/=!+X'?UM\
M/@R1IZD\GF.?P&,3XA"W\?OD0"LSYBVJ6G)#W_CHF:&``7%2^,37"3GP.&*M
MT=/8%W[//7#729]=`;T"\`%#P%XT8E>P4#`/`E#5EP"N+4!V/'%F)T>R`H[_
MN?,G8).U&^TUA]1(A(7Q!,^W;"Y-(_&B=`M):4J?/IE:S=-*Y_F2/JY)82K"
M*"$:.#;,&$R!]MQR!O!JT23#V+'ID`STK!\/1V"^$$`?Y-MBUHPLM7$H<<0$
M#R5NJZ"1F>(JOSX*?"1SP6)NXWZDUE-K%B\IX1#C->`2[1$*/]?NIA-..`2.
MLK/?)1@7*);TP?V=3->\:-0N0#==TS'@97K:^5:=Q%%@/C_U`LZ`Y8?Q>$R'
M>V*18/9,P-RUG(E+D:*$-=`<I8-%C-L`8T:9:$68$`:TF<WA#4$"L=F%C0D^
MQ=C!<,C0]X&50?7*Z`ZI0$O!1`?/GCS/%1/*&(>*/WDAN":!J2(-(IBD`AR1
M"N'0J'WYI<OM@AB2#QIW#A@,A<%*EVT_1\8283>[#(]XY8$"T'+BAZOWKEXS
MFHT,>0KXAITE6^5<\<EZ8V=DDM':8)9?<QLC(S(T+/$>X?H$IE-KU^:@#="E
MN\OOFQD90T<\9"^C#:_<'^5JTIFWY\6Y4W[A7&$F``AQC\[W!Z!VTHIBO46V
M63LK,ASP+P-GG+R,O$Z@$`O-^FU9=Q<=+3QU\B*,`,H8J\H-(,A)>ES>?E6B
M5\53D1M]U[&%9Y>(=W"?(B'U*LNL1%J]LLQ.FX:@K<@S.Y!%I8-2S9YOPU.@
M*]ZA`G&$8E@FYL#,\>^Y2KMQI(3%?*3<X7)(@TI514:6D,$]%&FHT7E_*L92
M$LAV,#!OR2B$2(U:,*+*<_+)-$B%7O(C3?BU?EMG?[^\O%EN_G#7&0-Z(V7>
M94PY%-I+0`#->Z:?JZ`?BFA.;G$M\FM"@V9"A5*2IB(3<29"6QJSS'#$!BYP
MG#0YT2T6<:V<,XS`16##G!GGS#7[W$TT]*Q`IFPC4OU+20-#-<\1]9:+S^*#
MH14X$T540>;9=TW4<0('CC=OF3@87QC"@[98S=E%9@K'DS`'8&=.N1DL&L+S
MF>N#%1,LXRS2>@X=2P*M<+@0,\9&IBUTMYQM[OTY+C?=$*PS%T308)HFEF7M
M8,&_1@<M8"?\+CCP*_P81";H9`=E'H!M3B8N6!<R3IGR"@Y)-@5FKF%0`Y/I
M;#9QP2K`_PIC%&CH3Z35A\%'M+W<Z1S/$K1R)T[,P!P&YF3$NGJCAO]OU<!B
M^/DGB57B"673+L:D[:,8!]C&G$=*Z<N#+D1PT2P79^:YM#\QGP_$-RP;)B83
MA0-]Y=AG?WQX=XZ':KA=,E2V3-SB8_(8Q`94YW7$YS`.GM8)HY:.D?D0$)2R
M2!@/P))S<"T87L*CW`C)#Q_$GN#JP#!AUVC&"A)\*JQQF_95"E]NZPWQL)=L
M--NWXC0GQY).!UIV%.L:J@V(V86)V$&XLXL25E.27IJEKH:OIIR3V'<@/"Q@
M#K4M_Y#X!N$FL:U$./I0(;=$A`Z>3EPJ03H-O2]ISN5]MVN,F+NN)@.^?9X[
MK986(T]2,\GU\:.BI>'!:P"[9(9*:7)!LK.21,LLDX6*RXQ6[:*E/%Z&GSJ:
MY&L)6BCL]K\`_TXDKBE'LL!GQ(;X@B?Y!,?P>YJUII'U2!;K6N68@%(\UQ*_
M(]S1[=C:S;C09-YQWL$@;>UXXD>0L+!M3%NF@V02&O*^AF(6D39!SR/FE&NA
M-Q(/:1;.HC![Y5Z4Q#2MW(MG0L-#^R"&1J)"9?[4X#D\5\I^MU#RQ5+R@:4U
M%<E!<PX`61(BL4V>9,H4K%P:%2B<:3)T:H-B3E@21Q5Y1"I32UI1(*G(LB<+
M`R@!%A/:,F@'62,'Y+TM16SB4H3`!$F>5QJ<.:0J>O?A[GU-;[[-14A3]&:^
MGL>]TDP=O7O^:W86E-J%N8K_5J4B=PI[@)!+0MZ-1-Z=0-Y-!GEW`GE79&^\
MX3#3'/J^).B[E>B[(?0M5Y@3A:$,_PBKIF1LHRRMBG'*P3A;6%K*4"HRGA+K
MG=SK_/.K[+'6(I-+>#K1K,VU:7Q7-S:,[U::_`0U><8:J^RRTZ=F4C"`/OY?
M,3J5[^XWK!;(!3;2PD59M(E"U'49IGD'*`7XO<R*%T[X;'X]AHE$7=-**2+2
MTZ2-B`(T3!=!LZ@P(29UYTY`%\F?O[V*P]K0-">_7@=#TY,EE;GXQJ5GWX@(
M+7V\'B2&[&T"V-MD6GCZ%NA%)X1>E.JO&QC/`A/A#JCWQ@6M]_O//_U-S?V%
M4\[C#=8NW"&?F2+XD@Z;O$;Q(OCPA0]^>W$E_O[6_O3N6T/_]D_3^X:"^:[1
M^";^?W?]K=GX!H9X_OL7OS_EG5K0A2#9+LFN>H3MG-]_GWWT9;*;CDDV8,0'
M+,L(F?WX+(3M(].K%OF3_!>!@#G[E>CH7B"IJ<'*BP,3J]I>Z>TKQ+A=Y-O"
M[5;%FTJ\U998.EL8-?B'@W]\NOW7U=6O1$$GH64J0(]`XFJ#5ANT<CQR`6&P
M01L:^SOW\)20748N'K%9[._@%TS81V?LH/%C^YXX]@$70GH(\G0PS?5WT!48
M^5AGX#_@Z3?Z`8[M4'[F)9A,GA./V3]\UZ92HX^176=GB$*.D1#/',,K<V!\
M2,]5%3!T./V)CWWR8VY=W_38OXB>&!:YPD!2P*ZP8"M@9R1RSC4,TZ5G\0!=
M,%.=4(5"3I:'*SET^C2\]MA[W@]BD!5,IPMW&D:^>IWV,R44P.XW0198&)[(
MY[QA7!6K1GF`@0`9-F"7PX"+2`@ED)/`J*4"XX,'*XAB$?J0TB-IWW)V^Z\/
M*#TR6>/"&T01A**%G2E?T6B\ED"E,R:_Z:_/92`Z!0;KSL?B6-P!*.,AH!(7
MWJZSFS@(8U,DP$39M_(X<<5\(9/I2A2G=C'=G`+2`28=J40]6$@VW]C"4D2L
MZ)^8D0CB(&Y`DD^H(-]?4KD5X*&(-?)@(PVG(IA-F4MA/,&C%]`%WM#'.7(]
M:BQ@:9HPFZM$C6P$0NT@'N)QFTV1IK`NT4LKMS74)7]*R-1BDTPFV)[P=1PY
MV`U,1+*DNAK$GBT2_I*7%!@(TR3@R6?`UC`PQ[+56II;E"'X(I00Z/8,'R8#
MAU%L3Y/ALS2@4E%Q8$)UK,FZ0IF%)+LTJ$9N="I"V9$/#G!9FLO>]P/5;:-2
M:*<O#"N%=OHTG#G!\_LPNI(C8_.[$%,#'[,)J6+,<<',Q9XYZA3ZUXKVITK[
MM?9O).JPTV'$"*_$*E<3+[EBM-U9'#Z8#S,LHE$!&OO8BB[`VR==<Q+""M5?
M&<ZIB78^:C[)0`&/K%$Z]@IZO`#-Y[IR[M]>-,1G>:DE?DY0MNH>S\S=F!1N
M4ILJ7-B"6UV=J<+&>KVU@(JK&GA;9*`F6!,#JJL[^]AT:_8W14&:<N8WN0GI
MO`L1Y"-^O-]>&`2:RK+8Z[(VNC!UC=M)5^!P"Q1G0OB;O2B:VV_SYAI3[HBW
M_[$LS@>#+.9F;Q%N=GJ+3S,P^7X`EB\H$9%D\QE$QENT2"]%S8+(W\EX*9_?
M7F;]$JP?#?@06X7XX'V9$TQO$IVX1!<<Z650WA.6^RY$G(*WG8015R,[^\Z"
M%;Y<^?+<I=<__Y2E>:?5T$`]KA@&WEEP7_-Q]\UR-L1:!NI,+%+)+.Y,I!M5
M0$'5*(9JIMZ_O=R`IH^T/75M%;&VI\[SZ/9?6ANJ<H%.GH2;T3!3!54<O@I'
M>)P`#D\:3<.VEHRR<X)IK3^MR3^IE1OU0/:GIAM-4>(9O^"_L958:+KB!`*'
MFY5L(<-4'U%2B9$<#/S_2B5K>D.6%B9R4I0O6DD$D4;64$&BV$W:YJN0&?\Q
M<0)>!5I.ED,K*7/Z-+R245-UAX8=<]CQ2O+,1>1%LF)R[8-L[T<]'X?./?PA
MWC7QBSY(!SP/J*D8<*82M,ZN92V-WJ.T;CTOVQ"E\-G%+K0BABT:RTXQ$,^P
MPO:E,'0P]B]>/^O#ET8C^ZTAZE<M_"'W>#-9HQ-FQ:OC)3%\>;ZIII%9ZF.L
M:N:BBG;`9<5]$JA7P:>CR;0J'Z/*QW@FT@SDQ2V?1*(6Y$)U9UQRQ"EPDCTQ
MI.-+$!_P,]Z&`\N-1K+,/&TXE1W1?\"Z<7A#E>7*8ERR>%#JX%#4P'2)R!0'
MEZ(D?/>)0%Z][.HM30>91/U9T6@#`<OO\;PSL=Z*3S*5()Z889JZ+L[+1,."
MM/6[JOLA>/T'RF&1O1!DU\M$9607@EW*X6E:A[#STE.XI3C"=IPI28NE+2U>
MRF-:^_PZJIKHDFS72N0^$QI>8Z-+-'Z,#@GEI7DG7K;U1W+$'U$FVHR@%@YM
M/AUM-LD"4QBP@2(6"[(;T07YE2''$ZVM^]C%R!$!O\"<D.N++4AL+#VTIF"^
MF/"(:(\Q"$1E@DBHD&V"/@+D\7_CL=FO75J&T<I7%]*-:FB6OFSJFMYMI2%"
MD'ZB!XOH<2/:>5-)I2@0RBV^SKY.Z,8*;L79+D,+/'^\8`%63,97+9Z0;(0W
M7G9Z6MMH*N.W\JQ/=E-5@K'4-%RS_?UL7WNU?6W8O=*0BK%>>IK:2"@^EON8
M4N:):P%(2*[;EGT!-.K6-?92[V(/\@X]]U(W>EH7C"TE;\&[QYY;VP%X2?'%
M>6B2XNZF7F31H]@$X:KZALD8YV`&TBY)WEE`,XEG>5E;V8AEV48;EL$4=-E>
M7SK^_-.6A(472T?:IUG>=..:HKDZ^(6XO*K0Z;')7076GH$4ODZ2Y]=RX$1S
M2)&GG??83/8/;KK1R,*>,&GA$7MC>M_I>M<HQ,Z>EGH9_ZWB712L5S=64?^<
M:[Q;VZ$+`T5?7!/LI@#TNS];>Z2IQCXP/=UHMQ@,2AOGYGAEB<`LG%AMH-IB
MFNH.0,N-0VJMN.92J.5NOH<]W:V.UPW(#O3%LU.B"O;QP8,/4S;&Y51#AE:-
M#[S^BT+*,*#KC`+?XMP.66`Z8=HK=#%LXOS$1":MR;O?R>Q2-QWF+MY-)S9V
MGU<=T>1G("M/'N8@DF274V4G)T:KS-J?P9AL=S6#1HEKFX>P-<AN%1UC)7(+
M;^59?1=/;EFY"PR*R)..E[NB4[;_('LWO=DS]H@W?'<-1*97;24SY"%3=Q?%
M,M(06$Z8]"MYDZX^N=3(P?LAP*`G*(HQFD<@S6Z.1:PV4X#!0FO$[=A5_:&F
M@H.S,"2SR]90;>7'2/A$SR[L&R(S]=9`ALE:OU`*J.5$<K?Q%(1D1@6&K:Z)
M#F.7*-#G5.ECNJYLS`+\QL>BW]1,L8@(WVP#:);2JT7/S+W6F=M25?5+VF'&
MM.^=$!/:LE=M9-\F3*B3!DS_B&"7X9VT"?+%$_3!G291)J.%NW*V'HM8(;D[
MD*)>9P[U-\[.B=(/[QR)R&N<LC$/ACP`(6")MF34B[R/'7'QY#<;OT.Q+QKL
MIBU$V)G\"M0N32,N.WPGK_HXEWJ)(F8!M>*-**M%N(5.M$!Z+*`#U0])9L<3
M[@4"V!P"3H9TP4Y.U*OME(%?-C8_<PA1FF+^+%&`<20Q9`\W.I\Q<T'".4*+
M?N5]9.F^?\]G[[&5+8)-Q2S(A@$+';"QS"`=+HOH0H1@[).JJ"B9$FTA1`6\
MH51DD;B<8U#9(2[1TWW0TSQ(T)6#,0O2)*/!37&@QS.B)CWADZ(S;^04VC$B
MDF)F>N[2O!X7/=G3+GJ4NI00@?*F8%=C*#89*\Q;3J+@SA,-J`5?SC.L)H2C
MN*=&M;?&HKR\^F%]:BL*7RJ+*&1C7%N?R^S5#14C[=TE<L8L-MQ0.17(W:O,
M/8S8$"C,T%!F:^!SFI"W67VGY#-)CY1`6D9ERR<+5X!W`Q1K<5TS6KK6T%L;
MZO,J5%02)Z6B0WGHL,Z18!+8[:W.U/"$$E_L6*YP')N+O*V\@9).BFFRLP#2
M[1A*!8JFM5*)B3RR;(Z8*D#>QA/3]N]C+;Q1]+B^"RH$Z6/46:81H[0ZYTWB
M)ORMG,`BF8Y-`1TOEJE_V]NY*H$Y<U:3:O+TJ,$&S\AUQ,T:Y)$G]PT/A.4A
MC0$@(!6$?#;E.?:[[,UR"\WE*O9UJN*LBE^6FH:82&QZHO5)<@'UC,\I#R3G
M'?0S_"I3W$=W"[$K\6N^S$]T:)H$SCWZ=JFP@A^R=Y//#*BT46ZLO.OR%7Q_
MC$<*H7V9:AK1,]849Z<S2YR;:'Z`W)2H)%`H)_=8;3M/\2#9N80?FTAJT'2@
M=AUQ8Q%Z>>BNS([Z0?VR$$_4GOQ7(F'R,)-IE#FJ9?/%%4XP$H&Z+7'-8:4M
M\`BZ>D-IM3,<Z>>?<DNE7V:Y(*?[`("7[3KF(X(^$1?'`Z9A&/+I!\X]KY'K
M6*B?9R'2FQV\^'R1GI77KZJH&7"B)31,+P=`/D$I"<Z];&I-(&JW33GP,Y9$
M4L*#%3LS')VF;<ZS6"$!--9'CE<M6D3FZZSIHL":\32ETYOXDX"NEVVMW6QK
M'2,).:4H4UZG3%/-P4UA4_*\%;>@APO66\"IUSZM&09OR"AS;BJR$@-:.*:9
MW6/=$_RKAO=71=7EGF62_Y4./WT:OHT#)2Z6YS"M.!_+>&08E\-8V`\'H\U@
MC[]LU"^P48Q+)P%+!)[PIT+EUQ2*[G97ZW7:FWI8J"WRPGHN"-\21965="D)
M9U;2Y9G0D/+8I\SH%KD0ZFQU+NR<F)KJ7$8<ALQ%EPI/&Q8P2WI]PP97*&1O
M7KB1]3XWV`3VTK/?_14[U%GO2%<OX)(V;,>TFKJSN^8`'9L*&7=5]Z5<+AO=
M?]#,W7^@B$$\E%!B)J-M7D@\2QPNQ$-W6S24?<5[5BUEX1JC5^^@;BH-&G.[
MD*M=*$[H*>2K3B"3EH)@JZV1K[Y6F\%G294\WU9(F>>/%2T,+5A</W`T-N+N
M/<=V6(`(6$FMZF"X;@?#-1IIG68'PR*9M]EFHF$^@M,<SDNP_>/I66,YIT8J
M;!\8VW,J^G`8+U?+SRW(NUYCSPJLO8%U^&:GC=92PWB+#74]&.!!$\^YKBOW
MTZ[-3#=]QYCK@"IEUSY1D<+3K,E`;3FQT=XS#[S<;)GSQ,CNG?V`I%\TM9[>
MVPRPUA:XW.V=Q\'_7"/>`^"_I5UT&_M&_Z&Z`2]3[WNRI7F(X6W+BL>QO)*%
MXP4ICK@>_H!FW\%461FLT4-8GELC["!V\!YY\$S')/?.[LRV'W#.EP4O*U9Y
M9%;16NTUQ7=I..5PYO/L$HV]+[$X`JUA!^;MJ&"44SFL!]9^WMYXCQEU8_$F
ML_VX[_+'L-OV(3Z.O32]:6B]AG%(WJV8Y!29Y.>?\FRB]8PM]<PZ=%Y\007"
M\8R/FJKSMPUS#"I4E`@5,GWK**AXF_'3DUJ\P:8M_BAE]&57:[1$U_F7,ZWS
MZFSI/&NV[A.S]+2+5J=PEGQSTL`76?))+4;HC[FJ9,&\?@F0N.ZC*$'"7C,Q
MMRE[`%JH6#`/U\5T?RQ.N-!TPV"RA8#MA!-?M'G(9+BF"6^;9*YE,][>\GZ5
MW':4Y+:+;');JF3HMQO1JI$(6^6V'273RWAT'!Y14*^%QFSQN4SF77Y/`,C`
ML1./945QMF)<WCABLI=ZJZ-UC5;ZK&HEI3J2H?3SZ:`L8*YC]AW7H7XS((YH
MT`FV(9JN?3.Y;/!L^P]>]HIK@$/K]5I8G*3J]!+MX(2JLTMR54KF<564#!!%
MINN.50F]A[VOA50'!;5N%<:"3K($]4N]86C=5DMVD6TT02/.JL(\@^?X?B5]
M-VPEZ\<1K%@T<NF;+A%CYD[RQ0Q`RK9UH?4Z#;D<P0=+EU.@UA:HI[P&H\)2
M&/`#D"B(J<8,-.`_N(V5=)?)C>J5FGM,&9W3A:U<HG=*P7!&`YY(>JBX9+!$
MR#[)U.?2*<2L1X`-M=,[7D2?)>4;I'5N,R_(.C@4,O@<=>((L0Q%O#]!+\.*
MJ/L25]<!#N(())1H".)9RTOD9HN<J;`Y9'V.]S10#S`%6N:UC`2>*8D.5;4.
M?9'`:LGV;=3=CS2B[0S4_;X2NJ)Y9NJM^U0[3%U`J+Z*6I,C&AQQ.8Z)C=XF
M<:+@!Z83P)-N+"H2L^7E`^<'MVO`2#7Z*U-GSGQ17D_4&A"I1!7V^\O;-^SR
M]HK=^1/'8I_].NOJ>3%T(<ND$W(.\3^B[TU1!S)%HF44*FCRM:RCIQAFM@G8
M&>C9>\>/0S1#9+M+C]@*'^3V^<(JJV0IB@7A@U.S'5?<E5'`D-0J1I16@CT4
M6ZH!G^C=-EM`G^.QY+'[Y/8.R<PY/CW#CGEIS:B562[9E7@-B)B(6`1AR;Y_
MCOPBL8!#]<%S'HMQ(KR%)`8C;9KTTSFGVG\)<%H[>I9CIX_^`_QR@\_D6A8H
M[J2[])).B<NQH.KZ45[F;X(:4(LZ>E9D?A.=G)Q8$4T?0,X17R6<EJ%3?K]E
MNTAZE#<!-F>8WM/LQ638(8Q+.Q`A(FT<R);?G*MU9'"3<!G(59YI+3'WW!HH
MRZTA@[%3TE>E*]4YKMI_`G92ZAN0F+$3.S3A32=U*=:.Z%V(JS[-4-9$A4<I
M=7H"Y%B+?U?4_JQ$6E7\\WR+?[!?5%C*9+W'PLA[-++_0"-[KPLK5WU'$9)=
M/MB..IOE^&P\Y9-9RN$+-O2>KM3+&Q&?U.9CF0N7LVN1`-N:!&J4"V-)KKFN
M]=I=O)/P2,!LFZN_8.:7JU>O+UE]6^LT.IK1:NT"0R6=*NET?.E4#`CUH!F`
M7*(87WK.9;EF&*;1-'"I\21J[H>R$.),[S6U=EO?<,+S\L"OM1H@6KO='5=0
MB9!*A!Q/A+`E-OA5<N=%&C`_@I,BX'H>A2.U#3!2%B?R.='G`NQD76O*HIRU
M,//S3UM1:I,]#U-4@O\I+N51:JD2#W>^)\K^"S_V($B,)5LW5RYQ'$FR+CBZ
MUNE<@.MM["#RCUFB<T1*+7;ICTF@GM8UVB#O.P<FT.+JF.K`ILHSJHI%MB@6
M6;]3>;MM:,!5F;M-\4`UN6Y4HWM/*?5`QB/$`_/GM_+RU7PJD4APRC0GCP"3
MF)R3;WJ>A`K$X&-N8NJHK0HR,(?)C]-+4.DND%`5<\CHC4B51?$C;SS"1-\:
MYA.9$P>F7=2LO"S\\:3J[DJ^/_*,FF3Z%#"U8$@P-BW9+R46M[?(S#R\&\3Q
M_#%>\85CB=`B_,;=-*4HTZXU#&-Q-R_="L--V%8JWSL<<1X19Q^*4TM.E.>[
MZGUF:Y`D^NV%.-A^L8?D#:/5K)(W-D[>V,*G4*W@9O,&E,+>=(X]@J".>C.M
MY?0-X=G$DW\N.3(;A16>0XK,TBR"*CFF"B&6*H0H^;R749!S8'TR@^]@UB4.
M42XC'$U%X>J(,G:\F.5,GS_!G4W$:&Z10+($QM4))/-O9TC6J1N+0WAK3+])
M_]1M>J[NM/!E>4.M>K>WR_1'E5J79$>!OY(O$-COOM\D;BD$?OUBT_2`0\FL
M1X7]V#DR7YSP.QM@TQ"'ZLS#B`4D?8S2Y(_H=7WQ[BJ>[)?RP+Y)T+P0]D/U
MF"V>_=^R!L/%PF!,<$C;1I<`G6OYR,WZ1LVN3\8@6F?MC8.N_=C"Z=T/K)D%
M577ONV8DDO?.FOL03#__M!>:=!8[*2473`60IQWHRBB8$EZP'2R7]6PV=;AK
ML[.+TBBJ#5*62BIC]K:"8TN*F\#OJ_1>++P57I6J`*<:[&ER;2U>CRW%)#MK
ME89]C,6)]R47)CM#?@@_YPNE:`(S`-DQ=&6*3_R'$T;(%$EQ]H#:*YVU2\,(
MIR]'FH_,$`7R`_]*6D*(DOB`..2LLV?";^P_=NJM#;(HR^7[;NJ9/6+NSQ[S
M-T[U3'#W0\"J@ANX)_(G2\+`G=ZF=SO-D53%?M>^JN:BVUW$XNO/BLD0XV5A
M:MDTQ.R#"347L,8&,6F_H46]>8!G[%0"_Q7[4?K\]=T5$V%RT1IBKJY4]"T4
M#W_^S^T[]NE?=_1D+I6IH)_)AHIE`7T7DG0S:9LGS$X6]*:`KL5[QIJ\MSNS
M!4[XO580?'S(]_WJ3X$M/74AO<B[01:X"X@%I^R-X[K8^D-F[V1Z;<TR:<4;
MN_%&\RB\\89;9ASR7&LWV^>B9=G(!+J:-O\K1E91\F0$5KT/K!#Y*>=0SU/Q
M`R(F>3:-)HGF7YGHTL"D_JC(@,"-E):XF/\R0R=#.$F_IXD9D,ZE/SV')ZVZ
M0G.,#&\#6H*IS%T<)BVF5_/F<O.H.?FQME+?=X-+86[5@//D@_(+=5`OC*$C
MI"]6ULY)63L7CV'M?$JW=*['))^-,()(Z7/6^$4:-]3G#24+IXBDK"&GKG41
M,`YH(I12V-!8C1,F;?/AOSSD7/38HS9]1U%(VZ=5E%T?M8ZBCXI8)51-`K-Q
M1]EZ<2;\J!)\>9H8?#1;Y.F2OKT/TB?:,QLIF*6YL@1DPTXR,>>#B^&RZ"*H
M?F*!&<X@<2&$"]H!S=8ORH95[V?Z@</4:_41GV_V/5D;JQ5+[L*2G:-(HR]X
M#TK(5>_CU$[UB\*;V*-`2"7U<\B6N%?[,4*WC-&QCJA\>0Y!N6R[_>U[Z6=[
M\F-[8R=2;V-C?7B;>];QNO#/THTP,S#'CCO]=34CS.)1&;Q3-T,@^HY:67O1
MS+</'`5+^N4B7G"!ZVNCF8?]8#("_OJ5F7'D%]GVQ3Q8R$3`,-B`5`Y5P'HK
MN&QUV#KAPS[^0=W]V[FVVAE>(#61XP9BPOY\C+BBXZ/1<<]5OT^,@!)K8`D%
M49EHN@'YU%[]")H9+U+#3?D%M+@9@%5XJ1J*;W@5QS[(7%$5?\\0K8L<OR65
MG_,F+8M,+:S@W.Q<(GN=2.[Z+3>S>P.U>\4E`.!M^1-Y"X3:S:KRUPEL-@$N
MQR"PN!DC[>&OYG+`V>O#2M153V/S.U>7:26A8T0O>HCQ9!#@0I+?3:Q/%H<@
MP#_@$@`%!)3^U'2C:?)D':^W,,6]#Y8;B_L-:'0`P(+)AQA%!]]SK?[IE0`Z
M00%4!<>/%AS/29^U*Y4Z<]'M3/[,.FQ@+O7BY^;;I(IL-ROVLH]'0>R-XX,T
M"\P)CP&9(<C`8))S7[)">.;^PYO`QQMRV-NLQ`5!=V/2_2C*OKI,;\5#&;QD
MXCH[0\;E@3ME[V%3BZ<XB.?DZ^\>WFP(LO4&+X]R\,K&$##`/IK]\!REI]%H
M-%%HTQ4[V#2%1.L]%[&ND/J1,(S*87-9N@^H[]M3$"6<;CGZ,Q9BGT`U79!4
MC(/[1H%$/+/TG=`'1N,@O;].Z#9>F"=[$]2">QG'ILWQ<EN)DP'GN>L9FQH(
M;?QGQZ!/I04.H`7PKM3*#JWL4-S'M+U3JS"U\!+[+^FG]+*C=5JTJ9-#1],:
M.2`LU;:?:423#"UO-Z/[O.";9)+U;M*I9$!E"3YO2["X9<FG9!LM-*E.LT/'
MC10]>UU6U:6C;.562=N&^3R?%*XS_5S8LDDPPW,B1[3F8S<C$VS/#^P*I#'E
MRMT%V"2-KA>5EJF->11HU:_R5/9]<<R.-Z9(3;MRD#+<E[*<L\Z,U13<DH2/
MM,E6T:8T.VP!09IK$*1D%"DN(,[=K]1J%%-E5>UQ6;;)Q3E&!UQ_2$A/@@V3
MB:MNDQDXKLCL`5?^:_VVSMZ_O2S+GM"U4]\5K7/VW@G"B.I2L'T-4"$TW3UW
MK]D%PXLX_#3XNWW.S`'8D,)+)$R_U!LJ3H2A+H]'A/'2]`0Y),JK@%<5\"I]
MP*L4J1`[IK=\I5/1):'L<&2Z+F751_ZR:#Z6!YJ@'6(O"J:U_K0F_\3D?0=M
M)W4@"J:2;E"Z;2+1R'R"668-*#RTC1R7X,'>SWBW^Z_8GP]&4/UVYL3FC(+2
M@'0LL;(I=9P.+*B,P"FL`WCRC'M\-E4)IFO%:S<*USYK"50FC3*G0+*!]#&/
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M1\<_H5L!:;>CXGK`'@GO.VTD:\5&.@:Z%]=%7IO?V1?''G+VV93W*WTT09*:
MU'[A[/K+YX_G"W.Y,,<T33$`DV$2@Z&"Q@:E.9FR:0?Z6+@A1>5UC*X8VD"+
M#!M-)D[!`Z!.,`Q.-^NH=C5J1KSVJIY!7/+7>QA;E$YF[3LTJ]*,7)R2++Z9
M"ZL:]29:;*Z\2#Q9#]AYA4LB2!%)RR"YF/%]@89DER4K24;)S0G`7"3`+`!@
MQLZJ1%(EDM98B5T"D;0ZN11V_?VM[\;B6BW8IMA^@?[XD\.FR?1P`1/SWK%X
MVI@AC&)[FMS^%<1#=FG5#*-5^T?\2>^UV!E688[-?NWR7,@C9W&+*^6F45:J
M]*0LY4E%N`G#PLV/@I+RN!*(G6P7&MCIE@]>Z^R->?5>LN=%6<)?L1/0,2%&
MIWYA-N:N9MS/*)DF'5M-B!,LA"TW4)IP9C1[Y,VBO"0)*?)A.P0-N;5%`UY[
M[#(>`@^PMG`$-79M13Y6LAN&EGKCG\PIT]M:1CZ;:68OS&B.Q66&*`<%P8FF
MF=O_%*W7Q[GG/V1P8\ZAW*@;"N5U=DEAPYF[%.=HI"<T2KQFZ8T3Z-0.@J5@
MS;!R']X-\\H)HX@)%YL!FJ$80I6:*ONH"`V$LC.6L%7EW#CUPF@!\D)8&;&[
MB;"??SH5G;'D!'Y;U"]W@=9&^<8VZXY!GKF@46%T9[-`U/I')0LN/CS)]5Q[
M0C#J+27CLX)IIK`C6UL73D#L^?AC*I[R!1WO\<=_Q!%&:4,0J])73TIJE=/^
M_A]77\!I1T\B=EP9W9T$_)[ND17])(<^*K(9%2V=BC=777:6'`BIRHWS.J.!
M29I;<0#"-P)!CZW>7(X"ML@&D+HW/\^<N,9.B-@R"JM),)Z.P&(K.9%<@JJ-
M39Q[4EEB`)>+KG:4PHW9)D+[W(.M/Q?H)<4SQ`L^2`G,5ZD@)+CDI$1%F!1"
M:XS-$'&*P2O6-[WO2EV('B*$$#$EV2G4B8]^%R:'='_@7=&89`"<!:JQF2I3
M?`7,B7I+?:'!"*"H:'FR[:<8QA;U-Q3L)G.'(,#?8?UUEIXF8I.3I"_D,JZ:
M\?T0S$$L22-([9I]P1(O=1F_G\`D>/B7MO>B8X7HP5=G@C#`2T,^C3%Q3J>$
M=::29U7H_,$,;)I/'3F(R41S(`L@=H0%2,_-EG0R_T%8$0).:9D.@;#B]A:P
M418<1*16B9K+CGDZ$NV5+$,EY0.T3C2394'2S&%GUI#6"N`=L-F3UZ+YE]U^
M>VKB<'&\?4$'P\4!F+6O]%8&^$Q<(SDJ&G!QY/VRTR(&)6X5?^>;2&F)!"`)
M@<?H:MO45\)_BM0J4,95?M"3SP]:<6`%*MOI!X[&1MR]YVAI`\4`";7JO&K3
M\ZKY>S+7Z^RVQA'6&JE'99)%!.9@S9.S4U_GM<QWT'MKN`.S9O*,^2\,A`41
MG9P9ASEC+YNZUFRWR5"C/HP3L*<IC(4-'<F(3TSW>1L];T>+4P`A'FOQA*JJ
MR9CJ:9V+GDPE:1;"EE'=L\M+XU6DEL'B<H7QK2PCQ[OWP0VQ1>C'%!GG(+#`
M$U$QS*760![914<9>CLI&U7HX5X`(F:3OH`[=5S<5`H<]]WRK?(TMOUPG3#0
MDS`9TZ"VT=U9Q*',^>J!`1Z$LKOP'?\!DNI3_2UX=.CA9N(>(MPA!-5L<)^\
M<>I)[V$VZP()Y(2S\D"FU6NR61'U"[+I8`%LBQKX!.BPRE9",%D4IP),",0+
MS,P7,,U`D[LI!+QB`LJX4'('@]6!'P]'0I1NUO2"1-O+9E/K7;3K3(K<Q`T*
MQ.T2PA.6.@`!*`B<RX$NM&:WB6)=Y*T10'<T$-U$0"$5RHI3H,OAA"*X>-9>
M;*FE9Z4C2L%V!.;H^9C`MWP2B9;=1GMG)?%/?^2%[!_^Y#O(X(RZ6&@:R\#T
MJ]DCZ33:*+2$ZD:$Y]Z>$X^98;06#KIRJ#@)R(*&B7QL)8`J`92'$X[2X&W2
M[P23;>(@C$TZ:<:X]@?O'G7(4.4<?08TO\5S^G<_^%BD^YQ]^/P6J-5M=,[1
M1Y\==1-OH0N:2Z?XKA3KJ`3]#1T%)Q.=CBAMNLAM,`RM>]'1<(VFY\5X$CTR
M@;VL:?J(UC!:A!1\"`^\B0$`E18/Z38:]61+J.L9!T%HJP?\5YJ^+6//]EK1
M1+UQ(8/<^>#?T_4)?O[I"4M\6%P)9*'S?&3^9_]>BGQ]9Y$?S?D%-]SSPJE[
M;WJ.60G^G02_KG4Z.PM^A88UI+^,N9!L3T-`ICV&T<,HH%L!*")4+-93Q%E6
M$$O0DD`.S&%&"VY1).>&SO+H]CWV3Q-T3S!E1[M`L;+CGZ*L^_/YR/1DQW2*
M`JPS(AW&B?%N06%MS4CTO_N^_0![4/8=];"_R!0$GU4HN<Y4LJG1>"W?3+[1
M7Y_7D^%(#.%E]UBE0C)+)*K0`^Q3#J(;3"NG7,(SZ^^?;LY5Z;,,MYAH&/J6
M*Z13FAL"KS@3=3*L4O4=M&19/`&!29?1D.)ISNH*&/4#H+<O8;_H&J]K;T"H
M4?!*A:SR^9Y@>X(MW-6;6J_=*`S*8V`J$Y?*YCJTVH;6Z35$4L/B6%(=M&G@
M^+9CI8:RDN=D,.?+0RT0"28L..V6N"`C5&1?CN%9>FW1^N8R39,4C4HHEW"5
MIR&LOC\CH8R[SB@\\IJ1R%=?KF?E,)B\[-JS2/S6<Y^V+"8@`5=[DU8PX:\B
MP2_)$9P5C-D8_B9U`(UZ-TU*GQ>-LP^GJ5_K10#0+,RCY#&3TC=-DCY@GDZ)
MBLL+$G<>K=Y\06EY5>'_:!7^"1W24\IU@A%H,>:"$"C'_,$`;QBD1:&/B='2
M]\X`9>@]]V*ND9O^'S_X#G_]1\BC=`1Q\Z"XLM"C"A_EFM:9DN$7&5]5U?C`
MPZI&Z");$50(.6;ASL(>%@-_T5X*_+7'YVRU<&81=#;85G(RUW($3#XT$<,-
MYTV.0&?]]XM"RQ</-$ET9\]E;3[Q0R<BK%Y.`L=5M57+56,8P\NHFY80W?4M
M51W5[/0`(C_PL'?2;02O1!I[9SLA)G!__B>"FXT:IYC#8]C,<8C4,^W9*'H8
M4_$KW:V`$2^Y*G&%P876:395YGIR^RIH6'-!<FIZ[^)F]R5F;UJ\Q5M<1[Z+
M9_#O_HH!*+R"K[ID\;EV+\.'^O@'W<38R96_"_X@_NLG6K`X`;4B\0F0>$:F
M5#0M+4V?W"T5CY!SK\_FW!^@F]2'_.E#WC3)G[H,'(_\9-.S1EP$)B=T>3)G
M$Q>PD*UQ5Z7YN;V9UNFO!1J=^H!9Q<2][92/:P98/Q?*RCB+._?<+IA$28B5
M<\RXYLU<0Q$T7X>!'X;BM)^#RTQU<WC>(ZO"'#H@\X.0G16NU5@3#BH9N@(#
M!CBE>"!]O8'."PQ4;+J74L@<)BT$F&6&(U6*M$\T]M*B)F$B1X`CCT_3LJ>+
MW#4Y3I"$+A:`$?`P=LF\E&V0$Y*()(UNIZFU6IVUH*VS#Z),+XOUF:XO8%^R
M5DO7NGH#VY\&`NP\0T:[H.QENRZK&&EXPI4J#M6;':W7,ECL.:)B;P!\7J-J
MQV0'B*X[%$T/+"?D\MYYQ$8O-[)@B'3GT!5I]`ZY*;*JE>+N:JI=UB6*+VF?
M4!4BB@<8%CT)S):5$384IJ8XX:`G!B:PP+WIQHFWEP",*VK4VVFUI!F"%R+\
M&#SDCAS7^:\*HKW!>U9JMQ;X!T@Q<42-F"G>5VNO:NS;W)V9*W./$RQ.'(>'
MV#$A_`[KYR+8"(P3L0"6.-+K[8M?-`JTT>G\O>^:.!XX5376[69_LAV,=P)#
M3!T\4:^QQB^:<,:3+D28J^0Z`T)7:V=ZR7.3!:$]&8A<:[BD"8?KYLE(&5!^
M'(61296V5<_=$H6GUBZ(K6RX$MIPUQC'PX"][.LZ8\4-'%?$<$;<'8#5-)3)
M+:3(0#()N\W#4J8QNZTUV1F\O4BD;&C7?,G.=JMFV\W"D241J`?X8"#JI!%^
M$633.]HNXE#%^)R0%<-.$M@DU8-13C!#J%8[#CFPS)ES#HC&ZHK,#Q)>B[(!
MB#(^@!V0S:'4HFB\@=7[,TE9=-\T6&L[F1I&([U%`G5QE#>M-6QS`1!A%%)^
MD36T7X&%0);(:X+RS*%%BM8!:6`QLUY:J=*2R]>ZR[+B,,$.)7F`_1F#<3X$
MD(;"ZA`S9RPC66"_``^B('%L3JGD3X8^$58T!D4RW?RZ:;,L.!+;<+/<)C=[
M;(F1Y-[=73<8VI:?/OXA8FGX#_!CG7W\>+6CFP-C[@B:38'OO+@K2`#$C#]<
M`#@+Z.-H(G.$CEEEBXP<X;-ICTN$W]I$3&]`%KGE8[P'@?&_8M%7LUEO_*+L
MW"('<Q&<B\Y>TQ.&KNP^$<T%\3=<1JNA_)X%<V8]\'F'K*WNA%D=VTN&3]-5
M9W"X@!R*2]?S^9ZAN5GV,.$QC,T2D:,LR%]^-W)%AW+0@<XV;I*HW25%[3)G
M6T5'(;+>-A_0=>B6>X^+:$M2Q7`E]`J=IK+KQ$B;5QSB]HL90!+[,-L"&35=
MQOIB[:[6Z[07A<\V#&!M'C)*6IO]_!,Z"_#OK<)&;/?83^Y,\H!Q(-'YK+K-
MHRS;N%)P9:-((ECCONM8B=S+G"8G-*LEZ5#%75P2XW?&@J?*(D-K&>1K%N4+
M><*9?`@<.M#`6RO(/\`WNYTVW1.:U@C1?3ZI,RL3-=4\LF/<_$D+B8G8=N!C
MIMF<0;[O\L,47=<N6KIFM!JI-S(1^$J@P`O<M'9'N-*I@,\>_66[<N>C#2";
M&UCA:RKYG3D%B<2IHL556E$R,T!?;V5/3$!4A\68#!=VH<P]OJ"'A>F&?G(4
M(PK^Y$L8OS&!'6HVN)=22V05H(Q%>-ER,M6!<H$6I(3B>R0P_`L8V?5%4A3H
M[0&,--7410KY:,;A97PSC6162;6/&2ZO!'QU6^!!=U0IP@1;)(-=SC3&%<E^
M6+H'R\$S`7!:O&>=)U9V\5GMUE,5N%7(J&1T6+<Q]4S5ANW@K:*1,'>9O.M9
MVJD8O@!;,U*G@DD_MTW[72I;^N*BI>GMSI(IR&NQ\)#0Q3/K.=-Y'J3K[)TZ
MBQ]$L+)C8=8>:ZH5)&Z.0`.&ES2LUFC-O*#+CO-%C^N]7G9QU)[.I-?(:$_R
MJRXR[>GEN6QN#C-*<J9H>.%`IM7+V96)UQ1ZT2>">9!-Z9A5-/E+;M6E$AIK
MY/#[)%.SH("ZVL_'V,_R5IW*KRB1!;H\GYU,2!DL%XY_@77YY`E5=H/RF>V;
MDI(CH<==[J0$ZQ!9&(_'>#8%VD=H?!%&@Y\PC\N)G&PI_U(;X]>*QF6@\;/>
M<S__5$P1/'%\3)KD*%'=!;_'NS7Z?A3YXQ3-V8X7&]RNA[WXP#?Z[45S51^<
MXXU4T(C&HN)TQ%M^EG_31I&E5X>`=JUN0PMH409</@I5+@%!YI!71'E$!M]@
MCB_*IS_D)*4@X0;P?HZQ'449=\D&4URER3D'78E*MCH*D=5`4EW6Q`!@%]1;
M"V+U:ZY+J7\Q8$W:BWU,R9K]39DB-.7,;](F#'W7L8OWP<RU?K7(G^3,JF1)
MR8&4K(I==#'@&B-\Q<*)_"!/"*OO9.Y>'L1^P%[AKS>8J?#$5GS'@W&F':AJ
M_XD?**Y[_L36NQW7?P#YYWBA8^VZ??[`_*"%VV<70;?]2*P/&!X&?NS9"NG_
M8UF<#P;92=0@$O5=O34;8Z3KO44!7UH6J\VWC%[($XJJ[>3\?.V[^^B=!=!L
M,,J%41S9IG%TK==M:<WNQ9&`V3,:7NZV^F;=6(]RNR^\M<7"EW#C)O37EV"@
M6V^N)OU^X-@S!M8@_;*%M[1>HZNU>^V#K'Y'445QJ2)!-0<&4QH+/^5ZQHB"
MLCU8MAL1>P&V>YV>IHMBL_W,]UCKJ'=;)[\('5-[3WX5M=F"]WW.?CA38_T=
MK.SVTFSB,UW7VJU-^7_>V'XD\!OU3K?B^N>WJJ/IXGDW(7<66A9D&]BV2NL:
MO9*PS6)#;I'I5K\X?24,AG=9%K$Q`;I:L]'06NV]+>"(ZC:K6O',M:2;M-ON
M:D:W<ZH<TJCW3E_7MNJ]TY61VH7>U1KZWCBHNBNB;#D][J$+,]0EF*=(PT5)
M/Z=;%+`@7Y^/)ZX_Q=IA3"+O^V9@LS'%ID,FHRY)^EZV#':=*F#1_B'?^R%D
M,/&0KM3%#/N7+5@*#OQ2U^L]>0<OE?-2^7$CDTA/@ZE<>RJG-=F%:)@J,N]%
M%KT"5B;GYSM(O.QD[N6A3F#880Z,!"L65^3$X;)V$;5<NX@Z^P/9L(^_JWO9
MUGL3GK3<V`8..M//T]KP0-8$Z/5N]Q=68T:]T?F%G1GG:;<(U0:B+1"CL;/F
M>6&;"7BFVZDWVK\@<N&O3ENVE3B[.&?_Y8$_WX&B*@PHRYY^;OF6Y:>(E+*;
M2-AEO2-:FF&(QMB)=(2OE>C"[T6L;,.V"]4&+@F[5!NX;!2YQ*M:Y?[*M/W,
M-*NFVKH^I[_&?A`!>FUA9XCF];`/)[(1;;[B+Q2&1^SAG7M#C][#6Q6X%XJ^
MLNK>/3`W<O*"C(^7>D/3V[*/3,:8BT;88FJQL)'%A;/%GN+>/X1\DIN;&C8V
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M'KA=1Y--^#?W&59Y##CM6;MM:`#*/M:U@0=5)L0N'$ZO7RQN#+1?L$X304<'
MKCR0E!!-Q[>6%&Q&&A#9H/?#(J(:&X57BM_>WM#>6,P:2T(SMA_W7;[$;Z0*
MY=9B@V[?JSLBKA>[%FL,DW,OFXL#`R>,G_V,E_-"6YMNLI-`U+X8J06.*A@[
M37VQL;,?+#V&!5Q`A[D.'S__=&K">#,"4VF.UN@\G5T`%#N$0-47^ZVGAJ'#
M"M0+XRDB:H\"5>\VM6;OT/KYV35>J9(W*SI4=#@U.E0)Z2=)PSUU(9+%/?D6
M0WJS@ZTF-^R!@4,X'E;H^ZIQ4-'@[:[6Z[2W&1L&FKB`=[I@UQSBOQT/'O,\
M+&.'1ZE1$0Y'=?)7KH\]A:K2]G(P:M69HV0$V5)RF&[H)^(#-E\8NQ%M\L+=
M/G,)][K;?</^9>TV=@01DRSH9$:M0F"L!$JZ#_QAQ+V"B[JI(\F81Y7L*`>K
M5K*C9`390';(H]ITXSUPV%QJ;]NL/Z5A5)7QR'=M+K=K(G-DWZ`6Y:OU,L(D
M)S1PXR_K_=5K:]UVM]K3Y6"A:D^7C"![ZT!%N['6-\/9=EP!%[T^06MGMKS<
MG%W-,,30+Q<WI_K;JSBL#4US\NLM3B*%Q;N_8B>:?O8C_M8)+3#[XX#?P2K?
MN/#,[S__]+?DI;@?\K]B6/F[>_A7F#R$A@SBY0L?_/;B2OS]K?WIW;>&_NV?
MIO<-EWW7:'P3_[^[_M9L?`.<Y+]_\?M3YM\GU1X&>85U66*`ZJ]9RAM,,`=Q
M73\)=51QCU))JXH,Y2!#I<5+1I"*#!49*C+D;=I_QNZT()0EW4J]T];`!,BX
ME?"?*'"H1WL2?IYU4#>A\#.D68ZS+:!7/W`T-N+N/<>,(N!I`*,F&;O2/R6C
MWO8$N?;$;NL4Q8X'CHOMG]E[@)/=UKJXK_S!0'1ZQEUGNM2Q.)[@+VVMTYJ-
M'N<"/I.`WSM^'+KI>58,$(G1A%/(/GA8OHR]HV]<TZNSFS@(8]S'T@E5H!1*
MAK:NM9I=-3V\87K)$5<^W)0+-%UTJ:ET)2$J"?%DJ;>[A-!SQTM?<>,^!`!J
M$&:BPZ(#/#:#A_%=/Z*S7]GB/'O.!!L3D[;P>]-E>JNCZ493;5PZ,,K)(=B^
M+SOU5B,]-JJCI'!C6X7`LM=#X.=B$'"WZW5#W6RCB;"SQBZMR/&<>)P[X2))
M1^/[D8F"4->Z1A90#'N!3`M18,%C\R%L<P*??CAC,^*`P)=ZL]Y)+M6A8Z^9
MWXUZ*_G=XQ$S!X!>9G,[MB*UT%@A'K](;L3!T6C9\*\@A5QVE:^LGTJV/6'J
M[2[;C%:1^4-]5.BZ*F%*F,.`BVP6.N\V,\?I=1`A&$X7XH)&29XNSN3!':L<
M&FDV9=V8U(3)S"*$!A[HCTT;+^UZ:<A744("%]S3P3N\U<=3>!^OJ[+5%6#)
M(8&Z!:R(&S,!^T6Q]VR`_@U>`\;#$!;7=SPZ-0AO?->QIE6$_G1W1RXJ(N+O
M9A0'I%L5Q;.Q^$SD/6$II5'9#7#R&%844V$*D`/T=IV=X9900QB-US,9)H:.
M*,L^,*NAX8EST?JZ[_@1MT8>,,=P2@=8N,W0\7`B>7IE\WON^A/<G/V`F]^C
M4>#'0\H]"\R)ZI!-5\;A;3*@CCVI73D8*Z&\[`X3VDP7Z,@F)I;9@._CC,>Q
MYXMAINSL\N;#W3DFO45(5G%O#BED=9*&WX0.,*P)3H\"&N:O)Q8(<*T_Y/02
M"1F<]&'DNR"D_`</)0/L2\=VS&"JL4_<3M\3>/UT^>%<8V?P/H<-2?9#P,$:
M"`0FL(.I.J=C9K@:PQX8&J9('7)=L^\')CEG?``K1-`01EC-$'#A`3M%<7(#
M(@@SL^\ZH4CQ`VF$%W>A1P@>WB3"/Q%=A!(P"6%=DPD,B?+*X\@UF-CXRF`6
M["?D'`:B$?Y-.$T?F/LY`J2,??K[UO5-K_8OVJ9(ORL39@[8%8EU=I99^J?;
M?UU=Y=8M_%*0^?03S#8-'0N$`OOP^2V[G$Q`Q)&T0S,4-8>1VI"`CMBS1N0X
MCT%N.S71D`M6'DQ\NKHPG`".?"()0>J`;K%B^&$\!3YU;)`M\7<^=DQ@J4\?
M@:-@+I3!]06&:O]/05/4-(*ST2HUP=8F?$GV%[K($0E?@0]&)?KP+EW,"$8/
M(6>`8@N1)1X@YG-@F!AO2_PO7;/D6RX9[2`AG;YOX^X!&GSG\N+)F1W":1>"
MCP`;3.P%,GHG`7(5/#8%(MD*)-17#+35E$U@3Z/3CYP5";]"[%21:"+8TIVA
M/MG<A1A"J8#5;_*VRS[G,OM481:_QV4O(`,IZPAQUP>$\7N""'BM<#)BZT0(
M/(`]+V8%H2R6C\S3%[=/HMRQ'337:;G3B0R;"&H\X#:&G>&(;LG%R(=G4=T/
M<'U5LDQ9-&=EZ9>`(D:OWLGF$E1TJ.CPG.E0U725CP[77MJBTNAJTIA<'(9@
MM"135-#,NE&WE%'_[H<%B!CRK$6K8>PU.4D11EVN3,#Z*W9P%KW1^$4%41?<
M_\G%44W(K3@0%PQE[*Y%#E_6T[CYD`?-P?LO!<Q,W56$<Z,5-!]'[?56`9@]
M==+0%I47F[]LU!MZ&D/69NH;P+Q&AQ)L9S#;U6]YE`K*($.I0>3YLO1GP!*S
MS+&X]1TC(`%X30C1[*/Y62/QO"B`TA@W@3@X6.:M].BJ46\VDU#Y+`,H.-D7
M=$]R+DV61KEC.;I=.3=E0@U['C@3[X<5"Y@!,<Q8P<D5L@OKRO#E?`V)&:;S
MHB-'IX*Y]1"H*'W4Z/!1#:ZA.ZN,:VQ&D9NL:.'"E<C3EZ`P+0JJ`Q0XGREX
M`MP2&"@ROW.,I[T"<H`_$L$V_Z^\NQ:,>`K=]:<8;,NA41.6/+`YKAJGP)@>
MN@/"M5&[+Q`3BNG)'0'L#<"/]RST=@*.'C)Y9S&XDIO&]4]7BDMA"OL[B!Y;
ML%=A_1-0JFO*\31]`*!^@%=0D$D%0C_XH"M,>?0F`BNP@36,R<O``\!M@M3H
M._XDI_:2$3*A1U6W)IW["`.-8PKK/`^VJ79QJ<A1_ET,IO$G"F(:(O4@7\"2
MB[EEH^+++5&-*1,#0^L>&6M^^LZ5#-)2;!<`N)P$CLMTO0"`W$"V/W8LQ^5I
M\L)MA!%.D#Z?^;UIF^I8,/GZ+7?-!U4`.P<3#7.%U[*$[`_`3$SY!F1*9\$M
M7.+SX-^<./GYIUFFAF\JD5*)E'F1<LLGD72W6VI7TP$,GM^3QRE/]Z^PF=X`
M#WIHOUX_>.`"C)P)^\0#*FPO$AK"2R?O:(5#+)(K'2\1!'GA`@XF"H19!P_G
MYL',&9WHML'=03%(9R;K->N=7^9.$,'U1N%3^)+%J2`0#_)^.&%4Z!L+8+3B
M`817)Z:41<-J;>0!(:I=5WKOY'\*I\E?L`K/CQ:/ECJ.Z$'E7&08;U7_`EB<
M2/+"AYM:K]/0]&8G,T`QAA9[KPB$KC4-0VNT6O.`Y"<ORKY8G%B12[\P0R>\
M'EPF#J-X1/R[*I9\2H)KLWI)8@QDN!N1GB@8ML:^>F9L.QBE^(!!16?,WB?1
MA0\>(D`\N2*YXXY"%M+%04D8)^,Z<ES@.1M3#T7/$6P%3UD$:3`C1#N(W!^9
MF2TR)&"7\^PI[23@$U-$/^=%=!HH`2L-AIVX\.Z0@YPV,6$"?D=93^^*G%4"
MD2PPL:U!R(),S@4GO]9OZ^SOEY<W.1F+&UHM+5V#DZ),2-("("E3/D;`Q#*'
ML6O*X-6@`*K;-*B*SR=QJ2O,9PG#PJ#ONWSN`DTK"[)1?E/*O-ZH_;]"V,N#
M^2[._R4!A]W6_K],$IL[)6T$_JM/@M>A9%N>C?YE%B_B5+X?">H%7,:205`G
MZ"04(LO`9N6%?"#B<;NQTB`./"?$Y(N`#S#3A2`6=_2*)\XH]!82U\!*Q-[&
MZ&H<4)9(YMES&2<GW2QY"%UYF4D,D@U\?Y%5X7$+I#6H5!'!8P/3"5*X%,J$
M]@S3&+=<H4C(P]QAVJT8=E7[4[V"FA$)H28"00NOVY2&<L\733"(8?783T>U
MT]D-N^'(CUT;LPT";MJRF]>?L3?3SDM-L7K`?"0\`1LAEIT,YJ[O(EX3?(9)
M(9R2FCP,K*0;O4C?FYX7)S%4!N"J;?&OM::E\+(PV9)UPL9C[WD_B)'N\NSF
MHGZLZO.2>%Z/W&T@HP>[:$ED5>P>>R9F++.U;*ZLE7:5;`/8)95M]MQMLYO4
M5"&/(,,<Z]A=F\AKI;47RD3!Q*$L'_'3\IFBIXO34$7V*JB9$+!%[C+U>02:
M6\G1<G:6]/0Z:^9QUQFCG\/M1?(SW8'+]E-VWWT-^?7@'1!O3)95M=.>VT[[
M*O@Y90$P#U)_YS:QSG).TAI;4/@DIJHHB\BRVFQ?XD.(:<RCV*\O(XWO,&.>
MHA,P-K]S3,F6F*!"DC",Q_(@G;)933K"EH:D3,8VQV+O8A9&&'*YBS%I&!-8
MR4T1;]@R3"8S']9P^1;-@V?M7BR!5!5LS$[;767.P44E"\9GA'$GS%^+S%21
M5ZL"\BC<DO6O%C)YX9$5*R"__>"&)O["+1>P(H*$@,?+Q'=XRT,K<"8R3K0O
MP6,[]PF#[U\&-5-[:AT9M"\SLGC7MXQZIX?_,YJ=1KO1:AW9L"1),DO?5<+A
M2I[P3I!%)',FG)TJNR`95A5ED"R@/\$+Q1TKWYUD))/@6<D"*:-NRHXYR]0,
M1Y>>C?_!\OM[T\7->3@3M>+?X_(O$I:D*/V1(?$Z6BZ-58M4I9!"*2/`"Z@C
MUX'![-2T(QWF!PXH=I##8RP72S(#L:2*J_Z$6&>%Y6.B1M%"N'@*5YW=QM:(
M]4T7`V@BZA&',6E`D22([\*8[]]^N,**HQC#3&@[4G%,5-#XL,B33X-8A2<#
M"!3&\VW0,Z$,EE#14=_TOB_8AFMMI;P:P>22:(IM+B)X$]^B$IW*0WSN=JMB
M#1$!5GRQ:L]^,JT18"P0K_'D-=Q#2:]/,-8L/XQD61BH%TM4]V$,%X`+3,1V
M#3$/S$YG"%@\K.PF&S8C'\0ND.8^N[=EQ^[W&'RE0E&1M_B#LA8."T"(QJ("
MX-_8'ER9J31K1'%H+([V75N3QJF</BG*M*QX'(N_$Y`HJDU#C'W,NDW2.I3(
M$P%_T4A5O#M$U8_R#=M`.*&*0$OQ(3+)0);6V1=P'QQYY\+81%_9H_,"LG5M
M)\6:-3+I$!C;[J3OK[1=UQ4M67'T88PPX4/7P5LG!,%GNM>#C[XW_(A9QY>$
MU,HR>"J604INW$1(YAK1F0E"YV1-/C9*4N=3ZEMB3R?^$`+7XQ79-(;<@71F
MELZ#O?LY;>9[$?L/9-:3\(>=`'8A9O!;](4M\B[(+Z5=:P8!'34*<QKVS93.
M0\19!&9A8X4DGKU$6'?K>,XX'LN@/Q@/&>]QX,<!&"M_Q6804:^4)/9?9Q\&
M6//+L5I`9G.DIUE">J22:!"3J(L]U80%77\T'08NT`>1X$O9EAZ,(&+$SD:[
M(TA[*],O,U:(7+`H7:`J=KPD`26C0V`Z.1J&:#B)"3"=59U'B4,UD9Q.3CRF
MNV:(H@YT*,^#7&WAS<N:5`M=EN@!O1;"'1YK"8#R4XH"V5FH%]A*V\B:K*QZ
M"SO\GLZ]*HGT9"12AJ@K>TN`_6YG'I\U,+)<*OA6.A0L''$>@:&2/!#*SBG)
MH3NLV$ZC;*!'/;3[OG-EL>1G%4W389*_8A]WNGQ47(!"]@A>3)+],CG(Q1-4
M/,0U[TW'%14K@PQ8^%BRX6W9@4*.)&;%\>A+W^8NQ?I5;A)\J4;W^]@51E2/
MBY=M,S*E^8-R#1_^,[:'PE1$PS$?(YO;O(LW7W:+(H;_P)5<#Y*(ZP</2!^/
M4[^H<FV>G6M#.^\/I4"RR4<);ZS:_>GF145G\P%M$#.4;49@DPFKX2'-59"5
M<Z#C0H[I(-))T-!>`%4DM#!AFCHEJ>CV5"2&HE$/&Q]V4[;T4JE%M;NIX84S
M,46;CJP,&CE@N@?6:$I]3L1QE^J-(G,%,P:'-XDC&8\?DIS!96'4!>\_HL`B
MGAD`P%+D2+%"F4>4"B(`DN87THOJ4:1-1FUN,K%[&88'BV5V^-C+R`X!E;`E
M"E>&G7AP2A=MGU^K%(@GF`+QE,5L&2[+2/\1TG7'NS,^8N$9TT&RDD#)7IWQ
MU1-);B`]]B%$$A\M/9?#%R(A[\B[D=UNL'[=HA"N?&/,30SADO&!IX55\E0E
M.2K)40K)811)#OF5:.0%^]Z;$R"4<$3^DQ)`(K4`"SM2>T)E7(K@04:>@,G%
M'1K==L!NB]"%"2@<)#ZI/-8Q4B;);\H#01Z=;+)7++'FY)Q6,$0J]M893PG,
M9+7HXYFR*YNS`FV;H8B=R<"+2+-"PPV[RL$B[GU,YA9`:2)-94JR-9Q@2V*-
M60&W'7C<";_#)QY9]7.!W]3H%(YG(+ND4R8*1=`H`$XIW$'@4Q]`D>"==2O[
M4_J9RY3RI.4;B/G%<>NG+!U*Z[Y5-XH_>P'?+#8-Y[P^DD0J%)4$T3.AJC0U
MK,@P3.HP/&D5_E^(*:2Y[#.S[\>1DG;YG+0"]UIZ]G&($"9AL$16SH+Q'.5.
M*5HML`YU?:MDS]-3'PD-*2!$41_:@R@V0H8&"[8''BU*&95N7T&PWLQ68E&A
MCU=+OQ$9`6!EN"3!\%S-F3N82H-2)LFF-5*"J+@Y6[5V>7O%ND8C6V6'?.;,
MA#`_I>ZK6&1ZGVG2#,N044QZ5\MDPRY*I\73P30]4*S/"4AX!ARLO^3,(1.X
M$_B`Q9+(%I(3,)5-R9<'C1E$99SOW/7-^1(!@#(,LT5LZ:"R.9L4SC':QW+^
M97.E&<KJW$&3F1#3;`9R&A*%.3(C+4*;IRX?F;BP.Y(N_<OX@[#V7+KOE%^6
M/`\ZE$(U'T,IBY[5F6'$"*]DQ>U*RDG0]5:[L]CTGC?1%Q&H`&%].M>I46?[
M20@K5']EV*8F0J5J/LD]((BM43+VSS^M/.%FV.M"SO[;BX;X/,$KD,3G!&F!
MPM@]=A_!#F.28?I^%/GCG?EW;C\4,NY&>RP%WLYS32F!G&?N\H&Y9'M%]CRV
M)1_5!(L`,/76'B1=182-B)`5[N+"AT3`"+K4I"+K@WWR??8W)>P$Y?*_2=Q0
M154IJ8IR$V2;]]L+XY0H+`/4U1X[F3U6$:$$1*@$W6D*.J/:8R>SQRHBE(`(
ME:`[34'7K/;8R>RQB@@E($(EZ$Y-T-UAL]IJAY5\A[V*@E..Z[(^[/9A@/=*
M*@%`!Q.OJX#O(POLLB[C:6([JQY=/JB$YR/B/\#)*P*<Y@:@*SEFEP9?5C2H
M1'ZYL%V)_/+@OQ+YU09X=O@OZS*>)K8K;B\/_BMQ7VV`9X?_LB[C:6*[XO;R
MX+\2]]4&>";X?T;'016#[1?,M.E>MNBMH,]695Q4LK7"?V5<E(0`U0:H?,FG
MC>UR<?O//ZU!`7CHZ=*@$OG/?A,\/_R7=1E/$]L5MY<'_Y6XKS;`L\-_69?Q
M-+%=<7MY\%^)^VH#/!/\/[W3HO^Q+,X'A?VB9`UAMZ'7VQV]VZ$;J%3E&O+<
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MW9A?#]X[GNE9CNE^\,(HB,?<B\(;WW6LZ>\___0W]<('S_+'_,[\(7ZZ`ZJ_
M<7WK.[,`0/CPA0]^>W$E_O[6_O3N6T/_]D_3^X;U-'>-QC?Q_[OK;\W&MW_&
M,]^_^#T+.OS95T12-5(-^M^&^,S1J+E92H7+HX@'M7!B6HXWS'Q?1&4_F(Q,
M+_R5F7'DY\]*_XS#R!E,Y9>.9W.<I674.SW\G]'L--J-5GK$&@4PT`#&Q=$]
M_EH<F!$<&9@?'-M_2.9[\`,[A;2!8P&[]K\[,!R."63UOW-U(QW^3IPF2,J`
MIH!$P3!=0]<%Q_3S7'0WXNS*'T],;\KB$)Z/X`LS#'G$3,].NN]-V9A'(]]F
MCL=,R_)C+P*8`,4!?$.S13A;G7T%1`0PB!/*-S1F\P$/`F[C(V+H,#>V`[.:
M`8?G@#!C((/-^F8(__8]9CL#>)E[%CS3Y]$#YQX;*+YF`9_X`0&"XZ6`,,L,
M@BE]/T900^8/%LX,GW'V,3?#&*&,0WP1T<`]TXHDW($9R8==\P&Q9$9`+-<%
MJ!`G',"TX)L1P(>O9N'&T?F/"1=C^0#U/0]"7F=9W,.7#H>!BY"%6#;9/>QJ
M,W(`*:;K^@^``B[Q%$_@2Y@:)@9R1`QQ[P?8.O$[=Z<(JP<,%@F@";JY29*U
M#&+716B`R__+[3J[+)I78\X`=B<L+C2#J8833@+_WK%A2'-H.B!OBA:B9>&%
M;6T..0JEA$,[KT-Z,@SQ:_@3L07P.H$$B,"H%PN^17(L*^N^\)";@36Z].RW
M>'6J/\&)W@%MO)"+]_8H]B;[EW7[.#S?60`>1Y(!@P1#QY,?5DO>1KW5<KQE
M%D&*PN0A$H:**VAW9_@"]F88K12@N;?MS-L6O:TVOX>,#QP-0BK&;5%G"U\,
MN#/NQR`A2&/3ST-`N1PLX!9>.0HR<DI[60D0&-N$'^W8HKT*`B]8"EE]W@J9
MY'?4&KLEN[D0$/B%]N@7[H*\M`F!E5WQ5.R*VQ$P8.T-R?`;<RK8<P/[@L/*
MQJ1'D7$'8*F2<N'(K-P$1@TC9!!_(K3-@QG`EA$:BS8`L^%EY/M41;_!&WIK
MM];(=V%8^>8D<'!EH`1M[A+W)].`CAC#$R&N)$S-#!S*-<,H^9T`236?#9@5
M&\X!F"9F``91^BON[R#"X3,;,J?5<L/*^6@Q\AV"1RQ2F`49Y&3,(K!W<%,C
MVO$MW,=D')#-)M"%=E!(0F+HH09G_CT7#]PC^@$K`*L#AIP=!_@)N(4D!./C
MB>M/.1>O_Q4[@;!6I&+''7+O6,+8^6$!]PYY?FZP%4*QD)K`JY41"$H&S@"7
M$(!&"%GL"@X!$R1K,2'H6D[:D:"3C*2&1F@4B]GX:<"=*,[1&<S2R`\PQR[S
MN[#MZNP&;3`_#LG^24#,K4+(]+$Y15/)M'&O*IMNX*(!2-BPHGA^@@190#[`
M;9Z].9!-LD*>3'7V[@>:661%];G'!P[:46!^`1:T1"%(6%$'`"YMVR%HD7JF
M8X,0`8-XXD2FN\!V6E-T9Z7].S/P`,SPA@<D%@XGY2=YC0X+Q<NK<ZI=R?<9
M\:[1YU3;HUCSAOA)0<_./OIA>,Y@%<A:N$=I-7-2+7VU6+3)74*LYEA"XSIN
MC-S!U5Q`T9S\@:V$<EMP%C$ORD"Y/>5&1T/A#0V9#'/F$LCSHY&8F="<(*J`
MR(ZMQ*0'%KYTC^3KYKWIN!A?0"[)BB>0I.#!A<J\$-8C\A;($3#8F1=3WN&<
M+/7C*(Q@W3BEE"WX?NJB*89^NPHO&O(Q;%$K=M5.IJ&B40#B"1Z+1B'N&/@I
MU]U#6Q<%!UW[Q(U#07OL7A]R,/?(T:RS]^NMHTG<0UK!^;%DN?08/B\DX\2/
M4+*8Z+X53,_.A'($X0&"1YJ3'HHWC]*.$1M.&B<ZA\63Y6JY,<X\@`TE'5M!
M/>2B>1Y45$..[G/+C$,N'3CE(/NQ:[,1(!1^!U\9X'`4M"LQE&Z]E.3993MA
M&!-9)5F`W`+ZK%U!3N4D!KL6E`+3M6:OJ_6:'?4.XB1!4/;)KM9N=^"?9D+T
M]=1]NJKEY-QY*8;6:QE:U^BM7$I/N]"[6J/5/<Q2FGM8BM%M:'KW8HVEM)HM
MK=V[V'0I*[V?%0HNJPL_\X?+)"9V`XH"_K1X)MYZ0.68U8/"NWTE;/[5SLYJ
M!WO6F2IV.(K<\(7N4('K4>BPK../9#QX"_W:E`@L3X6<.L\'T/LB8,H^@4TG
MMB&R3Q(ZSXYYBR*>S-0W/MINR-C`QH5/?)V0>8\CUAH]#9S]>^Z!,4]R%$D>
M@)48@EL6C=@5H!O44@`JXA+`M07(CB>BJ'(D*^#XGSM_`K9`N]%><TB-MDX8
M3S#B:'.IDL6+TG`D82TM_F1J-4\KG>=+^K@F-[%PLD)4K#;,&$R!BMQR!O!J
MT23#V+$I;`GRW8^'(U";!-`'^;:8-;.';1Q*!/W@H<2P%30R4USEUT=N43(7
M+.8V[D=J/;5F\9(2#C%>`RY1#U(<I78WG7#"(7"4G?TNP;A`L:0/[K9DNN9%
MHW8!,O&:`K.7:?SYK8J-DI6=GWH!9\#RPW@\IG"K6"2H6W!T@4LG+OF1"6N@
M&42A7O3J@#&CC#\3)H0!*6IS>$.00&QJ8=N`+3MVT&$:^CZP,HA\Z?N1Z+44
M3'04X,D(NYA0>D'*._5",(D#4_DBPM54+E"D7#P:M2^_=+E=X&'Z(.GG@$%'
M&5:Z;/LY,M(`N]EE&'27D3&@Y<0/5^]=O68T&QGR%/`-.TNVRKGBD_7&SL@D
MH[7!++_F-D9&9&A8,#;"]0E,IU:6S4$<HRMQE]\W,S*&8I5DIZ'MJ,QNY>+0
M*83GQ;ES%V'4X]D,J!*/3EP&(/?3^B2]139!.RLR'-!X@3-.7D9>)U"(A6;]
MA:R;A08^AD^]"",$,@*C3FL(<I(>E[=?E>A5T1;D1M#"MO`H$O$.9GLDI%X]
M-0+VJ%C3?^JD%D]2S>8UYKY1=)I(`7E,-N^!;`8=U$;V*`*>`FGX#D6D(T3?
MLHT,BMR_Y^JHSY$R!,]`<^<`(0TJA3&9$4+*]'#3HL[B_:D82^TQV\'@E"7]
M.W$<NV!$=;;JD_)+MW7R(TWXM7Y;9W^_O+Q9KN"YZXP!O9$R8#+&"HJE)2"`
M;CG3SU4X!840)X>C%ODUH2,R01@I*U*A@#@300,-?-MPQ`:N_Z",*O0*1,0@
MYV8@<!%HZ3/CG+EFG[N)#IH5.73"2<IM*6E@J.8YHMYR\5E\,+0"9Z*(*L@\
M^ZZ)4ES@P/'F=:^#GML0'K3%:LXN,E,XGH0Y`$MJRLU@T1">SUP?]'2PC+-(
MKCL4E@=:X7`AGE*/3%MH)SG;W/MS7&ZZ(=@?K@D29)H>9F<M/<&_1@=M/"?\
M+CCP*_P81"9H'0<E$(!M3B;@D*D(4,HK."1I33PM1W<1#_!M-G%![^%_A;D%
M-/0GTJ[!L`Y:%^YTCF<)6KD3)V9@#@-S,F)=O5'#_[=JJ!,%3HDCE,VV&(^V
MCR(5(!MS'BFE)D.]B-ZB.2[.S'-I7V$&0>"8(M`#\I$#;>7(9W]\>'>.067<
M*AD*6R9N[S'9PV+SJ7@U\3B,@]%J8;+1$0H?`G)2]@CC`=@I#JX$G78\QHB0
M]/!![`>N`N8)JT8S.E[PJ+`U;=I3*7RY;3?$@PZR0&S?BM.C4TN:U&BW4`1A
MJ#8?9C,D(@?ASBY*V`1).DN6LAJ^FG)-8KV`X+"`,=26_$-A^X/"MA+?Z"&$
MW!)Q#W@Z<1@$X33T+:2QDO=,KC$.Z;J:#*/U>>ZD1MI#/$D%(</>CXJ6A@</
M`>R0&2JE!VO)KDH2.[(L%BH>,UJUBY;RYQA^ZBBNEJ"%PBK]"_#O1.)*3R0+
M?$9LB"]X<I9V#*N^66L:67M[L9Y59C<HQ',ML:K#'8WJK8WH"TWF.>7-9]+4
MCB=^!.D*V\:TY5%HYC`O;TDK9A%'AO0\8DX9SGHCL?]GX2P*7A[&>#Y-R[#R
M(RK$;(Z8U>E*2]*'JXVW-AH/[;<9&LN>IM?@.8SX9[];J#%BJ3'`.IV*I((Y
MIXDL,)$,(\_59-I&/O5BHK)S<G8[YI$DT561?Z"R.Z3M"1*>O"&RS(`?P,Y$
M&Q"M1VOD@)ZTI6I*W+`0B)7DAJ0AFT.J\'<?[M[7].;;7-PT16_FZWG<*XW>
MT;OGOV9G06U7F-_T;Y72>Z>P!PBY).3=2.3=">3=9)!W)Y!W17;:&PXSS:'O
M2X*^6XF^&T+?<D-CHC"4X1]A#9:,;92%6C'.P1CGYY\V8ITM;%1E8A:9G8G?
M0T&)_/.K+-G6(F-5^(C1K+6Z:=Q7-S:,^RX["=[T>#=[-$R>WE\QYLW>'^,\
MN$J)/7)*;$)?)@B\03YL+GR1ED/(4A#<\J[+,)DQ0([E]S+O4[C:LQFD&`H2
M2>8K.5ZD]DB+!C=[F"Z"9E&!0$Q=S)WB+4@?7(O)L[LB*5+[F!;B?)+U-]?>
M%TQ:P@0R3'P+#YHU\<0J,^1^`5('T6,7:V0\@&Q91NJK1"(I:&M_)>EBVNXL
MWOEY4/"Y#3R1/A9:!-C@TC4G(:!+_94A?4UD`:OY)`<$/+)&ZWLOS.*N*^?^
M[45#?)9],_'S*;<*+>@(6F(@GTP=\7S_5<$B`$R]5;5@?<QF!IBKQH-$O`BZ
MJ#:Z?2QHF?U-B3I!N?QO$C>D\DM)592:(-L\S-H_(0I_Q%,!IE=[[&3V6$6$
M$A"A$G2G*>B,:H^=S!ZKB%`"(E2"[C0%W9HW)51[K`1[K")""8A0";I3$W1W
MF/-7[;"2[[!G=`54^:!_>NQ48?OQU>.IMDF=;39_NA2H&@576^#9X;^LRWB:
MV*ZXO3SXK\1]M0&>'?[+NHRGB>V*V\N#_TK<5QO@V>&_K,MXFMBNN+T\^*_$
M?;4!G@G^G]%A4,5@^P7S+?QY+_JH9.XU^K4R+LJRMRO6+R/^*^.BV@"/AO^?
M?ZJ\R8K?R[2PIX__2N!7&^#9X;^LRWB:V*ZXO3SXK\1]M0&>'?[+NHRGB>V*
MV\N#_TK<5QO@F>#_Z9T5_8]E<3XH[!4EZP>[#;W>[NC=#G7Y4U5KR'-[ZKWV
MS#GO,LHW=%]O_ZOBSO9F?2$K`NPN>G.HK^1P.8AQ8<Q2HS)+]@!FK=H2CP_F
M+O*IK&MZ!JBO]L'//Y6#')5RJ)3#$Z7!MENB52F'1T5]M0_V"^;+#36"7FF$
M`X#9T[I&6VL;G6I'/#Z8E68X2=17^Z#2#$^/"I5F*!&8S_2L:V%=5'6H=8!#
MK>3BN:9.!UMK=O\MZ8).!.]5&L'IXK^R,XX7DZSXOLJ6?#[8KKB]//BOI'PE
MY;=!^\\_E0+02LZ7&-M/B=]+`68EYQ\7S+;6:70TH]6J^/\4^+^LRWB:V*ZX
MO3SXKZ1])>U/'?T;'PN]BLR^R]6GB5J>JBQJT/\VA&1^=3MBR^51Q(-:.#$M
MQQMFOB]"FA],1J87_LK,./+S!X]A9`:1_"H*X*$!O(-O>ORU.%FB.3)`/CBV
M_Y",]>`'=@I%`\\U`=;^=P>&PS'#*/"_<W5I&_T^-H.AX]$'UJEW)FIZQ[,Y
MKKM1;SG>,A9+L;B2P!/\ZV^OXK`V-,W)K^]-)_C#=&/^,>UK]XF;81QP^]K[
MPJTX"&`A;\S0">\`IC>N;WW__>>?_J8&N+5&W(Y=?CWXPETSXO8-H&]ZAX@S
MK<CQO?`.F2=YEUD`#7SXP@>_O;@2?W]K?WKWK:%_^Z?I?</*J+M&XYOX_]WU
MMV;CVS_CF>]?_/Z4&?'X7)??`7_&8>0,IO-,F.-"P4DDJ9'`6884B'PE(%U-
M@"0'H-U)0)G#01X6?&X1G@M0(>]$!#YQS4D(2%1_9:A?,VU<N)I/,D'`(VN4
MCKT"IR^8Q5U7SOW;BX;X+$^=\?/:!^V9PVO\ZY/C\C`"P,*%6K+XFL$B>?"(
M-U#.7?=X8T[',-U^E[511L,:Z0,K<+@%BLF,V88VPO[<YLTUIMP1;ZM+C/5F
MIU>8Z$.OG.GG;``ZR!LR?\!,CWT&D?$VB(?L<C)Q`094)^Q,@-\UC,;KSV\O
MDT_ZZW.0IBS@PQCTD!],F3F9!/X]2""0(XR;U@A$,/!VR&T&/]BQ%:U,2\)2
MAG61O;S\(9.BMDU6&KW>:34T4'!;)E,==\\L9\$SXYS%$Z!F-.)`,HL[DPB)
M7D@]T!KTW-?Z;9V]?WNY`3T?:6OJVBI2;4^=U!A/K;A-C;"L`7<3^!,@\_3&
M!=/FTK/?_14[$Y3)!S79MC`35MLKLW;@&I:$T1/V]@;&1*$UMLHPV-AJ@EWG
M]`-'8R/NWG/<A8`(6$FM,IK6-9K6V+^G:305.8&;;28:YJ-S+^W)E2&8W?#T
MK+&\1<^/"MM;8WO+9-33]S(.YDM48.T-K,/[5XU6SMK8PX:Z'@S`R&9<687K
M[:==_:=-WS'FG"XIN_:)BA2>9JW%IMP,UM2>Q\9&>\\\L&%EU3PQLGMG/R#I
M%TVMI_<V`ZRU!2YW>^=Q\#_G_Q\`_RWMHMO8-_H/%818IM[W9$OS$&/QEA6/
M8_+`F<TG`;<<"EH=TNP[F"HK@S5Z",MS:X0=Q`[>(P^>Z;K6T-<LO#S\ECC?
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M.`"Y1)F5KBS\F#++-</0&:A$V\BG0-7<#V4AQ)G>:VKMMK[AA.?E@5]K-4"T
M=KL[KJ`2(94(.9X(84ML\*N1Z0TY<SPV0%O^?N^V_$&/>[8W7`X-3(9W:AOB
M<_M%5?39ACX78"?K6K.]./5_/W2JA'XE]!_C/#3Q;N?SFDMQ>+/R@..(4F13
M:/(51)T+<+N-#3&[/W%?6DHM=N>/2:!\G_/#$6AA&P;;N2]X47Y;5!JV_%@+
MC\+,R!NG'0&R;_S;#,!IC,)KCSH!7`_P"?(&/_DV=P]?XK]KO=@6I6&RX/W1
M2L.(1WY[(2+P+_9PRF2TFM4IT\:G3%OH;I5[/GO`H53FIG/L$005D\[DLNL;
MPK.)V?%<#O,VLH&>PUG>TN..ZA2O\G=*Y>](/N]E%.0<6)_,X#N/1$P+6Q58
M_GCL>S`"6CSPQUAT34*KBMEFQ-F9/A]JGCTQ:FYQTK4$QM4G7?-O9_M+U(W%
M_L8:TV]2L+5-D==."U]VP-FJ=WN[3']4J75)=A2W&?_!`\L).9L$CC4?9]UI
M$RY&Z`(4&O6+3<\Q#B6S'A7V8Q_F?7'"[VP0<(RZ@W;G8<0"DCY&:0ZZ]+J^
M>'<53_9+>6!?XN&O!_MQ.^M(3YVYV-P!3V+2.M42H!,?6IEZV:QO5%U[,@;1
M.FMO''3MQQ9.[WY,N(6JZMYWS4AD&9PU2R.8.HM=E)*+I9TA/ZY02OC`=NX=
MFWLVFSK<M=G916EX8?&YZJG(E[VMX-A2XB;P^RH'"1PKZ5$-!AP[SZ(*,[TI
MF\`GWV8^P,&DB&1GK=*PC[$X.[#DHF1GR`_AXWRA/!)@!B`[AJU,\8G_<,((
MF2(<F6#J"B8!L7+6+@TCG+X<:3XR0Q3(#_SK6@D$\G;!R4$..>OLF?`;^XZ=
M>FMO71Z/#?NF7MGFAY2EZ_<HRL".=J97E9F5[@`P\B=+0L#S_8E7-9*:(ZF*
M^Z[=%^>BVUW$XNO/>C?BN&,6AZC-B)KHFGTPH>:"U2%S0A#%V$I7-N6]\L<3
ML+L$?W8-O?,Z9,`S=BJ!_XK]*'W^^NZ*B1!Y2/UYYXI?J/.!?/CS?V[?L4__
MNJ,G<XE$]66H6TNQ+*#O0I)N)FWSA-G)@MX4T+5XSUB3]W9GML`)O]<*`H\/
M9LAL#M^,'0_8HS\%MO3`?B->BT/D'V2!NX!8<,K>.*[+3+3E9#/H$'U%)\^D
M/_]$;%IR[@`HR\X?S:/PQQMNF7'(LX*$V3[J*#]B(Q-H:]K\KQC91<F4$5CV
MV/8[\E/N80X($_$#(B9Y-HTF:31%)KHT,"UXFI@0.-(94RNN13R8&3H9PB&W
M`D7GQ`Q([]*?GB.BJ?A::(Z1Z6U`2R`:N@1\Z/C>NMRYW$1J3GZLK=BW,8"6
M:79A<M6`\W+U],E!O3"(]FDCY7=(9?&<IL5S\1@6SZ=T2V?T#6[0F2@CB)0^
M9XU?I(%#]PZ@9.$4E93%;B.PCYP(&`>T$4JIB3E-QA$6#8X,_^4AY\2=@S@"
M[704E;1]6D79]5'K*/JHB%5"(N@D'WL4-)T-00)KT'43_%YEO1[/&GFZI&_O
M@_2)]LQ&"V9IKBR!4&QS,C/G`XSAL@@CJ'YB@1G.('$AA`O:`<W6+\J.5>_'
M41C!3Y*-<KX.O3+G)VD9$]B=UO-Z<74\H6+)'5BR<Q1I]`4[PX:8?4^<DMJI
M?E&($XLIA512/X=LB8NU'R-TRSB=NKWP.03F_O9J3^422>5%<LF;NA0M^>(3
MCT:^?1H7*>)(I6D[EK/NB[GP,(W(,CS5Q1TQIYZJZ'`I?:7BNH7J^L4J5?\)
MY+>OOG[Q8<2])&+G>$[DD-ELLIL1^,[L`[L":4P!LSL0Z2[=TUC=JGB\K;"<
ML_!6Q544W)*$C[3)#G>-XE$RF\Z::Q#DM"B"38O*1)--M\C%.7OCP*M#0OA'
M@>7<!;/R"MH')QHE5XZ6!_NGOB-:Y^R]$X01'4YC_0I0(33=/9>O/%_^;I\S
M<P#VHPA7$Z9?ZK0@_`>C"1Z/"..E*0HX),JS?<&W<+*+&X3?8FSO#1XFH%P'
M`4*"XQ9#@]<3NF[W$L-W3C0]@,O^[?+!#.R[Z81?_G#";^_&$]>?<IZ9_1,%
M%*L6XX_08CSM,5X=;#Y:+X=-Q5KB$S=W3<_<WTA+PMFSL_R;M@NW#P;M81H^
M/'&J7`*"S.'F9LUS(<HQ&'R#.;[PL0E.F#<\Y"2E(.$&\'Z.J55,"7?)!E.@
MG1685A2;[D%7,AP&?`BN_5&(?*I1YW0?S!S<+\\YH[?\0=Z4VGR$],J-2<%V
M/'6LOI/M(/(@]@/V"G^]*>P1<=HKON/!.`7OS/'2#U0@N+C_RFFN=SNN_P#R
MS_%"Q]IU^Z17LQ1MGUT$W?8C;74.TET6R[].,W:>UA4>W9;6["[N4K9?8(Y_
MQ+-L]<WZJ=Y=L@G]EQUR=>O-U:3?#QSENKVEI?4:7:W=:Q]D]4<+[B9=]_%3
M-D7D0QC&^W&-]A'*[75ZFKZ_0.[CK:/>W;0*NGR+T!OU)T"*4\JS6'_;*F.]
M-#L7+X]O+[GCJGB^TK1=:-0[96D_MTOOB/35`\S^%%=UW-/5G&^P_`*$1T*V
MH?5:AM8U]M;:8<>5;-R3HE6_.'W-"]9V61:Q,0&Z6K/1T%KMO2W@^$WG2+7B
M06M)-VFWW=6,[J9])4O#(8UZ[_1U;:O>.UT9J5WH7:VA[XV#]G?)R+:I,>5/
MM)$U/=GDFBJ9H\P7<YQX`D&5UE%&JE1I'8_/X&5+ZSCNT?\>`1?Y'4P>K)=L
MQY0OQ2-_D'IH.I_V476::O%TUC2?8%$E59S^>O\HN*1ZRQV]_4G&]K[L877W
M\YVD2D+9?Q)*3VMWFIK16UUK6\HDE+WEXM0;J[,1GG0VRL4Z]VV5,AME;QCH
M:,U>6VLV%L?P3CLOY>\8+"O/\?9%HZWUC-,/6W?J2S*93F<1%Z>_B-*=9>^:
ME\+F[/?5R2H+3?\M#?\\<+N.)JBUA1>QRH?`:<_:;4,#4/:QK@U\JC(A=N%P
M>OUB<;;I?L$Z300=';CR0%)"-!W?6E*P&6F(9(/<HD5$-7:Z6%R\O;W=N[&8
M-98$:VP_[KM\B2=))^"MQ0;=OE=W1%POS@=88YB<G]E<_P[V$\+/?L;+N:.M
M33?922!J7XS4`D<5C)VFOMC8V0^6'L,"+J##!AED3X']>YK>:VF-SJ/M@9]_
M.H5=H-?UQ5[K"4N)`XC3"^,I(FJ/XE3O-K5F[]#:>76[[R?6%>K16D!)FB0W
M$^:3]K)]H9`6\S78%1T>E0Z/DN::MHO_Z(@K2/".J:+,U<OPV_7@6U/_]I9;
MF*/:S.>N%GS_@L6>(P;Y>OOV!;.YY0#.0TS%_+W=:72,5BM=5R$DQP+U6])!
M_\TT^?,?#@_,P!I-/_)[[E+^;?+;!V\"KC+]H,MLW)G5_@B=7SW'!:LOB/F+
M5Z>P$N/)K*19O))C<V!10O>B2Q"6@=KK&NVVT2D)J"7?+$=:R1$VRY%6LLYF
M69\#;>[\^LZ+0.M\\"S0RWY`:NFM&8'*RGVUI\M#]%ZO4],;M4;[;Z_6GSQ+
MF'=_Q?"&:+WZP;OG881-6:\?/!Z$(V=RDU[_OIA81E=),",'<^'W'_G0=`6<
M1!74TYX3C^<(,8D#GJ6$`<NM-QHI&=8&?>_K;7V[Y9-Y25[X_=;KO7CQ>Z/>
M:W:V73%UV[VB&XC)+L)&%6@+??!@-:%C<\$,[_U`#/M!WB)[:<''T%G(I5=@
MV_EC7.QQB`Y(Z,G>P;NM)LL&-X$_X4$TO7'!&K_T;'QI@LA\IRZ#^AKR0>Q^
MA$U>+*<VKF9:..6;:5+C],FT1F#C!]/L[ZKBZ6Z$E_U2#FC*$ALM)&$+,I_#
M=S^L$5YQ]051]SBT#K/$;B*QF\VFI'8!D-LN``AUH!V[Q0(4Z2YA"MMQ8U0D
MM]R*`](C\+@;V]Q^#ZXF^C:QN"#S>O#.#+"0(H1=3@-?COW8B];@S>8"WLQ\
MOR,H;Z;%`Q#ZE#_FV>I6KCE$BKOZLIC\\/G]B]\-H]O0NQ<IL^\%8R4EP2U,
M0A?(7;EF&(*'BU*.$)B1>NMBKM=JMMJ]T\1<4V#N<A*L6R9:2N;5F[TN:._G
M08*],F^WW>ZTV\V3Q-SF-<ZE9%ZCUS*Z1N]YD&"_DO="[S9:W0-@;M8"%M;%
MT=V4!>MN]CHP7F?>4!=@)@M0UI"-AGM)UZ(W#:.!T;&5$"?+^L)=M+5O3##%
MT\L*Y14G^V'3[!1W&-\W+=K>;Z;97X0;P<<^WF1UZ_JF]R\Z3`">NC(]BP=7
M5-HE4/'MH^\-L=[L)@XLO`T+%^A$PBFY@C&'?C"]'GR`[:&>L&F"S_SA;1`/
M,[<VK1%'Z;3P;$5B=2G"GBM:OW"+.Y/H>O"%#V.8'!X#%`?^O>FBH/AZ^]XV
MUT"TO@6F12GR]>`&J$DW(R_WIB[C8:$[./_]!OC]ZH&,#,!9!^3<\1]F^.DM
MZ"[XQO<*D'PY!'<8UR!$M;S"C6YP2WZ:=]GD\N8UWH5$URPB$@P)27QC.O97
M!"J9XX/W'W#)[Q[\NY$?AR:XX"Z_Y\MC)PWP]*>(*#V'0+VG&%3?"H%YQOS@
MA2`"8PS_"?1]X2''F&@A`N5-;&\Q*NI3!`%P?Y7<$>;\E[;Y8LS.LV&6"3=$
MWN9(OWO@[GUQT.Y9(=UH;(-U@;TML#YR@HA7S`YXWXK;%?X2S%\_@"J@M]?:
M)W?^>S]>28%&L]AX:EP4?'^R%.CJ+3VAP-9X3"^#-QU`HH<K><\Y.E%J/>KB
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MLW1VQ49JM-_Y[TQ4!10`6!:4[("1%Q3$08J^/T2<::L0R+Q:;.IZMS7GNN2P
ML`.6R.1UY[%4^/T&6'H?</L?<80)$TF`2*GQPV"IV6X?#$N%L;/3B*DML%_G
MG>&]X:JM_-897!5]OP&N_NF/O/`?_N0[<%2*MSUS4;?5T`^'&?W;9_^^`#-%
MWV_)13?<\\*I>V]ZCKGO'=;I'`XW:)8*>3/G.LY_7_8=UKQH=IN'0]4FVKS$
M(EMO'U(,'0I+!Q)#!=G9(DLM@IF_3L`S?.\'N0&?B[IJ-GL72K,OQL:."#MA
MG648W8O.H?%STIHK*V@.A:$TQ&G,ZJ_Y[TOL;71Z;:-Y-%SM-TQ\=`76ZUST
M-L;5VYA?^2'I,JS^>%)'^;\C[6JZ46OJ>;S,+#K!R5L>6H$S$=E5E&!QCW4#
M(8B#7+`!D*J"I$L1UBWV9AN=`H1M&.CX/?F6F?@U>W!<EP4$,V=GYCDSF66&
M(S;@G/&_8M@"D<_TQB_,'[!HQ-DP\,.030+?XMP.66!BSSCF>/0C@L9$=(2)
M&-WU8$![76-G?1S;\[V::5EH!]'%*OP'5M9R@,`9]^,@%*`E$QN[SVMZ-CNS
MSF=F@%%?ZHV&!C*5#?R`N9C/I:`)85PK#F`CLOZ4)ICDL5:7?+$%X0_&-`O$
M4:-7\/VF3)/L$$9;2B`><)UT+>Z)IL5L9-HL=,:.:P8,'AR'S`Q3"IEJ&`T1
M[,;8_F`K?M/VSTG()@\R=(O/3V38EHF(KWH9$RE-;_I_88[=]LT.*H:<&>/-
M--VYCR4[[N9W`H.]XP#&;!XZ0P^/K$8F"!)0+KZ2*CO@%=G,A/^+3-PB]DA'
ML<1[H7B/@N_(?!.0W.IAU((A]G=<0W`00^1GR$,FB\-8/('ON`P#JYG>I&L6
MG"ZV3!A;(P%%H0193O:]L\HA)<:_'XODR(^2-#N@^`9XP+>O!RJ\G[[X:)OO
MWTX$)B%K,UAR-$JP.'`\-%-=/T2FE5\26^>PH]A:G=PN7-^V*#CT.>/O+566
MN,$"9*DJ#.Z[CN6(!'BP;A^+B"N*4!NM='6+0)^ACV,)8_V]@ZD&:,S:]T[H
M`SR/;&BN3&3+$7+E,O:Z[`,*OD,M.R?$+FV;JHU--Q5C&2E&\#RJD9`8>L(0
MP/1R!RP$D$UFQ,Z<<^;D5`#"&L9C+"4&@Q$^CWDPY`%8>6EEM<;Z,8@X'B)I
MQWU`&%6/@[CW822P-E-GD9W)KT:FT/+B9%D569R#SQ.-:!XT#J:@<:+`MV,+
MM`=H&B=:8/1K15^R!S\&<T(Y4.9".]94%XC18I-B\L0JR,`?2J?%(41I!"YJ
M138AIL$10;Q+-6`.(BYL[00E<D+)2MA`2FP)FWBHCW91W[_G6HX$`0#MH%XU
M2:5X%JF3(+'FD^&RB"Y$"#J49`3BK]02#5$!;RA?(%7\`\7W:GA:N).T'6!]
MT_L.RU-(RD&6!03$*>A\3\P$*XZ(#J'LY22^\`.@NK3[@,UA*[".)E0E]X;F
M4"U"LFZAA;;.SBO*?5!)(&^F_P#K$Q:0Z*O'E\_%*2U&2V_HK?F$A\4KR9;>
M7>,&5%&K2\_.)-B]DW[:7BJ:#Q"#7!XL,WK=5J9;QNIU[ATKCU-OM!PKW5XK
M6X:\&58N@\@)(]!\."DE2OI3TXVF?X]-NE^$AVEMT_&S2]=&T.^4!2YE?1+G
MR(I8V&@@&B?F%*74I]M_75UA#,5D%,,(IK7^M";_!+D7.BB*`X$*E.DB@.&!
M)`MA?Y/]C\.Y(H/51B4+.@PP!",X+DV,2\&K'W]E9_HY*"-A0;-!X(^E[Q"$
M$?D)(MV51M90MIX9H"5'7$IX&`91SW],0$/4,W6GFU`N1W(1M\$*,92@&:0[
M\`Y&WB@1][,OPG"KSMP/$H??R\[HBK2GK==],*0=Z%SY(.)D)ZPEG7RX_39&
M8(3E+6IK/_,'^FF5NW"0'.15*KC5TKMZ1M>LMY(]K[WW[3WOSZ\=SVYF.S>L
M7$_CL1;S:.7ZN.I.T^CU3G_A'VZNUZYM;W=$;MX.:R[LO9I)UW\S31^1!167
M#V9@J\Y<813$I';(%KD#QT]VJOB[2,[V!`A'V/?2.MXLD_S8>,CA/G4?1%;S
M&JG9AQ>1RQ+5V[F>?8O@+\<:%['#ZD3\0Z]OH_3ZC>3$LK5UZJW#KTUO*$<Z
MO[;"[]&1YG_%Z*S<P[^2QGDSWQ]XE1*QDEVN@R\82,E5&Z0A;_EKJ#_"%CU`
MI<7<CMX*%R>)S,.7I9TRUC>14,5U7>_&$]>?@F/Z%CQ9*_*#D)#JA;$;I<VK
MOGU!]`N'QO&<<4%;GV5H;-6S;:\K-%+3T1\;HU'7ZU@,LS<\WLB,#VQS(S;-
MY;WIN.A28D(&?)/VSMK&+D1E,K_Y]W=\U&SJC6Z[D>O+NO:"%B&">MR"=_X!
MY@6__2;NNXZ5Y$"4$`OM=K/=,19@8>EJ]H>"`[M5!1$1_:*E&ZU=5YU!?NY4
M(Q/4>2R2_WZ9G(_Y20:.R`'Q!RQ,-R9E[^`QG:S0#=F#24DV`4<?2`0W7[8Q
ML8^2^^!1^`1,HP'74-I:0&%:[.5[C]%1^%?-=%U?1"D+C;1%R-HG;B]4/>=,
MH*7@>W'&JJ+*=-Z&0>5/'__`]6$VG2:RDBA;!N":RY7)'I?1`2E%E"_3L'5!
M!DZSOC`I+PDH%TU69]<>NYP$CLN,KKAA+1<5EWD[+:"5S.S!,\`D=PP#WLE$
MF+5)I(7-HH+M,["+PUW`17UK4B[L=ZW:7`_V=4ZSP,SX_:;YGS7:;Z?@/#;T
M.>W^^TWK`-#_G5AN/\<`RV5MZZ+;6`-^`F@_H._K'A/]HMG3>]O`?FE9\3BF
MN/I;/H'-YXB+'?C$Y11Q\K#541#)AB@+!SX.@;)&T+X@/S8V]D9SO:%W#HN.
MSW[$U>'+6E=TS/1/+?H^7XYQ$_"Q$X]%&A3?J'JEU>D:&6\K"^L6:]CH,+&L
M:]C$O]O7&EH7O>PM(HN6\);WHS0HK9+@9.`:G#C/<B8+JJZVB<KOCT*]7NXF
MJW56D5MWS.]\,,G!2PU"[!$"IL@(+%GX=,B3VT.M?[/59)(8U:5&RE'_2AGY
M>U<:BPZF>NUN6ABX`)I=H-U.J"^"MM.YZ+6--:$E6Q8<)W0(U9514W(WG8'L
MGWSGBU.A_+?[N29JY6IJ>J_9;JN"NJVA+;[P*[EVZWJ0?OF9'\4<67+/W2*P
M]K>((]R`MVP11,O,`Z5APOD5UO160^]UNY(!]P%TFNA)><4?O$)4[;5J8ND2
M+]J&WFPG+;O6`2K3US'XSB/Y7.9<XMK[Q,TP#DA3+*STW75++8H!,\?^[<5[
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ME@=VCTL\5=FRHOJYN]*P.C!>]Z@LYUG'*`7K'&J_KY$Q56@>=3N-]C-`R8+L
MIP4HZ1P4)6]1+7'//IP$S7>!S&^$"Y"AK_8&ZA.5A-DLS'7QLS><[BP%EY/?
MV"/Y#V:]'(L^'[Q)'(4W@=^784>,T0U,L`F/;=NTA&V3/89<`\I]+.J`6K<E
MM.X6BQ*W&N*NQY:>:3.6=\`WD>,-1>D2Y=CQXB*BG6)IJQ;6%M1JJOK\=2'=
MZ]*V"ZZMEA%M)2/R@?IT?ZG4QF,',ALS@':0"KW9`X4%<.YE00<./7>^):4J
M:Z]I7@[:?\:B>\>^.T:EQQ=OII_-"!AI5475W#&V/`):"^BY>TO%SI`_JS#O
MHRQMT=U";4-/SG^60EUPR*V>?U2:+3RXSYP=+P8Y6=7BRW$?_X;?RW[?CZ(W
M#O4H,B<\CAPKO/*#R8X7^][@G[<<EF/GNMM>#^0E9_:-Z!"Q3O_D[.UP&R"S
M(@#>MKD[_O7<[285`=8C`(SH^D-$O,3X9G>'ZQ77;X'T]]A#)KTQ$=W?BL$/
MA.M+[/5&"/_,(ZI[J%!]2&$N>+M2ICO@?S8#E9"6OV[UAMI+*9&]R2T/NV!6
MN0!?\&[FF'\!PVGH46^_Y/%//!KY=OZ!_R[PB3.12('.F8OH6@7?'_Y2"(54
MS[Z=P,`^C)*T95L7T;4VR)!&(]_197.L'0#GIRA7%HGP@VX42;Z=Z2<ZUXH]
ME$C"1>V4GZK4:3:R^K0`&PMN>!"M\>3S=WYV34?'W^'%R>]RO5B9*AHW%K0P
MI-+5/F=VS+'"]/T_KKY<%5^ML01Y)X#N0[/K[X4=)L6L;&9:AO-NTG=2W[WQ
MI%&7S=M5M^(=>D]NR1SRH>N!$KMIZ/NIZ_/B(RR57KP$,5LC[Y3WT@J\Z9O@
MK<`W7M)V[I2Q]ON-;E!>WO)UIT:$-(I@]YJVXR/@]_P32HU%EZX=$CO7YO<O
MCCWDGTW1V_NCV?<#,P(3;IVN_MB7)3$'EJWK1%?_3=".GKU[\.]&?AR:G@TL
M@<'.B/.5P;5:2YE-SQ)-[_UX;31=;(&FP/^36]&[,'+P!@4;KZA;JM,Z"[K*
MMW>[C^\2]/']K>_&],`ZBS6,W&H+UK'](O5OUU8TOTC#*/C^A!?YR9S.'W#K
M[8+O3W611JMX/QN=E07?GTPO'L`RJ>?L1K?1=O5FK[W?Y1Q4O6],,%W?/\$V
M3\?:`[6(^]9?S%O_P4M\]J(G'].T74[%67NT*>Q1E0.TP<J*L/'>#^1+:UV=
MU.@4I]1DOS\8`Y/5U4LI7KB,'199&@6I][*,O:]EYM,(]WO3\R$)F3N)08Z&
M9RXG>+F4Z>(E6KZ/UM;;(!Y>VF-X-(R"Q<7ELC%PD1]_"O[]>KTUYP1E,W<8
MN"U"*XJLH,CBIK%S.[QI[)4B[V-PRW(A,+J6)H&5+IL#[QP\E/_`*IXB(=8X
M#5=QBLV0M3:2Z9`'WX`7GQV&C4TPG,54FF_I>S`VO(G=H[#/DA/%PN=>=77G
MJ=TTO[R97RM!XU*,[(ZWQW"Q6FVCT]ML?3<C,QB;UG0U%]SR20$7M`N^WX`+
M_NF/O/`?_N0[;*N4(_9+=*.1V/.9U288N(1A;-%DS+=XB%?^/F%DI/Q?O.X,
MXT?B%@7'MT%FWZ6785X/TL:P!W!9OZ`_-;>FW^]&>(B63*PNY\2S,X^!:S%E
M;=$(M\Z^JCZ]=,"5N\`37]/R]\DQ,P:BPE.`3A?O[/3X0R@.\^@ZT%KDU^@/
M=9!'G723BSTC4$?B9X\P1C.ER*HGNW$-=*8\J;[Y@M"8;N9L[J@H/SJ:EBQ\
MIIEH$%.^V``Y5PJULMQREU5M-]SSPJE[;WJ.N6==ULYEGVR`DBPF/_*A>'"%
MP/OLWQ<(O*+ORXZH9,7YCG')L=P'3PK$96U9B[JS(T(*OE_NJW1GDHB*`,FG
M>17=`+H<YJ:0#G.7RVW>$(V\J[FTIZ40[>4&,GF_UG4<A1$(%E!5HDQE;UUG
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M:9!H?2_\]!R'1KVWQ\CTFJAX,MA_?,=A6XSW5T_9W]A7^<+')LAJ;X@(#C`5
MVG0Q9=(X]H4[W?]<?#+>SF#YN$M^@AC/<_OO-Q?_Z7[2VX^/9DI!I8%K:^RD
MVE)7A,^JC44S'YNEZ3*L1UGIDT+Q+`]W_M,2/%P"U!YUYQPYTT#(Y#RBC[O>
MIX;K>6G<_J2W'AG!^]($B\V:1=/KQ^;GUG]T_9/1V:/ZVV+13Q#G\WP-$KID
M6-Y/I/\#S.)XH6/1O1N/>I`Z6V[6:W3;&\5YMUWU":-V_<M6+CK-7KO9V&/N
M1'GQ>?!0Q@QNN\U&H]4^S.'GDT'M^JS::C?;1E,_3!G'X?`Y%_R[\R/370.U
M^[TV<4T\8SU6>\^IRNM@X`EB?/ZBRJWOGRQJ$E,1Z51O$ZVH>>RSZMFK#%_M
M<^U_\!`-=<].[DKW\:N,,7\Y'`9\""Q87ENEA>5H^A[-P*VQ\H1)LZ8.II,8
M?8\NSDZT6'3'9.;^W)`:TY_,=>8-'6^7W&A=IX.(!<?=Q8@PT/';#A&[\N2E
M;=.-)J:;S[,ZA7J>BXN6WNYDPYD'0,1>Y"!8(MXGWW8&\H*]3/<3[`R^OP#P
M3@C__7_=Z/7D?X?1Z_\UQY/7_Z.W&Z^O97L=M".8H`-V>('_@(!"KF0A;@/L
MT*.!Z:0>N8??65,TA@G9(/#'-,P04<ML8&!XP=!:,R_H=/%%\>-ZKZ<!M=7S
M(_.>,Y->`[>13033`F07ZO(,SP:8YH$RQ8#X*`U?9]@-)U"!O=S*Q&M#<6##
MX`/.,_"#,?8Q8Q0^I'EH8/\>+^MPQKR.:'Q%>-R#[EB#=?82XGV7M%3:IP#8
M\/1R[ZO8R^ZE?_TA.$T,>_2CA(M9Y.QI'?L\'1#FC9*;B28[,JZ6^G>=PA+[
M`ZPYBU?JE\/M\#V(M?4K'??K7]_0+=`\\8C7:NO>:;9:&5=DY3IV7_3QN0)]
M+L-H;+G*2]?U+6Q]5;PGT7+S%MQZGN_=U%RPU/3[I4OH71BYEF%K@;6GA>1I
MMN-"P"6X.)F5[![FA14_UF+WUSNL@:'J3J>GEX)L.ZZDV\4:W!-9R5X8L-<U
MC(M=%IQ(71[<.Q8O?N^S[]V+\`=*[)#BDMG?L7WW9S_Z#X]6W&.Z>?1GQ6V?
M>KN5,PD.MIPUVB&0\?"9/]`O>W()-PBZ+^>3=K>=301?9P6E6_*'F^MU&DL:
M+2//%&NOEF(1U+;[(7#0T%91FW*LK-MI=UJJ47`1F(5K2)IR[KU=[3KK^9U`
M2;K\AJKE;YR!,-/.%O[A`0@/QXM\]N!$(W9E>J9E^8'-_LZ]V(FF[(-GU9D9
M@K,_`0\?WC#QLC!VAL.^^)+[\L6YFB_DF`3DIO/R(&1GEN^ZG.X:<Z>B`?&+
MKYD'7IR++]6EHT`(/XDHX`_9AYG)FHV:;4Z9+W`,*YC(:\U8/,&/IL?,)%+%
M@$NS`0X`U*(]+8(R^+Q%80G\5\T$R4Z7+H<:<P8P$L!K1@2$/QCP@.(H6`I0
M+^"/(A989._C;L`(R?5`:J%5/6@?P\.A:_::,^[@\E6DO=5S!XM79CA:H]'N
M([EQS5XK<]M3(>`+UG4917[@\6EYUW;16+2T+.S)\A0=$U?NS51^]0_?Q1L*
M'LLHFX]O-]+F0^N!GEX_RX?)12<))*ODMJ+DQ;=/9H$_8!1\+QNW9Z=CR7PT
MB>EX*.,>?+ST.,0SC#CDX:_LS#D'08<1E<P/[&'D6",AKL*<3`)A)7<BQ5KQ
MYF/6G^:$*L@](1U?RH@O"47XUB'1DTI$#6;D,&R0QJT?E(B"P5_Y`1$E?$U3
MG3D$J;C(.54P&:`)7)2;:P`<ARF<)AN+`R(85I[XS<A@?/9EI[5L,3`IB.\Q
M:(L^IREE-#H$CA!*J@!XH>+H#EZ6R'30<:0H/WW\@U'H'_\![-;9QX]7[.P%
M?`^/8-C<9I^P)30S+F1/?G7![PJN2]A3'HQ=R\4NKKS;AB57GAAU6KG[Z(N`
MR2JU:[P`6'H\Y3%-<QHK!^*,0L[UBR\'^!UC5M_F@$SO24AL'/*_0G6Y*\B]
MK,%T-PK\>#BZAEUXJ:R;Z]5BKJFNK,NO6&\4?(_I1?RO&`9^=P__2F*-,]^O
MW52OU=&Q\=1^5IFYZP2-]T0[+'YC<<?+8R*GJ/M\[FJOS=:3<S/3)##1\0P^
M$'*%]_;!RUQ=\.AX6,0D74-PR3:+6H`,/.YU@*=(1'_A%@>/Q;XN%38*;WSK
MS)[8;+*D37`!'GW9D6&T-D1&?DUK]^/\DIR!"_F.,:X]MLK=""6IRGGW%_KN
M://Y'GJQFYO4>@=L:GUE5&<%$@Z$1G6]6!$3H<'3VI6Y5F`RS0=9$YFS[71W
M1^:V!]MB/7@56A!3@(.LHKN1Z<G#.P'*!\\*.+S[EHO_+MWC1>C&:VT[!R:#
M6@O>/@Q;F-(_UO,7._OJ;[PE.E>'@S(!YU+B_@,%]?U@G:MX+[IK1(XR"UY;
M:HCOW_N!/(!X&M+"V$1:S*$`D`?H^W]J-?;>]R//!W?YE@L]7:LA9EW'^_[K
M0/[V$3ZP'_15!&O\[04@C(,];;^0WP:^"]^.HFCRZZM7#P\/]1_]P*W[P?`5
M&*'-5_CS*WSP13*TZUNY$>F,S`_4@*,`%_X_"KB:_DU7/[EFG[OP@MG_EOOY
MU1S8ET%^#G"TU2#PYPJ8Y1.O\'K)FAKQ!?,#,`E^>Z'7&VJHR/_M10J(^A93
M[I8"N3$"C.4(,$X!`<;V"#"6<X!1%@XPEB#`V(4#C.4<8)2%`Y8C8`<.:"[G
M@&99.*"Y!`'-73B@N9P#FF7A@.4(V($#+I9SP$59..!B"0(N=N&`B^4<<%$6
M#EB.@!TXH+6<`UIEX8#6$@2T=N&`UG(.:)6%`Y8C8`<.:"_G@'99.*"]!`'M
M73B@O9P#VF7A@.4(V($#.LLYH%,6#N@L04!G%P[H+.>`3EDX8#D"BH#,00A^
MJQ\'%M_$R4QA^S%V`3O>$)Q5K_;U=@9A&7^%+N\>F\%W'K%[JI&=S?J1.3UF
MW[^')[D9QH$X^[7I5G4GE)5+\BYU>8C^?R&+`M-.#Z#_BOTH?>KZ[@J/?F'6
MD`W\@+WE%OG]K*G327"3CI[EPY__<_N.??K7'3WYS]CCK-E(SHMS&"P!2@V!
MTL`)O]<&`>>8.,:Q"HP%>"S_8(;,YN)&<T!'?PK(]TP10&-QJ`[_[P)"])2]
M<5P74\MDTA@,-!'I87.D*"$NFB]^?\,M,PYY+K_"]H%OX`%9=6?SOV)$C>*7
MD8-!LRDF-B28HFP%\0/>[9T\>^^[9N2X3B23Y=+/#'<K\`LB'&N4QI1NL`C?
MF:&3(9PD!6YB!EA.+?[T\'M'<&9HCI'`=AQ&`+"XRG[HT#7U9:/%Q8O?/Z4K
MS[`@KH/*.SF`/W6X:R/F^YPU?I$[.Y[`1D0"<"H=%LDYE"WB1.P!&12).3&G
MR3AB4^/(\%\><D[H&\1XNUT)<=,JQHU(')H$?M_L"YX"=A"+D+(Q2;(!7'#3
M&C&.,E0@J*1[LIU;J]H9H:`GB1B,Y^-*)SS`4P-XE/8!_^&(XM@D.W0@$V/%
MTF<P0GPAN`CW1;/U2Y+X*M]/VS0A^G)RG5Z9TPE:1ORYTQ+BMO/B]R3;5S!/
M*GEF\K$$E@%WDI_4SR%;HB"*EIS_YB-\H&]Q.<ZO^&_X^/\#4$L#!!0````(
M`*B%#$4SLF(`=0<```=9```5`!P`871N;2TR,#$T,#8S,%]C86PN>&UL550)
M``/;?.I3VWSJ4W5X"P`!!"4.```$.0$``.U<X6_:.A#_/FG_0Q[[NA1H]_;6
M:MU$H9V0NH':=6_?)I,<8"VQF>T4V%__[!`Z((EC*`U.]52IA?3.OKO?^7P^
MVWG_<18&SCTPCBDYKS6/&C4'B$=]3$;GM;NO5^Z[VL</+U^\_\MUOU_<7#L=
MZD4A$.%\EC1##+XSQ6+L7/YV+WTL*'.^+=IRFD>RL:.&(S]^C8#[:/[::46C
MB`NG>?S:.6XTW\@/9V].SAH-I_79<5W538#)SP'BX$BQ"#^OC868G-7KT^GT
M:#9@P1%EH_IQHW%27Q+6%I1G,X[7J*<G2]IF_?OGZUMO#"%R,>$"$>\/EVHF
MBZ]Y>GI:C_\K23D^XS'_-?60B`U5*)>32Z&^N4LR5SURF\?N2?-HQOV:L@&C
M`=S`T(F[/Q/S"9S7.`XG@1([?C9F,#RO(4%"5]FQ\?:DH;A?M2GA-,`^$N!?
MH$!I>CL&$/R.H$C"`W[-4:W?W70?5$">P`1'X62,6(@\B`3V4,"//!K6%6W=
MH-&Z$EMR>5$0V^=:"KDF/LP$$%]UOWBJ&MZK!+'O4&^MTT"A1=FZT9(^8TB&
MB`]B7"+NCA":U)4QZQ`(OGP2F]=M-!-X7B6/?[0XE]VW(\;D4%AV$*`!!'&W
M/[+IZB5+V49\W"*^^G/Y*\+W*)!2\)9H(\;F<H!_0T$$&NG-^#?!;[%U!1'S
MEGW(CVO(IP='0E'G41C&K;D2WG#)/V0TU!EXV2_=10^',A^8C($R!$9<"DDG
M2@`4U)PIX-%8R'^5#F&?P01A_W(V`<)!*M$38V"F[F?";3]\1C9(P#NV";R%
MB(7A0<IU8`#R+)]MXX(!4N[PH!-@8MZ7DX*0GJ&&]T2E)U]`/RXT;-:BH5?6
M;`"4"<XM>!'#8MZ!">58A\<FI;40I%1*K'YBC]6O,1K@``L,!A-$!G&YTK8\
MCT9R,NZC.1H$*KC+)RP"?RLUMFGE@+Z5KU,J\&YC%OO"\H;X-Q"HU+V/V$YP
M9K-7$<<<0]@7NK]0`4NAB_'*HJX$/)EJVA?2.\#DHD7@>]@J*FK9*H&/7O$$
MJ#?V`'4KJ/=S3`,I%U?9F9CKDIXT<=G),PQ!VM*/)2DJ!F11']")\DV=L7Q,
MJVG?G-FF84B)$10ITDK@D%;0OGFOY?MX(4,?8;]+VFB"A1(H/U?)X:@$)+GJ
MVC<'WH!`F(!_B1C!9,1E9A6%49Q.=6"(/>WZTH"Y$GB9&,&^67%E[I8+F:WF
MR$)6.](8K5J;(#YB"5<U5;,H#8-^?6,[Z</+%\N?/6V0W0KY6Y7/>&_8FP"+
MN]K;3EE1ZR5NF16)4G)5/!&!C)*"OJY`GJ8MNX9_`QSD<%'[1QVXAX#&%==$
M'.V4H^,[Z*9++@#IZ4:KNXW[99^`2.4"53#S0SE$N&#Q^K$8L"+.:D!6J+^-
M^V0=F##P<&P(;3UCA:P:<*QK9I95ESQ@9$)Y33GOD0[F\::&%*DW7&R#-'7C
M1<]8#7R*M"].IMWR(7O0KDOD?`]*?I,I=(7Z@*FD1OA-<#)0+)YRW/)+Y82N
MZU0\U^3SE"M[EPA@P`W2F4W*`WI0H<$W_2BEI85>]*?2O1*2'I[I3S,4\U8)
M+0-+V%<WE&(9!>-UND/"DB5P;@!>);6\5&&DF,8I'UN>>(+BA#JW>!70Z9/4
M)C(:/U!I(D.2DA,KZ3M*B#ZC]UBJ=S&_X^!WR<,P:$G5[N,JF'Z(FS92=N*X
M:Y0Z8":_/22IL;ZNM(U%BULY5.`"2<W:-%1QJ&@EG,-0<:3RS&![R4)^#B"V
M-_%;(64"_]ZFE)'+7G$XS4ST?TVD,H!6LEBRZFV]80<&0@H?'\KK,PAEGJ+;
MVR_DK3BB!L9)0/W;IO&Y+O85)HAX4M\VY?K;%CJV9X7DIDD2$-_:!***)ER%
M$Y`!Y7*FU(PP'ZO%P,(5"^*LGK?B<!H8)\'TGSU%V_1R5#V)!>F1]AB1$73)
M%<(L/KNEA%B69+*&G#EO18':PC@)4.^>%BBYQF$@<^<.+/YV2?;N[0W@<!`Q
MOCB.[H&4<Q!D57[WT6J5P7VL01/83ZW*AM)*)9<K.\D9V<Q+EMI]@9T:K*AC
M/-:,#\4'RYW"Y/K15DYAU."S<PHS,RZ=PJJ25*$RZU>9'N,,&RT]=R_8--P2
M?JO*6SEVZ!*9T3RV$I[52,D77]`\WG/X2EO>KP@SR+U9K=%NBT8.NQVV)9"I
MZS-;&,O"C?4<`SRLD!_CR5F-E'TK8I+`TQNN7F;4'DS-8;'/2S4@I8^JYAG"
M0I^4>GH`/K^2ANAR'JD7&O6&Z_?4Y,!:/`#UMB/U1!>+=FNPTHCO:L1]'A[)
M68NOBG8Y`^9A#NKH?7SN7LKT+V),QDY^19DR0M[B>]MF*@GG;@:S[WY:]CNF
M^L`P]3=S0LU(WJJ9`P*^B[H9._/&R;;EIXZ>T!R9J9IA$'N&YL@,*8;AX"D.
M;2VS8;22"'?4-<V`[W!*2]?:$Q_+TG5=^DOOGN*M7B7O4:Y>S2T^"+'+"G1O
M71RTY&("=L9K=?9D7,/5@27^_XGI#^X5,%8.YR)#&)\,RXC\[Q]>U2N__`=0
M2P,$%`````@`J(4,13;WEH;T-@``F'\#`!4`'`!A=&YM+3(P,30P-C,P7V1E
M9BYX;6Q55`D``]M\ZE/;?.I3=7@+``$$)0X```0Y`0``[7U;<^.VEN[[J3K_
MH4_/ZW2Z)=GN)#4Y4_(M\8QMN6QW]LP3BB8AB1.*5`C2;NU?/P!)4:2$*PD(
M8.*7Q&T#X%KKPW5=_^W?OZ^B#Z\P16$2__)Q],.7CQ]@["=!&"]^^?CM^?K3
MCQ___?__W__S;__OTZ?_.G^\_7"9^/D*QMF'.]QF'L+@PUN8+3]<_?/351!F
M2?KA]W*L#Z,?\&`_?/F`?WS.(0J\S;]^F.:+'&4?1N-__3#^,CK!/_Q\,OGY
MRY</T[L/GSZ1ST1A_,>+A^`'3%:,?OFXS++USY\_O[V]_?#])8U^2-+%Y_&7
M+Y//VX8?RY8_?T=AJ_7;9-MV]/F_[FZ?_"5<>9_"&&5>[.]ZD6%H_48__?33
MY^*ON"D*?T9%_]O$][)"4$*Z/C!;D']]VC;[1'[U:33^-!G]\!T%-5VX39#5
MGVD.</JY_.-'(BXO]=,D@H]P_J'Z\=OCS6&W,,X^!^'J<]7FLQ=%^$N$AI^S
MS1K^\A&%JW4$M[];IG#.9''[?4+Y*:'Y7\AHGWM0@W^&,9DSGP(X]_(HTTC;
MX=B:*$U67AB;(;0<NA>=Q1"?5G#U`E.=1+;&[4/A$A.3^OD+_%0SKI%.VNA]
MJ(V3;*IUR50#%C1M"1(-[F7QZA/9-K^<3;X4HUPD,4JB,/`R&)Q[$=G8GI80
M9NA;[.5X-X9X/]GGT?.S,`[SU7KII2O/AWD6^EZ$?O"3U>>"5XE!C9/]X*7X
MB%G"@C8C/+2_T).AJS_S,-L\>R\11!VH;77O2<HE1'X:KLDAE<S/<Q3&$"$O
M#I[RU<I+-\G\*5S$^-SVO3B;^GZ2QYBXQ0,6EA]"=`DS+XRZ\*#GN_J8G]5$
M3&LB9E)$/,/O6=YIUFG]?$]1/,+(*Z<YGEFI%R-"/5X5W1$6C6B6X.ZH2`[<
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MQ'Y(T@"FOWS$/7*$*4F*.R%9B>4[\&>R'>'9>!45W?`*@@ORP^[O48)@\,O'
M+,VA/9`N(@\A?&O-$O^/Z?=0:G;M]P%C$]!QM`<<*&MX!#!2>&`B>FQPFK1=
MMG10%%0.&X.)"3A8:C$.%C09TV&A,O'7P0-<-O62QG!I*U:-`5-SXPQ`3_C.
M#='T`0\)TQ0&!;EW+<4H;3]C]P(G1J"B:6P/8:(O!L9^QN7!,8#..P%$[05.
M!P40BX<M0"-'$+KHA!"U%S@;%$(L'K8(C1U!Z+(30M1>X.N@$&+QL$5HX@A"
M5YT0HO8"/PX*(18/6X1.>B!TJ&L@O]DNWN>W1%+J$KW`3XY+78Z'K=1/S4D=
M-X)=Y,[J!T9?AB1Z'AM;Z9\9D_YUDJ<=A,_J!D9&%#"&9,_C8BOZK]8/A"E"
M,$/3%Y2EGI]QSH!V0S`RHE"1A$)%*W9(MSLWVI*VBSPE3@#2&.RU!R,SRA0Y
M*"CBY>%`H=V9%^"%AY;3."#_(X:'5R\B6OUI=N&EZ2:,%[][4<Y3%DOU!R.;
M[W8V"`S=BBQ+SH"(=]RU%P97W]<P1A#3/LN6,&WQS8%0HC<8V7S7JP(HR9"C
M6Z+L5@A&-E_RJI@<D.[.`W[K\/$0$=^@AM?'/>0O&W8W,++YAI<^GD0LN+-"
MGJ"?IX59?)V@D`?+7DLPLOE6ET:"0K4["Z3D0K@O@9'-![KBG8P0ZXZ&ZC;T
M7L((BPP6/HODW;1,(DP<*KU!)*[)LD.`L<VWO,HC1H4C=Q9+@VKY-PZ[$QC;
M?/XK02!$D<*:,U?HRB<859Z5F%O\FS2'P2']O(U0?A0PMJE,$*#"V#G5N',5
MVX93<A=0J=W!V*8^0@>:3+;<N002S^<MN6+8**W!V*8>HA-*#"[<.>]V?M5*
M.R6O&QC;U#9T@DG$CI-733%*-&9L:ATZ84-G0H?Q4SLB<E"`L4WM@MX[(>'%
MG1.F$;@PW0N[X.G`V;W`V*;Z00-4`M[<.8<Z/9IY(K&IS-``')\U=\ZCMK58
M9&ZBM`83NPH-KIB9!@H:%\X\F,BB3V(I0/:;@HE-?44G-&@LN',D38,@+#_]
MX(7!37SAK</,BSB0,'J`B5WOA0[(<#AQY^!Y)!%P,0RNO#3&9R/"[^I\E1>/
MZ4LL:9]KK1!W!A.;FH5.L,DQY<X1=,BDTI4!3&QJ%3HA1&?"R2<1]?[3PPX"
M)HXH%S0\GI@,"I#\W`[4M1RZVTX'\Q['*TOQ>QSO>QSO>QSO>QSO>QSO>QRO
M:>^K]SC>]SA>AP%ZC^-U':'W.%[7$7J/XW4=H?<XWO<XWO<XWO<XWO<X7JH=
M]<%+9VGQ!@L*.]X#3)^67BIO3F8-,)RX7WE^W+D9MVDN"$33/%LF:?C/G=)9
M"-Y^1[L1PMU!H_'ASB691NL-0KDR4&4GNX'!?4':\>#.'9E&YRS/2.454E9&
M$:5&3[LAP'VAVF/$'4MGP_FDP_DET=MNF+`*;I+,Z+AW:\=.X=CB]+(;-MP1
M*QH3.F[GAC`2GE:,'G8#B7MALV/`G:O[`9%RAQ2OF]WXXUX([7&QA>E'^^X;
MK?HXQ];W$=F<>P@&6&`DEX=78IIZ\:(0]?EFU^3!VY!?3=^\-+B5\>7H/;@-
MWP]_"8,\@O@E+R(?L>@7NHWH^H8-CQ,=H+)TL!KE,FSGEI(5_!6!0TNKG0M.
M+#H1I$^2?9;=L1!WYGC'4AR01#'WW@H*O31,?,ZVW\T!MHQ]P@SK[S-)IS@=
M\1BR.J7<\S.Z6JVC9`-A<3.>%50(S;O,/E9]C$QM`O3YP9.!,^#^PR/<9T)`
M6^VL^B$=%\1]OMVQT(CN38UIAZ;X0?FZ?3&2ZF7GF+`_>CPWQ(-;]82R^>*0
M$HV3T^@@:(6D.:D6`)JEC^%BF2'%V:,VIE7GK"--&F6)".R,Q]0[Z:EI?.09
M?NV%:6&OJ)(1QLW,6'?00WD*@UG\2)(]IIA<W.`^B=/M/S'<(9+176G]C@4U
ME@[Z16HL;=^PH,;2C2]CJ]`IHF%KM&I)G&_J'W\+88K16FYNX2N,!*HNN0$<
MT(%IQ5PPK42R<.9I4I-9":"XVQ_2+M15*(UC6YTE#Y,`9DEF_^YH.Z)R.C+L
M[BF9:EIOXG6>H8+ED5`KP>EE5=&DO`H%J%+9<QJ[<2?LQ@[HEPQB-W90C42C
M<]()O(D#(7`&P=NQI\/QEQ7E4#ZD9W/*_6^:U60UKH+%W8^35$_'L%;5,H:?
M79KDX\Z"IB:]Y2QE:GLK,7BZH*"O:1:?_&/4DG9M5FO7IK5V;2:E72.:PUPE
M8P]C)^I'#$]?IG-X)369$4Y9&B]=0Q]1T:49&-I&JT<@+JBU$/1_6"2O>'\(
MR[T9_["_)>-?@5NX\*(KS$:V86BK**TLJJ1TPM2>`'0^-;]B9&$I:6!J$_:;
MV%(+,61V*-@]8H<B5<OJEX[BU:D^81Q*T^JRP(]N;K>RHO*@33[*QG]`J3/:
M"V:YO?.-A#>M1&\SV@S+F[D:_^Z\CICT$FJ%RF6)WH;4'](&!$E`%-%L\>?^
MTM4'IB/V`?.HNF<2N//\)=ZKTDV39*%FDM/+JAI+<FG1$>0SY0QBUWF*Y9JG
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MS:+7`RP)OAS2*NR(;=:]5P'OL)_=I'IZH*-SI>/NRC`*;Z.*XV`;+\HW#[/:
MV\V:UT'X0FX,)MOO^8XJW?%$#KI:/V(GY9[[WF.'4M)]1JKYR=S$?I*ND[2X
M5U]Z&9S-6[_B>M"(.I-:E8.<!#28VG-!30C.W$?+:/\[F"V3X`8?(B@C^M39
M6PQ3M`S7^#GEXW]["U[\M/088&Q#,7D4^#O)0L=*9QP0#<4JR>E*;@,W,2FP
M&N(O%M/P.DE+8F_B#*:8T*F/_XE"QB+7,"H8VRB.<!3X-4G'I?NUZ63C8QM%
M%XZZ%TA*P1V],M.]X`IEX8H0_PW!>1[=XDMR)_]#VCA@;$/A=-2)H"P/DV6Z
MBBS25]_])<D@]$BV)=9N3VD*QC8T4<?;PADLNU-(H*=:?+HB<C%G?"S'!V,;
M*K"C+FEM<C)8G>P@=[S$M:YL",8V%&%6;FH[AG54/&`@L=U0`G(?E`2%UP>,
MK87"'@4?$>\.53UXA!$YP/$%+]L\IUZ,2`]\Y[>45XY!SBTG]%6VJ]4B!BPQ
MGV]:?Y$N6*`PGH6L;A)0,,ZEKARZ$+VJ?=;O\2KPNY(?Q('D;)UQID\;)=Z=
M45XV:1.ZOAPVMIU634WH8N#<RY_6&R!'G)%,(76$F-T[N$K2T(N>HL2+_Q-F
M&23I22Z\V(?I!21J2+ZY5K:_U=1F]%5`N5@J<./,(KI-XL4S3%</>8IOQ0B2
M&W&8E7%V%YCM14*NW>1>L&T1"$ZZCB-:C!DV=.QU%X0[CDQL'A@<"#?BCB/:
M#C+N`:;J[!#)80![Q]$GAR-'N3NSY`B'_SU\NTSSQ72]CD+?XSH&<]M;#5+N
ML0PI-P`.B^9P>(0^#-<9.;46>42Z;3`!:?+J1415_.WI.O#XR,B/8#5`62]6
M2DR[<R(SKB:7.214/R?-OU_D:4I*=K!=\32,:B8*NL/=7$V7U8]C@\XUS0_?
MA1%$61(73K>51HRQ@CF=3$4Y]X)(5M#4E2M@UIT$EP(%OG+JRG<]_KL>_UV/
M_Z['?]?CO^OQW_7X[WK\=SW^X/7X+%?*UL=O8I2%64["/4HZ'B&"F/\E'Q>E
M0:S6()$&1Y4E@R\U\3S1`J+FSUBM5J)Q#:HR;;"&R2.^U1+_M#OOGUX,V?'W
M[,96=:#2H+!(-Q@`?.N%0>2]3>.B1*T7;_C"932WJK:4%B^;>(,N^__AK2!"
M%]XZS+SHUS3)UWP)L]H[HP;DBIA#O0XW?(:,?\V]!=ZS0HSL%*'$#S&Q@D!V
M3A=WU'E<40LXT.&:[F).4#/I\6P^^[F\NF,8Z9UXTDS\J(94H",F-'0VG'G9
M]X?$D:>]-FS<R^_5,QFHC3A;P>QGP$&CW1D4.F;NLJE.49+^`=T&G^7310J+
MQ<HXPP\;&4J!9N/0IC-G\.U;?XNYP=.:F<IC)CQM&?+A"7%'L<'B1UVE:/F`
M["/.(^BU+W`38I%_)JJDF@+^RXO7QTX.-^9TI(A91+TY6=^&/IXM\))4#DZ*
M!`2E(F.%]T!,2_C/PA].$H1.@]E)\J:"3F>VC";SB1%>A6&\>(+I*R80R2X4
M44>+6=ED5XL,"P8/SZMXX2W*K5-.YLP.%I.?2<J:2[I!#7+C"G7GQ6KBENEK
M,>^8I.1EN="A9=:DDLM?4!B$7KIY\LB56$HEQ^IC*#.8594<CU=W4CXUB"/)
M3F?SIO^G2!\D[FPJRY>\RHX+`P,Z*;:<44R8A]`5%9\I+(_PS'F(/+_:U(5'
M&JVMG2QIBBN"<K"Q>#$9:T/?O263'DMVMY,(K;M?L2IO[AB-9O,YOO6GB!C<
M\4[!2D+,:VXQ'YF*R.D[&(LA@U&#.6%H-G_`W\*+EJF@W6]G,6M8=S$S.3&I
M_BZROSUX8?`MQM^H[_DW\7]#+WU^2YZ728Z\.+B*X"MDJQK5AK&8-*PG/!T8
M-:E.EZ7F^0U&K[0PEB[#@+$U3<VQT-LQ:E#7($_-,DPSJ&'U;0<"$VOZGZ,A
MV&#5H$/<[`T&)4U2^\%S<IWD7"P[#P@FUC1+/3'MQ;)!1[P[S'@&8^(@?`TA
MR2RY=1.NHD>9UQ%Q3S"QEH"^)UIRO!G,)=M^QVU5\806N5=LLP>86$O]WA,&
M/D\&$\ANBPN1N@(P>$Z:^14JEQD6#A)=P<1:"O:>@$@R)\@7V\\V5W_IZCNQ
M$2+XD.)9H5`UH=,X8&(M$WM/S+IPN@7PI^-="%7O?6`R0"6#D*/=*]B`Y(,@
M+,<J*;C,H20$HHY@,E1-A!1K-2@&=!.M_-X725R2<YVD)*U/&%?Y[/&_7_#U
M@]Q'\#(-DX`%5<?AP&2HNHH>#->P&E!:-+Y>EB1K4"!<;U*=P62H"@II]FJ`
M#.@E[K#,5OGJ'KZ5%:*N0W+;#^/%/80!+'=FQG227HPZOP%.AJK-T"V%>E88
MT'3L$0D?/7Q;"LXW5?0A4S//[P9.AJJUD&"LAL.`<@+COPA?85R>S;/Y["4*
M%\7,8#Z#.5W`R5#5$0*F:@@,*")VE]7GY,HC^H_"9".^K;>:@Y.AJB`X#-5B
M-Z"`P.^R-/NVOH808]_R8&9)GMT#G`Q5W<#GJ9:_`35#]67\'+A(4`$_N:H(
M9+_7&IP,567`YJ>6N0'-0.LJ7Q8?*FB?P^).(/7D.>P&3H:J)Y!@;&=V-55H
MOJ4R>B1%HIA&'49[<#)4Y0"/HUKR!G0"59'[(AWOJZ+Z6:8O.!GJ:U^6NQH=
M`T_[UK(L*2&NR6@V;YLK\)&UM5A(;5UR0X&3H3[[.S);0VE`"=`B:6O;:)!V
MOJE)DX*0/P0X'>H37I')&C(#+_12#S";;W?E'3U,PRBS!S@=ZKN<SU,M?P-/
M<OQE'\/L+8B#<E%ELJRYBN_H'`!87<#I4)_D`J9J"$SX!A3@AW[Y+*K4:9CB
MX#5$2;H1'3J2W<'I4)_L"@S6,!EXPK<VS9V=:;=M-G;-XN"3.F)D!@*G0WWP
M=V*U!M&LN\'VJGF^^2V)@C!>U)NNA(\!NS,X':J60)J]&B`#2H/&8M^^"LXW
MNYC.ZY"M.)#H"DZ'JCR09&[G^6OVJG"=1]'FDA1PAT&5:[#T2/D3\_*<2#QL
MNXT&3H>J?.C.;XVIB02_WG=BS*L-$3G^SP/^+LRNOI-P&?:U0]P3G`Y5+2''
M6XV+`:7$=KEO27CDW"=H;<'I4-4*+&YJ:1L-:B@T4"C'!]TMQ.>?@C<;JR<X
M&ZJ60(ZW&A?[.15FV7*7%7L:!XTD--6ZI<`HWQF<#5"]H,9>#:8!3<,N$PU'
MM]!J!,Z&JDTX8*,6K`']P1/,LK(<417,4#C.B64MZ@?.AJHQD.&L1J2/JD#/
MOC5-LQ!ET^"5N.04P2G)QHNRS:\Y\97*($2[.I"\_#!*XX"S`2H5.G-:H]U'
MIZ`);=\GYRJIYD<T(`UAA)CLJCQ@'-PGL5_^@X>XZEC@;(#:B5[<ULCW45;H
M2L..WQ!EJ,UE3DIZE'?=TA7@'KX5?^+G9)<9`)P-4,FASN(N0-8^L(2Z<U*/
MMYEE8DH49J5ZYGRS:U(=2=,W+PU*9TQ2V27-B[VJN*8]+[VXLHS_6H9GQ4S'
MY&.3`,X&J("Q(:1Z>MI/`=-(/U1&BK%CZ41=P-D`=3HR3-5P]5'FZ('K$KYD
MNZG&<)5C-P9G`U3]\-FIP;&?\*_*"5]90V;I8[A89BV7LIWMOOHK&G'PZS0>
M^#I`G5)OCNM98%_3])`F/H0!(O6]RUUE^NJ%$;F5$G<G_)LGB.^@(;F8<L!7
M&09\';#V2971&NH^>BC]4)/+)WEQWA#Y>]%#_A*%_FP^+^KS2>+,'0-\':#&
MJQ.7-<(.5,?:70M:_@H-*<C=E%B]P=<!*M(4^:OQ-)B]@^H>W""*I>B4[0^^
M#E`EILQAC11#%?9YQ_TM_E!;'N0W+8%@^F`<P/IIVA()82(.\]4:W[)7G@_S
MC`3\H!_\9/6Y$`W>,M80LTSR).$G5F&.N(09/AK0Q^/O\P4I#Y%7:)%J>FZW
M64'Y&[R@,_AR_'VMSLC-)*](PLW;W"2'`$;N)EX4'2X7)9&S]C1YMIAI0C\0
MLH/L9S^),[P(KDI[PR\?$5Q4!N/J[U&"8/#+1_RD@38N+W3VSC?/^-N"?/,2
MO8%+B>?%8#(O+A)\.I.PG,TF_K(P8[E$;V`YZ;PD'HI@MOC[.X'I2/IY\ZBZ
M5WJR3#Y=$RLL?DAM#VRFKI=<3G346.PX@\]UGF*)YBG$G%V'W\E/[*K5XD[`
M9E+[7DAQ>7(GF7T1KBNXM=1M@!$SZ)'O)DUN',-!N%`:K8`9JZ'TE:(E1HZD
M:VJ=V:(ZB-J1`U]5YNX=WY4?N%#ZK7;`AH64,8GI4M\GUQUYEZG%Q/)NM@,V
MS)UJ\MXCUYU]G'DJW</MM9Q=[T=]$#"R8;?4H3%2XW$``']#<)Y'M^&<I_Z3
MZ`U&-LR2'6%1Q+;-I3.[))/>7],$==+G%1U);?N_*I(U@^ZLS*GOYZN\L/I<
MPG4*_;#,H`K7$2QD'Y/Z$FE654QFLL;W#M;R"3"R8;_4.C-TBD)';23SQW?'
M`QN,G-0V:=D%*O8$U9&.:?^\3S)8>;-;,GON-!3/J1<49<*WCCA8=*6;:_F'
M*4(P0S+6T,YC6C62RM$J;S%5&,^"^;0/1D*KJAKKMDRLK&#@;70K0\]XV,@I
M(ZBB[-M04GDS5RESK[J[4-AVS9-TX?`$J-/<J%F$EG6$W65YC&+3*5SA4[O*
MD5Y3(*@ZS>MDQ83'FHL4*8N(=^;MR_*3.]\T_R*R$$D/8L:@9V-G[\2[.Z_E
M)G%"KXC#QF9,@0KF)R6IBY&KN7)R878"R!6CE2&DCG%LM3+I"4XK2EM#-EI)
M0PIU=M..*CKEYL3:3K+&%RNMK5U[H*Q8&90;K.+>T'W@@^PBB5]AFH7X7^0/
M^X[O+($K#6+54JCQP=V)<X-(4A)'7N;P.=D&`8ES.LN/8,>$V$WB%-34&-5\
MNB/H_[!(7C'SKQ!EY&R?5#\34">-4[W\+;@I_D<VA2U55]_785J7>J/`*=G3
MCME0!XP*#+IS?6Z'55_C$[1,[L:YH[&ZV#$3ZD!.AC-W;#MM*K_%7FF>@L%E
MB'PE["A][5CTS('(8%%@Z>FE=VM:"ZOL_80#I@*.T=Z.O4W;><9C:Y>@Q_9:
M*ABJ6.4LFV8S,+*6*$O3"MGG9@N'_9#Z]MK=)GRM\NT\I&'LAVMJ83RU`<#(
M6AXL(YL<C\\MN/:CZ8OK;!GXD2)2D!Y?=9=)A*E336ZG.!(86<M,I0MN=8:W
MN#.B[H_IRW")I^<K/@CPO;CR91@=VYEA1\*MA)L"I;4%!X0=%2+7@KV6%IP&
MZ!)C;E[[Y`X[EEHM]LB^2P!%_@QU=8-H=^P)RF$OEH.66U+D"+JF=LBB=L58
MHRCSOTJ$D4T7S;U)3)?Z/KGNR+M3A)'-L%XY>>^1:U#9_Y2O5EZZF<VOO3#]
MW8MR.)OOCIHZ<5]\[J$0S>:D1:$=N$L"*#3G:!G<D+%?#BZI*Y)67@UB?>>E
M?\"LHJUANIC%=]!#>5HZ%G$*J4L/8,7VK!<&JE%5GGUGMLA:#E.$\'.O\'YH
MI>?D;)O"OE:,X29Q5N'<'7L0C=K'$/UQG4)X@]]@*439(WU=JPYAQ>AN"W&&
M`-RQ*M&GZ1KZ&0P$F:9%72U:YJVL[3;G.DQ-YB'^/8DPXU&8;3JL;OH@%BWY
M%F$_E($[UBX>W9?A:QC`..@!?W,(B\X`%L'?EX`[EK6:ZIMXG6?H(4U>O)=B
MFA+AM+0I/-39O2TZ#AP+<#[S.@QMC-=6\=*?S9N%8J^^AXC4+"O+WQ3YLR&M
M"HQ2?XLN!R8?6RKL"\QF?5"D;!S;O.>LUY-4/XL."291DV%[BY8#":L/C9R5
M==>>J;-1E>A7#.5M@J2"M.4&L&H0I1!VOOD-!@L\.0K'=G(H+\/U^>8FQ@C!
MIPP?R$5"'T(=_N/YAC88>:3)VUI-$V'5C"N`7FC9/8)PAFTTWG%WOKGWB@2;
M?`LRO8-3YN1C@"Z:>'O"<49YNJ/PWEN)\S?3FMLV9+.%+`*EQ<-?"Q)'#-YZ
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MHT`*)79WBPD%^L'#9\E%U]7@?_(RNQ(W=YA4/XMY`?IM?PQ>=#B:LE+RY809
M/$6*8[/ZZ#:*@;5XN)W`R%K`A_*2$3*BP\]3>*G>4B%*F<?N`4;60BXZ;%,\
M+@3.EL=T_"+16V&Q&I%7I/@@UTL8^V'M"'9L#[#;)%Z0Z(-M'L$=A;<2[E\2
MO2WX?K&I$CEL"7I:\+*2DS#C%!"S,VR_J&/G<;?O/R6!*$.)J<*E,^_;OOG`
M;6?S4!*Z&#CWW*)Z`^2*&<`04D=(V#Y]>4FR[#Q,2/)G;UU<.M!%DJ[Y2<8%
MW>QF!Z'.><K%3\R$P8SN<)6DH1<]18D7_R?,LN(I?$'R+Z<7D*@P!%G>)?O;
MS1LBBX0"-^YX+[%/T_/-!>9[D9!X%7+)VK8(!)>)CB.:\8,ZSLVB.\M#F`@,
M#H1G7<<1#7GS2-]8>H"I.CM$<G#FCN/0Y'#DMN3.+#E&01SRP>LP1=D%;DP4
M.L_DH)O-;T,?"PP?CFD2Y+ZH5([2*%:KO?18LI2+@3+CAI%\@GX2![VAE!_&
M:KT8`U@J<6[0M%H0\[P,T_Y@2H]BUVW*`)A*G!LTO>(G7)0L"!'5UZ?K=126
M;JE\`,4][7I>Z05-CEN#%2O*G1SS0`Q:^+GG16R_3WX'NWY;>F'A,FG0U#J=
MXX=U\?%[F)&O(H'2A]'>CJ.6&2QX/!JTO=[#M\LT7TCO6ZSV=ORLS$#!X]%D
M"ASHPW"=S>:/<)%'I-L&DY`FKUYTC3G^]G0=>'QPY$>PXVQE!BXUK@UFO[D+
M\:K-DAA614I$OL&L]G9<K7J9;H7\&+Q1LPFN"4(512PD%(:PZ%'%E2\%#T6N
M^"]8>_XF?M/?)"C]33+5Q$.<ZIW5EZ9[GBVW'$<2Z;Y*;B3J-+(<0Z3Z'=$M
M1$5>M)DLP<J[2\@P7$*D\11;J]\=0HYD7GEW"'EW"'EW"'EW"*&_8MX=0K1C
M,O/^>`R#!;SWRA%OO9<D+5ZV?"Q$_:Q6AY'&0((+@SK]*1[I]2F)\F+C%&P^
ME+96,YO([SATRDVJX%,8_)9G_C*,41*7*^H1(H@Y7,KL,[+]K1JAI>6OP(U!
M17QA3+O!5_";L&5-NT[2*;XXK+R7F_B*U&"--E,_S^#=!D9)&-S"_`^X"@7:
M2"V#6S5#2Z.IBU6#BOYO<?@*4U1$03[#[QZZN\3TXM]L9Y_,&E0:Q'*R#EGL
ME'DR:`+XCV09H]^2]1]X5]C1Q<>$U\=R]@Y9"$0L&-39WWIA$'EOA1:"+^?#
MEG9-P=+2I1,NR"NO:ZMY@'&,-M&K%XN."WXONZ;>3IL)G8FMW'\RL'MX*XC0
MA;<.,R_Z-4URP=.9U=ZN+5=^U^"0OWN;&;C()ND*GPK+$,ZOOD-\G&/(J\+U
M@ANLJ*-=JZS\W56&CQH!E]WDCQTO8<:P>PR]>P^.W^,E#CT9#!F1C0=,'%J:
M-4C"&2N`2_/#$8."2Q/E&$8(;9Z)0PR%&*FZ)AH/>SAV`(N5[#&&8%-GW9V3
M6BV=]=B(HNDH[@Q-'H:<@WIL1M'4(0GUF)E79H]>9ZX=7:3MR/5`7>Q_E4S4
M8ZNZO[V93!?\`<'NB+Q3*NJQ516@G,CW"38920C3,&%I*O9:@+$1E9[)(Y+"
M@4'K=/DAYGONH`T8FU'5"0\\FEB8@MO1:O">KBXYRX=7-Q$>X?7Y_)8\+Y.<
M.+WC14*"7#,(!0%9O#Y@;"UG[\'\HPA81/JQ!'V=Y,J";O<!8VM!(>J"/B3=
MX"$U7:2P<+CGG5.M1F!LKSI1GZ/J@`F3`;3;;_&WW;UF8&RI4A!#/CPA[B@V
MJ.SK*D47SJ^.XCQ&YIE2K70)7V&4K`L2X^#!RXH(PC+Z?TN60'>G.A"8V/`X
M8DY<VIVB"TOFH%+#@T6A#1\C%:&SZ389E5I]-`Z>UDF,DA0&6_].17&+1P`3
M&\J(+A#(\6+0N[NE"I<$@M<'3*S5"I(4O8AZDX_JR//+,VI1_$=NU^=U`A-K
MY7QD=W@1^0:OA8V(KSLO]A85'5)BE^D+)M9*]$A*7Y8+@X[63W#MI47D"MGM
M8)9%*C#(]083:P][22#D^3#H3HVG0#['LR$G,5R2`/#Z@(FU9[ZDV$74&_2D
M?L0?DCY2J8W!Q%J]'$GQ,LDVZ$W-4T?(U:"4'P%,K%7/,90=XI`_AYP<\"LP
MSN$C])-%*>PZ+\L=S)9)T&[P3VIER^Z#@1-KKV5%Q-J8]^/8&1OH,_27,4F+
MN'F"Z2M^'Z&+!'$KO3%Z@!-K#W`M.'+8<F>MWF%99#`F`6$BF/:;@A-KKW,M
M^-#X,?A"KS)2U6YJUY"9X8C2%)Q8>X_W$C:/'X,O]"/G3CNQ]GKO#XXBGP:?
M^?MYX"[II9*9;<&)M6=\?QA8#!FM3]FL]IMLO"C;5%]_3II14RP0I`<`)];>
M]?V14>+29![5\M.S^=9;?5<<G?D<97<!)];>_/TA$?!E4!M`22U=>BJP(&!V
M`"?6M`+]`>!R95!I4!M7XJ!I:R3594N=*%LQ(^@(3EQ4$<BN!QGN#$9H;^\.
M>'_T@C`ABNI7>.>1)%->Q(*$VPF<#O,1+\>9R3#NAS3Y'^AG5XCD9\%'$WG;
M<#P1#MJ"TV$^N[D,:8G:9EVCDK>X?N'0"!"?TPI#@--AOKJ[\%FC9N`YWB#E
M.DDK6B3PV34&IP-^DC,YJF5NX%7>,MD3N$D>J6U*^R2]3A+BQUG4*`A6N"EA
M(6LX-'(=&!3&`Z<#?J_W8;H&U\#K_3J/@_9[Z!M)-U4;E0AMY-;X_);\-[ZL
M,._+:L.`TP&_^3OP6B-H0!\@(J>(ER:$8'JZPM<<`YP.6"N@RF@-G`'-P'U.
M6,4G*E[HA"46./OMP.F`=0`T9FHA&WCY3U=)'F</7HAAO_+\9?5=EJP9S<'I
M@%_]')YJR1MX]#]E>'E]6U]#B#?$UO'']#9B]@"G`W[F\]FJ(3#PP*^^?)D7
MIC(R`WC*>7IK<#;@)SV;I9W)T&`D!R89A?@SW.LPO34X&_![GLU2+78S$<CS
M)%T1R_!Y$N?$_$4"I`XN9Y5=GZE=41L&G`WX9=^!UQI!$\;V0AD=^GBK+,JH
MO<+@?+/SG,6WZA4'-5%7<#;@E[\D?S4Z9H+2*RW/;'Z=1]'F,HQRH@$J<UX^
M98G_Q]6?F)?GA/";Q,5O.(!U&`V<#5@'T)WE&E8#&H!_>,3@D%U])T8A1);_
M?9+AQ5Z%\N[,J"PDI0<`9P-^]2MQ6>-EVO[_M/12B*:O7HA1":,PVYQO*A+Q
M)*MHEG($D!H)G`WX[=^-W1I*(Q$!14J<\H$VF\]RHE_'2Q[B:;8F+E=,G8"X
M)S@;L)9`CKT:&@-Z@_LD?H3S/`[(2K^)419F>3DVQP.0VPF<#5B'(.2LQL*`
M)N&AK,RYX?E>[IJ`LP'K"O;XJ*5J0#DPQ70&A-:'-/$A0IA4CH#IK<'7`2L'
MV"SM7%Q-;"R[6P-^61$?SC#VRD.I?G*Q-QB)SN#K@%4'TAS6&-GWQK^%'H+X
M8`I+/0=1,8TH"/*:@Z_#U"*(>*I1,E$:;3L='F$,W[Q(XJG"Z0*^#E@[(."K
M1L&$5F#K&#)=8"(6&/CRUL8\J1GMP=<AO^PY3-7"-U$Q;?O=:[Q)1N1>YD51
M6V>'SC>8O[47,_W!E08!7P?\AE?FM,;.P#M^YU&UIX3MA)W,(.#K@%_ORIS6
MV/5YN.NY($Q]/\V+#.=S<L^LGDWH(D]36.1<PL\KO_P'Y]Z@,`KX.LS'?T=6
M:ZC[*`)TW047):W<"V#5!GP=IDJ`RD@-0A\-@*Y0=IIC?:4ZX@##[0>^#E.O
M(,U<#6`?98,>`!L$WL35\YR#&ZTY^'&8J@D13[M(3NLHT6>4#&""GN#'86HP
M%-BK8;2OOGB"^"@-L\TE7"<HY-U`]EJ"'X>MM*"P4\/"T%=\WK%ZBX=L,T]^
MT^(>4P+C8)<HI<4_B2^*PWRU+E6^,,^(7QCZP4]6GPLY7/V9%\1E7ABAC\>>
M%,0^=D[*^I`K-3XBRNQ9N]BT\\VN274WG[YY:7"[38_#FT>]!P=?CK],_"4,
M\@A6MD,>^8A%?Y&QF2<87=\`1C90_%H^7(]:066M5(UR8:;<^4#X#K*??;R;
MX)5[5>:(^^4C@HM*)U_]/4KPT+]\S/`3Y?A/R8(5_!5!.:I6.V!DGY;*86X$
M0<:C<8]E9W(K=>=XQU(</$1>?.^MH+#*HXG/`3/*<>F"6@?8,O8),ZR_SR2=
MXG2D6)C5*>5>W;&KU3I*-A`6/H>S@@IA02QF'V"S9+NI38`^/W@R<`;<RI]-
M"&BK';!9_OVX(.[S[4ZFO\ZWZG(JHEF>H<R+`_P\?DPB$FI,_FCB;<;](+!A
M>3K*R\24N/Z24[",_CS.["N_!6P8PLQ/#N.3L9:>,V=87^9^)3L\NHE+W[)?
MTX2KH3;P-6"S"/O0IB)=?G^=31$+<`[#+$]AS:3!V4CY&K!96WYHLY$N/W<J
MI!>/CQN$<AA<%L462AK+()?&RP1M0URXDTUY,#"R86NU-IDZR4='VF0WMJZ=
MF^\QMB[*U\#(AGEXJ'L70X`Z,D*[,A]W(9FFWQ<'WP(C&S;PX<Y%BOATY,IV
M8R8VQ/D/&"Z6&0RFKS#U%G![%#RD],P31Z8`C&P$.PQUUBH(54<B<=NF(NH+
MS-1\UD<%&#EM=#CVG-8K6!VYV1V9UUO>K$]M)4+`R&EKC&NS6UFV.K+?.S+!
M*<H*6U-<D10P&J29R-8D[R!='=4$W+AK-YX2EN[:DA2`T;L)RHA0M91CT#B9
M7\1<ORB_,!XA@1G_GOBX$W]VDAX,IJNQ:&(?EQHP^ML9MXXO8)/E,`IZ/TG(
M\!/W00'W3R`60Y3I:X4.,/H[V,&LB=9D+9#CKT)F.C8+I(#QW\'F9E.Z6FJJ
MN'&_8-^J6!+@)3"R0`T8_^U,?L<7L)8Z,VZ\#AL2O\&,AC$*_=^]*#^2[:7]
M33!^MQ%J$J.60CIN3-$#%>5SDI&D1$>:K3*?!^-W,Z%^B6JI*>3&'/X=(G*V
MQ`%)(^+C'Y\3\JO&^5,G1#O:Q.Y,$QB_&Q"/)&91Q2=K:1:JY!''SK9P$7D(
MS>:%\^"M1`(%:GN[.1$(*>>;@C"%+`?[O2SD+6#)DK5NN,0/.[G`4X97*R&G
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M6Y$!EXD4HZ7=(-HNBX?B&4)GRYEE]I2_H#`(O73SY-4'A4B?QNIC*-+T"`HU
M'D?NW,D;Q)&48;-Y8QJ*,R4*.YL*N937N7%A8$`GQ98[Z\TXA(X<7L:P/,*A
M5:NDI@N>'H[9UG*<I]R*H)Q5+%Z<63W/849XNXF#\#4,2`I]P<.,UMY0G.(1
M7F8L;MS14AR0^(\P6S["J$SNL0S7S\E5G!%CMFBO4QS)5%R>_-.,"8XDF&+^
MW%V&1T39D>/-/-Q'..>VB8'199A"'_="9:42A#]+0N_Y)Y]<;[NQA5U6&>5@
ME&?5F35Z$[]"A,<6*XU;#>U&R?6'B\V50_K+3@4RS$2!F;^U''#ACIZ_>WB[
M.[4*#,58=2Q[,6)7LC+$O#,;[E]C,CERO;(\J]QS#M);^\+M4+6N.P%]BG"E
MX`R^CX1YP7V@;F,H6LO\7:#%@3M)%0NRQ!XNNU:FHHZD3]VV(#G"WM'KUE17
ME+8CQY*ZV-T[2>ZPZ%;Y2@A`JYW=P*/]F4P7_`'![HC<^RXG\F8[,+;I2"HI
M\GV"=3RR6<JJ(@BJBGY"V]JY3.44M348N^(<>LL.XQ'0[XX>XV\17FQ#>RF:
M`1W?0IKDX<RV>@E?LIL8RR4O7'+H*9O8C<'8AJJS&[9TZMW9"JJMK0HIF*6/
M)*5'*QU>_4=4_17Q\K=T&@^,;23*Z@9H9P;=\4:Z]L*TV!2F".6K<@]Y#-$?
MURDD\=0PA2A[]#+>%BX[!)C8R"35#5D5GMPQW-.HWH;-_YX0`TR$Q=`!3OH@
M8&)#`Z4/4#97[E@W>'0+#DM15S"QD2Y(/WQ;7MQ11?&HO21&41@'/59A<P@P
ML9$Z1S^(^SSI*'#!>(/RR4!^DL>L(T^I/YC84+>H0:/,D(X"#0Q<MC>ELN39
M<_*0I_X2/W,:(98L2"2Z@HD-34P'-"1Y&5`A`><+IDYL*)3LZ`<8[.O(U\]+
MG]N#XFD0A"4M;=I9>X&I[X&)^UHDXP)P+1=^#S;M5\:=#$=U98A]+9GF+4\G
MXL-PEP3A//2++I<0^6E8L#&-`U8Z[V-\%DR&HTHS+0<M">(M)]G>55B5VZYT
M?`.<#$=IIY5IU[*R=UD;Q7](MLRZ>+0PW;JFSX"3X:@&=?/M6GKS'@G>R^2K
MVQ.[UA.83-K/^B0X&8ZVTJ0,AI29_"]:(O-D."K7XTO&H:SC#VGB0QB@:RS$
MAN-PS1/O`B7L"T[<U^XJ,2/*E7W,C8706.H_+_.T/EV+B8I4D50?#)RXKRKN
MQUV-M7WM\30J!H<!?:LB=H@8\39_N0'`R7!TO/(<U3C:K[-:1VC`]!4?!732
M[Y,BHA.65V=4^*8U_WZ1H.P^R?X;9H_03Q9Q^$_NTC;V37#BOJ[W*$+8.2I9
MGV#-0XQL>%[LPQN"C1<]Y"]1Z,_F<TAV0,E3G3L&.!F.;E:)J1I0!S2NNQ0W
MQ>T1GUS%Y.6=Y8PNX&1`FDX.#S4Z]K64#7/S@Y?.TB)C>U"\0R6`DN@-3H>C
M691DIX;/`9TA[UYX#]^*/_'K;<@,`$X'I.>3YJC&T0$-'IWH8NKU@+'='YP.
M2+<FRU`-8A]%&<.GX5N,AWY+0Z+YW7I(L?P1:&W!J?LJ)"[QM7`-^.<UOSE=
MI+#04S7,>C*"IO4#I^YK;*09J0&PKZVAW3]W<0^*M_%=1W`Z'"V,F),:KSX:
M%ZE,EQ<>6EY#ZJ'`:0U.W=>/",BO16S`B:W]U6F&^\5P(R_F9@]PZKYR08*%
M7=B+]1VHLP6WE,<N)@_-LB5,GY=>3'67-&$\5R0!G`Y',7%,F=2ST4#0^G8?
MKU7HYYOJ5[\E$?XJ<P\0=@2G[NLMY#FI,>BCO6!@\`@7(2&1C%<7CY.X%(KZ
M@3/WM1#2C-0`]-$_,`"HLD1L=8DLDSRS+3AS7U/`);X6K@-*@9T*L3$#6CG"
MY92HK-[@;$`*`3EV:OCL^\T4IUEEQ>.]CUKMP)G[*@,FX;7PG7`*F4.$BH\S
M[N^LIN#,?04"C_8:!0>JH9/*$O#/')]A5Z_DAE?513]V0?0],FXE:J*SNM@H
MB]XF15@/G=+<0B%TC@!96SR=\($70=]C2IQ*FM'#A0+H#(#DX-SQX4Q6(@J)
MXF2^K#[6JZ"SY2T-D'NET#5#Y$AR2IU8N9>V<H]882Y%:GNKM=&Y2T,*(?<J
MI-?JA/*6291U24PN9:+SB-?/3`5UDZ>2@!MW\K3M$2C<]:CM#558ES^41.*F
MH\3BQ9G%I`D<5XXCK2@=H1K2\UMR"Q>>7UH6EJ5RFE\"B=,%V"Q[Q)SJ%*4E
MGP=G%D=E,Q">^ZUVP&8Q(TD06(0;3*6\+8XDF-U[S<P4M#<PHP_IUI$TDR'+
M714POC#WVYFJ):]?G#3*=22NY.;YOHE]3%?X"HLD#?PZ=*P.=NN'JXB8RX*.
MC)*L!$M[JM1*2RQ*KB[H9J@,>+=G%D='*,N+P9UXES"I]"7>9FP+SC>U*Q\^
MCI^7:9(OEK-7F)((KXQ<JV9<XW7O@4T5`Y>P6,A`0D%2"\O.W'=TAKA8*4?=
M$4H99DPNR!7Q4ZY]5=B3A95LL,,HA@I2FUQJRORYD[:\61X])Z+!_RCVBS(R
MX"96=H40#F.J./6Q%J`4@^[D,F]03NZN(2:K\'UZA#[$MZM@I@ZQ>!P[=8[U
M82S'H3O9S46DX_-"#\KM@>S41S8,\R&+[B1$YX;>/>)W/KX<D'P'I%GA`2S,
M`MQI0$/EEPWCWIE5'3G477?0+X6!']TIQ'TO8?E_WLPY,BFF:CN;G7,6A*0C
ML[S)@#9^&GKIOG;*]O:<#U)<.921GK=EEK^_3M(J84KG8^9@($,5?2T>+U06
M!;GB*5ZDG\F72;)#_(__!5!+`P04````"`"HA0Q%[[%P1%Y]``#]H`<`%0`<
M`&%T;FTM,C`Q-#`V,S!?;&%B+GAM;%54"0`#VWSJ4]M\ZE-U>`L``00E#@``
M!#D!``#MO7MSY,:1+_K_C;C?H:[/B?4H@B-I-))WY7V<:+XDKCE#'I)C'8?B
MA`,$JDFLT4`;0'.F_>EO/?#J!JI0#P"9]#IBU^*050G\"OFJK*S,?_M?7S8)
M>:%Y$6?IO__FW=??_H;0-,RB.'WZ]]]\>KA\^R^_^5__\?_^/__V_[U]^W].
M[Z[)>1;N-C0MR0<V9AW3B'R.RV=R\;>W%U%<9CGYHZ1%WGW-B'W]+6$_/NQH
M$07[$[+:/>V*DKS[[H1\]^V[[]D/O__^_>^__9:L/I"W;_ECDCC]RV-04,)>
M*RW^_3?/9;G]_3???/[\^>LOCWGR=98_??/=M]^^_Z8>^!LY\O=?BOA@].?W
M]=AWW_R?#]?WX3/=!&_CM"B#-&QG<3)#\][]^../WXB_LJ%%_/M"S+_.PJ`4
M"S7Z7D0Y@O_K;3WL+?_5VW??O7W_[NLO1?0;O@9YEM`[NB;B\;\O]UOZ[[\I
MXLTVX:\M?O><T_7P.R1Y_@V?_TU*GX*21IS^CYS^N]]Q^O^C^O5U\$B3WQ`^
M\M/=E1+.CP>TY*1O_H,L\8:W-(^SZ")U>]6CV8N^\WT9Y*7'6W?F+_3>#UD9
M)$YOW)FYT+M^I&YKV\Q;:DV9&J1N:]K.G/!=R_Y[6B]DNX)<4_.?K]GS#]Z,
M?BEI&M&H?C<^4Z,M!6&A987RS\(#8@E7MUE^B#,HT\U;;CV^_=W[;P42_IL_
MUW9IE3*Q+^-R?Y6NLWPCU/7JL2CS("QK0N+5!?D__^Z[?_[A_7<__OC#NY^^
M_;,YH6_^HUZ!@Q?.:9'M\I!:H9<?X?#-@L<__\OW/_[S#]^_>_?/[Z^^LW@S
M;M@8&6Z]:?KVT_UO_J.QV$$:$3F1=&:27^NY__??Y,M,AXWY%8]9(P9_EQ"C
MZM'B08`8OSY&MLH/A2G(P_KUV(\CT*H1WX09<Y:VY=L#)EWGV<9+>NKWRKR6
MZ!MCE5'!%!`+&G[]E+U\$]'X&ZY%^`]"G;S]]EWEA/T/]JL_R^?>T:>8/RXM
M/P8;.J`_OO_YIW]Y_]WW__G3U=7['YE*NOS/G_[P9^7\!=3&[_[SZML?OO_=
M]=4?_O##N]]]]R\_7U]]4+]0G\TJSFK'$3YP:<VP#(HE1,2.08XDPVX9EA"(
M,R:5>9!<,1O_Y0]T/V91U1.7MJ`Z"`KNJ082,9*PH:#V<0X`B]N(448:M`EC
M7#07RZ^8#8JX';I,@B<;Y7\X$5+K'T,XYI3F[X0/0*/F_5X;5*\/,LVH0A_B
MF+G8^FR7Y_Q)<1$&R9]HD%^DT3G;>9HH<^5<"'VN`7+,,-50(L<2/I@YT1'A
MP\'5^DPX0+3[&',I%?P(9\TE#/56XX&1M5'Q!_,@-?P1`.6VD?\=C7[W>6E0
M[3[$+J/*?8!7YF;G)@!NJMB')T)H=14$)9/(@7C4^=0`0/2XEI&42ES'17.S
M?&LY+MEO"A=E?DP"@U[OPU+R4=<I$(/1Z?LIP:"P`PJF,S8)PQRWC*A((54)
MBU(C]"=#6HDA*&,\5>E;$!%9#`BHU5`RV*CE4''7O&'-RSBA^1FS54]9/A34
M'(GB'DZ'C_(?PU'$!\4P4H]#8RPFQ(`@PC_(6H8!_B&^FCF^GVTV67I?9N%?
M[I\#]M5O=B5/F>+Y8!;!?AT5P,B_'IPJBBYF$3'MA,B)I#,3W((L"0[RQ,"`
M-<>.#\;YTE:\UD'Q*!#NBK=/0;"5,D:3LJA_<RQLU:__?%\RP>8F[V9]&:=!
M&L;,[F5%/)*Q,JANK&A"V2=+X,<<>QHD/'63,2FE90&8MC('N&8:R=:DF4CJ
MF1JT8";.A8^U=L^!B0&D]2%X3$8C:HI92YL^Y<NKV>]7,00V%6RZUU[<7.G9
M9=`\:7D%@,'/DJ`H;M;"2JZ^Q,:!M'%":`S/`,3>01L?PI6Q&,3T+QN&U-),
MA0:/)5&QH)WY4/#?<B+5?8'S;!/$O011E?H8F`EE.P9!C/&7'(C#BDP)`,R>
MJ%E):U.4?+2@7:%Y3(O5+2-)\YQ&XET^T,TCS:TMBX84N&W1PNPY+F(T:4;7
M;"<G(+,S+LA6Q]CP&9MQOC0S-Z-,N;2LG1K*VK#CJB$!MGW1PE)PX"D:Z9H1
M$QK[9,!Y^LW/*-LM+45GTUFL85(X+)8*IH(#S]!(U0S8WK[#(%_.#&5OM72,
MN;2\G?M;K6$2L%9+!4O!@^=HY&M&3,BLEI;S#*R6CNV6EJ*+Z:S6,"D<5DL%
M4\&!%VBD:@%L2&V6EC,M;):.+3WJ!U0&\>%SYF*'3$B`U`P8A:7T\]@4-%(S
M(:ZWWXW)BS<8^Y(`UF@Z>0LDS5(VGM(-/S8B1?W]2O;]M@W20GR_+"=99Z9N
M[-=$Q`[;$D]Q*O_PG"41S8O?$OK7'<\@B==';\`>TGT?MB+)G@0E*9_9W[;B
M-#M;BW_%1;&C^="32KK99GF0[SM/X40W<GY<"!QQ1`4=IIQ*MO)'9,&]#`N]
MHBZ%8*14)M![;!#U\1W,B$%Y#Z90U=J03T*C#V?!^/8]N&:<%)>)CA1?U5A+
M#HW^AYZ<S%^TTD=:C]%&&?GKSDLF![Y.HY(&I->H`:94E'P.&CTY);*WWX.K
MQRG@&&C%-?^$IDIQ:/`_=.*DON.8?AEU'D>4"T".V76<TBOVHWMR64L!/"(U
M!$J3J<B'$3$.A]\X`P[XD).2T>Q2R(ZY;#E1614%+0O3RI6*65!''[V7[]7O
M$0.PE)ZT?&UPXZ#G$>V)Q2"#+,W55:D7UTLNPT2@S8`*VC`/G9"ZD@_2>RRF
M<&H8<OSOT5D"+<<9&0,=NRV82QP4SZLTXO^Y8&[M2Y"PMRE6Y5F0YWOFD?\Q
M2';&UU+,B(%E'!M"[;$BFR"JXXH?.E-/^!:BGDW$=!3VQAMHR'^@[=3)46U[
M%>V70%:21_H4IRG_6FQ?)E]B)FQMAX%ED%'VV928X-++;;2+/N/<0K4LISW9
M[G<;Q-'%ERU-"\K>[X9M]O,#S6[KA9B0A/9)S&`?LVHUBU33A*81$\F1[X+*
M8?'#2N6T0H#-!-BP\FP",*??F_]LW!QS?@;:+MCM@1<40<U&2\UXP*+D],ZB
MV\N(7'B_>-EI1C/E:Q]N5-!87JW`&L!=WI)FS'<I][=LB45_!F;DMSQ4]I$Z
MF%`-+7C;J07:-R1R^`D1$V27CGK*"6&3D%E+)W0"%FUAI504K`C"<+?9);Q[
M$8GH-J=A+,ZPEE4.\P-&Z`2,2Z.A]1\5Q253F9F-B<O].=WRLA^FAO]X&ESB
M__'K]\^4Y0@N+'S(]'+2Z3ZVU$L#9O$/LLM(YOX0KRSMV;I%OL%-8_/R9N<C
M".+82J\0PHGU>5\X[]6$,>W#ZHL+WG4</,9)7/([VZE,AJBR4BY$MHCMB:LQ
M/2AK9`'XF.4Z4QM_ENG_&4^L[.V6#[RKU>G5]=7#U<4]67T\)_<_K^XN?KZY
M/K^XN_\MN?C?GZX>_H1B7S[A)[P_2,,ZI^LX1&3);853:^(M)1-$!7F>A&LH
M0?L(6I`:+EWD8%RK9J:#52-)VDFH?",G,)U)^$[[QT7+R#<9E:L%-PIAF.W2
MLK@-]CPGEFDR]IM\1Z/^.QH'R"U(@H7/K6#W]B'5;%)-%Z:O(D"&E`T*,S\1
MYFT'<U!AKH^WT%AZ![;6!\6M>1I,A.^H")3>!KE>=O4;+A.:T#Z`(?`QZ3TA
MU4Q23<5Y`.V+5B>WY"W)JS78,H)X^ARX\+A9>,"<P9>3Y(]92>LWLC2Z0U.A
MC.LPC&/&%*-:&<1D*6T`5&*%QO)I>$AKX=0,M!S_G],\?@G*^(4:>9]:C:&E
M!6VY1H#V^C(UPU%XES-!TVQCP>V/"6<:V1T#MH2,%#F$I:&MC1&;81`;][<_
M3(R:,]QCGQUE`6`@Q(/&;#KN"W$)L4=\%]PD'L+0R"_.:*V2Z8&9W?C[.\8O
ME[^HE&TV<;D16?]I=):E99P^T30<9O_AVP@:$F"7DK2P>L'R=K2\D=0=C\*N
M^>$)=7C@;K&,LY[^[LHHWRU9*L$B,V'D+CQD3L+(/7N+HVS1L6_LZ!K0V'B`
MB68"XU<.P@;.05I!E2?RIOI&7^$[)S1/+7!=(X`;;IWZ+E:W@8>F0IG981@#
MM[:ZA9A.R+MOOSWY5OY_W<3TZV_?\?,"LMJ5SUD>_XU&)^3;6?NVVB<OV:(M
M^F@+B?9_<KA;!C<X@)LA:5/K"?A_?EO#>^%3_I6M0+,`+6!>2ZJJX!3)>WR(
M^M@:R*G6-U$+Z;*N?=4^5Z5@M%JW-Q_:_Q@`-.3YM@V2Q:@3<B5X#)'O80Y$
MJ4).AG7(NW<G[W[X@8W[%TAE,BUXKDZ.]4E/H[:+\*_DNW\^^=VWWYV\^_$[
MH5>^^_[DA]_]</+]]_]<#QY6.B>$_6U+0QY-3O"=V:K$V<CU4<CR@ED5420Z
M`@?);1!'5^E9L(W+H,<\R@04Q72PA"<EG%["0#.2\*'D*B758!0FW@D(OWG^
M-DY).!,0ATO%QC#$1U"_.UR*E5Y`].E46NE83LCO:!G$*8TN@IQ7@RE6[473
M:G-IZX,84(3V2HQ`'W-A/8G4L\B;SKPZ7/(5*L/M!'1U<-=XXKC)CQ)42I\X
M?52@P-T%<UDT<B",!1$RYFKJ30S,!+M]/`3"*%ZW*LL\?MR5(@OQ(>/1DSE.
MX1WN)EM"^FU1Z3N:ACVW&\0I,D(@SR.+@\BP+&&-P!^R0*`/!J.I46>$Z+0I
M1'<:L#^$TQ<.="M#9_;RPZ\,=U%?J5_U=_55RA7/K6&/Q(YA>M`^J`%@L]O"
MJ!Q.!U12I25'V."5]#PX]=>%QU0YN(MJ*J:V230Z&84ZXF/>V4TN"M5'(@!W
M2W-Q\N5VZJ>DAN,@4`-V]&R0'P+>Y$3.EA%\PN;+<T(4WN$$6*O(=A/21F/S
M[9C6X@ALA&.AQ%*>/K>'SK:>P0@U:+]@%.RH.%;'\^TD5!Z"![Y*!'O'1^BL
MI!G#FA:-'>=66%&49[5N5O&``@Y+>`3*5-QF.K'VMW;&>`[%*Q[$@\3*#3&>
MA64;X#I8$>HD34UASKKD,-JS0[BF$@:6638QOH_9U[RDJQR*WC:;?JM#[0&<
M&.8E,;[FN2]](`EDOMM7$U*0=T7&8>HSS?BN-5MLUVI_)N.%<6RW"N*73(J(
M-WB1V@:-CV(A?*.W9,PD#T2Q^&[`=:2@O14]3+U"P;WO=D+V:G;<!NQIFW0)
MOM?NO8O=1ELU'8'-'MF2#HD53$KX-$!,-M;0!MD"R5%*=IP2^B5\9J,IW]94
M+<$+6?Z='W.Q7X;99ANDTQ_@B=+RO)+($JBS)*H_(D:7PSHFHE<0@'K.(QJB
MI87.N=#OK8?5X)Q1D$G]"QMPKR!J8,*E;BX&9+S@*F6JF3;=V&UK\ZNF0_D8
M:CC]9,9J3$%NUN2&;29%/R5T'=/-$<F1I!FJ00)FKD;836NN]+RV8`YSD-#B
MCK[0=$<=6K(=3X<V2GTX/5'A(U#9FO%WKOZ(SHHHF,>L%L(@YRS'^)623)^J
M#J:%K;50$X"R%SI(QRQUH:CP#6(6;%Z\&=L4.P8I%V+)$B8F88RAEKQ&5U"V
M#KPQ]SF3T"03K?VJU[(U$7IBT`9C#&I?%<OQ(MVU,Z/N?HWH+-<96D[#+(]H
M1-84F:GT^EI1.Z/I1)K3>/.X8RLLG&=T!M9($`VOSXU+X7(*YB>:,EV7\+8+
MT29.8Z[G>.1+K6(&]>T8&2A#/`[OF%&K&;+QR,&<V12+BZ'V`Q8<S$%CM0V9
M46N[S3AQR<KK;5=E6X-],!?:/A\!Z9<;G[%[M%_9=./WKAU9=-9GB(D,BZ+W
M.&A!VQ+$Z756%#?I>5S((Y4LO5G+_J'OC$V+G@J891D#U]._;`)YPZ=\11BK
M=69Q]V>F!KSVIY#6N/A@#B@Z!*1LO0YC+O&B,JM<`8,*SA,P4AUZ1\!$;P!&
MN6R=@3X!:(]@")(Z2`05Y_*&("_8JAKQ^:MHY\O"YB^?]4)UZ%P<I7P8^3DJ
MX0"0;WF>Q#6/=?RZ,Q4\<GT`0RW5?``*"V_VXA]I21)N!#E7UF*1I1C:O9@!
MN#9X>?BH>U\&S.+M/0%8LD-@FAV^1J5*7*OWCQ.$MM\FD'N27S[3G%0Y`6^J
M\;B*T[G#BBM8E9%$6/[>F$N-K*8IBRZ9-\1VK+30G'`I\C\.I\'E"1V_?C^;
M1HY`%4RV>&U%A`QD^^O_VH`)2X-\/I*H-,3D$#U$.UOKYG<.*4OC!*$MI`ED
M==_-$]*-^=VDI/LG-AG1";4+T#J85.7H,Z3K(*YOT65KPDPJB1H:N/;]+GCE
MQTSJ`*X*=F34=W5NA3D+^F\2OT\.[CX9JS#+CK-Z_85@$V/J2*D)P+4\5T/J
M5T!HQX+O4?S1T)(,[TL01"ML@%0QR"X4GH2@A`/FE8V*STB?=[WL+*@&:*F-
M0NJWF`>3H3VP8RA#0E)+NO"S$#E5)N^>`,1/O5^ZUD?)/`ON?"#B_>[@#LJ@
MY)K%<@;$=CF-4_<"J.M(G`9%')HZ'<.3H1P.%91>WG[=KJ,I[G)"Q%@4CH8I
MBIY(B/HG875!F<\D;\GC$"PP*ZWE-:V%UC$:G*R<Q\FNM"]WHB(#;;'5\$PD
MJ!J-RB2:(S*2IF@8(KCM&>%+(RND9\KE9.P7&C\]LP>OV'</GNC'W>:1YC?K
MWL5H*SME1Q3*?ME"/^;A>CZI"!!)H2TMV"T5@,GD308\J(!WY?:@B``ZD^C$
M[EI3Z<+KX.)=:1OO:A^VY*%-KOUR>`H]1BL]X2*8*`"L5MQ1-(RLNYM<+-D&
MKBKB<+,^"XKGRR3[;'V97$L#KC6<%IBR"`FO0<(G$#$#6PT29U29(2K`?EGC
MC#C2.6N4"Q<-)_.7N,VSESBBT>G^4T&CJ[3)VEOQ/MFRW8YKKIS]$Z!MKM.B
M#.T7!2?79,CIGKSAE,A5^A5ITVQ;:G,*L5>HVW\U.C)]R3-<A^#W4O*@@^43
MP%[=_TPNKV]^N2>7=S<?R,WMQ=WJX>KC3V1U]G#UQZN'JXM[A)F(SDK!-)SM
MIA&6[&/_7[NB%.4*'K([RA<S3NA!'/XA\U><BA;A,SP;RKN9:2'[7>N;Q_`F
MN<V#2.\,D?_YM:AE+"M:9J):B5S1M+YFP7[+?P[Y8F[KQ7QDB[DK1(G7KSI7
MDP(X)?]Z%K%:-[-E`_-_YU2-6K]Y1KVXX#:V.INBT5FVX1DD3L4C%%2@_68E
MN-YVCP]\^\A'DNY05`Z@.1I>E[5"$W:&HBTYH6="L\*".@Z$J<#"?DXH_X'7
MA]ED>1G_325<@XK-B!:4'V4(5%<!Y80T$V4%I,Y4%$9Y`HSH+H/8,*C6^EEP
MYX+;I,[#;];G]+$\CXLPVZ7E;4XW\6YC:]C&"4+;.!/(/3>P,X<'./DL4D\C
M;ZJ)F-(;G5!&T>])<`0UJJ:ALNQ3?,.(?T,5.G`+;RR81L;>5"JA%,]EG`9L
M,Y`^G65%:5R:04L#+%ZB!S;&E<T$(F9@"%?X`8KJ7I'K!EDX"S*G*,(RV."V
M^@92IM^RCXO8LB7K"AXEH,5->O&%!P1V<?$L3^*X4K-U5L8)0CLK)I"'+@,6
M,EA*Y=76PXG\W)E/1>2MN,(D8L-P`(Z)97VS<_K64SX^"WJ,$]Q=70@CN'=F
MK(F,O#-3-62B:8,RW0C]^>WOWG\KM"?_C7C$37HF;@9?I9=!G(O.HIQ\<R%X
MS.TR)[2T[V4#<9#]F(Z4$\E52OC4JC6PT)1@E^2GQ0A8#"#*PAWGYL%H'B#0
MKT$KI?@`%>4=WCP%XI#.M]S!XNZIM4H:]%%M]=&B#=9R&A3TG,K_=DZPSH)M
M7`:):RZ6!65HU]5J$0;ZFHE)Y$T]_2O.W>WA?D4"9\*5%W3)R\71.;(HC"NB
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M$'!E#;9PQP@QI1E,#-NKE"\T;$2NHXT.L/0C+10`Z/:/O\V1SSM!'&N(*L(8
MUC!XTUV@X/7CO2#V*(X99(D-3GZGX#?/D(V:A5&$:Z[;R.&$,9LAJGB\E!'P
MUM&;#AE<M\HFA!YUH+^**(Z&L5U#.6JNAA3E52B2-HO;8,^W1#Q[/`SS'?/G
MVM?U-\5&3\%GF@T7QU#D:VJD(B=O7$B"72V`^MC)<4D:[-L.]J#"/ENOO6F]
MEB6A(W1O;#2%H[MCH280Z<P[FO`-\&V0*Y2EH?'1D\7C`(W!-XS/'*O#$U)1
M(A4II`$:6_A&\D_>DKQ"OV640/(3)V%3-R?)A/4Q%D"R]8PL*$-[0U:+8%3H
M:*B.!B)?QQOP4,&&.7J-+E/!R`+D054*7/T!)F#AJ@Z,$?N"NVWVJFOB\DQ8
ME/55^D(+OZ)+#I3!NB:Y+$+?3ZM&SZF?G;HH38'NN-K<$%H\H2EWKM;W+')E
MZ>7DF;F`53V?5?C779Q3]K),S93[6_8Y2[8EO&"_%8?ZMLZ7!65HY\MJ$7IG
MHM5D7M:LFD[J^2=$4#@1FY"&""H7Q0\[>]/G@&^HLC6O0%:!WO*I`C.='O,$
MM]PFP=R%K,<*[J;8"[F1FV(MX1C=E.G=DU?@EICN(=NJC(MX*_:'9MZ0#S98
M<0-RQ@W6O"[9$,R+!R*JX'ZZOS@G5Q_9__WQXOZH!"Z&II>3L&^]?S1AV%?@
M;T[L9V)1Q$TABMFJF^N>`.UO.BV*I<)NZ]`@**,[_VH<[S>'X..Z;3<-[*/J
MYI=7'U<?SUYI=7,#I>`3/AO7",NIQ3NZK9SGF_7'K*3U48RI-ZJ<#^5[:@#U
MKE8T0_D62@RN#R41>)060)J=?Y:2E`VMCQQ1Y'S/@`/,71J3%JUS-"(J"X;:
M\BRD-"JX?;HJBAU31O1F?9M7V>*BAC';-,M?4/9'\1OKL)O;4Z!=(N?%Z5]1
MD(2JL'-%BA>":8@1,5?$;%IZ\I>(W*+)5N0^2&2`KN`#3D2U>_:O;,WF@57S
M6Y@9N((A<<T,(G)7,T,Q]-W!720_96$6OO/1%!Z7HKO/O?A"\S`NV'-OMN+X
MGCWPER#/`Z:N+[.<NW%C+I$339`"5_;`]<JMIL&56T5%W&VNZ1!&2&P1`=VJ
MJ8$+0>95H&@-GJNR"CS7Z)]K\&L&/IP#O'TQ+%#\O5O:,-6B'*5>73C*3>0Q
M1K[FBWB!NW56BS!!A`N5&^,-OM?8J2U3_)HRP#R^MLDW!O?5["5]XC#6XKJ-
MOQ=3L?P__(SWA>TP>#HQVT]DT7&ZL6E(RXHF5)C+$OA@E)I;:?%#A\()D33(
M0/8^@J"8)VPNVO'@[<1Y/#27(U9/B%<?S^XN5O<7_'Q5!.57'\_E#Q?_^]/5
M'U?7%Q\?,!RR3O`EVUJE0Q\/+$CHHI.T@4,'A;1@%[O==IN('M9!4O>PODJ9
MS[\1VQ+7PU13LM!^I3G\7C2L,[/M<TXZDP$K^RV!F7?,2;)BE\N@H/`QUWP)
MXI86OB-#2WXWZZ!GQ>Q+7H%D%IH6Y6T01Z;>T\$<N,N+!R_>SWB7?R;\[RB,
M_L@+"_4@"A[Q8$I<#49C\8;X9.0F8(])%KW8FVWH0_"%G\`-,O;8#>F#Z=`6
MJ`]GX"(N;WHMAH"PO.?['W)_R4>B,PL*IC*]$#_`4<MNHKG)^<CPLQ_;;+TT
M&MCCGS=FV_9BE?=S(#?;G@ND3!,[(1753J(HWY@/ILVUI+%5?9YAB13.(O<5
MTRQ]*]8L/EBSH:@DGKM=4XG9Z%YQ`AGS.%4]R]@S\T*T>>NFN;15/6KK_Y"=
M99M-EEJEEW@]`[2XM/O"])1'0XF?N!XDKAT4%VK\W(>,2(HS)9>XV/_YUD0H
M"+XF0Y4W:N>9E-EPQL7LQ[)85R.4'"(6!>2L=GIY-_'")E`H'MKR(0_28DUS
M?GA<5SO:GR5!4<3K.!0L])#QJ-_Q;T5S(J.4%,]'@&2H>"_+L4#4!&7"2D.2
M',[FBE)2/?K#B6SC!M^W;;Z%$0D=3:-$$AXN#-,/5"[,X1\0)+5@6Y**5Y"D
MNTRC8-39+Y-HE^7VNC?Y4Y!6;8B9TB^R)(YDD%4D&!8UYS4MBH/DGOU&;$.<
M;X9-\U#H0--42W<L;N>T"/-X6[?"/MT5<4H+F41VO]ML@GS/?W\?/Z6">=*R
MKB''=WJW[#7"F:^4^82WYEJU+MT3<D"Y3BAO:'?:P;.M=$M>LV;@`;5)!=4H
M##>EE+X2A=;9_Z=11\!:^:K%ZX%^*4^3X7WZ8+1C\?>""@X"?``O77"CT`6=
MV*+0O&/JEK\0$6^$(P*)X#M,8\G`_49HU:(-<`+IE25OY#9%4/?"N>:Q;)Y)
M[NA\CM*#]BL-`/=O[K85@_>D.PFK&[@42'"_S91]C5PR0]Z%%\Y6L5@[2C8D
MX2[5V\"V8.3N@28VAV(NT&CLNP,SCUQPM^7D1>^\#U>$<S6KXP2A[:H)Y('K
M?6T=P68"5J/J@["JB&D,%-RP&G.PZ9UK(_9%(*$>MM6*)I1QM01NQ]"8#>Q$
MP/4U;<&LJPL_:\VK`S,O)[WG]+$TR@S4ZC@%%6A+J@37NY7$BQ;5F3@H:]P9
M0UEMLKRLXBP\:!6QB2(+CP=*4'D!QI#X0+,42G!CKQ<G(PNOE24HQ6!MP573
MH8RU&LXHMV$SO^90NFH-C7T=82RM*=5SU9+"D<<O3,6^T*N4R>=.'B6FT<\T
M>K)/NA_1*.Z/@K>_/LO4%\R:&MIH\5R`28><<)LK@M9W#!`82&_),;2BOF*#
M6ILXV&./9\`9;:^%F4Z>\+D`,RT,GB#W%$(QXDMX2\2"5_VRS28NZU<\R\29
M-TW#25P,.^+03H7M4O2O6#3S926=+@6LCL6\H%^'Z^`D`T;.@HL`()-]:X?`
MDBK8%5Y;\.Z<C\W(SPL=C:%W8V_]95H7WEY.H.6M"E=K?30;VASWP!QS874O
M"ZEA]7]]<+LXS$Y&AF^0EQ:L0<;O8CYG243S0KX*CUAZ&#5S@E#VS`9RK[!"
M9^YOZ_N.(L:+V8SY();CT9@J:W[56BE;9EVR-N!C0?^Z8_;SXL7G_IR2#K31
MT@#L5S.IAQ(Y%JLEFPD3N'D;8T;#2GU:3H03+7L3IR0`9M(TD`PX#YV]<H-#
MQ6`\IFJ,S_2F:83)EI.7^BX6V](]QJG(:BG$79^]K3'24((V1UJ0QSS7W$[K
MCI:7T-@VI?HOH%!-A_1C4%9UP^IIZ(S3.'L:F:=1WEQ0X((B+F[61S?K]O)_
MK:V5(34HTV4,MB>$?"+GS';JR9(R:%^!WQ_JP6WDM^13&NRBN*S+E<6;SO7D
M3A%D-!;1CK&UYM&*JSV*3)TSIR+)1*[P?1D\4:8>MD%J((OJBER&)$$+[AG#
M[I]C-Q.)F$FJJ6CMXDQX$=7&<P=W4#DT:._;;^6GY#6%H]X"L*&\N5DHGX*L
M')Z=/(]7O[,2YB4/+#O7^QT=!RT-N,-(+;"!8H[M\$7=`[?C1BMPMWG,;/VV
MZ@Q[,!F-R3=AQ)&#Q%$N7$ZL/O'VA!=%&3/'RK[GW]%LZ"UO#\PQ?WV2;4F;
M(9CDQQ]9UD'&&R$-5/8Y\+?1V#$],QIM=@<Y<<G[JG&6RR9,=_2P`N0J^J]=
M(?(&.A6!3"V6-5VX>ZO6"]`ODG!<.A./<"Z%&8V5<V7HD4NK3MP,WD'2;6ML
M1Q3:=II"MVD>B49\ET6.SJY:L;59<JL%3R.H&N&X7S2FAZY:A,E62U,I`I/L
MS@7\M56*<-EJ6C+P@FW7-ML@SOF;W.3G<;'-BB"Y65]GZ=-U_$*C55%0;[OK
M]`QH,^RX,+TN;PT9<I.3FA#?^W)2;P4M(HEADO6%ER8;6`YTQMM'5,PZSKG+
M"<1U5@.U,'+W#T+H1VX+&O!M9S`FD9T4&!HK/,YNAM=`P07GDLFVZ*[1J8'<
MN9OJEO9D1A3:EII"/V9(/D^V;3FLC]Z9BTD"YUZ#3+$&Z"RE%:L;F48;/@?H
M6>QH"97SX3IT*P&IVQ=C$L'I4"&R@6-L-M+46\MC2Q;I+BA;!1ZMZF0V7'S9
MTK2@;M;/A"2T[3.#W3^.D+-$;*2;"%1-Q"1S2\(_RPJ$]LZ"M0T+[)OR]:)U
M"OCCQ1E155)<?`SG#"`S<H"5"0SA#MS+;V:2NMZ\F(M):"<&??\<Y/3M:5"(
MVOI[,+?4B]=,S*D=WRY8=2#(TSA]*FYI+KZ%9\AVC!RT51V'V[ML7,T@;`H1
M<S")XUQ@WUQG1?&5P%RW&N<4T%E00_8U*WM@Q+O+B>9'^KESER#/4O9C2#O[
M5D<3:DT7RI8Z+$#OLAC]?-"4[8`()D&>:P'N:$B/&M,=T$%C;%VY76MU'5D=
M[N*WJ6!;W8T'DVJKR_>F'-V[+(Y)C)=!C,X,6[&Q4VD&'.+:A)/KWN@Q+3[0
M@%]'BFZ87Q_N\IQI&G$3T-HNNQ&',LZN2Z$^IS@A'5*DID7$;KBB1N2UTU\?
M1$L.;.9ZJB7I-)<M:,FOM)7/).FLS:9>FX#]E:_?BSSG24E`\F:M'OEST-AW
M+]'1&GD?N5G0TH?/--HE]&:M:JPGF-K=Z-O2![?_]@O2$Y2*!#_EU?57!5<7
MLR]$JS&"ME9Y7BU)F34_;CEI?.Z#HVR8>1)N@H$@Z7FZ=&=X=\$(I&5W1W"Q
MG@YI1X"WW?1F^GK2FR=*;,9@H0>;`$Q@F4?HXK'(HPN@L\2*AAKPXCH[>-%8
MKP'_.<ASKK7B;E<1:9TQFV`SYK<TO4:<[U$3IY/GU3[J%_D!BINT*LW#1X@3
MN`]91)-1?_M`_TWUF*4-\'3+H\^R[$A]39C<I-6&G?V](4X$=03J8*%EZICV
M=J]>#.N*@N_A'^O26B_-DFWXDQ8OW[,D'[W4F:J6BP)2RV<6Q:#SFJ95/AYZ
M]D.<T*+,4EHG:S2_^$#+YRQRBV&XD`:M16:]#,<\WXQOLEY(^RM)`X&&G'$!
M.EIQTP#?2F*(ZI1-^*&W]8=N\6X$#63ER-Q$?+PLF9-\0^S^1/*'2$GK)FVM
MN)Y]DF?'I_MV3(5FQ8R5A&`:K)GN@6`EOB=<,MV>2B8)/HHDP8,LR>X#R./^
M8&#U$"*>4NE2'`&BU[]L</7+IQ92?;WSB25T.64F'\V>LOH26]>$.YP,'90Z
MAG+,\9)1^0#R*Q^"PTF:[.W!`T.#K&04_1GBHP7MN;/(MN^=1CP\_3'8T/-L
M$\3&1=]F>3:8E9]G(14=U2J[(X<AL=?++$!7%2C@P]G=&85);X+GDZ0%[UAL
MMDFVIU2T]KH1A?$^T,TCS6TMLYH0M)760>Q)>C66B,%$CB:_RO$+-T68#-0!
M%LYO\P'RNA+B"*E0P@%W4$:ER^SRQXAH+:<MJHBN4D,,*NC#25"NPO&K'W-4
M]7<@67=ZY169_:5=?!+#E5:+K7],M6G$\-,NCH(T[`6^?+FD:H()JGD,A,W$
MC1D23T1;(94/=1VG]*JD&^L0P@1/A/9H)EFTX>O.^I#<2$2.DR>"/B[/XA6N
M%[CK,IU@FJ7C3"65>$YE.NY:L:IRJ^SR>B9\$M9S&*-%<CE).#G8PA4GI*:^
MQ-FUO:\WSSJU!]F9W/VU&?@H7,6Y41>"!4:QHSTS,E<A7H=%QOH#1+D.-IUO
M<HORN_CI>9(,:-L'@7N!'DNDU:@=:K\E5>R;$SQILR>SG$BBX-ITN25JU4J3
M_!<7Q8Y&^'PW7^&QS*!VDQR`J]&RW/0JC?37,=F`CUF:'][.M,F?F>Z!X%>H
M)U@R37)V1:DJ>=+>I>;WB[KT4"7)O)*U@;]./96XF5VQGDC6`-32Z;[Y\>>8
MYKQ,XOZ:%TET29$QI`KMO1B#UQ5E:"9@S*]9!"&XKV''Q':%L4TX&$!<NXJY
M_X)VZ3AV1,&]`4/H.HX^-&L=>]=A=4PI-DBPPUMS&[8WL]@6/`\@YE?I=E<6
M0M^\<\N)T9%"8W\'8>J86$XX(6(*>8<SF<0.WA@4/%96S91VIE7)D;""]IU=
M:HF.!+BM'(1E+EC?X<KJL(,U!@'>FJF9SLQV*3D.5H#>3V>IWB.V5.\=!.K]
MZ[%4:GAC4%!:JO<36:KWT(+F$6+2Y2O-%D5;-&5IMNB<+@NG*^[R$2(^.EBM
M\R;515&K\IV`.4SH%S#S7$!XJS^E`,\>E79);5+4QJ@.+V_6`V^Q*MOJ'4<E
M25>/19D'86GJ3DSR+-#J&?X+I3HWYNV1AX1J578#03<#%85KXCC\EIF7*5N_
MIG+"\TF!B:\TH;A!-%ONO+"I4S0\&;[%\B$4=1/B1@7TJNR!.!<.`!(5`##C
MKF4HPT[*?6[R,+;GM`CS6*33W:Q/=P4SXP7W`!I)O8^?TG@=A[R\:-L"A/</
M8,]7)9JH5<T4SP,UNM,L6)]I&ZK<^-9TA>/:,<H=V@>M:"KJ4)DG_UBMB<ID
MS;]<S&5Y["Y7T4E`[BQ7T"[7MJ*.RV694&^-NRW3*2U;UZ6@X==/V<LW$8VE
MU\)^.'96V*_^?$V?@N2"/;;<*_)P#LS1T)2E'9/AU^['$-D((H<`)<[,\]:+
MNR`:-AET/-0\,A<3RP<I<U(&E4%O'I1S,`"@5["AX@>@C)&97AO,#JA81JO/
M%?SBX4'S2RAIO-N8G08/30$I9=U[[=Z-_6H`CJ-=+.]L7^O9^*7!+82&G=75
ME`=Y&4'3E].]:]T^$Y+0Y\QFL*WZP)R@+?ZW-%CP<VD+IC8ZGS;G:`2"R]_(
M+B_9A!2^?DU=F$Z\BRGQ>'F8"!LW]1C7L7/3,=<N)Y0?@O`Y3FF^[[Z/6Y:6
MCA2T]=3#[)6>KT<?]TW#F*'E`XV.0@.WC`8,:F01Q[ESP8RM79[&Y2[G%38O
MXR_\I\(RM5A-`2R72@>JE]=3#Q9L6`_'L?&<`-!Z#!!<KM$HZ^D3A\;X;CDA
M.LLVFZHXB)N]ZA.`ME)#D(X938ZIR@<A+/UJBP&5+9WL`X";3:5T&!E+E6@L
MV(<A+>,H3G8\_>&>IP:)[(>++V&RBVATR1:!EPC:R:C<S?HB8'HI?2IN:2Z+
M".V'"9@<E2WQ"E!&>MYE[<4Y.X-).QK#J=YK6!`P)V$!X=-Z&?-+'K0BTW;&
MT'<5&:,'[<08`#84BQ/"9^$Z/5T<);@G8<K`9IUMS+AWR5U$RMB@C!\3>LO(
MTCRGD7Y/,:@QQ\A`V?MQ>'WWMIE!FBES;S=<+/<RT,!LL"%C:NVH&5>""!LO
MP5?<!GN>*>>Z?=<1@[:"8U!UO"DFD&H&YBVFP=<TW&Z.?TJ/?)VZ=FP:U44?
M+3)WE)-!<G@T4(XYJFX_P\:2T:86,)DG8Q]&G8,R\E7`KD=<V_9]F/29K_B:
MQ+7F$O!4R?_7R!I`_&/9P"Y.F*Z;^^4)9+W))U9K<]^@.-9I</?=Z)=R%R2:
MJ^9]LS;M$T'\C*D7;2;=5#T(\!(Z[-)EBJ7+QI?N3?6DKW"X@K-(J=I_G$-$
MY[TD<Y6&6;[-<F$ISX.2WJP/?F7J<%I0A+]88P!:<7?E8-@)X7.Y5!S\&L&I
M.114!%=X3!G:\'*/(3<OV+M8M)KX0,OG++I*7VA1<D?WYG/*F.0YWMY2QES,
M\7TR;MM@3A`JVFP#6='%7$XF[>P3TLPG+0$4$6@?N.T?1?^K!F*<,B7"*+$M
M!:/.X]./>Q)FFVV0XJEI8<W:VBBU+5][[`4Z>2U71;'C0<:K]"Q+BSBB4DU<
M9KE\GZOJ0ZSX=RAB&Q,[Q:-`0SG>RZ3-F:I),B$G!T0)HUIW=*KID@YA/$&;
M>1<HKA<H3IGH=Q=HS1:(R@4Z5!0S+9![>`;I"B&+RDRCC\:#,9,H(P0WQ2Z*
M,MXPWR[Z5-#U+KF.7\R+<]D117=[3`'=\H)50X5(,D300>%-^2)OH>TDM&0(
M&KY+9#J>=KM.IF%HGR*=/+6.)^$]\Z;'=UQK6#E$0_-ABVD.`AILI%V0>A@1
MX_!X(E8@<AI2Q@QB3T&#\)FL;J](P?\FVR/RK4A34"&4!E<VJ15F]6`&H=4S
M>PTF`;T.J]6H`1!A`9%Y!AII,RBZJ10UZ+Q7XQS>U8;'7$UM^S0/>Z5)^<U2
MF6:;UY0))TTZM/F12TV=!UMD^_(3(I^`PDN8:ZUNLY)IG#A(DGV[NQ"*#H\+
M,:E(S9F`?R!/TX1KI$ISC<!4L[$$51HPVDWN_2#W`1Q2V+Z^=!F&A0='2,(&
M`3+'0"D35E&``X'PD-#:QXAX.&%<6/OGOEH"(*D/(Y!ZV\YZN`QG`LNO-YP!
M`0#T].>%`R+9EB(PFLE@($#+.?WWX3.-=@F]6=_1A$<@;H.\W#_D05H$H<C8
M/=T?_,6FFKC?0Z`O!+@N36_S6M'A>_5J/!$32)?6"=_B'_X94Z5P[(L"?K?"
M2Y",[ESX2-%R"L7LW6QN]5M0A(H'6($^%H4C_L9STWYV5&#[<GLFU6Z^K3D4
M1AS=KJ\/4("VS(.@1A@0XY7T"7&`VS\UHQD9-R67>6QU/]!-EL=!<I]D0?H'
M6K)]6)P^G04,9'Y&^:FYQ:U"8V(@6V`+J+WZ@M54(N:29C*1LXF<#E2X:EJD
M]W\X.\-Q)1XY%/M=_A0,6`@&_$O#@*%DP%!,1[+UM]4IZC"`I4)9SF6XSM*G
M!YIO;AG7/`<%Y4&*N)2EJ,^8DG[*^'4+?M>K'A&YE'!W?0RT\^&^/+U05S6:
M'^+Q\:29@+'"^PRX,T/<X,Z-IT@8>4!^\H!!/2C>TJY0O"MYJ*V_^W+T&E(Q
M2F\YJ48>2$OLA.BT!:8R\Q,O2#F^(`-J!%M!>D^AT48?_"3&8W_UD7X^SW=/
MJ^TVB4/A*MK5!=(3`3WZUT`[YE(VE/"QI#,85]UYW(C<TP,L(44<4M`.1I8F
M,"9-X]D"(Z+D(>EW/`UU6_*3AZ==PJ?MV5/R["5(>&K1I_O+*+"(I5B0`XFF
M6,'MQ^O$9&ZFV^FDGB\S^#Z1>\)H((I%3`(YTT'^^OYK<GF^PA2TF`ITWH(.
M:M#K+F@DP0M[,5:'+ZQE&/P(\MJVTI<Q/>B0A`%@_:E"9Q*^HEN+HP0/-Y@R
ML/7)BH9[P<7S?$>YXGC(NG\_V^4Y4^FFQ9RF>`2R'`+#93'F_!/"*$J3_.8A
M^^HPNX9MJB5E+/69YEF<3M&E39S0HLR8+M@&>^X]\#M7<D7*K/EQR^F"V_`)
M!<@EG<%">KRV&BWQ#_7'X?5E^<>QBBSH*8&&%\9`ZJ6YG4&J*5BN'-CBZB"I
MQ0]1?,'U*PEMT6J6!ANR@(.1I(U''4S$S.<2\\'QZ%5:E'&YX[6BY$GI'2TH
M6XEGB^B#'460`(0MZ)Z!.TKE:"CPJ$25UU$3012$\(;]ARM,X85IOF*;#Q$W
M7Y$Y+E5R1%X101)A<))6=9#!151G31CSU49J;3SULT']F^D7TC%K[54H0M!U
M%(EDHA(MI/)$P4K:_+/>7]%IX^5TB[%O.(]2\]E=,C'D6_\/P=^"E*K;I@_$
MS@=GPAQ/*4#T]B/5.%(-1.3IF4(XS[\FR\%P.$&R_10;.1")NZ85!\W9CT86
M/(3S.HBC)/B\2J,S63[5P8U2T0!UA]3`>BE/<J0PR-58A&X)4CSN3H8;H*K(
M+S)C/R)%XT9;+T(>\OV?P886Q5FPC<L@^2G/=EL+^ZN<#&*"-5"..48.)=58
M(@8CLL2^2*ZO4=U#L8<35G">^&`D=GE,4M2F>41,/*3WIUWPQ`MN,;VP*HHL
MC(.2JMORJ?63C@ZHE=8#/.:>>K2P!.UXA-;:$=<_!9OMOW:1@4KZ+)\M:,8C
ML^$&LC9NQ\<%S4,;K)YR2OD',ZGD,#`#Q&H?OW2O_&+]=PQ5&'"\L;T%-GYE
M)+9VD)/5!G:(C:>0([OB#(-S0:UG'XB&5S$58\#S]NXVT.+UD5DZ!?^/6[=A
MYO<I7<J&Q&&0//"`=4/=8H>J)0!B[T8@]>[E5L.)&$\Z'(]FMXH>D;V]=(54
M"D@!,FMJ(D5JXVH@0C[QY3BD:4'/Z0M-,M%W0<:X-C1GSG$2_TU\M''1U\3>
MG)X`&YMV7)1>8%32(1U"==3WD!0"O;+8:IS@6`Z/P/C$W!$=+4?86PY8A3:U
M:)L'W3TTAU>]]K38);Q3[CW-7]@[%$Z>SR@5&/?'`%R__'`]A]23$"BL5XW-
MP27R`U?4X-`Y1Z;2IO&0#$7-IT)\^A0\R1"'ARNDI@+J[NC`];LUUV,QB,GD
MF+!:VE'^&[>F8\SG(1V="U$?@M184/K*P(@0B-TTA'C,6MWKM>T\E-9S`H2;
M%F$`KQP6@XC$DMI(H=J86HC@@AT9=H]%',5!OK\/>+%WT1W"I<"BFA!TO0(=
MQ-XEF$`V"9`=6A#61;0"TXP](2;`P"L1C#*C6>>"$4Y<4+C:YW\,-NS'[OUF
MJSJ%!I2@*@D8@1R1,TP5!?WQG!`^D?_SH`8(MBJ!YMRIO;]OS)H>;O!M$H25
MN73;'PX2`-T:*B#U^D[6PX@8AS"(;0TDF!>(^\[6#0FR_:Q.5,:WLAHYF:C*
M1K=CR0/]4NZ"Q+3>CA4MH%)^ID"-*^@4I)J,I4C.?$#?5+._`C>1+ERK*UYG
MP[++N:<WZW4<TKS@%R\H>ZLAA3GFL@_2@-[Q*8`=LV(][+>D.Q"%9<6))*+K
M.(TYZ9]V<<2OS,Z$YY17WRZ"A-]A#/C9;<H58,ZD"(VQ-1$BH^VJ1H)\JF7O
MN.F^6=\R>LR2FR5-]R:!&-&!5^\56!9#>%6%>A!THR#SE\[:ER8T9<]*9FB<
M:VW0G=X?0>#9ZKVWU2`D8665C*H]"86`^F2$;[)=6MX&<?0IC6C>A*.OTC_1
M('_XG#T\9[LB2*.+A+Y0RXQQ2]JP&>76"]%+>A84""=!!(W.8=152C@9PNB0
MFA"1E%#X&],NP98OP4XL07M:%:>$L=\[1/O]V?'N^2<OV2<OZT].!25D(0-'
M'6"0->^D`);09@^?:?(RU%E\X,:.)4V8NV;6P+VUEZ0$[[E,!EVCM;Y#X.G,
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M#NFQ#C,Y8I');LT=01!-,"<8),[$N."HO851J?$0Z%^"/`^8:K@JBAV-'K)N
MU^PL%4FS5OZ`"3U0A\`,\#&+U;.(G,8W+@=-V+-49E;C\0D\<<82)_/*MS7.
M4.(L9`9Y\1SDJ)R&Z3_LZHGYY4]!2<F]`"N:9'0^-C)?PD*4QYT)<SGV*K?0
M$+OXPBL[%/0V9[KM-LAO\ON2YR3^,4AV]);FX@L8^1C61(&*,5A#[U_Q;UF1
MU$2(H,*35\E-3B0A(BB16]X`AM."#K5,AUWH(D)K[%N!?<N[D\R"TZ5TP[Q0
MV6?.&%KYF5_$9V[@(_%\7(5<5_3!2<)G.!B;Y/P+YS&7W6D6'K_''L_0(0TB
MOV8:0,A\E3&!<C\^FD#8HTBDD`>)?,;YCHY*_4`VP"@5F#P<`W`]MFKFU&<\
MO&<VL`:8'%IU9A$Q:-#*8$%L2)P$8YG39,L8"IR'9CBG19C'6_Z4F_59ELH'
M7F;Y`\TW<1K(/[!_/](@YW%8YH'$663E);@^`]2)<%^87H>SEI+<;E>T")M,
M.M3X'SOTB"2(QPV9;D7:)5BS)2@[2Y"M^:^:)=C.LP3NGLL\7,';2]HM"3+?
MQU.+C+M&?BK$IQA82_\\X%TK.\^P\Y[,*,&4`S,$V2LEU6%3/O%8@R'RI*:`
M&`6R%6Q7'#%Y5+-C1.)96<FDIC:8A4#Z9*?$:;S9;3[2SQ=_W<7E_C+FY]EQ
M^O21THC*K9Y"H_FY79,^&#;C9=HE[*592/*$T2?R`:1Y`I&/J+:&:M\-L^.V
MT/*E;/FH7+YULWRI7#ZY15,[.:B=O@77K\=^ANMWB=U#G$,+&N0/3:\"?>H#
M'+X&O0OB@D:G^ZH)JY$7.48#IGK`*+#>_?!C7J=$3B*G^[J-,+S3Z(;K0`=2
MDDM<C_NZFS`"3W$>8$C<0T,QT]SX-Y(Q#T7`=,M3_$)3&=6[6=\\)O&3^'IV
MF<HZ.J`.FQ[@,6_5H^M0/-M%=B;@\:,<4561:K:IRF9$Y>[>3`D+F==A(&CC
M3L2XE$UR#/^0700\KUE4&3$[CU/,!;X-?PQ$=^;^D!$^N*YN`V_RK6&(D^DR
M(S00*?EB-`G6I=@M;K8)%0U+PJ3;TPV!!V"-DT%\I!(MWWS0SE<CY7-0DN>@
M$(X`0\RS+)_I$6@DWL&(P)E<71^2-@\5<%\&>?EI>TDITS0'_?&LG`$-&5!?
M0`NO5].9#R:?MOP"@HBQ'/9WQ.,+V*-ZN]OR['TA/<#J8!E8R'R!<3$;=P5&
M9<Q?#9SOZ%E6"#W#H])&CH!B*H@?H(2A%'6>></'2H_@?*#@I/?K6V;S&F/@
MKUZ?F!0=:8#W8^P^`W]MGDD3\L\@;'PTQV>P=U.F@('$\=#+M]KOT`KW5)D_
M\C:(*)2\IB(,ZI[A,T`+3R;/(-"1C)WJJDP]29S[X/%$_.!QQ27AE34\?J[0
M_NMQ3U8_7Y\2-O:1/@?)FD]AOT'DM,RR`LB\%T-IM<RD48JJ3T4:0?O@%L,=
M6WLS3T8Y&::>C!I*KT:(9*:C.TMB-+PS@!2'0U47:R!'MXMR/AJ)0S`F*)I:
M*WHI\1;>XHZ&-'Z9XO*T$4%0]\`0\C!_%:2>]PKN3WLBS6NDJAO4B%R"N:$B
M\PYLQ';<1;"0V:GV'_)9P6-"BYOU87&(RRROZT,8N1`N=$&\"[<%&-FK=.B(
M5@U'!5YX2+4F!N^73+\"S)G/.RO`^P\<55+A<<IBKA6P]VB@EP")+^2A#-1N
MDKLFF$JMU24G.@\_W3</=P^QC-#%$VX978`1==;4,NGJM=-]J]?P>%?3X68B
M^[G&W17EQWTKRHA\K66!(_.\',3=,D9C).L^]>]$=NO-NMY.MD\T<K<TTV'J
MW^G@],JLB<%<T30!CX[2@7>07,`P(6J"'AV!0N#K3(@&B=LR+CN:$GAC@N,G
MTR'_-$^\2W26Q&$L/],E'0K#:AK;:NC`=G+6`AS@I6JT.,[IC.=Y)GA<"&=4
M_`RCBVJ.(VB/'L\3PD)F_@T$S:`!]*B4>9OW.)0Y*]4%F"!912]QD>5[J]"*
M*2U`PV\"=-C4Q&&3=-9,)O5L1$$3=YP?LK1\3O9-NM:Z@1G4,!%%1B;XG@9`
M43D2QE(ZYE68BNA4<8ZV4$V[2^EL4D24Q3W:840=3\S#<#%&(A^=4D<MF8/0
MAPSIXO%>IEX$9OV#=A':>,!!.$"&-!$Y.X"K@,PW<M80E@$2"_4P36'?^CCL
M=/]SED1Q^M1LW8R\*#-*T"5\M2"U=7N;4W"FK*JYG:@*O`/E"K+Z"WFF230@
M?7B.Q2?_KK)0;P..87^NOFL;DD'B2%F)J5$]WE$9G69S5I^VG^X_!"EC*/Z!
M+V/+/%P3>M!Q&P/`V@U:DW##U$L[D_"I>'PA-YS=#5J3@L*D;=/"7,\!TRNT
MX_,]1X`B<V@LI-4HZ&,HJA/%@2]W2;(_CY-=2:.S8!N702+KC?]U%R0/F3[!
M;W#'ZD(:*C3DM@SZ0+(@12I:I")6-R_@Y'A.(&0JX#(KP:O%B96(JI4(JY6H
MZON+E6#.$3*?",M2('&<_%2%-B#EKB>\FD)^X:6?FJ(-._8_MXPR+2^^;&E:
M#(:\=5WM1LD!-X4T@-OO+R@F=>NN[,1_Y$Q23\7C5WG![%0LV8G_;"5,.A=,
MGW:1,^)$YE:92ZI)PTA#,9U@TU8_Y,ZT7LO@1-"SLB,(2C^]51!W**JT&+[_
MS9;F@:B_DE`>N-A4^ZM60'(<E7MMO\<A`#P>A%(NQ@^L!H1BHK)*M[N\V`5I
M><UYP+?/D9(<DHY'&K@C=9CJ>41,Q-T'R1YE7:9I6Z.4&@%W=Z3I82(S_>9B
M:M,]:41&3=1*!5G`70?%H\"\*]X^!<'V&ZYNOJ%)6=2_$0KH[;?OWKY_)U10
M]>L_WY3/-*\[5J_2Z)R^T"3;\G>IW)$QO\&"TM*.A!7(GF7FD]K^\[RO>6=>
MO?$`=32\\-W6==*:;NV\=O,N9!M?<&-MSYV#UMN:-;T.7]-BEW!/SC:#]7`F
MJ)$^!C'0%:?Z.ZZL5(OWGDMNW8VIQ<LCW1X/\OZX.1QB?)_J9+0L$V%%;X,]
M_X]HPZ,5RH$22&-$8"J6C4/K59MJII!J3M79"U"`7R\PA[)@7LBV%3+9=JM&
MMJ9HLD%-A4U3-,Q,TI9SA5=Y&1?E*GKA!=4+YB;<9?L@*?<_[7B/A9*M/8_^
MQR5_5^/(O!MQ*"?`=2EZ6STQG]0$A/-<D2`MC1/2H8+"F9@*?XTU:I,`T5AL
M+W;7&G4?7E]0S,.0[\(+IG5X&N8=37CK\MN`O31[L5W.PY7LG3^RI97_,-T`
MVQ.&V@^[+$%/Q"L:I")R0BHRI**#8F<\!=*/5-ACD=%<9N3#_1_.SL"-L#<W
M:S?,KJR\G!2+(_BKHMC1Z'R7,X]!!NEEM<"/]+/XD[65-J0*;9Z-P?=+T/(<
M#SF3R*E5*[B3JH3HB6@Q)PDL6^-X'L0'Z<&Q(%!#1>5Q3`.PR)+YX$5T':?B
M&L-/NSCBMAWV*Q8SP8R+,,F*74X7AUE5\94`T3F,=BK7R%.TTK<+&A?^_-.@
MH!'OCT+30FS[5[DHS<F]UM-].Z3:O:X^!WDD>W)=I469BW!!(2+/#\]!6A6L
M^TE43[A*E;U2!XW\8N\#Y9`NN."#,O?VD1,FW8>3SM-YWG=W7!UW$J]P4G<)
M[+P%D8=')7L/4KW("9&O0N)TKNZKYBT$$*Q[4S;K2>P)%^]%^]K6`VR'L;0R
MU&Y,%M:$"YJ<(.&E-<1M+EXLF;V&`&*]@U'1`=^SJ`'V5#(;RB/?8O!)5=^;
MC9<Z&-.N!"TFKZV(.2H)8\M@%$,PX%W6$:DR<U+U(K6<CCBGCV6KP10=4`9U
M^,!,*%=O$$2_NL!CV?&G3N;I9V+O+YF_?-QY^7+@Y<',N9J)M(97R4'+L?]9
M$A1%<[/Y)K^+GY[+@PX#;7VZZJ_%.UO[Z?80:./JNC2].`NGP\U474@@RXD8
M?7+<;B/K%+ZM!V$*&$ZU(A>'S3DTU2K!C9V7?!A90A_A6$Y/W.992&E47+)E
MD[9[]1+$"3_(X&6TV6_N:;C+8WZ686I`K6A"F59+X'UG3DXGG-]([;`V)-ZN
ML_QMP7_;4D%@DCU!_Y1G3.-M#Z#SQL!%!;]08@6SX"[\K;7M#LP-(\T\',P#
M\E?\&")(;G>/21S>K->4AXYM+;TY86CK;K,$>J&N9Y-J.I'S24T`D0'W`2U.
M['LBO958L[FP^NRY?=`>J;"F6$F<*K\KN*]B+=5&_HFM2(.$]PX*PXF^AD$X
ME%6JC,<:D`([QS&".1(;.RHMV)F+P-UP0[AZ>LKID^S"+#FP<S^V=3'$^3W/
M,8K3%UHP5L211`6,&>[DPUQH]8<6QA+K<?NAWG<-MD+K/-;43;(C"GIKR0*Z
M\M1-U1JQJXU0>`R3(5;5@M0E+?LGUSC?DIH3,K+K5+:B/'[3RE*.%_2+PF<:
M[;AZ9+[;EN8E+XHK<DOY@:VXH?G`]Z'&SI$I/3`/R1QPSTVJIHKJ1]7D$R*F
MBPL6#0'RJR#Q?W$X#Q,`SAP!PWD.EFRM=Q_L>'K!V@'K=1S2YB4^T,TCS4W]
M"ST1Z)"+"EJO2(`8U^5$.71QV9L2#1U%`QX_T+*>4:Q`QW?+B9#HB;[Z$AL?
M1+03H"Q8]Y5[]][XW\BO_*\XK(_KRX)9CAY#:$W#,3<LS+AN&K\[%5K/'\)0
M<,AYM@GB%)=*]WEQ<.T]P#Q&.KO/.<LQ?%6V4<GR@])\.`E*8Q^_NJHH)Y3O
M,LM+@VGP04;1:O$A+EF0L>-4R]A:23Z<#*W-CZ'T>$;^':>3[OORX%I]D)&,
M]/H0%RV:83"\J[Z.4WI5THU-EM`8)<#<H'&0`\D#NJ`+GTK$7!PF8V&,D`E`
MA@P[EO9CQJT(1/$C+4_W#^SQJ\>BS(/0N#:N`V5H*V:U"%;LS"_WL_\YW1-.
MA6U]*SJX#*$7_OO=9A/D>U%2OJ(CUJ")::$SF_8\;YH+8\?P"*3\4T'7N^0Z
M7AN?]YB00F=R#V!:"K"<2_ADW#97"[)!\8(KK]:4+=WL:H\G$8B<2!Z<S)A*
M:F@-:`W64N;$-%RIL7;XCL]U7H>Y5Z%IO7/^G;9!CO`NCIF\^1GRKK`M6CYO
MM]F)>F#G=)O3,!:Y/.SGA(J[^&FTVF1Y&?]-_%[Y]J86?K+G`1;;FVK!!FKP
MU:1)ES;/H:VH"QGITC\Y3J4X.51W*+R*&=?LFA;%[TEWY:+.$Z9#_Z-$GXH4
MV.AUHH>L:CBIDADK=CBEAO%IVU61/DCMH5_*79#8QCV,Z<'V6C8"K'+7CF)U
MU41L88WI@;ZI9GZ%QNVQY5Z#WL/&K`N1K/J0![S->GLMDKVF+"@D_[`J"EH6
MCIFK-L3ATUCMED*7TUI-Z%PO%GPO2ZG5?Y3DD&:X3K06V21K@2#YU4%,##-A
M[67$RRS33;S;7,8IOU#8].JR.S$WH`1LBO4@^[9)C"?5A+89WWRGZ^Z71US!
MK2MP6)O3&7&FB;$=9TNO/M=I(*OS7<:Y80:5>B)(`QX%A'Y24CV,\'%PHC`%
M@C4;AZ3;C(Z#U!UF-.R#UVGLG>&;!N7='P0=K_=9HLD<2DVB!VAX?);%L?4P
M-8L#'FKW%C"S(I">TN5A/C]F):T:<;!'G64I8Z<R9O_B?RC&XT-]=6I'$<3@
MVH+NE8!AP^K6-(*Q.R2(H($@7@0"&S1ZY,N+HS;?A;6]NKXVUZCKF]7G._J0
MU=5GVGIX5OM$"[+`_6(MX"N:>L@R"TWQ!3:?%V-H*E7=M(4F4=CER7!7'5MD
MRX^J+('L,?6<9[NG9V6A2<!]]%RX*8EVHKE67'_V3J%-9'MN>Y$WZ81K*>^V
M^Y>"AE\_92_?R"([?/?ROOJ9*[7WG7V+_.V?K\1_.)?43[[XLHUS>3(6E*-A
M;5,R2SL7YO".V;>=TE:^;2<1/@O4?W!'UL"A+9QH`,[B#H(E+PYZ!7:,"%7,
M_3((Z4I4Q[+=]BOI0._J-0!'R[WST40.1Y1W9X&HZW9O&7,SNY;E>Y)R]SR8
M!Y=/D,$"V6T>IV&\9?NF81S@\8`QP3+:[H](%92:^)0&,A.%1N=Q$2KTA4'=
M_R%".#I"#$,<U1B=::2>AZ!<I`NV55,E,<OCISAEHB8Z`I)H+EPNI]ZOX*MY
MI."YH).Y=0??3&QE5)\-20L0C4ZQZ`BB5B@>T96#M#O1E^MFS>,X5K$4)1'0
MR(D&VH`^:(96K0-Y5(2/1N%$>.'92CQ,V:5SX'$/=4P#"%GL8DR@QB,5(]*T
MG&,DXKE5I-?4!SJ8`^7N'+WX4`2_J$/X"#P8H]?=RK^?D&Q7%F601D`UY\>_
MNHEE&V`3*(=?BE@<5JTLF\V77Y1`2157S$`#?M2SK.?6O7I%RT4Y'6U$P09O
M]CGE4B?"D=M=SEW-D@?0>:.+)EL-C?%Q8VZ'G?H(9R\HQCQ\+^]=YL5-+D+[
MSUD2L7^=[?*<BJLC']E2RG\8[^(MR8+MZ:WA]SA<'@C5-'B3N2X5!);1'V.U
MT\_YQ=R<BBX(3*9YXY9-EI;/R5ZTD0R2!$J8)^%!H\VD$U]#6>6KE'$++<J[
MH*3W)0\N,+T3\FW&DW7#9@O*N*SSR"*,6NAZ/N$$3H@D05H:*/:VDT"_/3H`
MB&OD.=`AVU0,Z6ZG#?A\^@L;C3>@/&GKIR<9D@+)D3.&:7YWHSW=F>GTS3HC
MSAMD[PX';^6J/<*:/>H$@A))*K^=;*H3_:P$TT>7R)W$IY3Y(HIG6H6C3>C!
M7@0S`MSCPVHO*J81I8)!8=0G@+D3,+<JX4,4QYX5)[+PMH6L&ER*,Q94'^UR
M&*^PU#(#VM6"'HS/8@6XQY9'43ULZF9JO!^J,$#5.+$*LZ/3/K-]9CO<6#P<
M>YG6N#G6`NVAC<YW,B'R9GWTV.(RF\3Y<7H`J#?DN"3]:&:55\M[MQTIL8(P
M4GATV')KP6OTUFNQK==BG6'2;)@7`YGSY:,\QKTQ#\TQ?2#IICWE]@\E]8EA
M"B8-034/)W5F8P\HV0#M!ULZ>0_H@TI3(\7B=EG*JG5H226H?@7_0DJCXI+A
M.KZK:A=5TA&"+O&G@SAP5B*&$SZ^?WL9CS-DB>LCY1'9"IML3M`]$T+DV+A^
M,"Z;I*!IS'R68O>8Y4Q0Q)'>+BUXK03V4ZB^%8/MEJ>)9!I5,1P32[_@475D
MQEL#B[AW4MU3N4I_>8[#YZ-G\NND-#(-)#G1A@HJ.2[$0.2AHB2[;%>T*N>%
M7*5$D.LI)B(I(O!NYE@*H:_JI:AB,G%*/HNEZ`JU/-Z>9RF<@E`XU@*+A^2G
M+[1!*@]E`97%\R$H>06?/;_^>TZ+,(^W0ZQEER^A(HHK=T<-?31MIYXJ+KSS
M0O/-;!2^F2_>LV,)WM1X2YIOT/@H3ASMD*>C9V</WT4TKZC=HZOT?O=8T+_N
M^"YKO:9,A3P5-^M.58R;G%>!?@D2.EQ*IZ_LO!X`XL5X+LDQ)PMRI''/F>O2
M4B0-2>[F'!3BN<E)ARZ\0S/+JC0[,6:YBW95LF95F)4/N^5JV)Z&SK@J]KX-
MQF5!XN9,H5K4OLX$>L7GA(X]XH5QR0NMRYA(5^J7N#SVL>P"2%:$84_D[):@
M[]#4T]LR/I(`X106"#G97Q>:`O=!]2VY+1$%MT1=G&R&"Q7NQXQ^0)NO6H'\
M//A5R9M[6FW=?_B*%R*(415:FX[)/QLQ.;+HFXN:,SA#M-=Q'JJZ5W'J)_X_
MW)&^#.+\CT&R&[VW;$P'Q%\U`SA>1HV(>6(_2?A,(J;">Y[>^"K1(T_B?WE%
M-;+F^%YFP6?O0\X+$(DW:"&&:J?/7`:]?+ONSKNNHG)'16>RA^R4IG0=AW&0
M2%U5L,]\2?G^W*X>BL=C@/T^C^49"6LUQ8=(18^7H&TIDI8DJ6CB\0HG7)4.
MXK!%O);CP<I/_;=E"1_W<>J%B=N%J?F`Y-7"5&4''G7<T[,&[JMC5M9KH<61
M1;^<E@2;R^UK?4P<<$_3`W54U-D=M*]VF\<A?3?FP]L3Q%&'40]Y])BH,_VD
MJRL%!80%#.W@=@!MAP`A*>UGP+86)?[&>78RY[?QJF]I?L\KQ7MXN'U:B-S8
M(:!CCDF[1^97"8B8AM4G,\'7.W)M]Y`\)5ZV"D#K7!E_P8X'-000703.2!YM
M;;Y*&#TTQ\67DJ81C>JCZKHJH<%Q2#]:8$P,).)F`?68!>NI;?Y&6TD4/,MV
M'J2;(Z3B\/)0U6`XR5T**I)XG*VXJH-REK+JY9PTF2\WZ^/'*KJAZ%3K&#5@
M!V4<;-_`-7.X0NDK&XCN*/-!9.)%>Z(WU#$%U$N9"2,Z1\50-DU<%3/!7#8*
MT>ZU*L5&H]:?DDFV5D$((WJ0,0A#P(-.=CNW"4$P_NT&)A!<0YP`[/&>239O
M%<5?PS#GY_Q-D;FP60;VJZS)WQ+]U\!=`E=&'PU;6'`Y(G$66Z(J*V%(J$=S
M@2VH8\A(MUH,1X&79(`NZ,R[`D,Y78_[[E&#HJ\"BKQU>TDP3F"W%@./S4';
M&;J77]0^LUB%[/?,C;#JT^Q(&B0VX;P,N@[N_63-CF@7I*:&JH7S]`O!A#CJ
M)?1UXHG,^%?4$(0S(.$C"7'X:01UP,-+'4R:="[292V#'L,TD*62U\!,LL;G
MR1F>,&T:'DR9E4$R)Y0'_H`VQWFFJ\>R,--]&>3EG&!.Z5.<IKRPRF.0\-(C
M<^6E2SP7J5/RC#&:>3%,F5MO("@-B^WX6'0Q,*V"=LF,[VIG#]/QP(@5:YKS
M`AC7<?`8)\PRG25!4<3K.!3?[B'C-Z2.?VOD'[M3!W&1?1:CI_@J6K).3D.-
M'$[D.8N2X-$?X-WD619#U*!)FL4(#Q>CS,1MQ=X?H%04ZD5!XDM[*Q"U.^VK
M/9:,&];JN<F?Z.X!/E*'KO&C%.'C@P:@U1;[I),G=4+8:!2>^JL!Y^KR>@$<
M<(!GO!#FY@7[`1R'A2`T:ZIL#,.QAIK&P\OL4)[7X9SD02"^YT1+=,S0G5S4
MFS5Y]4[I3*OD[9_.J`7MG=0Y64DFQ68=5GK5WNN4BDGMR$ZHE3R4\-DS^YKT
M*AU4\W58P2IF;$81-()L"KIW<BOF\:),AQIT(#2+PF^=`FR<0EY_7P;6\&$5
MMGBAE:B.1P]MY!1BT_S0[?RN\N]4T^`RX8Y?7Q.=_E6,@3W\GO+%`?/0!IEF
M)-ULB&,@&/TZ3NE523?&9E9'`D_\IPM+QTM\'!$#%Y>$Y9`@B@_TV,TR('#,
M:SY)6+O-)LCW-VNM#;I)3X,B+F[6?(1P%#YD$5M2JYRL29X$DZ(UT2+U,G4D
M7>Z_CGJSY"8E@C[_>_,$(AZ!*XUKYL5BCF+K-A8*OY&PI7D4J\7^_M*LUH8_
M`]QF3B]XFM2G":7.0\U\"/*_T+)Z?K?*9_J!!L4N%WUBK"^$F5,%W>O:@.\U
MLA1S6\UP6'*8R7]+`=E=L0E0-SO#P]JY3(X[J$7UM#?OOD*T,5X2.K(=LK6@
MC^^2;:5\N0U$HU-71;';B/MOQ<47FH=Q045]#].]\S@AJ-VT"43-V49GU@FI
MYR&J9>,";Q7]UZ[@EV5HC0=7*1MCKM1NSDU9$E;:[N+B+Y<YI5?5I;T["Q?"
MFB[TQMYB`4Q%DD\G?#ZI"9"[.;P(^R*-$X`6X-8<7'.G,\?B(LT'C[SY;@9?
MB*[C-.9O]],NCG@JQM+,*QVBH,N\N=GW!0_\V"HNHVB0I=:"=HJV-.2E"FF^
M\?.).G1PN40'`,T](CF-/`ST2)I7Z4X%C?^:[U,R.1JQ5Z>%4=^23.(7*MJX
M[&DP0V\'(STZ%::S+!7AFUV0,%SK&8Z.XR),,KX%6P"-R@K06H:&^HQY0]RR
M274,8`&0C4(8^E[(=A1]E>ZPH>CI<QR&ZH]9PCXYSP&::D>AH(QQ3Z%<!&NS
MUE)X#=L*8]P-OI=F)/I-A0\X\N;]:]E2V/&NSIQTX+^:785>?3GO*[2Z"X?"
M/H]?XHBFD4)=6YNU`WH8=QI'@*U5<ST?0#%/C;7!%-68]C%-8'N*SP>+O/D>
M2!G/PJ,Z%=P`AU+`?FK#URL>T$$`RO8JW>Y*WKCSL<J*YPD$ZV"76-^=-"&)
MQA_6PM9H6SGOA'1FRHP>,1>GFVB%M0LL6]<'TU4/5QXY"=(]V5;EE-GKD1]D
M+(6\^:&GM_`X4>-<;N<]C;*X1S+-'<\:OUG?4L8K:1GPGR^^Q$7)UE^6:!,=
M=6EDE)9G3`PD\\X":N]X1%PR8*+73I8EEN7TNKQA10#0`YH&*!/%;0M4%"&N
M@,J*I5)$ER_D"`B5O/G=\EE!@'B1W-VS54_JY$5+W33%1>C6#:O;DJL2>=0Y
M4*/$0+,1#:`:;29)/0LFG6=2@`T4D<G#MAM<[-[\,Z:<0M?/=KR_:ETU@159
M^J"I'(YG#1H*(<1MHT[-R9^".+W.BN)T_S.-GMB[B9Y^?!/X'&]/]U=IF&WH
M/6,7D>1XG<D[QZ?[(6+\]-_QQM[L;P1_&7"!1==<3.H\_83PYY,W_`V^(J=[
M4KT$Z;[%"?^#?!'2O`FI7T7\=9"Z3.C">:L1Z1=X5'V!1^T7>'3Y`@BN9RZE
M?`QO?BZD>2#4_.G^HVC!NF(NJVVH3$$%.CJF!*>KN,4D18XEO_+1F"]F#GTR
MR[N9`]\+@OD^!AMZGFV82-E[`YVY\';[`(B.S?A`\JL<BE'Q]K^(H8KL?0XD
M/NNU_Z5Y+54\RFX$O(O7\0KNW"^,&I$9,&%V2[-@P.F3-!IXH%]XOJ?5S7SU
M;)"8OPZ,ANFJP:CNPKM!*<B;:CC(@9D-@XR&<,=X:ZKFHD-7'\XI3PF.T\%@
MFWEOQ''2>-J.FBS#2`]2Q94P<D`&A<F:'GZV5ETJ(M&L\"=J5[H4?F118S=-
M8-G7U%0-3*71#G('Y(7W*GYM:-3-:`&9>%.@(\KJ*,NF*HM13<=@_Z?`R<]_
M=4DW",ZXEP&*Y(#;4DQUSI&-C$(D6HM2!YP5;M:VE6C-B$%O\L>@ZH["FQF<
M4V>K.CO%'1<+;$WAF<\*0.#[="/NM+SKH&9-#W/^<;=YI#D39I&K4M&M:V@8
M&7$]!1#3/0;JF*GD>&&<9;)2?=.VG@.=>><(J)60I@[,]+EU]H;8'4V52W8,
M"HG--9(EM:4U$:1)XF_U@YSJMFO((&GW.0!/$Y)K91^1=?1"I#**H`$`-RCI
ML1[#5FQ]7*AL^C,J)&HYI_HZ2Y_X/?=;QAK/04%Y);M8^!Q625MC9*!.;,?A
M'?,BG_%6E`^IYY!V$JH<)D=LI24VL$-J0];4GE>;\:6'C5T]/F9E>1IGY3/-
M@RW=E7%8G&7Y]@/EDFUE:,=H@5K;<:"]BH1B!CF:0O@<\JN<A>.0^37A<[?(
MS@`?CP"&;`XRHVPHA>.6V4P$/?3%+=="EW%>E&=L<!P&R4,>!\G-^CH.:<IV
M:[=Y%NW"4JD^^IL02Y(@^W-KV+W[G<):"0JD)D$$#>[(UU1(109,O\R&_.H8
M-?.0`Y+4N+=SX[;?\T\$?"T^>5B#+]7@D<0$W"1<'21P$F]?#75/&>[(446I
M];0M;5"/QWXAACE8DL"LM>9?@ROL^FO^)2@D&_0U&0H]-IW,&OM:;LK`5[,]
M/,>YJV)3*'MSDG"^EPWL8?X5%#!KL=F07Z'77K-"1ZJQO(71S/.R%6X/_<2V
MG4GVQ)]3/6"UW2950U\'9\N`'*A_903WF"W;2;7B(9UI"#VH.5"NXX1?#/T<
ME\_DT]?W7Y/+\Q5&U\D7>Z5G2-!.0^8<F8OLN#]D+*\^%47$/C+;;/@9<Y#<
M!PFU\';4LT$<&QV87A:1C!PU@PD?C<A508S%WOFP!Q.V8`HV&HE#,2HM:M]A
M3%1\CIS6)<T%_8^TY(0+E[,F%1'80R8UM-[A!!]:!8398"$#!4+[CQ>2QU&2
M+289Q$T9)B[=V%(ZQ@3*X-A(+TT8TCFN-?>B+8_?KY>\#&UYK'^MN0L\DMIQ
M#7?W>6J0ZAP/#4B$B1X]IG5,]CCF6)^>P3&3[C)+Z6VPYZ0U=YHU_4A51&`[
M`JNA]?K!UD-)-1;P@O,D@#I]O#<-MJV<ALM:C3&@0>M:/?=Y"(=:`IMG%M5#
MC3:<-O1`MJ!V@(=T-5$:I)9"+63PVU0_O!U$E6@MG[(\RS<4]G9;?\.P_8:;
M'F(D6UL'255O=NW%U$/'M,2+51KQ;G)Q^D33,*:%*F59K4Q'B8$:9`.H_>YZ
MS102\*R#[B2H].6_`X3NF^4)((;=2<@VSZ;B..Z6&,JBA^JX"?YR%T=/]*/X
MBD'"^#7+^>R]11!\E`B((V(`K5=>.O@+$7-(/8FTLQ"%QE\/-'O?PQ%;+K"E
M-;:DF87$NS`5-+5+82AE/F'T;1F_W&?)3A1S=0FA#Q&`#9\/0^K%9/DPTHS#
M&#1'!L0C5&Z#I*C'(;/Q.E$Q"(ZKY<3G)#NGT<^[,GR.TR)+SWASN/R.%I2!
M?3ZCO!J2S<&V*3&8<VYSJ+W35=YPIIU+Y&12SR9R.B)C_XJQ.IR3>X)];L&&
M$FQ>@PW%="3N@*VL:H[5[035-UGXBFU$KN*#[+_++%^%9;P)'J_2BR2B>;)?
MA;N2?MC3)(NC:[K["]W$@>OE".\GPE^9F&#15'>@^&;X*CY.QF74246>7*6D
M>@`13R#5(TC]#(3>SLRK]DT_?1G)BGE>RIB;T7JISVNV;$&U;'%*:+5L@5BV
M3;5L2?4,9#[<I/K,\'+'1,K,0XM_2F,FEH6H7O=`OP3%AW/V3NPWM?&P=A7M
M*(+XB[:@CX6@G<_O=P@*Y`,Y)S61VK-"YSQ."#QK@']]_O7BR.U=R6FAERWT
MH(9>>9BH'$LG\59[ERZR[:&<_C-[3HN?L^U?F#/;/MK!<]02`G4(1R`><Z$8
M3JKQI,.3^)PV],C<G2LG:,\5M%TS`9D#9")MXWZ-@:CYY,\$<90$G\7QEX5/
M,C`-)AMFZ/5["1-R4'5VB\A[L'K[?PHVVW^=]?T=$EELES_,-ML@Q7)HI&9^
M3>:)BO,GVC/<TC0M]LE+D#J%=$9(@9KF49CZ;4%W"D+S[(,N6PJ=NXGVA+?M
M3$%FILVD;]Q0&XF>S_E3EF_8AN`YINN++S3<\6J>-^MU'-H=/(U2@3EQ,@#7
M.Y$0<XB81)I9I)J&R,Z_)G`.9TH.Z-8272C0T09=)J<A<0^,!4YS>F0H;3['
M1C2/L\BFN>[Q--@#G.[K]X+CXH_8^N4JEMT@1'V\YMZ?W:RU;7\"3%F@PU=6
M?6PLK6N5RZRIW])?8X]/_/`Y>WC.=@7;.+'M!B\+4U+J4I=%2PA4^D<@'K,(
M&T[J\3Q$3NH9\]E#Q\+ZEL#8QW^OQ`"KZ$RX<%SU&;#@9))RR3ZR5E+Z8JXE
M`*(L1R"-2D8]`T@RO`'QCPPJ$99,,FH;#%C,QQV0A<'.Z0M-LJVX8YE&MT$I
MKB++VCY/.:7BAI1#HI`U=5B?TF$Q>MY(56&O0T1$,"69MDA630ACS&;*=8B.
MUF$KUZ$IF%430A;<<98+`V_>42A\3FM,17D@U@TFIP,Q=%/F6U#*[`]O;$$$
M\*IB2A1(@C1F4FP,?#(13:/[;98664ZC.EW8QP);D`4UO5;PE3S&[$LSO4VG
MA]<",^%..KB+!G>368]`<2SPP77`D3D5]C(^[DU8"[C/9B$)0D%P]23^Q]Z;
MT%.`B2Z.@.HYMO5X(B8@T"ZO$I-#H7!G4,&3_%]<'HB1-&EBQ@:BY"'K]W0;
MY.+C<-5"RS*I'N;NBQB2!/5#C&'WRG(U$Z4;TDQ%H"#^WN"Z>QUSXD7F;-@)
M\+BC826]/F4+@W2W#L)RE\?IDXN/H24`XF*,0.H5'^L.-Y`G&/-E\IW4ULO@
M(WGPT!U7#HF/K1JF`&J:5*".V4>.0VUV\$%Q-RF66+#N3;4B,VX==/(R3PF]
M:],RT>:$0(R#(43+XG+72$I$OU*(]KO3B3#"%]!SE)U1BV\A@3/5W*1?RAW3
M42YEL"W(HJW#V8-O)V]O*@)?H2R@O01P7`;;GM/]"EL.LOER_2+NZ`M-=_2.
MAME3&HM.4W7%W@^T?,ZBPP%_H]&87^!!&:J;A-,B]!U1,89TJ)RT);R))'1"
MCH8Q6BAZ34RR!!_K_BZ\.$J_\C6XV?5G>FW["6>.7T[<'VCXG/(N<_M[FK_$
M(2W.LJ(TOJHP1@;*2(_#ZR5H-B-)/92(L2ALKQ>>(&3C"K*F%(UE-60_K24U
MX[WE1.E#$*<E37E9$)4,#2J?WCPHJS<`H!\R;8;`2(?KBZ_2E'E59--Y?R!Y
M,.,!$_.B8!R?Q`-IEYM^QI?4KGG"T'S83.-!0+T3[*IC4=N[G%SVF0-NTV6&
MHGYUQM<J!PLP?.N,`5G\5B,B!BG)2OF8L/_8>5`.2>W`R=+01)B#NV$(XSW&
M^$#XN*OUZU>L3:(Y7M\^INKU_DB"ISHIT!R/JD7`0R+/:1'F\9:O_\WZ+ML'
M2;FO'O"0W=&$/22Z#?)R;V5<S:F"FEP;\,<<UIG+C7$UNY'VAXQ4!(B@@,="
M3P4Z6Y.\`HW/A,\'DI09R:LON^44D!E]:X$>=P5LI=DG2T-2OUG7K8AO:<Z+
M=@9/9GZ";CZ(NZ`'U(O#5KS&%$K;0[N=`>\^N,')%H)C[TXXXVG:@9-M,P.)
M>V$@0VHO8UR`?,I.\2;C_$")T8R#A-.792ZLG`LU%5!G0@>N5Y%)M)1O!PO1
M('(X'D_!'E'8(N+"P65C#D3N?L%4D)`9_5'!&C?R8U+EE7I973Y*H^X-YSQG
MJRU2P\Q,^R@5&`-O`*Y_W%K?2DNC@ZH`G6D(;+T#LBIVW5R[6^_2*$Z?,%AZ
MW^]T4+6@G8;%Z)O*F,;T&PJ83]"^ZK',MA%!%&>\'<D+_<#V#[R[AEWX7DL)
M-I`_`K(7TJ];;_,P0CN#U%/P.`3.R/@VNH-L4TTANX+MHGECFEPA:8A<AZG!
M(W,AC$33X-C`0"[]:A/]%PW+BX)WX2EIQ`\3C;R'P8DPEXN'(0P4R^'#2#-.
M'&+#>P66KT^;UP_90"'KAWVI"BX?4;Y[(JOP[7??_?#VY]V'=S_^@,!C\$**
MQ"W0R8OF'K%:6'R.&K+/:7.J./0(;:Q/$_&TH`M[W&"U`+VP-)M-.L?_PPH"
M,%HX*_`Z^L[KOP^KEBU<7'$NY.T?15^KC%\6:U'7ZR#0Y_2ONSBOO*FHLV+(
MW`P')6!P0&&M`:918Y=97CW-R`<9G@GBA*A`:)4.;[Q9#87W0ZP0U-J#"\=V
M)@3V#H8O!"0^AE8@U$Z&3AI\;GLEG8:=7/9YT\XM6[$7T;_S,LMXS=1SYG"N
MH@T;RN^N#'TQ_44;UX?`W@1S7YK>]:CDH"6O\#Q$7]Z*G/@')RA#G,*]/Z")
MQSF98U5DQ]UFQQ/4J\*L^+I>%+'G">9=%'?'!=&J(/-@?!6,P94[/^WB<T"[
M2Z/#E(Y/O(5H<X>?/YV?$SU\SOY$`\,N098T87H&60/OG1;N>`^!HZPO(JAT
MBE4(M2C.%7F5=4X*WI.:"#L7Z4N^`_EY5X;/<=KI.-R<HU2MA]E[D#=\ITKV
M[/=B9OE,R5HL3,D6AO^Z(+W;M0`^VD2+<YPT1G:",=IRG'P-6OR<%!+OSE$E
M:/H8.>F#&97::LUXDC^*/=$N$<6&,&QNBMT2N.DV042P+E=N>!R\*<!;*S>F
MSW(:B!597HW-NQ:CNDS"%JJ=*3-D[IN+-C#(GK%7!1X:K2%[EJ5%S)ZCVL'V
MU;EB*HC3I831RRII6.M@)'0;&H?W#V=]?WOWQO<3('%2]`*A]D6TTN#748^W
MI>0&XC1+=\5ML`\>$]IS=*I;X':9+Y:TH5LR6B[$P!E(38$($J2B,;BWJNC@
M<3ZF78!'L0#;:@&&]A#%3`O@D3<#PP+(W`Y'C6#4"-1!'7CHME]$\F-Y\84G
M"A?\61^SDE&N&E:V=X6,_!%S:B`NB@W88[:MYI+.9")G5YG^I#,?/@PT!53:
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M],G4JBJFPAREJ&#T&+D>2-J1..RG`X1M"P&'N?3&@,0^ZJ5"<YZB$PDO%[@-
M,5QF^0/--W$:2"^\"7):V4HSBJ!6U!1TWP?KQAAY2+PSE>_HF\EXK*\GUFK[
M+A+).EC9%C68#:N[N9[FP^K`(C/S5N([[@#8R.YR-;6O:5#0BR_;6!XB\_*,
M[\;\".U<J-K:"B"]^K=\&&G'S5/@U#PEP_+U[W=L[\81M.>G76F:I=RI2\%P
M0SAWM-O.>!0*6/5PG91H*XAK1&2*3"JV?O1SD.B/+]4:3D<'U(G0`U1G^53#
M(8\HIP)UW&61Y!4VR#/)J<!U@_8Y?0IR7FZI08C8)S"0O'%/8%SLIN@PL'IZ
MXDM;TM4FVQE6*U-.AJDYHH:B:3#0#"9R-'R,P`&'$($:1R!&\PY//#(=)`D?
M,GUC$(=:(Y,`0Q(]&!,<3>$1O=1,(<R7S"U*KMJOWZ9&%:?[LVRS#5*[6N=V
ME'&T&#%<!(UN$!1(AT0W]Z[@.005&3Q>@R_ZFUW)IHAZAMUR)&NQ$AU]TLW#
M+/B1>3C32DS0X01H*9#Y(D[*P:*%BH5FF$+%':>$&JHXC2(WH@CKV1B"UJBT
M?IKQ4BK-\M[)5)AEWM-1<CD6Y04(&YL;92//!KZ5A3`O%SU=A6&^H]%MGJWY
MN5&52U&<[?*<7Y]+HX]L^>0_3+TS%]+034#MEJ$7OI&S27<Z/]S%U1AT&HST
MRY:W)>M!`^\3ZL#)1KU#[=EXR;./)_DVY@<>]02X4X[VE?M'&T]`@F/]JK4X
MK*GH51WWFBT`1OJ/>&(DO'_($,OQ;J?6^55:Y2W8FIA!&M"V1`&L'T%NZ]K'
M:9T6A,IB&")Y$`4R^^5!RTP4G4)G*72<9V02-&RWG/P,MPW0B9*BK[V>#)2=
M&(=GW-UC1NFR/R;WQ-7MAA$.==<&LSN&_*BU1F;,N)R,B9LFIT'!J]ENN-\K
M=LV=UARG^W9(M=%;?0[RZ$:<A16=>-U=EO`B<OR/ME9NIK>`MI.S+6XOY813
M>?O(R9#NH[IM?WC(I3NN#EJ(!YZ0ZI'LATX$]E?^6%(]]_\NJUN0K.QNLPGR
M?>=.6D%$ZXFXC)'M?B'6I"BS\"\DDUD"ZG4!=XCF57-&+M6L.NY5&HR/N\TC
M'2WU.=^#H1R_.99P(8MP0N03440O_K&._764^>KW99"7Z-92_H&;C4]I7+(%
M.:5/<9IR1^,Q2/BIP4S+<9%&^!?C0KI<I\,K`;;IF4W?:[=)<RG[UV,G?Q*^
M)ML8"@[^*<_L8X=SO,)KWU(-+^N<6E\^481HQ#/Y;[*E`S4(UK15>`>;AB<^
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M%0,N1\?R;GD?];\;OUZCH&;UZ]7:Z34I][;(O2H+8M:@9/\%P'<%,RSI`IL&
M_CRHK`CP]>R,P>>!SB6BBP3M5?+Y>E1<YPC^%QH_/3/KO&+\'#S1VB>_S8<[
ME,V=AZ!]G=?JYYHO]V(I3O5[D.I%VN8?XE7^+ESB?RP[AI0SRZ4?6:'_%HEI
M4R_9WW_ZFHD56RJIS<"$(?(4"JL,!4MOP<\)G/#5T&^@)OT,+N:L<,^96]JH
MS9A--^MGN*-%R?[$5RK,-ANV_O)TF2<?9,?G760+X8<A7KU1*_=:4]2FU\#3
M[((G5[^OR.HUI\Z.AL_-WYGVK=#NEJ=>_%G-W4#^`3*+A_,CC*IKX&0'G*MV
M<#Y'#UP!/+468+2KW_9M#M7ZBNS90+X=JJV<[?N]^OV<_0>9U<H-IH(CLW/8
M/\BHQ0--'\8EOXMN5-R4"R+M;GX>B>$TS_1UT.Y/)EONQ5(<4.EI9(L^?CH"
MFR@!*H/+Y(39Z(.%U>[C.*Y'ZR.?.[H)8GY$>9:E91Z$Y2Y(>+_"[YS\ZH5?
M$85KO?AG@<L`:-Z*=%Y+-&_%%_P'_RP6JT?>L(W,G@9Y\=71)SAE1/@4G&XX
MC$8R]\1!U)%'@Q0IH0;VZZWVH(,>[QE4KSSF9L.\%$B;%H"E'];CIWH]?EKK
M\=/QDV\Z%!994(=;=HU!\`E<=?;P>:[_Z8!U"QI,:QA4:Y@W:QAVUI`W`!9-
M;5YHP4=OLUP\O[UQR7[LU)#EF0=5]XAD7Y?[(6P^(\H>5,9B=\F^R6]OTS^E
M']+SA_1G]I_[WQ+12Z8\$0^C7X+-E@_\[>V[/_WPX=W[\]^R]]NRCR-"D.4S
M?UW^*KQC`7M3\38I%1^:48A?*-DP$,],Q/@+E<\Q&TIY"^,]EJX\4$9$W=@'
MR(+X&N)%O0?CJFQ@[P?:&!+F@PQ:Z)&-5FV@!_99M7D^J(UM87)PU(E&]#TF
MV6+)C&-$O2^1K:VA&:^+=_,7.;#<_PV-,B[%;;)M!K8JKR>2JHX0JS"^LSK,
M6OC50`^V%O\,<(=<*'?=N#Z&JS'7G(G!704$7\TNRX9=UBX'>`[V[!!&&X^?
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M[R5.A>HW(V4F?GT4L57JJ]=T<6S!KS2NW_\NJSEZZZ)%MB>^BFA!VQ`^TVB7
MT)NUN$Y^NC]+@J)XX*]HO.O0D`#;+&AA]31>-9K[G?)6/5-O8@;Y5<SIM4R'
M\Y3&OY?>P1G]6,OQWFT>OS`)N&5^O!"J#]2E@K*""K1%5X([9KYJ(&E&DE_E
M6!"F<UEJ&\VJ_5K+L5Y;7DN(@9+S!F5P>#*4JE-!T504DSH.DLTLUM5$J^F^
MR'),=75[XZ;"VHG06JL+H=?6\_9&R3.`3KGNE6]WCPGSBV_6:RJ:5J#5K#W6
M,5*FQWRS'*L_L`?<K#L.\>I+/)1!/2CGPY.A]*<*RC$O\7'<0>SN@OF^]F.6
MO@TZOWM@/Q9!*!.-?^7$\&A8[6?3:EC=-UN.[;J%/-CNBBU]9^6["^^FAVW)
M0VMK^^7H11&Z]7_&N?D\X\DS^-2G(U\8*5DWIEA0%<<EW\Y=I5'\$D>[(+%2
MQ8.3P52Q`DI/%?-Q7!>W(]%I6MU7T6M:S2<!Y*I?XO+YCLH6R,5SO'W(+M(R
M+O=2)=AJ6EORT)K6?CGZVZ]V,`^!R^%X5:HC`QBI5+>O[W&=\&*S3;(]I<5Y
MG-.0S>*:_(P]:Y>4_)#9;/]O0PKD#KTQS%[_IWHB:682-I5TY@)M_>8`><(O
M4#6XN-?SF/';@1LQ<T:D]M?))_BB4?-%Q0WN=BZ2Z])VLJF^Y&PEF`L&A5)^
MOS[+'2-#A[.AS6`/3"]&5`U`'&D9_!YFX9:AC[$<)XF3FNK<YCI.Z55)!V^M
M#_JCPY.A''T5E&-VDF=PS:G<KWPL$8/Q>/K:SZ+U]'7?Q,?9^>N.N4X/]`N_
MVE*L'@MQS<54\^A(@%8@4,+JF3XQD-0CV<ZP&HLA:NT$Y4TU]"M$E^1M,91R
M)++KX'I9&;^QK144#QGFN;`B(615%+M-TR]9Y)*<QT68[=+R+BA'<S3LB(%L
M6BR@#F8,B[FD,[G--*NG$SX?-!EX$J0R-SIH)_/&&!74J(::SP'5?N,"]55A
M]C"VXJK>Q5C*JF^))8\<MU44B;XI07+8W,G*T9CM)>"+)<VSM(/)NL2P9B$9
MJ%G8U$1J'UJW[;NJ+ZE@\9L67%?9K)MO/8)V78INQYVJ`AXBEVQQMANH;M`]
M.WS<DZ(S;ENQG:A0U)08["SO4UYWBY0709'YBG,K3,/Z0/-IRU=P(^66<>&'
M+(K7<2BFG-,BS&.!;I5&JCI^T]XY,GF'5W=)TFQA9[@JPA],ND\^(9UGBYCU
M/*7W%KP7Z;:XW67(V^1-883`W=XE)7F>&WOF8OP*BJ.Q+4*<B\%V3OCT#X8^
MHIAR"6=0=^U3YO*M01HW6"X>BH)8"PF$S0G3U&+X"CPZ\3_\<ER</LEWMZO7
M.-4S7YW'-KQP,Z@L&2:HG@02$4"U<"_50FP'%^+U.6(:`9S'\5)+WRMPM`XN
M^-;[YR9H.Z2Z9NWBHWR/5^N&C2_P`O4*.N5YVM,(!%%0@-4]K,K3C8#^_?AL
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M_<:!`Q,/MG0%]U^LF-HL8F#!T1[YGI_2B.:?\YB'7>M,4J/T\<&)(*GB"@A]
M2],.:[*%H:^MNKQ[-->[V^=S^[P^DHNF.@%0)V1KN'\B85P]Y51$!CL9*%9)
MU*/$0).A#:!JN:B9T\T+0Y$U,0F\H($7S0C//:EX%GS(,GM-I7$\0]=0%&&B
M^-R3X#UI;M:_5,T57$+X`U0PQ.\'P>G=S7H*#VW7D]!%[AUPQ1U<GQ6X4,3L
MU0QI'+!7<J.'<6Z*TZZ>V/^<!<7S)37?J.I(@!IB):P>-S65B,5(PH<2/A:/
MU77`$@@L(<>RG@.+NXGU!X/,GNH%:-R*:J5G,L%>E6Q>2O<*X>YO(#330;;#
M6CAC0ET/!Q'LR;!(.0AJ+"""/2<8)%OG<<%1;Z!'I<9#H&N;WQS5G^ZK7_V<
M)<P3MS/:X]1`[;<)V%Y/[[J+6C.)7P:N?DNJ>7C,NA=$VD!\W-=^+WF>":*[
MM9\-(S(GP%@VQ_T!4\'TT"1W]"GFQ5OXY[QG7]4@(-=7DZ-$0-P$`VC]8J7M
M%-+,@0S`30^K:&!!!MX6PH7$CS"5,K4W82AB'IK@0_`EWNPV=<^(VSP.C5/M
MU`1`/0<%I&,VJH:U[3+$0#S>@26,K(:QG06&NP?@A0.9E==)R[AAUXC*<B'R
MF_*9YE62H'%$_'`25`#\^-6/64C\O<YZQ1';-GOEAN>IXMW!XM>#W*(-5P^Q
MRJ('0&M:%*+JBTT86SD?.K5J`-#`<4@S!$_@V@+`:A?%O(KR4#P+/`-*Q5&&
M_?\&V6G!I,3=8T'_NF.&^^*%_8]=I].AN6`7QX>!]#(*FV%$C,/7T53S0?07
MD-5?`XZ=V/,4_7?T684*,M#*5@UOE,]$OS2XKCQ.RVVCR?2?#)0#E3UYC`2P
M)8!%M74A&?(=8%L=RT5V477'GPB,V]RZ6@P30:;KE#TN^A85:Z\+[<=R47)`
MG2^:0)\LM\XONF0IY?WX+%K=Z8F`J;H1:(IJ^NTX;(WOC+Z57MD9?*@%;W$>
MOH1;N[MA(M`*3P5MC.?P-JW3?BPCA:?[4AZ'"@^?LVOZ%(2R]D=U8&O1=4XW
M'^1040^HU[#S<T;D<-(=CZ<%O>E'4A],C7\A#_:I.T]9]C4>G`MZ$M4'HNH@
M!LL<YLMI?-8Q_!T\F*+M;6>A2'J30+3'P*OW6G\U0Y!I"=6RJU6#8LV]6WQ=
ML3=/R_B%BE+&]II!305!HZ]A<`K7I!DLRXGCU!RC'\VTW93ZBX'%`:YM^Q$J
MYR.).5UKNA+V`P#7"/L2CGTAFX#3\>?Q:3MT2+FH>J<YM2D<HP7;!&@4Z!A?
M%74/PSE;&#IGXTR!#V-C0R]<5.+"V>S04/0,^M`8R9V'DF@;U8C=5''+/O]S
M(!)_FQNV;'OU\)QGNZ?G&\;#O`98R3_XC7FZKO]30)SG*1:GEW#0=F&21$E#
ME5\8Z-(E%6'"*9.&=%4$$SXO>.;E*>3R;)OE>=R377=YRFIY,D;Y;=`LSW#-
MW-GUW"M;'R1YRI/I'_6F<"KEXZ-E-[R827.I0OVHG_*LL+M*94D:U%&S7H8>
M]PL"G2M66@U)!!D$M;NF`7_1K0\\)-(GY&D6P.X>WN28R3%F$FS`"A]-)I3&
M[J"3L"\8J@@2>K,65=9D5T_V#Z%R9<VUJ_0A#]*"^:T&?J,33;"0AAWPWK:&
M3><<+@B<D+8C:N4A5E4*XY1TZ"`H:NH)6]32)&F#MG)H1$:Z=&=6;&H:[T":
M5OESHU'XQYZ]0>291]9CYBP)&W!'0QJ_T.AF1*#U*3-6Q*%/\&V78D3$#VB0
MF@C)`"5\5OC"'I'M0?$D<W$'";U-!=W5;0-/\7"2?K-<-P?1QZ/U;FGNY\>8
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M$*VHPEU*M`3OLLVJ_KK.\KK#WL*;JYF@5W_BHOL21S`=K*9@/B.S[,#/<CFN
M&>W_8#^S_W"GE/WA_P=02P,$%`````@`J(4,1:1L=F3)1P``4_,$`!4`'`!A
M=&YM+3(P,30P-C,P7W!R92YX;6Q55`D``]M\ZE/;?.I3=7@+``$$)0X```0Y
M`0``[7U;<^,XDN[[B3C_H4[OZU976;)=W1,[N^%KCW==EL)VS>P^(6@1DKE-
MD6I>7*7Y]0?@3:2$*PDJ";9?NJM4`(@OO\0MD<C\M__XL?8_O.$H]L+@KS^=
M_/SYIP\X6(2N%ZS^^M.WY]N/O_ST'__^?__/O_V_CQ__^_+Q_L-UN$C7.$@^
M?"5EEAYV/WSWDM</-__\>.-Z21A]^'O>UH>3GTEC/W_^0/[XG.+8=;;_^N$B
M7:5Q\N%D\J\?)I]/3LD?_G(Z_<OGSQ\NOG[X^)%^QO>"WU^<&'\@W0KBO_[T
MFB2;OWSZ]/W[]Y]_O$3^SV&T^C3Y_'GZJ2SX4U[R+S]BKU'Z^[0L>_+IO[_>
M/RU>\=KYZ`5QX@2+72W:#*O>R:^__OHI^U=2-/;^$F?U[\.%DV2"DO;K`[<$
M_=O'LMA'^M/'D\G'Z<G//V+W)RJ#*/3Q(UY^R#[_EV2[P7_]*?;6&Y]V._OM
M-<++O_[D),'Z(Y7CY_/I9UK[7TIR+@+W)DB\9'L7+,-HG?7YIP^TW6^/=U7G
MG47B!5ZZWKPZI,P"IXFW</SXYT6X_D3+?A(V]ZE;5Z_"(`Y]SW42[%XZ/B7E
MZ17C)/X6."G1).RVZ+!"H[UW>^Y$1&2O..M;+QB:7S`(Z"DA_Z6$Q[/E;(.C
MC&ACA,A:[PG(E1._WOKA]UYP,!KO".,:QXO(VU#9S):7:>P%.([)`'Q*UVLG
MVLZ63]XJ(!/OPB'C<K$(4S(P@]6<=&[AX;C-(._VP8YP'['OY"J=;)\C)XAI
M?XFP6P#A-M6QB_,H)-J:;.DL^$?J;2CU+;K';*9CUQ["!,^=K?-"BVKWJ%Z[
ML]9&WAL9T&\M57!7N_,LL%Y[238ZB:#)L*7*2C8T[<:&J+6.':4ZD&Q;]*FH
MV/'S3^E+C/](";*;-PJO14<.FC`W\X751.14$U$HGHC,S(!=/@P*_YF.XN.#
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MX9Q,-*%[$[3KZE[MH_;Y*2&[G@Z]KM4_4K^?P\3Q6_6X5O-(?7W`[61;U3N6
M3'$4XW8RW=4TV-?DL)_:@MQ)D,Q2FPC'9.K*+HSN23<:'23S+0Y<>JN3_TH;
M,'3%F5U(AXO&YWQZ!1Q&LOF;_H)$C5^\Q$E$NE<VY%.\6?-(N2[ZG,_B2GTL
M)))).\:+GU?AVR<7>Y]HM^D?LOY__'Q2W$3_"_D)Y5]^Q"N/?C!('IPU9G28
M5Q05^\DZ?Q=1LZ].M"A;)']LD'=X=5Z4^+3);D`_+EX]O^)]&85K??F5?0FE
M2#Z$D8NCO_Y$ZJ0QZ628&0+*E;YG"JX(DLCQ[XBB__@OO!5RL%<63>PEX1!*
MR<+)D6FX(#!<"N76=U8<\3?*H*F-8M^'4(I[<F1Q7Z4117GKQ62Z_A_L1&1_
M=4U6+([D><71J8TD"-"4?$R/S$<)YIDTR^&@7@2=V2CW/02EK$^!9%T=+`2*
MSRR+SFV6_CZ4DH8S(!IVP_"6_!)+B-@KC;[83,4AF)*,<U`R<A51IZ-6'OUB
M/R%-."4E7T`VIK>>CZ,K,E)7823>EC9*HE]MI($-I"3@%YB30;A>A\%3$BY^
M?R*'7!S/TH3Z.%,';O$Q05`1G7RVEQ\9L)*O7]E\?=JW-NS+P;`%0L%GN94:
M+9WX)9-_&G]<.<XFUR7L)W'YR[Y2%3^CRL%UMKSU`M(AC\PY8>Q)S!8ZU5M;
M+@R@>L[=)>7]SPH"V3`TA;DW&+A0N$:,#P3?$I-S1V[&%O0_Z[Q?6.>`*+SR
MG3B>+;,Q?O'#8^T"I'6`[")\:B04,OIO-YMU0-?AVO$"`8V'A8$,+$J\L*ED
M8K";PR>R%<7QQ;SL:H;M*UZ_X$@T)OFU@"PV8HHX(U.(PA2O;SAZ"7>7-!#T
M7K:BEUD+R##4GEX>"KX=VCY^KUKQRZP%9'IJSR\/!=_P;1^_UZWX9=8"LF>U
MYY>'@F](MX_?FU;\,FL!F<?:\\M#P3?>'X=?CD=`,>D\?P\5.5.H!61+T^%,
M#07?TC\(SD@AW(8U7CTH(UMKXD1`^!<#0^#N-DRC%M3QJJ$36*.0+G,B'/SK
M`ZL6PO(T?N\%^([\4<DD5!5&)Y89@QH]-W86@;$A7,0Q3F(%PW*S(#H9B`&H
MR06;N,.NC\(^D,,J_%64&=PKCTY@;3X,;D0D,GH_"BYI*!,:Y(#\CSYH>'-\
M3,,>)%=.%&V]8/5WQT]%UR9*]=$)K`&(3R''9*L*:A0J0/8(&\=S;WYL<!!C
M@GN6O.*H(3.!`BC41B>P]B%=^A4AC<,8J,KS'GQ8BY`NHP>=-V;H2^KO4XX]
M;O/GN7/?R=TFRC>Z#U@\8/G5T`FL)4AY49:!&,?8?,*+-,H>&6[HY;_0N-<H
MB4Y@K4/*/#+Z;6QH0IYKI!,IFL":@32WO[2[QHSG@'/FO>>\>+Z7T"O<(#>*
MO(8^@17GSWD53C.J3:#)0'R(5$ZJ.J#&,;?6$*N?9/F5T`36EJ1%H%0'&.!&
M<=0IXO/$1;@0(BGR2Y22KA]@%\W@ZJV@":RY2L(I9\K7PS=&S:B%%VJC$LSJ
M:`)K\3*A"UQ@XU@4:"BA$JJ<=$9I-(&U=+7BF(-C',XPNWA"6G.\J!J:P-JS
M6I$L`S0.UQ@MCEF"@+5KM6*6#<.8*\PP3FMJ-*()K/W*["Z<HC&VKB;UH"]'
MOF,21>?FWRSQ:Z$)K'G+`,T2=.-8>UO95P3BG,+:S`S0+@8WCC6XZ7,DNT!F
ME$93:,N9D"3NI2$+QR@.Q[6WM5)_@+VB:`KM8]6"2Q:(<1QP+US7R[L]=SSW
M+KAR-EY",?`M&^P::`KMA]6"5P&6<2RXCS3*9X#=&R<*R'XBOE@LTG6:F6RN
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MSF>A6!,Z\$AGIO>PC,,$4?.N:[%T*]2&CDZB1;LB'G.>#+#O`!HI6I06;$$M
MZ'`E;8EFX8`V9?1$L72=YM2`CF#2C=H=!F-6CB&-6[7%69B1"3C\23=Z]X#T
M:!"!]#.K9!3/EK,-CK+OP>6GN@M(+W'5*06W,DX-"$\RQ\?Q(W[#08K%T;GV
M2@+[DO$ER#,W'71_%-:&0OV#51$34"5N+;<.L!N9-J<B(.,P,#P2(H@0:<S/
M:Z*[?IB%DBO@"B@6U@/V-A.RQB9:!F<40_DW'!#!^#2HC;LFBR$5"HV*(&=;
M4A/8#ZT%WW)`XQC>UYAT=N%EC`CXK1<#]CIK0>9>[\=A&?S-\8+[,(YGP;47
M;PHG]MDRCTEX(AJKPHK`/F=MAJH,3W?3X*\YWP%>T<W_0/99.OLK8$^S%JRR
M((SAX5J%*]]K4L55(7)7&MBIK/T6N0%A#$&F'\(@;((KPZ++3T#2NL!^:-HT
MJP`:QQW-79!@0HK"&6BO)+2+FA)%;'892#J?>(:PJ.XBO]5V$=5O8G.4M"ZT
M8UL'OI6PC>,$Q)52F]D;VO6M`^5"3*-8KG&BM.=JE(/V<]-?A_=[/X9-<QF?
MI+SUOW1B;R&@D%D>VG]-FTHNBG'<A^_#N_;\-!'>AW-J0#NM=2:VA@/:\]\,
MM?_`WNJ5(+H@O7!6^"&E_O&SY<$-L6P<:[4#[=&FK0;:Z,;QNH`#NQ@$.EX4
MFBU!^[Z94A`1OE)%?AFOOP5-/7CKA]_AW"UJ862JSNB%\CFH!N!X07:*M!OS
M*'SS"$F7VV\Q=N^"REYW00AZRV-(*=BSM!L;3B@@%AG\W;4^3%-WPX!N;NW.
M3L!GX59<J9RJS,4*`J3TPOW?-,ZC;#^'CW@1!@O/QPV@SZ&Y":*/SP&[D9A4
ML)[$,X80^>79%[M7X9I:I&3."NP*P#XH?1',5B>N"$;AIU3WYR!_]G'&9>!>
MK,,H\?ZIX\S"JP[LY')<;5$4R#CL_>/TFSFNPBB[W+2_+QC"[6!=_\FQ&[\D
M!&Z6\VT>X34YNXKV.[*ZP"XYQU48%6F,PSN@B;2(,ANLKL)8G/E84`W8XP=2
M4PX$`1V)RMP:%%/!83*%WOR@,DJ]^#4W1]#1(5F&A'6!/8>.OQ+)I-']NJS;
M8L2)ID2[/@NN7IU@A>^"6\>+LI?-M-NEHP5KQE"N"^UN=!Q%T!)']]NU(6Q+
MB/PB3,YVUSC_?TUB1=86M0>`BHU`NS$==T+1DXNQ&SE`^XH`<;ZA[Z9-S3:@
M':0TZ=76D4.TP!87SN)S"(']PNT1>^N7-(KS!-<+3&93=KX'`ZT.P-=*@U;&
M,M0=_BB<:@_%0`YY&\>C.:4R"*5/8N#.DE<<Y<+5FEU4&AR`OU=K=>J.O+NQ
M;IBJE,'<$Z3>PL1H8``>9#VH"@_I.-X_"F163W_5:>_":&@`7F:];F`XD,=P
MD7B(^F*1V2#CN;.E*S"]\E@LHI1`4<JNWJ[!`;BAZ9*OJD6J\$?@/B$%_XBS
M/)IS)^JJ1<V6H`.['4]]#G&/XP92W6_$B,,==+@XPWY8&JA'\FJ)A?@N>,.Q
M*2]-06.#"49GPDU3@G,<LPN9/`M;Z<7BC]2+,)$"&1[)=NX[04*69)H"-C-#
M"!1%O1&:A7:`LXN,:K;>Z,$>A;%&77Y&YA4T&:13<#MUT8-M[@@UN-6HNJ8W
ML1H)&D.3@62=,+$:27":V[S`'9(>\::846?+AS#!Y<Y>H!2\*F@":\UM22);
M(T0@1[&J$#$M,';C6R)'&O"9)F6?+9MA_,ERFO^`:<9V^HMH0]*J032!M>L:
M59KV(H`UWG%N(.MP;G[@:.'%F`93SB(I$QS_<**(;+KBVS"B,N1=.6HV@R:P
MYELC&M$6^!B6%'4!&MEYH`FLL=;H#*('VY@_+N!^E<(E8X'^CQ[=WAR?+KIS
M''FANV]_%.B+3C-H,I#$&UI[5%V$XU6."S)&HFA+AD/F0ZBM%7OUT60@R3H,
MJ`,#FC%_[$VF:J2W43)F;9C::$Y5AF8L,%&N#3<!T/'E*=UL_$Q.CE_*Z2Y8
MAM$Z)TPAUH-:"VAJ8Q0$#7#CB&=4AK^<.YXH/E6]&)H")\'5X(AW/]M$,XJG
MP[G/^+/S@]I<)&0V2J(IL.G1`)\'@,9QXU6*XR$,%N2/._-[X#*.-O3AH1_&
M::02IKEKTV@ZD)RYVNM]5]30L<HX5J>KD(")XNQQ8=WRNG-5*J>]Y["6VXQG
M?6K9')K"VB6-$,RP2740QS"?23Q'3A"3KU,C6^G=M+WRG3CVEMXBH^TYI'OB
M_5]YIP4#K:(IK`FS+^7I+I4>E[-C![^[QO$B\C;Y*^C+-/8"'%.K[E.Z7CO1
M=K9\\E9!)H$@*=SFB-CGH>\MJ.GSV$DMHI43%(^V=V'[\B`B\YJ0J@?=CK^+
MZ*>2+\Y$^P`A]CKUNS9R".\BNI^)KEWZX@NT8W<%.+R?*8WA[)``I-G?`GGL
MN:WFU[O-)GU:@PCQV+,6KQ\*$Y*L*L!<P^O23MM4I@F-5H!'N`(%7.\+'8SC
M&7>E,V/#!_3XCB%LATJ%02>M"S#JN'W2&W8ZS0"/.Q46^!XL.BC',_+H6;AT
M?3MZK,271,ODQ:X`,+2:'5$919P:P`.&*U#.*.&C&,^`J(<X`DOY=1<0*M)\
MQQ^X?\/NJKVAN$.K($-+N[=JXZ]]L^"#M`M_W)'<21[C&>[4UNLE)7QR8*:'
M7!Q`F*H$7=&[&=)I!V"(*_5/95#K-00\C'59X5V`Z6(>SU#-#>S''I7Y5Q6&
M7;,@P+C*+JQ>0Y_0'>>=H9M[O2&EW`;P:#H0-L\?2`//>$;*4_H2XS]2TOK-
M&YTICIZ%:._[2EYI["H0XVBO*TKCAE<'.I<07ZR\$2-`,IX14KO$#*M+3*>Z
MQ`S%EYCOEYG#NLPL"22;HQ?2L<QDGG&T%8#E5QKW!:$0]R@\*6E6RGBVW!NW
MV_R_*K.Y6@/`2<3Z5A-5&0SR"6<MI"D!O<(TUY`3**B`1FW@'%\]\:\G@'$$
M;&R(3WV:$%4#SNG5\^0@03Z.?"G?Z*OEFSCQUD0PHC>[S8+`^;EZ9OX`ZSC2
MGLPC+XSR-Z6/>-'PX=P%^:\=&H07YGI-`:?GZEE?6DC#V%,]\*<?C&?+ZHN+
M2GW@3%U]KS**(AC'2SZN"XJZSJ@V`9RVJ_<I1UD*T$^!#+T<))MS+\K>4D5Y
MUD/'GRWO0QKV]@V[>7AU=2UJTQQP9J^>-:JE1$KM^L5J[:HYQ*CK$+\2=.ZO
MGE5%#+S4B%^MUHA:%K-*1C4W$JGE5:D^=&ZOGO5$608[\YK5.E,]\=98ASA5
MH!-U];W8"&!7RF#WLWAV[JDB89!T^E"H#9VOJV<5491`I2VV6V?7%%@FL.*!
M3)9S5\=0J]0"=%JNWHVVRE*H-,=N"^Z-$P5>L*+!XIY>"07J&B.I"9V5JV=-
M44!?:8C==M\'_+UVPQF%`?GC`M>V8.HJH]L4=+JNGG6HC3@JI;+;]+OO0J6K
M24KUH7-U]:P^RC*H=*8'ZZ]=7FG/]!'?NT_:0'S2J@-^+?785^Q0IV-W1O9?
MBS2*"'F9FXW*I-"JO7%[LK45R7C<6'GQ`F"F@G%%K7A:O&(W]?%L*92RTH*N
MV92U\2M:`!W/8"SO'9W:E2/,0/S3A++H="D^E.'61]B*<8ZPVN4:S,!Z?Z%?
MG^.9_=9;#\5-C/'EO0;V808>K=U<[A"4*7UF0?%N@);(^/H:NMB7[I0,M0S\
M),.HPI@3R8B"C]:>OSM[S]]A5H3A!VW@#..O'I%6$@:XS"Q;_?`5)Z^AJS9D
M]5JQ.P1#.\#CV7WE[^=AAIE%41BJ]3V[.B,S-+UFW=V\7M"Y>Y6;N"ZWNS*%
M/EU\=Z)<B93V3QV_84L4!X-X38U''^1J*8="OG+QPQ,]26J4`]X5&66/K2#[
M<.TFN;V8=G((7&H3>'#6^#I<.Y[HP5(?GP-^&WN@#YQYI1_D=FO?S7KCAUN<
MY^C-D[9^Q>L7'(E675X=X&>P?1',<9L12&$4@16*@Z=4'1KE@-_#'E<%]I&/
M(XV55(8\$9(3"+Y+\%JT5>G>./`+VB/L;XS(R)@N`NV*)&*NS;IQ86G;MKBA
M;=LX\%-<,QK2[OBE)!Q3"R!@@O>:')AA!2N[;/3HK5YUKT(TVP1^PWLD?=.6
M26_1B.SR!;S&B>/Y[\Z`0W,&S)\*D]Z*7=9(@8<PB)H>;!*CH+%O_$F<!@V(
MR>Z#?B6)RVWUQ[]Y.*(OR[;W]%V9Q,BHU@"P]=$HWQ*5DLEA)/I22"T;<(>`
MI?9&K7:`#8GJU$I40Q'K2#3D+MBD29S)YT1J+1+4`C8?:K,G40(FP%%8!ED0
M)ZV8GPS":M@C\Y.1&0=9&*>MJ"]J`9OS>J1^!W`<<5--[*U43,1&OP-LJ#OF
M?M20N*#G*8X'6Y5PG('N(MEY3NZ]!!.8&4PT"VR7,\X]PP>NNX1&L>?9.>36
MY*#DYE\K#Q0XSQ2/[`F(AW0\OI`UZ^RLLLY>5-;9F9)UEMJM4X+^W4C;T4C+
M30+0A22>O=54T^,TLQJ4SA!L(3%>_+P*WSZYV,L'&/G#_K@B/Z%[O'+\&P(C
MV7*,IHQ20)91DQ0UR6=CY/+8+R5Y'[C6R/TB0(9&CL@.Y;K75P-"Y<R:%\7:
MQSW",TH!V>E8<F%,1P=]'<7VD_OV]W*KX""N4!O(!-??]*2'W7)W*?[3</)E
MZ1V-0FU@,YTBB9H:T(`WA`U(>P7XZA`)!CC:UO%)[;*"6L"&,T7.V(2+88UB
M/;A-H\!+Z`O&P+WU?M`_Q7(S/+<2L!VK$]M"5-#63$.^B.59[(KFU"D\Y21K
M/K<.I!&JUY5>A-C8%0S,]%Y')%W.#PM#IV$0,L,FDPW"[D6:/DDO'*BE<_5!
M6>@4"1Q"..RQ>F\W>1=D*G(]/Z6&[B=J(L_LW#<_%G[J8O>6R(OZ1J>E'6T_
MJO+EEMV`[&EO?U^%RJS0_T+0L]",);P<DB(K/1Z6587.Q-`W\3KJUI2*W7.?
MV5?"P(D7E.AB,RW$-(IS9;M'O\`)$CHP>H!C'`?&JS`@WT\\LDS.RUZK[CN%
M-:'S&'2@6@'9.!SU:D#I`[IX[FSI?DF'^L-ZT!D(S!#/Q@6VH>-<RI6O:P.W
M?/PHOI[CE4<GL&:]%IQ)\1C+0&Z(JVX'F7N!/ZS)YM')V(Q^IJ4#G=F^'Z^F
MW.=,Y@1K]"-H`F-K-*X0QO6-(:@!G1GT/&UHWLIH$T89N]=.@F?+QD]"'QQ9
M932!,77VQ#'/O4=%#(;=J;K&Y,S#GMZ1_52<A5:=?0]P%+]ZFSF.%I2IE>C1
MNG(;:&*O:5*J`*VD`7TLY2Q/-3O_71RG=*F^RQQ,/=+;C+7;,,J!W@4))FP2
MD9&_QAYGDC#0*IK`&"&/HCR&Y#.6@VXEA[D3S:+LFM'-GC&4)EVU&S9>;32!
M,54>=1Y2E(.Q0_(P_2AOXL1;4^#?8KQ,_7N:=J2-RQRK'32QU[E268VT)3+0
M$U>F\/3.Z)4&MWJD7/'6*491-(&QCQYO\>&`+MFT.YEKQPO$BS65:7_7^7G[
M:`)CBCWJ=&),4J5B]I`QUM#..1]1"IOAO"":P%AU0?:W.\@ECU]`8DIR6"RG
M09?NOQ4)%=5!$WOMM&K<RM"7-/]B>TA'7DY,H&"-?[9TK9?;QK\HYUC1:&_$
MB5O9:.UV8E+#*O''5&]D,'E8-#EFJXP6[O'HB=0C\K`P<`Q#/:+D9(,'*^1E
MM,/K,*)A"OS0"?X+)V2Y)YN1*R=8X.@*4ZNGV&="M3YP4$(V%8Q]E08>NX?G
M?1BLGG&TGJ<1V4G&>)?G[W)[162U"NE6E5[CEB5<R9S>LD7H5"=F)_CV0K#\
MZ30?.`>V=$UHV2+P$^L."J"K43(Q#&RI><#?KZ-T=;'9D).N(W1^%Y8'?E+=
M@0_&>B,`.<Q,UH]X@;U-0J?+5>K3:EO2^2A\<WQJ3?SV=.LZ8E[56P!^3FV6
M:2W8T'X*O1X5[Q6BE\JJ`KV^/NZQL([6\I?7'(37*:;*_QS6__TJC2@'[4UJ
M*JU"O^56H5Q+651!#W59V76ZR@X>%SF0^"N)H!+T0^^N-#&7$`G>OO*%#<SH
M#Q0#]-WV_V[[?[?]O]O^WVW_[[;_=]O_N^T?*C$KS^.RT>V[($Z\)*6O87($
MCT3X1'"O8DZU&@$VW2L3JPL*VOK2>KP:40'#GP&VQQL<_;JPH5^'\([:I"GJ
MB/;5^:<38'Z,$GYA8`N\,J6\SD._P>`0<^]XKN]\OPBR]-!.L!53PRD.;#17
M)H??_8&^:/A/9XWC^,K9>(GC_Q:%Z4;,#Z\\L.E:F2!!_Z%?*7`8^BUU5D0"
M'M&IBS@.%QX!*HGY(:@R)`NQD"@)!FC/_2'&[@6V#1NV+`AQ6NY7TCED+[`-
M24@-FTXV"KLM0AUC]L(:A#B$<-AC]=YN\EI&,X0U^VB1=M!SL%F3EV!H%>%L
M'N$L>8>%H*-)&EKCV,#`O"%D]'"7*%8QJ"B0')F*!+_K\,",V%>D"+T]?J:V
MFZJ[XDV_J`Y4@$:NN!FLR/H_3!>/>V^!@QA?TZ3>81;2(#_[KW%$$R46:145
M*6S5&%0@1QUN6P,;J-&:QM-)??K"]0E';P1<K#I(915!@S&JCE05$`.U$]\$
M*V>5KQ!JC'$K@,8R5&1*V/FA1;:M[:*^.H$>2RIU02,'*A*FB@/:FFS(_)6^
MQ)[K.='VR:%[:B7S%Z\.5%S`OLQ?(IR69QFI(:(!GV?+NBNIS!PFKPP5Y$^-
M.@[=2J@&=DR9^\ZBF*&D,S2K+%0(/4VA,^9I'IH!Q>P=Y@L7H&AW4$]<AAO*
MCH=?,2RX8G6HD'=:!#'&MP:\40SYV7))SG%13+T6R$F=%Z9;5!PT\IP.7^RA
MS(,T3+/30TI7G-ER3OI)9,,UGN^7`XT/UYXD+A9C]B&3/JMY?,&YX[G?`M*[
MZOAV%_P/=J+G[^'S:YC&3N#>^/@-\^WJ>LV`AH?K2&T+J`.U+RDC>?Z._3?6
MTZ,VS:`IH"WJ6-SOH`[4U5$=R:L7)=C`R"\;0E-`T];1^*^!'>BF>O8=NSD>
MI7GL.;P-4Z$FM&X030&S9'34B$Z@C7EQFMP1?'6\(,$!]:B_Q9C&32W]ZHMW
MSMP-G+PFF@*FM.C(M!HZ:%]/)>M7>15&<:C9P.HUT!0PF41'$L6HC(5F-DM>
MF3R0YDC![G-8#X=3.+KQ6%2HBJ:`21TZTJD(SU@LYMY"I]_\H-X%,9Y'1!_G
MZCE@6K6#IH!>3QT9;X.UI/_7(2VSO*VD[CX;3:TT94DQ[:PEPQJT%Z[KY?W(
M>W^=8D4"9171U%Y[EQ*XBM*!>4@U\@5<A4$.Y3:,:.PY+R@R<Y"_OY#M'MW_
MD<G%"UT>T2V;0U-[;6(=(%=*,3#C6*WG>4K+6N^E8UVI,CJUUQ"F#+"B=V#V
MKZ]>X*W3]0/^GN<7O/7HR<X+5@\8NSA?CSB*K#P1F/P&.K77:F9:#I5.#<RB
MM@<0/SID=^I>;HOGU=Q[+W$U=&JO=4P!6D7FP)XR$\U;>6\XR/<SL^7LQ?=6
MF>RY)A-!%71JK^%+`JLB<&`FK]WAXCF\<:B5+KN*E9^O&L71J;W&+@&DBK2!
MF;K("3Y*OFUN,29:UWAEP^.-7P.=VFO8$J.JV!N80:OH-3G\785QIGAT<RAA
M;J\T.K77.,5'5#$V*!M4X]B6IZ[+4)/NT#V8T@'WL!HZM=<BI0!MY\PQK,$W
MRWK1,(H^T@2%W.M:3GET:J\92H2IXFU@UJ>\SW&6G>!-\WI'I2XZM=>NI(JO
MXG9@1J3&=)*CH$[:\6S9O(@DBWQY%ZDTZ:HUA<[L-3"UA%LIPL#,30TXY:UE
M#=;EMH*EI`#B)M"9O<8B39@5X0.S!>76JMFR7(MV6+@.%]P:Z,Q>"Y`85<7>
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M@WM,]@P:OLF\FNC<7HN4&KJ*5;O#7,V2UUTBE8O`K85!+.8;AA*H5T;G5IJR
M]`!6JC`PJ]8N%J+`CM4HA,[MM5P=`*EH&9BMZ@DGB9_-(\5#PLR%6LZ4K!XZ
MM]<ZI8*MXA/*+&5FQKV($B].+MPWZB"9/2L-MXZ?;']+J=]K@G&\2WLO"F>E
MU0XZM]*`U1IKI2M0]BM#NK)8T+T(S3A-+74U07H$<I'#.G`?PF"1_T6D+[IM
MH7,K+6&=\%9Z`V48,Y6[AYP8\T>RURG-G9>?37('IP?\/?LG<2(?E0;0N94&
M-7V0NY`>=JL%179)3C)N/9+8!34+YV;$R^VN2+$07WQW(C=WZJ<)&*,TFV.S
MC?'SJQ,4'CN_Y<^R`^X#F6-W`9U;:>R#$%.EW%`60N.!>_,7XOQ7]+(JZ-Q*
M^Z$*K(KLSH;#5H[)9JB^QB_)3L4YKLO\PNB+E49&,:"*V,Y61D!BBQ12Q4WE
M+'KT5J])P[UWYT]4_&M\(N"^57OHBY6VR\Z8*PWJ;-'T091G'H4+C-WXED@T
MGP(OWAS/IYM_ZC5*?GG"9*OOT?V_0&=TFD%?K#9OZD*M-`0F@)EY-:$[?&I2
MN`L(1L>?IR^^MY@MEUF^<44=$;:!OEAI4&V%L](.R_/>[G9/#=>IF@35MI2\
MVNB+E79:3825-G2VUII\`5<N?,R7)34X/!N\:GWTQ4I[JS;&BN4>[*R?ZK*[
M)]W<ER?]K2%0@@\'+J[DTA`I%4+@I>L-.0JMG05.$_K&-OYY$:[S'I#);H.)
MR&CP3G**SF[YKG%"%L3XI^.O45E7YKZ3&2FK_@A2'RC719^//Z=6J2VXO<NR
M68@F5L4F$&RB<17I\R96=81V9S?FPKO</I-O2Y)L*=1&0\FV)2>2N^]2P#A2
M+:`(I9FV%&HCV$Q;BAQJ*D`#GMT*D&<UJ9!)DYTSRR/8+%V*/'&\BSB`1I&U
MYS:-R$$QC3"1RJWW@_XIEE+,KX1@<W-UXEF("CJ+L!FVLZ@+DH6[*H-@\VYU
M7Y[K2(SQ!S,)9U"DX[)6"L%<^3-%+V"GZJS=:V3Q&D!*4*,<@KGZYLB?3=)^
MARVG*8]X*:>I7@[!7#+KT;378<MG.^Z$?Z^0/U1>&9W`7"P?X>#9P`B=WZQG
M97C`Y1FM@[7MH!%T,E#+5)-:3;U@PAS%`88+^5N,EZE_[RU%YDJ%VN@$UDRE
MR:FF8C1QCELC?HO"N-7*D55$)P,U5!G1@PHB;#I48_[XZ3K-;M>N,>GUPLM#
MXN.-CS/6`IH<+DJ\?V:_<X4B=M,W\@ET,E#+F(Y6F11&]TW+K[G^!7A%.S2P
M.8B(M>4V!9T,U+9F9/XI`!I+RYJ$B>,/X):ZCK&XI2[N]_^\E]6\H`0,D>WY
M0O#\/12JVG?AK(%L%/NV^M(A=!3?%0.Z0=9AACT/[H$8!7^_.5YP3W:1L^#:
MBS=A[!6QS.(8B]V_Q16![H>[<RR%U=M6^]B+W4.8X.+])I`G%GUL0:2\\,.8
M7N#)5S1V!5"?J^?(H1'@=K[<1.OR9V'Y/^2*H^Z`I=$>\.+()8,SLMIBA+J]
MX$7V*0/5<&YD#PL-QF-*4^Z,C<T^KJ%RPW5Q8A6#7*L.!"H2.KAO$O<,@-=D
MI2GRDE7=Y=[8R2L!>1[QQ,W<XHN[;_>=*\_+_7);_Q>93XIR(\`.2(9FR%:X
M+;_TK2.2^I4>%@;V5M)C2LYV!6IH$W0C!K5D7F:4A?9+8HJ8-2FS^SXP-IJ1
MA<5LL,I"NR"ILL'IN^4SGNYB<:_@_=*Z36`W)\,+9Q<Q0+O-<,9ZS<A"(%R%
M`6D^\<C?Z#_L/QKD30):C0S'3ZH%B8Q91!L\L%E6/;G"=8J?P_+EMSRGD7H+
M4-Y0+?EBD*Z'=4"&^!@O?EZ%;Y\\`CM.Z*HR+?Y,=6):6T_R7]%=]C^Z2):(
M;GYLO"B_BF<G?%6L">4"940+-#".XY%',_#0+=G'YJ&R)=9P5A4HGR<CQ*N`
M,[;6#R;,UK?`R5UML$M-ZEK$,^I"^2?UJ`$<E.9<3PP&PFBX314Y^RAXKCV:
M4Q[*><C<.BY"MHO[:?.\G4FCD)-@R-:+H1/`V+^F1N<^H))-FZ-7-6><,N5(
M$0%T'GG!PMM00(H3,Z\!=`(8V;>?V5D$M=2,SI&K(#6#'C[R)^51/(NR@\EK
MZ!-<NI'"-5M")X"A=HWIBC[F4FE@`ESU,9W<!:0KY##S2(XM3TEF0:WRCBE/
M*:)&T`FL,5#7'T0/&?0I3^_JNYH`N8<XC=IH`FO14R56$])`+;;%$O8M()WC
M@.'2*:^*)G8X;>G@,78&ZR==7A="U9M`$U@O+SUB]7!!G]1X*:O3W!`X6^[A
MB6]#7:;;M(4FL&\+M2AO"]#8N>XHZ^XL3>+$";+;I38K[T%]-(%]Z6=B[66"
M,G8J,\WK+BCR_H&#SR6_#IK`NI9I\B<&8NQ0U%_^Z6*?YQ?6^KO@'Z_>XG4/
M3)X62+#HMFF.1MRUA^GV&$LEL#OY6O/P]]5)J(O`EE[IB0-%:]5'$UB_M6XG
M8@&H4@>@$JEQ)H(L'$$YB=T%3^E+C/](Z0I41+*/:>;)ZF9_%M'G66^.CP5>
M#UW:1!-83SFM*:$KT)V!9%A*<4TZ_T8D_X;+*_Q\+ON'E^Q/<EPET&D#3>PP
M@[4"5I$,$^B#0_&!ET:6!XW.6[>.%_W=\5/NU:="532UR/REB*?B<6#&K^8*
M5%ZT%QZ_S^$E#O#26WB.GRMG3+I\B^DZQ26X?8MH:I&IK!O,2AULSB_6%$%M
M]MI!SC)DB1Z5*[>!IG:8VUH!J]1A:`:W/9^L8D(3)(-4J8:F-IG1Y%@J]@9F
M,KLIH@64YXK2'T=U$Z9:'TTM,IGI@*J('9C-K)$I:A\0QX=8K2*:6F0]4T)3
M<0AE0S.WUNY6CD)9L;N;F7);DFRI56D"3>VPJ[7!56F#_<8T(>0\ZWI^M.RD
M$XV&T-0^\YH>NDH_H`QMIAYI;XJ[OMS[5L%?E5<%3>TPJ:G@V#F@V![*:6=&
MBL%".94]V`TG^M[O;]A=T7M'@N`M>P.H&>^I=:LF8AONGC(>V.GJ_<E[L96]
MXFS7&GB0IRX,L+9IK<4PS'>=AQ;<;X''O\[@%(<,B=B>$"6#=HG/%'V;[(3V
ME#A18HC"+/('Z0&]=K_WG!?/)SBS3._>DDRTM)O/(;UMV?^51W+K!B$C41E5
M@RX2`(L/T>\(!WR1=Y01;B((>&.(WP1`8<!W""O[7EURXF#@\LI`P:Z,:H(6
M6F/^P>:G_EJOC:\")MH&BH]E?M8P)(R!>B)?O=)\7W<!<Q!(XWJH5`:*P&5>
M$5310OL=V[&4`#X.!%A*?C'GM<S:8L!;;4[>S3;'C^6]ZZTL2O=>R3&99O@0
M+0]DJY4[&=JGY$#V'*-VK<,CH$<K0S*LKTA#\@)RJL[:34^[#,FP[A][\F>3
MM-_A`460.W:B9%@/#S6V]CH,'0O`]+[C7B%$+*,T</!LY>6*W75H$GEW?NEZ
M[43;V5)X0)T%ET[LQ;,E+9$)_FOH8FD@5R.-`P?CYK#)NNDSA':8%W]?G>AW
MG!2PZ@]S@J_8H9OMS!%<X'VGW`#H*=\4APS]T!'`*!;H2H87<9RN,P3QS0\<
M+;P89][?@OE?6A<H%'B?6J*#'7HYZ4]#'KWX]]L(XWJ$)$U%834!%2<<2F%X
M,H`.0]3GU++!"_K\"$=K[9EE5Q4TFCC(S-+$#AW>J'\%^7OH$Z'1:[@6<PN[
M$=#@XX!*<R@%Z"O+_M7GVGOS7!RX'92GW@1H^')`U=F7P3AN0"O$=\$F36B`
M@Y?BRI\*=NFDON@F2:$V:*SS8ZF+&/Y`8SEEMKTLWE@5Z^;FAQ<G-"=,]M(B
MBVS!#P2D6A\T3'J?!V0=`0PT-A1CPBOCF?!.O$KU0&.H]\FY"O`>0T#!^T`4
M8:7?/2$@/2%JO?W-\8+[,(XOMT6GLZ`6=./RZFTNMW<!X3*/V$R+WX>YK][E
MEM48/8.K.UGTW8EQ^V\<07IV7V[OT%UN'[)0+!(_$7:%P3B-'(-PF=+M"68L
M"O+@K+$TNS&K.+"["I\8&9$-"';36.S'I&X1C7+`3BP\(MBT[??<;KZJ>2GS
M_I\MLSM!R=3,K0/LWC*$V5DD&\MS,=<12>?GP\+`#C1"8MA<,C%8/MR)5N/X
M9EYV-<,FG:P%M8#]8]@4<8:F$(7=O.IY7D-'%8&?INNR,'8G;8M7-VS(WH;H
M!>Q4G;5[9+;SZ@9.*[]'`)NE@QY;3E0KAVX@=PT]HO9[;/E&5+B`W&NY=XL:
M@/*J&-(ZJ2XI:,<=:3R1O0R:O+LP;@4H3XD65#!NNH2PANGS?;P;;4"?!C$O
MG:ZIS9FF`..<']45"M"S04</V@`SMN2;3&71""+,<AF^QN3/:R]P1*%?]%H!
M]670'NWZV*`]K%6H;KA6Y:]0"J\+)8[YU4&3O7<C5PP*>G=E>C)W_S?-$[?,
MEH*(/4KU0).V=YNV.6B,.3&;G*L?4GIZ)*J9;3**[I;O@GC#5E@)*H5ZN\$J
MA6+,@]CL"EM=;1;]EP7(XM>`RHS>=G(5X3#FQ`L=C)J^Y/2R.21V`O<J#.A!
M``<+#RPX=:U'%_L]TO'FTVH'P'_O/@Q6]-72/(T6KTZ,=_V5.=U):@)[RNG*
MG;/*R4':;2XNLHW-G2C99D$6Z5`E![#+;?U?9%=RRHT`.[XIL,FYRM%!.!Z-
MD/I''!:&#K:D192<;'!_-LZ.Z.+E)4R22R],7G'D;+(5-;X*HPWWXD>E&G08
M)J;@&;LB.8QAVH))]\+(<_PG/W2"_\))DIV,KYQ@@:,K3.TA8OI4ZT,':%+E
M40,/K.6O[[W6Y?:*2&P5T@="]`*D+.%*5MZ6+0([L;5>AMO#M?RNF`^<`UNZ
M<K=L$=A1KH,"Z&J43`P#VQ#,:>]NO2A.KDAA>KQ^IC/K;'GO+7!`.CZ/0C==
M\%W:6[0"[('7@3O&6J0-?9A;C`S&$UZ$Y-#;51'4FP%VQNM!$[2P0P>2$NG"
M\ZL7=5<%Y5:@??YZ4`4M[`.]N"1G)3]<40!%SR\V&[_(D2&F7UX3VGO0+.5J
M>*%O,GFA$[+UB^"G%SKD7.7X?)]J<05HMT&SI`IA0D=;XIEXEN2HFG7\`2>T
MQ['$ML,I#^WQ9Y9)$4KHZ$>\.V?\_3I*5\HS+J\\E(=?/T2*4`XU.!%>8&^3
MS):/>)7ZM-J6=#\*WQR?)J;Z]G3K.F)JU5N`<N/KAVP]W-!QB?JVV=PK./<K
MU(;R`>S1C-?`-M"M]%>/+#I)&.!YGB5<YHK/*P_EY:?+`LMN+X`T3+,('VR%
M)2[`\'C4:`+4F4](#H-,35S]\0OK=+2HNXBXN=-1`A-7;/B^1[R<EOP/\KR)
ME.K9[4ND"G$\?B/C]212YE+N6O+N1_3N1P1^;?CN1_3N1_3N1P3]OF'F_/[H
MN2O\X.1](<V&468E$?,HJP?LYZ/,GP*.@1H#+D@OWIY"/\U6!\FDR2@+[$^C
M/E.R^S[4:S#RV;^E"0$?Q&&0SP./1,!$.*\J\Z-J?6`'&&7V-/`,]#(LNXB_
M([OM.Z]Q$W\;1C3H\=IYN0MN?-)S?WNQ2!/\=8O]T'/O<?H[7GL2J[R1QJ'C
M4:GJ@BFP`[UL^Q9XI,$X>W_\C'\X\==K@I7\4NJ]ROC7:@3:XT69>6U4`[V&
M^\_P-8C_%FY^)[/9#I.845$=:/\590)E(*#OS7BV=\=S?>=[9BH1LW18$MH-
M19D;=M=[S+IA:I*<XR"(M_Z;$\B627$M:#>35M,@&T;)VJ_#8NT_G36.XRMG
MXR6._UL4IA(C#:\\M!^)^GPG`+`[QP^+)+*-6I.5]-7#RYL?F&R@B++-EDMO
M(3USR"I">X2HGS94D%3\C>Y%SK'?<D%&@FI_$](![?M;+D-ON0;K@")7`5VE
MD@IB:/<RQIQ_[7RCQ?%5$<$<YE4-R+L\H)!4/9&N#Q[Z/19$-@3(L%8='"+J
M_?_3I3"8#"#L>B5\`4&[[MKMD](NB\$$V`2UQP";IX,N`R^'D-D,)L"6*#7"
M]KL,O6CQ-C`X\D+>V76O!)H`QB#77X08O3=VH6TJK$/6.^X)\*`,F@!&_]X3
M)5?8NZX.[-3U_#U\?@U3Z@Y.5(B^^TXPEKS6$]5!$T#;S(&L&7S(.@\:>E^)
MI-LPU2:I60=-`*-MZY-TV/E!NK1=K"*<)6\1K1R-0F@"^&BFY>)Q`,"8^XPI
M.U+90?$2LE<,30!C6A_*5"3X78<'MI841HEK_(;]<)/A"=RYDV3OZ_+`$B4&
MB>U'MR$T!30%L(AA;03:@!H8PWHT\F#!F`!TN.+W?*!'EK+#@?NT"8,X)+TH
MO1TUR9*W@*:`#Y$T"51#,U!/ZX;M5Y%&41TTA;$2Z!`GZ_]`W:_GOK/(5_!5
M]A^U94Y4"4T!#0NJ2YH,P$!=JVO/V[XZ@;,J,"B1IE(730%-$HK<J>(8J-/S
M$R:BR.5*YGB<)+X.B6JUT130EJ%(HSH28Z[-AO:21.O2)5'`E#Y<4^1-5`=-
M`8T:BFS)^F_,G=D01X]4CJI;#V9A-`4T<2BRPNWX0'V9!9:;>T&<)>6Z:`IH
M"VEIEE+%-=#E3(1:+?VQ>@OH=)A^$TV>]#AF0!S%;?`C?L-!BA_Q(EP%7K99
M*R,4?<7):^@V"_R3F52Y?6/H%-!6HTDW^\ZY'>91Z,XS7KP&-++O]@E';]X"
MQU=A+$S7R:F!3@<:>499"P3`H`UZIMQ\O"#!`7W3*"-YOR@Z!;0*&6&7A6B@
M)KTBJESER'F+N1'"&$71Z4"=3:14B1`-U*1WY/B)IX`FH^[4:B(=J%UP/X[D
MM9-PAR>K+#H=Z,,D-1)YD`9Z9FID87\,MXZ?;(N>/X?UIWL\"I4;0*>`IJ7N
MO&KA'&@$A*+;LV7Y"F:.HP6E8L4=H8(JZ'2@CC=JA$J0#30H`B,C1>X+QB.0
M6P&=#M1`I4:?$-=`;8[5[7G@UCU8:&+V_.J(;Q665$1GPS1'J8Y%%7P##:]0
M[M;(JN"X7DAO`]_P5X?&$J1=XYQ+1)70F:T&(S5L0XW!,(_"_\6+Y":FX:S(
M<D[/P0+ONH.RZ,Q6$X\0DKF0"X:WKN'WH#H-LSHOW]UH-('.;+7PM$%:<3XP
MTT\-QFT8%3@4V-T51F=6FW^XF"K&!F8!:OBB446C`0/+'#YA=!N&]'5"EM+)
M79.B%#[MMY)OGD9[Z,QJVU`7V)5J#,Q2=)L&;O/L_(W&%:Q\""@NNLM__A[^
M#]D><D\X>LV@,ZOM2RW05OP/S/8D@Y)%[:`@"):VY-?;0&=66Z!TH5:T#\P*
M]9!2UR"R"R'RI^+@4;M?#IU9;6]BP:DH&IB5Z6(=ID$R=SRB<#?.XK7H,X\I
M3G%T9K6%28"JXFU@!J:GA$P+WS:W&)-EH+%EX#KQ<FN@<ZM-2F)@%8$#,R85
MO;Y.LTMXJGNBZS-V:71NM?F(#VKGCC`LTJH5F,"-/=)%X0&&71J=6VT[XH.J
M2!O4,_,YCI9AM*;>+I=AD-)K=>H7>["5+CR=N%9`O6;0N=4VI!9H*_8'9D?*
MKXJ\!5D>LAS#;]B]W.Z>\)`3U%K`N:PJ.K?:QJ2(L.)V8!:GG25SMKQ-?7][
M[?DIM7+F`:&?DG#Q^\T?1`[/(955&&2_".ANT1HZM]K:U!YTI10#LS7]PZ&7
MB<G-#WI='--IZR%,R"15!%+9.7?P]$"Y`71NM7U)"V?%]L`L2PUGG:=7(K?X
MXLWQ"*>>[R7;RVT!CZAW@5?)O4FI)71NM96I'>!*$09F:RK"&^9'^=EREM+;
M+S)58:+@&^H^R[4^R6NB<ZOM46H`*V('9J%Z"(-'O$P#E\Y0=T&<>$F:]TO@
M#2ZLA,ZMME9)L55,#LQF-<_SK&]%7OR[(NB+U5:I/205)P,S0UT0C"[%.8_"
M!8YC`E-`#[LT^F*U&8H/:O?48EBDU?=IY!1.7Q)X@9,OY-7QG#\U*E1&7ZPV
M4BECK!BV^SW;/79B3!9S+[?&43/J"8-_47'TQ5:+E0Q5Q?'`+%.5(C[B`']W
M?(6CJ:`*^F*U)4J"K.)P:!:HTM'N8D4`K(C*Y;ML[OZ&4QY]L=N*)(!543<P
M.U'5YUNR-/AT'^WX?M.N'5]NB6PV3L!]$Z75"/IBM;U(&VO%_,!L1COOV+UK
MCE;,JS2"OEAM*=+&6C'?V4C4ZBK0S*;J8K&(TBQWT)*>"HH#=GR51E3D1)3D
M(+[(_R+8:VFT@K[8:F9J";92$RB3DZG=]RK'*=QR%V70%UN-3TPH%850MB93
M@8-8S](*\ZB`5F$]](NM%BQE>!7]G<U:@!-]#=I=4!B!!)RSBJ-?;#6!R5#M
M8D^,<("KT"VIB7ZQU5*F`;!2`AC7+C,J\(3)UL-+MM=X$\:>:,^V5Q+]8KMI
MC`&HHM1D+L5/=0G=DY[L2XW^UA`;@8`#=Q>'KR$X^J`X\-+U)K]+P6E"77OC
MGQ?A.O_TS1]IABIQ/#_^Z<CZE']<$&B271!]/K[F+UZQF_JXN.:_I!E5Z6F-
MK.*%+E?/[\DY;E>F./==?'<B-XLF*AHSIKZ!8%->'I#%&U(&\=J=,S.'0KXB
MR43;*(=@4V8:98]S%MZ#:S?)[<6TDT/@SGTG>'#66)JPOH_/(=BDGP?ZP)E7
M^D%NM_;=K#=^N,4X<SZ=95V79GSEUD$P%V5]$\Q6)Y$41A&VMW!-E*I#HQR"
MN6V#48%]Y,9"^`YT)>+)[EX0[-]<XPCFCN^(&QLC,OJS*F$^!<>S-(D3)W#)
M6?XQ]&E<#_J/?2BF\(,(YEK2K"89UE*9P$:Q:AJ43A[MX#BJFW\+P5R3]J]9
MO6MR)3]32KS)7"RSA]QV*O)O=&L4WP6YK^AO42B\"^CA:PCF.MA6969+T-AN
MPL5++\][\EOJN=3/Q3J-)A0LL9>D1)]*,?6HT8ROH1.8:V];59HC0F,I.2"O
MW*C5X2Z.4^Q>9TG\<GCY8\.:22(NGQH*556[,70">Y=P=$UL):'N"45^S14M
MR#Q_73LW`KN'`\>8-AE?0R?`5R*639L<$7;/E3(&;88]GYW`WK38ILE,`1K+
M(I,?T6X"2S6Y'IZB;TT^^!8Z&?A=T<`TF2E`Z!0YP]#C&A7_P-[JE2PM%P20
ML\+E9FP>L>./';D'Z&3@EV,#TWD-L1K+-#1\LQOW<HEIQ^EK1)CK!3H!OM<;
MVJ@P*UKH-$X#&16E7,`'AE9'T(FEUXA08T-;NL828D':`KM*C6$GA1H>FEU!
M)^\WEGW+UURJL2&/D?$<,MZO/7L2J[DD;N.Q'`$-!L4>H,G[A6E/8C67W0YZ
M57B1R^M%>_)XQ-1UF/Q.WQ72]TXTT#..UA/9H#AN;]#D3W:/"R/BH286S+!^
M5)#_1Z$Q`N_O(7G"8"@_2#_0Y,]Q(PPF7'/I$DUF+#G^Z.>&Q@;H"IK\.2Z/
M(>4+GB9R&/LB_CZ2)SU14%6`WJ#)G_!Z^O@B-I=>$_H088:K.R(B+XB]Q=\=
M/SV2,:GY331YOZ,V)DASJ4F'?RVM>S'S'"8TU.F1]%WE\VCR?A'=ATS!$[T.
M8P0,;)I_OU@V)DASB7`MOQ?X.X[IQB]P:1S+!?GC<TA_JFT.JRCF1QL"K?N$
M)N]7RT<3M+FTQ/L'`=#`>44<P??X>0KQ\^@CJLOME>_$L49$O/U:]L6X8R"P
M.Z04.:4D>1YKBJE`*(E@QZTSG&AV+)XXY`K`V$UM'9`TTMQA8>`X<4)>V%0R
M,=C-X3SRWH@<YCY9O:@PI/&]V!6`8[VQB6&3R`5@-Y$VQF?3H6UDT=5J2;ZE
ME!V4!8Y]ID,;J^_&(B[`4/=(SC&11\\T:O0QRP-'!-.AD-?_[O$,0&F\F\^D
MU%5E@$-AZ=!5[W/W1_KP%VHT"N=L6;,\2`X/S/+0T9_:'!QX0"Q?^>K/$_),
M5<[NEV?RIYA:5<(@EHY.S9:@XR5Q^633WP(=U`Z6XV!U[WBN[WS/TFEPR>24
MA`XIU$;Z#,<C-C"[3QI/Z4OLN9X3;9^<:DJ3671X=<"C\;0RZ8C06+Z[K2&B
M0:]GRYJRR],)2"N#QZP14L>A6PG5P";?RKYQL1*9=;AEP4.RJ`F=,>?RT(PB
MH/"SEU"YW`6N]^:Y-"N59#?,*@\>>J35=IB'Q/)SZ`&N?WC)ZR/V\Y!KK][F
M.;P)$GJ+*)M]-5N"#K7!)U11`>3P!C8GETE"XFLOP@M2*\Y3S<6IG]`H'N)9
M6JTV=)"(-BPQ)G%UL*8X!C1QW`5O."9MR^U1C8+0X0ZZ4\W'9;N1HYZ$2F3"
M:"2K@GZLWV99/D!@S.8XT(PC%B1@`W[G?J@2G'-53]CM-J^8S<$V]!?=;2EF
M:Y10#B/8*#Q2L4F6E*H,^+/F-LM)H_?&8O,"7113+/+KX5TIZ#>Y3>$+"-IU
MU^ZY]JL7>.MT+>6H40[Z->@^`VR>#KIL.5/.#S6FZN6@GR\J,K7?9<O//G5G
MA7N%7)#,\N#/[]HL7EPDQD)SFS)$98[IQ7N$6/`T0%`:^M$87]@L<Q(7P@AV
MA7^*U[@PIBZ9\K0\V!J2R`AT]QJ_)'<!D6B:.5:PHT+Q"Z,)C,FLG5ZP^V]L
MN0>DL9B,"R?M6?1(HWXTH@16_Q@7_QJ+@KRT:@]-8>Q>[92A-<0Q)*R[=;PH
MF\8NXCA=Y[/>HQ?_?AMA^AX4$P*31R<1+3NJ3:`IC`FLG5;HH#)V\3V`;)PL
MW.73X;^']$K))X)LH1+L1M`4QC9F3BGXN(Q=P`Q<+22;!5E5-(4QMIE7@1*-
M,7.IZ\4+/XS3"`^2^&MZW8P#M\-L4&\"36'L>>8581^5,;-#IYF`8X,0`XD7
M81KPM@!:]=$4Q@BH1Z\V)&,YKLS&$"YWK'EVW.=PGD:+5W+,K;T#Y!&J4!5-
M8:R"+;A41/,G2<BDGVV^1X,3*[?]%,:8"6-?X@@`-ON1*$IS!ZP7KNOE*)JH
M>;-07]]#4QLLF+V+X#U]$#OM4H_3'>-K:&J3V;0G`9A+X#.`\U)K&5'?JJ^A
MZRV]15;E&L>+R,L$<1&XO*CUQ_@L.K7)G-NW)/[<&7;(*<B+LL)JTZ6);Z!3
MFPS'1F&#9Z@!GA2S_]!XE5ZPRJ4BS4A@Z#/HU";#M&GDP(EB@">Y1NC4<J=2
MV83ZS(G!^R0ZM<E&WJ<4S*5R@=;,5M[X=N?-/K7)P']\V9C+NS*`&\-Y%"XP
M=N-;0D/M&4@E%='645H7G=IPEZ`%QUQ6$MBM'L67V]JOTZC:560#)=;5`_W&
MT*D-%Q/=\)G+W#&`:>+"SQK'+GNZI;=N02Q:PM0:0*<VW2NH8S*7Y`)P.U2]
M%L31&UD*V:`?PNQM.LZ/+''FB5O_]ZLP3A["Y']P\H@7X2KP_BF<6GK[)CJU
MX7[A*&+H+WT$T#Z&3M5TEKRCDZ;CS],7WUO,E@0(F;L5]S/"-M"I3?<!6K`J
M9;#9O;H6#"O;M9/U.ALRHCT,IPHZL\JJ+D!1,=O9(@ZZ<ZTYA,R=:!9E>0G<
MS/*@0+-";71FDQU;$5!%?F<+->2P%NW#'_#W[)_$B5)4&D!G5MF4E3%5.C`&
M3V<.[$SQ.ZA"LSXZL\J>JPJI4@08XRS'<^E;0#KU/?+H'4?IO<GS.F*516<V
MF"V%W:^(@<GHK$#,Q2K"F56U=NVN0A*K'CJSP3JH#*4BSV[+(.NTL'M9IWEZ
MVE5$9S99_.18*K:A/)&5XAA?.?'K+68NA(+2Z,P&*YP$0$509Y-;GP1=)*1>
M@+?J)-5KH#,;C%@*('9/,ZV>.UO[=^2RW+UUCV?)*XZ>7YV`Z8+>AW.-9A?0
MF4TFL&-*I=)E&`N:Y*%1=45UN2U^^EOHD_YR9Q]I171N@X5,'4O%'Y2=C,/@
M(UYY%![M2Y6,4V$;+JN'SFVP=RE#J>B#\L7DT%>$+2MM[3R7'VY9=&Z#54K8
M_8J:S@8HV%5^9V2OZ5XCXX;:10.O-CJWRNRD!J@BO[/1"93\;/TO;O9%I^%&
M.71N@VF*V_6*NLYF*6C+QA+'<=9QSGF+5Q2=VV"J$O6^XK`'Z]2GNE3N28_V
M)45_:XB*8,&!N_/\:`B+SAF!EZXW9$>^)J?&-/$6!/C/BW"=]X`FI<)_I*3U
MFS>Z)[_&B>/Y\4\`B=WJW1#$A91509]!TM+5NI*%ZE3O>1G9$SHW&4>8O*6*
M#<+N4+_[H.19-#@U$'#\<PXY:E3N,(R.37E2#%X=!)\\D,.1,JF[],UCHE4:
MEYM9'@&G&!2QHT1H!<-R,DO30[XSHR;%,,A6(,F\*ZJ'@',,ZLV^$B26AV3?
M0R6=@)GE$7!$=AE%;&9Y4`:6&O#Y>WB/5\XB-]N_YM9;<3Y`014$&YJ=*W.&
M;4V,PNYYM;#%2Q?'1CD$F]1/D3M>UXU-E)UBJG`&69EF4#*P]HHAV*Q\.H/I
ML.=@V<@Y%.Q2>(HYV"^'3F!SVNFPP.H[6))B80:0.S*L@L1[PUD0&G'V65X%
M=`)K-=%A1@C"]L25S0WOO4+F'5X5=&*QY:2!8FC3W[Z)KS""RS+P2*JADT'9
M19H,,(:A`AQ3&S^S=]Z[R(;Y<X0RJ*M[N:T\:LGV]?DU"M/5ZXQ\G#ZI3>BI
M92;T:>C<,#H!O)%3X9.A!D9``RO*\-[WG0#>[.DK@@H<8V<*PY/!FCYSJ%RO
M^&K*BV?<HA6:0]TB=ELB'$.&FYI"/Z1TBTG^DLUR^8.FNT#;NT;:##H!=',W
M,O25(!H[2@U#.^AIT2.`,K8>\0*3@XD[TU</>3OH!-"[WHA^J&$T=I`;RIZ`
M"9NLD&9TI-D0.@'T@^]/20Y!&LN6,]RX5X^8R,VCV4.R8MD#`&ERA58-H@F@
MSWP'K6D-UEAJG2&'@VS]B"07XUVPB#"I>XWS_XNT[LA=01/`-P(=]!5`3,82
M#0TLF-)L*<Y)I%P730`?,K37)25<(TE/))KF\]]OPZB(1=9Z<3QH"$T`GSWT
MM"@R0?:6.(CIB/V)]IK&<"9_^?]02P,$%`````@`J(4,1>RJ=5F<%@``?_0`
M`!$`'`!A=&YM+3(P,30P-C,P+GAS9%54"0`#VWSJ4]M\ZE-U>`L``00E#@``
M!#D!``#M/=MRVSBR[UNU_\#CISE5JSA.9N9L4I/9DF\9[]J6RE9VYCQM020D
MX80"-`0I6_/UIQN\@@1OEI*`8[\D,M'=0'<#C6Y<&C_]XW'M.UL:2";XAZ.3
M5Z^/',I=X3&^_'#T:78Y^OO1/W[^ZU]^^J_1Z+?3NVOG7+C1FO+0N0&8!:.>
M\\#"E7/QQ^C"8Z$(G'_'M)R35T#LU6L'?LXB*CVR^YLSCI:1#)V3-W]SWKP^
M^1Y^O/_^[?O7KYWQC3,:83727=$U<4(2+&EX2]94;HA+/QRMPG#S_OB8N"'C
M+%IO5B180T$4,I?X\I4KUL=(\?6/;Y$!GV(3+T6P/J<+$OGAAZ/?(^*K]AXY
MP#&7[TG(USWI*L0,Y^'AX=7#VU<B6`+(ZY/CWVZN[U7KTQI\QC]KT(_SP$_A
MWQYC\9Q(FH)CJ1=F"$7@'X[CP@S4;Z#[VS40+A)E#<",RY!P-V]$I=$)BR?O
MWKT[5J4I**=+$E*OEOB[XT#X]#@!2[$B.5H2LLFP%D3.%492H,0]>GTR>GM2
M0AF1,*Q'@\*`S:.0RA3-%1$/@YTN4$G=5TNQ/4X*L;:W>FUN%`0P`NKPDE)#
M,SW*S#A08`"GC^[*#(\E!@3&MU2&9I2XS,`-)\R59AQ5A"@G.HIDKAD!"@S@
MH(!PMZ'2J!I58N!%AIN@IA(H,=02T$5M1_OQ&$IS+6P"ZK9T3!*XJF\N8-R/
MZ./&)YR`[=I=PM^9Y`3GT=I,Q`N#8V3M&(!&`$4#YF9X[4@)`MH[PKD(20@&
M\^>?R&;#^$+@9QQG[[&),T!P\,>GNZM.UDKQE1KI,?<N>,C"W170!5"LY\AA
M()I&B*P%'EU`1:IU8.&<46[]"S\)]YR8AE,@\M-QF4)*-)+4F_"?U6_0E00:
M"@/-5H*5@)@P<H+=X$$P;N375W"LB?H`LC\37`J?>=@%3XF/QO5^16DH/W$2
MP12)IA`UT`'.K(<W(/Q[$!E-%%$DY"24G)B4\UU&[+]?%%(KZ"D!FQZNJ,+L
MJAT=R:RJMT]3E?.=1OQ%=2BO3(YRLIAL:*":T32HVA#,*ON^264Y24<LG)SH
MRSAK4-89D:M+7SQTU94!WJRJ'[JK"FDZBNB+JM`_H-(-V`8KG"Q.(\DXE1)<
M@?MHO2;!;K*X9TL.T9)+P$-PE:\,\>`4A.LR=+"5![$?#;-*?T3'@DG7%S(*
M*/Z1UX)Z3.M13D=2$WXOU.7DE3EI;<]6T7?4)_%<%>YF`>$2,6"8Q"JL+34K
MYW_*RDGP'47`*5)XM@*?!@)FA7"'?O7O$=N@!8J%;2PQ"_KO94&GN+&OG6(_
M6R'?BI!.R8[,?1K+MOC!+-)W99$BBI/@/%M!GD,<NH7ZMKE1SS\8!7GRNFJA
M,Y1G*\<SL5ZS4'D;,+S!#\'9A_)\LFP",,OYI"SG`@EE!C0BSU;R:`S#72SD
MY+=9GF_*\HRAGZW@[J.YI+]'P-7%%OM4+,+*5[,PWY:%F>,Y,>*SE6O!8169
M6TPRMU@TN\6U+O8^M,PZ_/[+N-K.=^FOE_#J:7J;H4MRD!Z04#+K_X<OI?^X
MUN>K_;JHJJC7%ABSQBK!<7W\]:*%-&0BA7"KJ(&&<K/T*]&O.2A[D7PA(-!-
M6?FS6<Z5X+>`^"+<0A1`2H%$4=CM8&;A5\+DQJCC11UQ$%&4O/;%*.0WE1`Z
MQGF1YG[>SCD-"?,/XCBEI,SZJX3FA_*<DFI?.L#3]A02\<WH8QBE^[@'I6CN
M#I65A0-W!R>I_OEVBSIO61OQ;4!FY556,II\ZF<_/EMDK(V\CK!FM506)SJH
MY66<F&(:;8PT`9@545DEJ(MZGOW8,.WOF<9%!SBS*BKA?XLJ7L9#85M0&P:&
M[V:15V+^XJ[A2Y\OAOHE[[ORW2S@YF#_1;X5.9[4"?BD1L*5B-XD8>?D1<;;
MN@"BKM@H[[=-^^,OIKG+.I9F23K`F?70;__\Q=:4-.(6I>/%L@F+XZ([N%D_
ME:BYFWY>1DZ\6*@-$OV36=Z50#==='SV'5^3GF;[C25F\58"UI)X7_IM^6B)
MUH/K"LW"K@2EE>,G?YINC?_@)=$[NG#4[<OW>(7LPY%DZPV>?HR_K=3U.+S1
M.DIOJ_X'6'KUN/93$*3<<`]4J:@LA:3BE$1R:Z[Y=B@045$I&.WCM/%'QP?@
M!P3>EQ]=1U9QXY-Y7VX`A?K6,0+]NB\CI:%P6':.TUN4\"N_6PD%P(D(0H=7
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MQ9@S/O1KA."W3VE'<SZ-I\^9BI91)TG^'-66YE01X[D,`]4M,8I#S_`_W<!C
M]U)EIWD/WQA?7H5TC:'/D4,2J`]'81"A\ZF@P-UCPILI/"\*DEP6G/D^;L:D
ML!(B0:@TPM*/@8@V:24,R`-W3H6]>Z!+Y=GL04S!O:4P;7GWH7`_W]#UG`8%
MQMH`8Y;BM"'O/;$FC']KGL!AIQVYJ@>UCZ]+$07=V*J'M(BKCU#WA)^M"%_2
M*WY)6/!OXD=TLJA<SU.L=0,O#K"U@%F)!#L3@POBRQ8.X[)YG*[BPY$+HF3A
M(1B_XD`+XI5S&O]_Q>^HI#!QK<!XG-,M]87:TKZC;#V/`HFUW5&7`I?9U4\E
MDGT)#4%8TT"XE'KR,A#KBT<:N$Q23&RA#L$`F[^2("`\E)<BP&P'!>GTQOQR
MXO#H_##2.!,\25HW6>"FO$PVY8&=L>L"4>^*AS2`D&PF<&=!<#7Z"U)Y,H4A
M=!9U0`JL'JK\FI$Y\V$B/O.)E.K$(1*:B7B)6O^J3$E!2OL2&H*P"@;B/B1+
M"MK>$+Y3!S%WN&Y_ZNM=IRN"-L>$Z?<GLK\_G\:I(AW\$WY*)).3!4*H*F^$
M1WUU)-TD@T,0LTP^-\R'T0Z=%"R!VH?,/MS0<`4UULFB+Z)E?&=GH=,!#I[3
M#4RC$8RP<9@K&B957-8!7UUIU^#[[TW)GK!@OX/CLY*#<A!J7UDX7OA^!9B!
M&\WI59V8QLFV7\4!+Q=8Y&]7/9]*Z^M!+.)COTYU#>#8<GFP;EJ@^*<9Q_&N
MO6F9X[!T[1%8P=>]DC)"8E<<4ZLQ+TEW!W%"[/&E#O+8A3\EBUM0<+#W(Y2,
M-!AF:(2@@=]N@EP1:-W%HZMB[CND6YST3*5%?7K496OB?[/F%Q01M]6LI+1,
MZXKJ6Z^6QYN@!W',4YEZV&_J>6@&LX<=F$)$P(A_[PO"_T5#Z/,PSL\PG`G.
M*`Z!RCS4'<6B>>F6/IP'T7*\V?A),%CAJQ[$(C[4"M$FG"SNZ!+/*XA@!PT.
MQ);X&`Y_NK_T2(6S/DA6\9K?ULJB%YG$,QI[C7`#6#G2A](5C]$IYAW%494N
M'%97E/OA6:3;=B/R5)D<G+)%4KL3DJ(G=T/^(-"1JP/=7&X1!]>$>3YY4`GG
MU`)5A8=:"(NX^"=NB,HSLF$A\15*A8UZ$(OX^!B1)?S%<'U92N$RL*/5P+,1
MRB)NQLN`JK_'CZSHBY6^?_TE"X]![;BJ7[]DD3;Q7$G0U/BTQ"*!G_F,XXGJ
M&=K;K*&5_M,,9A$_UPQ".MRQRY;28RNTQOTIXK,_X@,#M8P^$=\B"6`H'/FX
M*G!/@RVP(QO4V@YK$6<7?`E63.FDEJ,&&(LX*20:N"&\E:ENX!;Q-_6)FS32
MQ(^YV*+VU^;1JUVWZXQASXK<;81RGRRF0)%FJ5KC.+I25&PV`P]\28-OMO`T
M7N.RYQ2<S$_<HT$V$*[X_X+7/WL0LY6(\/K@A0]F7)N)^V(.89^Y,U.S!^IO
MZ5/$D6+^N<2Q8D%(G]8_<MPAB&3R0+V8M4[=?B;P?%M)-'O0&(*(;@A:-8YD
M+RG%'9=T#2'=?"^N3W0`'@+3^CR<NH#(4NUDK0,-8%TNW6C%O2+JS<0T`C41
M2<VGMSI![[GT_X7V8-(C>-,`]`-^R"10;Q5YZFC$E`9JX\*\1=,15=LY4]^^
MU99'G9WN8,J',3+'GJ>V*\%S5'R<1[2>TW;8O5G.=/>EAJFV[PUA:<S2I0AF
M-%@S3N("^'L.=A;KGJK6U>V<]Z'0S2/_*L.YT-1S@LO9A>::5-\17MLU!KAO
M>!2.LW6TOJ4/\0;])<-)%"1^2ZE'XY%:H[HFU1^6[!<;+(<S#R5.Z1T!Z^V=
M[I+E=GU'M!ER`-R"CI8,?,K8O$T6D[G/EDI[13^E$6H0-C^;L6;B@J`OJ8)O
MXYQ6@K#?OH-#$82?-N`VXG6`XFIR<2^T`6@P+,+T>R:DTA+:Y"I[%0!KS+,V
MA<8'7=*#^F@RZR9;$Z1%DVI\Z%+S<>_P7$_E7*8)Q#H^9'S!J#V4Z09N42RC
M]:G\&I6<+/00%&Q#&H76]<BNV!9I5VM_&H86^#C=97S4<=V&91&WL:\U6>3W
MQM+&%U<>&H#LX@6/D9(E-/!>'<2-L\/`-*8S4P^E1=;?]$QJ+'/FQG-PXDA#
M9.EMF13!SC#P.F,,P0?3QE,>6.<CJC"@E#FI&XO=<"WJQ859(9TH3G>_"-^#
M1F4#S[Q\U`1OT?Q2Z*CII'BZR_=3+YGFX72"'D*7+AJ>R\CW=^?,CT+J)>>:
MX@7`WR-PM&MNM#Z5@#U&[88\XOI`%AE&\,\4VD@Q@PD>]]`7]]N!![#NG?;?
ME(\[W5B9BP?`5S$&!L,C(S`SUW@YOWD1N!YX`#SGQW1TGZ+T?0"<W-,PC#\D
M.V5JJ=;(7#OH`/A-'59C]%5P&`Q;4.TH%GD/IM<GZ@_+=(*VYZ#,-*!K%JV3
M%=3Z8UHM<!:=;]+]F.KY>V.Q1>TOO+01OWN^Q:2=\)?*N%'?\7KBV=,%#=[V
M>41G0MV`A,YFC)_[(%GDI\.D#4J)#]JF2P"H'WU>KP&QRB8:S<$4&N6R3;I;
MVVX_*@CV+X4G,[;:>*OAJLAW%^B!A%K*J>[)?A^L(8CA/*D"XB:=-4P%U2Z/
MIZ%KFR@)!=N&/L22./!PB:3KX#>@#&#X%S*#E2?9F@1B5;`!;$P75T82*PV.
MA5+3%?]UQ=Q5B:WX6%G-VDHO"OLMKASP*!9`29EJ\HKG3R9,%@MU.5-BW)8Y
M(A.5FF%+_-*1ROW(#,(J5M)9Q;K\E85E)>O[6GW0+'+CKE3F<OR0-/PC_H,[
MWEG")BW58@?H8:AY'N)]Y$!EJ\7G1'`P)]=#9N*4<KI@N$&2)PJ\I"2,M+.9
M^Q"Q?WK0N<OT:SBCV@JIF<'^1U(/>COM,:3@NGDWJ`<6[M*XI&%L=T>QRKO1
M-KK*/)3.O'2`M2ADNW=7U(M\4_+!O!M*S$&VA>:;,M4]D8`]*PW5^>839V'S
MC)1`[#GY'-`I>7)ZT4.D*+5J%B[DTSR$4`Y#;@`+]XUYL$UK;=W@A^#!9*GF
MGI*+M2E[YW[T[#&1-R3X3,.$DV)0PI.DI,IIT^?!'CA[^C0'-*/J#*1:ALF"
MU(M')E6^`&765'"F!;3=4:R)8+-N.8;`:IVX*G'0J4Z"FLQ?+:@]RLN'6%.V
MR5H8>X:;?K*3R<^7`:5I:L<[&#+G-,PO=-0>"6U'M,@1U9H^#<0\F5\GB]AJ
M))VNCMDF#(NX3-,,Q)8AF0G2TYZ&=`0U<!:Y6_F`2MML\!6:@"SB93R?BS`\
M92)<T8!LU-.K\DP$U419K9`6;1U/<1OTD@4RU"Z88&YQE?G'@['C1:YA=[\G
MHFT\WU-7<.\I3/?!M(UK3-3P)*9[(%K$,XQ!7RRQR4E;F[*E=@&VB+=X[&6I
MN.Z)3RLL-<!8Q,EX`7Z':NHM#;&-U81]]2`6\5%^H,+@8=:#V.-@7@N^Q%MK
MQ?-V3.U%-*6L[84UA!6/K/TR/AN%,1OEIF<GVD&_LG([O2DQ(9_OF+>DMXHV
M&#TR%X'*I%Q]IZ$5U*)1.`:G?WLO?(5BL"3&8HO:#U&9]TL4NBL(?@77$_C6
MY"_OCF(1G\JMN((!<\4TO^)2!+@AL";S*W[A>S3P=V,W"NG-COJ">=<T^DS7
MK)H2_$#T+)+0)\[4;B9&K3/Z2.3-^1A/0V4ZKND./?$LXOB?8L7E+V+S&3IR
MSD4U$W$CF$7\%#,_-Z:%MK#MQ5XTI9S+G;\EW##PV@`MX@EL`;C"9RM&\18M
M6`%H^62Q`'??8%3;82WB+-XK+Z6)+G[\^BY(>X[HN'V5!-'Z9XN$7$CK-\Z3
M'E;STS:"6<M/FJ&PA9\RF$7\)`L1>K;J*0GA1QK2-]Q6Z8UK$>>M[`V(!^[=
M;\`U%^#49N\+M_+5!<DB7O6;[PV]LAG.(H[NZ8;$U%`7V67%>M:Z(EC$XPWA
MT0)JBW#ZK.>L&<PB?O"6<],S!S7E%G'0L/1B>GFQ&[@]2W%-*TNUN]A]D.QA
M-;O5G%CT4KH84^D`5A'+Z[WE8S#&XB)?]B1`NQ,[XH>[I*4S44SQ7WO*H!''
MHJWWI*&31;J]D)_8T1ZC:H#:[P#/%]X9BD.JYIVA%$;K?M_Z<'7FS'&OZ)KC
M^8!E^:9<!]@!F(QT`P5&#_&8('@XFMX0?-I-RP[9`C<$3@/Q?]0-+R2NSF(&
M'2%+:1$,Q0/@ZUP\\&S",G%A-"Z]L.PQ-H5FJ_NHJMUFMHKE`U"CMHN`"L"=
MA/2141%<"H'+(>J!56\-H-CDTI&[IY/86SY?_-K29<0]?4;7TZRK['<PR<P>
M!#Z)49Q[^F(.7QCJ_$+R,D@/2>AH]HLA:[CV`+GI[;\2@$6N()C9A0C6*)E3
MP2.9)$BI=-$DDZ.^;MT/\XLI]'"W'_33I22^@L?2[/"-*9NZX%BD=T,.Y_&6
M,#\Y.'RZJ^1=;4X`W8IL$>^W@M_1!1@C)),^'ZR.>NAA>`O<`";U*>AF3=Q=
M:7FA^'4`7(SAMX=_JQ0!4E:RQ=4!#("WHJTH/U=BRH_2$=ZBT9:UZHYR^D!\
MLQ5MA+*(FRQF&2^AQ4OP9*K)7&I!!M`?L\9C+AH?C1[Q?7TFEZ:G1GKB#4D2
M94>GJR2ZX0U`$FJ&'YT22=63[I3+>",K7VHZW15@TL.^#R3PDG<(5#X/ZOU*
MV7(%_X^WX`HOZ1W%S108S;AJCUQB&F']J8FO7[55ZX&*M7D[]_,:Y@L)I#H*
M0):%_[5KMTK^%^N-+W:4RG,64#<40;+'A(EH\<I6]07JC@@6;2K&M_23O3)I
MV&&K`[!G-\UP,U=BOFX7>ER6/T??B^J.8L_BHQIL'6QAG2G,GR7X&.>2XI6-
MDB]7A=9;ONW=1K5$\1`PW"E.=:V=\#05#V">+C8\\Z?-[G8[J$T^MW8LZ(S(
M5>,KM3G``'16.O(4PI3!Z:Z1/QUH`#RF%YS352'O=)=\PB=#:""KJVE-L!99
MDCNZS'8QU*NY]2.N'=2B$9<\@U&7"<-<;)%>9@_B&B)O-YZL5G'/,9WTK8>R
MR$.+TR,*`P>5$HM:G7N]E697BRQJ=^SN7G%T]=B6@NVMGA%O@+&(DSR/ZL46
MS\?5'Z)KA;3'U\\]S'CC(3T8`A-%YM3`,)ZM@-IR-8%X<^S[0AT0G%06'?>G
M99'1BU<9LXFSOM4JW6[EH9SNB%:Z',?27=$U^?FO?_E_4$L!`AX#%`````@`
MJ(4,1;A>H&2\P0``Z[D(`!$`&````````0```*2!`````&%T;FTM,C`Q-#`V
M,S`N>&UL550%``/;?.I3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`J(4,
M13.R8@!U!P``!UD``!4`&````````0```*2!!\(``&%T;FTM,C`Q-#`V,S!?
M8V%L+GAM;%54!0`#VWSJ4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*B%
M#$4V]Y:&]#8``)A_`P`5`!@```````$```"D@<O)``!A=&YM+3(P,30P-C,P
M7V1E9BYX;6Q55`4``]M\ZE-U>`L``00E#@``!#D!``!02P$"'@,4````"`"H
MA0Q%[[%P1%Y]``#]H`<`%0`8```````!````I($.`0$`871N;2TR,#$T,#8S
M,%]L86(N>&UL550%``/;?.I3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MJ(4,1:1L=F3)1P``4_,$`!4`&````````0```*2!NWX!`&%T;FTM,C`Q-#`V
M,S!?<')E+GAM;%54!0`#VWSJ4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`*B%#$7LJG59G!8``'_T```1`!@```````$```"D@=/&`0!A=&YM+3(P,30P
M-C,P+GAS9%54!0`#VWSJ4W5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"
(``"ZW0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements Of Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
        <td class="nump">2,001,937<span></span></td>
        <td class="nump">509,262<span></span></td>
        <td class="nump">4,462,905<span></span></td>
        <td class="nump">1,594,968<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">2,414,627<span></span></td>
        <td class="nump">966,367<span></span></td>
        <td class="nump">4,090,680<span></span></td>
        <td class="nump">1,899,503<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">8,052<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">9,457<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,122<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">4,424,616<span></span></td>
        <td class="nump">1,475,629<span></span></td>
        <td class="nump">8,563,042<span></span></td>
        <td class="nump">3,498,593<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(4,424,616)<span></span></td>
        <td class="num">(1,475,629)<span></span></td>
        <td class="num">(8,563,042)<span></span></td>
        <td class="num">(3,498,593)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(634)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,209)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
        <td class="nump">7,939,711<span></span></td>
        <td class="num">(1,307,748)<span></span></td>
        <td class="num">(4,621,360)<span></span></td>
        <td class="nump">26,764<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income and (expense)</a></td>
        <td class="nump">7,939,711<span></span></td>
        <td class="num">(1,308,382)<span></span></td>
        <td class="num">(4,621,360)<span></span></td>
        <td class="nump">25,555<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="nump">$ 3,515,095<span></span></td>
        <td class="num">$ (2,784,011)<span></span></td>
        <td class="num">$ (13,184,402)<span></span></td>
        <td class="num">$ (3,473,038)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share - basic</a></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.52)<span></span></td>
        <td class="num">$ (0.16)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share - diluted</a></td>
        <td class="nump">$ 0.10<span></span></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.52)<span></span></td>
        <td class="num">$ (0.16)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
        <td class="nump">25,795,573<span></span></td>
        <td class="nump">22,178,637<span></span></td>
        <td class="nump">25,513,505<span></span></td>
        <td class="nump">21,791,673<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
        <td class="nump">35,862,173<span></span></td>
        <td class="nump">22,178,637<span></span></td>
        <td class="nump">25,513,505<span></span></td>
        <td class="nump">21,791,673<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeGainLossOnDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b>Note 7 &#8211; Equity</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 11pt; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">In January 2014, the Company completed the final tranche of a private placement of the Company</font>&#8217;<font style="font-size: 10pt;">s common stock and warrants and received</font>&#160;<font style="font-size: 10pt;">approximately $3.3 million total gross proceeds from accredited investors (</font>&#8220;<font style="font-size: 10pt;">2014 Closing</font>&#8221;<font style="font-size: 10pt;">). The Company paid its placement agent total cash fees of</font>&#160;<font style="font-size: 10pt;">approximately $395,000 and paid attorney fees of $40,000 for their services</font>&#160;resulting in net proceeds of $2,873,557<font style="font-size: 10pt;">. In the 2014 Closing, the Company sold 551,810 shares of common stock at</font>&#160;<font style="font-size: 10pt;">$6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five</font>&#160;<font style="font-size: 10pt;">years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing</font>&#160;<font style="font-size: 10pt;">model utilizing the following assumptions: risk free interest rateh1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5</font>&#160;<font style="font-size: 10pt;">years. As of&#160;</font>June 30<font style="font-size: 10pt;">, 2014, all the warrants were outstanding.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 11pt; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">On March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the</font>&#160;&#8220;<font style="font-size: 10pt;">Registration Statement</font>&#8221;<font style="font-size: 10pt;">) which was effective on April 17,</font>&#160;<font style="font-size: 10pt;">2014. This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to</font>&#160;<font style="font-size: 10pt;">$200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by</font>&#160;<font style="font-size: 10pt;">us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the&#160;</font>&#8220;<font style="font-size: 10pt;">Sales</font>&#160;<font style="font-size: 10pt;">Agreement</font>&#8221;<font style="font-size: 10pt;">) with MLV &amp; Co. LLC (</font>&#8220;<font style="font-size: 10pt;">MLV</font>&#8221;<font style="font-size: 10pt;">) dated March 24, 2014. The Company will pay MLV in cash, upon the sale of common stock pursuant to the</font>&#160;<font style="font-size: 10pt;">Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.&#160;</font>On April 28, 2014 the Company issued&#160;<font style="font-size: 10pt;">500 shares&#160;</font>and received net proceeds of $6,000<font style="font-size: 10pt;">&#160;under the Sales Agreement</font>&#160;with MLV<font style="font-size: 10pt;">.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><b>Placement Agent &#8211;&#160;</b>During January 2014, in connection with the Common Stock Offering, the Company issued the Placement Agent warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.2 million
 was
 determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &#8211; 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><b>Public Offering</b>&#160;- On June 30, 2014, the Company received gross proceeds of $12,525,000. The Company paid an underwriting discount of $876,750, paid the other offering expenses of $125,000, and paid attorney and auditor fees of $72,000 resulting in net proceeds of $11,451,250 from the public offering of 1,670,000 shares of the Company&#8217;s common stock, $0.001 par value per share at a price to the public of $7.50 per share less underwriting discounts. Under the terms of the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><font style="font-size: 10pt;"><b>Approval of the Equity Incentive Plan</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">During the six months ended June 30, 2013, the Company did not grant any shares of restricted stock. During the six months ended June 30, 2014, the Company granted 445,167 shares of restricted stock and cancelled 50,000 shares of restricted stock. Of the total shares of restricted stock, 20,000 shares vest 3 months from the grant date, 22,500 shares vest 1 year from the grant date, 199,167 shares have a vesting period of 4 years and 200,000 shares vest at date of grant. The remaining restricted shares granted are performance based and upon the achievement of certain milestones.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: right; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><b>Stock Option Plan</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;">The following is a summary of stock options activities for the six months ended June 30, 2014:</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start;
 text-transform: none;
 white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td></td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td style="text-align: center;" colspan="3">Remaining</td><td>&#160;</td><td style="text-align: center;" colspan="3"></td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Number</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td style="text-align: center;" colspan="3">Contractual</td><td>&#160;</td><td style="text-align: center;" colspan="3">Aggregate</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"><p style="margin-top: 0px; margin-bottom: 0px;">of</p><p style="margin-top: 0px; margin-bottom: 0px;">Units</p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Exercise&#160;<br />Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Term&#160;(in&#160;years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"><p style="margin-top: 0px; margin-bottom: 0px;">Intrinsic</p><p style="margin-top: 0px; margin-bottom: 0px;">Value</p></td></tr><tr style="vertical-align: bottom;"><td></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1,985,384</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">3.23</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">8.34</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">5,908,696</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">979,100</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9.85</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-&#160;&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt;">Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(11,655</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.78</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-&#160;&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-&#160;&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Outstanding, June 30, 2014</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,952,829</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">5.45</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.35</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">8,300,565</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Exercisable, June 30, 2014</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">868,287</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.98</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.99</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">5,418,017</td><td style="text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000;
 font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto;
 text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">During the six months ended June 30, 2014, the Company granted employees and board members 979,100 options to purchase the Company&#8217;s common stock with exercise prices ranging from $5.55 to $11.95 and a term of 10 years and with vesting over a 4-year period. The options have a fair value of $7.1 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.88% - 2.07% (2) expected life of 6 years, (3) expected volatility of 87.06% to 87.76%, and (4) zero expected dividends.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">During six months ended June 30, 2014, the Company received gross proceeds of $5,220 for exercise of options for 11,655 shares of the Company&#8217;s common stock.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2014 was $10,165,000. During the three months ended June 30, 2014 and 2013, the Company recorded option expense of $607,791 and $94,200, respectively. During the six months ended June 30, 2014 and 2013, the Company recorded option expense of $889,195 and $188,400, respectively.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b>Warrants</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">Following is a summary of warrant activities for the six months ended June 30, 2014:</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none;
 white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><table style="font: 10pt/normal 'times new roman', times,
 serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td style="text-align: center;" colspan="3">Remaining</td><td>&#160;</td><td style="text-align: center;" colspan="3">Aggregate</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Number of</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td style="text-align: center;" colspan="3">Contractual</td><td>&#160;</td><td style="text-align: center;" colspan="3">Intrinsic</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Exercise&#160;Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Term&#160;(in&#160;years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Value</td></tr><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">9,673,290</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1.06</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">4.89</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">47,396,307</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">406,928</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.96</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.46</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; padding-bottom: 1pt;">Exercised</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(662,160</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt;">1.44</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 2.5pt;">Outstanding, June 30, 2014</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;">9,418,058</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">1.33</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">4.54</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">56,362,310</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 2.5pt;">Exercisable, June
 30, 2014</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">9,195,074</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align:
 left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">1.16</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">4.42</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">56,183,393</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">During the six months ended June 30, 2014, the Company granted warrants to purchase 137,952 shares of the Company&#8217;s common stock to investors and warrants to purchase 68,976 shares of the Company&#8217;s common stock to its placement agent in connection with the 2014 Closing.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">During the six months ended June 30, 2014, the Company also granted consultants warrants to purchase 200,000 shares of the Company&#8217;s common stock with exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants vest when certain milestones are met.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">During the six months ended June 30, 2014, 662,160 warrants were exercised by the warrant holders. The Company issued 573,299 shares of common stock and received gross proceeds of $96,868.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">During the six months ended June 30, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $98,224 and $0, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><b>Note 6 &#8211; Commitments and Contingencies</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><font style="font-size: 10pt;"><b>License and Research Agreements</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.55in;">&#160;</td><td style="width: 78px; text-align: left;"><font style="font-size: 10pt;">a.</font></td><td style="width: 3px;">&#160;</td><td style="text-align: justify;"><font style="font-size: 10pt;">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 12pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">750,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td
 style="text-align: right;">1,500,000</td><td
 style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(4) Biological License Application filing with U.S. FDA</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(5) First commercial sale</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(6) after the first $10,000,000 in net sales</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 12pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase 2 Clinical Trial and no payment has been made to Abbott Biotherapeutics Corp. since the July 24, 2012 payment.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.55in;">&#160;</td><td style="width: 78px; text-align: left; padding: 0px;"><font style="font-size: 10pt;">b.</font></td><td style="width: 3px;">&#160;</td><td style="padding: 0px; text-align: justify; text-indent: 0px;"><font style="font-size: 10pt;">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; see related party disclosure.</font></td></tr><tr style="vertical-align: top;"><td>&#160;</td><td style="text-align: right; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td><td>&#160;</td><td style="text-align: justify; padding: 0px; text-indent: 0px;"><font style="font-size: 10pt;">&#160;</font></td></tr><tr style="vertical-align: top;"><td>&#160;</td><td style="text-align: left; padding: 0px;"><font style="font-size: 10pt;">c.</font></td><td>&#160;</td><td style="text-align: justify; padding: 0px; text-indent: 0px;"><p style="margin: 0px;">Oak Ridge National Laboratory (ORNL) &#8211; The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;For 2013, the Company was obligated and paid approximately $0.3 million to purchase of radioactive material with ORNL.&#160;&#160;For 2014, the Company signed a contract with ORNL to purchase $0.4 million of radioactive material.</p></td></tr><tr style="vertical-align: top;"><td>&#160;</td><td style="text-align: right; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td><td>&#160;</td><td style="text-align: justify; padding: 0px; text-indent: 0px;"><font style="font-size: 10pt;">&#160;</font></td></tr><tr style="vertical-align: top;"><td>&#160;</td><td style="text-align: left; padding: 0px;"><font style="font-size: 10pt;">d.</font></td><td>&#160;</td><td style="text-align: justify; padding: 0px; text-indent: 0px;"><font style="font-size: 10pt;">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company&#8217;s Phase 1 and Phase 2 clinical trials.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million. As of June 30, 2014, approximately $1.1 million has been expensed to date. &#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></td></tr><tr style="vertical-align: top;"><td>&#160;</td><td style="text-align: right; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td><td>&#160;</td><td style="text-align: justify; padding: 0px; text-indent:
 0px;"><font style="font-size: 10pt;">&#160;</font></td></tr><tr style="vertical-align: top;"><td>&#160;</td><td
 style="text-align: left; padding: 0px;"><font style="font-size: 10pt;">e.</font></td><td>&#160;</td><td style="padding: 0px; text-indent: 0px;"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC) to build upon previous and ongoing clinical trials, with BC8 (licensed antibody). FHCRC has currently completed Phase 1 and Phase 2 of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="margin: 0px;">During the six months ended June 30, 2014 and 2013, the Company recorded fees of $75,000 and $75,000, respectively, related to this agreement.&#160;</p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;"></p></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 12pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 53px; text-align: justify;">&#160;</td><td style="width: 78px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">f.</font></td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. The Company paid a start-up fee of $19,749 in 2013.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable. For the six months ended June 30, 2014, the Company paid approximately $16,000 for patient enrollment.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">g.</font></td><td><p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify;">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500. The estimated cost is based on treating 24 patients through 2013. Upon execution of the agreement, the Company paid $33,946. During 2013, there was one patient treated and the Company paid $34,383 in July 2013. There have been no patients treated in 2014.</p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p></td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">h.</font></td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. There were no payments made during the six months ended June 30, 2104 for this agreement.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td><td style="text-align:
 justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;"><font style="font-style: normal;
 font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">i.</font></td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable. The Company accrued the $16,000 fee at December 31, 2013 and paid the fee in January 2014.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">j.</font></td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On January 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc.&#160;&#160;(&#8220;Goodwin&#8221;). Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab&#8482;-B. Total cost of the agreement is $2,813,960. The Company paid a non-refundable payment of $562,790 upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of June 30, 2014, the remaining cost of the agreement is approximately $2.1 million.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: justify;">&#160;</td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">k.</font></td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On June 20, 2014, the Company entered into a CRO agreement with Act Oncology. Act Oncology provides project management services for the study of Iomab-B used for the intended Phase 3 clinical trial. The total project is estimated to cost approximately $0.8 million. The Company paid approximately $0.1 million during the six months ended June 30, 2014. Act Oncology bills the Company when services are rendered and the Company records the related expense to research and development costs.&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue, New York, NY. The agreement terminated on May 31, 2013. On June 4, 2013 and amended on October 4, 2013, the Company entered into two rental agreements for office space at 546 Fifth Avenue, New York, NY. One of the agreements terminated on July 6, 2014. The Company maintains office space at 546 Fifth Avenue, New York, NY through December 31, 2014. The Company paid a one month refundable deposit. On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement terminates on September 30, 2016. The Company issued a security deposit of $34,733 to the existing tenant.&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details) (Memorial Sloan Kettering Cancer Center [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of milestone payments related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Receipt of Regulatory Approval From U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of milestone payments related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RelatedPartyMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,750,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RelatedPartyMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Related party milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RelatedPartyMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">750,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(4) Biological License Application filing with U.S. FDA</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">(5) First commercial sale</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(6) after the first $10,000,000 in net sales</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,500,000</td><td style="text-align: left;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePaymentsMilestoneMethodTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments milestone method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MilestonePaymentsMilestoneMethodTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of set forth liabilities measured at fair value on a recurring basis</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 1</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 2</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 3</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Total</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style:
 normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Derivative liabilities:</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt;
 line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"><td style="width: 801.671875px; padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">At June 30, 2014</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size:
 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9,826,627</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9,826,627</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">At December 31, 2013</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal;
 font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">6,707,255</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">6,707,255</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"><font style="font-size: 10pt;"><b>Note 8 &#8211; Subsequent Events</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">During July 2014, the Company issued 176,211 shares of restricted stock to warrant holders.</p><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">On July 7, 2014, the Company filed a Form S-8 to offer the resale of up to 6,750,000 shares of common stock previously granted under the Equity Incentive Plan. Pursuant to the Form S-8, the Company issued 61,538 shares to an investor and received proceeds of $48,000.</p><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">On July 10, 2014, the Underwriters exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. Including the exercise of the over-allotment option of $1.2 million, gross, Actinium&#8217;s offering totaled 1,827,123 shares, representing gross proceeds of approximately $13.7 million and approximately $12.5 million net after deducting the underwriting discount and the other offering expenses.</p><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px; text-align: justify; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;">On July 25, 2014, the Company entered into an agreement with a consultant. According to the agreement, the Company granted and issued 150,000 restricted shares to a consultant and also made a $250,000 for services to be provided over a six month period.&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Nature of Business</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><b>Nature of Business &#8211;</b>&#160;Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Actinium&#8221;) is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) initiated collaborative efforts with large institutions to establish the proof of concept of APIT and has supported one Phase 1/2 clinical trial and one Phase 1 clinical trial at Memorial Sloan-Kettering Cancer Center (&#8220;MSKCC&#8221;) under an MSKCC Physician IND Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 29.7pt;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock. The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API was considered the acquirer for accounting and financial reporting purposes.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On March 20, 2013, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start;
 text-transform:
 none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company&#8217;s common stock. A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Basis of Presentation - Unaudited Interim Financial Information &#8211;</b>&#160;The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2013, as filed with the SEC February 28, 2014.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Principles of Consolidation &#8211;</b>&#160;The condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Use of Estimates in Financial Statement Presentation &#8211;</b>&#160;The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Reclassification &#8211;</b>&#160;Certain prior period amounts have been reclassified to conform to current period presentation.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Cash and Cash Equivalents &#8211;</b>&#160;The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2014 and December 31, 2013, all of the Company&#8217;s cash was deposited in one bank.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Property and Equipment &#8211;</b>&#160;Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Impairment of Long-Lived Assets &#8211;&#160;</b>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Derivatives &#8211;</b>&#160;All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Fair Value of Financial Instruments &#8211;</b>&#160;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-size: 10pt;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-size: 8pt; margin: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-size: 10pt;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 0px 0px 0.55in; text-align: justify;"><font style="font-size: 10pt;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px 7.7pt; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of June 30, 2014 and December 31, 2013. As required by ASC 820 &#8220;<i>Fair Value Measurements and Disclosures&#8221;</i>, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 1</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 2</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 3</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Total</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight:
 normal; font-size:
 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Derivative liabilities:</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new
 roman', times, serif;"><font
 style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: #cceeff;"><td style="width: 801.671875px; padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">At June 30, 2014</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight:
 normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9,826,627</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9,826,627</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;"><td style="padding-left: 10pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">At December 31, 2013</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">6,707,255</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">6,707,255</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Income Taxes &#8211;</b>&#160;The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"><font style="font-size: 10pt;"><b>Research and Development Costs &#8211;</b>&#160;Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Share-Based Payments &#8211;</b>&#160;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
        <td class="text"><p><font size="2" style="font-family: times new roman,times;"><strong>Earnings (Loss) Per Common Share &#8211;</strong>&#160;The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share, as calculated for the three months ended June 30, 2014, is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. For the three months ended June 30, 2013 and the six months ended June 30, 2014 and 2013, the potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the three months ended June&#160;30, 2014, potentially issuable shares included stock options to purchase 1,398,937 shares and warrants to purchase 8,667,663 shares of the Company&#8217;s common stock. For the six months ended June 30, 2014, potentially issuable shares included stock options to purchase 2,952,829 shares and warrants to purchase 9,418,058 shares of the Company&#8217;s common stock. For the six months ended June 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the Company&#8217;s common stock.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Recent Accounting Pronouncements &#8211;&#160;</b>In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers. Amendments in this Update create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition&#8212;Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs&#8212;Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2011-230&#8212;Revenue Recognition (Topic 605) and Proposed Accounting Standards Update 2011&#8211;250&#8212;Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this Update are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-10, Development Stage Entities. The amendments in this Update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder&#8217;s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Finally, the amendments also remove paragraph 810-10-15-16, which states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity (VIE) if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities it is currently engaged in and (2) the entity&#8217;s governing documents and contractual arrangements allow additional equity investments. Under the amendments, all entities within the scope of the Variable Interest Entities Subsections of Subtopic 810-10, Consolidation&#8212;Overall, would be required to evaluate whether the total equity investment at risk is sufficient using the guidance provided in paragraphs 810-10-25-45 through 25-47, which requires both qualitative and quantitative evaluations. This Accounting Standards Update is the final version of Proposed Accounting Standards Update 2013-320&#8212;Development Stage Entities (Topic 915), which has been deleted. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein, and early adoption is required. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-12, Compensation- Stock Compensation. The amendments in this update apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&#8212;Compensation&#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The proposed amendments would apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target could be achieved after the requisite service period. This Accounting Standards Update is the final version of Proposed Accounting Standards Update EITF-13D&#8212;Compensation&#8212;Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite
 Service Period, which has been deleted. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div><b style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 52.79999923706055px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Subsequent Events &#8211;</b>&#160;The Company&#8217;s management reviewed all material events through the date of the condensed consolidated financial statements were issued for subsequent event disclosure consideration.</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of activities related to related party</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>Milestones</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Payments</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left;">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval for each licensed product</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">750,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIVDM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="3">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="4">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 24, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Stock Option Plan [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Stock Option Plan [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Stock Option Plan [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Employees, consultants and board members [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Employees, consultants and board members [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Employees, consultants and board members [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Employees, consultants and board members [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Investor [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 10, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Private Placement [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw and Co [Member]

</div>
          <div>Placement agent [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Public Offering [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_EquityTextualsAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Fair value of warrants determined utilizing the Black-Scholes option pricing model</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.55<span></span></td>
        <td class="nump">$ 11.66<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.19%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.27%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.64%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">87.06%<span></span></td>
        <td class="nump">87.76%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">88.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value assumptions, expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_FairValueAssumptionsExpectedDiscountRate', window );">Fair value assumptions, expected discount rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.88%<span></span></td>
        <td class="nump">2.07%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsIssuedToPurchaseCommonStock', window );">Warrants issued to purchase common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">979,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod', window );">Number of additional stock option granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">445,167<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock option cancelled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Description restricted stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><p>&#160;Of the total shares of restricted stock, 20,000 shares vest 3 months from the grant date, 22,500 shares vest 1 year from the grant date, 199,167 shares have a vesting period of 4 years and 200,000 shares vest at date of grant. The remaining restricted shares granted are performance based and vest over time.</p><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">7,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option exercise prices</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 5.55<span></span></td>
        <td class="nump">$ 11.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,220<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,873,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of option exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">11,655<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Expense related to common stock granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">607,791<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">94,200<span></span></td>
        <td class="nump">889,195<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">188,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">98,224<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,165,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,165,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from the public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,636,720<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,451,250<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.50<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">551,810<span></span></td>
        <td class="nump">573,299<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,670,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">96,868<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,525,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UnderwritingDiscount', window );">Underwriting discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">876,750<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_UnderwritingAgreementDescription', window );">Underwriting agreement description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Under the terms of the underwriting agreement entered into with Canaccord Genuity Inc. as representative (the "Representative") of the several underwriters (collectively, the "Underwriters"), the Company also granted the Underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentCashFees', window );">Placement agent cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">395,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PlacementAgentAttorneyFees', window );">Placement agent attorney fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">137,952<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_WarrantsExercisedByWarrantHolders', window );">Warrants exercised by warrant holders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">662,160<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_RegistrationStatementDescription', window );">Registration statement description</a></td>
        <td class="text">This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200,000,000 of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the "Sales Agreement") with MLV &amp; Co. LLC ("MLV") dated March 24, 2014.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_MaximumOfferingPrice', window );">Maximum offering price</a></td>
        <td class="nump">75,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Aggregate offering amount of securities sold to investors</a></td>
        <td class="text">The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014 the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other offering expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Auditor fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 72,000<span></span></td>
      </tr>
      <tr>
        <td colspan="29"></td>
      </tr>
      <tr>
        <td colspan="29">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityTextualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_EquityTextualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FairValueAssumptionsExpectedDiscountRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Assumptions Expected Discount Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_FairValueAssumptionsExpectedDiscountRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaximumOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_MaximumOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentAttorneyFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent attorney fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentAttorneyFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PlacementAgentCashFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent cash fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PlacementAgentCashFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RegistrationStatementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registration statement description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_RegistrationStatementDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options additional grants in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnderwritingAgreementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriting agreement description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_UnderwritingAgreementDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnderwritingDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriting discount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_UnderwritingDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsExercisedByWarrantHolders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercised by warrant holders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsExercisedByWarrantHolders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 7<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4,6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfessionalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569655-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockDescriptionOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of significant modifications (such as a change in expiration dating, vesting rights, or exercise prices) to an equity-based compensation plan, including the terms of the modifications.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 9,826,627<span></span></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract', window );"><strong>Summary of liabilities measured at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 9,826,627<span></span></td>
        <td class="nump">$ 6,707,255<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_SummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36459792&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">$ 8,052<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 9,457<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">$ (4,122)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PropertyAndEquipmentTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_PropertyAndEquipmentTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3QAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (13,184,402)<span></span></td>
        <td class="num">$ (3,473,038)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">3,141,144<span></span></td>
        <td class="nump">188,400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
        <td class="nump">9,457<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,122<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_GainOnChangeInFairValueOfDerivatives', window );">Loss (gain) on change in fair value of derivative liabilities</a></td>
        <td class="nump">4,621,360<span></span></td>
        <td class="num">(26,764)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable', window );">R&amp;D reimbursable receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,126)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(389,716)<span></span></td>
        <td class="nump">85,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(34,733)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">666,466<span></span></td>
        <td class="num">(103,414)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">108,352<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(5,062,072)<span></span></td>
        <td class="num">(3,327,820)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(128,439)<span></span></td>
        <td class="num">(1,112)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(128,439)<span></span></td>
        <td class="num">(1,112)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="num">(102,855)<span></span></td>
        <td class="num">(103,050)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sales of stock, net of offering costs</a></td>
        <td class="nump">14,328,725<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash', window );">Proceeds from the exercise of options and warrants for cash</a></td>
        <td class="nump">102,088<span></span></td>
        <td class="nump">3,463,641<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">14,327,958<span></span></td>
        <td class="nump">3,360,591<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash</a></td>
        <td class="nump">9,137,447<span></span></td>
        <td class="nump">31,659<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump">5,533,366<span></span></td>
        <td class="nump">5,618,669<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump">14,670,813<span></span></td>
        <td class="nump">5,650,328<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">561<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock', window );">Conversion of notes payable and accrued interest to stock</a></td>
        <td class="nump">1,501,988<span></span></td>
        <td class="nump">590,217<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_TransferFromLiabilityClassificationToEquityClassificationValue', window );">Transfer from liability classification to equity classification</a></td>
        <td class="nump">$ 30,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of notes payable and accrued interest to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ConversionOfNotesPayableAndAccruedInterestToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GainOnChangeInFairValueOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain on change in fair value of the derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_GainOnChangeInFairValueOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase decrease in Research and development reimbursable receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_IncreaseDecreaseInResearchAndDevelopmentReimbursableReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from the exercise of options and warrants for cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_ProceedsFromExerciseOfOptionsAndWarrantsForCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_TransferFromLiabilityClassificationToEquityClassificationValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transfer from liability classification to equity classification, Value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_TransferFromLiabilityClassificationToEquityClassificationValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;"><b>Note 5 &#8211; Derivatives</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">Activities for derivative warrant instruments during the six months ended June 30, 2014 were as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Balance, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1,968,623</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">6,707,255</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Transfer from liability classification to equity classification</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(193,661</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,501,988</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,621,360</td><td style="text-align: left;
 padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;
 background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 2.5pt;">Balance, June 30, 2014</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,774,962</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">9,826,627</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During the six months ended June 30, 2014, 662,160 warrants were exercised, of which 193,661 were derivative warrants. The fair value of these warrants totaling approximately $1,501,988 were measured on the various exercise dates and reclassified to additional paid-in capital.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 29.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">June 30,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 953px; text-align: left;">Market value of common stock on measurement date (1)</td><td style="width: 13px;">&#160;</td><td style="width: 13px; text-align: left;">$</td><td style="width: 113px; text-align: right;">7.22</td><td style="width: 13px; text-align: left;">&#160;</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: left;">$</td><td style="width: 112px; text-align: right;">5.89</td><td style="width: 12px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Adjusted exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.48</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.19</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.27</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Warrant lives in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font-size: 10pt;">3.5 years</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font-size: 10pt;">0.5 years</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align:
 left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td
 style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected dividend yield (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Probability of stock offering in any period over 5 years (5)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">25</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Range of percentage of existing shares offered (6)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">35</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Offering price range (7)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7.50</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">9</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 79px; text-align: center;"><font style="font-size: 10pt;">(1)</font></td><td style="width: 1488px; text-align: justify;"><font style="font-size: 10pt;">The market value of common stock at the above measurement dates is based on the Company&#8217;s trading price quoted on the OTC Markets for December 31, 2013 and on the NYSE MKT for June 30, 2014.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: center;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(2)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: center;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(3)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></td></tr></table><p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 79px; text-align: center;"><font style="font-size: 10pt;">(4)</font></td><td style="width: 1488px; text-align: justify;"><font style="font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: right;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(5)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Management determines the probability of future stock offering at each evaluation date.</font></td></tr><tr style="vertical-align: top;"><td style="text-align: right;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(6)</font></td><td style="text-align: justify;"><p style="margin: 0px;">Management estimates that the range of percentages of existing shares offered in each stock offering will be 0% and 35% of the shares outstanding at June 30, 2014 and December 31, 2013, respectively.</p><font style="font-size: 10pt;"></font></td></tr><tr style="vertical-align: top;"><td style="text-align: right;">&#160;</td><td style="text-align: justify;">&#160;</td></tr><tr style="vertical-align: top;"><td style="text-align: center;"><font style="font-size: 10pt;">(7)</font></td><td style="text-align: justify;"><font style="font-size: 10pt;">Represents the estimated offering price range in future offerings as determined by management.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 7.7pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font-size: 10pt;">&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708775-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624181-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708773-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624177-113959<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5580258-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41641-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2013

</div>
          <div>Premium Finance Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atnm_NotePayableAndConvertibleNotesTextualAbstract', window );"><strong>Note Payable and Convertible Notes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 54,970<span></span></td>
        <td class="nump">$ 157,825<span></span></td>
        <td class="nump">$ 157,825<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Down payment pursuant to the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,995<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent', window );">Amount required to pay in monthly installment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,995<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="nump">$ 102,855<span></span></td>
        <td class="nump">$ 103,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NotePayableAndConvertibleNotesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>atnm_NotePayableAndConvertibleNotesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>atnm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payments applied to principal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentPeriodicPaymentPrincipal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-04.12(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 4<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13, 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>124</ContextCount>
  <ElementCount>235</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/NotePayable</Role>
      <ShortName>Note Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Derivatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Derivatives</Role>
      <ShortName>Derivatives</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Derivatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesTables</Role>
      <ShortName>Derivatives (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/NotePayableDetails</Role>
      <ShortName>Note Payable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetails</Role>
      <ShortName>Derivatives (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Derivatives (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetails1</Role>
      <ShortName>Derivatives (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Derivatives (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DerivativesDetailsTextual</Role>
      <ShortName>Derivatives (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Commitmentsandcontingenciesdetailstextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element atnm_CommonStockExercisePriceParOrStatedValuePerShare had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element atnm_FairValueAssumptionOfferingPrice had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element atnm_ProjectEstimatedCost had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized had a mix of decimals attribute values: -6 0.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">'Monetary' elements on report '034 - Disclosure - Equity (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '035 - Disclosure - Subsequent Events (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>atnm-20140630.xml</File>
    <File>atnm-20140630.xsd</File>
    <File>atnm-20140630_cal.xml</File>
    <File>atnm-20140630_def.xml</File>
    <File>atnm-20140630_lab.xml</File>
    <File>atnm-20140630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.55in;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td></td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td style="text-align: center;" colspan="3">Remaining</td><td>&#160;</td><td style="text-align: center;" colspan="3"></td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Number</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td style="text-align: center;" colspan="3">Contractual</td><td>&#160;</td><td style="text-align: center;" colspan="3">Aggregate</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"><p style="margin-top: 0px; margin-bottom: 0px;">of</p><p style="margin-top: 0px; margin-bottom: 0px;">Units</p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Exercise&#160;<br />Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Term&#160;(in&#160;years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3"><p style="margin-top: 0px; margin-bottom: 0px;">Intrinsic</p><p style="margin-top: 0px; margin-bottom: 0px;">Value</p></td></tr><tr style="vertical-align: bottom;"><td></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1,985,384</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">3.23</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">8.34</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">5,908,696</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">979,100</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9.85</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10.00</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt;">Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(11,655</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.78</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-&#160;&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-&#160;&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Outstanding, June 30, 2014</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,952,829</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">5.45</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.35</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">8,300,565</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Exercisable, June 30, 2014</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">868,287</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.98</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.99</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">5,418,017</td><td style="text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td colspan="3">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="3">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Weighted</td><td>&#160;</td><td style="text-align: center;" colspan="3">Remaining</td><td>&#160;</td><td style="text-align: center;" colspan="3">Aggregate</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="3">Number of</td><td>&#160;</td><td style="text-align: center;" colspan="3">Average</td><td>&#160;</td><td style="text-align: center;" colspan="3">Contractual</td><td>&#160;</td><td style="text-align: center;" colspan="3">Intrinsic</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Units</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Exercise&#160;Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Term&#160;(in&#160;years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="3">Value</td></tr><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="3">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Outstanding, December 31, 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">9,673,290</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">1.06</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">4.89</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">47,396,307</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">406,928</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.96</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.46</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; padding-bottom: 1pt;">Exercised</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(662,160</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt;">1.44</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 2.5pt;">Outstanding, June 30, 2014</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double; text-align: right;">9,418,058</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">1.33</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">4.54</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">56,362,310</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 2.5pt;">Exercisable, June 30, 2014</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">9,195,074</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom:
 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">1.16</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right;">4.42</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left;">$</td><td style="padding-bottom: 2.5pt; text-align: right;">56,183,393</td><td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify; text-indent: 0.55in;"></p><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
